<SEC-DOCUMENT>0001558370-21-015483.txt : 20211110
<SEC-HEADER>0001558370-21-015483.hdr.sgml : 20211110
<ACCEPTANCE-DATETIME>20211110160703
ACCESSION NUMBER:		0001558370-21-015483
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		58
CONFORMED PERIOD OF REPORT:	20210930
FILED AS OF DATE:		20211110
DATE AS OF CHANGE:		20211110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Armata Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0000921114
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				911549568
		STATE OF INCORPORATION:			WA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37544
		FILM NUMBER:		211396565

	BUSINESS ADDRESS:	
		STREET 1:		4503 GLENCOE AVENUE
		CITY:			MARINA DEL REY
		STATE:			CA
		ZIP:			90292
		BUSINESS PHONE:		310-665-2928

	MAIL ADDRESS:	
		STREET 1:		4503 GLENCOE AVENUE
		CITY:			MARINA DEL REY
		STATE:			CA
		ZIP:			90292

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AmpliPhi Biosciences Corp
		DATE OF NAME CHANGE:	20130222

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TARGETED GENETICS CORP /WA/
		DATE OF NAME CHANGE:	19940331
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>armp-20210930x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.7908.23199 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 11/10/2021 8:45:54 PM -->
      <!-- iXBRL Library version: 1.0.7908.23207 -->
      <!-- iXBRL Service Job ID: 9ddc2ed3-d22c-40b6-b1d6-c7108e2d04da -->

  <html xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:armp="http://www.armatapharma.com/20210930" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_Vjudgl28B0mPQxo1Uew1Pg">24965086</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="dei:EntityRegistrantName" id="Hidden_b__5oMo-IECTetnOZMckgw">Armata Pharmaceuticals, Inc.</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="dei:EntityCentralIndexKey" id="Tc_l1wOJKeGE0ixIvloPIS6Cw_2_1">0000921114</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="dei:CurrentFiscalYearEndDate" id="Tc_qSXV9q-IqkOkkLSJVlBhVw_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="dei:DocumentFiscalYearFocus" id="Tc_FuoL7QFiTEizq70wqgZUPw_4_1">2021</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="dei:DocumentFiscalPeriodFocus" id="Tc_6lt0Owc9XEyaq7iKzYr5HQ_5_1">Q3</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="dei:AmendmentFlag" id="Tc_uRfEXY4LI0iriyi8-9HqhQ_6_1">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg" decimals="INF" name="us-gaap:CommonStockSharesIssued" id="Hidden_vHdyLOLd_0OZchY-bVdk5A">18688461</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_armp_Assumed2006And2016PlanMember_K1n3aKUECkaYA26IMMHaPw" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="Hidden_FoLyPbG9hUC2OJDlbr-6vQ">P2Y</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_pure_EPrTQjTDQkGfR4N7mgNYUg" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_PlanNameAxis_armp_Assumed2006And2016PlanMember_jwnQgOCvrEi-zQv25P1M9Q" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Hidden_6HHTzro5OEGysvS9SNdMCQ">0.0714</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_EPrTQjTDQkGfR4N7mgNYUg" contextRef="Duration_8_9_2021_To_8_9_2021_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_armp_StockOptionsAndRestrictedStockAwardsMember_HSuu2yjbeUO8uzqPtQxFDA" decimals="2" name="armp:ShareBasedCompensationArrangementPercentageOfOutstandingAwardsVestedForAdvisoryServicesProvided" id="Hidden_9mekj5kubk-rv8woYRxrCg">0.50</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="armp-20210930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MYGe64DLVEKoqqG1PLm-1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DVIyohuaMEqe9vySm_9bHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_28_2021_To_10_28_2021_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_j_mhEXexkkyt_KqjZVElLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-28</xbrli:startDate><xbrli:endDate>2021-10-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_28_2021_To_10_28_2021_srt_CounterpartyNameAxis_armp_CysticFibrosisFoundationMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_r2L1o1zLc0ewvdxbb5OLYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:CysticFibrosisFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-28</xbrli:startDate><xbrli:endDate>2021-10-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_17_2021_To_3_17_2021_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementSecondTrancheMember_7NUySWdWyU2T6PeqoKx_hg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis">us-gaap:CommonStockSubjectToMandatoryRedemptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:SecuritiesPurchaseAgreementSecondTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-17</xbrli:startDate><xbrli:endDate>2021-03-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_26_2021_To_1_26_2021_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_z5LGiY7OL0Scv3M4U-b1Wg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis">us-gaap:CommonStockSubjectToMandatoryRedemptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-26</xbrli:startDate><xbrli:endDate>2021-01-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_26_2021_To_1_26_2021_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementFirstTrancheMember_vU5i9LO2uU6jsVJ4911Zlg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis">us-gaap:CommonStockSubjectToMandatoryRedemptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:SecuritiesPurchaseAgreementFirstTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-26</xbrli:startDate><xbrli:endDate>2021-01-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_27_2020_To_3_27_2020_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_tEurHl-WuEy8GrS4QYXwGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis">us-gaap:CommonStockSubjectToMandatoryRedemptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-27</xbrli:startDate><xbrli:endDate>2020-03-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BCCyhEU1tEi9VSOL9PeeDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CnAXtkAfOkyr84AqUZmq-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_SPUy-mdqVEWQXJUyR4SwLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rkFIJlcvhkG9sE5lG-I4MQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_5jY2Kblz0kWsExJk25jZVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_KEunbq8Lv0G2CGYZpXLKlA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_nIezyXT0BUyf5xGYCsZfTA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MTZvL_NcmESOrJIA_0-1jw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_NKaGlnEUNkec6voi3tIaYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ZmXsDKp77EKqicmltHHhGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_SxvMMY1Sa0GTX13IRJGJ4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_Lk4NTSOZBE25mumJD7-ddw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_I_LPYFq-_Eu5aKaleEMQgQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KEkptw3IX0mcgqD8P-u1tQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zJn5M0sFjE-rqqEDYPJ3Uw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_W4e7PNLj70SPGz46YLofww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_d2NNZnl0VUWMFpJen2dwnw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_65fdseHmlkygQFXjdAowrA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_aIHcMH7w-kKjUPzazac1VQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SL0WNDAfdkevFGn-ljnxpQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_28_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_XMDfJAOuaESQwElJtiy_ew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_26_2021_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_zFjpWhEkUkiNbRFtUmSseg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis">us-gaap:CommonStockSubjectToMandatoryRedemptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_26_2021_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_TImvJ_eQD0OgW_ZO7Ry9TQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_27_2020_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_9mH04W5WikCikSJLnqxw9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis">us-gaap:CommonStockSubjectToMandatoryRedemptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_PlanNameAxis_armp_Assumed2006And2016PlanMember_jwnQgOCvrEi-zQv25P1M9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">armp:Assumed2006And2016PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_8rl-g37700qfCCqQwUULVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_armp_EquityIncentivePlan2016Member_nK9yLVbEL06fLvTMqAkXxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">armp:EquityIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_armp_EquityIncentivePlan2016Member_owlriQq-j0-oYrcsBY5Gjw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">armp:EquityIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_hi0c_0vE9E-W67zzRNTT2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_UrkFQ9x-qEmjvoP_lxEMWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_TDb9Z5iGoUePxWE6REEZBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_uMrMSnX6sk6VBfvSkKl9Vg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_armp_EquityIncentivePlan2016Member_a2GP2RQyPUaGZD8_SYwXvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">armp:EquityIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_armp_Assumed2006And2016PlanMember_K1n3aKUECkaYA26IMMHaPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">armp:Assumed2006And2016PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_armp_Assumed2006And2016PlanMember_oXCoqIfziE2VJlO7Y9J9yA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">armp:Assumed2006And2016PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_15_2020_To_7_15_2020_srt_CounterpartyNameAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_ITaRqTiHmk-EtdzqEDU-gw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:MedicalTechnologyEnterpriseConsortiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-15</xbrli:startDate><xbrli:endDate>2020-07-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_TechnologyEquipmentMember_p5J4JOCTc02vC-jcH_EpAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:TechnologyEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_TOBly1V2sk6aoZBdLy5BKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_RNSsP7qTGEmVKWcf_xwJ3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_1p7SIRia1U-1Q9bpInZOaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_TechnologyEquipmentMember_nIlwPHC5LUOeeFklieSIRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:TechnologyEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_v1yZA3mZRkKG-s3xNs7sqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_Va3hG_KZOUiqR-V5nrMt6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_8b0rBWMKHUqzS1cwV6K4xQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_20_2020_To_4_20_2020_us-gaap_DebtInstrumentAxis_armp_PaymentProtectionProgramNoteMember_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember_7RzbJhwJ1ESFRjadZeEXiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">armp:PaymentProtectionProgramNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-20</xbrli:startDate><xbrli:endDate>2020-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_17_2021_To_3_17_2021_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementSecondTrancheMember_OI9uPwtYu02QjGR7dFobAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:SecuritiesPurchaseAgreementSecondTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-17</xbrli:startDate><xbrli:endDate>2021-03-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_26_2021_To_1_26_2021_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementFirstTrancheMember_wOZbvf2jHEW62lNLQlwkHw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:SecuritiesPurchaseAgreementFirstTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-26</xbrli:startDate><xbrli:endDate>2021-01-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_12_2020_To_2_12_2020_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_kE6uyStxdEyj3mI3KbQoTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-12</xbrli:startDate><xbrli:endDate>2020-02-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_27_2020_To_3_27_2020_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_9V8h1NEgnkCy2Hyg6zq7fg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-27</xbrli:startDate><xbrli:endDate>2020-03-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_armp_AssetAcquisitionAxis_armp_SyntheticGenomicsIncMember_dei_LegalEntityAxis_armp_C3jTherapeuticsIncMember_NBfmWnEmKk6A5v2Z9Ffejw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="armp:AssetAcquisitionAxis">armp:SyntheticGenomicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:C3jTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_20_2018_To_12_20_2018_armp_AssetAcquisitionAxis_armp_SyntheticGenomicsIncMember_dei_LegalEntityAxis_armp_C3jTherapeuticsIncMember_srt_StatementScenarioAxis_armp_ScenarioAmendedExpectedPaymentTwoMember_rqhFNiTiRE2BmMr7XyphyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="armp:AssetAcquisitionAxis">armp:SyntheticGenomicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:C3jTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">armp:ScenarioAmendedExpectedPaymentTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-20</xbrli:startDate><xbrli:endDate>2018-12-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_20_2018_To_12_20_2018_armp_AssetAcquisitionAxis_armp_SyntheticGenomicsIncMember_dei_LegalEntityAxis_armp_C3jTherapeuticsIncMember_srt_StatementScenarioAxis_armp_ScenarioAmendedExpectedPaymentThreeMember_R1Aa4SvwlUuog7rLKl3MqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="armp:AssetAcquisitionAxis">armp:SyntheticGenomicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:C3jTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">armp:ScenarioAmendedExpectedPaymentThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-20</xbrli:startDate><xbrli:endDate>2018-12-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_20_2018_To_12_20_2018_armp_AssetAcquisitionAxis_armp_SyntheticGenomicsIncMember_dei_LegalEntityAxis_armp_C3jTherapeuticsIncMember_srt_StatementScenarioAxis_armp_ScenarioAmendedExpectedPaymentOneMember_zNXu_So6HEuNH4kwwRcmWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="armp:AssetAcquisitionAxis">armp:SyntheticGenomicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:C3jTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">armp:ScenarioAmendedExpectedPaymentOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-20</xbrli:startDate><xbrli:endDate>2018-12-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_28_2018_To_2_28_2018_armp_AssetAcquisitionAxis_armp_SyntheticGenomicsIncMember_dei_LegalEntityAxis_armp_C3jTherapeuticsIncMember_srt_StatementScenarioAxis_armp_ScenarioOriginalExpectedPaymentTwoMember_gEaPDWofx0qOEWXTSGF3Tw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="armp:AssetAcquisitionAxis">armp:SyntheticGenomicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:C3jTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">armp:ScenarioOriginalExpectedPaymentTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-28</xbrli:startDate><xbrli:endDate>2018-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_28_2018_To_2_28_2018_armp_AssetAcquisitionAxis_armp_SyntheticGenomicsIncMember_dei_LegalEntityAxis_armp_C3jTherapeuticsIncMember_srt_StatementScenarioAxis_armp_ScenarioOriginalExpectedPaymentThreeMember_jidGEQgNYECfuWhjbDYubA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="armp:AssetAcquisitionAxis">armp:SyntheticGenomicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:C3jTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">armp:ScenarioOriginalExpectedPaymentThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-28</xbrli:startDate><xbrli:endDate>2018-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_28_2018_To_2_28_2018_armp_AssetAcquisitionAxis_armp_SyntheticGenomicsIncMember_dei_LegalEntityAxis_armp_C3jTherapeuticsIncMember_srt_StatementScenarioAxis_armp_ScenarioOriginalExpectedPaymentOneMember_clsnrNZH1UazMXYm92c0Pg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="armp:AssetAcquisitionAxis">armp:SyntheticGenomicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:C3jTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">armp:ScenarioOriginalExpectedPaymentOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-28</xbrli:startDate><xbrli:endDate>2018-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_28_2018_To_2_28_2018_armp_AssetAcquisitionAxis_armp_SyntheticGenomicsIncMember_dei_LegalEntityAxis_armp_C3jTherapeuticsIncMember_srt_StatementScenarioAxis_armp_ScenarioOriginalExpectedPaymentFourMember_gxbq2ISe3UijfOm_OFNWLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="armp:AssetAcquisitionAxis">armp:SyntheticGenomicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:C3jTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">armp:ScenarioOriginalExpectedPaymentFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-28</xbrli:startDate><xbrli:endDate>2018-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_28_2018_To_2_28_2018_armp_AssetAcquisitionAxis_armp_SyntheticGenomicsIncMember_dei_LegalEntityAxis_armp_C3jTherapeuticsIncMember_RidG05BOeEyASZ1M8D09rA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="armp:AssetAcquisitionAxis">armp:SyntheticGenomicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:C3jTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-28</xbrli:startDate><xbrli:endDate>2018-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MAx1Qhihl0-QjfrmaUOYJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7TWvDwySBEWUWI9x7ArVBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_bgCDlfNMOkqVq2IlJzSALA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_UxaVXkDGlUCs8nQaDlXZoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_30_2020_1iPl4CxS1EenIgtFs0sC1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_joNmkWmSp0eoVV34drwlKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_armp_StockOptionsAndRestrictedStockAwardsMember_pNotzPzMhUuSettHWcT5dw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">armp:StockOptionsAndRestrictedStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_20_2020_us-gaap_DebtInstrumentAxis_armp_PaymentProtectionProgramNoteMember_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember_etlcSyw6QUy7OhSC2F0meg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">armp:PaymentProtectionProgramNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_28_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_tDI9aHgnU02SEE2i4-rltw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_17_2021_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementSecondTrancheMember_8WtQB3s-wk2b0we6rBXeVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis">us-gaap:WarrantsAndRightsSubjectToMandatoryRedemptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:SecuritiesPurchaseAgreementSecondTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_26_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_z1sUig3BpUiBHLBYltqXRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis">us-gaap:WarrantsAndRightsSubjectToMandatoryRedemptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_26_2021_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_u_eCCek3qkqRByQzE5fczw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis">us-gaap:WarrantsAndRightsSubjectToMandatoryRedemptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_26_2021_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementFirstTrancheMember_4VDPa4otSk6JCKDKNZvQ0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis">us-gaap:WarrantsAndRightsSubjectToMandatoryRedemptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:SecuritiesPurchaseAgreementFirstTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_27_2020_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_VI0dYZLlxkey_j7O6lL4cA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis">us-gaap:WarrantsAndRightsSubjectToMandatoryRedemptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceTwoMember_NdqVRbX3oU27C0EB3fq9hQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceThreeMember_KFYsa4JmTkqWUhYzwZ9UJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSixMember_WimCD-fx60m_KUK0LywoTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSevenMember_gY_GNEB58Eym-DuN9BtbEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFourMember_JSSFhCnciUaDzuCmVBpOig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFiveMember_CxNNWMACKU-ycnzc8b5FtA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceEightMember_fpCbl3DW_keRXlZj4Fhy1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_9M2XeqAfdE-lB78H_jYHfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_zW8zVq9yIEyTGkUsiRdNWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_DeTK3m4stEG86-3yphL8Ow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_dGzT0B8rlE25dvbTXP9MPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_0tfpWQr4U0atNpxzVyKU4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_C-PpNtLO1EyP8fYs3gQBWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_T0uD7MiwsUiVBvYkYdc0sA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_Lq1HnOsnGU-O85aEcig2uA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_IORuHvJJb02yQ5UUN4uyzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_77ETOpJ7T0afQOPGHLIu-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_1dzTloLluU2mQIMpctnh9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_G0J-iJ-hkEmVgCIOKKuQUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_0sFoug39yEW-7YiIxYw6ZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_iXH_BdY7Yky0pOj-w2anUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_GodB2f3XM0-WcLyJqnzVFg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_v1HeSfyr9Em3B6Qct7RwOA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_we94IQA0Ok-L_lCieSHSdw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9Eff9cku9kikyLYc9MKX0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_0veJ9SwbfEiLVcv9uwtSJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_C3Blutz6cUqC03qQKsaYEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_5_2021_r_KKuBvaXUe98RPh8rYZpA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-11-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceTwoMember_JdmRRsSJmk-a_ZNRg_kXxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceThreeMember_EJFiwcEwBEuQa1IR4jmJ5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSevenMember_u78Ah4LoqUKqzJVIAxTUEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFourMember_jfTPvaUXH0maozOHI-CL3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFiveMember_E28RzePRZEuFR_T3YSIfYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceEightMember_xrUR_X3n30aS1ib7pRRXLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_13_2020_dei_LegalEntityAxis_armp_CysticFibrosisFoundationMember_srt_RangeAxis_srt_MaximumMember_QdkZoWNHYkyCGniRryGR1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:CysticFibrosisFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_armp_StockOptionsAndRestrictedStockAwardsMember_NAa3wvdW6ku9ixKdaxeq_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">armp:StockOptionsAndRestrictedStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_9_2021_To_8_9_2021_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_armp_StockOptionsAndRestrictedStockAwardsMember_HSuu2yjbeUO8uzqPtQxFDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">armp:StockOptionsAndRestrictedStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-09</xbrli:startDate><xbrli:endDate>2021-08-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VJKQAeK86kCfqs_DrKEH6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VoZ8oQm5tUCLM6PYYrJGCA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Rmv1hE9bF0aKaK_8FzTl-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HzaMhmdSwEmOsLQZS5Pg1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_dei_LegalEntityAxis_armp_CysticFibrosisFoundationMember_RpwT93VR-ECLCn7xD0c95g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:CysticFibrosisFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_dei_LegalEntityAxis_armp_CysticFibrosisFoundationMember_oDkg0nbvCUGTMxn-UCPsfA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:CysticFibrosisFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_28_2021_To_10_28_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_46a9XzfZPkSGKc4-ttN9fw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-28</xbrli:startDate><xbrli:endDate>2021-10-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_27_2020_To_3_27_2020_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_NmhuJtI8WkCb1aWkNG0-5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-27</xbrli:startDate><xbrli:endDate>2020-03-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_27_2020_To_1_27_2020_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_kxspnM04HEGpag_N6znvkw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-27</xbrli:startDate><xbrli:endDate>2020-01-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2018_To_2_28_2018_armp_AssetAcquisitionAxis_armp_SyntheticGenomicsIncMember_dei_LegalEntityAxis_armp_C3jTherapeuticsIncMember_Z8D7DoUmZ0qMYFL0DwXLPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="armp:AssetAcquisitionAxis">armp:SyntheticGenomicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:C3jTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-01</xbrli:startDate><xbrli:endDate>2018-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_EHL267Iy5kqlAVaXmlK6uQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_M1wYd_bHtkSmPDl5gRx6tg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_Y-YOyctUPkCj1ByCpX0cjA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_ZYsQgyW6mkWdASHXKWLehQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_TcHNTAeDIUqS5KTjdnYf_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_8qAqLG7eF0q7G6Mr5Lp6tg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_i9PzMC1lVUqwLuTxFWfdLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_JmEBEeGO8UeggSG1K-jwFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_si4L1iko2E64STirrO48PA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_c6MOz2oxDUaT_X0fkJA_DA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_vGTpt-wF-kumWbrMGmDgMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_NRyFSCYoD020FMLell9_Bw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_bMElE1RKukaULS3RIlENIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_xmm1FvADiUqkK7ZP4Vv_tA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_28_2018_armp_AssetAcquisitionAxis_armp_SyntheticGenomicsIncMember_dei_LegalEntityAxis_armp_C3jTherapeuticsIncMember_mk1RLuCDkk6c_shfOgofxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="armp:AssetAcquisitionAxis">armp:SyntheticGenomicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:C3jTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2021_egZlLrGpKk2-r-0udRYIlQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_13_2020_dei_LegalEntityAxis_armp_CysticFibrosisFoundationMember_Vmk5a-OLzkuheIihAx82BA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:CysticFibrosisFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_13_2020_To_3_13_2020_dei_LegalEntityAxis_armp_CysticFibrosisFoundationMember_bkw-_kZsEUWVZ6CfCvxnag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:CysticFibrosisFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-13</xbrli:startDate><xbrli:endDate>2020-03-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_4_30_2020_97rB72XwWUSnYAu0RGwgjQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_dei_LegalEntityAxis_armp_CysticFibrosisFoundationMember_tYChB5g8O0GcrXG6pdzhcA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:CysticFibrosisFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_EPrTQjTDQkGfR4N7mgNYUg"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:8.24%;padding-right:8.24%;position:relative;"><div style="margin-top:21.6pt;min-height:28.8pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:1pt;padding-top:1pt;text-align:center;text-indent:0pt;border-bottom:1px solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-family:'Times New Roman Bold';font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-family:'Times New Roman Bold';font-size:5pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_792bf9f1_336d_45b6_9155_952e2f7ac4df"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="dei:DocumentType" id="Narr_T7k6-48B2EykGlvJJawkZg"><b style="font-weight:bold;">10-Q</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_281597ca_39c9_4584_a30b_69fddc6afb2d"></a><a id="Tc_7oLhEpfiT0m9cMsBaf2EwA_1_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-9.765625E-4%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:10.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:79.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:10.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="dei:DocumentQuarterlyReport" id="Tc_frgt2dW24Ueueuq-j8-eHw_1_0"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9746;</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:79.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE</b><br /><b style="font-weight:bold;">SECURITIES EXCHANGE ACT OF 1934</b></p></td><td style="vertical-align:top;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 4pt 0pt;">For the quarterly period ended <ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="dei:DocumentPeriodEndDate" id="Narr_TLJpFSXNwkiL812uHlcAag">September 30, 2021</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">OR</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_bd8b668b_2d14_4bf5_be08_ca4895f5011d"></a><a id="Tc_Bi9SEh34UE-ecVt55pQl4Q_1_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-9.765625E-4%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:10.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:79.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:10.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="dei:DocumentTransitionReport" id="Tc_xaeci2mzsECRhK6diGaQRw_1_0"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9744;</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:79.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE</b><br /><b style="font-weight:bold;">SECURITIES EXCHANGE ACT OF 1934</b></p></td><td style="vertical-align:top;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 4pt 0pt;">For the transition period from _________________ to _______________________</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Commission file number: </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="dei:EntityFileNumber" id="Narr_nb-kP7B8i0iWYpzc8hwx7w"><b style="font-weight:bold;">001-37544</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_b__5oMo-IECTetnOZMckgw;"><b style="font-family:'Times New Roman','Times','serif';font-size:16pt;font-style:normal;font-weight:bold;text-align:center;">ARMATA PHARMACEUTICALS, INC.</b></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">(Exact name of registrant as specified in its charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><a id="_56c2d1b9_d708_43f3_858e_35ce83153187"></a><a id="Tc_8DUE-ZchjUiXjuICuLnUtA_2_0"></a><a id="Tc_NEJ9G-4iM06V6av58yv8bw_2_1"></a><a id="Tc_1GbmqkdOwEafPuVGv3XUNA_3_0"></a><a id="Tc_LoFjaOQX90SaXDslRPnllw_6_0"></a><a id="Tc_wn7CvR1o-0SG5i80WaAGEw_7_0"></a><a id="Tc_NOz0KfYYQE69e3jzx2-8hg_7_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-9.765625E-4%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="dei:EntityIncorporationStateCountryCode" id="Tc_hCkCIuVPy0ybAiJ5WhmXkQ_1_0"><b style="font-size:9pt;font-weight:bold;">Washington</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="dei:EntityTaxIdentificationNumber" id="Tc_pSd92nbU6ESaXltFeP_wnQ_1_1"><b style="font-size:9pt;font-weight:bold;">91-1549568</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;">(State or other jurisdiction of</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;">(I.R.S. Employer Identification Number)</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;">incorporation or organization)</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="dei:EntityAddressAddressLine1" id="Tc_MOVHmt83gECZvg6I_spDwg_5_0"><b style="font-size:9pt;font-weight:bold;">4503 Glencoe Avenue</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="dei:EntityAddressCityOrTown" id="Narr_W40YDqMtKUq5j_NEMrbBag"><b style="font-size:9pt;font-weight:bold;">Marina del Rey</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="dei:EntityAddressStateOrProvince" id="Narr_32ECs7bMRkCsWvsi0hiSjw"><b style="font-size:9pt;font-weight:bold;">CA</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="dei:EntityAddressPostalZipCode" id="Tc_gtU9w88k0EyV-9lQszAXeQ_6_1"><b style="font-size:9pt;font-weight:bold;">90292</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;">(Address of principal executive offices)</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;">(Zip Code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:9pt;">Registrant&#8217;s telephone number, including area code: </span><b style="font-size:9pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="dei:CityAreaCode" id="Narr_s-E0czk_r0iXlCnqSahaFw"><b style="font-size:9pt;font-weight:bold;">310</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="dei:LocalPhoneNumber" id="Narr_1ud0D_6J6kqcDWRUDg3tJA"><b style="font-size:9pt;font-weight:bold;">665-2928</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:6pt 216pt 6pt 0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section 12(b) of the Act:</b></p><a id="_f8397ec0_e991_451c_91e2_afd54e325f01"></a><a id="Tc_dE9Hs1omeUapq34Pnwg79Q_1_0"></a><a id="Tc_aFhqxR8KEE2685FEEPg98w_1_1"></a><a id="Tc_rvahpU7Tp0S-QIEefMRqOA_1_2"></a><a id="Tc_jK4YR2JlRE-P3t0cxKVn3g_2_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:97.72%;"><tr style="height:1pt;"><td style="vertical-align:top;width:36%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:18.05%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:45.94%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:36%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:6pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:top;width:18.05%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:6pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Trading Symbol(s) </b></p></td><td style="vertical-align:top;width:45.94%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:6pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:top;width:36%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="dei:Security12bTitle" id="Narr_ZKHoKuvAQk2MfEHBGk5CVQ"><span style="font-size:8pt;">Common Stock</span></ix:nonNumeric><span style="font-size:8pt;">, $0.01 par value per share</span></p></td><td style="vertical-align:top;width:18.05%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="dei:TradingSymbol" id="Tc_29I-m2xMZUKstoRadYkqEw_2_1"><span style="font-size:8pt;">ARMP</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:45.94%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="dei:SecurityExchangeName" id="Tc_IKds9j-GtEOIYagXF7nmhg_2_2"><span style="font-size:8pt;">NYSE American</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:0pt;margin:0pt 0pt 4pt 0pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="dei:EntityCurrentReportingStatus" id="Narr_HR4TfOcFAkabl1zPvt8fpw"><span style="font-size:9pt;">Yes</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160; </span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span><span style="font-size:9pt;"> &#160;&#160;&#160;&#160; No&#160;&#160;&#160;&#160; </span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:0pt;margin:0pt 0pt 4pt 0pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="dei:EntityInteractiveDataCurrent" id="Narr_CP0SVGx_w0Cdjz0dWJAFWA"><span style="font-size:9pt;">Yes</span></ix:nonNumeric><span style="font-size:9pt;"> &#160;&#160; </span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span><span style="font-size:9pt;"> &#160;&#160;&#160;&#160;No&#160;&#160;&#160;&#160; </span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:0pt;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company as defined in Rule&#160;12b-2 of the Exchange Act. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-9.765625E-4%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:64.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:35.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:64.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Large accelerated filer&#160;&#160; <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:35.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Accelerated filer&#160;&#160; <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr><td style="vertical-align:top;width:64.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="dei:EntityFilerCategory" id="Narr__3bWzddok06ncOn5TAvB6Q">Non-accelerated filer</ix:nonNumeric>&#160;&#160;&#160;&#160; <span style="font-family:'Segoe UI Symbol';">&#9746;</span></p></td><td style="vertical-align:top;width:35.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Smaller reporting company&#160;&#160; <ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="dei:EntitySmallBusiness" id="Narr_YmHN5EGPc0ScP2D0ScofvQ"><span style="font-family:'Segoe UI Symbol';">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:64.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:35.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Emerging growth company&#160;&#160; <ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="dei:EntityEmergingGrowthCompany" id="Narr_pg2Fx5k-2Ei1Q4KdYKEyow"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 4pt 0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;<span style="white-space:pre-wrap;">of the Exchange Act.  </span><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 4pt 0pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 4pt 0pt;">Yes <ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="dei:EntityShellCompany" id="Narr_7F2pHAK2H0GHd092Op8DKw"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric> &#160;&#160;&#160;&#160;No <span style="font-family:'Segoe UI Symbol';">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The number of shares of the registrant&#8217;s Common Stock, par value $0.01 per share, outstanding as of November 5, 2021 was <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_11_5_2021_r_KKuBvaXUe98RPh8rYZpA" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_sWMV5RAYzUy4zeWe2SdSWQ">27,086,299</ix:nonFraction>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:1pt;padding-top:1pt;text-indent:0pt;border-bottom:3.0pt solid #000000;border-top:1px solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:83.53%;border:0;margin:30pt 8.24% 30pt 8.24%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_405a1383_c6ec_41a4_a543_e27fa14fea30"></a><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">TABLE OF CONTENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:10.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:82.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:7.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:10.11%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:82.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:7.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Page</p></td></tr><tr><td style="vertical-align:top;width:10.11%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:82.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:7.13%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PART&#160;I. FINANCIAL INFORMATION</p></td><td style="vertical-align:top;width:7.13%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:9.9pt;"><td style="vertical-align:top;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Item&#160;1.</p></td><td style="vertical-align:top;width:82.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Financial Statements (unaudited)</p></td><td style="vertical-align:top;width:7.13%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ConsolidatedBalanceSheets_25890"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Condensed Consolidated Balance Sheets</span></a></p></td><td style="vertical-align:top;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">3</p></td></tr><tr><td style="vertical-align:top;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:82.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.11%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:82.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ConsolidatedStatementsofOperations_41511"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Condensed Consolidated Statements of Operations</span></a></p></td><td style="vertical-align:top;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">4</p></td></tr><tr style="height:8.55pt;"><td style="vertical-align:top;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:82.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.13%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ConsolidatedStatementsofStockholdersEqui"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Condensed Consolidated Statements of Stockholders&#8217; Equity</span></a></p></td><td style="vertical-align:top;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:top;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.11%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:82.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ConsolidatedStatementsofCashFlows_440434"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Condensed Consolidated Statements of Cash Flows</span></a></p></td><td style="vertical-align:top;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">7</p></td></tr><tr><td style="vertical-align:top;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:82.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.13%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.11%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:82.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CondensedNotestoConsolidatedFinancialSta"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Notes&#160;to Condensed Consolidated Financial Statements</span></a></p></td><td style="vertical-align:top;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">8</p></td></tr><tr><td style="vertical-align:top;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2MANAGEMENTSDISCUSSIONANDANALYSIS_77"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;2.</span></a></p></td><td style="vertical-align:top;width:82.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2MANAGEMENTSDISCUSSIONANDANALYSIS_77"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:top;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">19</p></td></tr><tr><td style="vertical-align:top;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3QUANTITATIVEANDQUALITATIVE_125432"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;3.</span></a></p></td><td style="vertical-align:top;width:82.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3QUANTITATIVEANDQUALITATIVE_125432"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:top;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">26</p></td></tr><tr><td style="vertical-align:top;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4CONTROLSANDPROCEDURES_448420"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;4.</span></a></p></td><td style="vertical-align:top;width:82.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4CONTROLSANDPROCEDURES_448420"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Controls and Procedures</span></a></p></td><td style="vertical-align:top;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">26</p></td></tr><tr><td style="vertical-align:top;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:82.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIIOTHERINFORMATION_905682"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">PART&#160;II. OTHER INFORMATION</span></a></p></td><td style="vertical-align:top;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">27</p></td></tr><tr><td style="vertical-align:top;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:82.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.13%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1LegalProceedings_580710"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;1.</span></a></p></td><td style="vertical-align:top;width:82.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1LegalProceedings_580710"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Legal Proceedings</span></a></p></td><td style="vertical-align:top;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">27</p></td></tr><tr><td style="vertical-align:top;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:82.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.13%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_490547"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;1A.</span></a></p></td><td style="vertical-align:top;width:82.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_490547"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Risk Factors</span></a></p></td><td style="vertical-align:top;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">27</p></td></tr><tr><td style="vertical-align:top;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:82.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.13%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2UnregisteredSalesofEquitySecurities"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;2.</span></a></p></td><td style="vertical-align:top;width:82.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2UnregisteredSalesofEquitySecurities"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td><td style="vertical-align:top;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">52</p></td></tr><tr><td style="vertical-align:top;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:82.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.13%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3DefaultsuponSeniorSecurities_670807"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;3.</span></a></p></td><td style="vertical-align:top;width:82.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3DefaultsuponSeniorSecurities_670807"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Defaults upon Senior Securities</span></a></p></td><td style="vertical-align:top;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">52</p></td></tr><tr><td style="vertical-align:top;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:82.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.13%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosures_193094"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;4.</span></a></p></td><td style="vertical-align:top;width:82.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosures_193094"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:top;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">52</p></td></tr><tr><td style="vertical-align:top;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:82.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.13%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5OtherInformation_112654"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;5.</span></a></p></td><td style="vertical-align:top;width:82.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5OtherInformation_112654"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Other Information</span></a></p></td><td style="vertical-align:top;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">52</p></td></tr><tr><td style="vertical-align:top;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:82.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.13%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6Exhibits_175538"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;6.</span></a></p></td><td style="vertical-align:top;width:82.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6Exhibits_175538"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Exhibits</span></a></p></td><td style="vertical-align:top;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">53</p></td></tr><tr><td style="vertical-align:top;width:10.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:82.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.13%;margin:0pt;padding:0pt;"></td></tr><tr><td colspan="2" style="vertical-align:top;width:92.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SIGNATURES_76302"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">SIGNATURES</span></a></p></td><td style="vertical-align:top;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">55</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_ac9b5c07_cfd0_4cb3_8fe3_bca020ba067d"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">Armata Pharmaceuticals, Inc.</p><a id="ConsolidatedBalanceSheets_25890"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">Condensed Consolidated Balance Sheets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_a8b35b75_8784_45d9_b725_f855fd2c03d4"></a><a id="_47b52b36_0b0f_4a1e_80fe_df67735b5296"></a><a id="_fcd0e73d_5927_47b0_a10b_e6f60e841945"></a><a id="_9835c99c_3c14_4525_93b5_77b884638f53"></a><a id="_bb8f4d51_2ea5_4c15_a24e_31e49a5a0961"></a><a id="_b1034f60_4bd6_4ca7_9078_b87a50cac3fa"></a><a id="_01cdb8b5_b415_4be3_9dc3_30b47f5281c7"></a><a id="_572f3967_d48d_4b9f_bcde_6e6c3c718e5e"></a><a id="_1614c5da_f6b7_49f6_b804_851bf146a2ae"></a><a id="_80582d6d_b379_46fc_b5a1_2d91bdfdc90a"></a><a id="Tc_dW2JI9Pd406lUNzpY3i2zw_1_2"></a><a id="Tc_NjYkUwIvs0WjSNS4uHIYLA_1_5"></a><a id="_edca56dd_538a_4f75_9516_4f69cd320365"></a><a id="Tc_vMwwpxqmf06kgZ-Hzlq34A_2_2"></a><a id="_c1d6b086_90cb_4ed8_b962_92483293730f"></a><a id="Tc_wrwPjyvOG06-_vmt5ToFrw_3_0"></a><a id="_6c833668_b60f_4d85_9b21_ee2a1b11fbf8"></a><a id="Tc_ta3nhuuBM0Gq5Y3j54Ui8Q_4_0"></a><a id="_d1dcb137_31cc_4d9c_85ba_1b18117ba544"></a><a id="Tc_l2w493swzk2FM6d83bHmtg_5_0"></a><a id="Tc_UW7BUUGmwECXdfVhmG3Atw_5_2"></a><a id="Tc_-rIG3-bJ1UG-rNlXRb1rcg_5_5"></a><a id="_2d2895cd_5388_4727_9a73_1471b845971b"></a><a id="Tc_LZ8iG2iUm0-FQo55hO7ErA_6_0"></a><a id="_aa15fa12_034c_47da_8d7e_732677041e31"></a><a id="Tc_twByFcM8UkOAxdOxKJtKJA_7_0"></a><a id="_7b548502_6ca2_4d84_9fa4_d67a04fd705e"></a><a id="Tc_-P1pcfXT00SnEGTeMCBG5g_8_0"></a><a id="_59eb8f82_14f8_46b5_880e_25436f886ac0"></a><a id="Tc_HeW5xxlTekG7T5fn-EIaVQ_9_0"></a><a id="_331c5bc0_0b9b_4b8d_aec1_304b89cc9b25"></a><a id="Tc_BDhMvmkOlEaSCbbniomFpg_10_0"></a><a id="_76619cc2_789c_40c2_9a79_fc72baad4031"></a><a id="Tc_F4Lhbjw4A0iyS6dDjxuFxg_11_0"></a><a id="_f6916ffd_5fe5_436a_9378_0a92d52ba153"></a><a id="Tc_EjTEN1bim0a_-L-YsdaNRw_12_0"></a><a id="_1e17961f_83f4_45c6_84ff_a57ac23f13bb"></a><a id="Tc_bMt9Q5_WxUa8GeFKYnwEIA_13_0"></a><a id="_29297497_e608_426d_a19d_ab1ea9517b8d"></a><a id="Tc_AoGai-bBQ0a--H3m7bKoIQ_14_0"></a><a id="_b93594be_b49c_4718_9c69_21a5ba482649"></a><a id="Tc_MtSExE1aC06NYCz0kgZ9RQ_15_0"></a><a id="Tc_jrmiKzi7LkeX4DSJZKayeg_15_2"></a><a id="Tc_MEVQRQxBfkmRUjE9PoIqSQ_15_5"></a><a id="_4fd5fe3e_17c8_4a14_bb53_3f07e493e9f7"></a><a id="_05ed0a06_c9c5_4d5f_9a76_000e3f4c909c"></a><a id="Tc_6D2tdHdCEkaCMoZvPu2wdA_17_0"></a><a id="_6ae4b304_32c6_40a3_9050_827429d86c73"></a><a id="Tc_iaMYCT_GKUC-hSro7w3T5A_18_0"></a><a id="_0fd6a464_23aa_43fb_b4d4_d79f7d49e5a5"></a><a id="Tc_V0LciPWpu0eAWV3HgaltGw_19_0"></a><a id="Tc_BGMQcEmu9ECIfodnED-zyw_19_2"></a><a id="Tc_cR2gHBUJwEG56Ne2sN5tfA_19_5"></a><a id="_d4eb9983_2841_4192_8bf0_64e725e8cdc2"></a><a id="Tc_u3-Z9BY2E0-PXEz8-r1tqQ_20_0"></a><a id="_9980e238_8274_449d_97b6_d499ea2c0d3f"></a><a id="Tc_5yJz1jEATk6wEhBt9Mb1Aw_21_0"></a><a id="_d2292435_657a_439e_84a3_e850c4cf3d24"></a><a id="Tc_ZSQs1WXte0qRsXIAtkoVqg_22_0"></a><a id="Tc_I07VpRSeaku7CheDquKVVw_22_3"></a><a id="_265e938e_05df_41c6_a630_814509f869d2"></a><a id="Tc_YYPcuhQ_Ak6jodj3gWw2Jg_23_0"></a><a id="Tc_CbAfRg_a6UCoCybkHpZiXA_23_3"></a><a id="_6d99690d_8157_4368_9757_a13b7ef2cc3e"></a><a id="Tc_zfyAYcYgw0ePXFmtWODkOA_24_0"></a><a id="_ef09d6ab_b82b_4ff6_b6b1_3f84c1be023e"></a><a id="Tc_k0PPGgUo8ECGWvjzNweb7g_25_0"></a><a id="_9b109fcf_3f72_4d08_9da4_c1ba45434722"></a><a id="Tc_jWWrSKcsEkGn3a8pBiIrsQ_26_0"></a><a id="_3cb2bd35_c611_4e77_97a3_61909f3fddc6"></a><a id="Tc_xyNN7PdZJ0itioIY43WaFA_27_0"></a><a id="_dad04612_0b1b_4575_9783_944403a67ebd"></a><a id="_888fc396_aa7a_4e0b_9ad7_0342927c3dab"></a><a id="Tc_-xB6EQZvukSf2aitaTfRFg_29_0"></a><a id="_dc2d93f9_ca62_4471_b7b1_5fc2ad704189"></a><a id="Tc_OLUfzuzbzUO-KsPMKEm7tQ_30_0"></a><a id="_383844d6_ee40_4dd1_b3b2_4554e8948f20"></a><a id="Tc_BV-UqXZeUUWJX4J-ZjoFRQ_31_0"></a><a id="_508e03b3_936c_42f7_ae08_e3edd4cfe01d"></a><a id="Tc_8g9kGzD410yIRU7DnCiISw_32_0"></a><a id="_2217e66b_6157_4192_9608_ef5a3ee97cf0"></a><a id="Tc_rYeQoumdtk6G22v2ihaldA_33_0"></a><a id="_ea29262e_5245_47a3_9c70_2777cf21c8f1"></a><a id="Tc_f3zd0WcasUegz-pgx2kaEg_34_0"></a><a id="Tc_mH0rV9227EGaMxo_huo42w_34_2"></a><a id="Tc_8ooROItaS0WbD_rf3LHCAQ_34_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited) </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash and cash equivalents</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_MZ9iUOPT1EaH9cD-rP-TaA_5_3">12,076,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_2Y0GvTrSdU2a2EkwgwHIRg_5_6">9,649,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Awards receivable </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA" decimals="0" format="ixt:numdotdecimal" name="armp:AwardReceivable" scale="0" id="Tc_2Ka-XyTnWU2A-N0cfpISpg_6_3">1,251,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg" decimals="0" format="ixt:numdotdecimal" name="armp:AwardReceivable" scale="0" id="Tc_DuuZshKZGkimPwPqzrPchA_6_6">561,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Prepaid expenses and other current assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="Tc_ERo4bWSl3UiXObA3FtwaOQ_7_3">851,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="Tc_JxpMe2Ibz0efUmdwXdqBhA_7_6">636,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_LwNdDNTiuEO0JuI62VPwoA_8_3">14,178,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_37TYBwu8_Ua9VILLcizAfA_8_6">10,846,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted cash</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="0" id="Tc_pGK3OkoFOUuw7afWlZkdhQ_9_3">1,200,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="0" id="Tc_k0nVTPkrf0iM972C_25pFg_9_6">1,200,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="Tc_WsGiFR8G8EyM1ofxge4s3w_10_3">2,107,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="Tc_Sg9hhYl5kEiDSSYysmbUXg_10_6">2,047,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease right-of-use asset</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="Tc_VfBGphhE50-D25_HQSPfVg_11_3">10,531,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="Tc_nt_JZQoV90-Ve2KPAUQrBw_11_6">10,790,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In-process research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="0" id="Tc__aN9EFpxo0eOC4ganwbJfA_12_3">10,256,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="0" id="Tc_JJd6BnZ2KUqMP9Ymve_gqQ_12_6">10,256,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Goodwill</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" id="Tc_9xBN3QGfiUmzNinymEkppw_13_3">3,490,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" id="Tc_Vs_E2CK1UkatTr-wtOjdBA_13_6">3,490,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="Tc_m4rcI-GOckeAfEmoc3wngw_14_3">909,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="Tc_DYhft6luW0GJJB05kfNIHg_14_6">887,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total assets</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="Tc_n5y2wZZ5rkSGO4MOdtdlYA_15_3">42,671,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="Tc_JVEfv4RDi0iH7bSS4hFCjQ_15_6">39,516,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Liabilities and stockholders&#8217; equity</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accounts payable and accrued liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" id="Tc_GpggTV24Uker_DHN6ke_xg_19_3">1,811,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" id="Tc_J9L22cTqVEyXoLE6eL8jqg_19_6">1,929,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationLiabilityCurrent" scale="0" id="Tc_BZD-ljl5RUaJMFnAo-AfEw_20_3">1,714,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationLiabilityCurrent" scale="0" id="Tc_EBHUm3n13UiyoUz4e_9WbQ_20_6">563,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Current portion of operating lease liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="Tc_Uduk8RV1ykev9fmVv8G4eQ_21_3">1,729,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="Tc_JSD9INqH6kmFK5j7yVzeeg_21_6">1,551,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Paycheck Protection Program Loan </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg" decimals="0" format="ixt:numdotdecimal" name="armp:PaycheckProtectionProgramLoan" scale="0" id="Tc_5hvzSW22aka68I17DGYS3g_22_6">722,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Deferred asset acquisition consideration</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="0" id="Tc_oPw_c77uLkKvC5nLTmImnA_23_6">1,940,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_HLInkIm8vUuMApFUD2CGhw_24_3">5,254,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_4X1B8o7S7Eak5sM_yl-OGg_24_6">6,705,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:14.5pt;"><td style="background-color:#cceeff;vertical-align:top;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease liabilities, net of current portion</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="Tc_ADkqhs6MAk-FZCFnyVL9QQ_25_3">10,585,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="Tc_zyGWk2cGCUSwePdzl-rV6g_25_6">10,877,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="0" id="Tc_KCgf9bj5gkuvxQniokLBQA_26_3">3,077,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="0" id="Tc_GPetNfiDzUeri4jzPGg_8A_26_6">3,077,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total liabilities</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="Tc_0V48V47rMk-R7RgalIj0-A_27_3">18,916,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="Tc_pAOOaHfjqEW5Mcz_BCdHZw_27_6">20,659,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217; equity</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q" contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_gfmfgsijCEiwWh8gOgPBPg"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q" contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_oDf9jPBS3U6XZ-j53xOllg">0.01</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_Y4e4xlG130CIveNLlHSvvg"><ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_yW3WyEpW1UOMFrb1OOjfSw">217,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_Qg6efRqDaU6YDFSPm5O6wQ">24,965,086</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_qEQ5ZHMaCkm6l-gNBjGmig">18,688,461</ix:nonFraction> shares <span style="-sec-ix-hidden:Hidden_vHdyLOLd_0OZchY-bVdk5A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_Vjudgl28B0mPQxo1Uew1Pg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">outstanding</span></span> at September 30, 2021 and December 31, 2020, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_OubsBbzGk0i7jStfzqnJ7Q_30_3">249,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_QNIgXz_jeEeSA8DDDWBdLg_30_6">187,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:12.25pt;"><td style="background-color:#cceeff;vertical-align:top;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Additional paid-in capital</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc_n1OYREqeOU6CxsoToVDYug_31_3">220,316,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc_gUD8uwaKYUarIkTNXxP53A_31_6">198,372,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:9.1pt;"><td style="vertical-align:top;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_kEJ6bG0b6Ue8QMkIn7MAxw_32_3">196,810,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_kklq83LXsEGyYgehorBhog_32_6">179,702,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total stockholders&#8217; equity</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_QfAAo30UEUyF7v6fvbo8YQ_33_3">23,755,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_3XAbvrcgV0eUQni9qcxN8Q_33_6">18,857,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total liabilities and stockholders&#8217; equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_MScit_fnlkWOsKIZkmZN_w_34_3">42,671,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_K5BO2fnjlE6icw6aCKgX0Q_34_6">39,516,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_e4f56009_af98_452e_8238_c8cab03ebe0b"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt;">See accompanying notes to condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_5bc5d59b_9901_40b9_b298_3b43afe32811"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">Armata Pharmaceuticals, Inc.</p><a id="ConsolidatedStatementsofOperations_41511"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">Condensed Consolidated Statements of Operations </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_9efdfcb6_5383_4b9c_8f59_7d09e92a1361"></a><a id="Tc_wQGXwsWB1Ey6grCKAjFONw_1_2"></a><a id="Tc_gnkNsZ1V9UyvWbGhsdCV1A_1_8"></a><a id="Tc_DSTyCTH8fEmqggd8TPmWNQ_2_2"></a><a id="Tc_Mj0sFr_TBEq4CIJItqqYdw_2_8"></a><a id="Tc_tXRHTCEyWEio7C02ww848Q_3_2"></a><a id="Tc_G33rg9btIEuCWFH7WO7lNw_3_5"></a><a id="Tc_kQVkNI-cS0aKNO8HKyexGw_3_8"></a><a id="Tc_gSVPY7uPe0WV6KuIES9b-w_3_11"></a><a id="Tc_pJYQAFihiEOdUaqJrHcUaw_4_3"></a><a id="Tc_AdD8vwifDE2pagTZnNM5dw_4_6"></a><a id="Tc_iJEDlQA150mjdL21bMxnHQ_4_9"></a><a id="Tc_6K32AIuH0k-yNxHhYAnZzw_4_12"></a><a id="Tc_5YDNPNZt7ES2b1NtMP32IQ_5_0"></a><a id="Tc_uzeNfZF3HEuLc6lyahL2Ww_5_2"></a><a id="Tc_WE5hy6ZVGkWowONnKNJBoA_5_5"></a><a id="Tc_mg7rn9_o_EWgkux19frTuQ_5_8"></a><a id="Tc_EhnSRLWgG0GInEdjdOscFA_5_11"></a><a id="Tc_34n0v-00502Dnq2R5Ja4vg_6_0"></a><a id="Tc_y12gghzk70ejvRgBASfvPQ_7_0"></a><a id="Tc_1pn7bdOi90eNP10GVpTkag_8_0"></a><a id="Tc_JuEPAFEKck6NqVm8eCnLVQ_9_0"></a><a id="Tc_urkpHZapd0uSTpG1SXuh5w_10_0"></a><a id="Tc_iYp-QEpFD0a-1UrHIbbwlA_11_0"></a><a id="Tc_WKUir1Ej50q9w_XikfG4NA_12_0"></a><a id="Tc_NrPeACe3fkm9uAl76fZJzw_12_6"></a><a id="Tc_c8dCNJJucE-EHzOynDwnVw_12_12"></a><a id="Tc_ORRzTbjDwEagyoC2iBl28Q_13_0"></a><a id="Tc_SgL3kZ7avUOIzm3qalap0Q_13_3"></a><a id="Tc_fXEnEkB5H0-euEO_6-gDOA_14_0"></a><a id="Tc_UCCFGxi9oECzNnhboRtpwQ_15_0"></a><a id="Tc_VP3nF2yqpEixGtGvOcYstQ_16_0"></a><a id="Tc_6sID3Y0abUG-nfBMY5rIEQ_16_2"></a><a id="Tc_ccjA2bi0Kk6DvPAr8llSuA_16_5"></a><a id="Tc_x4KNUFvOCk2jA3mJzfVNDQ_16_8"></a><a id="Tc_n5scCxyJ_EGmZD-vLwjveg_16_11"></a><a id="Tc_FOVd05w690KgO5Qu_ibvMw_17_0"></a><a id="Tc_l4Ip7m3ctUSRL5Fm5T1_tw_18_0"></a><a id="Tc_SnH44_Sb30CJeLEIJmVllw_18_2"></a><a id="Tc_yLQhcxFGWkyKtRGkBlZfcA_18_5"></a><a id="Tc_-Cb4LYauK0KrpmbCLMMXGw_18_8"></a><a id="Tc_l9ZjmbCSH0Kbn2WTVIhH_g_18_11"></a><a id="Tc_5yyBg4HQu0GU94vkxwhzDg_19_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited) </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited) </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited) </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited) </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:44.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Grant revenue</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_7_1_2021_To_9_30_2021_EHL267Iy5kqlAVaXmlK6uQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="0" id="Tc_5FyTwbiTXE-XypM_1l0-QA_5_3">1,251,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_7_1_2020_To_9_30_2020_C3Blutz6cUqC03qQKsaYEg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="0" id="Tc_2ZVp4zXitEGF_WZVTe2WQQ_5_6">288,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="0" id="Tc_yqiA46pVsUqvfsTBAnDHhA_5_9">3,485,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="0" id="Tc_djL8fTkkHk27VCj8GBrMQA_5_12">319,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:44.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_7_1_2021_To_9_30_2021_EHL267Iy5kqlAVaXmlK6uQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="0" id="Tc_3GlCR5FA5USHF4QpG88VOg_7_3">5,626,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_7_1_2020_To_9_30_2020_C3Blutz6cUqC03qQKsaYEg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="0" id="Tc_X25tR670lkiZoAi5LTkLxA_7_6">4,066,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="0" id="Tc_BtCWGb_2Xkm5BKhT_s0I7g_7_9">15,201,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="0" id="Tc_WAyXdPiPAkWnrErwxTK6og_7_12">9,464,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_7_1_2021_To_9_30_2021_EHL267Iy5kqlAVaXmlK6uQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_dyXBTULynU6ilw---DhOVw_8_3">1,768,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_7_1_2020_To_9_30_2020_C3Blutz6cUqC03qQKsaYEg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_7_e01iKkmUmyE2XUfG6neA_8_6">1,845,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc__tp4fBp-C0yFsf-eKmxPGw_8_9">6,058,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_4IYCC7G0cEWNmTmkIHkI7w_8_12">5,989,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:44.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total operating expenses </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_7_1_2021_To_9_30_2021_EHL267Iy5kqlAVaXmlK6uQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_CvCoL8VxikeercbrQ7vgsA_9_3">7,394,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_7_1_2020_To_9_30_2020_C3Blutz6cUqC03qQKsaYEg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_HcTH1m4KBEymgVtoB2PHzw_9_6">5,911,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_y_XoxQt0v0O9G1xMHSOXuA_9_9">21,259,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_6Wl0XzLtD0STtn8UPD1-yg_9_12">15,453,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Loss from operations</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_7_1_2021_To_9_30_2021_EHL267Iy5kqlAVaXmlK6uQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_JPGIro_YA02xIJkg_kulKg_10_3">6,143,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_7_1_2020_To_9_30_2020_C3Blutz6cUqC03qQKsaYEg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_gX-DBaOtS0qphJumAHPE6w_10_6">5,623,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_UE4qH_rJSkS2x5HLZH1Cjw_10_9">17,774,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_ZVC1faV36kKfuTXmnvIxsA_10_12">15,134,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:44.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other income (expense)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Gain upon extinguishment of Paycheck Protection Program loan </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_7_1_2021_To_9_30_2021_EHL267Iy5kqlAVaXmlK6uQ" decimals="0" format="ixt:numdotdecimal" name="armp:GainLossOnExtinguishmentOfPaycheckProtectionProgramSinceInception" scale="0" id="Tc_kGpA4O154USmQCsPW0ighw_12_3">726,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" decimals="0" format="ixt:numdotdecimal" name="armp:GainLossOnExtinguishmentOfPaycheckProtectionProgramSinceInception" scale="0" id="Tc_TdzSA8b5ekW1wlUjj-rS0Q_12_9">726,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:44.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest income</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_7_1_2020_To_9_30_2020_C3Blutz6cUqC03qQKsaYEg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="Tc_dj9Bu4znLkS2kctqmi7EbQ_13_6">4,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="Tc_VnNnrQ51uEqXHNVMueODLw_13_9">4,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="Tc_3DmP25y57kSIwNK6EZF2MQ_13_12">28,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_7_1_2021_To_9_30_2021_EHL267Iy5kqlAVaXmlK6uQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="Tc_pKnFYrvLREiJIZhUf7u-HA_14_3">2,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_7_1_2020_To_9_30_2020_C3Blutz6cUqC03qQKsaYEg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="Tc_X9kfTgo03E-NGx7epS5mcg_14_6">150,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="Tc_NFkQ0Pw0ykOzp4Qc2btvWg_14_9">64,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="Tc_B7BDqL_qqU654Hh4tO1mfg_14_12">451,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:44.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total other income (expense), net</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_7_1_2021_To_9_30_2021_EHL267Iy5kqlAVaXmlK6uQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" id="Tc_YClvqI9wwE-GFSgehq94pQ_15_3">724,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_7_1_2020_To_9_30_2020_C3Blutz6cUqC03qQKsaYEg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" sign="-" scale="0" id="Tc_jmR-LQPXvUGOu923j6YDPg_15_6">146,000</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" id="Tc_ha4YRkdMDk6nYf-BaINciQ_15_9">666,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" sign="-" scale="0" id="Tc_YfgVcMTDOEKFco1_qbh-EA_15_12">423,000</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net loss </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_7_1_2021_To_9_30_2021_EHL267Iy5kqlAVaXmlK6uQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_ZvYt0zw_aU637yuSUUGmSA_16_3">5,419,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_7_1_2020_To_9_30_2020_C3Blutz6cUqC03qQKsaYEg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_trrJn8Bi2U-uMgc_DPwMmA_16_6">5,769,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_d74AcKuKfkytzyWn6uJ9sA_16_9">17,108,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_ROpiPocBKk2TQR-wfj9E7g_16_12">15,557,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:44.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Per share information:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share, basic and diluted </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q" contextRef="Duration_7_1_2021_To_9_30_2021_EHL267Iy5kqlAVaXmlK6uQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_gYkGpe2CdECqfATWHWQhWw_18_3">0.22</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q" contextRef="Duration_7_1_2020_To_9_30_2020_C3Blutz6cUqC03qQKsaYEg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_9wYVMzp7ykm3DUIw0vt5dw_18_6">0.31</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_INV1cnH3a0e74oF8RjiKuw_18_9">0.73</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q" contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_caQwNYC9n0aKGX3cjfcGGg_18_12">0.99</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:44.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares outstanding, basic and diluted</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="Duration_7_1_2021_To_9_30_2021_EHL267Iy5kqlAVaXmlK6uQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_V3GZVNgWMU-zjkJzsQ5c-A_19_3">24,820,233</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="Duration_7_1_2020_To_9_30_2020_C3Blutz6cUqC03qQKsaYEg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_ggMm9I-mSEiyvASIj1n_-w_19_6">18,394,614</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_3xwWFtPDsUCSwePZzPg7jQ_19_9">23,363,113</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_VNtbNLpgi0aXtd-YqsTgWw_19_12">15,740,858</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">See accompanying notes to condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"> <span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_8a74daed_23f8_432f_b863_698527a87982"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">Armata Pharmaceuticals, Inc.</p><a id="ConsolidatedStatementsofStockholdersEqui"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">Condensed Consolidated Statements of Stockholders&#8217; Equity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Three Months Ended September 30, 2021 and 2020</b></p><a id="_6bf2afe5_eb98_40e6_9f7a_0ffd0dbe5188"></a><a id="Tc_97VnVD0ctESzr5Fm5-tHhA_1_2"></a><a id="Tc_mMJdIXrDsk6NywVqna8DIQ_2_2"></a><a id="Tc_1xEaHDJVBkuBsS7l9ttOHQ_3_7"></a><a id="Tc_YQgYQRlzZkSA64UGChrB3A_3_13"></a><a id="Tc_lWHHIwttTkms01CkT1KRRA_4_7"></a><a id="Tc_xB3iDZDL1UeGWPjgA2IJTg_4_10"></a><a id="Tc_LlDjENVPjUOuyybHyRhSrg_4_13"></a><a id="Tc_gHBqVTqHeEqBXLqd_SGkPA_5_2"></a><a id="Tc_8T97UexDyE25TSPG1J2R7w_5_4"></a><a id="Tc_6AM9AAZkZkSThpaUD74IUA_5_7"></a><a id="Tc_hPFON_ZKQkesFTpK3G8d4A_5_10"></a><a id="Tc_IV3JcoS13UWvdWer0DjBWQ_5_13"></a><a id="Tc_PPsqVXiOdUCgOeNKkgmY5A_6_0"></a><a id="Tc_m-RE3tf_WkWtask_p1XetQ_6_4"></a><a id="Tc_LRkZiIUjd0Wxic-KxD0-sw_6_7"></a><a id="Tc_gz52nc-JrUu_Q_bgRM_-LA_6_10"></a><a id="Tc_tP_R0S9BGUmBiCQ0DNJyjQ_6_13"></a><a id="Tc_q-ypvGRf20Gnl1LFn6t93g_7_0"></a><a id="Tc_OKxeFK-7okesVObOV5FHHA_7_11"></a><a id="Tc_Aje32OGfWEuHUwtmtbaGTA_8_0"></a><a id="Tc_fb_Ftni8BkGNzM12008Xgw_8_2"></a><a id="Tc_gEp_W_kX0U--wVI98_LG8A_8_5"></a><a id="Tc_HQxFsJ9MG06zQ23q_F6F_Q_8_11"></a><a id="Tc_bqN7f5mjwkKdtB-pyiQd1w_9_0"></a><a id="Tc_rliV3TRYrESOzOKr34t20Q_9_2"></a><a id="Tc_xS7vAaZwQ0mtxqhn6YmoGw_9_5"></a><a id="Tc_hBHEac_FJ0uwtR4XlDdHsQ_9_8"></a><a id="Tc_XmqWn-acdkuFCKR3yImDwA_10_0"></a><a id="Tc_3zhwhnA8tEC5Z7dixnsHlg_10_4"></a><a id="Tc_e6zBKMT8jkCK5W96rk_iSg_10_7"></a><a id="Tc_ayA-_b6anE-17nwwdwTM0g_10_10"></a><a id="Tc_yl3PAgvFREW4SujVxqfstQ_10_13"></a><a id="Tc_eD59zNrlT0mlIhLIHYyDmQ_12_0"></a><a id="Tc_ea5FwhKAWUeQZpyXXLWTyQ_12_4"></a><a id="Tc_MDRrEXAsn0S-UonOZVwg9A_12_7"></a><a id="Tc_h037-HKcz0ie1AK9k8vwkQ_12_10"></a><a id="Tc_8UDVo3Iwh0OWtsS3tXVlrQ_12_13"></a><a id="Tc_YL7vQaihy0iEBqb1oBTLZQ_13_0"></a><a id="Tc_ch6-3eV5AUW_l3tGOhHpWg_13_2"></a><a id="Tc_XKJIQel3aEGBuU6wn8ZWhw_13_5"></a><a id="Tc_TWeR2XXjpU-XM7p3JFLdTA_13_8"></a><a id="Tc_Xs92Smurv0-LkHlKnxjx5w_13_11"></a><a id="Tc_JDbDNpKVdkuG8GTh7ln2Hg_13_14"></a><a id="Tc_HTehbMu3j0S24OaiBDU8WQ_14_0"></a><a id="Tc_4QKGUuHsFUW10TDp56sbIA_14_5"></a><a id="Tc_iHuw5H_Zwk-K8GJueS-O9w_14_11"></a><a id="Tc_0rTXKSUnHESjNreMotJpHw_15_0"></a><a id="Tc_QjO_5DtKHEmRWSTOWix-zA_15_5"></a><a id="Tc_xc9TuRJMzESGtuRCGa8zDA_15_8"></a><a id="Tc_ftb9ccDLNUG4iUt0RzUHsg_15_11"></a><a id="Tc_uzksFYd1q0aP6O6xIlVMGw_15_14"></a><a id="Tc_DnW7squrqk6DVzDWRGT6Bg_16_0"></a><a id="Tc_m4kwRGRoZ0afDADB9RtDbA_16_2"></a><a id="Tc_LQP9N8kgq0ucJAF0jf_4Jw_16_5"></a><a id="Tc_wRXBmdM_hE6GcqFxUeA2Kg_16_11"></a><a id="Tc_SeAfaJQMdUiWPR6uumZI7Q_17_0"></a><a id="Tc_0E_KlxaY2E-GhTQsmTBSTA_17_2"></a><a id="Tc_KlUhYdyjQ02gVFFsvBxONQ_17_5"></a><a id="Tc_JOwZVUb-VE2wkBYva9UNoA_17_8"></a><a id="Tc_rCAqap6dAUOBaM1O-T9o8w_18_0"></a><a id="Tc_oPfCavLBXEiwJTqY-Hw3Sw_18_4"></a><a id="Tc_C5uXxlEV00eYoCqSshV7XA_18_7"></a><a id="Tc_t13hdtNFP0SvMMWxKI0Mig_18_10"></a><a id="Tc_FpTBIih5RkGG3wCEyVqFTQ_18_13"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:35.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:35.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:62.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stockholders&#8217;&#160;Equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:20.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Paid-in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Equity</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:35.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balances, June&#160;30,&#160;2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_aIHcMH7w-kKjUPzazac1VQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_Wua95J5RZkG0bsqGsI4-4A_6_2">18,641,501</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_aIHcMH7w-kKjUPzazac1VQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_s4JOqc2uLEOUCaM8Cfzokw_6_5">186,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_SxvMMY1Sa0GTX13IRJGJ4A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_3xlYJ29N2UuUwDtnNnZnfA_6_8">196,761,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ZmXsDKp77EKqicmltHHhGA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_k-qxqXN-JUah7bYXcX-SAw_6_11">167,309,000</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_6_30_2020_Lk4NTSOZBE25mumJD7-ddw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_ZEiFTOvUiUC5hqKEZWgicw_6_14">29,638,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:35.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of employee stock options </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MYGe64DLVEKoqqG1PLm-1A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_8LIc-ouy50m1MqCOuTRgHw_7_2">27,382</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MYGe64DLVEKoqqG1PLm-1A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_VXt6mnCPskKwZagWPkB80g_7_5">1,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_0veJ9SwbfEiLVcv9uwtSJA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_DguxZdudk0mruqOIHqIqsQ_7_8">86,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_7_1_2020_To_9_30_2020_C3Blutz6cUqC03qQKsaYEg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_b_OFFoHDBEKsXuRUXgzf_w_7_14">87,000</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:35.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock-based compensation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_0veJ9SwbfEiLVcv9uwtSJA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_ylQYsNpbQEuQi35mZICf8A_8_8">663,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_7_1_2020_To_9_30_2020_C3Blutz6cUqC03qQKsaYEg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_-wVB6FXm30aqD4v7VNX6nw_8_14">663,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:35.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_bgCDlfNMOkqVq2IlJzSALA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_53OuP03NXUeiYSwewmmnmQ_9_11">5,769,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_7_1_2020_To_9_30_2020_C3Blutz6cUqC03qQKsaYEg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_2ViYsztPHUS7lOQThVOSgg_9_14">5,769,000</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:35.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balances, September&#160;30,&#160;2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_65fdseHmlkygQFXjdAowrA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_Sbi3IWlWNEuaaEOPJ-yg8A_10_2">18,668,883</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_65fdseHmlkygQFXjdAowrA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc__6vgmdZmwkedG_cW2bYpNA_10_5">187,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_NKaGlnEUNkec6voi3tIaYQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_q8mX919bB0isLWF8bTYSHQ_10_8">197,510,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MTZvL_NcmESOrJIA_0-1jw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_CcT9GIjstkKpltXQU06m_g_10_11">173,078,000</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2020_zW8zVq9yIEyTGkUsiRdNWQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_Ph83D4IwNUuAWvxshxPJmg_10_14">24,619,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:35.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:35.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balances, June 30,&#160;2021</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_W4e7PNLj70SPGz46YLofww" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_UHl3Eyrm1U26c3xQjHRZ1A_12_2">24,937,826</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_W4e7PNLj70SPGz46YLofww" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_alDa_vF3R0uciUbRjxs0YQ_12_5">249,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rkFIJlcvhkG9sE5lG-I4MQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_ljzrcHgk-Eav6FzboDgcQA_12_8">219,761,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_SPUy-mdqVEWQXJUyR4SwLw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_WZPJkOk0OE-7dM03F4AQ8Q_12_11">191,391,000</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_6_30_2021_5jY2Kblz0kWsExJk25jZVg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_PGzQZMf2QUSwMfsi99wTLQ_12_14">28,619,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:35.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sale of common stock, net of issuance costs </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:35.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercises of stock options </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DVIyohuaMEqe9vySm_9bHg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_znOXyFyP70OXT9pAy8NSUA_14_2">27,383</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9Eff9cku9kikyLYc9MKX0Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_wKykETz0aUyPVuSBsr4FkQ_14_8">86,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_7_1_2021_To_9_30_2021_EHL267Iy5kqlAVaXmlK6uQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_eTX8mr7wT0utD6ZrTuVU-Q_14_14">86,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:35.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeiture of restricted stock awards </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DVIyohuaMEqe9vySm_9bHg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" scale="0" id="Tc_xBohw7PlpE6pSOK7fbKdFw_15_2">123</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:35.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock-based compensation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9Eff9cku9kikyLYc9MKX0Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_yFi0pQ-5h0yjHBMHVRbWBg_16_8">469,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_7_1_2021_To_9_30_2021_EHL267Iy5kqlAVaXmlK6uQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_HsePT7Fzl0Km1djc9XHhVw_16_14">469,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:35.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MAx1Qhihl0-QjfrmaUOYJA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_kN4oBrUwmEuSfjG5jxyuyA_17_11">5,419,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_7_1_2021_To_9_30_2021_EHL267Iy5kqlAVaXmlK6uQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_Jf_QumuD10WjqENgVOqNGw_17_14">5,419,000</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:35.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balances, September&#160;30,&#160;2021</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zJn5M0sFjE-rqqEDYPJ3Uw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_uhMRwiCNFESEJDC9B82f1A_18_2">24,965,086</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zJn5M0sFjE-rqqEDYPJ3Uw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_hCFnQFFm-UaTbJTcgrJDRw_18_5">249,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CnAXtkAfOkyr84AqUZmq-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_Nfa43BDOVESIN93J1oqMjA_18_8">220,316,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BCCyhEU1tEi9VSOL9PeeDA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_sJQeahzMWU2HmaDVEWGgUA_18_11">196,810,000</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_ZQ9ktrsS30i6JBMyAC4Vog_18_14">23,755,000</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt;">See accompanying notes to condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">Armata Pharmaceuticals, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">Condensed Consolidated Statements of Stockholders&#8217; Equity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Nine months ended September 30, 2021 and 2020</b></p><a id="_64833497_97f7_4c82_80cb_8a8b248fb5b8"></a><a id="Tc_gxqLS3dBFkCEUiUXBAya0A_1_2"></a><a id="Tc_oEmBxG5N5UmdP7H-Z1dcRg_2_2"></a><a id="Tc_epo80vRHXkutFCBwDxWo_Q_3_7"></a><a id="Tc_ziGOCzRFY0iJ1IrGKt3Fow_3_13"></a><a id="Tc_crrEakEDSES6FYXfUq-DMQ_4_7"></a><a id="Tc_6lexm9dg1Uaqot_DH-PmTw_4_10"></a><a id="Tc_HvaIMaNwtEGpPJfAc5ONSA_4_13"></a><a id="Tc_32wJFvy1sU-66MVcDnthaw_5_2"></a><a id="Tc_ncv5Lm-89kK_6ythb8pcDA_5_4"></a><a id="Tc_jcNVZv1YhkOlEZittZVv3A_5_7"></a><a id="Tc_-qx51u90xkeQfX_3nbWcyw_5_10"></a><a id="Tc_U7aT_4b7Bk6z_my-jInNdw_5_13"></a><a id="Tc_SdA4aKFBTUGV8LDHY_fErA_6_0"></a><a id="Tc_yLiBkplEpkqaWEed0dO1Zw_6_4"></a><a id="Tc_ZF4jTgyL2ECtu9QFyddYig_6_7"></a><a id="Tc_mPEj1lPl50eKYkS-fLGtDA_6_10"></a><a id="Tc_J43d5eyiP0yernVQUALjVQ_6_13"></a><a id="Tc_eWnvc_1ZhUWJzK2R-kuk8Q_7_0"></a><a id="Tc_NIo3bxcpVUSduc4e-2CwJA_7_11"></a><a id="Tc_cGQpQq1ZRkWE1rGwjhMMDg_8_0"></a><a id="Tc_NZqtCVIYg0Sd54dHrgoFhA_8_5"></a><a id="Tc_DZmWvY66eU6eOiGewuQVMw_8_11"></a><a id="Tc_oDXjFb07906NiBOVPbvpwg_9_0"></a><a id="Tc_jE-B4AMTgEOREpaos49X9Q_9_5"></a><a id="Tc_F5rkt3v2_kC-0-c6gJzTrQ_9_11"></a><a id="Tc_GYcJNJ7t20C_yekdoV1sLQ_10_0"></a><a id="Tc_01NPiNtRQUGH3-aNcpa5AQ_10_5"></a><a id="Tc_PAzVKPz8m0KJjnbxcLuBOA_10_8"></a><a id="Tc_tM99JtcBE0mxdy79oM0ctw_10_11"></a><a id="Tc_WufzzblcREeUre0io1VK5A_10_14"></a><a id="Tc_ZTOesqwvS0KF-XE-i2Rmmg_11_0"></a><a id="Tc_qx6HB1QgyUO1fFHytI09bg_11_11"></a><a id="Tc_lrF--KIXxUqlshbdfWqbBQ_12_0"></a><a id="Tc_YIklHXsnSkKJfAMnJAZsxg_12_2"></a><a id="Tc_hRs3d4pY10eDAjh8PgxxIg_12_5"></a><a id="Tc_3879W7Ipy0OLv5fRCtuFsA_12_11"></a><a id="Tc_J3aZPYcuYUGVCRUGuNhSOw_13_0"></a><a id="Tc_SahLpecNqUKI8ex_ar1c3Q_13_2"></a><a id="Tc_4th3kUKdTk2z0784_mnwuA_13_5"></a><a id="Tc_KnVdL1Ca5E2adS48FEUnjw_13_8"></a><a id="Tc_QWj-rypRikieP8f0wO_3CQ_14_0"></a><a id="Tc_8fhJEDWDSEuvoHj_cX-kUg_14_4"></a><a id="Tc_D9Nje5kvKEik9pZK3B2IYQ_14_7"></a><a id="Tc_9fQQQovnrk6VJ2vrX-P7Xg_14_10"></a><a id="Tc_Ytpw5DmVXUKqqIH_9p9f_g_14_13"></a><a id="Tc_4geennI01Eaj8Qh7AmQ1Vg_16_0"></a><a id="Tc_Ynw9tDVWvE6sxzDeqwJkyg_16_4"></a><a id="Tc_poesBV6Hpkm8W1_HFYb9HQ_16_7"></a><a id="Tc_I3F_SlcF8UiS_t6mCGPY2Q_16_10"></a><a id="Tc_62x_s4STpUGnZoQ3Sh7Usg_16_13"></a><a id="Tc_JtNaXKFjkkGEEpO4-j9Z4Q_17_0"></a><a id="Tc_itpi1-5bVUuBc69A72aadg_17_11"></a><a id="Tc_ne6e5OdQFUOf3Ka4tWTm8w_18_0"></a><a id="Tc_rU2M2GdUoUm3Np5VbFGU3A_18_11"></a><a id="Tc_wWgCbOPMXUa_QIFdSt7_CQ_19_0"></a><a id="Tc_-i6rjcEmNEa-BIhtj8FmFA_19_5"></a><a id="Tc_BsRztKZMo0q5tdTJxl35bQ_19_11"></a><a id="Tc_20UOd-MCjE6cgrYs3HSspA_20_0"></a><a id="Tc_hckc3PWGMkquhwg_VphpYA_20_5"></a><a id="Tc_65kUXmQEdUqNJUnSJEj3QQ_20_8"></a><a id="Tc_nJgRjwJwh0-K9gjfmSUh2A_20_11"></a><a id="Tc_ULbi1uDLoUm6_xR6a1Ynhw_20_14"></a><a id="Tc_th0bZpOv5EeB2-gi7v7yGg_21_0"></a><a id="Tc_6kAiv29ba0ySZTLeJzQNoA_21_5"></a><a id="Tc_OlsA7t3zIE27q2PtQF2nNA_21_11"></a><a id="Tc_WNNWLTDuQ0-s5h7_Rc_V4g_22_0"></a><a id="Tc_mtqToY2etEiKQqSfkzOl4w_22_5"></a><a id="Tc_pZDGUFP4JEOh8e-CClNILw_22_8"></a><a id="Tc_9HMJRDUxBEOv6VBiUQFetg_22_11"></a><a id="Tc_yRdx5KTCTESpZDkaqcew1g_22_14"></a><a id="Tc_BMwNkOfwAU-FpL6CMIbilQ_23_0"></a><a id="Tc_zKtyWUJENE-ccyA97gqQnw_23_2"></a><a id="Tc_RG_P8bXbLke_Y_p8_S1PbQ_23_5"></a><a id="Tc_ZuBpkFyTJEK1HIo0CYy49A_23_11"></a><a id="Tc_o7tzL8fqDEe8Jy890OPUOw_24_0"></a><a id="Tc_vAhvQNCXOU2XUesbXpX7_A_24_2"></a><a id="Tc_JrhgkAmJNEqkXzvjfkO_0A_24_5"></a><a id="Tc_ntL1v77mRkiBKGg8lD3RUA_24_8"></a><a id="Tc_TM5XR7-Tu0eWle9-4Zrz5w_25_0"></a><a id="Tc_VhcYLzJx2k2_zGIDFGsXzA_25_4"></a><a id="Tc_Tx_MpKalr02DVGWGdZhBYQ_25_7"></a><a id="Tc_-Ab9S8lreEu2d6HV2Lrjsg_25_10"></a><a id="Tc_9vJkvHjDXUSfzoic54VKdA_25_13"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:34.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:34.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:64.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stockholders&#8217;&#160;Equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:21.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Paid-in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Equity</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:34.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balances, December&#160;31,&#160;2019</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SL0WNDAfdkevFGn-ljnxpQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_ANwrvgZwg0a7gLBTg-081Q_6_2">9,922,758</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SL0WNDAfdkevFGn-ljnxpQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_rROVDWyzWEWYJ-BkxmjCGw_6_5">99,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KEkptw3IX0mcgqD8P-u1tQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_Jx5Q_j4we0y5JSbuhgdjDA_6_8">172,015,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_I_LPYFq-_Eu5aKaleEMQgQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_ilhzSMOfTUmEMd_Gyi1Sww_6_11">157,521,000</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_12_31_2019_9M2XeqAfdE-lB78H_jYHfQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_ByBs0_1wjk2v3DDsR7HtTw_6_14">14,593,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:34.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sale of common stock, net of issuance costs </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HzaMhmdSwEmOsLQZS5Pg1w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_ueqA1itMB0ajezdEKGKFxg_7_2">8,710,800</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HzaMhmdSwEmOsLQZS5Pg1w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_zohw2wVwWUu0H4Ql6oWD6Q_7_5">87,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VoZ8oQm5tUCLM6PYYrJGCA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_0YJ0fYLwA0m8ASMNj__hSQ_7_8">22,723,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_SqIncy23102yKoKZoFGa1Q_7_14">22,810,000</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:34.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of warrants </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HzaMhmdSwEmOsLQZS5Pg1w" decimals="INF" format="ixt:numdotdecimal" name="armp:StockIssuedDuringPeriodSharesExerciseOfWarrants" scale="0" id="Tc_B06J15zOXkiupc5MVivrIA_8_2">14,464</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VoZ8oQm5tUCLM6PYYrJGCA" decimals="0" format="ixt:numdotdecimal" name="armp:StockIssuedDuringPeriodValueExerciseOfWarrants" scale="0" id="Tc_MlLDxwH0uUyAEWZ7gyT5tg_8_8">81,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw" decimals="0" format="ixt:numdotdecimal" name="armp:StockIssuedDuringPeriodValueExerciseOfWarrants" scale="0" id="Tc_mSgrTtHNMkyhv6k9ttIdrQ_8_14">81,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:34.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Return of restricted stock awards for tax withholdings </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HzaMhmdSwEmOsLQZS5Pg1w" decimals="INF" format="ixt:numdotdecimal" name="armp:RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings" scale="0" id="Tc_GATy5arK9U20qDergpOp0A_9_2">2,511</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VoZ8oQm5tUCLM6PYYrJGCA" decimals="0" format="ixt:numdotdecimal" name="armp:RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings" scale="0" id="Tc_4lErt86iF0GPhjp7xmIm6Q_9_8">8,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw" decimals="0" format="ixt:numdotdecimal" name="armp:RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings" scale="0" id="Tc_Kqb1uIMHuUiWW2PRLW2-cA_9_14">8,000</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:34.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeiture of restricted stock awards</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HzaMhmdSwEmOsLQZS5Pg1w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" scale="0" id="Tc_KlW3-0QSDUe5XMOoRbU1Rg_10_2">4,010</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:34.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of employee stock options </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HzaMhmdSwEmOsLQZS5Pg1w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_xvwBzfxOIE6Wt5TalVM6Rg_11_2">27,382</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HzaMhmdSwEmOsLQZS5Pg1w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_zi3KC1LIiE63bY2xLnz9pw_11_5">1,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VoZ8oQm5tUCLM6PYYrJGCA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_M7Zbmk9V3EePezIgB7_XmQ_11_8">86,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_mbKz5xZ5Sk-oH64wS0kybw_11_14">87,000</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:34.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock-based compensation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VoZ8oQm5tUCLM6PYYrJGCA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_At0D1D17CUWpEGbayIqIZg_12_8">2,613,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_3S9ftvw7E02g4r_NLnrCjw_12_14">2,613,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:34.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_UxaVXkDGlUCs8nQaDlXZoQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_55e6e30OWEmfs0xyXb3HxQ_13_11">15,557,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_gvCOF8lz3E2logY4z9AzwQ_13_14">15,557,000</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:34.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balances, September&#160;30,&#160;2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_65fdseHmlkygQFXjdAowrA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_B2tzdLHMGkC0i8A3vjxmbA_14_2">18,668,883</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_65fdseHmlkygQFXjdAowrA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_nG6k6BwvHEyQ5ImX_Pa3-Q_14_5">187,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_NKaGlnEUNkec6voi3tIaYQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_Pr6dJ2ylpk6FRyWzrP1-Kw_14_8">197,510,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MTZvL_NcmESOrJIA_0-1jw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_k6YyXbp5h0yCSQsT7Go2vA_14_11">173,078,000</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2020_zW8zVq9yIEyTGkUsiRdNWQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_FFc6wYKUgU-1-mD5oK6Ifw_14_14">24,619,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:34.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:34.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balances, December&#160;31,&#160;2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_d2NNZnl0VUWMFpJen2dwnw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_R-EoC0dlCkeazyxwpAbtMA_16_2">18,688,461</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_d2NNZnl0VUWMFpJen2dwnw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_lw5LYPtp5kq8ZomeHlGHRw_16_5">187,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_nIezyXT0BUyf5xGYCsZfTA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_Gk9MxZ8lYUuSa8FOwncEFw_16_8">198,372,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_KEunbq8Lv0G2CGYZpXLKlA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_EVBslbVzZ0KXPjjTvsW7Fw_16_11">179,702,000</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_zHEIE6XIT0mcHMmQs031zA_16_14">18,857,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:34.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sale of common stock, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Rmv1hE9bF0aKaK_8FzTl-Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_02WWOs0pAk2vdTEG48EZWA_17_2">6,153,847</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Rmv1hE9bF0aKaK_8FzTl-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_n1NT_hiPG0a_WTiEOv8eIg_17_5">61,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VJKQAeK86kCfqs_DrKEH6g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc__cj5P3iKKEevnwS3DfY3GA_17_8">19,302,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_JZPBQCR8IEG0aMmxJoofmQ_17_14">19,363,000</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:34.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercises of warrants </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Rmv1hE9bF0aKaK_8FzTl-Q" decimals="INF" format="ixt:numdotdecimal" name="armp:StockIssuedDuringPeriodSharesExerciseOfWarrants" scale="0" id="Tc_evZ10KAAmEqUhHN5Q8uSGg_18_2">52,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Rmv1hE9bF0aKaK_8FzTl-Q" decimals="0" format="ixt:numdotdecimal" name="armp:StockIssuedDuringPeriodValueExerciseOfWarrants" scale="0" id="Tc_0O3v-VNjjkyISE5RtMF90Q_18_5">1,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VJKQAeK86kCfqs_DrKEH6g" decimals="0" format="ixt:numdotdecimal" name="armp:StockIssuedDuringPeriodValueExerciseOfWarrants" scale="0" id="Tc_szaPBAYnCkuIkmELcBDOuA_18_8">290,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" decimals="0" format="ixt:numdotdecimal" name="armp:StockIssuedDuringPeriodValueExerciseOfWarrants" scale="0" id="Tc_xJfZu34hGUWUv6rDZ6Eqtg_18_14">291,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:34.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Return of restricted stock awards for tax withholdings </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Rmv1hE9bF0aKaK_8FzTl-Q" decimals="INF" format="ixt:numdotdecimal" name="armp:RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings" scale="0" id="Tc_G0D4inYtRUOQuKza4qLDdw_19_2">25,424</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VJKQAeK86kCfqs_DrKEH6g" decimals="0" format="ixt:numdotdecimal" name="armp:RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings" scale="0" id="Tc_QqtzvBUf3kieXBPFMv_ewg_19_8">106,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" decimals="0" format="ixt:numdotdecimal" name="armp:RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings" scale="0" id="Tc_OkbUFCEASU2tG6aplDYQrg_19_14">106,000</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:34.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeiture of restricted stock awards </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Rmv1hE9bF0aKaK_8FzTl-Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" scale="0" id="Tc_yqaa1IjnT02JKwIMPZJ5ww_20_2">1,047</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:34.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of stock options </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Rmv1hE9bF0aKaK_8FzTl-Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_TLkFf199QEy6g4XeAyXfuQ_21_2">73,517</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VJKQAeK86kCfqs_DrKEH6g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_QgLyOpBzzkqtB2pbK7rEzw_21_8">240,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_614K-_JzoEKD-o3KvBUVRA_21_14">240,000</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:34.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of inducement stock awards</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Rmv1hE9bF0aKaK_8FzTl-Q" decimals="INF" format="ixt:numdotdecimal" name="armp:StockIssuedDuringPeriodSharesInducementStockAwards" scale="0" id="Tc_nmntK40O5UWVwdo47eBKrw_22_2">23,732</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:34.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VJKQAeK86kCfqs_DrKEH6g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_F6RcVMt5zUSX33qeKVJejQ_23_8">2,218,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_en2TNaE2NUWTkIjZJ8ifmA_23_14">2,218,000</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:34.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7TWvDwySBEWUWI9x7ArVBg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_ec4LO8pBcEeTjNu0VpCMjA_24_11">17,108,000</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_RN59CeLl6ki0qwqkJiPIzw_24_14">17,108,000</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:34.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balances, September&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zJn5M0sFjE-rqqEDYPJ3Uw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_gQHweL8yL0CWyCGBxqrw6w_25_2">24,965,086</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zJn5M0sFjE-rqqEDYPJ3Uw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_4394SgzM_06GmM-bD2CDIg_25_5">249,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CnAXtkAfOkyr84AqUZmq-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_mOFySPSW1U-S7mW6uFUVvA_25_8">220,316,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BCCyhEU1tEi9VSOL9PeeDA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_cjSl9qGP9kuJ6pwOhBrvBg_25_11">196,810,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_wYnpevHwV0Kas_eLM6IuuQ_25_14">23,755,000</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_9112b045_2537_48d2_9c2b_c963379868fa"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">Armata Pharmaceuticals, Inc.</p><a id="ConsolidatedStatementsofCashFlows_440434"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">Condensed Consolidated Statements of Cash Flows</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_3701ec09_4ed3_4a96_8cf6_4ab781ab278f"></a><a id="Tc_UJ2Xa61ui0S5uCs2KCy51Q_1_2"></a><a id="Tc_fXu42zAYJkiIbgVgN5TSmA_2_2"></a><a id="Tc_ljRMmHUpakOoh1u6YCcfcg_2_5"></a><a id="Tc_RFZ4gZyPA0e7Wf7YqgZo5A_3_2"></a><a id="Tc_0fqOKHRbKUyTlT-2QXtGLA_3_5"></a><a id="Tc_rPegBNZvcEq-cxKoyYEhQg_4_0"></a><a id="Tc_XLhMuUD47k6vhTHq8-Y5xg_5_0"></a><a id="Tc_ob1ALLC4nUCHVYozMRlaeQ_5_2"></a><a id="Tc_mHbIlRwiyEG36Lw_W9nTNA_5_5"></a><a id="Tc_GSPMJ45vZESJLh9q1-jNtg_6_0"></a><a id="Tc_Y526YaisbkGS8n-NGl_eaQ_7_0"></a><a id="Tc_l78GGrWpEkSs0qEONCFH0A_8_0"></a><a id="Tc_f53BYZrl6kSRR2BDgQI08g_8_6"></a><a id="Tc_g9YShNcUYE2n75xmVXBoSw_9_0"></a><a id="Tc_ck-cWIXX906fifNULBlq7w_10_0"></a><a id="Tc_bFwlIjXOAUSwz0ocv9pNRQ_11_0"></a><a id="Tc_86H74KZVt0qn8jwexd0Tag_11_6"></a><a id="Tc_-VZUcfoxp0yZC7McJa1F9g_12_0"></a><a id="Tc_Vr2ITRJczkGxYQTPFrsFyA_13_0"></a><a id="Tc_tVQPaC2vq0SudrgLv5bgxg_14_0"></a><a id="Tc_d5K2i5zDRUCstOWYnzOwcA_15_0"></a><a id="Tc_9dNjY4FoMkSExR9rnV3lOg_16_0"></a><a id="Tc_LtBp6O7Rx0OQ9QqAOhpCrQ_17_0"></a><a id="Tc_1pEXBAt1F0-Srw8AVTMZrg_18_0"></a><a id="Tc_bQv9Xi8wWkSIa0PaNWj_DA_19_0"></a><a id="Tc_h3HSIQzX60qrsJdsPbphyw_20_0"></a><a id="Tc_GyXuwbQm_0CwsrchcnVi5A_21_0"></a><a id="Tc_Ev77MrPtC0abMtk5RVoblg_22_0"></a><a id="Tc_qP1XJkIO-Ey3_iSAMsDmag_23_0"></a><a id="Tc_12ITYRF7T0eAi3iclPvzPA_24_0"></a><a id="Tc_ew-AS1yjIEOyu4Z5JOBXWQ_24_3"></a><a id="Tc_3XEHvLa7QEqOAGfsS3gvlQ_25_0"></a><a id="Tc_DRDgkZCJ8kq7JThoiyYvaQ_26_0"></a><a id="Tc_CIdmvVqufEWqAZLlfLdK2w_27_0"></a><a id="Tc_v7kKcftRdEe0MzfIBo94Ww_28_0"></a><a id="Tc_aMBYHEVVhE-TE6KWvJMhHQ_29_0"></a><a id="Tc_HtU0JxGOlESeG_qgrl6WBQ_30_0"></a><a id="Tc_64xcK9LEVUKhkP3g44jD7A_30_2"></a><a id="Tc_gzaXoZQ-JEKFLbP5ahLyOw_30_5"></a><a id="Tc_A-ZEPQZSjUSJcWGwzTjDhw_31_0"></a><a id="Tc_4SnxVshQ30CVs6iROmQN9w_32_0"></a><a id="Tc_4quXc7Ug-0mN0nRSPhlvjQ_32_2"></a><a id="Tc_XqMnTi1B5EW17ELVftSepA_32_5"></a><a id="Tc_exrGYx_-vU6KsVqzRNQvrw_32_6"></a><a id="Tc_RaRjE6GBSkObNPY2oQlltQ_33_0"></a><a id="Tc_McUqJ_7PmUOqUOHwxTKDyA_33_2"></a><a id="Tc_O2wKqrTK40SPaVotJ0Mr1g_33_3"></a><a id="Tc_y8DrJTjkI0y-gLwGTvuk6w_33_5"></a><a id="Tc_KlgP2eydG0mSRrJp5FcU0w_34_0"></a><a id="Tc_S01WjnMDr0qC7ZqE-L_g2w_34_2"></a><a id="Tc_xVoOPIKVLEiY2MuVPw4IEg_34_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(unaudited) </b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating activities:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="0" id="Tc_cUvHttQn0UCwQUq9NxLw0A_5_3">17,108,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="0" id="Tc_63CLJCaEuEK8sPOURke5LA_5_6">15,557,000</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Adjustments required to reconcile net loss to net cash used in operating activities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="0" id="Tc_9aHrxut2MUCfoUGVAcPTwg_7_3">892,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="0" id="Tc_QAJd8A6_hkKr_28NWcephQ_7_6">840,000</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Gain upon extinguishment of Paycheck Protection Program loan </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" decimals="0" format="ixt:numdotdecimal" name="armp:GainLossOnExtinguishmentOfPaycheckProtectionProgramLoan" scale="0" id="Tc_kgwGiPb-mkmcVg8u9Fl44Q_8_3">722,000</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_rwEgsS6uhEu8PlElRpmVNA_9_3">2,218,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_4EvkYNcvAU2ZdsWRnW-Yrg_9_6">2,613,000</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Non-cash interest expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherNoncashExpense" scale="0" id="Tc_UXL1oEaJv0i7NBU-7evwuw_10_3">60,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherNoncashExpense" scale="0" id="Tc_hCx6yuRisU2o_1ryEkMiVg_10_6">457,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Payment of accreted interest for deferred consideration for asset acquisition </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" decimals="0" format="ixt:numdotdecimal" name="armp:AccruedInterestForDeferredConsiderationOnAssetAcquisition" scale="0" id="Tc_QNZuGRkkQU-MsyLJAMKrAA_11_3">586,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Changes in operating assets and liabilities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Award receivable </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" decimals="0" format="ixt:numdotdecimal" name="armp:IncreaseDecreaseInAwardReceivable" scale="0" id="Tc_cwMOVjbeF0CEIzcZdCfong_13_3">690,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw" decimals="0" format="ixt:numdotdecimal" name="armp:IncreaseDecreaseInAwardReceivable" scale="0" id="Tc_a-KiT0Xp2E-aG4kA7YcBiw_13_6">241,000</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accounts payable and accrued liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" sign="-" scale="0" id="Tc_GNze7TFZ0Eyl-UQKFdOefA_14_3">100,000</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" id="Tc_jA9RV4JZrU-kQqTvHoe5XA_14_6">492,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accrued compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredCompensation" scale="0" id="Tc_L2zMfW_PhkKea_DfLQzL3Q_15_3">1,151,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredCompensation" sign="-" scale="0" id="Tc_a9Ry0b0Un0iyI5Gi9IHFEg_15_6">21,000</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease right-of-use asset and liability, net </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" decimals="0" format="ixt:numdotdecimal" name="armp:IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet" scale="0" id="Tc_7A11xK5z4EWndjlEXqGFew_16_3">145,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw" decimals="0" format="ixt:numdotdecimal" name="armp:IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet" scale="0" id="Tc_SyBG0v0AV0uBdY1hfVlJ5Q_16_6">611,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" id="Tc_A5Piu5kXXEOOWBy5Ro1azg_17_3">237,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" id="Tc_wHCN5WbRvEm6L0_-3yoOVw_17_6">1,162,000</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net cash used in operating activities</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_S_pgfwxiukqEtcwOyCAACg_18_3">14,977,000</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_VnDHgC55C0WRRH6pCinl6Q_18_6">11,968,000</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Investing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Purchases of property and equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="Tc_jlGdhNtoNk6Yvw79hu4UZQ_20_3">1,076,000</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="Tc_-tsEyVC940mEYWVc4sTUbQ_20_6">458,000</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net cash used in investing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="0" id="Tc_kBK2GxMhykSV8IlXN8bf-A_21_3">1,076,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="0" id="Tc_xEOO7S24jkymXGEFK5r6_w_21_6">458,000</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Financing activities:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Principal payment of deferred consideration for asset acquisition</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" sign="-" scale="0" id="Tc_E6c2qPyHqkOh9R4x1sLgAQ_23_3">1,414,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" sign="-" scale="0" id="Tc_xjpGqp_ookmKvsgHUVJ00Q_23_6">1,000,000</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Proceeds from Paycheck Protection Program Loan </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw" decimals="0" format="ixt:numdotdecimal" name="armp:ProceedsFromPaycheckProtectionProgram" scale="0" id="Tc_OVC3gVKnZ0-6Bzrega42JQ_24_6">717,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Proceeds from sale of common stock, net of offering costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="Tc_BVCFrAC1Wk-gepnIMWVXEQ_25_3">19,363,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="Tc_7ETSF2GrikOMAqGdH_k-Lw_25_6">22,893,000</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Proceeds from exercise of warrants and stock options </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" decimals="0" format="ixt:numdotdecimal" name="armp:ProceedsFromExerciseOfWarrantsAndStockOptions" scale="0" id="Tc_D_CltQ92J0mckMbwdQKBbA_26_3">531,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw" decimals="0" format="ixt:numdotdecimal" name="armp:ProceedsFromExerciseOfWarrantsAndStockOptions" scale="0" id="Tc_QvyOUohFNE6hmLBmpRvapQ_26_6">168,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net cash provided by financing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_V16qHFk89kqS27oERucNiw_27_3">18,480,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_ZyOExLw3kEq-RaxQRCnlsA_27_6">22,778,000</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net increase in cash, cash equivalents and restricted cash</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="Tc_Zt6iuoxRs0aX9q2T6aIS4w_28_3">2,427,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="Tc_TU6FtHV_IkWMrXHy6XuQ4g_28_6">10,352,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash, cash equivalents and restricted cash, beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_lpjPrUIbrES5C9Ptg3h4kQ_29_3">10,849,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_12_31_2019_9M2XeqAfdE-lB78H_jYHfQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_hBFWpDn_eUOQmoTA62WjSQ_29_6">6,733,000</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash, cash equivalents and restricted cash, end of period</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_Ex_YwdcDi0ipS6pTfHBekg_30_3">13,276,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2020_zW8zVq9yIEyTGkUsiRdNWQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_wtMi0QB670SD9wPwN-RcvQ_30_6">17,085,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Supplemental disclosure of cash flow information: </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Paycheck Protection Program loan forgiveness </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" decimals="0" format="ixt:numdotdecimal" name="armp:ForgivenessRelatedToPaycheckProtectionProgram" scale="0" id="Tc_8XXFBkAR0kyTpCj16D5gig_32_3">722,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unpaid offering costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw" decimals="0" format="ixt:numdotdecimal" name="armp:OfferingCostsIncludedInAccountsPayable" scale="0" id="Tc_q09L2sd-ekGfSZBsCOjyng_33_6">65,000</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment included in accounts payable </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContributionOfProperty" scale="0" id="Tc_kxuKDFihxku8_Ox9tAxhBw_34_3">124,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContributionOfProperty" scale="0" id="Tc_EBlYHpChCEiDoFVerimOCg_34_6">145,000</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statement of cash flows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_1f9bd8c3_35e7_437c_ade1_c2563f042760"></a><a id="Tc_PHqu9PKtb0qjcVs8wiDXzQ_1_2"></a><a id="Tc_UIob0B_-jUiRD7wDr0midA_2_2"></a><a id="Tc_LzTnr_LA10KERRC5_rzmYg_2_5"></a><a id="Tc_dHwJrdV_EEWFrAJd5sFQ0g_3_0"></a><a id="Tc_vuIY47zTnEuW68IA0vp1Zg_3_2"></a><a id="Tc_2Hrcro18NUSgf9K592HJ_Q_3_5"></a><a id="Tc_tWTQjkdAzUKKffwCQ3B2JQ_4_0"></a><a id="Tc_YWIjgNEDFEWIcDT0b8UI7g_5_0"></a><a id="Tc_low73zrEhE2h2tbt5O7fQA_5_2"></a><a id="Tc_bvMV5AUUJkSt2POFDiaNAQ_5_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:72.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:72.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_-vtMnKuqF0CZYGWoEV52JQ_3_3">12,076,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2020_zW8zVq9yIEyTGkUsiRdNWQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_SagYOq01GUevs5yMb2FN_Q_3_6">15,885,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:72.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="0" id="Tc_WKfb3p34PEyfRCcdRLcPBg_4_3">1,200,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2020_zW8zVq9yIEyTGkUsiRdNWQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="0" id="Tc_UP0GLmDl7Ui4RTzy7XCFGw_4_6">1,200,000</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:72.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash, cash equivalents and restricted cash</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_80qu_Wixjk6GRjjZJY1jPA_5_3">13,276,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2020_zW8zVq9yIEyTGkUsiRdNWQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_pQPQ5IliPEmLWyP8en7bSw_5_6">17,085,000</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt;">See accompanying notes to condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e2391b0e_af8b_4dde_9f67_2a1ae30a5c41"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">Armata Pharmaceuticals, Inc.</p><a id="CondensedNotestoConsolidatedFinancialSta"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">Notes&#160;to Condensed Consolidated Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Tb__6J39S74W0SX-pHMaZeOEg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1. Organization and Description of the Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Armata Pharmaceuticals,&#160;Inc. (&#8220;Armata&#8221;, and together with its subsidiaries referred to herein as, the &#8220;Company&#8221;) is a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The Company was created as a result of a business combination between C3J Therapeutics, Inc. (&#8220;C3J&#8221;), a Washington corporation, and AmpliPhi Biosciences Corporation (&#8220;AmpliPhi&#8221;) that closed on May 9, 2019, where Ceres Merger Sub, Inc., a wholly owned subsidiary of AmpliPhi, merged with and into C3J (the&#160;&#8221;Merger&#8221;), with C3J surviving the Merger as a wholly owned subsidiary of AmpliPhi. Immediately prior to the closing of the Merger, AmpliPhi changed its name to Armata Pharmaceuticals, Inc. Armata&#8217;s common stock is traded on the NYSE American exchange under the ticker symbol &#8220;ARMP&#8221;.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"> <span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock" id="Tb_nbFZHg30Vkyqku2AcH7bVw" continuedAt="Tb_nbFZHg30Vkyqku2AcH7bVw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2. Liquidity</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="armp:LiquidityAndGoingConcernPolicyTextBlock" id="Tb_oJNMjFGvD0qXqncsA1rwjg" continuedAt="Tb_oJNMjFGvD0qXqncsA1rwjg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="us-gaap:SubstantialDoubtAboutGoingConcernManagementsEvaluation" id="Narr_sYlOfWmxGE6p4oL3t_Ra6Q">The Company has prepared its consolidated financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. However, the Company has incurred net losses since its inception and has negative operating cash flows. These circumstances raise substantial doubt about the Company&#8217;s ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty concerning the Company&#8217;s ability to continue as a going concern.</ix:nonNumeric></p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';"> </span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman','Times','serif';">On October 28, 2021, the Company entered into a securities purchase agreement (the &#8220;October 2021 Securities Purchase Agreement&#8221;) with the Cystic Fibrosis Foundation, a Delaware corporation (&#8220;CFF&#8221;), the Company&#8217;s partner for its lead Phase 1b/2 clinical development program, and Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc. (Nasdaq: INVA) (collectively, &#8220;Innoviva&#8221;) for the private placement of newly issued shares of common stock, par value </span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q" contextRef="As_Of_10_28_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_tDI9aHgnU02SEE2i4-rltw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_od8vMjiKM02w9px2h5kbYw">0.01</ix:nonFraction></span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman','Times','serif';"> per share, of the Company (&#8220;Common Stock&#8221;). Pursuant to the October 2021 Securities Purchase Agreement, the Company issued and sold </span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="Duration_10_28_2021_To_10_28_2021_srt_CounterpartyNameAxis_armp_CysticFibrosisFoundationMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_r2L1o1zLc0ewvdxbb5OLYQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_nSo0ER5PyEu89q22RAF6bA">909,091</ix:nonFraction></span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman','Times','serif';"> shares to CFF and </span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman','Times','serif';"><ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="Duration_10_28_2021_To_10_28_2021_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_j_mhEXexkkyt_KqjZVElLw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_3g0S0k5CVkSCnYrLcMgMDQ">1,212,122</ix:nonFraction></span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman','Times','serif';"> shares to Innoviva, each at a per share price of </span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q" contextRef="As_Of_10_28_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_XMDfJAOuaESQwElJtiy_ew" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_O8L2vb50bUujTZT-1W8duQ">3.30</ix:nonFraction></span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman','Times','serif';"> (the &#8220;October 2021 Private Placements&#8221;). The Company received aggregate gross proceeds from the October 2021 Private Placements of approximately </span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman','Times','serif';">$<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_10_28_2021_To_10_28_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_46a9XzfZPkSGKc4-ttN9fw" decimals="-5" format="ixt:numdotdecimal" name="armp:ProceedsFromEquityOfferingsGross" scale="6" id="Narr_wBgbJVci10uwaCuRlp5aBw">7.0</ix:nonFraction></span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman','Times','serif';"> million, before deducting transaction expenses</span><span style="font-family:'Times New Roman','Times','serif';">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"> On January&#160;26, 2021, the Company entered into a securities purchase agreement (the &#8220;January 2021 Securities Purchase Agreement&#8221;) with <span style="background-color:#ffffff;">Innoviva, </span>pursuant to which the Company agreed to issue and sell to Innoviva, in a private placement, up to <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="Duration_1_26_2021_To_1_26_2021_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_z5LGiY7OL0Scv3M4U-b1Wg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_k7fXWDNhtka4x6j-RBhfxw">6,153,847</ix:nonFraction> newly issued shares of Common Stock, and warrants (the &#8220;Common Warrants&#8221;) to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="As_Of_1_26_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_z1sUig3BpUiBHLBYltqXRg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_dOOmcPIyvkWs13whT1P1EA">6,153,847</ix:nonFraction> shares of Common Stock, with an exercise price per share of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q" contextRef="As_Of_1_26_2021_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_zFjpWhEkUkiNbRFtUmSseg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_YwFI9MX1Akii8mXhVICHtw">3.25</ix:nonFraction> (the &#8220;January 2021 Private Placement&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The January 2021 Private Placement closed in two tranches. On January&#160;26, 2021 and concurrently with entering into the January 2021 Securities Purchase Agreement, the Company completed the first tranche (the &#8220;First Closing&#8221;) of the January 2021 Private Placement. At the First Closing,&#160;Innoviva purchased <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="Duration_1_26_2021_To_1_26_2021_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementFirstTrancheMember_vU5i9LO2uU6jsVJ4911Zlg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_HLj_2jeSUEWT695u5p_93g">1,867,912</ix:nonFraction> shares of Common Stock and Common Warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="As_Of_1_26_2021_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementFirstTrancheMember_4VDPa4otSk6JCKDKNZvQ0w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_gf89xAEJJ02pmp8IdkO7_g">1,867,912</ix:nonFraction> shares of common stock, for an aggregate purchase price of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_26_2021_To_1_26_2021_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementFirstTrancheMember_wOZbvf2jHEW62lNLQlwkHw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="6" id="Narr_AvhxNk2DfEePRuvEzY2J1A">6.1</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">At the closing of the second tranche (the &#8220;Second Closing&#8221;), which was approved by the Company&#8217;s stockholders,&#160;Innoviva purchased <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="Duration_3_17_2021_To_3_17_2021_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementSecondTrancheMember_7NUySWdWyU2T6PeqoKx_hg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_bBTI05xw2kaRC61JofhUqw">4,285,935</ix:nonFraction> shares of Common Stock and Common Warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="As_Of_3_17_2021_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementSecondTrancheMember_8WtQB3s-wk2b0we6rBXeVg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_l_fTbsTA_k6PdHL-SRJx4w">4,285,935</ix:nonFraction> shares of Common Stock for an aggregate purchase price of $<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_3_17_2021_To_3_17_2021_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementSecondTrancheMember_OI9uPwtYu02QjGR7dFobAA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="6" id="Narr_6xZ0ywZtsk6fnC4i9Y1sug">13.9</ix:nonFraction> million. The Second Closing was completed on March 17, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On March 27, 2020, the Company completed a private placement transaction and sold to Innoviva Inc. <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="Duration_1_27_2020_To_3_27_2020_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_tEurHl-WuEy8GrS4QYXwGQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_n6oowjca5EKc4SaG43fDZQ">8,710,800</ix:nonFraction> newly issued shares of Common Stock and warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="As_Of_3_27_2020_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_VI0dYZLlxkey_j7O6lL4cA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_-05Hy1DPtU2XmWENdbX1zQ">8,710,800</ix:nonFraction> shares of common stock, with an exercise </p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_nbFZHg30Vkyqku2AcH7bVw_cont1"><ix:continuation id="Tb_oJNMjFGvD0qXqncsA1rwjg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">price per share of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q" contextRef="As_Of_3_27_2020_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_9mH04W5WikCikSJLnqxw9w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_hiJq-enCtkiTN3e0bE4Vzw">2.87</ix:nonFraction> (the &#8220;2020 Private Placement&#8221;). Each share of common stock was sold together with <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="Duration_3_27_2020_To_3_27_2020_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_NmhuJtI8WkCb1aWkNG0-5Q" decimals="INF" format="ixt-sec:numwordsen" name="armp:NumberOfCommonWarrantsSoldPerShareOfCommonStock" scale="0" id="Narr_YrDA87WcXkiyX2ObUBns2g">one</ix:nonFraction> common warrant granting the warrant holder the right to purchase an additional share of common stock at $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q" contextRef="As_Of_3_27_2020_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_9mH04W5WikCikSJLnqxw9w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_nTACFhgpgUW7n_jE3lCS9w">2.87</ix:nonFraction> per share. The 2020 Private Placement was closed in two tranches raising total gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_27_2020_To_3_27_2020_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_9V8h1NEgnkCy2Hyg6zq7fg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="6" id="Narr_puAQqwJPXEKFZK1kkFGGvg">25.0</ix:nonFraction> million.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of September 30, 2021, the Company had cash and cash equivalents of $<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="Narr_1_b2hGKH_Umpi51fluAjIQ">12.1</ix:nonFraction> million. Considering the Company&#8217;s current cash resources, management believes the Company&#8217;s existing resources will be sufficient to fund the Company&#8217;s planned operations into the first quarter of 2022. For the foreseeable future, the Company&#8217;s ability to continue its operations is dependent upon its ability to obtain additional capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Management plans to raise additional capital through equity offerings, debt financings, or other capital sources, including potential collaborations, licenses and other similar arrangements. While management believes this plan to raise additional funds will alleviate the conditions that raise substantial doubt, these plans are not entirely within its control and cannot be assessed as being probable of occurring. The Company&#8217;s ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic. The Company may not be able to secure additional financing in a timely manner or on favorable terms, if at all. Furthermore, if the Company issues equity securities to raise additional funds, its existing stockholders may experience dilution, and the new equity securities may have rights, preferences and privileges senior to those of the Company&#8217;s existing stockholders. If the Company raises additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to its potential products on terms that are not favorable to the Company. If the Company is unable to raise capital when needed or on attractive terms, it would be forced to delay, reduce or eliminate its research and development programs or other operations. If any of these events occur, the Company&#8217;s ability to achieve the development and commercialization goals would be adversely affected.</p></ix:continuation></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_GH-bTE2pIkmQCNEyUwleXQ" continuedAt="Tb_GH-bTE2pIkmQCNEyUwleXQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3. Significant Accounting Policies</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_u-hf1hQr2Eq7tCq1RzPYZA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The consolidated financial statements include the accounts of Armata and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated. The accompanying unaudited condensed consolidated financial statements of the Company should be read in conjunction with the audited financial statements and accompanying notes thereto as of and for the year ended December 31, 2020&#160;included in the Company&#8217;s Form 10-K, filed with the U.S. Securities and Exchange Commission on March 18, 2021. The accompanying unaudited financial statements have been prepared in conformity with accounting principles generally accepted&#160;in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial statements. Any reference in the Notes to applicable guidance is meant to refer to authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In the opinion of management, the accompanying consolidated financial statements include all adjustments that are of a normal and recurring nature and that are necessary for the fair presentation of the Company&#8217;s financial position and the results of its operations and cash flows for the periods presented. Interim results are not necessarily indicative of results for the full year or any future period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="us-gaap:UseOfEstimates" id="Tb_o4Y0UkB6K02uoHHXWOn8NA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in its consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates these estimates and judgments, which are based on historical and anticipated results and trends, and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management&#8217;s estimates.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_GH-bTE2pIkmQCNEyUwleXQ_cont1" continuedAt="Tb_GH-bTE2pIkmQCNEyUwleXQ_cont2"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="Tb_cS_u3kSRC0GSwMyjptUKUw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair Value of Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The carrying amounts of cash equivalents, other current assets, accounts payable, and accrued liabilities approximate fair value because of the short-term nature of these instruments.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="us-gaap:InProcessResearchAndDevelopmentPolicy" id="Tb_d_GyFoPEH06op5zfkXc6uw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">In-Process Research and Development (&#8220;IPR&amp;D&#8221;) </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:13.2pt;margin:0pt;">IPR&amp;D assets are intangible assets with indefinite lives and are not subject to amortization. The Company&#8217;s IPR&amp;D assets represent capitalized incomplete research projects that the Company acquired through the Merger, which is related to the development of AP-SA01, a phage combination for the treatment of <i style="font-style:italic;">Staphylococcus aureus</i> infections (&#8220;<i style="font-style:italic;">S. aureus</i>&#8221;). Such assets are initially measured at their acquisition-date fair values and are subject to impairment testing at least annually until completion or abandonment of research and development efforts associated with the projects. Upon successful completion of each project, the Company makes a determination as to the then remaining useful life of the intangible asset and begins amortization. </p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="Tb__lTexhmVdEC3OjDtp3Igpg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Goodwill</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:13.2pt;margin:0pt;">Goodwill, which has an indefinite useful life, represents the excess of purchase consideration over fair value of net assets acquired. Goodwill is not subject to amortization and is required to be tested for impairment at least on an annual basis. The Company tests goodwill for impairment as of December 31 of each year. The Company determines whether goodwill may be impaired by comparing the carrying value of the single reporting unit, including goodwill, to the fair value of the reporting unit. If the fair value is less than the carrying amount, a more detailed analysis is performed to determine whether goodwill is impaired. The impairment loss, if any, is measured as the excess of the carrying value of the goodwill over the implied fair value of the goodwill and is recorded in the Company&#8217;s consolidated statements of operations.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:13.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="armp:ZeroCouponDebtInstrumentPolicyTextBlock" id="Tb_X7CYFreUFkuCWS4fKKpvMw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Settlement of Zero-coupon Debt Instrument </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">      </span><span style="font-style:normal;font-weight:normal;white-space:pre-wrap;">The Company&#8217;s deferred purchase consideration arrangement with Synthetic Genomics (Note 11) does not have a stated interest rate.  Upon repayment of deferred purchase consideration, the Company classifies the portion attributable to accreted interest as a cash outflow for operating activities, and the portion relating to principal as a cash outflow for financing activities.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_In0KbaBOEkmuO0lG1mOLLg" continuedAt="Tb_In0KbaBOEkmuO0lG1mOLLg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basic and Diluted Net Loss per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net earnings or loss per share (&#8220;EPS&#8221;) is calculated in accordance with the applicable accounting guidance provided in ASC 260,&#160;<i style="font-style:italic;">Earnings per Share.&#160;</i>The Company uses the two-class method for the computation and presentation of net income (loss) per common share attributable to common stockholders. The two-class method is an earnings allocation formula that calculates basic and diluted net income (loss) per common share for each class of common stock separately based on dividends declared and participation rights in undistributed earnings as if all such earnings had been distributed during the period. Under the two-class method, warrants issued to Innoviva are assumed to participate in undistributed earnings on an as-exercised basis, in accordance with the warrant agreements. Undistributed net losses are allocated entirely to common shareholders since the participating security has no contractual obligation to share in the losses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Accordingly, basic income or loss per share is calculated by dividing net income or loss by the weighted-average number of common shares outstanding, or using the two-class method, whichever is more dilutive.&#160;&#160;Diluted net income or loss per share is computed using the more dilutive of the treasury stock method which reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted to common stock, or the two-class method. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The calculation of diluted loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of liability classified warrants, and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to net loss available to common stockholders used in the calculation is required to remove the change in fair value of the warrants from the numerator for the period. </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_GH-bTE2pIkmQCNEyUwleXQ_cont2" continuedAt="Tb_GH-bTE2pIkmQCNEyUwleXQ_cont3"><ix:continuation id="Tb_In0KbaBOEkmuO0lG1mOLLg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any, under the treasury stock method. </p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="armp:GrantsAndAwardsPolicyTextBlock" id="Tb_S7zHWiGlJkyft5FAjiYSNw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Grants and Awards</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="white-space:pre-wrap;">        In applying the provisions of ASC Topic 606, </span><i style="font-style:italic;">Revenue from Contracts with Customers</i> (&#8220;ASC 606&#8221;)<i style="font-style:italic;">, </i>Armata has determined that grants and awards are out of the scope of ASC 606 because the funding entities do not meet the definition of a &#8220;customer&#8221;, as defined by ASC 606, as there is not considered to be a transfer of control of goods or services. With respect to each grant or award, the Company determines if it has a collaboration in accordance with ASC Topic 808, <i style="font-style:italic;">Collaborative Arrangements</i> (&#8220;ASC 808&#8221;). To the extent the grant or award is within the scope of ASC 808, the Company recognizes amounts received as a contra-expense or grant revenue on the consolidated statement of operations when the related research and development expenses are incurred. For grant and awards outside the scope of ASC 808, the Company applies ASC 606 or International Accounting Standards No. 20, <i style="font-style:italic;">Accounting for Government Grants and Disclosure of Government Assistance</i>, by analogy, and revenue is recognized when the Company incurs expenses related to the grants for the amount the Company is entitled to under the provisions of the contract. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="white-space:pre-wrap;">        Armata also considers the guidance in ASC Topic 730, </span><i style="font-style:italic;">Research and Development </i>(&#8220;ASC 730&#8221;), which requires an assessment, at the inception of the grant or award, of whether the agreement is a liability<i style="font-style:italic;">. </i>If Armata is obligated to repay funds received regardless of the outcome of the related research and development activities, then Armata is required to estimate and recognize that liability. Alternatively, if Armata is not required to repay the funds, then payments received are recorded as revenue or contra-expense as the expenses are incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="white-space:pre-wrap;">       Deferred grant or award liability represents award funds received or receivable for which the allowable expenses have not yet been incurred as of the balance sheet date.</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_opDtieiPwECk04gDNkud9Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development (&#8220;R&amp;D&#8221;) costs consist primarily of direct and allocated salaries, incentive compensation, stock-based compensation and other personnel-related costs, facility costs, and third-party services. Third-party services include studies and clinical trials conducted by clinical research organizations. R&amp;D activities are expensed as incurred. The Company records accruals for estimated ongoing clinical trial expenses. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Judgments and estimates are made in determining the accrued balances at the end of the reporting period.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_FhUNzvDkGkSbYh6rxLu8KA" continuedAt="Tb_FhUNzvDkGkSbYh6rxLu8KA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Accounting Pronouncements Not Yet Adopted</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="background-color:#ffffff;color:#212529;">In June 2016, the FASB issued ASU 2016-13,&#160;</span><i style="background-color:#ffffff;color:#212529;font-style:italic;">Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses</i><span style="background-color:#ffffff;color:#212529;">&#160;on Financial Instruments. The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that aren&#8217;t measured at fair value through net income. For available-for-sale debt securities, entities will be required to recognize an allowance for credit losses rather than a reduction in carrying value of the asset. Entities will no longer be permitted to consider the length of time that fair value has been less than amortized cost when evaluating when credit losses should be recognized.&#160;</span>This new guidance is effective for calendar-year smaller reporting public entities in the first quarter of 2023. The Company is currently evaluating the impact of this ASU and&#160;<span style="color:#212529;">does&#160;</span>not expect that adoption of this standard will have a material impact on its consolidated financial statements or related disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:18pt;margin:6pt 0pt 0pt 0pt;">In August 2020, the FASB issued &#8203;ASU No. 2020-06&#8203;, &#8203;<i style="font-style:italic;">Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)&#8203; (&#8220;ASU 2020-06&#8221;).</i> &#8203;ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#8217;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in ASU </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk14237557"></a><ix:continuation id="Tb_GH-bTE2pIkmQCNEyUwleXQ_cont3"><ix:continuation id="Tb_FhUNzvDkGkSbYh6rxLu8KA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="white-space:pre-wrap;">2020-06 are effective for the Company as of January 1, 2024. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2020-06 on its financial statements and does not expect the adoption of this ASU to have a material impact on the Company&#8217;s consolidated financial statements.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recently Adopted Accounting Standards</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 14pt 0pt;">In December 2019, the FASB issued ASU 2019-12,&#160;<i style="font-style:italic;">Income Taxes (&#8220;ASC 740&#8221;)</i>, which simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740 related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill.&#160;The guidance became effective for the Company on January 1, 2021 and the adoption did not have a material impact on its&#160;consolidated financial statements or related disclosures.  </p></ix:continuation></ix:continuation><a id="_c5b22c1a_7418_4570_997b_12e4a5c3b960"></a><a id="Tc_tHr-5bpIMEWvHnKL-oDhvA_1_2"></a><a id="Tc_dj5HlXF9DEKYAMv_WuBwjQ_1_4"></a><a id="Tc_ti-4a1ER-kSGIMOI0uHSwA_2_0"></a><a id="Tc_FsQosxPX902SAhIigYBU4w_3_0"></a><a id="Tc_q-CsZgnrYUOdFBfH8SqTsA_3_4"></a><a id="Tc_F_m5rSJtGUuOZiMWGvyrew_4_0"></a><a id="Tc_5g09c-_dskGDH1cGty5NVw_5_0"></a><a id="Tc_UcxbXsCCC0S2JQkoOGpkNQ_6_0"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="us-gaap:EarningsPerShareTextBlock" id="Tb_aHrXWp3orkGHBC8tgVyKcg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">4. Net Loss per Share </p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_Pc71nO4EFUqPUsIEYaTHtA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following outstanding securities as of September 30, 2021 and 2020 have been excluded from the computation of diluted weighted average shares outstanding, as they would have been anti-dilutive:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_dGzT0B8rlE25dvbTXP9MPQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_o4cDakyY40yzgARAIr8evQ_2_2">2,439,651</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_Lq1HnOsnGU-O85aEcig2uA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_sCD7CgoWNUmIE4yLLzxghA_2_4">1,446,614</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_0tfpWQr4U0atNpxzVyKU4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_rgls6Mc8yUS5eIaBkyMfVg_3_2">30,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock awards</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_C-PpNtLO1EyP8fYs3gQBWw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_YG8QwhaCl0i_bf4Bj-oX1g_4_2">124,018</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_IORuHvJJb02yQ5UUN4uyzw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_TeuJqcyBk02djwu51hJ4Hw_4_4">262,558</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_DeTK3m4stEG86-3yphL8Ow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_keYJygxkY0ip-YfgL9ZuLw_5_2">16,647,219</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_T0uD7MiwsUiVBvYkYdc0sA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_JW-a4v3POEOa0SWmbF-Fdw_5_4">10,547,618</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_qj__EIqicE6f2uR2XYrdXw_6_2">19,240,888</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_XmkjKhNEGEmdNMI91sRsrA_6_4">12,256,790</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><a id="Tc_BNF0Ew3Y_0aV6CmuApKPSQ_1_2"></a><a id="Tc_4S08C7pUvkKkd8IGFHWyDw_1_5"></a><a id="Tc__r5U7LkTmEWoGHIbQU7lag_2_0"></a><a id="Tc_yOCnLSfNeE-weQeoKIC9Qw_2_2"></a><a id="Tc_B-onv83WGEW9G0Z-mpwh2Q_2_5"></a><a id="Tc_aiPZvG9SfE6DWCJJKz6L5w_3_0"></a><a id="Tc__OHL7GkorECJNR-tcSkdhg_4_0"></a><a id="Tc_rFFroT9C4UWB0TNaf2Z-4A_5_0"></a><a id="Tc_SWxTzYJxl0qZAJz2c1_2xw_6_0"></a><a id="Tc_dSHK8FZOd0OXXjcrgdygWw_7_0"></a><a id="Tc_dMBrYdjqx0edGKgUx41-Jw_8_0"></a><a id="Tc_GdGkRz0nmUSfrV1TxzaxkA_8_2"></a><a id="Tc_nIiqe-bM9U--NkzxdbRZ9Q_8_5"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="Tb_5ar4UJs4GEaumdX3kfCiXA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">5. Balance Sheet Details</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Property and equipment as of September 30, 2021 and December 31, 2020 consisted of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Tb_bSyEx-zVQEukH4WfzvNCdg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:69.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:69.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_TechnologyEquipmentMember_p5J4JOCTc02vC-jcH_EpAg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_-bO5esUZn06tov-L5pvY-A_2_3">7,362,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_TechnologyEquipmentMember_nIlwPHC5LUOeeFklieSIRw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_VSXhF-VtWE2iDV8OHkA8ZA_2_6">6,547,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_1p7SIRia1U-1Q9bpInZOaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_xWcB6DuJx0qFvOVYSQId4w_3_3">817,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_8b0rBWMKHUqzS1cwV6K4xQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_aRstltpo6ECdwGvUZtVy2g_3_6">719,000</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:69.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Office and computer equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_TOBly1V2sk6aoZBdLy5BKw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_5Hu4JZXLS0iatGL8L68-jA_4_3">451,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_v1yZA3mZRkKG-s3xNs7sqw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_MX_VPpgJbUmg55Mlg2KWog_4_6">413,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_RNSsP7qTGEmVKWcf_xwJ3Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_z5_MMBGEw02vrVJKr6XjQA_5_3">3,423,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_Va3hG_KZOUiqR-V5nrMt6w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_DNRKgUPH7EqTxeROQxFMuA_5_6">3,423,000</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:69.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_YYd1AMydpEWL3ehQs07OdA_6_3">12,053,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_RpaZ-6KZUUeT3hVmbcbk-w_6_6">11,102,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:69.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" id="Tc_Mh-FnbtaD0K7x0FWJtRGkg_7_3">9,946,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" id="Tc_t5qJaPCWzU2TtTjPUHhdow_7_6">9,055,000</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:69.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="Tc_STBDKHEusEWbZW3obsaHCg_8_3">2,107,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="Tc_S_z6KeeVDEC32tZR1jJMVw_8_6">2,047,000</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Depreciation expense totaled $<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_7_1_2020_To_9_30_2020_C3Blutz6cUqC03qQKsaYEg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="Narr_H1JIXiBZR0CqO32X6BzIyQ"><ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_7_1_2021_To_9_30_2021_EHL267Iy5kqlAVaXmlK6uQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="Narr_GZhlSLwrekOoTR3WNOjfig">0.3</ix:nonFraction></ix:nonFraction> million for each of the three months ended September 30, 2021 and 2020, respectively. Depreciation expense totaled $<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="Narr_kDxVMbC4G0eyD7Gvl7QmuQ">0.9</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="Narr_EjWT1Z1oPUe1NTrjmyYVmA">0.8</ix:nonFraction> million for the nine months ended September 30, 2021 and 2020, respectively.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="us-gaap:LongTermDebtTextBlock" id="Tb_p9hW3U2FfkG8oLaIMioIGw" continuedAt="Tb_p9hW3U2FfkG8oLaIMioIGw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">6. Paycheck Protection Program Loan </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;">In April 2020, the Company received loan proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_4_20_2020_To_4_20_2020_us-gaap_DebtInstrumentAxis_armp_PaymentProtectionProgramNoteMember_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember_7RzbJhwJ1ESFRjadZeEXiw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromUnsecuredNotesPayable" scale="0" id="Narr_RZPf1skQVky7OQ3KubmnEQ">717,000</ix:nonFraction> (&#8220;PPP Loan&#8221;) under the Paycheck Protection Program (&#8220;PPP&#8221;).&#160; The PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act, provides for loans to qualifying businesses for amounts up to 2.5 times the average monthly payroll expenses of the qualifying business, calculated as provided under the PPP. The PPP Loan was unsecured, evidenced by a promissory note (the &#8220;Note&#8221;) given by the Company as borrower through its bank, serving as the lender.&#160; The interest rate on the Note was <ix:nonFraction unitRef="Unit_Standard_pure_EPrTQjTDQkGfR4N7mgNYUg" contextRef="As_Of_4_20_2020_us-gaap_DebtInstrumentAxis_armp_PaymentProtectionProgramNoteMember_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember_etlcSyw6QUy7OhSC2F0meg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_-V9CSU1-HkCzqFS6MHvsbg">1.0</ix:nonFraction>% per annum. </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_p9hW3U2FfkG8oLaIMioIGw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;">In July 2021, the Company received notification of forgiveness of the full loan amount and associated interest from the Small Business Administration. The Company recorded a gain of $<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_7_1_2021_To_9_30_2021_EHL267Iy5kqlAVaXmlK6uQ" decimals="-5" format="ixt:numdotdecimal" name="armp:GainLossOnExtinguishmentOfPaycheckProtectionProgramLoan" scale="6" id="Narr_tWqzFHA4j0ud4zQwQfLzFQ">0.7</ix:nonFraction> million from the PPP loan extinguishment in the statement of operations during the three months ended September 30, 2021.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_N1nDQvbwPk-VBtWD8szroA" continuedAt="Tb_N1nDQvbwPk-VBtWD8szroA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">7. Stockholders&#8217; Equity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Private Investment </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">October 2021 Private Placement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background-color:#ffffff;color:#222222;">On October 28, 2021, the Company entered into the October 2021 Securities Purchase Agreement with CFF and Innoviva for the private placement of newly issued shares of the Company&#8217;s common stock. Pursuant to the October 2021 Securities Purchase Agreement, the Company issued and sold </span><span style="background-color:#ffffff;color:#222222;"><ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="Duration_10_28_2021_To_10_28_2021_srt_CounterpartyNameAxis_armp_CysticFibrosisFoundationMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_r2L1o1zLc0ewvdxbb5OLYQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_yQOenA6TL0-CyhGhsKlH_Q">909,091</ix:nonFraction></span><span style="background-color:#ffffff;color:#222222;"> shares to CFF and </span><span style="background-color:#ffffff;color:#222222;"><ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="Duration_10_28_2021_To_10_28_2021_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_j_mhEXexkkyt_KqjZVElLw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_VcqL7hQGV0mCIjOhPo0olg">1,212,122</ix:nonFraction></span><span style="background-color:#ffffff;color:#222222;"> shares to Innoviva, each at a per share price of </span><span style="background-color:#ffffff;color:#222222;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q" contextRef="As_Of_10_28_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_XMDfJAOuaESQwElJtiy_ew" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_2-eWNj_ULUi7vYLwN6EsBQ">3.30</ix:nonFraction></span><span style="background-color:#ffffff;color:#222222;">. The Company received aggregate gross proceeds from the October 2021 Private Placements of approximately </span><span style="background-color:#ffffff;color:#222222;">$<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_10_28_2021_To_10_28_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_46a9XzfZPkSGKc4-ttN9fw" decimals="-5" format="ixt:numdotdecimal" name="armp:ProceedsFromEquityOfferingsGross" scale="6" id="Narr_4TBYYkzECUe_J5E3S2kgCQ">7.0</ix:nonFraction></span><span style="background-color:#ffffff;color:#222222;"> million, before deducting transaction expenses</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">January 2021 Private Placement </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On January&#160;26, 2021, the Company entered into the January 2021 Securities Purchase Agreement with Innoviva, pursuant to which the Company agreed to issue and sell to Innoviva, in a private placement, up to <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="Duration_1_26_2021_To_1_26_2021_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_z5LGiY7OL0Scv3M4U-b1Wg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_v4GH1IeGBEq8QOw2KsuJfg">6,153,847</ix:nonFraction> newly issued shares of common stock, and Common Warrants to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="As_Of_1_26_2021_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_u_eCCek3qkqRByQzE5fczw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_KgTHkDoUSESQLJaQICh3iQ">6,153,847</ix:nonFraction> shares of common stock, with an exercise price per share of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q" contextRef="As_Of_1_26_2021_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_TImvJ_eQD0OgW_ZO7Ry9TQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_o6SpirV34kGT_kVVet3_6A">3.25</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The January 2021 Private Placement closed in two tranches. On January&#160;26, 2021 and concurrently with entering into the January 2021 Securities Purchase Agreement, the Company completed the first tranche (the &#8220;First Closing&#8221;) of the January 2021 Private Placement. At the First Closing,&#160;Innoviva purchased <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="Duration_1_26_2021_To_1_26_2021_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementFirstTrancheMember_vU5i9LO2uU6jsVJ4911Zlg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_bqOUOF_nFUS6PxI_XVFvyA">1,867,912</ix:nonFraction> shares and Common Warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="As_Of_1_26_2021_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementFirstTrancheMember_4VDPa4otSk6JCKDKNZvQ0w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_mWfEoUGAOkqK30Wugraotw">1,867,912</ix:nonFraction> shares of common stock, for an aggregate purchase price of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_26_2021_To_1_26_2021_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementFirstTrancheMember_wOZbvf2jHEW62lNLQlwkHw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="6" id="Narr_LmhXgqCeAUC6NNTGR3wgBA">6.1</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">At the closing of the second tranche (the &#8220;Second Closing&#8221;), which was approved by the Company&#8217;s stockholders,&#160;Innoviva purchased <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="Duration_3_17_2021_To_3_17_2021_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementSecondTrancheMember_7NUySWdWyU2T6PeqoKx_hg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_tsiicp9gcEGd1YARbk_iAw">4,285,935</ix:nonFraction> shares and Common Warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="As_Of_3_17_2021_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementSecondTrancheMember_8WtQB3s-wk2b0we6rBXeVg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_GZ194enIXESuIwODnnQCzA">4,285,935</ix:nonFraction> shares of common stock for an aggregate purchase price of $<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_3_17_2021_To_3_17_2021_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementSecondTrancheMember_OI9uPwtYu02QjGR7dFobAA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="6" id="Narr_2qV1xtuoV0CG8eeJvMrVKg">13.9</ix:nonFraction> million. The Second Closing was completed on March 17, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On January 27, 2020, the Company entered into a securities purchase agreement with Innoviva, pursuant to which the Company agreed to issue and sell to Innoviva, in the 2020 Private Placement, <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="Duration_1_27_2020_To_3_27_2020_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_tEurHl-WuEy8GrS4QYXwGQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_qHL6J1lJOEybZvlDHsGHQw">8,710,800</ix:nonFraction> newly issued shares of the Company&#8217;s common stock and warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="As_Of_3_27_2020_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_VI0dYZLlxkey_j7O6lL4cA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_XJeQSrlJBkmtL8-aAVdM7g">8,710,800</ix:nonFraction> shares of common stock, with an exercise price per share of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q" contextRef="As_Of_3_27_2020_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_9mH04W5WikCikSJLnqxw9w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_OA6Oj4kGi0SxPbRYIGWjnA">2.87</ix:nonFraction>. Each share of common stock was sold together as a unit with <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="Duration_1_27_2020_To_1_27_2020_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_kxspnM04HEGpag_N6znvkw" decimals="INF" format="ixt-sec:numwordsen" name="armp:NumberOfCommonWarrantsSoldPerShareOfCommonStock" scale="0" id="Narr_CX0W9NZPq0yIyaFL6tfKPg">one</ix:nonFraction> common warrant granting the warrant holder the right to purchase an additional share of common stock at $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q" contextRef="As_Of_3_27_2020_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_9mH04W5WikCikSJLnqxw9w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_9mOtoDkBK0-gNmUaKNbwtQ">2.87</ix:nonFraction> per share. The 2020 Private Placement occurred in two tranches. The first closing occurred on February 12, 2020, at which time Innoviva purchased <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="Duration_2_12_2020_To_2_12_2020_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_kE6uyStxdEyj3mI3KbQoTg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_wU_GDJkh2EeiRMqnqQLPAA">993,139</ix:nonFraction> units in exchange for an aggregate gross cash payment of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_2_12_2020_To_2_12_2020_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_kE6uyStxdEyj3mI3KbQoTg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="6" id="Narr_Fc183NoAYkWMzigAHIe2Pw">2.8</ix:nonFraction> million. On March 27, 2020, the second closing occurred subsequent to shareholder approval, at which time Innoviva purchased <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="Duration_3_27_2020_To_3_27_2020_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_NmhuJtI8WkCb1aWkNG0-5Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_HYMVfVyVcU2frBcOsj9mrg">7,717,661</ix:nonFraction> units in exchange for aggregate gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_3_27_2020_To_3_27_2020_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_NmhuJtI8WkCb1aWkNG0-5Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="6" id="Narr_XS6Gu6Mz40G2dgapDGr0bA">22.2</ix:nonFraction> million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The warrants issued to Innoviva during 2021 and 2020 expire <ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" format="ixt-sec:durwordsen" name="armp:TermOfWarrant" id="Narr_FWFEWEcEr0mixU26_M4TyA">five years</ix:nonNumeric> from the respective issuance date. The Company reviewed the authoritative accounting guidance and determined that the warrants meet the criteria to be accounted for as permanent equity. </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_59c08175_3dce_439c_8a98_043e58cbcb7b"></a><a id="Tc_zwST6xnn5k6IcXCvGeC1fQ_1_0"></a><a id="Tc_QQvxgqdtHkKNsrPfxXArVg_1_2"></a><a id="Tc_OZOsvfHzoky8TjnZTaXmmg_1_5"></a><a id="Tc_-p7bcqKoE02bAKbdoAbu8g_2_2"></a><a id="Tc_KMETn2FHN0qyfkSb-afmnQ_3_2"></a><a id="Tc_o62ai_sA5Em9NpfE62eIxw_4_2"></a><a id="Tc_ywwqj1NUVkugmcLIiQtAmA_5_2"></a><a id="Tc_vEsJ-w20p0-DhUocB_t8YA_6_2"></a><a id="Tc_JX8guU8BGEqicrrh5zFe7A_7_2"></a><a id="Tc_JSEpA6R_sESLFOtNUAZlow_8_2"></a><a id="Tc_XChnW_iKf0uxzDCq0WNGEw_8_5"></a><ix:continuation id="Tb_N1nDQvbwPk-VBtWD8szroA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Warrants</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="Tb_OUW2t0ayd0WDjtSZ1urd6A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On September 30, 2021, outstanding warrants to purchase shares of common stock are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares Underlying Outstanding Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:28.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Expiration Date</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceTwoMember_NdqVRbX3oU27C0EB3fq9hQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_4hxvAQMroEa-lOibOzqnLw_2_0">597,881</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q" contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceTwoMember_NdqVRbX3oU27C0EB3fq9hQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_2UAOfFsLfUWmVhv4RJzKiw_2_3">21.00</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceTwoMember_JdmRRsSJmk-a_ZNRg_kXxQ" format="ixt:datemonthdayyearen" name="armp:WarrantExpirationDate" id="Tc_nuvhmyDyo0yzMGi8YtuQlw_2_5">May 10, 2022</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:36.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceThreeMember_KFYsa4JmTkqWUhYzwZ9UJQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_XwK97JmS30qPd3Otpz-pDw_3_0">1,183,491</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q" contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceThreeMember_KFYsa4JmTkqWUhYzwZ9UJQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_DXXa5qD4IEi06mxTz2TgqQ_3_3">5.60</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceThreeMember_EJFiwcEwBEuQa1IR4jmJ5g" format="ixt:datemonthdayyearen" name="armp:WarrantExpirationDate" id="Tc_kWxjaRN280eGa1jimCw1_g_3_5">October 16, 2023</ix:nonNumeric></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFourMember_JSSFhCnciUaDzuCmVBpOig" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_KuyMEvSnE0Clyp5L0c7P5A_4_0">993,139</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q" contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFourMember_JSSFhCnciUaDzuCmVBpOig" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_ECwIhdZCsE-TTOD0yRzsMg_4_3">2.87</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFourMember_jfTPvaUXH0maozOHI-CL3g" format="ixt:datemonthdayyearen" name="armp:WarrantExpirationDate" id="Tc_ljOOlqBdWEuOIrZj-XCCtg_4_5">February 11, 2025</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:36.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFiveMember_CxNNWMACKU-ycnzc8b5FtA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_w6qLtxSvF0izFdkKIsLshA_5_0">7,717,661</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q" contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFiveMember_CxNNWMACKU-ycnzc8b5FtA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_UM3ED7uwqUySYptj7QXo-A_5_3">2.87</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFiveMember_E28RzePRZEuFR_T3YSIfYw" format="ixt:datemonthdayyearen" name="armp:WarrantExpirationDate" id="Tc_Pz0mV53XZkSuVpKr2Tw_wA_5_5">March 27, 2025</ix:nonNumeric></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSevenMember_gY_GNEB58Eym-DuN9BtbEw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_IWdGEbImgkmO9FnVEUonZw_6_0">1,867,912</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q" contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSevenMember_gY_GNEB58Eym-DuN9BtbEw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_5Mawu2Jq-kKjxIJe9hckMg_6_3">3.25</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSevenMember_u78Ah4LoqUKqzJVIAxTUEA" format="ixt:datemonthdayyearen" name="armp:WarrantExpirationDate" id="Tc_PxSgtEjejUmOJqzvCEqDGQ_6_5">January 26, 2026</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:36.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceEightMember_fpCbl3DW_keRXlZj4Fhy1A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_w6M4-u7aHkmEkRXSPjROMw_7_0">4,285,935</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q" contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceEightMember_fpCbl3DW_keRXlZj4Fhy1A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_T-Dx-n8q006qNpk7S4_zkQ_7_3">3.25</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceEightMember_xrUR_X3n30aS1ib7pRRXLA" format="ixt:datemonthdayyearen" name="armp:WarrantExpirationDate" id="Tc_43pvc1GqIE6pI4ZlCc1fTA_7_5">March 16, 2026</ix:nonNumeric></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSixMember_WimCD-fx60m_KUK0LywoTg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_FvOxF1BkL06DNk2rwbAqBQ_8_0">1,200</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q" contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSixMember_WimCD-fx60m_KUK0LywoTg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_QHrPSDGDaEu8t80TdjpagA_8_3">1,680.00</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">None</p></td></tr><tr><td style="vertical-align:bottom;width:36.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_7MERSqkpGkudjgBi5oe7BQ_9_0">16,647,219</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_1053e0b5_c967_4b50_955f_48bf60d19a9a"></a><a id="Tc_mZHjlmXKckGXvrSSeOC6tQ_1_1"></a><a id="Tc_tmRjCUS0c0S1cL9Z0m_OSA_2_1"></a><a id="Tc_uOZU_YLVek-sAr7nlJmKIg_2_3"></a><a id="Tc_prNNHzxWl0ukavAx1OuH6Q_3_0"></a><a id="Tc_xp5UuzNrJUaY-CuXRnmzQg_3_1"></a><a id="Tc_PUIBOAuSjUK8nUmLgvQ-nQ_3_3"></a><a id="Tc_zNggD1s_Q0C4YUOatC71SQ_4_0"></a><a id="Tc_dBfVEyVx0UiBNdSK1fagXw_4_1"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_mIG1lkVL-0atlGMJAE4_KQ" continuedAt="Tb_mIG1lkVL-0atlGMJAE4_KQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">8. Equity Incentive Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Stock Award Plans</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company maintains a 2016 Equity Incentive Plan (the &#8220;2016 Plan&#8221;), which provides for the issuance of incentive share awards in the form of non-qualified and incentive stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards and performance-based stock awards. The awards may be granted by the Company&#8217;s Board of Directors to its employees, directors and officers and to consultants, agents, advisors and independent contractors who provide services to the Company or to a subsidiary of the Company. The exercise price for stock options must not be less than the fair market value of the underlying shares on the date of grant. Stock options expire no later than <ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_armp_EquityIncentivePlan2016Member_owlriQq-j0-oYrcsBY5Gjw" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_VpQCGr030EKsK8iqt9-psA">ten years</ix:nonNumeric> from the date of grant and generally vest and typically become exercisable over a <ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_armp_EquityIncentivePlan2016Member_a2GP2RQyPUaGZD8_SYwXvg" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_3OjoO_imCESTvj2hkdZUKw">four-year</ix:nonNumeric> period following the date of grant. Under the 2016 Plan, the number of shares authorized for issuance automatically increases annually beginning January 1, 2017 and through January 1, 2026. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the Merger, the Company assumed the C3J Jian, Inc. Amended 2006 Stock Option Plan (the &#8220;Assumed 2006 Plan&#8221;) and the C3J Therapeutics, Inc. 2016 Stock Plan (the &#8220;Assumed 2016 Plan&#8221;). These plans provided for stock option and restricted stock awards (&#8220;RSAs&#8221;) to C3J employees in years prior to the merger with AmpliPhi. The number of shares subject to each outstanding stock option and RSA under those assumed plans, along with the exercise price of stock options, were equitably adjusted pursuant to the terms of the plans to reflect the impact of the Merger and the one-for-<span style="-sec-ix-hidden:Hidden_6HHTzro5OEGysvS9SNdMCQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">fourteen</span></span> reverse stock split, in each case in a manner intended to preserve the then-current intrinsic value of the awards. <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_PlanNameAxis_armp_Assumed2006And2016PlanMember_jwnQgOCvrEi-zQv25P1M9Q" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="Narr_J66k4trYLkmedeHcnqow2Q">No</ix:nonFraction> additional awards will be made under either plan. The assumed C3J stock options were substantially vested and expensed as of the merger date. Vesting of the assumed C3J RSAs is based on the occurrence of a public liquidity event, or a change in control. In the event of a public liquidity event, service or milestone based vesting schedules begins. Service periods are generally <span style="-sec-ix-hidden:Hidden_FoLyPbG9hUC2OJDlbr-6vQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">two</span></span> to <ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_armp_Assumed2006And2016PlanMember_oXCoqIfziE2VJlO7Y9J9yA" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="Narr_xkwVoL5yDkWw8743uTGsWw">four years</ix:nonNumeric>. In the event of a change in control, <ix:nonFraction unitRef="Unit_Standard_pure_EPrTQjTDQkGfR4N7mgNYUg" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_C2GaHAyHpE6EcXNP5iHB6w">100</ix:nonFraction>% vesting occurs upon the closing of such an event. The merger with AmpliPhi constituted a public liquidity event and triggered the start of vesting of RSAs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company estimates the fair value of stock options with performance and service conditions using the Black-Scholes valuation model. Compensation expense related to stock options granted is measured at the grant date based on the estimated fair value of the award and is recognized on the accelerated attribution method over the requisite service period.</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_AupTqBP7MEWlwFe049z-Vw" continuedAt="Tb_AupTqBP7MEWlwFe049z-Vw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The assumptions used in the Black-Scholes model are presented below:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:31.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine months ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:68.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:68.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_EPrTQjTDQkGfR4N7mgNYUg" contextRef="As_Of_9_30_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_M1wYd_bHtkSmPDl5gRx6tg" decimals="2" format="ixt:numdotdecimal" name="armp:EquitySecuritiesMeasurementInput" scale="0" id="Narr_mZebpA0e2U2V1voGwvnL6Q">0.73</ix:nonFraction>% -- <ix:nonFraction unitRef="Unit_Standard_pure_EPrTQjTDQkGfR4N7mgNYUg" contextRef="As_Of_9_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_TcHNTAeDIUqS5KTjdnYf_A" decimals="2" format="ixt:numdotdecimal" name="armp:EquitySecuritiesMeasurementInput" scale="0" id="Narr_PaOtGrsaRE6URshfiwrjYQ">1.29</ix:nonFraction>%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_EPrTQjTDQkGfR4N7mgNYUg" contextRef="As_Of_9_30_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_si4L1iko2E64STirrO48PA" decimals="2" format="ixt:numdotdecimal" name="armp:EquitySecuritiesMeasurementInput" scale="0" id="Narr_eIGnbYkwvEiARNniqZUMVQ">0.25</ix:nonFraction>% -- <ix:nonFraction unitRef="Unit_Standard_pure_EPrTQjTDQkGfR4N7mgNYUg" contextRef="As_Of_9_30_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_vGTpt-wF-kumWbrMGmDgMA" decimals="2" format="ixt:numdotdecimal" name="armp:EquitySecuritiesMeasurementInput" scale="0" id="Narr_vqSlAKUUZkqKrMbNPu4sPw">1.51</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:top;width:68.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_EPrTQjTDQkGfR4N7mgNYUg" contextRef="As_Of_9_30_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_Y-YOyctUPkCj1ByCpX0cjA" decimals="2" format="ixt:numdotdecimal" name="armp:EquitySecuritiesMeasurementInput" scale="0" id="Narr_qklNxGLWAEypGHpBvwgAgQ">84.04</ix:nonFraction>% -- <ix:nonFraction unitRef="Unit_Standard_pure_EPrTQjTDQkGfR4N7mgNYUg" contextRef="As_Of_9_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_8qAqLG7eF0q7G6Mr5Lp6tg" decimals="2" format="ixt:numdotdecimal" name="armp:EquitySecuritiesMeasurementInput" scale="0" id="Narr__9CHtHYp3EmDy7edvmD1UQ">93.37</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_EPrTQjTDQkGfR4N7mgNYUg" contextRef="As_Of_9_30_2020_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_bMElE1RKukaULS3RIlENIw" decimals="2" format="ixt:numdotdecimal" name="armp:EquitySecuritiesMeasurementInput" scale="0" id="Tc_pOmYlvyftkm7vPCiFBIM3w_4_3">90.43</ix:nonFraction>%</p></td></tr></table></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_yVOO6OPMrUq-FVHStlOGJg_5_0"></a><a id="Tc_qKnTRzDWnk2sm9c5F7geKw_5_1"></a><a id="Tc_sEQNPQS9Fk2Rys4NDJPkxA_5_3"></a><a id="Tc_pGsjnRHFWkC6sQHH4UE4bw_6_0"></a><a id="_b0f4a721_fe5c_427e_aa2c_d201eab519dc"></a><a id="Tc_bW0uSz7SQEmaZOgBitirtQ_1_2"></a><a id="Tc_VCgvYPsXqkSb-b1Zzr-hHw_1_8"></a><a id="Tc_TlLypYqDvk60_J9agaHZlw_2_2"></a><a id="Tc_ITDuum7Ov0W6q2LsiNgHiQ_2_5"></a><a id="Tc_uG_hXhqRgUis6ogEnI-_gA_2_8"></a><a id="Tc_6wu1jPQwsUaCIuHPDgeS2g_2_11"></a><a id="Tc_CEBPO198_EC0G7LIRlLX8g_4_0"></a><a id="Tc_LTxqnyvAHE-3Nt234dKHIQ_4_2"></a><a id="Tc_wPjBOkhdFkeYzoA01j4p0g_4_5"></a><a id="Tc_bTnc4Ob76Uqh1L5EYXnCdw_4_8"></a><a id="Tc_7L_Hwf_NokeF24nEwIZR0w_4_11"></a><a id="Tc_pU3SRNYz0Eywfd-9NYAt9w_5_0"></a><a id="Tc_2MJr8OJszUSCJiPN7deM8w_6_0"></a><a id="Tc_z-bJfl5WPkWKT7TF6K5ESA_6_2"></a><a id="Tc_RnpafDHFf0OpGnq3gyoLqQ_6_5"></a><a id="Tc_a702xa-gPUuJC1eclOxZaQ_6_8"></a><a id="Tc_szAd8r3eEEiWCcDqirXYvg_6_11"></a><a id="_c2fe4613_4c36_43d0_aabd_0c63c89ae3c5"></a><a id="Tc_0f7l--jGSU6guYKw4mdJAg_1_2"></a><a id="Tc_CvxD8FKuX0mVUv6FLTw6NA_2_7"></a><a id="Tc_glsJS4FhNEKA0NRyYCVMlg_3_7"></a><a id="Tc_528-0D6u9U2dzRmcmbqnwg_4_4"></a><a id="Tc_uvKXSvyuGUy0MbtQ0cOGdA_4_7"></a><a id="Tc_PjHjBTV5ZUy8cLjTZZ9JAQ_5_4"></a><a id="Tc_8xb_wLa3ckSsq1B0tZcVAg_5_7"></a><a id="Tc_s2PFIkhfXEm7D3wkh63nWw_5_9"></a><a id="Tc_4YlVeihZdU-ERZNFR9rTqw_6_4"></a><a id="Tc_2Wi3WwIWZUupV_Xo0YtcoA_6_7"></a><a id="Tc_UFxyK6gnkkq3Yf4oW55qIw_6_9"></a><a id="Tc_SfoYU4w9K0qxsoJeYjzz9A_7_2"></a><a id="Tc_MJJewOsNIEGz-TYj0nn_tw_7_4"></a><a id="Tc_EGfEJB1FKUyttKeGCGq_uQ_7_7"></a><a id="Tc_fw4mqCIpMUaAL39XY3edeQ_7_9"></a><a id="Tc_8qN5f8lnSU-Vbfhop1HnKQ_8_0"></a><a id="Tc_rqEVmuRMjkuX_W2e-vkurw_8_4"></a><a id="Tc_OS614XPk-UWbcJq0L9cEdw_8_10"></a><a id="Tc_tqNWarZvbkGdbEKSmxY8pg_9_0"></a><a id="Tc_fFFIebkeHE-RCRpHpVl9-w_9_10"></a><a id="Tc_BzHbeKHMi0Oxy4eur427Ww_10_0"></a><a id="Tc_oufYB5Bd_0ir7bYzUDRkMA_10_9"></a><a id="Tc_TFSfFATNXE6cpBBl6vqHsw_11_0"></a><a id="Tc_ZDkK-41AfkWvLZLGoEfgMA_11_10"></a><a id="Tc_pp71rZyMQ0-h7Jxv2kMAUg_12_0"></a><a id="Tc_yjr5yRtO90isTkpyGJHVsg_12_4"></a><a id="Tc_WZA9oS8SukK_bZErj1LYhw_12_9"></a><a id="Tc_8Bbca0Qt_EaaJm37aIgVTw_13_0"></a><a id="Tc_18ciml5RhUmlLGQdiFifmg_13_4"></a><a id="Tc_F0kvuGGmMUevK7wzNVe7iQ_13_9"></a><a id="Tc_1YSvt8prwEyrzgKBGwbPwQ_14_0"></a><a id="Tc_a5iQvO-9dkaBz3G_NKkyiw_14_4"></a><a id="Tc_YSXRrj9vgUGbETdQtgYH9g_14_9"></a><a id="_ef17c27f_fec9_4b0c_af8c_33e6345b973c"></a><a id="Tc_d_0gHSGjaEmtFFFtvGTPVg_1_4"></a><ix:continuation id="Tb_mIG1lkVL-0atlGMJAE4_KQ_cont1" continuedAt="Tb_mIG1lkVL-0atlGMJAE4_KQ_cont2"><ix:continuation id="Tb_AupTqBP7MEWlwFe049z-Vw_cont1"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="background-color:#cceeff;vertical-align:top;width:68.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (in years)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_EPrTQjTDQkGfR4N7mgNYUg" contextRef="As_Of_9_30_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_ZYsQgyW6mkWdASHXKWLehQ" decimals="2" format="ixt:numdotdecimal" name="armp:EquitySecuritiesMeasurementInput" scale="0" id="Narr_rtk9eoSNLEW0Qls9-11sng">5.50</ix:nonFraction> - <ix:nonFraction unitRef="Unit_Standard_pure_EPrTQjTDQkGfR4N7mgNYUg" contextRef="As_Of_9_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_i9PzMC1lVUqwLuTxFWfdLA" decimals="2" format="ixt:numdotdecimal" name="armp:EquitySecuritiesMeasurementInput" scale="0" id="Narr_Hgyp5lJJsk6JLeOwrKMZww">7.00</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_EPrTQjTDQkGfR4N7mgNYUg" contextRef="As_Of_9_30_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_c6MOz2oxDUaT_X0fkJA_DA" decimals="2" format="ixt:numdotdecimal" name="armp:EquitySecuritiesMeasurementInput" scale="0" id="Narr_KhzOHvR6oEqUaDte-T3NLg">5.50</ix:nonFraction> - <ix:nonFraction unitRef="Unit_Standard_pure_EPrTQjTDQkGfR4N7mgNYUg" contextRef="As_Of_9_30_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_NRyFSCYoD020FMLell9_Bw" decimals="2" format="ixt:numdotdecimal" name="armp:EquitySecuritiesMeasurementInput" scale="0" id="Narr_cym8a42UEkGrRvG2h2bbmA">7.00</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_EPrTQjTDQkGfR4N7mgNYUg" contextRef="As_Of_9_30_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_JmEBEeGO8UeggSG1K-jwFw" decimals="0" format="ixt:numdotdecimal" name="armp:EquitySecuritiesMeasurementInput" scale="0" id="Tc_4s9wGSZn80mIZxeCfU17Vw_6_1">0</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_EPrTQjTDQkGfR4N7mgNYUg" contextRef="As_Of_9_30_2020_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_xmm1FvADiUqkK7ZP4Vv_tA" decimals="0" format="ixt:numdotdecimal" name="armp:EquitySecuritiesMeasurementInput" scale="0" id="Tc_Tj4JXXzZAka_4OVNzhEEFQ_6_3">0</ix:nonFraction>%</p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. Expected volatility is based on the historical volatility of Armata and peer companies&#8217; common stock. The expected term represents the period that the Company expects its stock options to be outstanding. The expected term assumption is estimated using the simplified method set forth in the SEC Staff Accounting Bulletin 110, which is the mid-point between the option vesting date and the expiration date. For stock options granted to parties other than employees or directors, the Company elects, on a grant by grant basis, to use the expected term or the contractual term of the option award. The Company has never declared or paid dividends on its common stock and has no plans to do so in the foreseeable future. Forfeitures are recognized as a reduction of stock-based compensation expense as they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="color:#231f20;">On August 1, 2021, Todd R. Patrick, who has served as the Company&#8217;s Chief Executive Officer (&#8220;CEO&#8221;) since May 2019, retired from day-to-day active management of the Company and resigned as CEO. On August 9, 2021, the Company and Mr. Patrick entered into a letter agreement, which among other things, provides that if</span> Mr. Patrick provides advisory services through the end of December 31, 2022 (the &#8220;Transition Period&#8221;), <span style="-sec-ix-hidden:Hidden_9mekj5kubk-rv8woYRxrCg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">one half</span></span> of the outstanding and unvested Company stock options and restricted share units held by Mr. Patrick as of the last day of the Transition Period will become fully vested, and all vested stock options held by Mr. Patrick as of that date will remain exercisable for the remainder of the <ix:nonNumeric contextRef="Duration_8_9_2021_To_8_9_2021_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_armp_StockOptionsAndRestrictedStockAwardsMember_HSuu2yjbeUO8uzqPtQxFDA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_4g5c-Hjq1UyPI6ln_pM_ow">10</ix:nonNumeric>-year term from the original grant date. The Company measured the stock-based compensation expense related to the modification and pre-vesting forfeitures of Mr. Patrick&#8217;s stock options and restricted share units to be a net credit of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2021_To_9_30_2021_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_armp_StockOptionsAndRestrictedStockAwardsMember_NAa3wvdW6ku9ixKdaxeq_Q" decimals="-5" format="ixt:numdotdecimal" name="armp:StockBasedCompensationExpenseRelatedToPreVestingForfeituresReversed" scale="6" id="Narr_xoG7HNqJpkKHPQyV2x9Baw">0.3</ix:nonFraction> million, which will be amortized as a credit to stock-based compensation over the remaining substantive requisite service period through December 31, 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="color:#231f20;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_gAWVsV3hrUqHsHllEjO7Rg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The tables below summarize the total stock-based compensation expense included in the Company&#8217;s consolidated statements of operations for the periods presented:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_77ETOpJ7T0afQOPGHLIu-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_Ab6mexXUTk-1ZlokGAJo4A_4_3">369,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_iXH_BdY7Yky0pOj-w2anUw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_OOrV9FHKakmkmJX-O0pEeA_4_6">205,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_G0J-iJ-hkEmVgCIOKKuQUA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_bCZArh26gEyD0w6XY6knYQ_4_9">1,121,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_v1HeSfyr9Em3B6Qct7RwOA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_EYHIoOtaJE-Ukdp1NFR_lA_4_12">841,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_1dzTloLluU2mQIMpctnh9g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_AvzHaewS2Ei5VEgG_bHZ8g_5_3">100,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_GodB2f3XM0-WcLyJqnzVFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_QEg4C0gKKUabrb-mMx4pXw_5_6">458,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_0sFoug39yEW-7YiIxYw6ZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_pmVpBKM6c0GUUKGLcl1RDw_5_9">1,097,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_we94IQA0Ok-L_lCieSHSdw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_-JSG3b22Hkq5Dc1tjNMCIw_5_12">1,772,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total stock-based compensation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_7_1_2021_To_9_30_2021_EHL267Iy5kqlAVaXmlK6uQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_XtmdsEp5mkiiI26QyTQf2w_6_3">469,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_7_1_2020_To_9_30_2020_C3Blutz6cUqC03qQKsaYEg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_DtSvMhIfHk61fgEwGxtHxw_6_6">663,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_2DwAXzjBKUiuwv7S-5EHSw_6_9">2,218,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_q4zFh0m5eEWWcNE5CGGkoA_6_12">2,613,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="background-color:#ffff00;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_8CdI1D5X20SRfD1ucyxKdQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Stock option transactions during the nine months ended September 30, 2021 are presented below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:40.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options&#160;Outstanding</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:58.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_p06NfnjXykOW1VGJD_YdZA_8_2">1,668,926</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q" contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_ubJMFjGnUUaM8BpdWi1a6g_8_5">6.30</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_8rl-g37700qfCCqQwUULVg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_Ul3YgzbZ0UOsPCJaysN0ZQ_8_7"> 8.32</ix:nonNumeric></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:58.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_8HygOds5xE6QKjtvEa03Wg_9_2">856,150</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_rrAGQvk570mYbqVErDBW5w_9_5">4.77</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:58.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_IG4Rr5oiaUeZGAdGIISfZA_10_2">73,517</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_7M7BdoKM-EOZuGUW6H5qsA_10_5">3.27</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="0" id="Tc_7QLiW2SinEagarbHlyXq1g_10_10">98,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:58.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited/Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_JnonAZg8tEKsU7FS_xv3nw_11_2">11,908</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_ttEidR7r906ymderfHZ7ag_11_5">48.67</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:58.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at September&#160;30,&#160;2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_9-9JcLnQEke3ssPsgm_bJw_12_2">2,439,651</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q" contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_TnzBp82gSEas9-wvlNIrXg_12_5">5.65</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_-NDD9k0xckCdFXW8RVgPtQ_12_7"> 8.19</ix:nonNumeric></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="Tc_88Eigdu5TkWbDy9WWilSkg_12_10">609,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:58.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested and expected to vest at September&#160;30,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="Tc_ls0v5vEaZE2XraKOLhPhuQ_13_2">2,439,651</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q" contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_Kz6kPzo0fEuJKJB1n1x8ww_13_5">5.65</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="Tc_zN4hUJcg30ukW0XOohxrLA_13_7"> 8.19</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="0" id="Tc_4YrMwclAmkev3WSOW4RfBA_13_10">609,000</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:58.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable at September&#160;30,&#160;2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_b7bGCQzTU06PoEnhdP5t4g_14_2">733,721</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q" contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_nA0sMj9peke-YboNvllHTw_14_5">9.48</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Tc_c3n5a02F2UWaWhejjayezw_14_7"> 6.55</ix:nonNumeric></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" id="Tc_JKwYX2Upb0ulIF683zMMrQ_14_10">252,000</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="armp:ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock" id="Tb_SOYehXkkdEm18jByP9QMZg" continuedAt="Tb_SOYehXkkdEm18jByP9QMZg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Restricted stock awards and restricted stock units during the nine months ended September 30, 2021 are presented below: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted Avg</b></p></td></tr></table></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_84xvPCfAfkemfg2CCJ7PNw_2_4"></a><a id="Tc_XtJKWBF0YEy-Tj2Otul83g_3_2"></a><a id="Tc_Ccc850ExNE-1mAZ23xC-Bw_3_4"></a><a id="Tc_TjCwrwpvgUild5yTVfx1Lw_4_0"></a><a id="Tc_m_p2YQ-ayUeGz3jp958vZg_4_4"></a><a id="Tc_dSw8R4iR306yXXj9MfpYZw_5_0"></a><a id="Tc_rfZk573RO0eEwUcU1badJQ_5_2"></a><a id="Tc_GbG4z-KneUiU4DRE_m2HjQ_5_5"></a><a id="Tc_H1afX-Z5PEGzkdM746-saQ_6_0"></a><a id="Tc_r9bE5m-XgUq8--3_rjbhOQ_7_0"></a><a id="Tc_aX-IjulANUuallDCP3oBtw_8_0"></a><a id="Tc_ZKE_8SavXUiApdu63UsuJA_8_4"></a><a id="_ddc40b43_95ba_42b6_8701_37f62426c6ec"></a><a id="Tc_WOpR_Um8LUmId3dh_YJAkQ_1_2"></a><a id="Tc_PmfOrYMI1kuY83_Vot1Jkw_2_0"></a><a id="Tc_epMMhfcIwkuhKALvqZrFQg_3_0"></a><a id="Tc_ETRY5Jg9JUyzdsEqIRh3gw_4_0"></a><a id="Tc_KbmvUN-euUymWcG2CsO7JA_5_0"></a><a id="Tc_r97sNbi_qkOqe8biRpyqpA_6_0"></a><a id="Tc_5KOS7OR_G0WR2CkD1XtunA_7_0"></a><ix:continuation id="Tb_mIG1lkVL-0atlGMJAE4_KQ_cont2"><ix:continuation id="Tb_SOYehXkkdEm18jByP9QMZg_cont1"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December 31, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_TDb9Z5iGoUePxWE6REEZBg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_AiCEJ6oSQEmzdPzSjivTiw_4_2">322,756</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_TDb9Z5iGoUePxWE6REEZBg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_bSwhliAVEES44eTF2pXEqQ_4_5">19.55</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited/Cancelled</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_uMrMSnX6sk6VBfvSkKl9Vg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="Tc_0l4SBd3hbECisgfSd97ycw_6_2">1,047</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_uMrMSnX6sk6VBfvSkKl9Vg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="Tc_GH67I8p-YEqT3jUfV4qx6g_6_5">6.89</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested and Issued as Common Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_uMrMSnX6sk6VBfvSkKl9Vg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Tc_ntG8Hn0VUU2p2IgK5ypgnw_7_2">167,691</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_uMrMSnX6sk6VBfvSkKl9Vg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_2IUMg_lupkWCawbqeoljhw_7_5">12.33</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at September&#160;30,&#160;2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="As_Of_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_UrkFQ9x-qEmjvoP_lxEMWQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_iPT2uSbTtU-AfDw7i-lqsQ_8_2">154,018</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q" contextRef="As_Of_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_UrkFQ9x-qEmjvoP_lxEMWQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_knJyw7xpykC5MzIYNnUVUA_8_5">27.49</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">     </span><span style="visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">      The aggregate intrinsic value of options at September 30, 2021 is based on the Company&#8217;s closing stock price on that date of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q" contextRef="As_Of_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_joNmkWmSp0eoVV34drwlKA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_zMj_xreAbU-oFmAMbW410w">3.62</ix:nonFraction> per share. As of September 30, 2021, there was $<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_joNmkWmSp0eoVV34drwlKA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="Narr_bXOX3UdRikSziF6X--Fr2A">3.9</ix:nonFraction></span> million of total unrecognized compensation expense related to unvested stock options and RSAs, which the Company expects to recognize over the weighted average remaining period of approximately <ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_armp_StockOptionsAndRestrictedStockAwardsMember_pNotzPzMhUuSettHWcT5dw" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_ZkSdQsPah0-A5zvpfxrMtg">1.8</ix:nonNumeric> years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Shares Reserved for Future Issuance</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="armp:ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" id="Tb_7RIzWjyxL0iMZyUtb48o2A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of September 30, 2021, the Company had reserved shares of its common stock for future issuance as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares&#160;Reserved</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options outstanding</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_HKQIeuwM4Ei-Kss2c3BNRg_2_2">2,439,651</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="As_Of_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_hi0c_0vE9E-W67zzRNTT2g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_x67k3SMdNkCNExDjRcPbGA_3_2">30,000</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Employee stock purchase plan</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="As_Of_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_joNmkWmSp0eoVV34drwlKA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_uIBRjoBgc0muX7tWNlx7Zg_4_2">9,748</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Available for future grants under the 2016 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="As_Of_9_30_2021_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_armp_EquityIncentivePlan2016Member_nK9yLVbEL06fLvTMqAkXxg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Tc_im9GablRjkeZZjuIuXi20w_5_2">227,856</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants outstanding</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_Qawt27rV906ktG1cA9YYyw_6_2">16,647,219</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total shares reserved</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg" contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_Xxj7S6sYl0CsSij_m2QllA_7_2">19,354,474</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_goDr4Ik9fUGt2bT1Lwseig" continuedAt="Tb_goDr4Ik9fUGt2bT1Lwseig_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">9. Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company leases office and research and development space under a non-cancelable operating lease in Marina del Rey, CA. The lease commenced January&#160;1, 2012 and in April 2020, the Company amended the lease (&#8220;Lease Amendment&#8221;) which, among other things, extended the lease term through December 31, 2031. Base annual rent for calendar year 2022, the first year under the Lease Amendment extended term, will be approximately $<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_4_1_2020_To_4_30_2020_97rB72XwWUSnYAu0RGwgjQ" decimals="-5" format="ixt:numdotdecimal" name="armp:OperatingLeaseBaseRent" scale="6" id="Narr_SdEVG1sj7UO58d6EhJYSiQ">1.9</ix:nonFraction> million, and base rent increases by <ix:nonFraction unitRef="Unit_Standard_pure_EPrTQjTDQkGfR4N7mgNYUg" contextRef="Duration_4_1_2020_To_4_30_2020_97rB72XwWUSnYAu0RGwgjQ" decimals="2" format="ixt:numdotdecimal" name="armp:AnnualIncreaseInRentPercentage" scale="-2" id="Narr_-g-SEEGIV0mlwX0i5V0pVg">3</ix:nonFraction>% annually and will be $<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_4_1_2020_To_4_30_2020_97rB72XwWUSnYAu0RGwgjQ" decimals="-5" format="ixt:numdotdecimal" name="armp:OperatingLeaseBaseRentEndOfLeaseTerm" scale="6" id="Narr_Sn-fqXh6B0Ox5VMJzJN-3A">2.5</ix:nonFraction><span style="white-space:pre-wrap;"> million by the end of the amended term.  In addition, the Company received a six-month rent abatement in 2020. The Company is entitled to use an allowance for tenant improvements of </span>$<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_4_1_2020_To_4_30_2020_97rB72XwWUSnYAu0RGwgjQ" decimals="-5" format="ixt:numdotdecimal" name="armp:LeaseAndRentalAbatementCredit" scale="6" id="Narr_pN-P5jzCn0uc_8j2evihqQ">0.8</ix:nonFraction> million during 2021, with any unused tenant improvement amount as of December 31, 2021 to offset future payments. In accordance with authoritative guidance, the Company re-measured the lea<span style="background-color:#ffffff;color:#222222;">se liability in April 2020 to be </span><span style="background-color:#ffffff;color:#222222;">$<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_4_30_2020_1iPl4CxS1EenIgtFs0sC1g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="Narr_C0uec1SFo06bsyYQQFeA1g">11.7</ix:nonFraction></span><span style="background-color:#ffffff;color:#222222;"> million and related&#160;right of use asset of </span><span style="background-color:#ffffff;color:#222222;">$<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_4_30_2020_1iPl4CxS1EenIgtFs0sC1g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="Narr_5A63Ey2QnEaC_ETzms82AA">11.0</ix:nonFraction></span><span style="background-color:#ffffff;color:#222222;"> million as of the Lease Amendment date with an incremental borrowing rate of </span><span style="background-color:#ffffff;color:#222222;"><ix:nonFraction unitRef="Unit_Standard_pure_EPrTQjTDQkGfR4N7mgNYUg" contextRef="As_Of_4_30_2020_1iPl4CxS1EenIgtFs0sC1g" decimals="4" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="Narr_qHtYj7jSJUyVkCDR19tnUA">12.89</ix:nonFraction>%</span><span style="background-color:#ffffff;color:#222222;">. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="background-color:#ffffff;color:#222222;">On October 28, 2021, the Company entered into a lease for office and research and development space under a non-cancellable lease in Los Angeles, CA (the &#8220;2021 Lease&#8221;). The 2021 Lease payment start date is May 1, 2022 and the total lease term is for </span><ix:nonNumeric contextRef="As_Of_10_31_2021_egZlLrGpKk2-r-0udRYIlQ" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" id="Narr_P9zda716GU-9NzjCDjFb0g"><span style="background-color:#ffffff;color:#222222;">16 years</span></ix:nonNumeric><span style="background-color:#ffffff;color:#222222;"> and runs through 2038. Monthly rent for 2022 and 2023 will be fully or partially abated while the lessor and the Company complete planned tenant improvements to the facility. Base monthly rent will be approximately </span><span style="background-color:#ffffff;color:#222222;">$<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_10_31_2021_egZlLrGpKk2-r-0udRYIlQ" decimals="-4" format="ixt:numdotdecimal" name="armp:BaseAnnualRentToBePaidYearOne" scale="6" id="Narr_Qs_y_0LSkkCVGT50EyhmRg">0.25</ix:nonFraction></span><span style="background-color:#ffffff;color:#222222;"> million in 2024. The Company is entitled to receive an allowance for tenant improvements of up to </span><span style="background-color:#ffffff;color:#222222;">$<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_10_31_2021_egZlLrGpKk2-r-0udRYIlQ" decimals="-5" format="ixt:numdotdecimal" name="armp:MaximumAllowanceForTenantImprovementsReceivable" scale="6" id="Narr_0OPjtn7XXkCjgdPPYkDX4Q">6.5</ix:nonFraction></span><span style="background-color:#ffffff;color:#222222;white-space:pre-wrap;"> million.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">From time to time, the Company may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of business. Any of these claims could subject the Company to costly legal expenses and, while management generally believes that there is adequate insurance to cover many different types of liabilities, the Company&#8217;s insurance carriers may deny coverage or policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on the consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage the Company&#8217;s reputation and business. The Company is currently not a party to any legal proceedings, </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_goDr4Ik9fUGt2bT1Lwseig_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">the adverse outcome of which, in management&#8217;s opinion, individually or in the aggregate, would have a material adverse effect on our consolidated results of operations or financial position.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="armp:AwardTextBlock" id="Tb_T6XRdTFWGkq0Xyb2v6mydQ" continuedAt="Tb_T6XRdTFWGkq0Xyb2v6mydQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">10. Grants and Awards</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">MTEC Grant </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On June 15, 2020, the Company entered into a Research Project Award agreement (the &#8220;MTEC Agreement&#8221;) with the Medical Technology Enterprise Consortium (&#8220;MTEC&#8221;), pursuant to which the Company expects to receive a $<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_7_15_2020_To_7_15_2020_srt_CounterpartyNameAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_ITaRqTiHmk-EtdzqEDU-gw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="6" id="Narr_XJTKfs1BgU6aKmB9oA0JIQ">15.0</ix:nonFraction> million&#160;grant and entered into a three-year program administered by the U.S. Department of Defense through MTEC with funding from the Defense Health Agency and Joint Warfighter Medical Research Program. The MTEC funds are to partially fund a Phase&#160;1b/2, randomized, double-blind, placebo-controlled, dose escalation clinical study of Armata&#39;s therapeutic phage-based candidate, AP-SA02, for the treatment of complicated&#160;<i style="font-style:italic;">Staphylococcus aureus</i>&#160;bacteremia infections. The MTEC Agreement specifies that the grant will be paid to the Company through a cost reimbursable model, based on agreed upon cost share percentages, and the grant money received is not refundable to MTEC. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> &#160; &#160; &#160; &#160;</span></span>Upon license or commercialization of intellectual property developed with the funding from the MTEC Agreement, additional fees will be due to MTEC. &#160;The Company will elect whether to (a) pay a fixed royalty amount, which is subject to a cap based upon total funding received, or (b) pay an additional assessment fee, which would also be subject to a cap based upon a percentage of total funding received. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The MTEC Agreement will be effective through January 25, 2024. &#160;The MTEC Agreement may be terminated in whole or in part, 30 calendar days following the written notice from the Company to MTEC. In addition, MTEC has the right to terminate the MTEC Agreement upon material breach by the Company. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company determined that the MTEC Agreement is not in the scope of ASC 808 or ASC 606. Applying ASC 606 by analogy the Company recognizes proceeds received under the MTEC Agreement as grant revenue on the statement of operations when related costs are incurred. The Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_7_1_2021_To_9_30_2021_EHL267Iy5kqlAVaXmlK6uQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="6" id="Narr_8IfgGJqHjUuc9MdCF_xeEg">1.3</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="6" id="Narr__wz_Ubkz9kiqMQn19eZlbQ">3.5</ix:nonFraction> million in grant revenue from the MTEC Agreement during the three and nine months ended September 30, 2021, respectively. The Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="6" id="Narr__NnXVV8gI0aDX6BEYieDeQ"><ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_7_1_2020_To_9_30_2020_C3Blutz6cUqC03qQKsaYEg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="6" id="Narr_gCtQYfAjjU6QBzL_6G8sSA">0.3</ix:nonFraction></ix:nonFraction> million in grant revenue from the MTEC Agreement during each of the three and nine months ended September 30, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CFF Therapeutics Development Award </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On March 13, 2020, the Company entered into an award agreement (the &#8220;Agreement&#8221;) with CFF, pursuant to which the Company received a Therapeutics Development Award of up to $<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_3_13_2020_dei_LegalEntityAxis_armp_CysticFibrosisFoundationMember_srt_RangeAxis_srt_MaximumMember_QdkZoWNHYkyCGniRryGR1w" decimals="-5" format="ixt:numdotdecimal" name="armp:ThresholdDevelopmentAward" scale="6" id="Narr_vzkAwgdWI0GBjvg_8vAGyA">5.0</ix:nonFraction> million (the &#8220;Award&#8221;). The Award will be used to fund a portion of the Company&#8217;s Phase 1b/2 clinical trial of the&#160;<i style="font-style:italic;">Pseudomonas aeruginosa</i>&#160;(&#8220;<i style="font-style:italic;">P. aeruginosa</i>&#8221;) phage candidate, AP-PA02, as a treatment for&#160;<i style="font-style:italic;">Pseudomonas</i>&#160;airway infections in people with cystic fibrosis (&#8220;CF&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The first payment under the Agreement, in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_3_13_2020_dei_LegalEntityAxis_armp_CysticFibrosisFoundationMember_Vmk5a-OLzkuheIihAx82BA" decimals="-5" format="ixt:numdotdecimal" name="armp:AwardReceivable" scale="6" id="Narr_Gr3H9cU3L0WmGGPi3YHbrw">1.0</ix:nonFraction> million, became due upon signing the Agreement and was received in April 2020. During the quarter ended September 30, 2021, an additional $<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_7_1_2021_To_9_30_2021_dei_LegalEntityAxis_armp_CysticFibrosisFoundationMember_tYChB5g8O0GcrXG6pdzhcA" decimals="-5" format="ixt:numdotdecimal" name="armp:AmountReceivedUponAchievementOfMilestone" scale="6" id="Narr_lL_Q4Ab-jUKIZxnba79k5Q">0.8</ix:nonFraction><span style="white-space:pre-wrap;"> million was received upon achievement of a milestone.  The remainder of the Award will be paid to the Company incrementally in installments upon the achievement of certain milestones related to the development program and progress of the Phase 1b/2 clinical trial of AP-PA02, as set forth in the Agreement. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">If the Company ceases to use commercially reasonable efforts directed to the development of AP-PA02, or any other Product (as defined in the Agreement), for a period of <ix:nonNumeric contextRef="Duration_3_13_2020_To_3_13_2020_dei_LegalEntityAxis_armp_CysticFibrosisFoundationMember_bkw-_kZsEUWVZ6CfCvxnag" format="ixt-sec:durwordsen" name="armp:AwardAgreementInterruptionPeriod" id="Narr_Rl9vaqdtIES5htHknBnlCA">360 days</ix:nonNumeric> (an &#8220;Interruption&#8221;) and fails to resume the development of the Product after receiving from CFF notice of an Interruption, then the Company must either repay the amount of the Award actually received by the Company, plus interest, or grant to CFF (1) an exclusive (even as to the Company), worldwide, perpetual, sublicensable license under technology developed under the Agreement that covers the Product for use in treating infections in CF patients (the &#8220;CF Field&#8221;), and (2) a non-exclusive, worldwide, perpetual, sublicensable license under certain background intellectual property covering the Product, to the extent necessary to commercialize the Product in the CF Field.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_T6XRdTFWGkq0Xyb2v6mydQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Upon commercialization by the Company of any Product, the Company will owe a fixed royalty amount to CFF, which is to be paid in installments determined, in part, based on commercial sales volumes of the Product. The Company will be obligated to make an additional fixed royalty payment upon achieving specified sales milestones. The Company may also be obligated to make a payment to CFF if the Company transfers, sells or licenses the Product in the CF Field, or if the Company enters into a change of control transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#160;</span></span>The term of the Agreement commenced on March 10, 2020 and expires on the earlier of the date on which the Company has paid CFF all of the fixed royalty payments set forth therein, the effective date of any license granted to CFF following an Interruption, or upon earlier termination of the Agreement. Either CFF or the Company may terminate the agreement for cause, which includes the Company&#8217;s material failure to achieve certain development milestones. The Company&#8217;s payment obligations survive the termination of the Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the CFF award is in the scope of ASC 808. Accordingly, as discussed in Note 3, award amounts received from CFF upon achievement of certain milestones are recognized as credits to research and development expenses in the period the expenses are incurred. During the three months ended September 30, 2021 and 2020, the Company did not recognize any credits to research and development expenses related to the CFF award. During the nine months ended September 30, 2021 and 2020, the Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2021_To_9_30_2021_dei_LegalEntityAxis_armp_CysticFibrosisFoundationMember_RpwT93VR-ECLCn7xD0c95g" decimals="-5" format="ixt:numdotdecimal" name="armp:ResearchAndDevelopmentCreditsRecognized" scale="6" id="Narr_A6Y80DgIx0KN1-ijysfYbA">0.8</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2020_To_9_30_2020_dei_LegalEntityAxis_armp_CysticFibrosisFoundationMember_oDkg0nbvCUGTMxn-UCPsfA" decimals="-5" format="ixt:numdotdecimal" name="armp:ResearchAndDevelopmentCreditsRecognized" scale="6" id="Narr_OaASiwxC0Eq5FZJwGv5Dmg">1.0</ix:nonFraction><span style="white-space:pre-wrap;"> million in credits to research and development expenses related to the CFF award, respectively. In addition, the Company concluded under the guidance in ASC 730 that it does not have an obligation to repay funds received once related research and development expenses are incurred.  </span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" name="armp:AssetAcquisitionTextBlock" id="Tb_FAjFAcysCk-hpcvErqiDWw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">11. Synthetic Genomics Asset Acquisition </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February&#160;28, 2018, C3J completed an acquisition of certain synthetic phage assets (the &#8220;synthetic phage assets&#8221;) from Synthetic Genomics, Inc. (&#8220;SGI&#8221;) for consideration consisting of $<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="As_Of_2_28_2018_armp_AssetAcquisitionAxis_armp_SyntheticGenomicsIncMember_dei_LegalEntityAxis_armp_C3jTherapeuticsIncMember_mk1RLuCDkk6c_shfOgofxw" decimals="-5" format="ixt:numdotdecimal" name="armp:CashPaidForProductiveAssets" scale="6" id="Narr_21YBChtJs0SnLso8ISd_LA">8.0</ix:nonFraction> million in cash and $<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_2_28_2018_To_2_28_2018_armp_AssetAcquisitionAxis_armp_SyntheticGenomicsIncMember_dei_LegalEntityAxis_armp_C3jTherapeuticsIncMember_RidG05BOeEyASZ1M8D09rA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" scale="6" id="Narr_lbNnDYDfvkCunF3nqqgquA">27.0</ix:nonFraction> million in equity. The cash payments consisted of: $<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_2_28_2018_To_2_28_2018_armp_AssetAcquisitionAxis_armp_SyntheticGenomicsIncMember_dei_LegalEntityAxis_armp_C3jTherapeuticsIncMember_srt_StatementScenarioAxis_armp_ScenarioOriginalExpectedPaymentOneMember_clsnrNZH1UazMXYm92c0Pg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="Narr_58cAe3JpakabZ7EeRXvqGA">1.0</ix:nonFraction> million paid at closing on February 28, 2018, $<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_2_28_2018_To_2_28_2018_armp_AssetAcquisitionAxis_armp_SyntheticGenomicsIncMember_dei_LegalEntityAxis_armp_C3jTherapeuticsIncMember_srt_StatementScenarioAxis_armp_ScenarioOriginalExpectedPaymentTwoMember_gEaPDWofx0qOEWXTSGF3Tw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="Narr_euZqF872M0KAAdepcL_y0A">1.0</ix:nonFraction> million at one year from closing, $<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_2_28_2018_To_2_28_2018_armp_AssetAcquisitionAxis_armp_SyntheticGenomicsIncMember_dei_LegalEntityAxis_armp_C3jTherapeuticsIncMember_srt_StatementScenarioAxis_armp_ScenarioOriginalExpectedPaymentThreeMember_jidGEQgNYECfuWhjbDYubA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="Narr_noevNoeUiUq3YWUVx8Td2w">1.0</ix:nonFraction> million at two years from closing, and $<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_2_28_2018_To_2_28_2018_armp_AssetAcquisitionAxis_armp_SyntheticGenomicsIncMember_dei_LegalEntityAxis_armp_C3jTherapeuticsIncMember_srt_StatementScenarioAxis_armp_ScenarioOriginalExpectedPaymentFourMember_gxbq2ISe3UijfOm_OFNWLw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="Narr_AI-j1D9540CvPPT4YeRGCg">5.0</ix:nonFraction> million at three years from closing (the payments due on the one, two, three year anniversary are collectively the &#8220;time-based payment obligation&#8221;). The equity payment (the &#8220;equity payment&#8221; and, together with the time-based payment obligation, the &#8220;deferred purchase price arrangement&#8221;) was due upon the earlier of the initial public offering of shares of C3J&#8217;s common stock pursuant to an effective registration statement under the Securities Act of 1933, as amended, the sale of all or substantially all of C3J&#8217;s assets to a third party, or a consolidation or merger into a third party. On December&#160;20, 2018, in contemplation of the Merger (see Note&#160;1), the deferred purchase price arrangement was amended. Under the amended agreement, the purchase consideration consisted of (i)&#160;closing consideration of $<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_2_28_2018_To_2_28_2018_armp_AssetAcquisitionAxis_armp_SyntheticGenomicsIncMember_dei_LegalEntityAxis_armp_C3jTherapeuticsIncMember_RidG05BOeEyASZ1M8D09rA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="Narr_ClnA7Gh2ZUKe4gRN55_XEg">1.0</ix:nonFraction> million paid on February&#160;28, 2018, (ii)&#160;cash payments of $<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_12_20_2018_To_12_20_2018_armp_AssetAcquisitionAxis_armp_SyntheticGenomicsIncMember_dei_LegalEntityAxis_armp_C3jTherapeuticsIncMember_srt_StatementScenarioAxis_armp_ScenarioAmendedExpectedPaymentOneMember_zNXu_So6HEuNH4kwwRcmWw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="Narr_wgr4-YBNn0SDlniTKP0k2g">1.0</ix:nonFraction> million on January&#160;31, 2019, $<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_12_20_2018_To_12_20_2018_armp_AssetAcquisitionAxis_armp_SyntheticGenomicsIncMember_dei_LegalEntityAxis_armp_C3jTherapeuticsIncMember_srt_StatementScenarioAxis_armp_ScenarioAmendedExpectedPaymentTwoMember_rqhFNiTiRE2BmMr7XyphyQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="Narr_sSsCYeKa0k-Rg-1wceAZ7A">1.0</ix:nonFraction> million on January&#160;31, 2020, and $<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_12_20_2018_To_12_20_2018_armp_AssetAcquisitionAxis_armp_SyntheticGenomicsIncMember_dei_LegalEntityAxis_armp_C3jTherapeuticsIncMember_srt_StatementScenarioAxis_armp_ScenarioAmendedExpectedPaymentThreeMember_R1Aa4SvwlUuog7rLKl3MqA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="Narr_Mv2fGIL5Y0eI1jcKSuxdTA">2.0</ix:nonFraction> million on January&#160;31, 2021, (iii)&#160;an issuance of that number of shares of C3J&#8217;s common stock equal to <ix:nonFraction unitRef="Unit_Standard_pure_EPrTQjTDQkGfR4N7mgNYUg" contextRef="Duration_2_1_2018_To_2_28_2018_armp_AssetAcquisitionAxis_armp_SyntheticGenomicsIncMember_dei_LegalEntityAxis_armp_C3jTherapeuticsIncMember_Z8D7DoUmZ0qMYFL0DwXLPw" decimals="INF" format="ixt-sec:numwordsen" name="armp:PercentageOfFullyDilutedCapitalizationForIssuanceOfCommonStock" scale="-2" id="Narr_2EF_DCyfb0S_eETDfoNGgQ">ten</ix:nonFraction>&#160;percent of C3J&#8217;s fully-diluted capitalization, excluding options and restricted stock awards, immediately prior to the closing of the Merger, and (iv)&#160;potential milestone payments of up to $<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_2_1_2018_To_2_28_2018_armp_AssetAcquisitionAxis_armp_SyntheticGenomicsIncMember_dei_LegalEntityAxis_armp_C3jTherapeuticsIncMember_Z8D7DoUmZ0qMYFL0DwXLPw" decimals="-5" format="ixt:numdotdecimal" name="armp:MaximumPotentialMilestonePayments" scale="6" id="Narr_SEfw6pdqykGnCQyuoEP6JQ">39.5</ix:nonFraction> million related to the development and relevant regulatory approval of products utilizing bacteriophage from the synthetic phage assets acquired from SGI (the &#8220;milestone payment obligation&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The equity payment was settled on May 9, 2019, the date of the Merger (Note 1). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The present value of the time-based payment obligations was included in the Company&#8217;s balance sheet, with interest accreted to the maturity date. The Company paid the last installment of the time-based payment obligation in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2021_To_3_31_2021_armp_AssetAcquisitionAxis_armp_SyntheticGenomicsIncMember_dei_LegalEntityAxis_armp_C3jTherapeuticsIncMember_NBfmWnEmKk6A5v2Z9Ffejw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="Narr_gTPLyV9pzkmTlW5wt51kGw">2.0</ix:nonFraction> million during the three months ended March 31, 2021. For the nine months ended September 30, 2021 and 2020, the Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="6" id="Narr__O_0QSzHPEO2arABuaglPQ">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g" contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="6" id="Narr_QxTgJ0E1T0KyDduYvntqQw">0.5</ix:nonFraction> million of interest expense related to the time-based payment obligations, respectively.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_ab2a4446_071e_4d68_a45e_2a8586057862"></a><a id="Item2MANAGEMENTSDISCUSSIONANDANALYSIS_77"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited consolidated financial statements and related notes included in this Quarterly Report on Form 10-Q, and our audited financial statements and notes thereto as of and for the year ended December 31, 2020 included in our Form 10-K filed on March 18, 2021 with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our predecessor, C3 Jian, Inc., was incorporated under the laws of the State of California on November&#160;4, 2005. On February&#160;26, 2016, as part of a reorganization transaction, C3 Jian, Inc. merged with a wholly owned subsidiary of C3J Therapeutics, Inc. (&#8220;C3J&#8221;), and as part of this process, C3 Jian, Inc. was converted to a limited liability company organized under the laws of the State of California named C3 Jian, LLC. On May 9, 2019, C3J completed a reverse merger with AmpliPhi Biosciences Corporation, a bacteriophage development stage company (&#8220;AmpliPhi&#8221;), where Ceres Merger Sub, Inc., a wholly-owned subsidiary of AmpliPhi, merged with and into C3J (the&#160;&#8220;Merger&#8221;). Following the completion of the Merger, and a $10.0 million concurrent private placement financing, the former C3J shareholders owned approximately 76% of our common stock and the former AmpliPhi shareholders owned approximately 24% of our common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Immediately prior to the Merger, AmpliPhi completed a 1-for-14 reverse stock split and changed its name to Armata Pharmaceuticals, Inc. Our common stock is traded on the NYSE American exchange under the symbol &#8220;ARMP.&#8221;  We are headquartered in Marina del Rey, CA, in a 35,000 square-foot research and development facility built for product development with capabilities spanning from bench to clinic. In addition to microbiology, synthetic biology, formulation, chemistry and analytical laboratories, the facility is equipped with two licensed GMP drug manufacturing suites enabling the production, testing and release of clinical material.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Statements contained in this Quarterly Report on Form 10-Q that are not statements of historical fact are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, without limitation, statements concerning product development plans, commercialization of our products, the expected market opportunity for our products, the use of bacteriophages and synthetic phages to kill bacterial pathogens, having resources sufficient to fund our operations into the first quarter of 2022, future funding sources, general and administrative expenses, clinical trial and other research and development expenses, costs of manufacturing, costs relating to our intellectual property, capital expenditures, the expected benefits of our targeted phage therapies strategy, the potential market for our products, tax credits and carry-forwards, and litigation-related matters. Words such as &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;plan,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;will,&#8221; &#8220;goal,&#8221; &#8220;potential&#8221; and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. These statements are subject to risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under Item 1A, &#8220;Risk Factors&#8221; in our Form 10-K for the year ended December 31, 2020, filed on March 18, 2021 with the SEC, and under Item 1A, &#8220;Risk Factors&#8221; and elsewhere in this Quarterly Report on Form 10-Q. These forward-looking statements speak only as of the date on which they were made, and we undertake no obligation to update any forward-looking statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using our proprietary bacteriophage-based technology. Bacteriophages or &#8220;phages&#8221; have a powerful and highly differentiated mechanism of action that enables binding to and killing specific bacteria, in contrast to traditional broad-spectrum antibiotics. We believe that phages represent a promising means to treat bacterial infections, especially those that have developed resistance to current standard of care therapies, including the so-called multidrug-resistant or &#8220;superbug&#8221; strains of bacteria. We are a leading developer of phage therapeutics which are uniquely positioned to address the growing worldwide threat of antibiotic-resistant bacterial infections.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are combining our proprietary approach and expertise in identifying, characterizing and developing both naturally-occurring and engineered (synthetic) bacteriophages with our proprietary phage-specific current good manufacturing practice regulation (&#8220;cGMP&#8221;) manufacturing capabilities to advance a broad pipeline of high-quality bacteriophage product candidates. We believe that synthetic phage, engineered using advances in sequencing and synthetic biology techniques, represent a promising means to advance phage therapy, including phage-based diagnostics and improving upon the ability of natural phage to treat bacterial infections, especially those that have developed resistance to current antibiotic therapies, including the multidrug-resistant or &#8220;superbug&#8221; bacterial pathogens.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We are developing and advancing our lead clinical phage candidate for&#160;<i style="font-style:italic;">Pseudomonas aeruginosa</i>. On October 14, 2020, Armata received the approval to proceed from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) for its Investigational New Drug application for AP-PA02. We plan to continue to advance the &#8220;SWARM-<i style="font-style:italic;">P.a.</i>&#8221; study &#8211; a Phase 1b/2a, multicenter, double-blind, randomized, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial to evaluate the safety and tolerability of inhaled AP-PA02 in subjects with CF and chronic pulmonary&#160;<i style="font-style:italic;">P. aeruginosa&#160;</i>infection, provided that the impacts of COVID-19 do not further impede our ability to enroll subjects in this clinical trial. This study is supported by the CFF, which granted us a Therapeutics Development Award of up to $5.0 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We are also developing a phage product candidate for<i style="font-style:italic;">&#160;Staphylococcus aureus</i>&#160;for the treatment of&#160;<i style="font-style:italic;">S. aureus</i>&#160;bacteremia. On June 15, 2020, we entered into an agreement (the &#8220;MTEC Agreement&#8221;) with the Medical Technology Enterprise Consortium (&#8220;MTEC&#8221;), pursuant to which we expect to receive a $15.0 million&#160;grant and entered into a three-year program administered by the U.S Department of Defense (&#8220;DoD&#8221;) through MTEC with funding from the Defense Health Agency and Joint Warfighter Medical Research Program. We expect to use the grant to partially fund a Phase 1/2, multi-center, randomized, double-blind, placebo- controlled dose escalation study,&#160;<span style="color:#231f20;">provided that the COVID-19 pandemic has been reduced to the point that clinical trials in patients are enrolling,&#160;</span>that will assess the safety, tolerability, and efficacy of this development program, using our phage-based candidate, AP-SA02, for the treatment of adults with <i style="font-style:italic;">S. aureus</i>&#160;bacteremia.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In partnership with Merck &amp; Co., known as Merck Sharp &amp; Dohme outside of the United States and Canada (&#8220;Merck&#8221;), we are developing proprietary synthetic phage candidates to target undisclosed infectious disease agents. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Our&#160;proprietary phage engineering platform serves to enhance the clinical and commercial prospects of phage therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Attributes of engineered phages can include expanded host range, improved potency which is a fundamental drug property that can translate into improved clinical efficacy, and importantly, biofilm disruption, which is a critical aspect of serious infections that needs to be addressed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to our more advanced pipeline programs, we have phage discovery efforts underway to target other major pathogens of infectious disease (including ESKAPE pathogens) and preventable infectious disease of the microbiome.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are committed to conducting randomized controlled clinical trials required for FDA approval in order to move toward commercialization of alternatives to traditional antibiotics and provide a potential method of treating patients suffering from drug-resistant and difficult-to-treat bacterial infections.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following chart summarizes the status of our phage product candidate development programs and partners.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:198.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><img src="armp-20210930x10q001.jpg" alt="Graphic" style="display:inline-block;height:198.75pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:409.41pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have generally incurred net losses since our inception and our operations to date have been primarily limited to research and development and raising capital. As of September 30, 2021, we had an accumulated deficit of $196.8 million. We anticipate that a substantial portion of our capital resources and efforts in the foreseeable future will be focused on completing the development and seeking to obtain regulatory approval of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We currently expect to use our existing cash and cash equivalents for the continued research and development of our product candidates, including through our targeted phage therapies strategy, and for working capital and other general corporate purposes. We expect to continue to incur significant and increasing operating losses at least for the next several years. We do not expect to generate product revenue unless and until we successfully complete development and obtain marketing approval for at least one of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We may also use a portion of our existing cash and cash equivalents for the potential acquisition of, or investment in, product candidates, technologies, formulations or companies that complement our business, although we have no current understandings, commitments or agreements to do so. Our existing cash and cash equivalents will not be sufficient to enable us to complete all necessary development of any potential product candidates. Accordingly, we will be required to obtain further funding through one or more other public or private equity offerings, debt financings, collaboration, strategic financing, grants or government contract awards, licensing arrangements or other sources. Our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic. Adequate additional funding may not be available to us on acceptable terms, or at all. If we are unable to raise capital when needed or on acceptable terms, we may be required to defer, reduce or eliminate significant planned expenditures, restructure, curtail or eliminate some or all of our development programs or other operations, dispose of assets, enter into arrangements that may require us to relinquish rights to certain of our product candidates, technologies or potential markets, file for bankruptcy or cease operations altogether. Any of these events could have a material adverse effect on our business, financial condition and results of operations and result in a loss of investment by our stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Business Update Regarding COVID-19</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="color:#231f20;">On January 30, 2020, the World Health Organization (&#8220;WHO&#8221;) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the &#8220;COVID-19 outbreak&#8221;) and the risks to the international community as the virus spread globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="color:#231f20;">The COVID-19 pandemic has directly and indirectly impacted our business, results of operations and financial condition and is expected to continue to impact our business. For example, the COVID-19 pandemic has resulted in </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">delays in our clinical trials due to the implementation of COVID-19 protocols at investigator sites, which resulted in longer than anticipated site identification and initiation activities. In addition, while we currently do not anticipate any interruptions in our supply chain, it is possible that the COVID-19 pandemic and the continuing response efforts may have a future impact on our third-party suppliers and partners. It is possible that due to the continued development and manufacturing of vaccines for COVID-19, certain basic supply chain materials such as resins, vessels, vials and stoppers may be in high demand by the pharmaceutical companies developing and manufacturing vaccines and our ability to obtain these materials for our development activities could be negatively impacted. Although we have experienced some delays of this nature in 2021, such delays have not had a material adverse impact on our business, results of operations or financial condition</span><span style="font-size:12pt;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="color:#231f20;">The full extent of the COVID-19 pandemic impact continues to depend on future developments that remain highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19, the actions taken to contain it or treat its impact, the identification and spread of COVID-19 variants such as the Delta variant, the distribution of vaccines, the acceptance of vaccines and the implementation of vaccine mandates, and the economic impact on local, regional, national and international markets. Management continues to actively monitor the developments regarding the pandemic and the impact that the pandemic could have on our financial condition, liquidity, ability to enroll patients in our contemplated clinical trials, manufacturing and research and development operations, suppliers to our operations and suppliers to our outside clinical trial organizations, biotech industry overall, and importantly the health and safety of our workforce. Given the continued volatility of the COVID-19 pandemic and the global responses to curb its spread, we are not able to estimate the effects of the COVID-19 pandemic on our results of operations, financial condition, or liquidity for the remainder of fiscal year 2021 or 2022. Any recovery from negative impacts to our business and related economic impact due to the COVID-19 pandemic may also be slowed or reversed by a number of factors, including the current widespread resurgence in COVID-19 infections attributable to the Delta variant, combined with the seasonal flu.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Recent Events</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">October 2021 Private Placements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="background-color:#ffffff;color:#222222;">On October 28, 2021, we entered into a securities purchase agreement (the &#8220;October 2021 Securities Purchase Agreement&#8221;) with the Cystic Fibrosis Foundation, a Delaware corporation (&#8220;CFF&#8221;), our partner for the lead Phase 1b/2 clinical development program, and Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc. (Nasdaq: INVA) (collectively, &#8220;Innoviva&#8221;) for the private placement of newly issued shares of our common stock, par value $0.01 per share (&#8220;Common Stock&#8221;). Pursuant to the October 2021 Securities Purchase Agreement, we issued and sold 909,091 shares to CFF and 1,212,122 shares to Innoviva, each at a per share price of $3.30 (the &#8220;October 2021 Private Placements&#8221;). We received aggregate gross proceeds from the October 2021 Private Placements of approximately $7.0 million, before deducting transaction expenses</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">2021 Lease Agreement </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="background-color:#ffffff;color:#222222;">On October 28, 2021, we entered into a lease for office and research and development space under a non-cancellable lease in Los Angeles, CA (the &#8220;2021 Lease&#8221;). The leased space comprises approximately 56,000 square feet. The 2021 Lease commencement date is May 1, 2022 and the total lease term is for 16 years and runs through 2038. Monthly rent for 2022 and 2023 will be fully or partially abated while we and the lessor complete planned tenant improvements to the facility. Base monthly rent will be approximately $0.25 million in 2024. We are entitled to receive an allowance for tenant improvements of up to $6.5 million. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="background-color:#ffffff;color:#222222;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="background-color:#ffffff;color:#222222;font-style:italic;">Executive Transition </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="color:#231f20;">On August 1, 2021, Todd R. Patrick, who has served as the Company&#8217;s Chief Executive Officer (&#8220;CEO&#8221;) since May 2019, retired from day-to-day active management of the Company and resigned as CEO. Mr. Patrick will continue to serve as an advisor to the Company&#8217;s CEO through December 31, 2022 and will continue to serve as a member of the Board of Directors (the &#8220;Board&#8221;) until at least the Company&#8217;s next Annual Meeting of Shareholders. In connection with </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">Mr. Patrick&#8217;s retirement, Brian Varnum, Ph.D. was appointed to serve as CEO of the Company and as a member of the Company&#8217;s Board. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="color:#231f20;">On August 1, 2021, the Company and Dr. Varnum entered into an amended employment agreement, which sets forth the terms and conditions of his new position with the Company as previously disclosed in the Form 8-K filed on August 4, 2021.&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="color:#231f20;">On August 9, 2021, the Company and Mr. Patrick entered into a letter agreement, which amends his employment agreement and sets forth the terms and conditions of his continuing relationship with the Company as previously disclosed in the Form 8-K filed on August 4, 2021.&#160; The letter agreement also provides that if the Company terminates Mr. Patrick&#8217;s employment other than for cause prior to December 31, 2022, he will continue to receive his salary, bonus, subsidized health insurance premiums and equity vesting from the date of termination through December 31, 2022.</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Comparison of three and nine months ended September 30, 2021 and 2020 </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Grant revenue </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Company recognized $1.3 million and $0.3 million of grant revenue during the three months ended September 30, 2021 and 2020, respectively, and $3.5 million and $0.3 million of grant revenue during the nine months ended September 30, 2021 and 2020 respectively, which represents MTEC&#8217;s share of the costs incurred for the Company&#8217;s AP-SA02 program for the treatment of <i style="font-style:italic;">Staphylococcus aureus</i>&#160;bacteremia. These amounts have been invoiced to MTEC. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-weight:normal;">Research and Development </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Research and development expenses for the three months ended September 30, 2021 and 2020 were $5.6 million and $4.1 million, respectively. The net increase of $1.5 million was primarily related to an increase of $0.7 million related to increased clinical trial activities and trial-related outsourcing expenses, $0.6 million in personnel costs, and a $0.2 million increase in professional services expenses.<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses for the nine months ended September 30, 2021 and 2020 were $15.2 million and $9.5 million, respectively. The net increase of $5.7 million was primarily related to an increase of $2.2 million in personnel costs, an increase of $3.0 million in clinical trial and related outsourcing expenses, $0.8 million in professional service expenses, and an increase of $0.2 million related to lease expenses. These increases were offset by credits to research and development expenses of $0.8 million related to our award agreement with CFF and a $0.7 million tax rebate from Australian tax authorities during the nine months ended September 30, 2021, as compared to $1.1 million received from CFF and the NIH during the nine months ended September 30, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-weight:normal;white-space:pre-wrap;">General and Administrative   </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses were $1.7 million for the three months ended September 30, 2021, as compared to $1.8 million during the same period in 2020. The decrease in general and administrative expenses of $0.1 million was primarily due to a reduction of $0.4 million in stock-based compensation expenses, offset by an increase of $0.3 million related to general corporate and personnel costs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses were $6.0 million for the nine months ended September 30, 2021, which remained consistent with the amount for the nine months ended September 30, 2020. For the nine months ended September 30, 2021, general and administrative expenses increased by $0.3 million for personnel costs, and $0.3 million in public company and insurance costs, which were offset by a reduction of $0.6 million in stock-based compensation expenses when compared to the nine months ended September 30, 2020. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-weight:normal;">Gain upon extinguishment of Paycheck Protection Program loan </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">       In April 2020, we received loan proceeds of $717,000 (&#8220;PPP Loan&#8221;) under the Paycheck Protection Program (&#8220;PPP&#8221;).&#160; The PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act, provides for loans to qualifying businesses for amounts up to 2.5 times the average monthly payroll expenses of the qualifying business, calculated as provided under the PPP. The PPP provides a mechanism for forgiveness of up to the full amount borrowed, and in July 2021, we received notification of forgiveness of the full loan amount and associated interest from the Small Business Administration. We recorded a gain of $0.7 million from the PPP Loan extinguishment in the statement of operations during the three and nine months ended September 30, 2021.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-weight:normal;">Other Income (Expense)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the three and nine months ended September 30, 2021 and 2020, we recorded noncash interest expense of $0 and $0.2 million, and $0.1 million and $0.5 million, respectively, as a result of interest accretion on the time-based cash payments due in connection with the asset acquisition transaction with Synthetic Genomics, Inc. (&#8220;SGI&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-weight:normal;">Income Taxes</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There was no income tax expense or benefit for the three or nine months ended September 30, 2021 and 2020. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Operating activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Net cash used in operating activities for the nine months ended September 30, 2021 was $15.0 million, as compared to $12.0 million for the nine months ended September 30, 2020. The increase of $3.0 million was primarily due to a $1.6 million increase in net loss, a $2.0 million reduction of non-cash reconciling items from net loss to cash used in operating activities, offset by an increase of $0.6 million of cash used for operating assets and liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Investing activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net cash used in investing activities was $1.1 million and $0.5 million for the nine months ended September 30, 2021 and 2020, respectively, and primarily related to capital equipment purchases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Financing activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;white-space:pre-wrap;">       Net cash provided by financing activities was $18.5 million for the nine months ended September 30, 2021, which was primarily comprised of $19.4 million net proceeds raised from the 2021 private placement transactions with Innoviva, and $0.5 million of proceeds received from stock option exercises, offset by a principal payment of $1.4 million in deferred consideration related to the time-based payment obligation in connection with the SGI asset acquisition.</span><span style="font-style:normal;font-weight:normal;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;white-space:pre-wrap;">       </span><span style="font-style:normal;font-weight:normal;">Net cash provided by financing activities was $22.8 million for the nine months ended September 30, 2020, which was comprised of net cash proceeds of $22.9 million </span><span style="font-style:normal;font-weight:normal;">raised from the 2020 private placement transaction with Innoviva, $0.7 million proceeds from the Paycheck Protection Program loan, and $0.2 million of proceeds received from warrant and employee stock option exercises, </span><span style="font-style:normal;font-weight:normal;">offset by a payment of $1.0 million in deferred consideration related to the time-based payment obligation in connection with the SGI asset acquisition</span><span style="font-style:normal;font-weight:normal;">. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Liquidity, Capital Resources and Financial Condition</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We have prepared our consolidated financial statements on a going concern basis, which assumes that we will realize our assets and satisfy our liabilities in the normal course of business. However, we have incurred net losses since our inception and have negative operating cash flows. These circumstances raise substantial doubt about our ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty concerning our ability to continue as a going concern. While </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">management believes this plan to raise additional funds will alleviate the conditions that raise substantial doubt, these plans are not entirely within its control and cannot be assessed as being probable of occurring. The Company may not be able to secure additional financing in a timely manner or on favorable terms, if at all.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of September 30, 2021, we had unrestricted cash and cash equivalents of $12.1 million. Considering our current cash resources, management believes our existing resources will be sufficient to fund our planned operations into the first quarter of 2022. For the foreseeable future, our ability to continue our operations is dependent upon our ability to obtain additional capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Future Capital Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We will need to raise additional capital in the future to continue to fund our operations. Our future funding requirements will depend on many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the effects of the continuing COVID-19 pandemic on our clinical programs and business, including delays or difficulties in enrolling patients in our clinical trials, shortage in supply chain materials, labor shortages impacting our ability to hire and retain qualified personnel, and changes in local, state or federal regulations as part of a response to the COVID-19 pandemic;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the costs and timing of our research and development activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;white-space:pre-wrap;">the progress and cost of our clinical trials and other research and development activities;  </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">manufacturing costs associated with our targeted phage therapies strategy and other research and development activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the terms and timing of any collaborative, licensing, acquisition or other arrangements that we may establish;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">manufacturing costs associated with our targeted phage therapies strategy and other research and development activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the terms and timing of any collaborative, licensing, acquisition or other arrangements that we may establish;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">whether and when we receive future Australian tax rebates, if any; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the costs and timing of seeking regulatory approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the costs of filing, prosecuting and enforcing any patent applications, claims, patents and other intellectual property rights; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the costs of lawsuits involving us or our product candidates.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may seek to raise capital through a variety of sources, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the public equity market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">private equity financings;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">collaborative arrangements, government grants or strategic financings;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">licensing arrangements; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">public or private debt.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Any additional fundraising efforts may divert our management team from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates. Our ability to raise additional funds will depend, in part, on the success of our product development activities, including our targeted phage therapies strategy and any clinical trials we initiate, regulatory events, our ability to identify and enter into in-licensing or other strategic arrangements, and other events or conditions that may affect our value or prospects, as well as factors related to financial, economic and market conditions, many of which are beyond our control. We cannot be certain that sufficient funds will be available to us when required or on acceptable terms, if at all. If we are unable to secure additional funds on a timely basis or on acceptable terms, we may be required to defer, reduce or eliminate significant planned expenditures, restructure, curtail or eliminate some or all of our development programs or other operations, dispose of technology or assets, pursue an acquisition of our company by a third party at a price that may result in a loss on investment for our stockholders, enter into arrangements that may require us to relinquish rights to certain of our product candidates, technologies or potential markets, file for bankruptcy or cease operations altogether. Any of these events could have a material adverse effect on our business, financial condition and results of operations. Moreover, if we are unable to obtain additional funds on a timely basis, there will be substantial doubt about our ability to continue as a going concern and increased risk of insolvency and loss of investment by our stockholders. To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of such securities could result in dilution to our existing stockholders. Our ability to raise additional capital may be adversely impacted by potential worsening of global economic conditions and volatility of financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Off-Balance Sheet Arrangements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of September 30, 2021, we did not have off-balance sheet arrangements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Refer to <i style="font-style:italic;">Note&#160;3</i> of the condensed consolidated notes to the consolidated financial statements contained elsewhere in this report.</p><a id="_2e08ccd1_1c95_46f5_8d9d_d4669ec95d19"></a><a id="Item3QUANTITATIVEANDQUALITATIVE_125432"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are a smaller reporting company as defined by Rule&#160;12b-2 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and are not required to provide the information required under this item.</p><a id="_0204d4f0_ee84_42db_ace5_04550be4be43"></a><a id="Item4CONTROLSANDPROCEDURES_448420"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;4. CONTROLS AND PROCEDURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Disclosure Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Exchange Act, as of the end of the period covered by this quarterly report on Form&#160;10-Q. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives and management necessarily applies its judgment in evaluating the cost benefit relationship of possible controls and procedures. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of September 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Changes in Internal Control over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">An evaluation was also performed under the supervision and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer, of any change in our internal control over financial </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">reporting that occurred during our last fiscal quarter and that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.&#160;That evaluation did not identify any change in our internal control over financial reporting that occurred during our latest fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</p><a id="_21b8bd62_dc53_4c09_b78e_6bbd32e15c7c"></a><a id="PARTIIOTHERINFORMATION_905682"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">PART&#160;II. OTHER INFORMATION</p><a id="Item1LegalProceedings_580710"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1. Legal Proceedings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">From time to time, we are a party to certain litigation that is either judged to be not material or that arises in the ordinary course of business.  We intend to vigorously defend our interests in these matters. We expect that the resolution of these matters will not have a material adverse effect on our business, financial condition or results of operations. However, due to the uncertainties inherent in litigation, no assurance can be given as to the outcome of these proceedings.</span></p><a id="_44c5ea59_f8ba_4986_8689_0b8dff9d7e70"></a><a id="Item1ARiskFactors_490547"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1A. Risk Factors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">You should consider carefully the following information about the risks described below, together with the other information contained in this Quarterly Report and in our other public filings in evaluating our business.</i><i style="font-style:italic;">&#160;</i><i style="font-style:italic;">If any of the following risks actually occur, our business, financial condition, results of operations, and future growth prospects would likely be materially and adversely affected. In these circumstances, the market price of our common stock would likely decline. In addition, the global economic climate and effects of the COVID-19 pandemic may amplify many of the risks described below or their impact on us.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Summary of Risk Factors </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background-color:#ffffff;">Our ability to execute on our business strategy is subject to a number of risks, which are discussed more fully below in this section. You should carefully consider these risks before making an investment in our common stock. These risks include, among others, the following:</span></p><div style="margin-top:6pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:42.5pt;"></td><td style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="background-color:#ffffff;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Public health crises such as pandemics or similar outbreaks could materially and adversely affect our preclinical and clinical trials, business, financial condition and results of operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:42.5pt;"></td><td style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:6pt 0pt 0pt 0pt;">&#9679;</td><td style="background-color:#ffffff;padding:6pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">There is substantial doubt about our ability to continue as a going concern, which may affect our ability to obtain future financing and may require us to curtail our operations. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:42.5pt;"></td><td style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:6pt 0pt 0pt 0pt;">&#9679;</td><td style="background-color:#ffffff;padding:6pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">We will need to raise additional capital to support our operations; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:42.5pt;"></td><td style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:6pt 0pt 0pt 0pt;">&#9679;</td><td style="background-color:#ffffff;padding:6pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">We have incurred losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future, and our future profitability is uncertain; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:42.5pt;"></td><td style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:6pt 0pt 0pt 0pt;">&#9679;</td><td style="background-color:#ffffff;padding:6pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">We have never generated any revenue from product sales and may never be profitable, </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:42.5pt;"></td><td style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:6pt 0pt 0pt 0pt;">&#9679;</td><td style="background-color:#ffffff;padding:6pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Maintaining and improving our financial controls and the requirements of being a public company may strain our resources, divert management&#8217;s attention and affect our ability to attract and retain qualified board members;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:42.5pt;"></td><td style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:6pt 0pt 0pt 0pt;">&#9679;</td><td style="background-color:#ffffff;padding:6pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate financial statements on a timely basis could be impaired and our public reporting may be unreliable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:42.5pt;"></td><td style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:6pt 0pt 0pt 0pt;">&#9679;</td><td style="background-color:#ffffff;padding:6pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">If we fail to develop and maintain proper and effective processes and operating procedures as a non-traditional government contractor, our ability to adhere to the DoD and related entity standards could impact our ongoing and future development financing awards from the U.S. government;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:42.5pt;"></td><td style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:6pt 0pt 0pt 0pt;">&#9679;</td><td style="background-color:#ffffff;padding:6pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">If we are unable to obtain FDA approval of our products, we will not be able to commercialize our products in the United States;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:42.5pt;"></td><td style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:6pt 0pt 0pt 0pt;">&#9679;</td><td style="background-color:#ffffff;padding:6pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Results from preclinical studies and Phase 1 or 2 clinical trials of our product candidates or from single-patient expanded access treatments may not be predictive of the results of later stage clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:42.5pt;"></td><td style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:6pt 0pt 0pt 0pt;">&#9679;</td><td style="background-color:#ffffff;padding:6pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">We are seeking to develop antibacterial agents using bacteriophage and synthetic phage technology, a novel approach, which makes it difficult to predict the time and cost of development. No bacteriophage products have been approved in the United States or elsewhere;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:42.5pt;"></td><td style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:6pt 0pt 0pt 0pt;">&#9679;</td><td style="background-color:#ffffff;padding:6pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Delays in our clinical trials could result in us not achieving anticipated developmental milestones when expected, increased costs and delay our ability to obtain regulatory approval for and commercialize our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:42.5pt;"></td><td style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:6pt 0pt 0pt 0pt;">&#9679;</td><td style="background-color:#ffffff;padding:6pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">We have not completed formulation development of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:42.5pt;"></td><td style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:6pt 0pt 0pt 0pt;">&#9679;</td><td style="background-color:#ffffff;padding:6pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Our product candidates must undergo rigorous clinical testing, such clinical testing may fail to demonstrate safety and efficacy and any of our product candidates could cause undesirable side effects, which would substantially delay or prevent regulatory approval or commercialization;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:42.5pt;"></td><td style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:6pt 0pt 0pt 0pt;">&#9679;</td><td style="background-color:#ffffff;padding:6pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">We must continue to develop manufacturing processes for our product candidates and any delay in or our inability to do so would result in delays in our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:42.5pt;"></td><td style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:6pt 0pt 0pt 0pt;">&#9679;</td><td style="background-color:#ffffff;padding:6pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">We may conduct clinical trials for our products or product candidates outside the United States and the FDA may not accept data from such trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:42.5pt;"></td><td style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:6pt 0pt 0pt 0pt;">&#9679;</td><td style="background-color:#ffffff;padding:6pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">We are subject to significant regulatory approval requirements, which could delay, prevent or limit our ability to market our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:42.5pt;"></td><td style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:6pt 0pt 0pt 0pt;">&#9679;</td><td style="background-color:#ffffff;padding:6pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Failure to comply with health and data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation and/or adverse publicity and could negatively affect our operating results and business; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:42.5pt;"></td><td style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:6pt 0pt 0pt 0pt;">&#9679;</td><td style="background-color:#ffffff;padding:6pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">A variety of risks associated with our international operations could materially adversely affect our business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:42.5pt;"></td><td style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:6pt 0pt 0pt 0pt;">&#9679;</td><td style="background-color:#ffffff;padding:6pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">We depend upon key personnel who may terminate their employment with us at any time and we may need to hire additional qualified personnel in order to obtain financing, pursue collaborations or develop and market our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:42.5pt;"></td><td style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:6pt 0pt 0pt 0pt;">&#9679;</td><td style="background-color:#ffffff;padding:6pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">We must manage a geographically dispersed organization;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:42.5pt;"></td><td style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:6pt 0pt 0pt 0pt;">&#9679;</td><td style="background-color:#ffffff;padding:6pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">We rely on third parties to conduct our clinical trials, and their failure to perform their obligations in a timely or competent manner may delay development and commercialization of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:42.5pt;"></td><td style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:6pt 0pt 0pt 0pt;">&#9679;</td><td style="background-color:#ffffff;padding:6pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">We are dependent on patents, trade secrets and other forms of non-patent intellectual property protection. If we fail to adequately protect this intellectual property or if we otherwise do not have exclusivity for the marketing of our products, our ability to commercialize products could suffer;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:42.5pt;"></td><td style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:6pt 0pt 0pt 0pt;">&#9679;</td><td style="background-color:#ffffff;padding:6pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">If we are sued for infringing intellectual property rights of third parties or if we are forced to engage in an interference proceeding, it will be costly and time-consuming, and an unfavorable outcome in that litigation or interference would have a material adverse effect on our business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:42.5pt;"></td><td style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:6pt 0pt 0pt 0pt;">&#9679;</td><td style="background-color:#ffffff;padding:6pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">If our competitors are able to develop and market products that are more effective, safer or more affordable than ours, or obtain marketing approval before we do, our commercial opportunities may be limited;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:42.5pt;"></td><td style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:6pt 0pt 0pt 0pt;">&#9679;</td><td style="background-color:#ffffff;padding:6pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">There is a substantial risk of product liability claims in our business. If we do not obtain sufficient liability insurance, a product liability claim could result in substantial liabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:42.5pt;"></td><td style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:6pt 0pt 0pt 0pt;">&#9679;</td><td style="background-color:#ffffff;padding:6pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Even if we receive regulatory approval to market our product candidates, the market may not be receptive to our product candidates upon their commercial introduction, which would negatively affect our ability to achieve profitability;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:42.5pt;"></td><td style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:6pt 0pt 0pt 0pt;">&#9679;</td><td style="background-color:#ffffff;padding:6pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">The uncertainty associated with pharmaceutical reimbursement and related matters may adversely affect our business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:42.5pt;"></td><td style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:6pt 0pt 0pt 0pt;">&#9679;</td><td style="background-color:#ffffff;padding:6pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Innoviva may exert a substantial influence on actions requiring stockholder vote, potentially in a manner that you do not support;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:42.5pt;"></td><td style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:6pt 0pt 0pt 0pt;">&#9679;</td><td style="background-color:#ffffff;padding:6pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">The price of our common stock has been and may continue to be volatile; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:42.5pt;"></td><td style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:6pt 0pt 0pt 0pt;">&#9679;</td><td style="background-color:#ffffff;padding:6pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">We have never paid dividends on our common stock, and we do not anticipate paying any cash dividends on our common stock in the foreseeable future.</span></td></tr></table><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 60.5pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Financial Condition and Need for Additional Capital</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Public health crises such as pandemics or similar outbreaks could materially and adversely affect our preclinical and clinical trials, business, financial condition and results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In March 2020, the World Health Organization declared COVID-19 a global pandemic and the United States declared a national emergency with respect to COVID-19.&#160; The COVID-19 pandemic continues to impinge upon the U.S. and global economies and has directly and indirectly impacted our business, results of operations and financial condition and is expected to continue to impact our business. For example, the COVID-19 pandemic has resulted in delays in our clinical trials due to the implementation of COVID-19 protocols at investigator sites, which resulted in longer than anticipated site identification and initiation activities. In addition, while we currently do not anticipate any interruptions in our supply chain, it is possible that the COVID-19 pandemic and the continuing response efforts may have a future impact on our third-party suppliers and partners and the conduct of future clinical trials. It is possible that due to the continued development and manufacturing of vaccines for COVID-19, certain basic supply chain materials such as resins, vessels, vials and stoppers may be in high demand by the pharmaceutical companies developing and manufacturing vaccines and our ability to obtain these materials for our development activities could be negatively impacted. Although we have experienced some delays of this nature in 2021, such delays have not had a material adverse impact on our business, results of operations or financial condition. Moreover, the COVID-19 pandemic may adversely affect the operations of the FDA and other health authorities, resulting in delays of reviews and approvals with respect to our product candidates. While the full scope of the economic impact brought by, and the ultimate duration of, the COVID-19 pandemic remains difficult to assess or predict, the continued impact of the COVID-19 pandemic on the global financial markets may reduce our ability to access capital, which could negatively impact our short-term and long-term liquidity. In addition, the loss of any of our employees as a result of COVID-19 (including as a result of vaccine mandates), or another pandemic, may adversely affect our operations. The ultimate impact of the COVID-19 pandemic remains highly uncertain, and we do not yet know the full extent of potential delays or impacts that COVID-19 may have on our business, financing or clinical trial activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Some examples of potential disruptions that have resulted or may result from COVID-19 include but are not limited to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">delays or difficulties in enrolling patients in our clinical trials;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">delays or difficulties in initiating or expanding clinical trials, including delays or difficulties with clinical site initiation and recruiting clinical site investigators and clinical site staff;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">increased rates of patients withdrawing from our clinical trials following enrollment as a result of contracting COVID-19 or other health conditions or being forced to quarantine;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">interruption of key clinical trial activities, such as clinical trial site data monitoring and efficacy, safety and translational data collection, processing and analyses, due to limitations on travel imposed or recommended by federal, state or local governments, employers and others or interruption of clinical trial subject visits, which may impact the collection and integrity of subject data and clinical study endpoints;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">delays or disruptions in preclinical experiments and IND-enabling studies due to restrictions of on-site staff and unforeseen circumstances at contract research organizations, or CROs, and vendors;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">interruption or delays in the operations of the FDA and comparable foreign regulatory agencies;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">interruption of, or delays in receiving, supplies of our product candidates from our contract manufacturing organizations due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">delays in receiving approval from local regulatory authorities to initiate our planned clinical trials;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">limitations on employee or other resources that would otherwise be focused on the conduct of our clinical trials and pre-clinical work, including because of sickness of employees or their families, the desire of employees to avoid travel or contact with large groups of people, an increased reliance on working from home, school closures or mass transit disruptions or a refusal to comply with vaccine mandates;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">changes in regulations as part of a response to the COVID-19 pandemic which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">delays in necessary interactions with regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government or contractor personnel; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">refusal of the FDA to accept data from clinical trials in affected geographies outside the United States.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The COVID-19 global pandemic remains volatile. The extent to which the pandemic may affect our clinical trials, business, financial condition and results of operations remains dependent on future developments, which are highly uncertain and cannot be predicted at this time, such as the evolution and spread of COVID-19 variants, such as the Delta variant, the ultimate duration of the pandemic, business closures or business disruptions, the effectiveness of actions taken in the United States and other countries to contain and treat the disease, the acceptability, safety and effectiveness of COVID-19 vaccines, and compliance with vaccine mandates. Future developments in these and other areas present material uncertainty and risk with respect to our clinical trials, business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">There is substantial doubt about our ability to continue as a going concern, which may affect our ability to obtain future financing and may require us to curtail our operations. We will need to raise additional capital to support our operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The December 31, 2020 audited financial statements and accompanying notes thereto included disclosures and an opinion from our independent registered public accounting firm stating that our recurring losses and negative cash flows from operations raise substantial doubt about our ability to continue as a going concern. Our financial statements as of September 30, 2021 and December 31, 2020 were prepared under the assumption that we will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty. At September 30, 2021, we had cash and cash equivalents of $12.1 million, and we have had recurring losses from operations and negative operating cash flows since inception. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We will need to raise additional capital to support our operations and product development activities. In the near term, we expect to continue to fund our operations, if at all, primarily through equity and debt financings. Our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions, including the current recession, and the recent disruptions to, and volatility in, financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic. We may also seek funds through arrangements with collaborators, grant agencies or others that may require us to relinquish rights to the product candidates that we might otherwise seek to develop or commercialize independently. If we are unable to secure additional funds when needed or on acceptable terms, we may be required to defer, reduce or eliminate significant planned expenditures, restructure, curtail or eliminate some or all of our development programs or other operations, dispose of technology or assets, pursue an acquisition of our company by </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">a third party at a price that may result in a loss on investment for our stockholders, enter into arrangements that may require us to relinquish rights to certain of our product candidates, technologies or potential markets, file for bankruptcy or cease operations altogether. Any of these events could have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:12.95pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On March 27, 2020, we completed a private placement (the &#8220;2020 Private Placement&#8221;) transaction in which we sold to Innoviva, Inc. a total of 8,710,800 newly issued shares of the Company&#8217;s common stock and warrants to purchase 8,710,800 shares of common stock, with an exercise price per share of $2.87. The 2020 Private Placement was closed in two tranches for total aggregate gross proceeds of $25.0 million.&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:12.95pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On January&#160;<span style="white-space:pre-wrap;">26, 2021, we completed a private placement (the &#8220;January 2021 Private Placement&#8221;) transaction in which we sold to Innoviva Strategic Opportunities LLC, a subsidiary of Innoviva Inc. a total of 6,153,847 newly issued shares of the Company&#8217;s common stock and warrants to purchase 6,153,847 shares of common stock with an exercise price per share of $3.25. The 2021 Private Placement was closed in two tranches for total aggregate proceeds of $20.0 million.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:12.95pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On October 28, 2021, we completed a private placement (the &#8220;October 2021 Private Placement&#8221;) transaction in which we sold to CFF and Innoviva Strategic Opportunities LLC, a total of 2,121,213 shares of our newly issued shares of common stock, par value $0.01 per share, for aggregate gross proceeds of approximately $7.0 million, before deducting transaction expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">While we believe that our existing resources including the proceeds from the January and October 2021 Private Placements will be sufficient to fund our planned operations into the first quarter of 2022, we cannot provide assurances that our estimates are accurate, that our plans will not change or that changed circumstances will not result in the depletion of our capital resources more rapidly than we currently anticipate. Developing drugs and conducting clinical trials is expensive. Our future funding requirements will depend on many factors, including:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the costs and timing of our research and development activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the progress and cost of our clinical trials and other research and development activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">manufacturing costs associated with our targeted phage therapies strategy and other research and development activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the terms and timing of any collaborative, licensing, acquisition or other arrangements that we may establish;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">whether and when we receive future Australian tax rebates, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the costs and timing of seeking regulatory approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the costs of filing, prosecuting, defending and enforcing any patent applications, claims, patents and other intellectual property rights; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the costs of lawsuits involving us or our product candidates.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In addition, raising additional capital through the sale of securities could cause significant dilution to our stockholders. Any additional fundraising efforts may divert our management from their day to day activities, which may adversely affect our ability to develop and commercialize our product candidates. Our ability to raise additional funds will depend, in part, on the success of our product development activities, including our targeted phage therapies strategy and any clinical trials we initiate, regulatory events, our ability to identify and enter into in-licensing or other strategic arrangements, and other events or conditions that may affect our value or prospects, as well as factors related to financial, economic and market conditions, many of which are beyond our control. There can be no assurances that sufficient funds will be available to us when required or on acceptable terms, if at all.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We have incurred losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future, and our future profitability is uncertain.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:13.2pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> </span></span>As of September 30, 2021, our accumulated deficit was $196.8 million and we expect to incur losses for the foreseeable future. We have devoted, and will continue to devote for the foreseeable future, substantially all of our resources to research and development of our product candidates. For the nine months ended September 30, 2021 and the year ended December 31, 2020, we had losses from operations of $17.7 million and $21.6 million, respectively. Additional information regarding our results of operations may be found in our consolidated financial statements and in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included in Item 2 of Part I in this report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We have never generated any revenue from product sales and may never be profitable. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Clinical trials and activities associated with discovery research are costly. We do not expect to generate any revenue from the commercial sales of our product candidates in the near term, and we expect to continue to have significant losses for the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our ability to generate meaningful revenue and achieve profitability depends on successfully completing the development of, and obtaining the regulatory approvals necessary to, commercialize our product candidates. If any of our product candidates fail in clinical trials or if any of our product candidates do not gain regulatory approval, or if any of our product candidates, if approved, fail to achieve market acceptance, we may never become profitable. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our ability to generate future revenues from product sales depends heavily on our success in:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">completing research and preclinical and clinical development of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">seeking and obtaining regulatory and marketing approvals for product candidates for which we complete clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">developing a sustainable, scalable, reproducible, and transferable manufacturing process for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">launching and commercializing product candidates for which we obtain regulatory and marketing approval, either by establishing a sales force, marketing and distribution infrastructure, or by collaborating with a partner;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">obtaining market acceptance of any approved products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">addressing any competing technological and market developments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">implementing additional internal systems and infrastructure, as needed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">identifying and validating new product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">maintaining, protecting and expanding our portfolio of intellectual property rights, including patents, trade secrets and know-how; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">attracting, hiring and retaining qualified personnel.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Even if one or more of the product candidates that we develop is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product. Our expenses could increase beyond </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">expectations if we are required by the FDA, the European Medicines Agency (&#8220;EMA&#8221;), or other foreign regulatory authorities to perform clinical trials and other studies in addition to those that we currently anticipate. Even if we are able to generate revenues from the sale of any approved products, we may not become profitable and may need to obtain additional funding to continue operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Maintaining and improving our financial controls and the requirements of being a public company may strain our resources, divert management&#8217;s attention and affect our ability to attract and retain qualified board members.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a public company, we are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act and the rules&#160;of the NYSE American. The requirements of these rules&#160;and regulations increase our legal and financial compliance costs, make some activities more difficult, time-consuming or costly and place strain on our personnel, systems and resources. The Exchange Act requires, among other things, that we file annual, quarterly and current reports with respect to our business and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. Ensuring that we have adequate internal financial and accounting controls and procedures in place is a costly and time-consuming effort that needs to be re-evaluated frequently.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We currently do not have an internal audit group, and we may need to hire additional accounting and financial staff with appropriate public company experience and technical accounting knowledge. Implementing any appropriate changes to our internal controls may require specific compliance training for our directors, officers and employees, entail substantial costs to modify our existing accounting systems, and take a significant period of time to complete. Such changes may not, however, be effective in maintaining the adequacy of our internal controls, and any failure to maintain that adequacy, or consequent inability to produce accurate financial statements on a timely basis, could increase our operating costs and could materially impair our ability to operate our business. Moreover, effective internal controls are necessary for us to produce reliable financial reports and are important to help prevent fraud.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In accordance with NYSE American rules, we are required to maintain a majority independent board of directors. The various rules&#160;and regulations applicable to public companies make it more difficult and more expensive for us to maintain directors&#8217; and officers&#8217; liability insurance, and we may be required to accept reduced coverage or incur substantially higher costs to maintain coverage. If we are unable to maintain adequate directors&#8217; and officers&#8217; insurance, our ability to recruit and retain qualified officers and directors will be significantly curtailed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate financial statements on a timely basis could be impaired and our public reporting may be unreliable. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:13.2pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We are required to maintain internal control over financial reporting adequate to provide reasonable assurance regarding the reliability of financial reporting and the preparation of our consolidated financial statements in accordance with generally accepted accounting principles. We do not expect that our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. Over time, controls may become inadequate because changes in conditions or deterioration in the degree of compliance with policies or procedures may occur. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. Material weaknesses in our internal controls have been identified in the past, and we cannot assure you that significant deficiencies or material weaknesses in our internal control over financial reporting will not be identified in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">If we are unable to maintain effective controls and procedures, or identify any future material weaknesses, the accuracy and timing of our financial reporting may be adversely affected, we may be unable to maintain compliance with securities law requirements regarding timely filing of periodic reports and we may experience a loss of public </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">confidence, which could have an adverse effect on our business, financial condition and the market price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If we fail to develop and maintain proper and effective processes and operating procedures as a non-traditional government contractor, our ability to adhere to the Department of Defense and related entity standards could impact our ongoing and future development financing awards from the U.S. government. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> </span></span>On June 15, 2020, we entered into the &#8220;MTEC Agreement&#8221;, pursuant to which we have started to receive an up to $15 million grant and have entered into a three-year program administered by the DoD through MTEC with funding from the Defense Health Agency and Joint Warfighter Medical Research Program. We plan to use the grant to partially fund a Phase&#160;1b/2, randomized, double-blind, placebo-controlled, dose escalation clinical study of Armata&#39;s therapeutic phage-based candidate, AP-SA02, for the treatment of complicated&#160;<i style="font-style:italic;">S. aureus</i>&#160;bacteremia infections. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background-color:#ffffff;color:#212529;">As an organization, we are relatively new to government contracting and new to the regulatory compliance obligations that such contracting entails. If we fail to maintain compliance with those obligations, we may be subject to potential liability and may result in the termination of our government contracts, including the MTEC Agreement. </span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:0pt;"><span style="color:#212529;">Government contracts and grants normally contain additional requirements that may increase our costs of doing business and expose us to liability for failure to comply with these terms and conditions. These requirements include, for example:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="background-color:#ffffff;color:#212529;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="background-color:#ffffff;padding:0pt;"><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">tracking of contract costs and maintenance of effective controls over tracking of such costs; </span></td></tr></table><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 0pt 72pt;"><span style="color:#212529;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="background-color:#ffffff;color:#212529;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="background-color:#ffffff;padding:0pt;"><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">completion and submission of periodic reporting packages;</span></td></tr></table><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="color:#212529;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="background-color:#ffffff;color:#212529;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="background-color:#ffffff;padding:0pt;"><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;white-space:pre-wrap;">mandatory financial audits and potential liability for failing such audits; and  </span></td></tr></table><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="color:#212529;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="background-color:#ffffff;color:#212529;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="background-color:#ffffff;padding:0pt;"><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">mandatory socioeconomic compliance requirements, including labor standards, non-discrimination, and affirmative action programs, and environmental compliance requirements. </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">While we believe we are in compliance with all requirements under the MTEC Agreement, potential failure to maintain such compliance could result in reduction of the grant or termination of the contract, which could in turn negatively impact our business.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Business</b> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We have limited operating history, have incurred significant operating losses since inception and expects to incur significant operating losses for the foreseeable future. We may never become profitable or, if achieved, be able to sustain profitability.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">To date, we have funded our operations primarily through private placement offerings of equity securities. As of September 30, 2021, we had cash and cash equivalents of $12.1 million. We have incurred significant operating losses since our inception and expect to incur significant losses for the foreseeable future as we continue our development programs for our product candidates. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We currently generate no revenue from product sales, and may never be able to commercialize our product candidates, or other future product candidates. We do not currently have the required approvals to market our product candidates and we may never receive them. We may not be profitable even if we or any of our future development partners succeed in commercializing any of our product candidates. Because of the numerous risks and uncertainties associated with developing and commercializing our product candidates, we are unable to predict the extent of any future losses or when it will become profitable, if at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to obtain FDA approval of our products, we will not be able to commercialize our products in the United States. </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:0pt;">We need FDA approval prior to marketing our product candidates in the United States. If we fail to obtain FDA approval to market our product candidates, we will be unable to sell our products in the United States, which will significantly impair our ability to generate any revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:24pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:0pt;">This regulatory review and approval process, which includes evaluation of pre-clinical studies and clinical trials of our product candidates as well as the evaluation of our manufacturing processes, is lengthy, expensive and uncertain. To receive approval, we must, among other things, demonstrate with substantial evidence from well-controlled clinical trials that our product candidates are both safe and effective for each indication for which approval is sought. Satisfaction of the approval requirements typically takes several years and the time needed to satisfy them may vary substantially, based on the type, complexity and novelty of the product. We do not know if or when we might receive regulatory approvals, including approval for an Investigational New Drug application (&#8220;IND application&#8221;), for any of our product candidates currently under development, other than for our product candidate AP-PA02, for which we received FDA clearance of our IND application. Moreover, approvals that we obtain may not cover all of the clinical indications for which we are seeking approval, or could contain significant limitations in the form of narrow indications, warnings, precautions or contra-indications with respect to conditions of use. In such event, our ability to generate revenues from such products would be greatly reduced and our business would be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:24pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:0pt;">The FDA has substantial discretion in the approval process and may either refuse to consider any of our applications for substantive review or may form the opinion after review of our data that one or more of our applications are insufficient to approve if we our product candidates. If the FDA does not consider or approve any of our applications, it may require that we conduct additional clinical, pre-clinical or manufacturing validation studies and submit that data before it will reconsider our application. Depending on the extent of these or any other studies, approval of any applications that we submit may be delayed by several years, or may require us to expend more resources than we have available. It is also possible that additional studies, if performed and completed, may not be successful or considered sufficient by the FDA for approval or even to make our applications approvable. If any of these outcomes occur, we may be forced to abandon one or more of our applications for approval, which might significantly harm our business and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:24pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:0pt;">It is possible that none of our products or any product we may seek to develop in the future will ever obtain the appropriate regulatory approvals necessary for us to commence product sales. Any delay in obtaining, or an inability to obtain, applicable regulatory approvals would prevent us from commercializing our products, generating revenues and achieving and sustaining profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:24pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Results from preclinical studies and Phase 1 or 2 clinical trials of our product candidates or from single-patient expanded access treatments may not be predictive of the results of later stage clinical trials.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Preclinical studies, including studies of our product candidates in animal disease models, may not accurately predict the result of human clinical trials of those product candidates. In particular, promising animal studies suggesting the efficacy of prototype phage products in the treatment of bacterial infections, such as<i style="font-style:italic;">&#160;P. aeruginosa&#160;</i>and<i style="font-style:italic;">&#160;S. aureus,</i> may not predict the ability of these products to treat similar infections in humans. Despite promising data in our completed Phase 1 clinical trials, our phage technology may be found not to be safe or efficacious in treating bacterial infections alone or in combination with other agents, when studied in later-stage clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In addition, we have used our bacteriophage technology in the area of targeted medicine under single-patient expanded access guidelines, which permit the use of phage therapy outside of clinical trials, in the United States and Australia. Despite prior single-patient expanded access successes, no assurance can be given that we will have similar single-patient expanded access treatment successes in the future. Single-patient expanded access is a term that is used to refer to the use of an investigational drug or therapy outside of a clinical trial to treat a patient with a serious or immediately life-threatening disease or condition who has no comparable or satisfactory alternative treatment options. Regulators often allow single-patient expanded access on a case-by-case basis for an individual patient or for defined groups of patients with similar treatment needs. In some countries, such as Australia, the treating physician can </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">administer treatment under single-patient expanded access guidelines without pre-approval from the applicable regulatory authority.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In September 2018, we received the official minutes from our August&#160;2018 Type B pre-IND meeting with the FDA regarding our AP-SA01 bacteriophage therapy product candidate. The FDA expressed general agreement with our proposed clinical trial designs and, based on the current FDA feedback, no additional clinical or nonclinical data are required to proceed with human clinical trials. Subsequent to the Type B meeting, we have changed the bacteriophage product candidate to AP-SA02. While we believe the FDA comments and stances related to AP-SA01 will apply to AP-SA02, there can be no assurances that is the case. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">To satisfy FDA or foreign regulatory approval standards for the commercial sale of our product candidates, we must demonstrate in adequate and controlled clinical trials that our product candidates are safe and effective. Success in early clinical trials, including Phase 1 and Phase 2 trials, or in our single-patient expanded access program does not ensure that later clinical trials will be successful. Our initial results from early stage clinical trials or our single-patient expanded access program also may not be confirmed by later analysis or subsequent larger clinical trials. A number of companies in the pharmaceutical industry have suffered significant setbacks in advanced clinical trials, even after obtaining promising results in earlier clinical trials and most product candidates that commence clinical trials are never approved for commercial sale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are seeking to develop antibacterial agents using bacteriophage and synthetic phage technology, a novel approach, which makes it difficult to predict the time and cost of development. No bacteriophage products have been approved in the United States or elsewhere.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are developing our product candidates with bacteriophage and synthetic phage technology. We have not, nor to our knowledge has any other company, received regulatory approval from the FDA or equivalent foreign agencies for a pharmaceutical drug based on this approach. While<i style="font-style:italic;"> in vitro</i> studies have characterized the behavior of bacteriophages in cell cultures and there exists a body of literature regarding the use of phage therapy in humans, the safety and efficacy of phage therapy in humans has not been extensively studied in well-controlled modern clinical trials. Most of the prior research on phage-based therapy was conducted in the former Soviet Union prior to and immediately after World War II and lacked appropriate control group design or lacked control groups at all. Furthermore, the standard of care has changed substantially during the ensuing decades since those studies were performed, diminishing the relevance of prior claims of improved cure rates. We cannot be certain that our approach will lead to the development of approvable or marketable drugs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Developing phage-based therapies on a commercial scale will also require developing new manufacturing processes and techniques. We and our third-party collaborators may experience delays in developing manufacturing capabilities for our product candidates, and may not be able to do so at the scale required to efficiently conduct the clinical trials required to obtain regulatory approval of our product candidates, or to manufacture commercial quantities of our products, if approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the FDA or other regulatory agencies may lack experience in evaluating the safety and efficacy of drugs based on these approaches, which could lengthen the regulatory review process, increase our development costs and delay or prevent commercialization of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Delays in our clinical trials could result in us not achieving anticipated developmental milestones when expected, increased costs and delay our ability to obtain regulatory approval for and commercialize our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Delays in our ability to commence or enroll patients for our clinical trials could result in us not meeting anticipated clinical milestones and could materially impact our product development costs and delay regulatory approval of our product candidates. Planned clinical trials may not be commenced or completed on schedule, or at all. Clinical trials can be delayed for a variety of reasons, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">delays in the development of manufacturing capabilities for our product candidates to enable their consistent production at clinical trial scale;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">failures in our internal manufacturing operations that result in our inability to consistently and timely produce bacteriophages in sufficient quantities to support our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the availability of financial resources to commence and complete our planned clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">delays in reaching a consensus with clinical investigators on study design;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">delays in reaching a consensus with regulatory agencies on trial design or in obtaining regulatory approval to commence a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">delays in obtaining clinical materials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">slower than expected patient recruitment for participation in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">failure by clinical trial sites, other third parties, or us to adhere to clinical trial agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">delays in reaching agreement on acceptable clinical trial agreement terms with prospective sites or obtaining institutional review board approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">changes in local regulations as part of a response to the COVID-19 pandemic, which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">adverse safety events experienced during our clinical trials.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we do not successfully commence or complete our clinical trials on schedule, the price of our common stock may decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Completion of clinical trials depends, among other things, on our ability to enroll a sufficient number of patients, which is a function of many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the therapeutic endpoints chosen for evaluation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the eligibility criteria defined in the protocol;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the perceived benefit of the product candidate under study;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the size of the patient population required for analysis of the clinical trial&#8217;s therapeutic endpoints;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">our ability to recruit clinical trial investigators and sites with the appropriate competencies and experience;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">our ability to obtain and maintain patient consents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">delays or difficulties in enrolling patients in our clinical trials as a result of impacts associated with the COVID-19 pandemic; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">competition for patients from clinical trials for other treatments.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may experience difficulties in enrolling patients in our clinical trials, which could increase the costs or affect the timing or outcome of these clinical trials. This is particularly true with respect to diseases with relatively small patient populations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have not completed formulation development of our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The development of our bacteriophage product candidates requires that we isolate, select and combine a number of bacteriophages that target the desired bacteria for that product candidate. The selection of bacteriophages for any of our product candidates is based on a variety of factors, including without limitation the ability of the selected phages, in combination, to successfully kill the targeted bacteria, the degree of cross-reactivity of the individual phages with the same part of the bacterial targets, the ability of the combined phages to satisfy regulatory requirements, our ability to manufacture sufficient quantities of the phages, intellectual property rights of third parties, and other factors. While we have selected initial formulations of AP-SA02 for the treatment of<i style="font-style:italic;"> S. aureus</i> infections, and the initial formulations of AP-PA02 for the treatment of <i style="font-style:italic;">P. aeruginosa </i>infections in CF patients, there can be no assurance that these initial formulations will be the final formulations of AP-SA02 or AP-PA02 for commercialization if approved. If we are unable to complete formulation development of our product candidates in the time frame that we have anticipated, then our product development timelines, and the regulatory approval of our product candidates, could be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our product candidates must undergo rigorous clinical testing, such clinical testing may fail to demonstrate safety and efficacy and any of our product candidates could cause undesirable side effects, which would substantially delay or prevent regulatory approval or commercialization.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Before we can obtain regulatory approval for a product candidate, we must undertake extensive clinical testing in humans to demonstrate safety and efficacy to the satisfaction of the FDA or other regulatory agencies. Clinical trials of new drug candidates sufficient to obtain regulatory marketing approval are expensive and take&#160;years to complete.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We cannot be certain of successfully completing clinical testing within the time frame we have planned, or at all. We may experience numerous unforeseen events during, or as a result of, the clinical trial process that could delay or prevent us from receiving regulatory approval or commercializing our product candidates, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">our clinical trials may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical and/or preclinical testing or to abandon programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the results obtained in earlier stage clinical testing may not be indicative of results in future clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">clinical trial results may not meet the level of statistical significance required by the FDA or other regulatory agencies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">we, or regulators, may suspend or terminate our clinical trials if the participating patients are being exposed to unacceptable health risks; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">our product candidates may have unintended or undesirable effects on patients that may delay or preclude regulatory approval of our product candidates or limit their commercial use, if approved.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We must continue to develop manufacturing processes for our product candidates and any delay in or our inability to do so would result in delays in our clinical trials.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We are developing novel manufacturing processes for our product candidates at our facility in Marina del Rey (near Los Angeles), California. The manufacturing processes for our product candidates, and the scale up of such processes for clinical trials, is novel, and there can be no assurance that we will be able to complete this work in a timely manner, if at all. The manufacture of our product candidates requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers often encounter difficulties in production, particularly in scaling up for commercial production. These problems include difficulties with production costs and yields, quality control, including stability of the equipment and product candidates and quality assurance testing, shortages of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. If we were to encounter any of these difficulties, our ability to provide our products to patients in our clinical trials or to commercially launch a product would be jeopardized. Any delay or interruption could postpone the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">completion of our clinical trials, increase the costs associated with maintaining our clinical trial program and, depending upon the period of delay, require us to commence new trials at significant additional expense or terminate the trials completely.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any delay in the development or scale up of these manufacturing processes could delay the start of clinical trials and harm our business. In the event our facility in Marina del Rey does not receive a satisfactory cGMP inspection for the manufacture of our product candidates, we may need to fund additional modifications to our manufacturing process, conduct additional validation studies, or find alternative manufacturing facilities, any of which would result in significant cost to us as well as a delay of up to several&#160;years in obtaining approval for such product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our manufacturing facility will be subject to ongoing periodic inspection by the FDA&#160;for compliance with cGMP regulations. Compliance with these regulations and standards is complex and costly, and there can be no assurance that we will be able to comply. Any failure to comply with applicable regulations could result in sanctions being imposed (including fines, injunctions and civil penalties), failure of regulatory authorities to grant marketing approval of our product candidates, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions and criminal prosecution. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any of these factors could cause a delay of clinical trials, regulatory submissions, approvals or commercialization of our products, entail higher costs or result in our being unable to effectively commercialize our products. Furthermore, if we fail to deliver the required commercial quantities on a timely basis, pursuant to provided specifications and at commercially reasonable prices, we may be unable to meet demand for our products, which would negatively impact our revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may conduct clinical trials for our products or product candidates outside the United States and the FDA may not accept data from such trials.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We completed an investigator-sponsored clinical trial of AP-SA01 at the University of Adelaide in Australia for CRS in December&#160;2016. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of such study data by the FDA is subject to certain conditions. For example, the study must be well designed and conducted and performed by qualified investigators in accordance with ethical principles. The study population must also adequately represent the U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful. Generally, the patient population for any clinical studies conducted outside of the United States must be representative of the population for whom we intend to label the product in the United States. In addition, such studies would be subject to the applicable local laws and FDA acceptance of the data would be dependent upon its determination that the studies also complied with all applicable U.S. laws and regulations. There can be no assurance the FDA will accept data from trials conducted outside of the United States. Further, with respect to AP-SA01, we have changed the product formulation to AP-SA02 and any work related to AP-SA01 may not be relevant to the FDA or other international regulatory authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may need to license additional intellectual property rights.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The development and commercialization of phage-based antibacterial agents may require us to obtain rights to intellectual property from third parties. We may also determine that it is necessary or advisable to license other intellectual property from third parties. There can be no assurance that such intellectual property rights would be available on commercially reasonable terms, if at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are subject to significant regulatory approval requirements, which could delay, prevent or limit our ability to market our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our research and development activities, preclinical studies, clinical trials and the anticipated manufacturing and marketing of our product candidates are subject to extensive regulation by the FDA and other regulatory agencies in the United States and by comparable authorities in Europe and elsewhere. There can be no assurance that our manufacturing facilities will satisfy the requirements of the FDA or comparable foreign authorities. We require the approval of the relevant regulatory authorities before we may commence commercial sales of our product candidates in a </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">given market. The regulatory approval process is expensive and time-consuming, and the timing of receipt of regulatory approval is difficult to predict. Our product candidates could require a significantly longer time to gain regulatory approval than expected, or may never gain approval. We cannot be certain that, even after expending substantial time and financial resources, we will obtain regulatory approval for any of our product candidates. A delay or denial of regulatory approval could delay or prevent our ability to generate product revenues and to achieve profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Changes in regulatory approval policies during the development period of any of our product candidates, changes in, or the enactment of, additional regulations or statutes, or changes in regulatory review practices for a submitted product application may cause a delay in obtaining approval or result in the rejection of an application for regulatory approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Regulatory approval, if obtained, may be made subject to limitations on the indicated uses for which we may market a product. These limitations could adversely affect our potential product revenues. Regulatory approval may also require costly post-marketing follow-up studies. In addition, the labeling, packaging, adverse event reporting, storage, advertising, promotion and record-keeping related to the product will be subject to extensive ongoing regulatory requirements. Furthermore, for any marketed product, its manufacturer and its manufacturing facilities will be subject to continual review and periodic inspections by the FDA or other regulatory authorities. Failure to comply with applicable regulatory requirements may, among other things, result in fines, suspensions of regulatory approvals, product recalls, product seizures, operating restrictions and criminal prosecution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Failure to comply with health and data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation and/or adverse publicity and could negatively affect our operating results and business. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We and any potential collaborators may be subject to federal, state and foreign data protection laws and regulations (i.e., laws and regulations that address privacy and data security). In the United States, numerous federal and state laws and regulations, including federal health information privacy laws, state data breach notification laws, state health information privacy laws and federal and state consumer protection laws (e.g., Section&#160;5 of the Federal Trade Commission Act), that govern the collection, use, disclosure and protection of health-related and other personal information could apply to our operations or the operations of our collaborators. In addition, we may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under the HIPAA, as amended by HITECH. Depending on the facts and circumstances, we could be subject to criminal penalties if we knowingly obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">International data protection laws, including Regulation 2016/679, known as the General Data Protection Regulation (GDPR) may also apply to health-related and other personal information obtained outside of the United States. The GDPR went into effect on May&#160;25, 2018. The GDPR introduced new data protection requirements in the European Union, as well as potential fines for noncompliant companies of up to the greater of &#8364;20&#160;million or 4% of annual global revenue. The regulation imposes numerous new requirements for the collection, use and disclosure of personal information, including more stringent requirements relating to consent and the information that must be shared with data subjects about how their personal information is used, the obligation to notify regulators and affected individuals of personal data breaches, extensive new internal privacy governance obligations and obligations to honor expanded rights of individuals in relation to their personal information (e.g., the right to access, correct and delete their data). In addition, the GDPR includes restrictions on cross-border data transfer. The GDPR will increase our responsibility and liability in relation to personal data that we process, and we may be required to put in place additional mechanisms to ensure compliance with the new EU data protection rules. Further, the United Kingdom&#8217;s vote in favor of exiting the EU, often referred to as Brexit, has created uncertainty with regard to data protection regulation in the United Kingdom. In particular, it is unclear whether the United Kingdom will enact data protection legislation equivalent to the GDPR and how data transfers to and from the United Kingdom will be regulated. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In addition, California recently enacted legislation that has been dubbed the first &#8220;GDPR-like&#8221; law in the United States.&#160;&#160;Known as the California Consumer Privacy Act, it creates new individual privacy rights for consumers (as that </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">word is broadly defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households.&#160;&#160;The CCPA requires covered companies to provide new disclosures to California consumers, provide such consumers new ways to opt-out of certain sales of personal information, and allow for a new cause of action for data breaches. The CCPA may impact (possibly significantly) our business activities and exemplifies the vulnerability of our business to the evolving regulatory environment related to personal data and protected health information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Compliance with U.S. and international data protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Failure to comply with U.S. and international data protection laws and regulations could result in government enforcement actions (which could include civil or criminal penalties), private litigation and/or adverse publicity and could negatively affect our operating results and business. Moreover, clinical trial subjects about whom we or our potential collaborators obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information. Claims that we have violated individuals&#8217; privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time consuming to defend and could result in adverse publicity that could harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">A variety of risks associated with our international operations could materially adversely affect our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to our U.S. operations, we have operations and a subsidiary in Australia and a subsidiary company in the United Kingdom. We face risks associated with our international operations, including possible unfavorable regulatory, pricing and reimbursement, political, tax and labor conditions, which could harm our business. We are subject to numerous risks associated with international business activities, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">compliance with differing or unexpected regulatory requirements for the development, manufacture and, if approved, commercialization of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">difficulties in staffing and managing foreign operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">foreign government taxes, regulations and permit requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">U.S. and foreign government tariffs, trade restrictions, price and exchange controls and other regulatory requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">anti-corruption laws, including the Foreign Corrupt Practices Act;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">economic weakness, including inflation, natural disasters, war, events of terrorism or political instability in particular foreign countries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">fluctuations in currency exchange rates, which could result in increased operating expenses and reduced revenues, and other obligations related to doing business in another country;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">compliance with tax, employment, immigration and labor laws, regulations and restrictions for employees living or traveling abroad;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">workforce uncertainty in countries where labor unrest is more common than in the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">changes in diplomatic and trade relationships; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">challenges in enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">These and other risks associated with our international operations may materially adversely affect our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We depend upon key personnel who may terminate their employment with us at any time and we may need to hire additional qualified personnel in order to obtain financing, pursue collaborations or develop and market our product candidates </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our success depends on our continued ability to attract, retain and motivate highly qualified management, clinical, manufacturing, and scientific personnel and on our ability to develop and maintain important relationships with leading academic institutions, clinicians and scientists. Our success will depend on our ability to retain and motivate personnel and hire additional qualified personnel when required, including personnel with expertise in clinical trials, government regulation, cGMP manufacturing, and other areas. Competition for qualified personnel in the biotechnology field is intense. We face competition for personnel from other biotechnology and pharmaceutical companies, universities, public and private research institutions and other organizations. We also face competition from other more well-funded and well-established businesses, and we may also be viewed as a riskier choice from a job stability perspective due to our relative newer status than longer existing biotech and pharmaceutical companies. If we are unable to attract and retain key personnel and advisors, it may negatively affect our ability to successfully develop, test, commercialize and market our products and product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We must manage a geographically dispersed organization.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">While we are a small company, we currently have operations in the United States and Australia. In the future, we may also locate facilities in other locations based on proximity to personnel with the expertise needed to research, develop and manufacture phage-based therapeutics, costs of operations or other factors. Managing our organization across multiple locations and multiple time zones may reduce our efficiency, increase our expenses and increase the risk of operational difficulties in the execution of our plans. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Because the Merger resulted in an ownership change under Section 382 of the Internal Revenue Code for Armata, Armata&#8217;s pre-Merger net operating loss carryforwards and certain other tax attributes will be subject to limitations. The net operating loss carryforwards and other tax attributes of C3J may also be subject to limitations as a result of ownership changes.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">If a corporation undergoes an &#8220;ownership change&#8221; within the meaning of Section 382 of the Internal Revenue Code of 1986, as amended, such corporation&#8217;s net operating loss carryforwards and certain other tax attributes arising from before the ownership change are subject to limitations on use after the ownership change. In general, an ownership change occurs if there is a cumulative change in the corporation&#8217;s equity ownership by certain stockholders that exceeds fifty percentage points over a rolling three-year period. Similar rules may apply under state tax laws. The Merger resulted in an ownership change for AmpliPhi and, accordingly, AmpliPhi&#8217;s net operating loss carryforwards and certain other tax attributes may be subject to limitations (or disallowance) on their use after the Merger. C3J&#8217;s net operating loss carryforwards may also be subject to limitation as a result of prior shifts in equity ownership and/or the Merger. Additional ownership changes in the future could result in additional limitations on our net operating loss carryforwards. Consequently, even if we achieve profitability, we may not be able to utilize a material portion of our net operating loss carryforwards and other tax attributes, which could have a material adverse effect on cash flow and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2020, we had federal net operating loss carryforwards of approximately $110.5 million.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Reliance on Third Parties</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We rely on third parties to conduct our clinical trials, and their failure to perform their obligations in a timely or competent manner may delay development and commercialization of our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We use third parties, such as clinical research organizations, to assist in conducting our clinical trials. However, we may face delays outside of our control if these parties do not perform their obligations in a timely or competent fashion or if we are forced to change service providers. This risk is heightened for clinical trials conducted outside of the United States, where it may be more difficult to ensure that clinical trials are conducted in compliance with FDA requirements. Any third party that we hire to conduct clinical trials may also provide services to our competitors, which could compromise the performance of their obligations to us. If we experience significant delays in the progress of our clinical trials and in our plans to submit Biologics License Applications, the commercial prospects for product candidates could be harmed and our ability to generate product revenue would be delayed or prevented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our clinical research operations could also be negatively impacted by delays, supply chain issue and labor shortages resulting from the COVID-19 pandemic. We are not able to predict the impact on the timing and costs of our planned clinical trials as a result of the COVID-19 pandemic.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Intellectual Property</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are dependent on patents and proprietary technology. If we fail to adequately protect this intellectual property or if we otherwise do not have exclusivity for the marketing of our products, our ability to commercialize products could suffer.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our commercial success will depend in part on our ability to obtain and maintain patent protection sufficient to prevent others from marketing our product candidates, as well as to defend and enforce these patents against infringement and to operate without infringing the proprietary rights of others. Protection of our product candidates from unauthorized use by third parties will depend on having valid and enforceable patents cover our product candidates or their manufacture or use, or having effective trade secret protection. If our patent applications do not result in issued patents, or if our patents are found to be invalid, we will lose the ability to exclude others from making, using or selling the inventions claimed therein. We have a limited number of patents and pending patent applications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The patent positions of biotechnology companies can be uncertain and involve complex legal and factual questions. This is due to inconsistent application of policy and changes in policy relating to examination and enforcement of biotechnology patents to date on a global scale. The laws of some countries may not protect intellectual property rights to the same extent as the laws of countries having well-established patent systems, and those countries may lack adequate rules&#160;and procedures for defending our intellectual property rights. Also, changes in either patent laws or in interpretations of patent laws may diminish the value of our intellectual property. We are not able to guarantee that all of our patent applications will result in the issuance of patents and we cannot predict the breadth of claims that may be allowed in our patent applications or in the patent applications we may license from others.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Central provisions of The Leahy-Smith America Invents Act, or the America Invents Act went into effect on September&#160;16, 2012 and on March&#160;16, 2013. The America Invents Act includes a number of significant changes to U.S. patent law. These changes include provisions that affect the way patent applications are being filed, prosecuted and litigated. For example, the America Invents Act enacted proceedings involving post-issuance patent review procedures, such as <i style="font-style:italic;">inter partes</i> review (&#8220;IPR&#8221;), and post-grant review, that allow third parties to challenge the validity of an issued patent in front of the United States Patent and Trademark Office (&#8220;U.S. PTO&#8221;) Patent Trial and Appeal Board. Each proceeding has different eligibility criteria and different patentability challenges that can be raised. IPRs permit any person (except a party who has been litigating the patent for more than a&#160;year) to challenge the validity of the patent on the grounds that it was anticipated or made obvious by prior art. Patents covering pharmaceutical products have been subject to attack in IPRs from generic drug companies and from hedge funds. If it is within six&#160;months of the issuance of the challenged patent, a third party can petition the U.S. PTO for post-grant review, which can be based on any invalidity grounds and is not limited to prior art patents or printed publications.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In post-issuance proceedings, U.S. PTO rules&#160;and regulations generally tend to favor patent challengers over patent owners. For example, unlike in district court litigation, claims challenged in post-issuance proceedings are given their broadest reasonable meaning, which increases the chance a claim might be invalidated by prior art or lack support in the patent specification. As another example, unlike in district court litigation, there is no presumption of validity for an issued patent, and thus, a challenger&#8217;s burden to prove invalidity is by a preponderance of the evidence, as opposed to the heightened clear and convincing evidence standard. As a result of these rules&#160;and others, statistics released by the U.S. PTO show a high&#160;percentage of claims being invalidated in post-issuance proceedings. Moreover, with few exceptions, there is no standing requirement to petition the U.S. PTO for inter partes review or post-grant review. In other words, companies that have not been charged with infringement or that lack commercial interest in the patented subject matter can still petition the U.S. PTO for review of an issued patent. Thus, even where we have issued patents, our rights under those patents may be challenged and ultimately not provide us with sufficient protection against competitive products or processes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">we might not be the first to file patent applications for our inventions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">others may independently develop similar or alternative product candidates to any of our product candidates that fall outside the scope of our patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">our pending patent applications may not result in issued patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">our issued patents may not provide a basis for commercially viable products or may not provide us with any competitive advantages or may be challenged by third parties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">others may design around our patent claims to produce competitive products that fall outside the scope of our patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">we may not develop additional patentable proprietary technologies related to our product candidates; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">we are dependent upon the diligence of our appointed agents in national jurisdictions, acting for and on our behalf, which control the prosecution of pending domestic and foreign patent applications and maintain granted domestic and foreign patents.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">An issued patent does not guarantee us the right to practice the patented technology or commercialize the patented product. Third parties may have blocking patents that could be used to prevent us from commercializing our patented products and practicing our patented technology. Our issued patents and those that may be issued in the future may be challenged, invalidated or circumvented, which could limit our ability to prevent competitors from marketing the same or related product candidates or could limit the length of the term of patent protection of our product candidates. Moreover, because of the extensive time required for development, testing and regulatory review of a potential product, it is possible that, before any of our product candidates can be commercialized, any related patent may expire or remain in force for only a short period following commercialization, thereby reducing any advantage of the patent. Patent term extensions may not be available for these patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We rely on trade secrets and other forms of non-patent intellectual property protection. If we are unable to protect our trade secrets, other companies may be able to compete more effectively against us.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We rely on trade secrets to protect certain aspects of our technology, including our proprietary processes for manufacturing and purifying bacteriophages. Trade secrets are difficult to protect, especially in the pharmaceutical industry, where much of the information about a product must be made public during the regulatory approval process. Although we use reasonable efforts to protect our trade secrets, our employees, consultants, contractors, outside </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">scientific collaborators and other advisors may unintentionally or willfully disclose our information to competitors. Enforcing a claim that a third party illegally obtained and is using our trade secret information is expensive and time-consuming, and the outcome is unpredictable. In addition, courts outside the United States may be less willing to or may not protect trade secrets. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are sued for infringing intellectual property rights of third parties or if we are forced to engage in an interference proceeding, it will be costly and time-consuming, and an unfavorable outcome in that litigation or interference would have a material adverse effect on our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our ability to commercialize our product candidates depends on our ability to develop, manufacture, market and sell our product candidates without infringing the proprietary rights of third parties. Numerous United States and foreign patents and patent applications, which are owned by third parties, exist in the general field of anti-infective products or in fields that otherwise may relate to our product candidates. If we are shown to infringe, we could be enjoined from use or sale of the claimed invention if we are unable to prove that the patent is invalid. In addition, because patent applications can take many&#160;years to issue, there may be currently pending patent applications, unknown to us, which may later result in issued patents that our product candidates may infringe, or which may trigger an interference proceeding regarding one of our owned or licensed patents or applications. There could also be existing patents of which we are not aware that our product candidates may inadvertently infringe or which may become involved in an interference proceeding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The biotechnology and pharmaceutical industries are characterized by the existence of a large number of patents and frequent litigation based on allegations of patent infringement. For so long as our product candidates are in clinical trials, we believe our clinical activities fall within the scope of the exemptions provided by 35 U.S.C. Section&#160;271(e)&#160;in the United States, which exempts from patent infringement liability activities reasonably related to the development and submission of information to the FDA. As our clinical investigational drug product candidates progress toward commercialization, the possibility of a patent infringement claim against us increases. While we attempt to ensure that our active clinical investigational drugs and the methods we employ to manufacture them, as well as the methods for their use we intend to promote, do not infringe other parties&#8217; patents and other proprietary rights, we cannot be certain they do not, and competitors or other parties may assert that we infringe their proprietary rights in any event.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may be exposed to future litigation based on claims that our product candidates, or the methods we employ to manufacture them, or the uses for which we intend to promote them, infringe the intellectual property rights of others. Our ability to manufacture and commercialize our product candidates may depend on our ability to demonstrate that the manufacturing processes we employ and the use of our product candidates do not infringe third-party patents. If third-party patents were found to cover our product candidates or their use or manufacture, we could be required to pay damages or be enjoined and therefore unable to commercialize our product candidates, unless we obtained a license. A license may not be available to us on acceptable terms, if at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Industry</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If our competitors are able to develop and market products that are more effective, safer or more affordable than ours, or obtain marketing approval before we do, our commercial opportunities may be limited.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Competition in the biotechnology and pharmaceutical industries is intense and continues to increase. Some companies that are larger and have significantly more resources than we do are aggressively pursuing antibacterial development programs, including traditional therapies and therapies with novel mechanisms of action. In addition, other companies are developing phage-based products for non-therapeutic uses, and may elect to use their expertise in phage development and manufacturing to try to develop products that would compete with ours.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We also face potential competition from academic institutions, government agencies and private and public research institutions engaged in the discovery and development of drugs and therapies. Many of our competitors have significantly greater financial resources and expertise in research and development, preclinical testing, conducting clinical trials, obtaining regulatory approvals, manufacturing, sales and marketing than we do. Smaller or early-stage </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established pharmaceutical companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our competitors may succeed in developing products that are more effective, have fewer side effects and are safer or more affordable than our product candidates, which would render our product candidates less competitive or noncompetitive. These competitors also compete with us to recruit and retain qualified scientific and management personnel, establish clinical trial sites and patient registration for clinical trials, as well as to acquire technologies and technology licenses complementary to our programs or advantageous to our business. Moreover, competitors that are able to achieve patent protection, obtain regulatory approvals and commence commercial sales of their products before we do, and competitors that have already done so, may enjoy a significant competitive advantage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Generating Antibiotics Incentives Now Act is intended to provide incentives for the development of new, qualified infectious disease products. These incentives may result in more competition in the market for new antibiotics, and may cause pharmaceutical and biotechnology companies with more resources than we have to shift their efforts towards the development of products that could be competitive with our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">There is a substantial risk of product liability claims in our business. If we do not obtain sufficient liability insurance, a product liability claim could result in substantial liabilities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our business exposes us to significant potential product liability risks that are inherent in the development, manufacturing and marketing of human therapeutic products. Regardless of merit or eventual outcome, product liability claims may result in:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">delay or failure to complete our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">withdrawal of clinical trial participants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">decreased demand for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">injury to our reputation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">litigation costs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">substantial monetary awards against us; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">diversion of management or other resources from key aspects of our operations.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we succeed in marketing products, product liability claims could result in an FDA investigation of the safety or efficacy of our products, our manufacturing processes and facilities or our marketing programs. An FDA investigation could also potentially lead to a recall of our products or more serious enforcement actions, or limitations on the indications, for which they may be used, or suspension or withdrawal of approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have product liability insurance that covers our clinical trials up to a $10.0 million annual per claim and aggregate limit. We intend to expand our insurance coverage to include the sale of commercial products if marketing approval is obtained for our product candidates or any other compound that we may develop. However, insurance coverage is expensive and we may not be able to maintain insurance coverage at a reasonable cost or at all, and the insurance coverage that we obtain may not be adequate to cover potential claims or losses.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even if we receive regulatory approval to market our product candidates, the market may not be receptive to our product candidates upon their commercial introduction, which would negatively affect our ability to achieve profitability.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our product candidates may not gain market acceptance among physicians, patients, healthcare payors and the medical community. The degree of market acceptance of any approved products will depend on a number of factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the effectiveness of the product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the prevalence and severity of any side effects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">potential advantages or disadvantages over alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">relative convenience and ease of administration;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the strength of marketing and distribution support;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the price of the product, both in absolute terms and relative to alternative treatments; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">sufficient third-party coverage or reimbursement.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If our product candidates receive regulatory approval but do not achieve an adequate level of acceptance by physicians, healthcare payors and patients, we may not generate product revenues sufficient to attain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The uncertainty associated with pharmaceutical reimbursement and related matters may adversely affect our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Market acceptance and sales of any one or more of our product candidates will depend on reimbursement policies and may be affected by future healthcare reform measures in the United States and in foreign jurisdictions. Government authorities and third-party payers, such as private health insurers and health maintenance organizations, decide which drugs they will cover and establish payment levels. We cannot be certain that reimbursement will be available for any of our product candidates. Also, we cannot be certain that reimbursement policies will not reduce the demand for, or the price paid for, our products. If reimbursement is not available or is available on a limited basis, we may not be able to successfully commercialize any product candidates that we develop.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In the United States, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (the &#8220;MMA&#8221;), changed the way Medicare covers and pays for pharmaceutical products. The legislation established Medicare Part D, which expanded Medicare coverage for outpatient prescription drug purchases by the elderly but provided authority for limiting the number of drugs that will be covered in any therapeutic class. The MMA also introduced a new reimbursement methodology based on average sales prices for physician-administered drugs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The United States and several foreign jurisdictions are considering, or have already enacted, a number of legislative and regulatory proposals to change the healthcare system in ways that could affect its ability to sell its products profitably. Among policy makers and payers in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access to healthcare. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. we expect to experience pricing pressures in connection with the sale of any products that we develop due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, and additional legislative proposals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act (collectively, the &#8220;ACA&#8221;), became law in the United States, which substantially </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">changed the way healthcare is financed by both governmental and private insurers. While we cannot predict what impact on federal reimbursement policies this legislation will have in general or on our business specifically, the ACA and any amendments thereto may result in downward pressure on pharmaceutical reimbursement, which could negatively affect market acceptance of, and the price we may charge for, our products that receive regulatory approval. We also cannot predict the impact of ACA and its amendments on us as many of the ACA, as amended, requires the promulgation of detailed regulations implementing the statutory provisions, which have not yet been fully implemented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Innoviva may exert a substantial influence on actions requiring stockholder vote, potentially in a manner that you do not support.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#160;&#160;&#160;&#160;&#160;</span></span>&#160;Following the January 2021 Private Placement and October 2021 Private Placement, Innoviva holds approximately 59.6% of our outstanding shares and 14,864,647 warrants to purchase shares of our common stock. If Innoviva were to exercise the warrants held by them, they would hold approximately 74.7% of our issued and outstanding shares of common stock.&#160;&#160;Innoviva&#8217;s large ownership stake may allow it to exert a substantial influence on actions requiring a stockholder vote, potentially in a manner that you do not support, including amendments to our articles of incorporation, adoption of measures that could delay or prevent a change in control or impede a merger, takeover, or other business combination involving us, and approval of other major corporate transactions. In addition, Innoviva&#8217;s stock ownership may discourage a potential acquirer from making a tender offer or otherwise attempting to obtain control of us, which in turn could reduce our stock price or prevent our stockholders from realizing a premium over our stock price. Accordingly, our stockholders other than Innoviva may be unable to influence management and exercise control over our business. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The price of our common stock has been and may continue to be volatile.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">As of September 30, 2021, we had outstanding common warrants to purchase an aggregate of 16,647,219 shares of our common stock at a weighted-average exercise price of $3.98 per share. As of September 30, 2021, in-the-money warrants included warrants issued to Innoviva during the January 2021 Private Placement which have an exercise price of $3.25, as well as warrants issued to Innoviva during the 2020 Private Placement which have an exercise price of $2.87 per share. We also have outstanding options to exercise 2,439,651 shares of our common stock at a weighted-average exercise price of $5.65 per share.  Although we cannot determine when these warrants or options will ultimately be exercised, it is reasonable to assume that such warrants and options will be exercised only if the exercise price is below the market price of our common stock. To the extent any of our outstanding warrants or options are exercised, additional shares of our common stock will be issued that will generally be eligible for resale in the public market (subject to limitations under Rule 144 under the Securities Act for certain of our warrants and with respect to shares held by our affiliates), which will result in dilution to our security holders. The issuance of additional securities could also have an adverse effect on the market price of our common stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have never paid dividends on our common stock, and we do not anticipate paying any cash dividends on our common stock in the foreseeable future.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have never declared or paid cash dividends on our common stock. We do not anticipate paying any cash dividends on our common stock in the foreseeable future. We currently intend to retain all available funds and any future earnings to fund the development and growth of our business. As a result, capital appreciation, if any, of our common stock will be our stockholders&#8217; sole source of gain for the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">General Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our business and operations might be adversely affected by security breaches, including any cybersecurity incidents.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We depend on the efficient and uninterrupted operation of our computer and communications systems, which we use for, among other things, sensitive company data, including our financial data, intellectual property and other proprietary business information.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">While certain of our operations have business continuity and disaster recovery plans and other security measures intended to prevent and minimize the impact of IT-related interruptions, our IT infrastructure and the IT infrastructure of our consultants, contractors and vendors are vulnerable to damage from cyberattacks, computer viruses, unauthorized access, electrical failures and natural disasters or other catastrophic events. We could experience failures in our information systems and computer servers, which could result in an interruption of our normal business operations and require substantial expenditure of financial and administrative resources to remedy. System failures, accidents or security breaches can cause interruptions in our operations and can result in a material disruption of our targeted phage therapies, bacteriophage product candidates and other business operations. The loss of data from completed or future studies or clinical trials could result in delays in our research, development or regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liabilities and the development of our product candidates could be delayed or otherwise adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even though we believe we carry commercially reasonable business interruption and liability insurance, we might suffer losses as a result of business interruptions that exceed the coverage available under our insurance policies or for which we do not have coverage. For example, we are not insured against terrorist attacks or cyberattacks. Any natural disaster or catastrophic event could have a significant negative impact on our operations and financial results. Moreover, any such event could delay the development of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Interruptions in the availability of server systems or communications with Internet or cloud based services, or failure to maintain the security, confidentiality, accessibility or integrity of data stored on such systems, could harm our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We rely upon a variety of Internet service providers, third-party hosting facilities and cloud computing platform providers to support our business. Failure to maintain the security, confidentiality, accessibility or integrity of data stored on such systems could damage our reputation in the market, cause us to lose revenue or market share, increase our service costs, cause us to incur substantial costs, subject us to liability for damages and/or fines and divert our resources from other tasks, any one of which could materially adversely affect our business, financial condition, results of operations and prospects. Any damage to, or failure of, such systems, or communications to and between such systems, could result in interruptions in our operations. If our security measures or those of our third-party data center hosting facilities, cloud computing platform providers, or third-party service partners, are breached, and unauthorized access is obtained to our data or our information technology systems, we may incur significant legal and financial exposure and liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We do not have control over the operations of the facilities of our cloud service providers and our third-party providers may be vulnerable to damage or interruption from natural disasters, cybersecurity attacks, terrorist attacks, power outages and similar events or acts of misconduct. In addition, any changes in our cloud service providers&#8217; service levels may adversely affect our ability to meet our requirements and operate our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If securities or industry analysts do not publish research or publish unfavorable research about our business, our stock price and trading volume could decline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. We currently have three securities analysts and may never obtain additional research coverage by other securities and industry analysts. If no additional securities or industry analysts commence coverage of our company, the trading price for our stock could be negatively impacted. If we obtain additional securities or industry analyst coverage and if one or more of the analysts who covers us downgrades our stock or publishes inaccurate or unfavorable research about our business, our stock price would likely decline. If one or more of these analysts ceases coverage of us or fails to publish reports on us regularly, demand for our stock could decrease, which could cause our stock price and trading volume to decline.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Sales of a substantial number of shares of our common stock in the public market by our existing stockholders could cause our stock price to decline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Sales of a substantial number of shares of our common stock in the public market or the perception that these sales might occur, could depress the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict the effect that sales may have on the prevailing market price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Future sales and issuances of our common stock or rights to purchase common stock by us, including pursuant to our equity incentive plans, could result in additional dilution of the&#160;percentage ownership of our stockholders and could cause our stock price to decline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are generally not restricted from issuing additional common stock, including any securities that are convertible into or exchangeable for, or that represent the right to receive, common stock. The market price of our common stock could decline as a result of sales of common stock or securities that are convertible into or exchangeable for, or that represent the right to receive, common stock or the perception that such sales could occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect that significant additional capital will be needed in the future to continue our planned operations, including conducting clinical trials, commercialization efforts, expanded research and development activities and costs associated with operating as a public company. To the extent we raise additional capital by issuing equity or convertible securities, our stockholders may experience substantial dilution. We may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. Such sales may also result in material dilution to our existing stockholders, and new investors could gain rights superior to our existing stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to our 2016 Equity Incentive Plan (the &#8220;2016 Plan&#8221;), our management is authorized to grant stock options and other equity-based awards to our employees, directors and consultants. The number of shares available for future grant under the 2016 Plan will automatically increase on January&#160;1<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">st</sup> of each&#160;year by up to 5% of all shares of our capital stock outstanding as of December&#160;31<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">st</sup> of the preceding calendar&#160;year, subject to the ability of our board of directors to take action to reduce the size of the increase in any given&#160;year. In addition, we may grant or provide for the grant of rights to purchase shares of our common stock pursuant to our 2016 Employee Stock Purchase Plan (&#8220;ESPP&#8221;). The number of shares of our common stock reserved for issuance under the ESPP will automatically increase on January&#160;1<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">st</sup> of each calendar&#160;year by the lessor of 1% of the total number of shares of our common stock outstanding on December&#160;31<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">st</sup> of the preceding calendar&#160;year and 30,000 shares, subject to the ability of our board of directors to take action to reduce the size of the increase in any given&#160;year. Currently, we plan to register the increased number of shares available for issuance under the 2016 Plan and ESPP each&#160;year. Increases in the number of shares available for future grant or purchase may result in additional dilution, which could cause our stock price to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Provisions of Washington law and our current articles of incorporation and bylaws may discourage another company from acquiring us and may prevent attempts by our stockholders to replace or remove our current management.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Provisions of Washington law and our current articles of incorporation and bylaws may discourage, delay or prevent a merger or acquisition that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace or remove our board of directors. These provisions include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">authorizing the issuance of &#8220;blank check&#8221; preferred stock without any need for action by stockholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">requiring supermajority stockholder voting to effect certain amendments to our articles of incorporation and bylaws; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">establishing advance notice requirements for nominations for election to our board of directors or for proposing matters that can be acted on by stockholders at stockholder meetings.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, because we are incorporated in Washington, we are governed by the provisions of Chapter&#160;23B.19 of the Washington Business Corporation Act, which, among other things, restricts the ability of stockholders owning 10% or more of our outstanding voting stock from merging or combining with us. These provisions could discourage potential acquisition attempts and could reduce the price that investors might be willing to pay for shares of our common stock in the future and result in the market price being lower than it would without these provisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Although we believe these provisions collectively provide for an opportunity to receive higher bids by requiring potential acquirers to negotiate with our board of directors, they would apply even if an offer may be considered beneficial by some stockholders. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Foreign governments tend to impose strict price controls, which may adversely affect our future profitability.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In some foreign countries, particularly in the European Union, prescription drug pricing is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our profitability will be negatively affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may incur significant costs complying with environmental laws and regulations, and failure to comply with these laws and regulations could expose us to significant liabilities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our research and development activities use biological and hazardous materials that are dangerous to human health and safety or the environment. We are subject to a variety of federal, state and local laws and regulations governing the use, generation, manufacture, storage, handling and disposal of these materials and wastes resulting from these materials. We are also subject to regulation by the Occupational Safety and Health Administration (&#8220;OSHA&#8221;), state and federal environmental protection agencies and to regulation under the Toxic Substances Control Act. OSHA, state governments or federal Environmental Protection Agency, may adopt regulations that may affect our research and development programs. We are unable to predict whether any agency will adopt any regulations that could have a material adverse effect on our operations. We have incurred, and will continue to incur, capital and operating expenditures and other costs in the ordinary course of our business in complying with these laws and regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Although we believe our safety procedures for handling and disposing of these materials comply with federal, state and local laws and regulations, we cannot entirely eliminate the risk of accidental injury or contamination from the use, storage, handling or disposal of hazardous materials. In the event of contamination or injury, we could be held liable for any resulting damages, and any liability could significantly exceed our insurance coverage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Taxing authorities could reallocate our taxable income among our subsidiaries, which could increase our overall tax liability.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:13.2pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We are organized in the United States, and we currently have subsidiaries in the United Kingdom and Australia. If we succeed in growing our business, we expect to conduct increased operations through our subsidiaries in various tax jurisdictions pursuant to transfer pricing arrangements between us and our subsidiaries. If two or more affiliated companies are located in different countries, the tax laws or regulations of each country generally will require that transfer prices be the same as those between unrelated companies dealing at arm&#8217;s length and that appropriate documentation is maintained to support the transfer prices. While we believe that we operate in compliance with applicable transfer pricing laws and intend to continue to do so, our transfer pricing procedures are not binding on applicable tax authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">&#160;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If tax authorities in any of these countries were to successfully challenge our transfer prices as not reflecting arm&#8217;s length transactions, they could require us to adjust our transfer prices and thereby reallocate our income to reflect these revised transfer prices, which could result in a higher tax liability to us. In addition, if the country from which the income is reallocated does not agree with the reallocation, both countries could tax the same income, resulting in double taxation. If tax authorities were to allocate income to a higher tax jurisdiction, subject our income to double taxation or assess interest and penalties, it would increase our consolidated tax liability, which could adversely affect our financial condition, results of operations and cash flows.</p><a id="_b0e7695c_eef0_483b_b3d6_289bd118662c"></a><a id="Item2UnregisteredSalesofEquitySecurities"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On October 28, 2021, we entered into the October 2021 Securities Purchase Agreement with CFF and Innoviva for the private placement of newly issued shares of our common stock, par value $0.01 per share (&#8220;Shares&#8221;). Pursuant to the October 2021 Securities Purchase Agreement, we issued and sold 909,091 Shares to CFF and 1,212,122 Shares to Innoviva, each at a per Share price of $3.30 (the &#8220;October 2021 Private Placements&#8221;). We received aggregate gross proceeds from the October 2021 Private Placements of approximately $7.0 million, before deducting transaction expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We also entered into a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;) with the Purchasers. Pursuant to the Registration Rights Agreement, we must file a registration statement on Form S-1 or Form S-3 (the &#8220;Shelf Registration Statement&#8221;) covering the resale of the securities issued and sold pursuant to the October 2021 Securities Purchase Agreement with the U.S. Securities and Exchange Commission (the &#8220;Commission&#8221;) on a continuous basis pursuant to Rule&#160;415&#160;promulgated under the&#160;Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), or if Rule 415 is not available for offers and sales of such securities, by such other means of distribution of such securities as the Purchasers may reasonably specify. We must use commercially reasonable efforts to cause the Shelf Registration Statement to be declared effective under the&#160;Securities Act&#160;as promptly as possible after the filing thereof, but in any event (i) no later than the fifteenth (15th) day following the filing of the Shelf Registration Statement in the event of no &#8220;review&#8221; by the Commission, (ii) no later than the sixtieth (60th) day following the filing of the Shelf Registration Statement in the event of &#8220;limited review&#8221; by the Commission, or (iii) in the event of a &#8220;review&#8221; by the Commission, the one hundred and twentieth (120th) day following the filing of the Shelf Registration Statement, subject to certain exceptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We also entered into an Amended and Restated Voting Agreement with Innoviva and Innoviva, Inc. (the &#8220;Voting Agreement&#8221;), pursuant to which Innoviva and Innoviva, Inc. agreed not to vote or take any action by written consent with respect to shares of our common stock held by Innoviva, Innoviva, Inc. or any of its subsidiaries which represent, in the aggregate, more than 49.5% of the total number of shares of common stock issued and outstanding as of any given record date for voting (such shares, the &#8220;Excess Shares&#8221;) on the matters related to the election of directors to the Board or removal of directors from the Board (&#8220;Board Matters&#8221;) presented at any meeting of our stockholders (or any adjournment or postponement thereof) or for their action by written consent, in each case, unless the Board authorizes Innoviva to vote such Excess Shares with respect to Board Matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_90310f2f_18d4_4c0f_831c_8289aabb074c"></a><a id="Item3DefaultsuponSeniorSecurities_670807"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;3. Defaults upon Senior Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_723eb9fc_08b4_4b15_b8b3_1777b7d64ca4"></a><a id="Item4MineSafetyDisclosures_193094"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;4. Mine Safety Disclosures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_88e55116_5119_4297_90fa_8c7d4fefa85d"></a><a id="Item5OtherInformation_112654"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;5. Other Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">None.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_45dcad48_6ddc_45ae_9f02_fd204381775c"></a><a id="Item6Exhibits_175538"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Item&#160;6. Exhibits </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td colspan="2" style="vertical-align:top;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Number</p></td><td colspan="2" style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:top;width:87.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Description</p></td></tr><tr><td style="vertical-align:top;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.1</p></td><td colspan="2" style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:84.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/921114/000110465920040578/tm2014179d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Articles of Amendment to Articles of Incorporation of the Company (effective March 26, 2020) (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on March 30, 2020)</span></a>.</p></td></tr><tr><td style="vertical-align:top;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background-color:#ffff00;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:84.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.2</p></td><td colspan="2" style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:84.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/921114/000155837019008168/armp-20190630ex35124c484.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.5 to the Company&#8217;s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2019)</span></a>.</p></td></tr><tr><td style="vertical-align:top;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:84.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.3</p></td><td colspan="2" style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:84.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/921114/000110465919071854/tm1924941d1_ex3-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Amendment to Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.2 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on December 11, 2019)</span></a>.</p></td></tr><tr><td style="vertical-align:top;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:84.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.4</p></td><td colspan="2" style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:84.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/921114/000110465920025375/tm2010968d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Amendment to Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on February 26, 2020)</span></a>. </p></td></tr><tr><td style="vertical-align:top;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:84.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.1</p></td><td colspan="2" style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:84.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reference is made to Exhibits 3.1 through 3.4 and Exhibit 10.3.</p></td></tr><tr><td style="vertical-align:top;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background-color:#ffff00;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:84.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.1 </p></td><td colspan="2" style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:84.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/0000921114/000110465921131905/tm2131430d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Securities Purchase Agreement, dated October 28, 2021, by and among the Company, Innoviva, and CFF (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on October 29, 2021)</span></a>.</p></td></tr><tr><td style="vertical-align:top;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:84.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.2</p></td><td colspan="2" style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:84.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/0000921114/000110465921131905/tm2131430d1_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Registration Rights Agreement, dated October 28, 2021, by and among the Company, Innoviva, and CFF (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on October 29, 2021)</span></a>.</p></td></tr><tr><td style="vertical-align:top;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:84.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.3</p></td><td colspan="2" style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:84.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/0000921114/000110465921131905/tm2131430d1_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Amended and Restated Voting Agreement, dated October 28, 2021, by and among the Company, Innoviva, and Innoviva, Inc. (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on October 29, 2021)</span></a>.</p></td></tr><tr><td style="vertical-align:top;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:84.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.4</p></td><td colspan="2" style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:84.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/0000921114/000110465921133195/tm2131735d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Lease Agreement, dated October 28, 2021, by and between the Company and 5005 McConnell Avenue, LLC (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on November 2, 2021</span></a>.</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:87.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">31.1</p></td><td colspan="2" style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:87.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="armp-20210930xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certification of Principal Executive Officer required by Rule&#160;13a-14(a)&#160;or Rule&#160;15d-14(a)</span></a>.</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:87.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">31.2</p></td><td colspan="2" style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:87.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="armp-20210930xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certification of Principal Financial Officer required by Rule&#160;13a-14(a)&#160;or Rule&#160;15d-14(a).</span></a></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:87.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">32.1</p></td><td colspan="2" style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:87.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="armp-20210930xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certification of Principal Executive Officer Required by Rule&#160;13a-14(b)&#160;or Rule&#160;15d-14(b)&#160;and 18 U.S.C. 1350.</span></a></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:87.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">32.2</p></td><td colspan="2" style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:87.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="armp-20210930xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certification of Principal Financial Officer Required by Rule&#160;13a-14(b)&#160;or Rule&#160;15d-14(b)&#160;and 18 U.S.C. 1350.</span></a></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:87.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.INS</p></td><td colspan="2" style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:87.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. </p></td></tr><tr><td colspan="2" style="vertical-align:top;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:87.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.SCH</p></td><td colspan="2" style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:87.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Schema Document.</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:87.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.CAL</p></td><td colspan="2" style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:87.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:87.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.DEF</p></td><td colspan="2" style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:87.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document.</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:87.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.PRE</p></td><td colspan="2" style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:87.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td colspan="2" style="vertical-align:top;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:87.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.LAB</p></td><td colspan="2" style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:87.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Label Linkbase Document.</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:87.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">104</p></td><td colspan="2" style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:87.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d36dbe63_b11e_4ac1_b5f4_fd158d464bae"></a><a id="SIGNATURES_76302"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:12pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:4.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:3.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:41.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:49.82%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:top;width:50.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ARMATA PHARMACEUTICALS, INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.82%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:top;width:50.17%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:49.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: November 10, 2021 </p></td><td style="vertical-align:top;width:4.97%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By</p></td><td style="vertical-align:top;width:41.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Brian Varnum </p></td></tr><tr><td style="vertical-align:top;width:49.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:4.97%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.58%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Brian Varnum </p></td></tr><tr><td style="vertical-align:top;width:49.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:4.97%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: Chief Executive Officer</p></td></tr><tr><td style="vertical-align:top;width:49.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:4.97%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr><tr><td style="vertical-align:top;width:49.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By</p></td><td style="vertical-align:top;width:41.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Steve R. Martin</p></td></tr><tr><td style="vertical-align:top;width:49.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.58%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Steve R. Martin</p></td></tr><tr><td style="vertical-align:top;width:49.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: Chief Financial Officer</p></td></tr><tr><td style="vertical-align:top;width:49.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial and Accounting Officer)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>armp-20210930xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 11/10/2021 08:46:30 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO</b><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;"><br></b><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">I, Brian Varnum, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">I have reviewed this quarterly report on Form 10-Q of Armata Pharmaceuticals, Inc.;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">2.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">3.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">4.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">d)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">5.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Date: November 10, 2021 </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Brian Varnum </p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Brian Varnum </p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>armp-20210930xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 11/10/2021 08:46:33 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">I, Steve R. Martin, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">I have reviewed this quarterly report on Form 10-Q of Armata Pharmaceuticals, Inc.;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">2.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">3.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">4.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">d)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="display:inline-block;font-family:'Times New Roman';min-width:35.4pt;text-indent:0pt;white-space:nowrap;">5.</font>The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Date: November 10, 2021</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Steve R. Martin</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Steve R. Martin</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>armp-20210930xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 11/10/2021 08:46:35 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">PURSUANT TO 18 U.S.C. SECTION 1350,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In connection with the quarterly report of Armata Pharmaceuticals, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended September 30, 2021 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), I, Brian Varnum, Chief Executive Officer of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section 1350 of the United States Code, that to the best of my knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">This Certification has not been, and shall not be deemed, &#8220;filed&#8221; with the Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: November 10, 2021</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Brian Varnum</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Brian Varnum</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>armp-20210930xex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 11/10/2021 08:46:38 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">PURSUANT TO 18 U.S.C. SECTION 1350,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In connection with the quarterly report of Armata Pharmaceuticals, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended September 30, 2021 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), I, Steve R. Martin, Chief Financial Officer of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section 1350 of the United States Code, that to the best of my knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 54pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">This Certification has not been, and shall not be deemed, &#8220;filed&#8221; with the Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: November 10, 2021 </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Steve R. Martin</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Steve R. Martin</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>armp-20210930x10q001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 armp-20210930x10q001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &K W # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<#)K?BJY%F)9A(/+#I]_Y>@S7,6UQ<7FKZ!-)YBM'<D26\5AY,5L3_#D#DT
M>E'Q3H7G+$=6LA(SE IF .X'!%6;#6=-U-Y4L+ZWN7B.)!%(&*_6O++JR)\"
MZJWV5C*^KC/[L[B-V/3.,5UVG6ZP_$V?RX=D7]C1CY4PN=XX].@% ':T444
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M1[58OM7T[3+9;F]O8+>%_NO(X ;Z>M>=^)(+BQ\5:E+-(\%M=6BQPE;#[2)
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M!6F6]S!*9;Z9()/,A@GN6DCC;U"FM_=/_P \D_[[_P#K4;I_^>2?]]__ %J
M)J,5#NG_ .>2?]]__6HW3_\ /)/^^_\ ZU $U%0[I_\ GDG_ 'W_ /6HW3_\
M\D_[[_\ K4 345#NG_YY)_WW_P#6HW3_ //)/^^__K4 345#NG_YY)_WW_\
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M #R3_OO_ .M1NG_YY)_WW_\ 6H EHJ+=/_SR3_OO_P"M1NG_ .>2?]]__6H
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M4YLMUJ:.BAMH(-WDPQQ[CD[% S^5(EK;Q2M)'!$CM]YE0 GZFGQ,SQ(S !B
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MKJ:XTN&2YN9F$C%YT4(RC'JHP*B*BY7+DYJ%NO\ P25-<N([.^^U11B[M6"
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M/*J",Y+;L 8/6MK2\OO,?<[O[CB1X7UX=-#U ?2U;_"G_P#",Z__ - 34/\
MP&?_  KL[WQGXRL;5;F0:5+ 6V>;;8E56]"5?BK;^)/&L1"S3:!$Y ;9).BL
M >>A>JYY^1')3\_N."_X1G7O^@+J'_@,_P#A2_\ ",Z]_P! 74/_  &?_"NZ
M@\4^,YK2&YW:)'%."8_.E6,MSC@%ZSKOXA^*K"[DM;J.SCFB.'0P'C_QZFIU
M'HK$N%-:N_W'+_\ ",Z]_P! 74/_  &?_"GCPUKO_0&U#_P&?_"N@'Q.\0_]
M.7_?@_\ Q5*/B;X@_P"G+_OP?_BJN]7LB;4>[.>'AK7?^@-?_P#@,_\ A3_^
M$;UW_H#:A_X#-_A70#XE^(/^G+_OP?\ XJE'Q*U__IR_[\'_ .*HO5[(5J/=
MG/#PWKO_ $!K_P#\!F_PIP\-ZY_T!]0_\!V_PKH!\2=?_P"G/_OP?_BJ</B1
MKW_3G_WY/_Q5.];LA6H=V<^/#FN?] ?4/_ =O\*/^$=UM1DZ/?@#N;=O\*Z(
M?$?7O^G/_OR?_BJ&^(FO.I4_8\'_ *8G_P"*IWK=D%J'=G/_ /".ZW_T!K__
M ,!V_P *=_PCNM_] B__ / =O\*Z ?$37?\ IS_[\G_XJG_\+#US_IS_ ._)
M_P#BJ/WW9"M0[LYS_A'=;_Z!%_\ ^ [?X4X>'M:_Z!%]_P" [?X5T(^(6N?]
M.G_?D_\ Q5._X6#KGI:?]^3_ /%4?O\ L@_<=V<Z/#VM?] B^_\  =O\*4>'
MM:_Z!-]_X#M_A71?\+ UO_IT_P"_)_\ BJ/^%@:W_P!.G_?D_P#Q5/\ ?]D'
M[CNSGQX?UG_H$WO_ (#M_A2CP_K/_0)O?_ =O\*Z#_A/];_Z=/\ OR?_ (JE
M_P"$^UO_ *=/^_)_^*HO7[(FU#NSGQH&L_\ 0)O?^_#?X4[^P=9_Z!5[_P!^
M&_PK?_X3[6_^G3_OR?\ XJG?\)[K7_3K_P!^C_\ %4[U^R"V'[O[CG_[ UC_
M *!5[_WX;_"E_L'6/^@5>_\ ?EO\*Z#_ (3W6O\ IU_[]'_XJC_A/-9_Z=?^
M_1_^*IWQ'9"MA^[^XP/[!UC_ *!=Y_WX;_"E_L+5_P#H%WG_ 'X;_"M__A.]
M9_Z=?^_1_P#BJ7_A.]9]+7_OT?\ XJC_ &CL@MA^[^XY\:%JY) TR\R.O[AO
M\*7^P=7_ .@7>?\ ?EO\*WE\<:N&)'V7).3^Z/\ C3_^$YUC_IU_[]'_ !H_
M?]D*V'[O[CG_ .PM7_Z!=Y_WX;_"E_L/5O\ H%WG_?EO\*W_ /A.=8_Z=?\
MOT?\:7_A.-7_ .G7_OT?\:=\1V06P_=_<8']AZM_T#+S_ORW^%+_ &'JW_0,
MO/\ ORW^%;__  F^K_\ 3M_WZ/\ C2_\)MJ__3M_WZ/^-'^T=D%L/W?W'/\
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M)Z'?3QDD^9J[[OR(M/N?M,!/D2P[&*!95P3CC(]JN4 "BM$K(YFTW<6BBBF
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MV]I' [-*D.UU0>60 @9<'G':L;5?"UY<7$PMQ;O&URS*/.12%,2(#@J0.5/
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MUTNUAN3%Y\<2K)Y2[4W <X'85=I:Y9U'-69V4Z,8.Z"BBBLS8**** "BBB@
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MNF,9+HS736)L_M404KY@PV"I.,'ZT>SH]@]K6VO^1T(^*J'_ )A#_P#?\?\
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M M_^_P"/\*/^%DI_T"W_ ._X_P *\_%**?U.EV#ZY6[_ )'H'_"R$_Z!;_\
M?X?X4O\ PL=/^@6W_?\ '^%<!2BG]4H]OS%]=K]_R.__ .%C1_\ 0+?_ +_#
M_"E_X6+'_P! Q_\ O\/\*X&G"G]4H]OS#Z[7[_D=[_PL6/\ Z!C_ /?X?X4O
M_"Q(_P#H&/\ ]_A_A7!BE%'U2CV_,7UVM_-^".[_ .%A)_T#7_[_  _PI?\
MA8*?] U_^_P_PKA12BG]3H]OS%]>K?S?@CN?^$_7_H'-_P!_1_A6SH7B.'6F
MD01F&5.=C-G(]:\O%7=+NI[/48)[<$R!@ H_BSVJ*F#I\KY59ET\;54USNZ/
M6H_];-_O#^0J:H("6:0D8)(R/3@5/7D'N!1110 4444 %%%% !1110 4444
M%%%% !4/_+T/]P_SJ:H?^7H?[A_G0!-1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5%)_KXOJ?Y5+44G^OB^I_E0!+1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 5(;&&"YN+A0WF3D%R3GH,#'I5630[.5IRRO\ OIDG
M<!R!O7&"/3H,^M:E+34FM4R7"+5F@JI<6$-S<032 [X&+)@XYJW24DVMAM)[
ME5[&"2^CO&!,L:%%YX /7CUJ*?2K2YN6GECW,T)@8$\,AYP15^EQ34FNHG"+
MW1DVF@V=I)YBF:1PGEJ996?8OHN>E)%X?LX9HY<W$GEG,:RSLZH?8$UKT4^>
M7<GV<>Q#<J6M90!DE"!^5>!2> ?%#N[+I$A5B2#YD?\ \57T _\ JV^AI(O]
M4OTJJ=5PV%4HJIN>':KX0\4:I>K<G07C*PQQ8\Z-ON*%SG/?%3)X8\4+X=?2
M?[!E^:Y%QYOGQ\8&,8S^N:]NHJ_K$MK&?U6-[W9Y,^G^)IYYQ<>&)GM)X8HG
MA6[1&!08#!P>#^%10Z%KEO?F2'PFZVK0-!)"UX&=P>I+ENOT%>O44O;OL/V"
M[_D>6P6.O6DFF"U\*2Q0V$DCJAO$8ON&.6]:R_\ A&_$W]@S:7_8<G[R[%SY
MGG1\?+MVXS^M>S44UB&NGYB>&3ZO\/\ (\KDTWQ#=37BWGAJ26SN3&QA%TBL
MCHH4,&S[>E*^F^)F%Q&OAUXX'M?LL,8N$/EKG.2<_,?RKU.BCZP^R#ZLN[_
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M6<\94G%Q+IX&G"2E=NQ''_K9O]X?R%35#'_K9O\ >'\A4U<IVA1110 4444
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MC[0?[OZU#10!-]H/]W]:C\\_: =O\'K[TVF'_7C_ '?ZT 6?M!_N_K1]H/\
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M44 %%%% !3&_UD?X_P J?3&_UD?X_P J 'T444 %%%% !1110 4444 %%%%
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M9ZB\::2TVF^(D%@J!K2WMRL4C*<[R>#GN1CG'6A0@[77Y^03K55>S_+S_P"
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M #X7?_?A_P#"G#2]0_Y\+O\ [\/_ (4O9S[#]O3_ )D5:<*L?V7J'_/A=?\
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M?^>M'^>M)17IGSMQ?Q/YTF2>YHHH"X4444 %,/\ KQ_N_P!:?3#_ *\?[O\
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M]2H=OQ8?VOB_Y_P7^1YS_P *PG_Z"\/_ (#M_P#%4?\ "L9_^@M#_P!^&_\
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MN8)6-S"9VC$64<H6C!^5<E6QQUX//:HF\):DSVV!$7BCPMQ+>.TD?[MEV !
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MQY\4:CYT<_F:2;5[5Y0D=P6.X$8&<#D9Y':EMO&<UVEN6AMX?,BW$+.'8L&
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1152XU"SL
MV"W-W!"S#($DBJ3^9H MT57CN[:6 S1W$3Q#K(K@J/QZ4^*6.>(20R+(C<AD
M8$'\10!+1110 4444 %%%% !112$X&3TH 6BJL-[:74C1P74$LB_>5) Q'U
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#B@!/](](_S-'^D>D?YFD6Y@=MJS1LV=N X)SZ57MK])K59IU6U9MV5>1#@
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MV* .1TKQR^I>.;GPZ; 1)#;+/YQER3D X(Q[U#HWQ /B+QI=:+I6G>=8V?\
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MY)CP1@ 9W9]JKOX DM/B /%&C:@MF)1B[M/*)6;/WN0>,\'Z\UWE% !1110
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M#_='YU#10!-]H/\ ='YT?:#_ '1^=0T4 3?:#_='YT?:#_='YU#10!-]H/\
M='YT?:#_ '1^=0T4 3?:#_='YT?:#_='YU#10!-]H/\ ='YT?:#_ '1^=0T4
M 3?:#_='YT?:#_='YU#10!-YY_NC\Z/M!_NC\ZAHH F^T'^Z/SH^T'^Z/SJ&
MB@";[0?[H_.C[0?[H_.H:* )OM!_NC\Z/M!_NC\ZAHH F^T'^Z/SH^T'^Z/S
MJ&B@";[0?[H_.C[0?[H_.H:* +:G<H/J*=38_P#5K]*=0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 1O$'.<XIOV<?W
MC4U% $/V<?WC1]G']XU-10!#]G']XT?9Q_>-344 0_9Q_>-'V<?WC4U% $/V
M<?WC1]G']XU-10!#]G']XT?9Q_>-344 0_9Q_>-'V<?WC4U% $/V<?WC1]G'
M]XU-10!#]G']XT?9Q_>-344 0_9Q_>-'V<?WC4U% $/V<?WC1]G']XU-10!#
M]G']XT?9Q_>-344 0_9Q_>-'V<?WC4U% $/V<?WC1]G']XU-10!#]G']XT?9
MQ_>-344 0_9Q_>-'V<?WC4U% $/V<?WC1]G']XU-10!#]G']XT?9Q_>-344
M0_9Q_>-'V<?WC4U% $/V<?WC1]G']XU-10!#]G']XT?9Q_>-344 (HVJ!Z4M
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>armp-20210930.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7908.23199 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/10/2021 8:46:05 PM-->
<!--Modified on: 11/10/2021 8:46:05 PM-->
<schema xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns="http://www.w3.org/2001/XMLSchema" targetNamespace="http://www.armatapharma.com/20210930" elementFormDefault="qualified" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:armp="http://www.armatapharma.com/20210930" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations" id="StatementConsolidatedStatementsOfOperations">
        <link:definition>00200 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" id="StatementConsolidatedStatementsOfCashFlowsParenthetical">
        <link:definition>00405 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails" id="DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails">
        <link:definition>40502 - Disclosure - Balance Sheet Details (Property and Equipment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSharesReservedForFutureIssuanceDetails" id="DisclosureEquityIncentivePlansSharesReservedForFutureIssuanceDetails">
        <link:definition>40806 - Disclosure - Equity Incentive Plans (Shares Reserved for Future Issuance) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity" id="StatementConsolidatedStatementsOfStockholdersEquity">
        <link:definition>00300 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlans" id="DisclosureEquityIncentivePlans">
        <link:definition>10801 - Disclosure - Equity Incentive Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureLiquidityNarrativeDetails" id="DisclosureLiquidityNarrativeDetails">
        <link:definition>40201 - Disclosure - Liquidity (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails" id="DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails">
        <link:definition>40401 - Disclosure - Net Loss Per Share (Antidilutive Shares Excluded from Computation of Diluted Shares Outstanding) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsNarrativeDetails" id="DisclosureBalanceSheetDetailsNarrativeDetails">
        <link:definition>40501 - Disclosure - Balance Sheet Details (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosurePaycheckProtectionProgramLoanNarrativeDetails" id="DisclosurePaycheckProtectionProgramLoanNarrativeDetails">
        <link:definition>40601 - Disclosure - Paycheck Protection Program Loan (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureStockholdersEquityNarrativeDetails" id="DisclosureStockholdersEquityNarrativeDetails">
        <link:definition>40701 - Disclosure - Stockholders Equity (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureStockholdersEquitySummaryOfWarrantsOutstandingDetails" id="DisclosureStockholdersEquitySummaryOfWarrantsOutstandingDetails">
        <link:definition>40702 - Disclosure - Stockholders Equity (Summary of Warrants Outstanding) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails" id="DisclosureEquityIncentivePlansNarrativeDetails">
        <link:definition>40801 - Disclosure - Equity Incentive Plans (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails" id="DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails">
        <link:definition>40802 - Disclosure - Equity Incentive Plans (Assumptions Used in the Black-Scholes Model) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAllocationOfStockBasedCompensationExpenseDetails" id="DisclosureEquityIncentivePlansAllocationOfStockBasedCompensationExpenseDetails">
        <link:definition>40803 - Disclosure - Equity Incentive Plans (Allocation of Stock-Based Compensation Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardDetails" id="DisclosureEquityIncentivePlansRestrictedStockAwardDetails">
        <link:definition>40805 - Disclosure - Equity Incentive Plans (Restricted stock award) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" id="DisclosureCommitmentsAndContingenciesNarrativeDetails">
        <link:definition>40901 - Disclosure - Commitments and Contingencies (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureGrantsAndAwardsNarrativeDetails" id="DisclosureGrantsAndAwardsNarrativeDetails">
        <link:definition>41001 - Disclosure - Grants and Awards (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureSyntheticGenomicsAssetAcquisitionDetails" id="DisclosureSyntheticGenomicsAssetAcquisitionDetails">
        <link:definition>41101 - Disclosure - Synthetic Genomics Asset Acquisition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusiness" id="DisclosureOrganizationAndDescriptionOfBusiness">
        <link:definition>10101 - Disclosure - Organization and Description of the Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureLiquidity" id="DisclosureLiquidity">
        <link:definition>10201 - Disclosure - Liquidity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureSignificantAccountingPolicies" id="DisclosureSignificantAccountingPolicies">
        <link:definition>10301 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
        <link:definition>10401 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureBalanceSheetDetails" id="DisclosureBalanceSheetDetails">
        <link:definition>10501 - Disclosure - Balance Sheet Details</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosurePaycheckProtectionProgramLoan" id="DisclosurePaycheckProtectionProgramLoan">
        <link:definition>10601 - Disclosure - Paycheck Protection Program Loan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>10701 - Disclosure - Stockholders Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>10901 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureGrantsAndAwards" id="DisclosureGrantsAndAwards">
        <link:definition>11001 - Disclosure - Grants and Awards</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureSyntheticGenomicsAssetAcquisition" id="DisclosureSyntheticGenomicsAssetAcquisition">
        <link:definition>11101 - Disclosure - Synthetic Genomics Asset Acquisition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureLiquidityPolicies" id="DisclosureLiquidityPolicies">
        <link:definition>20202 - Disclosure - Liquidity (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies" id="DisclosureSignificantAccountingPoliciesPolicies">
        <link:definition>20302 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
        <link:definition>30403 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsTables" id="DisclosureBalanceSheetDetailsTables">
        <link:definition>30503 - Disclosure - Balance Sheet Details (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureStockholdersEquityTables" id="DisclosureStockholdersEquityTables">
        <link:definition>30703 - Disclosure - Stockholders Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansTables" id="DisclosureEquityIncentivePlansTables">
        <link:definition>30803 - Disclosure - Equity Incentive Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails" id="DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails">
        <link:definition>40804 - Disclosure - Equity Incentive Plans (Summary of Stock Option Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="armp-20210930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="armp-20210930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="armp-20210930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="armp-20210930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <import namespace="http://fasb.org/us-roles/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" />
  <import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
  <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
  <element id="armp_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" name="ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="armp_WarrantExpirationDate" name="WarrantExpirationDate" nillable="true" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="armp_LiquidityAbstract" name="LiquidityAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="armp_EquityIncentivePlan2016Member" name="EquityIncentivePlan2016Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="armp_ProceedsFromEquityOfferingsGross" name="ProceedsFromEquityOfferingsGross" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="armp_OfferingCostsIncludedInAccountsPayable" name="OfferingCostsIncludedInAccountsPayable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="armp_C3jTherapeuticsIncMember" name="C3jTherapeuticsIncMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="armp_SyntheticGenomicsIncMember" name="SyntheticGenomicsIncMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="armp_PercentageOfFullyDilutedCapitalizationForIssuanceOfCommonStock" name="PercentageOfFullyDilutedCapitalizationForIssuanceOfCommonStock" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="armp_MaximumPotentialMilestonePayments" name="MaximumPotentialMilestonePayments" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="armp_Assumed2006And2016PlanMember" name="Assumed2006And2016PlanMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="armp_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock" name="ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="armp_CashPaidForProductiveAssets" name="CashPaidForProductiveAssets" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="armp_LiquidityAndGoingConcernPolicyTextBlock" name="LiquidityAndGoingConcernPolicyTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="armp_AnnualIncreaseInRentPercentage" name="AnnualIncreaseInRentPercentage" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="armp_LeaseAndRentalAbatementCredit" name="LeaseAndRentalAbatementCredit" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="armp_ExercisePriceTwoMember" name="ExercisePriceTwoMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="armp_ExercisePriceThreeMember" name="ExercisePriceThreeMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="armp_ExercisePriceFourMember" name="ExercisePriceFourMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="armp_ExercisePriceFiveMember" name="ExercisePriceFiveMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="armp_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="armp_OperatingLeaseBaseRent" name="OperatingLeaseBaseRent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="armp_OperatingLeaseBaseRentEndOfLeaseTerm" name="OperatingLeaseBaseRentEndOfLeaseTerm" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="armp_AwardReceivable" name="AwardReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="armp_StockIssuedDuringPeriodValueExerciseOfWarrants" name="StockIssuedDuringPeriodValueExerciseOfWarrants" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="armp_StockIssuedDuringPeriodSharesExerciseOfWarrants" name="StockIssuedDuringPeriodSharesExerciseOfWarrants" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="armp_IncreaseDecreaseInAwardReceivable" name="IncreaseDecreaseInAwardReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="armp_GrantsAndAwardsPolicyTextBlock" name="GrantsAndAwardsPolicyTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="armp_ExercisePriceSixMember" name="ExercisePriceSixMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="armp_CysticFibrosisFoundationMember" name="CysticFibrosisFoundationMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="armp_ThresholdDevelopmentAward" name="ThresholdDevelopmentAward" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="armp_AwardAgreementInterruptionPeriod" name="AwardAgreementInterruptionPeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="armp_AwardTable" name="AwardTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration" />
  <element id="armp_AwardLineItems" name="AwardLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="armp_AwardTextBlock" name="AwardTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="armp_AwardAbstract" name="AwardAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="armp_TermOfWarrant" name="TermOfWarrant" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="armp_PaymentProtectionProgramNoteMember" name="PaymentProtectionProgramNoteMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="armp_PaycheckProtectionProgramLoan" name="PaycheckProtectionProgramLoan" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings" name="RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="armp_RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings" name="RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="armp_ProceedsFromPaycheckProtectionProgram" name="ProceedsFromPaycheckProtectionProgram" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="armp_MedicalTechnologyEnterpriseConsortiumMember" name="MedicalTechnologyEnterpriseConsortiumMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="armp_IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet" name="IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="armp_EquitySecuritiesMeasurementInput" name="EquitySecuritiesMeasurementInput" nillable="true" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <element id="armp_AccruedInterestForDeferredConsiderationOnAssetAcquisition" name="AccruedInterestForDeferredConsiderationOnAssetAcquisition" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="armp_SecuritiesPurchaseAgreementSecondTrancheMember" name="SecuritiesPurchaseAgreementSecondTrancheMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="armp_SecuritiesPurchaseAgreementFirstTrancheMember" name="SecuritiesPurchaseAgreementFirstTrancheMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="armp_ZeroCouponDebtInstrumentPolicyTextBlock" name="ZeroCouponDebtInstrumentPolicyTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="armp_ProceedsFromExerciseOfWarrantsAndStockOptions" name="ProceedsFromExerciseOfWarrantsAndStockOptions" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="armp_StockOptionsAndRestrictedStockAwardsMember" name="StockOptionsAndRestrictedStockAwardsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="armp_AssetAcquisitionAbstract" name="AssetAcquisitionAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="armp_AssetAcquisitionTextBlock" name="AssetAcquisitionTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="armp_AssetAcquisitionAxis" name="AssetAcquisitionAxis" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" xbrli:periodType="duration" />
  <element id="armp_AssetAcquisitionDomain" name="AssetAcquisitionDomain" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="armp_ExercisePriceSevenMember" name="ExercisePriceSevenMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="armp_ExercisePriceEightMember" name="ExercisePriceEightMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="armp_NumberOfCommonWarrantsSoldPerShareOfCommonStock" name="NumberOfCommonWarrantsSoldPerShareOfCommonStock" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="armp_ResearchAndDevelopmentCreditsRecognized" name="ResearchAndDevelopmentCreditsRecognized" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="armp_ScenarioOriginalExpectedPaymentOneMember" name="ScenarioOriginalExpectedPaymentOneMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="armp_ScenarioOriginalExpectedPaymentTwoMember" name="ScenarioOriginalExpectedPaymentTwoMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="armp_ScenarioOriginalExpectedPaymentThreeMember" name="ScenarioOriginalExpectedPaymentThreeMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="armp_ScenarioOriginalExpectedPaymentFourMember" name="ScenarioOriginalExpectedPaymentFourMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="armp_ScenarioAmendedExpectedPaymentOneMember" name="ScenarioAmendedExpectedPaymentOneMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="armp_ScenarioAmendedExpectedPaymentTwoMember" name="ScenarioAmendedExpectedPaymentTwoMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="armp_ScenarioAmendedExpectedPaymentThreeMember" name="ScenarioAmendedExpectedPaymentThreeMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="armp_StockIssuedDuringPeriodValueInducementStockAwards" name="StockIssuedDuringPeriodValueInducementStockAwards" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="armp_StockIssuedDuringPeriodSharesInducementStockAwards" name="StockIssuedDuringPeriodSharesInducementStockAwards" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="armp_AmountReceivedUponAchievementOfMilestone" name="AmountReceivedUponAchievementOfMilestone" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="armp_GainLossOnExtinguishmentOfPaycheckProtectionProgramLoan" name="GainLossOnExtinguishmentOfPaycheckProtectionProgramLoan" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="armp_ForgivenessRelatedToPaycheckProtectionProgram" name="ForgivenessRelatedToPaycheckProtectionProgram" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="armp_ShareBasedCompensationArrangementPercentageOfOutstandingAwardsVestedForAdvisoryServicesProvided" name="ShareBasedCompensationArrangementPercentageOfOutstandingAwardsVestedForAdvisoryServicesProvided" nillable="true" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="armp_StockBasedCompensationExpenseRelatedToPreVestingForfeituresReversed" name="StockBasedCompensationExpenseRelatedToPreVestingForfeituresReversed" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="armp_BaseAnnualRentToBePaidYearOne" name="BaseAnnualRentToBePaidYearOne" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="armp_MaximumAllowanceForTenantImprovementsReceivable" name="MaximumAllowanceForTenantImprovementsReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="armp_InnovivaStrategicOpportunitiesLlcMember" name="InnovivaStrategicOpportunitiesLlcMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="armp_GainLossOnExtinguishmentOfPaycheckProtectionProgramSinceInception" name="GainLossOnExtinguishmentOfPaycheckProtectionProgramSinceInception" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>armp-20210930_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7908.23199 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/10/2021 8:46:05 PM-->
<!--Modified on: 11/10/2021 8:46:05 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#DisclosureStockholdersEquity" roleURI="http://www.armatapharma.com/role/DisclosureStockholdersEquity" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#DisclosureEquityIncentivePlansAllocationOfStockBasedCompensationExpenseDetails" roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAllocationOfStockBasedCompensationExpenseDetails" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#StatementConsolidatedStatementsOfCashFlowsParenthetical" roleURI="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails" roleURI="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#DisclosureEquityIncentivePlansSharesReservedForFutureIssuanceDetails" roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSharesReservedForFutureIssuanceDetails" />
  <calculationLink xlink:role="http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Consolidated Balance Sheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637721739639776104" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_637721739639776104" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637721739639776104" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637721739639776104" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637721739639776104" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_AwardReceivable" xlink:label="armp_AwardReceivable_637721739639776104" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637721739639776104" xlink:to="armp_AwardReceivable_637721739639776104" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637721739639776104" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637721739639776104" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637721739639776104" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill_637721739639776104" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_Goodwill_637721739639776104" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637721739639776104" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637721739639776104" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_637721739639776104" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_637721739639776104" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_637721739639786114" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent_637721739639786114" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637721739639786114" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637721739639786114" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_637721739639786114" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_637721739639786114" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637721739639786114" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_637721739639786114" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637721739639786114" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637721739639786114" xlink:to="us-gaap_CommonStockValue_637721739639786114" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_637721739639786114" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637721739639786114" xlink:to="us-gaap_AdditionalPaidInCapital_637721739639786114" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637721739639786114" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637721739639786114" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637721739639786114" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637721739639786114" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_637721739639786114" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637721739639786114" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637721739639786114" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637721739639786114" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_637721739639796102" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637721739639786114" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_637721739639796102" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637721739639796102" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637721739639786114" xlink:to="us-gaap_LiabilitiesCurrent_637721739639796102" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_637721739639796102" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637721739639796102" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_637721739639796102" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationLiabilityCurrent" xlink:label="us-gaap_DeferredCompensationLiabilityCurrent_637721739639796102" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637721739639796102" xlink:to="us-gaap_DeferredCompensationLiabilityCurrent_637721739639796102" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637721739639796102" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637721739639796102" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637721739639796102" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_PaycheckProtectionProgramLoan" xlink:label="armp_PaycheckProtectionProgramLoan_637721739639796102" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637721739639796102" xlink:to="armp_PaycheckProtectionProgramLoan_637721739639796102" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_637721739639796102" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637721739639796102" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_637721739639796102" order="5" use="optional" weight="1" priority="3" />
  </calculationLink>
  <calculationLink xlink:role="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Consolidated Statements of Operations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_637721739639806110" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_637721739639806110" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_GainLossOnExtinguishmentOfPaycheckProtectionProgramSinceInception" xlink:label="armp_GainLossOnExtinguishmentOfPaycheckProtectionProgramSinceInception_637721739639806110" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense_637721739639806110" xlink:to="armp_GainLossOnExtinguishmentOfPaycheckProtectionProgramSinceInception_637721739639806110" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_637721739639806110" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense_637721739639806110" xlink:to="us-gaap_InvestmentIncomeInterest_637721739639806110" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_637721739639806110" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense_637721739639806110" xlink:to="us-gaap_InterestExpense_637721739639806110" order="3" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637721739639806110" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_637721739639806110" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_637721739639806110" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637721739639806110" xlink:to="us-gaap_RevenueNotFromContractWithCustomer_637721739639806110" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_637721739639806110" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637721739639806110" xlink:to="us-gaap_OperatingExpenses_637721739639806110" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_637721739639806110" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637721739639806110" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_637721739639806110" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637721739639806110" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637721739639806110" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637721739639806110" order="2" use="optional" weight="1" priority="3" />
  </calculationLink>
  <calculationLink xlink:role="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Consolidated Statements of Cash Flows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637721739639816107" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637721739639816107" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637721739639816107" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637721739639816107" xlink:to="us-gaap_ProfitLoss_637721739639816107" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashExpense" xlink:label="us-gaap_OtherNoncashExpense_637721739639816107" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637721739639816107" xlink:to="us-gaap_OtherNoncashExpense_637721739639816107" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_AccruedInterestForDeferredConsiderationOnAssetAcquisition" xlink:label="armp_AccruedInterestForDeferredConsiderationOnAssetAcquisition_637721739639816107" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637721739639816107" xlink:to="armp_AccruedInterestForDeferredConsiderationOnAssetAcquisition_637721739639816107" order="3" use="optional" weight="-1" priority="4" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_IncreaseDecreaseInAwardReceivable" xlink:label="armp_IncreaseDecreaseInAwardReceivable_637721739639816107" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637721739639816107" xlink:to="armp_IncreaseDecreaseInAwardReceivable_637721739639816107" order="4" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637721739639816107" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637721739639816107" xlink:to="us-gaap_ShareBasedCompensation_637721739639816107" order="5" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCompensation" xlink:label="us-gaap_IncreaseDecreaseInDeferredCompensation_637721739639816107" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637721739639816107" xlink:to="us-gaap_IncreaseDecreaseInDeferredCompensation_637721739639816107" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet" xlink:label="armp_IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet_637721739639816107" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637721739639816107" xlink:to="armp_IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet_637721739639816107" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_GainLossOnExtinguishmentOfPaycheckProtectionProgramLoan" xlink:label="armp_GainLossOnExtinguishmentOfPaycheckProtectionProgramLoan_637721739639816107" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637721739639816107" xlink:to="armp_GainLossOnExtinguishmentOfPaycheckProtectionProgramLoan_637721739639816107" order="8" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637721739639816107" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637721739639816107" xlink:to="us-gaap_Depreciation_637721739639816107" order="9" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637721739639826107" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637721739639816107" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637721739639826107" order="10" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637721739639826107" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637721739639816107" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637721739639826107" order="11" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637721739639826107" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637721739639826107" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637721739639826107" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637721739639826107" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637721739639826107" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637721739639826107" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637721739639826107" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ProceedsFromPaycheckProtectionProgram" xlink:label="armp_ProceedsFromPaycheckProtectionProgram_637721739639826107" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637721739639826107" xlink:to="armp_ProceedsFromPaycheckProtectionProgram_637721739639826107" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637721739639826107" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637721739639826107" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637721739639826107" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ProceedsFromExerciseOfWarrantsAndStockOptions" xlink:label="armp_ProceedsFromExerciseOfWarrantsAndStockOptions_637721739639826107" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637721739639826107" xlink:to="armp_ProceedsFromExerciseOfWarrantsAndStockOptions_637721739639826107" order="3" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_637721739639826107" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637721739639826107" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_637721739639826107" order="4" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" xlink:type="extended" xlink:title="00405 - Statement - Consolidated Statements of Cash Flows (Parenthetical)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637721739639836099" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637721739639836099" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_637721739639836099" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashNoncurrent_637721739639836099" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Balance Sheet Details (Property and Equipment) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637721739639836099" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637721739639836099" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_637721739639836099" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_637721739639836099" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSharesReservedForFutureIssuanceDetails" xlink:type="extended" xlink:title="40806 - Disclosure - Equity Incentive Plans (Shares Reserved for Future Issuance) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637721739639836099" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637721739639836099" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_637721739639836099" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_637721739639836099" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_637721739639836099" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_637721739639836099" order="3" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_637721739639836099" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_637721739639836099" order="4" use="optional" weight="1" />
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>armp-20210930_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7908.23199 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/10/2021 8:46:05 PM-->
<!--Modified on: 11/10/2021 8:46:05 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#StatementConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#DisclosureLiquidityNarrativeDetails" roleURI="http://www.armatapharma.com/role/DisclosureLiquidityNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails" roleURI="http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails" roleURI="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#DisclosurePaycheckProtectionProgramLoanNarrativeDetails" roleURI="http://www.armatapharma.com/role/DisclosurePaycheckProtectionProgramLoanNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#DisclosureStockholdersEquityNarrativeDetails" roleURI="http://www.armatapharma.com/role/DisclosureStockholdersEquityNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#DisclosureStockholdersEquitySummaryOfWarrantsOutstandingDetails" roleURI="http://www.armatapharma.com/role/DisclosureStockholdersEquitySummaryOfWarrantsOutstandingDetails" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#DisclosureEquityIncentivePlansNarrativeDetails" roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails" roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#DisclosureEquityIncentivePlansAllocationOfStockBasedCompensationExpenseDetails" roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAllocationOfStockBasedCompensationExpenseDetails" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#DisclosureEquityIncentivePlansRestrictedStockAwardDetails" roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardDetails" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#DisclosureEquityIncentivePlansSharesReservedForFutureIssuanceDetails" roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSharesReservedForFutureIssuanceDetails" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#DisclosureGrantsAndAwardsNarrativeDetails" roleURI="http://www.armatapharma.com/role/DisclosureGrantsAndAwardsNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#DisclosureSyntheticGenomicsAssetAcquisitionDetails" roleURI="http://www.armatapharma.com/role/DisclosureSyntheticGenomicsAssetAcquisitionDetails" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
  <definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" />
  <definitionLink xlink:role="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - Consolidated Statements of Stockholders' Equity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637721739639846106" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_637721739639846106" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="armp_StockIssuedDuringPeriodValueExerciseOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="armp_StockIssuedDuringPeriodValueExerciseOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="armp_StockIssuedDuringPeriodSharesExerciseOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="armp_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:to="armp_StockIssuedDuringPeriodSharesExerciseOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings" xlink:label="armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings" xlink:label="armp_RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings" xlink:to="armp_RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_StockIssuedDuringPeriodValueInducementStockAwards" xlink:label="armp_StockIssuedDuringPeriodValueInducementStockAwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="armp_StockIssuedDuringPeriodValueInducementStockAwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_StockIssuedDuringPeriodSharesInducementStockAwards" xlink:label="armp_StockIssuedDuringPeriodSharesInducementStockAwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="armp_StockIssuedDuringPeriodValueInducementStockAwards" xlink:to="armp_StockIssuedDuringPeriodSharesInducementStockAwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/DisclosureLiquidityNarrativeDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Liquidity (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637721739639866102" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637721739639866102" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_SecuritiesPurchaseAgreementMember" xlink:label="armp_SecuritiesPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="armp_SecuritiesPurchaseAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_SecuritiesPurchaseAgreementFirstTrancheMember" xlink:label="armp_SecuritiesPurchaseAgreementFirstTrancheMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="armp_SecuritiesPurchaseAgreementMember" xlink:to="armp_SecuritiesPurchaseAgreementFirstTrancheMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_SecuritiesPurchaseAgreementSecondTrancheMember" xlink:label="armp_SecuritiesPurchaseAgreementSecondTrancheMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="armp_SecuritiesPurchaseAgreementMember" xlink:to="armp_SecuritiesPurchaseAgreementSecondTrancheMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis" xlink:label="us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis" xlink:to="us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain_637721739639876112" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis" xlink:to="us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain_637721739639876112" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuritiesSubjectToMandatoryRedemptionMember" xlink:label="us-gaap_SecuritiesSubjectToMandatoryRedemptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain" xlink:to="us-gaap_SecuritiesSubjectToMandatoryRedemptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSubjectToMandatoryRedemptionMember" xlink:label="us-gaap_CommonStockSubjectToMandatoryRedemptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SecuritiesSubjectToMandatoryRedemptionMember" xlink:to="us-gaap_CommonStockSubjectToMandatoryRedemptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember" xlink:label="us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain" xlink:to="us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637721739639936102" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637721739639936102" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_CysticFibrosisFoundationMember" xlink:label="armp_CysticFibrosisFoundationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="armp_CysticFibrosisFoundationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_InnovivaStrategicOpportunitiesLlcMember" xlink:label="armp_InnovivaStrategicOpportunitiesLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="armp_InnovivaStrategicOpportunitiesLlcMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637721739639936102" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_637721739639936102" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637721739639946102" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_637721739639946102" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ProceedsFromEquityOfferingsGross" xlink:label="armp_ProceedsFromEquityOfferingsGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="armp_ProceedsFromEquityOfferingsGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernManagementsEvaluation" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernManagementsEvaluation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernManagementsEvaluation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_NumberOfCommonWarrantsSoldPerShareOfCommonStock" xlink:label="armp_NumberOfCommonWarrantsSoldPerShareOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="armp_NumberOfCommonWarrantsSoldPerShareOfCommonStock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Net Loss Per Share (Antidilutive Shares Excluded from Computation of Diluted Shares Outstanding) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_637721739639966099" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_637721739639966099" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Balance Sheet Details (Property and Equipment) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637721739639976115" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637721739639976115" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TechnologyEquipmentMember" xlink:label="us-gaap_TechnologyEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_TechnologyEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherTypesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherTypesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LandAndBuildingMember" xlink:label="us-gaap_LandAndBuildingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LandAndBuildingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LandAndBuildingMember" xlink:to="us-gaap_LeaseholdImprovementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/DisclosurePaycheckProtectionProgramLoanNarrativeDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Paycheck Protection Program Loan (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_637721739639986100" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_637721739639986100" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnsecuredDebtMember" xlink:label="us-gaap_UnsecuredDebtMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_UnsecuredDebtMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637721739639986100" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_637721739639986100" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_PaymentProtectionProgramNoteMember" xlink:label="armp_PaymentProtectionProgramNoteMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="armp_PaymentProtectionProgramNoteMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromUnsecuredNotesPayable" xlink:label="us-gaap_ProceedsFromUnsecuredNotesPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromUnsecuredNotesPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_GainLossOnExtinguishmentOfPaycheckProtectionProgramLoan" xlink:label="armp_GainLossOnExtinguishmentOfPaycheckProtectionProgramLoan" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="armp_GainLossOnExtinguishmentOfPaycheckProtectionProgramLoan" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/DisclosureStockholdersEquityNarrativeDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Stockholders Equity (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_CysticFibrosisFoundationMember" xlink:label="armp_CysticFibrosisFoundationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="armp_CysticFibrosisFoundationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_InnovivaStrategicOpportunitiesLlcMember" xlink:label="armp_InnovivaStrategicOpportunitiesLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="armp_InnovivaStrategicOpportunitiesLlcMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis" xlink:label="us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis" xlink:to="us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuritiesSubjectToMandatoryRedemptionMember" xlink:label="us-gaap_SecuritiesSubjectToMandatoryRedemptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain" xlink:to="us-gaap_SecuritiesSubjectToMandatoryRedemptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSubjectToMandatoryRedemptionMember" xlink:label="us-gaap_CommonStockSubjectToMandatoryRedemptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SecuritiesSubjectToMandatoryRedemptionMember" xlink:to="us-gaap_CommonStockSubjectToMandatoryRedemptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember" xlink:label="us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain" xlink:to="us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_SecuritiesPurchaseAgreementMember" xlink:label="armp_SecuritiesPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="armp_SecuritiesPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_SecuritiesPurchaseAgreementFirstTrancheMember" xlink:label="armp_SecuritiesPurchaseAgreementFirstTrancheMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="armp_SecuritiesPurchaseAgreementMember" xlink:to="armp_SecuritiesPurchaseAgreementFirstTrancheMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_SecuritiesPurchaseAgreementSecondTrancheMember" xlink:label="armp_SecuritiesPurchaseAgreementSecondTrancheMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="armp_SecuritiesPurchaseAgreementMember" xlink:to="armp_SecuritiesPurchaseAgreementSecondTrancheMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ProceedsFromEquityOfferingsGross" xlink:label="armp_ProceedsFromEquityOfferingsGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="armp_ProceedsFromEquityOfferingsGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_NumberOfCommonWarrantsSoldPerShareOfCommonStock" xlink:label="armp_NumberOfCommonWarrantsSoldPerShareOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="armp_NumberOfCommonWarrantsSoldPerShareOfCommonStock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/DisclosureStockholdersEquitySummaryOfWarrantsOutstandingDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Stockholders Equity (Summary of Warrants Outstanding) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_SecuritiesPurchaseAgreementMember" xlink:label="armp_SecuritiesPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="armp_SecuritiesPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis" xlink:label="us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis" xlink:to="us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuritiesSubjectToMandatoryRedemptionMember" xlink:label="us-gaap_SecuritiesSubjectToMandatoryRedemptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain" xlink:to="us-gaap_SecuritiesSubjectToMandatoryRedemptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSubjectToMandatoryRedemptionMember" xlink:label="us-gaap_CommonStockSubjectToMandatoryRedemptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SecuritiesSubjectToMandatoryRedemptionMember" xlink:to="us-gaap_CommonStockSubjectToMandatoryRedemptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember" xlink:label="us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SecuritiesSubjectToMandatoryRedemptionMember" xlink:to="us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_637721739640046115" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_637721739640046115" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ExercisePriceTwoMember" xlink:label="armp_ExercisePriceTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="armp_ExercisePriceTwoMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ExercisePriceThreeMember" xlink:label="armp_ExercisePriceThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="armp_ExercisePriceThreeMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ExercisePriceFourMember" xlink:label="armp_ExercisePriceFourMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="armp_ExercisePriceFourMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ExercisePriceFiveMember" xlink:label="armp_ExercisePriceFiveMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="armp_ExercisePriceFiveMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ExercisePriceSixMember" xlink:label="armp_ExercisePriceSixMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="armp_ExercisePriceSixMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ExercisePriceSevenMember" xlink:label="armp_ExercisePriceSevenMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="armp_ExercisePriceSevenMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ExercisePriceEightMember" xlink:label="armp_ExercisePriceEightMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="armp_ExercisePriceEightMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_WarrantExpirationDate" xlink:label="armp_WarrantExpirationDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="armp_WarrantExpirationDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_TermOfWarrant" xlink:label="armp_TermOfWarrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="armp_TermOfWarrant" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Equity Incentive Plans (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_637721739640076113" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_637721739640076113" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_EquityIncentivePlan2016Member" xlink:label="armp_EquityIncentivePlan2016Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:to="armp_EquityIncentivePlan2016Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637721739640076113" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637721739640076113" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_StockOptionsAndRestrictedStockAwardsMember" xlink:label="armp_StockOptionsAndRestrictedStockAwardsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="armp_StockOptionsAndRestrictedStockAwardsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637721739640086105" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_637721739640086105" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_Assumed2006And2016PlanMember" xlink:label="armp_Assumed2006And2016PlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="armp_Assumed2006And2016PlanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_637721739640096099" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_637721739640096099" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ShareBasedCompensationArrangementPercentageOfOutstandingAwardsVestedForAdvisoryServicesProvided" xlink:label="armp_ShareBasedCompensationArrangementPercentageOfOutstandingAwardsVestedForAdvisoryServicesProvided" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="armp_ShareBasedCompensationArrangementPercentageOfOutstandingAwardsVestedForAdvisoryServicesProvided" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_StockBasedCompensationExpenseRelatedToPreVestingForfeituresReversed" xlink:label="armp_StockBasedCompensationExpenseRelatedToPreVestingForfeituresReversed" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="armp_StockBasedCompensationExpenseRelatedToPreVestingForfeituresReversed" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Equity Incentive Plans (Assumptions Used in the Black-Scholes Model) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_637721739640126099" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_637721739640126099" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_EquitySecuritiesMeasurementInput" xlink:label="armp_EquitySecuritiesMeasurementInput" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="armp_EquitySecuritiesMeasurementInput" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAllocationOfStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="40803 - Disclosure - Equity Incentive Plans (Allocation of Stock-Based Compensation Expense) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637721739640136123" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_637721739640136123" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardDetails" xlink:type="extended" xlink:title="40805 - Disclosure - Equity Incentive Plans (Restricted stock award) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSharesReservedForFutureIssuanceDetails" xlink:type="extended" xlink:title="40806 - Disclosure - Equity Incentive Plans (Shares Reserved for Future Issuance) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_EquityIncentivePlan2016Member" xlink:label="armp_EquityIncentivePlan2016Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:to="armp_EquityIncentivePlan2016Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/DisclosureGrantsAndAwardsNarrativeDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Grants and Awards (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_AwardTable" xlink:label="armp_AwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="armp_AwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="armp_AwardTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_637721739640176112" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_637721739640176112" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_CysticFibrosisFoundationMember" xlink:label="armp_CysticFibrosisFoundationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="armp_CysticFibrosisFoundationMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="armp_AwardTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_MedicalTechnologyEnterpriseConsortiumMember" xlink:label="armp_MedicalTechnologyEnterpriseConsortiumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="armp_MedicalTechnologyEnterpriseConsortiumMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_AwardLineItems" xlink:label="armp_AwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="armp_AwardLineItems" xlink:to="armp_AwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="armp_AwardLineItems" xlink:to="us-gaap_RevenueNotFromContractWithCustomer" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ThresholdDevelopmentAward" xlink:label="armp_ThresholdDevelopmentAward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="armp_AwardLineItems" xlink:to="armp_ThresholdDevelopmentAward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_AwardReceivable" xlink:label="armp_AwardReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="armp_AwardLineItems" xlink:to="armp_AwardReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_AmountReceivedUponAchievementOfMilestone" xlink:label="armp_AmountReceivedUponAchievementOfMilestone" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="armp_AwardLineItems" xlink:to="armp_AmountReceivedUponAchievementOfMilestone" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_AwardAgreementInterruptionPeriod" xlink:label="armp_AwardAgreementInterruptionPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="armp_AwardLineItems" xlink:to="armp_AwardAgreementInterruptionPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ResearchAndDevelopmentCreditsRecognized" xlink:label="armp_ResearchAndDevelopmentCreditsRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="armp_AwardLineItems" xlink:to="armp_ResearchAndDevelopmentCreditsRecognized" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.armatapharma.com/role/DisclosureSyntheticGenomicsAssetAcquisitionDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Synthetic Genomics Asset Acquisition (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_AssetAcquisitionAxis" xlink:label="armp_AssetAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="armp_AssetAcquisitionAxis" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_AssetAcquisitionDomain" xlink:label="armp_AssetAcquisitionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="armp_AssetAcquisitionAxis" xlink:to="armp_AssetAcquisitionDomain" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_AssetAcquisitionDomain" xlink:label="armp_AssetAcquisitionDomain_637721739640196106" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="armp_AssetAcquisitionAxis" xlink:to="armp_AssetAcquisitionDomain_637721739640196106" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_SyntheticGenomicsIncMember" xlink:label="armp_SyntheticGenomicsIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="armp_AssetAcquisitionDomain" xlink:to="armp_SyntheticGenomicsIncMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_C3jTherapeuticsIncMember" xlink:label="armp_C3jTherapeuticsIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="armp_C3jTherapeuticsIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_637721739640206112" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_637721739640206112" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScenarioPlanMember" xlink:label="us-gaap_ScenarioPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ScenarioOriginalExpectedPaymentOneMember" xlink:label="armp_ScenarioOriginalExpectedPaymentOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ScenarioPlanMember" xlink:to="armp_ScenarioOriginalExpectedPaymentOneMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ScenarioOriginalExpectedPaymentTwoMember" xlink:label="armp_ScenarioOriginalExpectedPaymentTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ScenarioPlanMember" xlink:to="armp_ScenarioOriginalExpectedPaymentTwoMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ScenarioOriginalExpectedPaymentThreeMember" xlink:label="armp_ScenarioOriginalExpectedPaymentThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ScenarioPlanMember" xlink:to="armp_ScenarioOriginalExpectedPaymentThreeMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ScenarioOriginalExpectedPaymentFourMember" xlink:label="armp_ScenarioOriginalExpectedPaymentFourMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ScenarioPlanMember" xlink:to="armp_ScenarioOriginalExpectedPaymentFourMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ScenarioAmendedExpectedPaymentOneMember" xlink:label="armp_ScenarioAmendedExpectedPaymentOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ScenarioPlanMember" xlink:to="armp_ScenarioAmendedExpectedPaymentOneMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ScenarioAmendedExpectedPaymentTwoMember" xlink:label="armp_ScenarioAmendedExpectedPaymentTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ScenarioPlanMember" xlink:to="armp_ScenarioAmendedExpectedPaymentTwoMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ScenarioAmendedExpectedPaymentThreeMember" xlink:label="armp_ScenarioAmendedExpectedPaymentThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ScenarioPlanMember" xlink:to="armp_ScenarioAmendedExpectedPaymentThreeMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_CashPaidForProductiveAssets" xlink:label="armp_CashPaidForProductiveAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="armp_CashPaidForProductiveAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_PercentageOfFullyDilutedCapitalizationForIssuanceOfCommonStock" xlink:label="armp_PercentageOfFullyDilutedCapitalizationForIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="armp_PercentageOfFullyDilutedCapitalizationForIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_MaximumPotentialMilestonePayments" xlink:label="armp_MaximumPotentialMilestonePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="armp_MaximumPotentialMilestonePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_InterestExpense" priority="1" use="optional" />
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>armp-20210930_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7908.23199 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/10/2021 8:46:05 PM-->
<!--Modified on: 11/10/2021 8:46:05 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Document And Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_AwardReceivable" xlink:label="armp_AwardReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_AwardReceivable" xlink:to="armp_AwardReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_AwardReceivable_lbl" xml:lang="en-US">The carrying amount as of the balance sheet date of award receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_AwardReceivable_lbl" xml:lang="en-US">Award Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_AwardReceivable_lbl" xml:lang="en-US">Award receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="armp_AwardReceivable_lbl" xml:lang="en-US">Awards receivable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US">Restricted Cash, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US">Restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US">Restricted cash</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use asset</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">In-process research and development</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US">Goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US">Goodwill</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable and accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationLiabilityCurrent" xlink:label="us-gaap_DeferredCompensationLiabilityCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationLiabilityCurrent" xlink:to="us-gaap_DeferredCompensationLiabilityCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationLiabilityCurrent_lbl" xml:lang="en-US">Deferred Compensation Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCompensationLiabilityCurrent_lbl" xml:lang="en-US">Accrued compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Current portion of operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_PaycheckProtectionProgramLoan" xlink:label="armp_PaycheckProtectionProgramLoan" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_PaycheckProtectionProgramLoan" xlink:to="armp_PaycheckProtectionProgramLoan_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_PaycheckProtectionProgramLoan_lbl" xml:lang="en-US">Paycheck protection program loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_PaycheckProtectionProgramLoan_lbl" xml:lang="en-US">Paycheck Protection Program Loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_PaycheckProtectionProgramLoan_lbl" xml:lang="en-US">PPP Loan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_lbl" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_lbl" xml:lang="en-US">Deferred asset acquisition consideration</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liabilities, net of current portion</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xml:lang="en-US">Deferred Tax Liabilities, Net, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xml:lang="en-US">Deferred tax liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.01 par value; 217,000,000 shares authorized; 24,965,086 and 18,688,461 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional Paid in Capital, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained Earnings (Accumulated Deficit), Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders Equity Attributable to Parent, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Balances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Balances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Equity, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Consolidated Statements of Operations [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueNotFromContractWithCustomer" xlink:to="us-gaap_RevenueNotFromContractWithCustomer_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_lbl" xml:lang="en-US">Revenue From Grants Non Gaap</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_lbl" xml:lang="en-US">Revenue from grants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_lbl" xml:lang="en-US">Grant revenue</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US">Research and development</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and Administrative Expense, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Operating Expenses, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income (Loss), Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherExpensesAbstract" xlink:label="us-gaap_OtherExpensesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpensesAbstract" xlink:to="us-gaap_OtherExpensesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpensesAbstract_lbl" xml:lang="en-US">Other Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherExpensesAbstract_lbl" xml:lang="en-US">Other income (expense)</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_GainLossOnExtinguishmentOfPaycheckProtectionProgramSinceInception" xlink:label="armp_GainLossOnExtinguishmentOfPaycheckProtectionProgramSinceInception" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_GainLossOnExtinguishmentOfPaycheckProtectionProgramSinceInception" xlink:to="armp_GainLossOnExtinguishmentOfPaycheckProtectionProgramSinceInception_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_GainLossOnExtinguishmentOfPaycheckProtectionProgramSinceInception_lbl" xml:lang="en-US">Gain (loss) on extinguishment of paycheck protection program since inception.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_GainLossOnExtinguishmentOfPaycheckProtectionProgramSinceInception_lbl" xml:lang="en-US">Gain Loss On Extinguishment Of Paycheck Protection Program Since Inception</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_GainLossOnExtinguishmentOfPaycheckProtectionProgramSinceInception_lbl" xml:lang="en-US">Gain upon extinguishment of Paycheck Protection Program loan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Investment Income, Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income (expense), net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US">Per share information:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Net loss per share, basic and diluted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted average shares outstanding, basic and diluted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balances (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balances (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl" xml:lang="en-US">Forfeiture of restricted stock awards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xml:lang="en-US">Forfeiture of restricted stock awards (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Sale of common stock, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Sale of common stock, net of issuance costs (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Common stock issued in registered public financings (in shares)</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="armp_StockIssuedDuringPeriodValueExerciseOfWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:to="armp_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl" xml:lang="en-US">Equity impact of shares issued on exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl" xml:lang="en-US">Stock Issued During Period, Value, Exercise Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl" xml:lang="en-US">Exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="armp_StockIssuedDuringPeriodSharesExerciseOfWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:to="armp_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xml:lang="en-US">Number of shares issued on exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Exercise Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xml:lang="en-US">Exercise of warrants (in shares)</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings" xlink:label="armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings" xlink:to="armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings_lbl" xml:lang="en-US">Restricted stock returned value shares issued net of tax withholdings .</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings_lbl" xml:lang="en-US">Restricted Stock Returned Value Shares Issued Net Of Tax Withholdings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings_lbl" xml:lang="en-US">Return of restricted stock awards for tax withholdings</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings" xlink:label="armp_RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings" xlink:to="armp_RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings_lbl" xml:lang="en-US">Restricted stock returned shares issued net of tax withholdings.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings_lbl" xml:lang="en-US">Restricted Stock Returned Shares Issued Net Of Tax Withholdings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="armp_RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings_lbl" xml:lang="en-US">Return of restricted stock awards for tax withholdings, shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise stock options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Shares, Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options (in shares)</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_StockIssuedDuringPeriodValueInducementStockAwards" xlink:label="armp_StockIssuedDuringPeriodValueInducementStockAwards" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_StockIssuedDuringPeriodValueInducementStockAwards" xlink:to="armp_StockIssuedDuringPeriodValueInducementStockAwards_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_StockIssuedDuringPeriodValueInducementStockAwards_lbl" xml:lang="en-US">Equity impact of the value of inducement stock awards issued during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_StockIssuedDuringPeriodValueInducementStockAwards_lbl" xml:lang="en-US">Stock Issued During Period, Value, Inducement Stock Awards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_StockIssuedDuringPeriodValueInducementStockAwards_lbl" xml:lang="en-US">Issuance of inducement stock awards</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_StockIssuedDuringPeriodSharesInducementStockAwards" xlink:label="armp_StockIssuedDuringPeriodSharesInducementStockAwards" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_StockIssuedDuringPeriodSharesInducementStockAwards" xlink:to="armp_StockIssuedDuringPeriodSharesInducementStockAwards_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_StockIssuedDuringPeriodSharesInducementStockAwards_lbl" xml:lang="en-US">Number of inducement stock awards issued during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_StockIssuedDuringPeriodSharesInducementStockAwards_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Inducement Stock Awards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_StockIssuedDuringPeriodSharesInducementStockAwards_lbl" xml:lang="en-US">Issuance of inducement stock awards (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Operating activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments required to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_GainLossOnExtinguishmentOfPaycheckProtectionProgramLoan" xlink:label="armp_GainLossOnExtinguishmentOfPaycheckProtectionProgramLoan" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_GainLossOnExtinguishmentOfPaycheckProtectionProgramLoan" xlink:to="armp_GainLossOnExtinguishmentOfPaycheckProtectionProgramLoan_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_GainLossOnExtinguishmentOfPaycheckProtectionProgramLoan_lbl" xml:lang="en-US">Gain (loss) on extinguishment of paycheck protection program loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_GainLossOnExtinguishmentOfPaycheckProtectionProgramLoan_lbl" xml:lang="en-US">Gain Loss On Extinguishment of Paycheck Protection Program Loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_GainLossOnExtinguishmentOfPaycheckProtectionProgramLoan_lbl" xml:lang="en-US">Gain upon extinguishment of Paycheck Protection Program loan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based Compensation, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashExpense" xlink:label="us-gaap_OtherNoncashExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashExpense" xlink:to="us-gaap_OtherNoncashExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashExpense_lbl" xml:lang="en-US">Other Noncash Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNoncashExpense_lbl" xml:lang="en-US">Non-cash interest expense</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_AccruedInterestForDeferredConsiderationOnAssetAcquisition" xlink:label="armp_AccruedInterestForDeferredConsiderationOnAssetAcquisition" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_AccruedInterestForDeferredConsiderationOnAssetAcquisition" xlink:to="armp_AccruedInterestForDeferredConsiderationOnAssetAcquisition_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_AccruedInterestForDeferredConsiderationOnAssetAcquisition_lbl" xml:lang="en-US">Accrued interest for deferred consideration on asset acquisition.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_AccruedInterestForDeferredConsiderationOnAssetAcquisition_lbl" xml:lang="en-US">Accrued Interest For Deferred Consideration On Asset Acquisition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="armp_AccruedInterestForDeferredConsiderationOnAssetAcquisition_lbl" xml:lang="en-US">Payment of accreted interest for deferred consideration for asset acquisition</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_IncreaseDecreaseInAwardReceivable" xlink:label="armp_IncreaseDecreaseInAwardReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_IncreaseDecreaseInAwardReceivable" xlink:to="armp_IncreaseDecreaseInAwardReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_IncreaseDecreaseInAwardReceivable_lbl" xml:lang="en-US">The increase (decrease) during the period in the carrying value of award receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_IncreaseDecreaseInAwardReceivable_lbl" xml:lang="en-US">Increase (Decrease) In Award Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="armp_IncreaseDecreaseInAwardReceivable_lbl" xml:lang="en-US">Award receivable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCompensation" xlink:label="us-gaap_IncreaseDecreaseInDeferredCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredCompensation" xlink:to="us-gaap_IncreaseDecreaseInDeferredCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredCompensation_lbl" xml:lang="en-US">Increase (Decrease) in Deferred Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredCompensation_lbl" xml:lang="en-US">Accrued compensation</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet" xlink:label="armp_IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet" xlink:to="armp_IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet_lbl" xml:lang="en-US">Amount of net increase (decrease) in operating lease right of use asset and liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet_lbl" xml:lang="en-US">Increase Decrease In Operating Lease Right of Use Asset And Liability, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet_lbl" xml:lang="en-US">Operating lease right-of-use asset and liability, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Investing activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Financing activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" xml:lang="en-US">Principal payment of deferred consideration for asset acquisition</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ProceedsFromPaycheckProtectionProgram" xlink:label="armp_ProceedsFromPaycheckProtectionProgram" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ProceedsFromPaycheckProtectionProgram" xlink:to="armp_ProceedsFromPaycheckProtectionProgram_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ProceedsFromPaycheckProtectionProgram_lbl" xml:lang="en-US">Proceeds from paycheck protection program.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ProceedsFromPaycheckProtectionProgram_lbl" xml:lang="en-US">Proceeds From Paycheck Protection Program</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_ProceedsFromPaycheckProtectionProgram_lbl" xml:lang="en-US">Proceeds from Paycheck Protection Program Loan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from sale of common stock, net of offering costs</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ProceedsFromExerciseOfWarrantsAndStockOptions" xlink:label="armp_ProceedsFromExerciseOfWarrantsAndStockOptions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ProceedsFromExerciseOfWarrantsAndStockOptions" xlink:to="armp_ProceedsFromExerciseOfWarrantsAndStockOptions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ProceedsFromExerciseOfWarrantsAndStockOptions_lbl" xml:lang="en-US">Proceeds from exercise of warrants and stock options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ProceedsFromExerciseOfWarrantsAndStockOptions_lbl" xml:lang="en-US">Proceeds From Exercise Of Warrants And Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_ProceedsFromExerciseOfWarrantsAndStockOptions_lbl" xml:lang="en-US">Proceeds from exercise of warrants and stock options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase in cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Redeemable Convertible Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information:</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ForgivenessRelatedToPaycheckProtectionProgram" xlink:label="armp_ForgivenessRelatedToPaycheckProtectionProgram" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ForgivenessRelatedToPaycheckProtectionProgram" xlink:to="armp_ForgivenessRelatedToPaycheckProtectionProgram_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ForgivenessRelatedToPaycheckProtectionProgram_lbl" xml:lang="en-US">Forgiveness related to paycheck protection program.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ForgivenessRelatedToPaycheckProtectionProgram_lbl" xml:lang="en-US">Forgiveness Related To Paycheck Protection Program</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_ForgivenessRelatedToPaycheckProtectionProgram_lbl" xml:lang="en-US">Paycheck Protection Program loan forgiveness</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_OfferingCostsIncludedInAccountsPayable" xlink:label="armp_OfferingCostsIncludedInAccountsPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_OfferingCostsIncludedInAccountsPayable" xlink:to="armp_OfferingCostsIncludedInAccountsPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_OfferingCostsIncludedInAccountsPayable_lbl" xml:lang="en-US">Represents the portion of offering costs included in accounts payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_OfferingCostsIncludedInAccountsPayable_lbl" xml:lang="en-US">Unpaid offering costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContributionOfProperty" xlink:label="us-gaap_ContributionOfProperty" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContributionOfProperty" xlink:to="us-gaap_ContributionOfProperty_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContributionOfProperty_lbl" xml:lang="en-US">Contribution of Property</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContributionOfProperty_lbl" xml:lang="en-US">Property and equipment included in accounts payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xml:lang="en-US">Reconciliation of cash, cash equivalents, and restricted cash</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization and Description of the Business</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization and Description of the Business</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_LiquidityAbstract" xlink:label="armp_LiquidityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_LiquidityAbstract" xlink:to="armp_LiquidityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_LiquidityAbstract_lbl" xml:lang="en-US">Liquidity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_LiquidityAbstract_lbl" xml:lang="en-US">Liquidity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xml:lang="en-US">Substantial Doubt about Going Concern [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xml:lang="en-US">Liquidity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Net Loss per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Net Loss per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Balance Sheet Details</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Balance Sheet Details</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Paycheck Protection Program Loan.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US">Long-term Debt [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US">Paycheck Protection Program Loan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xml:lang="en-US">Stockholders Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Stock-based Compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Equity Incentive Plans</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_AwardAbstract" xlink:label="armp_AwardAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_AwardAbstract" xlink:to="armp_AwardAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_AwardAbstract_lbl" xml:lang="en-US">Represents about award abstract.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_AwardAbstract_lbl" xml:lang="en-US">Grants and Awards</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_AwardTextBlock" xlink:label="armp_AwardTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_AwardTextBlock" xlink:to="armp_AwardTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_AwardTextBlock_lbl" xml:lang="en-US">represents about award text block.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_AwardTextBlock_lbl" xml:lang="en-US">Award Text Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_AwardTextBlock_lbl" xml:lang="en-US">Grants and Awards</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_AssetAcquisitionAbstract" xlink:label="armp_AssetAcquisitionAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_AssetAcquisitionAbstract" xlink:to="armp_AssetAcquisitionAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_AssetAcquisitionAbstract_lbl" xml:lang="en-US">Asset Acquisition [Abstract].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_AssetAcquisitionAbstract_lbl" xml:lang="en-US">Synthetic Genomics Asset Acquisition</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_AssetAcquisitionTextBlock" xlink:label="armp_AssetAcquisitionTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_AssetAcquisitionTextBlock" xlink:to="armp_AssetAcquisitionTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_AssetAcquisitionTextBlock_lbl" xml:lang="en-US">The entire disclosure for asset acquisition.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_AssetAcquisitionTextBlock_lbl" xml:lang="en-US">Asset Acquisition [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_AssetAcquisitionTextBlock_lbl" xml:lang="en-US">Synthetic Genomics Asset Acquisition</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_LiquidityAndGoingConcernPolicyTextBlock" xlink:label="armp_LiquidityAndGoingConcernPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_LiquidityAndGoingConcernPolicyTextBlock" xlink:to="armp_LiquidityAndGoingConcernPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_LiquidityAndGoingConcernPolicyTextBlock_lbl" xml:lang="en-US">Disclosure of accounting policy for reporting when there is a substantial doubt about an entity's ability to continue as a going concern for a reasonable period of time (generally a year from the balance sheet date). Disclose: (a) pertinent conditions and events giving rise to the assessment of substantial doubt about the entity's ability to continue as a going concern for a reasonable period of time, (b) the possible effects of such conditions and events, (c) management's evaluation of the significance of those conditions and events and any mitigating factors, (d) possible discontinuance of operations, (e) management's plans (including relevant prospective financial information), and (f) information about the recoverability or classification of recorded asset amounts or the amounts or classification of liabilities. If management's plans alleviate the substantial doubt about the entity's ability to continue as a going concern, disclosure of the principal conditions and events that initially raised the substantial doubt about the entity's ability to continue as a going concern would be expected to be considered. Disclose whether operations for the current or prior years generated sufficient cash to cover current obligations, whether waivers were obtained from creditors relating to the company's default under the provisions of debt agreements and possible effects of such conditions and events, such as: whether there is a possible need to obtain additional financing (debt or equity) or to liquidate certain holdings to offset future cash flow deficiencies. Disclose appropriate parent company information when parent is dependent upon remittances from subsidiaries to satisfy its obligations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_LiquidityAndGoingConcernPolicyTextBlock_lbl" xml:lang="en-US">Liquidity and Going Concern Policy Text Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="armp_LiquidityAndGoingConcernPolicyTextBlock_lbl" xml:lang="en-US">Liquidity Policy</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xml:lang="en-US">In Process Research and Development, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xml:lang="en-US">In-Process Research and Development ("IPR&amp;D")</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xml:lang="en-US">Goodwill</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ZeroCouponDebtInstrumentPolicyTextBlock" xlink:label="armp_ZeroCouponDebtInstrumentPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ZeroCouponDebtInstrumentPolicyTextBlock" xlink:to="armp_ZeroCouponDebtInstrumentPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ZeroCouponDebtInstrumentPolicyTextBlock_lbl" xml:lang="en-US">The policy related to the zero coupon debt instrument.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ZeroCouponDebtInstrumentPolicyTextBlock_lbl" xml:lang="en-US">Zero Coupon Debt Instrument [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_ZeroCouponDebtInstrumentPolicyTextBlock_lbl" xml:lang="en-US">Settlement of Zero-coupon Debt Instrument</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Basic and Diluted Net Loss per Share</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_GrantsAndAwardsPolicyTextBlock" xlink:label="armp_GrantsAndAwardsPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_GrantsAndAwardsPolicyTextBlock" xlink:to="armp_GrantsAndAwardsPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_GrantsAndAwardsPolicyTextBlock_lbl" xml:lang="en-US">Represents about the grants and awards policy.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_GrantsAndAwardsPolicyTextBlock_lbl" xml:lang="en-US">Grants And Awards Policy Text Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_GrantsAndAwardsPolicyTextBlock_lbl" xml:lang="en-US">Grants and Awards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements Not Yet Adopted and Recently Adopted Accounting Standards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Diluted Weighted Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Summary of Warrant Information</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Assumptions used in the black-Scholes model</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Allocation of Stock-Based Compensation Expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Summary of Stock Option Activity</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock" xlink:label="armp_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock" xlink:to="armp_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock_lbl" xml:lang="en-US">The number of shares under options that were assumed in merger during the reporting period pertaining to the stock option plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Share Based Compensation Restricted Stock Award Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of restricted stock awards</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" xlink:label="armp_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" xlink:to="armp_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_lbl" xml:lang="en-US">Tabular disclosure of components of common shares reserved for future issuance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_lbl" xml:lang="en-US">Schedule of Common Stock, Capital Shares Reserved for Future Issuance [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="armp_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_lbl" xml:lang="en-US">Shares Reserved for Future Issuance</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ProceedsFromEquityOfferingsGross" xlink:label="armp_ProceedsFromEquityOfferingsGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ProceedsFromEquityOfferingsGross" xlink:to="armp_ProceedsFromEquityOfferingsGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ProceedsFromEquityOfferingsGross_lbl" xml:lang="en-US">The gross cash inflow, before deducting the underwriting discount and commissions and other offering expenses payable from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ProceedsFromEquityOfferingsGross_lbl" xml:lang="en-US">Proceeds from equity offerings, gross</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernManagementsEvaluation" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernManagementsEvaluation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernManagementsEvaluation" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernManagementsEvaluation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernManagementsEvaluation_lbl" xml:lang="en-US">Substantial Doubt about Going Concern, Management's Evaluation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernManagementsEvaluation_lbl" xml:lang="en-US">Liquidity, management evaluation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Number of securities called by warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Proceeds from issuance of private placement</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_NumberOfCommonWarrantsSoldPerShareOfCommonStock" xlink:label="armp_NumberOfCommonWarrantsSoldPerShareOfCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_NumberOfCommonWarrantsSoldPerShareOfCommonStock" xlink:to="armp_NumberOfCommonWarrantsSoldPerShareOfCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_NumberOfCommonWarrantsSoldPerShareOfCommonStock_lbl" xml:lang="en-US">Number of common warrants sold per share of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_NumberOfCommonWarrantsSoldPerShareOfCommonStock_lbl" xml:lang="en-US">Number Of Common Warrants Sold Per Share Of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_NumberOfCommonWarrantsSoldPerShareOfCommonStock_lbl" xml:lang="en-US">Number of common warrants sold per share of common stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive securities excluded from computation of diluted weighted shares outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Property Plant And Equipment Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xml:lang="en-US">Machinery And Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xml:lang="en-US">Machinery and Equipment [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TechnologyEquipmentMember" xlink:label="us-gaap_TechnologyEquipmentMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TechnologyEquipmentMember" xlink:to="us-gaap_TechnologyEquipmentMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TechnologyEquipmentMember_lbl" xml:lang="en-US">Technology Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TechnologyEquipmentMember_lbl" xml:lang="en-US">Laboratory Equipment [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office and Computer Equipment [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherTypesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherTypesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherTypesMember_lbl" xml:lang="en-US">Property Plant And Equipment Other Types [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherTypesMember_lbl" xml:lang="en-US">Property, Plant and Equipment, Other Types [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture And Fixtures [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LandAndBuildingMember" xlink:label="us-gaap_LandAndBuildingMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandAndBuildingMember" xlink:to="us-gaap_LandAndBuildingMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LandAndBuildingMember_lbl" xml:lang="en-US">Land And Building [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LandAndBuildingMember_lbl" xml:lang="en-US">Land and Building [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Total property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: accumulated depreciation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromUnsecuredNotesPayable" xlink:label="us-gaap_ProceedsFromUnsecuredNotesPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromUnsecuredNotesPayable" xlink:to="us-gaap_ProceedsFromUnsecuredNotesPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromUnsecuredNotesPayable_lbl" xml:lang="en-US">Proceeds from unsecured notes payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt instrument, interest rate, stated percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Schedule of Stock by Class [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price of warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Common stock closing price</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_WarrantExpirationDate" xlink:label="armp_WarrantExpirationDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_WarrantExpirationDate" xlink:to="armp_WarrantExpirationDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_WarrantExpirationDate_lbl" xml:lang="en-US">Represents the terms related with expiration of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_WarrantExpirationDate_lbl" xml:lang="en-US">Warrant Expiration Date</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_TermOfWarrant" xlink:label="armp_TermOfWarrant" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_TermOfWarrant" xlink:to="armp_TermOfWarrant_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_TermOfWarrant_lbl" xml:lang="en-US">Term of warrant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_TermOfWarrant_lbl" xml:lang="en-US">Term Of Warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_TermOfWarrant_lbl" xml:lang="en-US">Term of warrant</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Expiration period of share-based payment award</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xml:lang="en-US">Employee service period for share-based award</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Vesting period of share-based compensation award</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US">Reverse stock split ratio</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US">Additional awards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Vesting percentage</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Unrecognized compensation cost related to unvested options</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ShareBasedCompensationArrangementPercentageOfOutstandingAwardsVestedForAdvisoryServicesProvided" xlink:label="armp_ShareBasedCompensationArrangementPercentageOfOutstandingAwardsVestedForAdvisoryServicesProvided" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ShareBasedCompensationArrangementPercentageOfOutstandingAwardsVestedForAdvisoryServicesProvided" xlink:to="armp_ShareBasedCompensationArrangementPercentageOfOutstandingAwardsVestedForAdvisoryServicesProvided_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ShareBasedCompensationArrangementPercentageOfOutstandingAwardsVestedForAdvisoryServicesProvided_lbl" xml:lang="en-US">Percentage of outstanding awards that are vested in exchange for advisory services provided under share based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ShareBasedCompensationArrangementPercentageOfOutstandingAwardsVestedForAdvisoryServicesProvided_lbl" xml:lang="en-US">Share Based Compensation Arrangement, Percentage Of Outstanding Awards Vested For Advisory Services Provided</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_ShareBasedCompensationArrangementPercentageOfOutstandingAwardsVestedForAdvisoryServicesProvided_lbl" xml:lang="en-US">Percentage of outstanding awards vested for advisory services provided</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Total stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_StockBasedCompensationExpenseRelatedToPreVestingForfeituresReversed" xlink:label="armp_StockBasedCompensationExpenseRelatedToPreVestingForfeituresReversed" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_StockBasedCompensationExpenseRelatedToPreVestingForfeituresReversed" xlink:to="armp_StockBasedCompensationExpenseRelatedToPreVestingForfeituresReversed_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_StockBasedCompensationExpenseRelatedToPreVestingForfeituresReversed_lbl" xml:lang="en-US">Amount of stock based compensation expense related to pre-vesting forfeitures reversed.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_StockBasedCompensationExpenseRelatedToPreVestingForfeituresReversed_lbl" xml:lang="en-US">Stock Based Compensation Expense Related To Pre-vesting Forfeitures Reversed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_StockBasedCompensationExpenseRelatedToPreVestingForfeituresReversed_lbl" xml:lang="en-US">Stock based compensation reversed amount</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Weighted-average remaining period for recognition of compensation costs related to unvested options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Vested (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Vested and expected to vest at December 31, 2020</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Forfeited/Cancelled (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Cancelled (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Outstanding at end of period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Outstanding at beginning of period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Stock outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Outstanding at end of period (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Outstanding at beginning of period (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Nonvested, RS units, grant date fair value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US">Measurement Input Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US">Measurement Input Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Measurement Input Risk Free Interest Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Measurement Input Price Volatility [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Measurement Input, Price Volatility [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Measurement Input Expected Term [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Measurement Input, Expected Term [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US">Measurement Input Expected Dividend Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_EquitySecuritiesMeasurementInput" xlink:label="armp_EquitySecuritiesMeasurementInput" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_EquitySecuritiesMeasurementInput" xlink:to="armp_EquitySecuritiesMeasurementInput_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_EquitySecuritiesMeasurementInput_lbl" xml:lang="en-US">Value of input used to measure investment in equity security measured at fair value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_EquitySecuritiesMeasurementInput_lbl" xml:lang="en-US">Equity Securities Measurement Input</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_EquitySecuritiesMeasurementInput_lbl" xml:lang="en-US">Fair value input, equity securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research And Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and development expense [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General And Administrative Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and administrative expense [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Shares, Balance Ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Shares, Balance Beginning</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Stock options outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Shares, Granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Shares, Forfeited/Cancelled</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Exercisable at September 30, 2020</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding Ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding Beginning</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Forfeited/Cancelled</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Vested or expected to vest at September 30, 2020</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercisable at September 30, 2020</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years), Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years), Vested or expected to vest at September 30, 2020</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years), Exercisable at September 30, 2020</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding Ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding Beginning</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Exercised</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Vested or expected to vest at September 30, 2020</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable at September 30, 2020</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Equity Award [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock Awards [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US">Shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Vested and Issued as Common Stock (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US">Weighted Avg Grant Date Fair Value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Forfeited/Cancelled (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Vested and Issued as Common Stock (in dollars per shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_lbl" xml:lang="en-US">Employee Stock Ownership Plan (ESOP) Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_lbl" xml:lang="en-US">Employee Stock Ownership Plan E S O P Plan [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_lbl" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Plan [Domain]</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_EquityIncentivePlan2016Member" xlink:label="armp_EquityIncentivePlan2016Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_EquityIncentivePlan2016Member" xlink:to="armp_EquityIncentivePlan2016Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_EquityIncentivePlan2016Member_lbl" xml:lang="en-US">Equity Incentive Plan 2016 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_EquityIncentivePlan2016Member_lbl" xml:lang="en-US">Equity Incentive Plan2016 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_EquityIncentivePlan2016Member_lbl" xml:lang="en-US">Equity Incentive Plan 2016 [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Available for future grants under the 2016 Plan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Total shares reserved</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_lbl" xml:lang="en-US">Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_lbl" xml:lang="en-US">Lease term</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_BaseAnnualRentToBePaidYearOne" xlink:label="armp_BaseAnnualRentToBePaidYearOne" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_BaseAnnualRentToBePaidYearOne" xlink:to="armp_BaseAnnualRentToBePaidYearOne_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_BaseAnnualRentToBePaidYearOne_lbl" xml:lang="en-US">Amount for base rent to be paid in year one.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_BaseAnnualRentToBePaidYearOne_lbl" xml:lang="en-US">Base Annual Rent To Be Paid, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_BaseAnnualRentToBePaidYearOne_lbl" xml:lang="en-US">Base annual rent for 2023</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_MaximumAllowanceForTenantImprovementsReceivable" xlink:label="armp_MaximumAllowanceForTenantImprovementsReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_MaximumAllowanceForTenantImprovementsReceivable" xlink:to="armp_MaximumAllowanceForTenantImprovementsReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_MaximumAllowanceForTenantImprovementsReceivable_lbl" xml:lang="en-US">Amount of maximum allowance for tenant improvements receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_MaximumAllowanceForTenantImprovementsReceivable_lbl" xml:lang="en-US">Maximum Allowance For Tenant Improvements Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_MaximumAllowanceForTenantImprovementsReceivable_lbl" xml:lang="en-US">Maximum allowance for tenant improvements</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_OperatingLeaseBaseRent" xlink:label="armp_OperatingLeaseBaseRent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_OperatingLeaseBaseRent" xlink:to="armp_OperatingLeaseBaseRent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_OperatingLeaseBaseRent_lbl" xml:lang="en-US">Amount of operating lease base rent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_OperatingLeaseBaseRent_lbl" xml:lang="en-US">Operating Lease Base Rent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_OperatingLeaseBaseRent_lbl" xml:lang="en-US">Operating lease base rent</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_AnnualIncreaseInRentPercentage" xlink:label="armp_AnnualIncreaseInRentPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_AnnualIncreaseInRentPercentage" xlink:to="armp_AnnualIncreaseInRentPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_AnnualIncreaseInRentPercentage_lbl" xml:lang="en-US">Annual increase in rent percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_AnnualIncreaseInRentPercentage_lbl" xml:lang="en-US">Annual Increase in Rent Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_AnnualIncreaseInRentPercentage_lbl" xml:lang="en-US">Annual increase in rent percentage</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_OperatingLeaseBaseRentEndOfLeaseTerm" xlink:label="armp_OperatingLeaseBaseRentEndOfLeaseTerm" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_OperatingLeaseBaseRentEndOfLeaseTerm" xlink:to="armp_OperatingLeaseBaseRentEndOfLeaseTerm_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_OperatingLeaseBaseRentEndOfLeaseTerm_lbl" xml:lang="en-US">Amount of base rent for operating lease at the end of lease term.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_OperatingLeaseBaseRentEndOfLeaseTerm_lbl" xml:lang="en-US">Operating Lease Base Rent, End OF Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_OperatingLeaseBaseRentEndOfLeaseTerm_lbl" xml:lang="en-US">Base rent at the end of lease term</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_LeaseAndRentalAbatementCredit" xlink:label="armp_LeaseAndRentalAbatementCredit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_LeaseAndRentalAbatementCredit" xlink:to="armp_LeaseAndRentalAbatementCredit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_LeaseAndRentalAbatementCredit_lbl" xml:lang="en-US">Lease and rental abatement credit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_LeaseAndRentalAbatementCredit_lbl" xml:lang="en-US">Lease And Rental Abatement Credit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_LeaseAndRentalAbatementCredit_lbl" xml:lang="en-US">Lease and rental abatement credit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating Lease, Liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_AwardTable" xlink:label="armp_AwardTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_AwardTable" xlink:to="armp_AwardTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_AwardTable_lbl" xml:lang="en-US">Represents about award table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_AwardTable_lbl" xml:lang="en-US">Award [Table]</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_AwardLineItems" xlink:label="armp_AwardLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_AwardLineItems" xlink:to="armp_AwardLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_AwardLineItems_lbl" xml:lang="en-US">Represents about award line items.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_AwardLineItems_lbl" xml:lang="en-US">Award [Line Items]</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ThresholdDevelopmentAward" xlink:label="armp_ThresholdDevelopmentAward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ThresholdDevelopmentAward" xlink:to="armp_ThresholdDevelopmentAward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ThresholdDevelopmentAward_lbl" xml:lang="en-US">The threshold amount of development award under the award agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ThresholdDevelopmentAward_lbl" xml:lang="en-US">Threshold Development Award</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_ThresholdDevelopmentAward_lbl" xml:lang="en-US">Amount of threshold development award</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_AmountReceivedUponAchievementOfMilestone" xlink:label="armp_AmountReceivedUponAchievementOfMilestone" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_AmountReceivedUponAchievementOfMilestone" xlink:to="armp_AmountReceivedUponAchievementOfMilestone_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_AmountReceivedUponAchievementOfMilestone_lbl" xml:lang="en-US">The amount received during the period for the achievement of milestone.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_AmountReceivedUponAchievementOfMilestone_lbl" xml:lang="en-US">Amount Received Upon Achievement of Milestone</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_AmountReceivedUponAchievementOfMilestone_lbl" xml:lang="en-US">Additional amount received</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_AwardAgreementInterruptionPeriod" xlink:label="armp_AwardAgreementInterruptionPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_AwardAgreementInterruptionPeriod" xlink:to="armp_AwardAgreementInterruptionPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_AwardAgreementInterruptionPeriod_lbl" xml:lang="en-US">Represents the period for which the company ceases to use commercially reasonable efforts directed to the development of the product.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_AwardAgreementInterruptionPeriod_lbl" xml:lang="en-US">Award Agreement, Interruption Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_AwardAgreementInterruptionPeriod_lbl" xml:lang="en-US">Award agreement interruption period</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ResearchAndDevelopmentCreditsRecognized" xlink:label="armp_ResearchAndDevelopmentCreditsRecognized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ResearchAndDevelopmentCreditsRecognized" xlink:to="armp_ResearchAndDevelopmentCreditsRecognized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ResearchAndDevelopmentCreditsRecognized_lbl" xml:lang="en-US">Research and development credits recognized.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ResearchAndDevelopmentCreditsRecognized_lbl" xml:lang="en-US">Research And Development Credits Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_ResearchAndDevelopmentCreditsRecognized_lbl" xml:lang="en-US">Research and development credits recognized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_AssetAcquisitionAxis" xlink:label="armp_AssetAcquisitionAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_AssetAcquisitionAxis" xlink:to="armp_AssetAcquisitionAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_AssetAcquisitionAxis_lbl" xml:lang="en-US">Information by asset acquisition.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_AssetAcquisitionAxis_lbl" xml:lang="en-US">Asset Acquisition [Axis]</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_AssetAcquisitionDomain" xlink:label="armp_AssetAcquisitionDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_AssetAcquisitionDomain" xlink:to="armp_AssetAcquisitionDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_AssetAcquisitionDomain_lbl" xml:lang="en-US">Asset acquisition.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_AssetAcquisitionDomain_lbl" xml:lang="en-US">Asset Acquisition [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_AssetAcquisitionDomain_lbl" xml:lang="en-US">Asset Acquisition [Domain]</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_SyntheticGenomicsIncMember" xlink:label="armp_SyntheticGenomicsIncMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_SyntheticGenomicsIncMember" xlink:to="armp_SyntheticGenomicsIncMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_SyntheticGenomicsIncMember_lbl" xml:lang="en-US">Represents information pertaining to Synthetic Genomics Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_SyntheticGenomicsIncMember_lbl" xml:lang="en-US">Synthetic Genomics Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_SyntheticGenomicsIncMember_lbl" xml:lang="en-US">Synthetic Genomics Inc [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario Unspecified [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario, Unspecified [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScenarioPlanMember" xlink:label="us-gaap_ScenarioPlanMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioPlanMember" xlink:to="us-gaap_ScenarioPlanMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScenarioPlanMember_lbl" xml:lang="en-US">Scenario Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScenarioPlanMember_lbl" xml:lang="en-US">Scenario, Plan [Member]</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ScenarioOriginalExpectedPaymentOneMember" xlink:label="armp_ScenarioOriginalExpectedPaymentOneMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ScenarioOriginalExpectedPaymentOneMember" xlink:to="armp_ScenarioOriginalExpectedPaymentOneMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ScenarioOriginalExpectedPaymentOneMember_lbl" xml:lang="en-US">Scenario Original Expected Payment One [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ScenarioOriginalExpectedPaymentOneMember_lbl" xml:lang="en-US">Scenario Original Expected Payment One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_ScenarioOriginalExpectedPaymentOneMember_lbl" xml:lang="en-US">Scenario Original Expected Payment One [Member]</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ScenarioOriginalExpectedPaymentTwoMember" xlink:label="armp_ScenarioOriginalExpectedPaymentTwoMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ScenarioOriginalExpectedPaymentTwoMember" xlink:to="armp_ScenarioOriginalExpectedPaymentTwoMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ScenarioOriginalExpectedPaymentTwoMember_lbl" xml:lang="en-US">Scenario Original Expected Payment Two [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ScenarioOriginalExpectedPaymentTwoMember_lbl" xml:lang="en-US">Scenario Original Expected Payment Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_ScenarioOriginalExpectedPaymentTwoMember_lbl" xml:lang="en-US">Scenario Original Expected Payment Two [Member]</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ScenarioOriginalExpectedPaymentThreeMember" xlink:label="armp_ScenarioOriginalExpectedPaymentThreeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ScenarioOriginalExpectedPaymentThreeMember" xlink:to="armp_ScenarioOriginalExpectedPaymentThreeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ScenarioOriginalExpectedPaymentThreeMember_lbl" xml:lang="en-US">Scenario Original Expected Payment Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ScenarioOriginalExpectedPaymentThreeMember_lbl" xml:lang="en-US">Scenario Original Expected Payment Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_ScenarioOriginalExpectedPaymentThreeMember_lbl" xml:lang="en-US">Scenario Original Expected Payment Three [Member]</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ScenarioOriginalExpectedPaymentFourMember" xlink:label="armp_ScenarioOriginalExpectedPaymentFourMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ScenarioOriginalExpectedPaymentFourMember" xlink:to="armp_ScenarioOriginalExpectedPaymentFourMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ScenarioOriginalExpectedPaymentFourMember_lbl" xml:lang="en-US">Scenario Original Expected Payment Four [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ScenarioOriginalExpectedPaymentFourMember_lbl" xml:lang="en-US">Scenario Original Expected Payment Four [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_ScenarioOriginalExpectedPaymentFourMember_lbl" xml:lang="en-US">Scenario Original Expected Payment Four [Member]</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ScenarioAmendedExpectedPaymentOneMember" xlink:label="armp_ScenarioAmendedExpectedPaymentOneMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ScenarioAmendedExpectedPaymentOneMember" xlink:to="armp_ScenarioAmendedExpectedPaymentOneMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ScenarioAmendedExpectedPaymentOneMember_lbl" xml:lang="en-US">Scenario Amended Expected Payment One [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ScenarioAmendedExpectedPaymentOneMember_lbl" xml:lang="en-US">Scenario Amended Expected Payment One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_ScenarioAmendedExpectedPaymentOneMember_lbl" xml:lang="en-US">Scenario Amended Expected Payment One [Member]</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ScenarioAmendedExpectedPaymentTwoMember" xlink:label="armp_ScenarioAmendedExpectedPaymentTwoMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ScenarioAmendedExpectedPaymentTwoMember" xlink:to="armp_ScenarioAmendedExpectedPaymentTwoMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ScenarioAmendedExpectedPaymentTwoMember_lbl" xml:lang="en-US">Scenario Amended Expected Payment Two [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ScenarioAmendedExpectedPaymentTwoMember_lbl" xml:lang="en-US">Scenario Amended Expected Payment Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_ScenarioAmendedExpectedPaymentTwoMember_lbl" xml:lang="en-US">Scenario Amended Expected Payment Two [Member]</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ScenarioAmendedExpectedPaymentThreeMember" xlink:label="armp_ScenarioAmendedExpectedPaymentThreeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ScenarioAmendedExpectedPaymentThreeMember" xlink:to="armp_ScenarioAmendedExpectedPaymentThreeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ScenarioAmendedExpectedPaymentThreeMember_lbl" xml:lang="en-US">Scenario Amended Expected Payment Three [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ScenarioAmendedExpectedPaymentThreeMember_lbl" xml:lang="en-US">Scenario Amended Expected Payment Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_ScenarioAmendedExpectedPaymentThreeMember_lbl" xml:lang="en-US">Scenario Amended Expected Payment Three [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_CashPaidForProductiveAssets" xlink:label="armp_CashPaidForProductiveAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_CashPaidForProductiveAssets" xlink:to="armp_CashPaidForProductiveAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_CashPaidForProductiveAssets_lbl" xml:lang="en-US">Cash paid for productive assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_CashPaidForProductiveAssets_lbl" xml:lang="en-US">Cash Paid for Productive Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_CashPaidForProductiveAssets_lbl" xml:lang="en-US">Cash paid for productive assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xml:lang="en-US">Payments to Acquire Productive Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xml:lang="en-US">Cash paid acquisition of assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_lbl" xml:lang="en-US">Stock Issued During Period, Value, Purchase of Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_lbl" xml:lang="en-US">Issuance of common stock and conversion of deferred consideration for asset acquisition</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_PercentageOfFullyDilutedCapitalizationForIssuanceOfCommonStock" xlink:label="armp_PercentageOfFullyDilutedCapitalizationForIssuanceOfCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_PercentageOfFullyDilutedCapitalizationForIssuanceOfCommonStock" xlink:to="armp_PercentageOfFullyDilutedCapitalizationForIssuanceOfCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_PercentageOfFullyDilutedCapitalizationForIssuanceOfCommonStock_lbl" xml:lang="en-US">The percentage of fully diluted capitalized for issuance of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_PercentageOfFullyDilutedCapitalizationForIssuanceOfCommonStock_lbl" xml:lang="en-US">Percentage of Fully Diluted Capitalization for Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_PercentageOfFullyDilutedCapitalizationForIssuanceOfCommonStock_lbl" xml:lang="en-US">Percentage of fully diluted capitalized for issuance of common stock</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_MaximumPotentialMilestonePayments" xlink:label="armp_MaximumPotentialMilestonePayments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_MaximumPotentialMilestonePayments" xlink:to="armp_MaximumPotentialMilestonePayments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_MaximumPotentialMilestonePayments_lbl" xml:lang="en-US">The amount of maximum potential milestone payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_MaximumPotentialMilestonePayments_lbl" xml:lang="en-US">Maximum Potential Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_MaximumPotentialMilestonePayments_lbl" xml:lang="en-US">Maximum potential milestone payments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid In Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Arrangements And Nonarrangement Transactions [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_SecuritiesPurchaseAgreementMember" xlink:label="armp_SecuritiesPurchaseAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_SecuritiesPurchaseAgreementMember" xlink:to="armp_SecuritiesPurchaseAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">Securities Purchase Agreement [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">Securities Purchase Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">Securities Purchase Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_SecuritiesPurchaseAgreementFirstTrancheMember" xlink:label="armp_SecuritiesPurchaseAgreementFirstTrancheMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_SecuritiesPurchaseAgreementFirstTrancheMember" xlink:to="armp_SecuritiesPurchaseAgreementFirstTrancheMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_SecuritiesPurchaseAgreementFirstTrancheMember_lbl" xml:lang="en-US">Securities Purchase Agreement First Tranche [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_SecuritiesPurchaseAgreementFirstTrancheMember_lbl" xml:lang="en-US">Securities Purchase Agreement First Tranche [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_SecuritiesPurchaseAgreementFirstTrancheMember_lbl" xml:lang="en-US">Securities Purchase Agreement First Tranche [Member]</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_SecuritiesPurchaseAgreementSecondTrancheMember" xlink:label="armp_SecuritiesPurchaseAgreementSecondTrancheMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_SecuritiesPurchaseAgreementSecondTrancheMember" xlink:to="armp_SecuritiesPurchaseAgreementSecondTrancheMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_SecuritiesPurchaseAgreementSecondTrancheMember_lbl" xml:lang="en-US">Securities Purchase Agreement Second Tranche [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_SecuritiesPurchaseAgreementSecondTrancheMember_lbl" xml:lang="en-US">Securities Purchase Agreement Second Tranche [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_SecuritiesPurchaseAgreementSecondTrancheMember_lbl" xml:lang="en-US">Securities Purchase Agreement Second Tranche [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis" xlink:label="us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis" xlink:to="us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_lbl" xml:lang="en-US">Schedule of Financial Instruments Subject to Mandatory Redemption by Settlement Terms [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain" xlink:to="us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain_lbl" xml:lang="en-US">Shares Subject To Mandatory Redemption Financial Instrument [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain_lbl" xml:lang="en-US">Financial Instruments Subject to Mandatory Redemption, Financial Instrument [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuritiesSubjectToMandatoryRedemptionMember" xlink:label="us-gaap_SecuritiesSubjectToMandatoryRedemptionMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuritiesSubjectToMandatoryRedemptionMember" xlink:to="us-gaap_SecuritiesSubjectToMandatoryRedemptionMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecuritiesSubjectToMandatoryRedemptionMember_lbl" xml:lang="en-US">Securities Subject To Mandatory Redemption [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SecuritiesSubjectToMandatoryRedemptionMember_lbl" xml:lang="en-US">Securities Subject to Mandatory Redemption [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSubjectToMandatoryRedemptionMember" xlink:label="us-gaap_CommonStockSubjectToMandatoryRedemptionMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSubjectToMandatoryRedemptionMember" xlink:to="us-gaap_CommonStockSubjectToMandatoryRedemptionMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSubjectToMandatoryRedemptionMember_lbl" xml:lang="en-US">Common Stock Subject To Mandatory Redemption [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSubjectToMandatoryRedemptionMember_lbl" xml:lang="en-US">Common Stock Subject to Mandatory Redemption [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember" xlink:label="us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember" xlink:to="us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember_lbl" xml:lang="en-US">Warrants And Rights Subject To Mandatory Redemption [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember_lbl" xml:lang="en-US">Warrants and Rights Subject to Mandatory Redemption [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US">Repurchase Agreement Counterparty Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_CysticFibrosisFoundationMember" xlink:label="armp_CysticFibrosisFoundationMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_CysticFibrosisFoundationMember" xlink:to="armp_CysticFibrosisFoundationMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_CysticFibrosisFoundationMember_lbl" xml:lang="en-US">Represents the information pertaining to Cystic Fibrosis Foundation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_CysticFibrosisFoundationMember_lbl" xml:lang="en-US">Cystic Fibrosis Foundation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_CysticFibrosisFoundationMember_lbl" xml:lang="en-US">Cystic Fibrosis Foundation [Member]</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_InnovivaStrategicOpportunitiesLlcMember" xlink:label="armp_InnovivaStrategicOpportunitiesLlcMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_InnovivaStrategicOpportunitiesLlcMember" xlink:to="armp_InnovivaStrategicOpportunitiesLlcMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_InnovivaStrategicOpportunitiesLlcMember_lbl" xml:lang="en-US">Innoviva Strategic Opportunities LLC [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_InnovivaStrategicOpportunitiesLlcMember_lbl" xml:lang="en-US">Innoviva Strategic Opportunities Llc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_InnovivaStrategicOpportunitiesLlcMember_lbl" xml:lang="en-US">Innoviva Strategic Opportunities LLC [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Stock Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Stock Options [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units R S U [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Unvested Restricted Stock Units [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US">Long-term Debt, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xml:lang="en-US">Longterm Debt Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xml:lang="en-US">Long-term Debt, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnsecuredDebtMember" xlink:label="us-gaap_UnsecuredDebtMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnsecuredDebtMember" xlink:to="us-gaap_UnsecuredDebtMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnsecuredDebtMember_lbl" xml:lang="en-US">Unsecured Debt [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnsecuredDebtMember_lbl" xml:lang="en-US">Unsecured Debt [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_PaymentProtectionProgramNoteMember" xlink:label="armp_PaymentProtectionProgramNoteMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_PaymentProtectionProgramNoteMember" xlink:to="armp_PaymentProtectionProgramNoteMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_PaymentProtectionProgramNoteMember_lbl" xml:lang="en-US">Payment Protection Program Note [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_PaymentProtectionProgramNoteMember_lbl" xml:lang="en-US">Payment Protection Program Note [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_PaymentProtectionProgramNoteMember_lbl" xml:lang="en-US">Payment Protection Program Note [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class Of Warrant Or Right [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ExercisePriceTwoMember" xlink:label="armp_ExercisePriceTwoMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ExercisePriceTwoMember" xlink:to="armp_ExercisePriceTwoMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ExercisePriceTwoMember_lbl" xml:lang="en-US">Exercise Price Two [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ExercisePriceTwoMember_lbl" xml:lang="en-US">Exercise Price Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_ExercisePriceTwoMember_lbl" xml:lang="en-US">Exercise Price $21.00 [Member]</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ExercisePriceThreeMember" xlink:label="armp_ExercisePriceThreeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ExercisePriceThreeMember" xlink:to="armp_ExercisePriceThreeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ExercisePriceThreeMember_lbl" xml:lang="en-US">Exercise Price Three [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ExercisePriceThreeMember_lbl" xml:lang="en-US">Exercise Price Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_ExercisePriceThreeMember_lbl" xml:lang="en-US">Exercise Price $5.60 [Member]</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ExercisePriceFourMember" xlink:label="armp_ExercisePriceFourMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ExercisePriceFourMember" xlink:to="armp_ExercisePriceFourMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ExercisePriceFourMember_lbl" xml:lang="en-US">Exercise Price Four [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ExercisePriceFourMember_lbl" xml:lang="en-US">Exercise Price Four [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_ExercisePriceFourMember_lbl" xml:lang="en-US">Exercise Price $2.87 [Member]</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ExercisePriceFiveMember" xlink:label="armp_ExercisePriceFiveMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ExercisePriceFiveMember" xlink:to="armp_ExercisePriceFiveMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ExercisePriceFiveMember_lbl" xml:lang="en-US">Exercise Price Five [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ExercisePriceFiveMember_lbl" xml:lang="en-US">Exercise Price Five [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_ExercisePriceFiveMember_lbl" xml:lang="en-US">Exercise Price $2.87 [Member]</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ExercisePriceSixMember" xlink:label="armp_ExercisePriceSixMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ExercisePriceSixMember" xlink:to="armp_ExercisePriceSixMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ExercisePriceSixMember_lbl" xml:lang="en-US">Represents Exercise Price Five Member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ExercisePriceSixMember_lbl" xml:lang="en-US">Exercise Price Six [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_ExercisePriceSixMember_lbl" xml:lang="en-US">Exercise Price $1,680.00 [Member]</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ExercisePriceSevenMember" xlink:label="armp_ExercisePriceSevenMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ExercisePriceSevenMember" xlink:to="armp_ExercisePriceSevenMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ExercisePriceSevenMember_lbl" xml:lang="en-US">Exercise Price Seven [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ExercisePriceSevenMember_lbl" xml:lang="en-US">Exercise Price Seven [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_ExercisePriceSevenMember_lbl" xml:lang="en-US">Exercise Price $3.25 [Member]</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ExercisePriceEightMember" xlink:label="armp_ExercisePriceEightMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_ExercisePriceEightMember" xlink:to="armp_ExercisePriceEightMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_ExercisePriceEightMember_lbl" xml:lang="en-US">Exercise Price Eight [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_ExercisePriceEightMember_lbl" xml:lang="en-US">Exercise Price Eight [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_ExercisePriceEightMember_lbl" xml:lang="en-US">Exercise Price $3.25 [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Employee Stock Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Stock Option [Member]</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_StockOptionsAndRestrictedStockAwardsMember" xlink:label="armp_StockOptionsAndRestrictedStockAwardsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_StockOptionsAndRestrictedStockAwardsMember" xlink:to="armp_StockOptionsAndRestrictedStockAwardsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_StockOptionsAndRestrictedStockAwardsMember_lbl" xml:lang="en-US">Stock Options And Restricted Stock Awards [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_StockOptionsAndRestrictedStockAwardsMember_lbl" xml:lang="en-US">Stock Options And Restricted Stock Awards [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_StockOptionsAndRestrictedStockAwardsMember_lbl" xml:lang="en-US">Stock Options And Restricted Stock Awards [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_Assumed2006And2016PlanMember" xlink:label="armp_Assumed2006And2016PlanMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_Assumed2006And2016PlanMember" xlink:to="armp_Assumed2006And2016PlanMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_Assumed2006And2016PlanMember_lbl" xml:lang="en-US">Represents information pertaining to assumed 2006 and 2016 plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_Assumed2006And2016PlanMember_lbl" xml:lang="en-US">Assumed2006 And2016 Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_Assumed2006And2016PlanMember_lbl" xml:lang="en-US">Assumed 2006 and 2016 Plan [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title Of Individual With Relationship To Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title of Individual [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Mr.Patrick</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_MedicalTechnologyEnterpriseConsortiumMember" xlink:label="armp_MedicalTechnologyEnterpriseConsortiumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_MedicalTechnologyEnterpriseConsortiumMember" xlink:to="armp_MedicalTechnologyEnterpriseConsortiumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_MedicalTechnologyEnterpriseConsortiumMember_lbl" xml:lang="en-US">Medical Technology Enterprise Consortium [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_MedicalTechnologyEnterpriseConsortiumMember_lbl" xml:lang="en-US">Medical Technology Enterprise Consortium [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_MedicalTechnologyEnterpriseConsortiumMember_lbl" xml:lang="en-US">Medical Technology Enterprise Consortium [Member]</label>
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_C3jTherapeuticsIncMember" xlink:label="armp_C3jTherapeuticsIncMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="armp_C3jTherapeuticsIncMember" xlink:to="armp_C3jTherapeuticsIncMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="armp_C3jTherapeuticsIncMember_lbl" xml:lang="en-US">C3j Therapeutics Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="armp_C3jTherapeuticsIncMember_lbl" xml:lang="en-US">C3j Therapeutics Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="armp_C3jTherapeuticsIncMember_lbl" xml:lang="en-US">C3J [Member]</label>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>armp-20210930_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7908.23199 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/10/2021 8:46:05 PM-->
<!--Modified on: 11/10/2021 8:46:05 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.armatapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#StatementConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#StatementConsolidatedStatementsOfCashFlowsParenthetical" roleURI="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#DisclosureOrganizationAndDescriptionOfBusiness" roleURI="http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusiness" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#DisclosureLiquidity" roleURI="http://www.armatapharma.com/role/DisclosureLiquidity" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#DisclosureSignificantAccountingPolicies" roleURI="http://www.armatapharma.com/role/DisclosureSignificantAccountingPolicies" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#DisclosureNetLossPerShare" roleURI="http://www.armatapharma.com/role/DisclosureNetLossPerShare" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#DisclosureBalanceSheetDetails" roleURI="http://www.armatapharma.com/role/DisclosureBalanceSheetDetails" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#DisclosurePaycheckProtectionProgramLoan" roleURI="http://www.armatapharma.com/role/DisclosurePaycheckProtectionProgramLoan" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#DisclosureStockholdersEquity" roleURI="http://www.armatapharma.com/role/DisclosureStockholdersEquity" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#DisclosureEquityIncentivePlans" roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlans" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.armatapharma.com/role/DisclosureCommitmentsAndContingencies" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#DisclosureGrantsAndAwards" roleURI="http://www.armatapharma.com/role/DisclosureGrantsAndAwards" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#DisclosureSyntheticGenomicsAssetAcquisition" roleURI="http://www.armatapharma.com/role/DisclosureSyntheticGenomicsAssetAcquisition" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#DisclosureLiquidityPolicies" roleURI="http://www.armatapharma.com/role/DisclosureLiquidityPolicies" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#DisclosureSignificantAccountingPoliciesPolicies" roleURI="http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#DisclosureNetLossPerShareTables" roleURI="http://www.armatapharma.com/role/DisclosureNetLossPerShareTables" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#DisclosureBalanceSheetDetailsTables" roleURI="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsTables" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#DisclosureStockholdersEquityTables" roleURI="http://www.armatapharma.com/role/DisclosureStockholdersEquityTables" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#DisclosureEquityIncentivePlansTables" roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansTables" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#DisclosureLiquidityNarrativeDetails" roleURI="http://www.armatapharma.com/role/DisclosureLiquidityNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails" roleURI="http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#DisclosureBalanceSheetDetailsNarrativeDetails" roleURI="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails" roleURI="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#DisclosurePaycheckProtectionProgramLoanNarrativeDetails" roleURI="http://www.armatapharma.com/role/DisclosurePaycheckProtectionProgramLoanNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#DisclosureStockholdersEquityNarrativeDetails" roleURI="http://www.armatapharma.com/role/DisclosureStockholdersEquityNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#DisclosureStockholdersEquitySummaryOfWarrantsOutstandingDetails" roleURI="http://www.armatapharma.com/role/DisclosureStockholdersEquitySummaryOfWarrantsOutstandingDetails" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#DisclosureEquityIncentivePlansNarrativeDetails" roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails" roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#DisclosureEquityIncentivePlansAllocationOfStockBasedCompensationExpenseDetails" roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAllocationOfStockBasedCompensationExpenseDetails" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails" roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#DisclosureEquityIncentivePlansRestrictedStockAwardDetails" roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardDetails" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#DisclosureEquityIncentivePlansSharesReservedForFutureIssuanceDetails" roleURI="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSharesReservedForFutureIssuanceDetails" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#DisclosureCommitmentsAndContingenciesNarrativeDetails" roleURI="http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#DisclosureGrantsAndAwardsNarrativeDetails" roleURI="http://www.armatapharma.com/role/DisclosureGrantsAndAwardsNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="armp-20210930.xsd#DisclosureSyntheticGenomicsAssetAcquisitionDetails" roleURI="http://www.armatapharma.com/role/DisclosureSyntheticGenomicsAssetAcquisitionDetails" />
  <presentationLink xlink:role="http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document And Entity Information">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637721739640236114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_637721739640236114" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport_637721739640246115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport_637721739640246115" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_637721739640246115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_637721739640246115" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637721739640246115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_637721739640246115" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637721739640246115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_637721739640246115" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637721739640246115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_637721739640246115" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637721739640246115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_637721739640246115" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637721739640246115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_637721739640246115" order="8" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637721739640246115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_637721739640246115" order="9" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637721739640246115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_637721739640246115" order="10" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_637721739640246115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_637721739640246115" order="11" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637721739640246115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_637721739640246115" order="12" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637721739640246115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_637721739640246115" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637721739640246115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_637721739640246115" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637721739640256109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_637721739640256109" order="15" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637721739640256109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_637721739640256109" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637721739640256109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_637721739640256109" order="17" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_637721739640256109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_637721739640256109" order="18" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_637721739640256109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_637721739640256109" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_637721739640256109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_637721739640256109" order="20" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_637721739640256109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_637721739640256109" order="21" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637721739640256109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637721739640256109" order="22" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_637721739640256109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_637721739640256109" order="23" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_637721739640256109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_637721739640256109" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637721739640256109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_637721739640256109" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_637721739640256109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_637721739640256109" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_637721739640266101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_637721739640266101" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_637721739640266101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_637721739640266101" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637721739640266101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_637721739640266101" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Consolidated Balance Sheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_123" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_637721739640266101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_123" xlink:to="us-gaap_AssetsAbstract_637721739640266101" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_637721739640266101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637721739640266101" xlink:to="us-gaap_AssetsCurrentAbstract_637721739640266101" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637721739640266101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637721739640266101" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637721739640266101" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_AwardReceivable" xlink:label="armp_AwardReceivable_637721739640266101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637721739640266101" xlink:to="armp_AwardReceivable_637721739640266101" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637721739640266101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637721739640266101" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637721739640266101" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637721739640266101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637721739640266101" xlink:to="us-gaap_AssetsCurrent_637721739640266101" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_637721739640266101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637721739640266101" xlink:to="us-gaap_RestrictedCashNoncurrent_637721739640266101" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637721739640266101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637721739640266101" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637721739640266101" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637721739640276107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637721739640266101" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637721739640276107" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_637721739640276107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637721739640266101" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_637721739640276107" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill_637721739640276107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637721739640266101" xlink:to="us-gaap_Goodwill_637721739640276107" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_637721739640276107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637721739640266101" xlink:to="us-gaap_OtherAssetsNoncurrent_637721739640276107" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_637721739640276107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637721739640266101" xlink:to="us-gaap_Assets_637721739640276107" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637721739640276107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_123" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637721739640276107" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_637721739640276107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637721739640276107" xlink:to="us-gaap_LiabilitiesCurrentAbstract_637721739640276107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_637721739640276107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637721739640276107" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_637721739640276107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationLiabilityCurrent" xlink:label="us-gaap_DeferredCompensationLiabilityCurrent_637721739640276107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637721739640276107" xlink:to="us-gaap_DeferredCompensationLiabilityCurrent_637721739640276107" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637721739640276107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637721739640276107" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637721739640276107" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_PaycheckProtectionProgramLoan" xlink:label="armp_PaycheckProtectionProgramLoan_637721739640276107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637721739640276107" xlink:to="armp_PaycheckProtectionProgramLoan_637721739640276107" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_637721739640276107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637721739640276107" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_637721739640276107" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637721739640276107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637721739640276107" xlink:to="us-gaap_LiabilitiesCurrent_637721739640276107" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637721739640276107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637721739640276107" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637721739640276107" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_637721739640286100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637721739640276107" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_637721739640286100" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637721739640286100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637721739640276107" xlink:to="us-gaap_Liabilities_637721739640286100" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_637721739640286100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637721739640276107" xlink:to="us-gaap_StockholdersEquityAbstract_637721739640286100" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637721739640286100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637721739640286100" xlink:to="us-gaap_CommonStockValue_637721739640286100" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_637721739640286100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637721739640286100" xlink:to="us-gaap_AdditionalPaidInCapital_637721739640286100" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637721739640286100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637721739640286100" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637721739640286100" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637721739640286100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637721739640286100" xlink:to="us-gaap_StockholdersEquity_637721739640286100" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637721739640286100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637721739640276107" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_637721739640286100" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - Consolidated Balance Sheets (Parenthetical)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_287" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637721739640296108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_287" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637721739640296108" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637721739640296108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_287" xlink:to="us-gaap_CommonStockSharesAuthorized_637721739640296108" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_637721739640296108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_287" xlink:to="us-gaap_CommonStockSharesIssued_637721739640296108" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637721739640296108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_287" xlink:to="us-gaap_CommonStockSharesOutstanding_637721739640296108" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Consolidated Statements of Operations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_306" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_637721739640296108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_306" xlink:to="us-gaap_RevenueNotFromContractWithCustomer_637721739640296108" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_637721739640296108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_306" xlink:to="us-gaap_OperatingExpensesAbstract_637721739640296108" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_637721739640296108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637721739640296108" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_637721739640296108" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637721739640296108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637721739640296108" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637721739640296108" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_637721739640296108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637721739640296108" xlink:to="us-gaap_OperatingExpenses_637721739640296108" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637721739640296108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_306" xlink:to="us-gaap_OperatingIncomeLoss_637721739640296108" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherExpensesAbstract" xlink:label="us-gaap_OtherExpensesAbstract_637721739640296108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_306" xlink:to="us-gaap_OtherExpensesAbstract_637721739640296108" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_GainLossOnExtinguishmentOfPaycheckProtectionProgramSinceInception" xlink:label="armp_GainLossOnExtinguishmentOfPaycheckProtectionProgramSinceInception_637721739640296108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherExpensesAbstract_637721739640296108" xlink:to="armp_GainLossOnExtinguishmentOfPaycheckProtectionProgramSinceInception_637721739640296108" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_637721739640296108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherExpensesAbstract_637721739640296108" xlink:to="us-gaap_InvestmentIncomeInterest_637721739640296108" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_637721739640296108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherExpensesAbstract_637721739640296108" xlink:to="us-gaap_InterestExpense_637721739640296108" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_637721739640296108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherExpensesAbstract_637721739640296108" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_637721739640296108" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637721739640306110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_306" xlink:to="us-gaap_NetIncomeLoss_637721739640306110" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_637721739640306110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_306" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_637721739640306110" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_637721739640306110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract_637721739640306110" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_637721739640306110" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_637721739640306110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract_637721739640306110" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_637721739640306110" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - Consolidated Statements of Stockholders' Equity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637721739640386097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_637721739640386097" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637721739640386097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637721739640386097" xlink:to="us-gaap_StatementEquityComponentsAxis_637721739640386097" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637721739640386097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637721739640386097" xlink:to="us-gaap_CommonStockMember_637721739640386097" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_637721739640386097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637721739640386097" xlink:to="us-gaap_AdditionalPaidInCapitalMember_637721739640386097" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_637721739640386097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637721739640386097" xlink:to="us-gaap_RetainedEarningsMember_637721739640386097" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637721739640386097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637721739640386097" xlink:to="us-gaap_EquityComponentDomain_637721739640386097" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637721739640386097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637721739640386097" xlink:to="us-gaap_StatementLineItems_637721739640386097" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637721739640386097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637721739640386097" xlink:to="us-gaap_StockholdersEquity_637721739640386097" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_637721739640396112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637721739640386097" xlink:to="us-gaap_SharesOutstanding_637721739640396112" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_637721739640396112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637721739640386097" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_637721739640396112" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_637721739640396112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_637721739640396112" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_637721739640396112" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_637721739640396112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637721739640386097" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_637721739640396112" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637721739640396112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues_637721739640396112" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637721739640396112" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="armp_StockIssuedDuringPeriodValueExerciseOfWarrants_637721739640396112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637721739640386097" xlink:to="armp_StockIssuedDuringPeriodValueExerciseOfWarrants_637721739640396112" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="armp_StockIssuedDuringPeriodSharesExerciseOfWarrants_637721739640396112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="armp_StockIssuedDuringPeriodValueExerciseOfWarrants_637721739640396112" xlink:to="armp_StockIssuedDuringPeriodSharesExerciseOfWarrants_637721739640396112" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings" xlink:label="armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings_637721739640396112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637721739640386097" xlink:to="armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings_637721739640396112" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings" xlink:label="armp_RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings_637721739640396112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings_637721739640396112" xlink:to="armp_RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings_637721739640396112" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637721739640396112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637721739640386097" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637721739640396112" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637721739640396112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637721739640396112" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637721739640396112" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_StockIssuedDuringPeriodValueInducementStockAwards" xlink:label="armp_StockIssuedDuringPeriodValueInducementStockAwards_637721739640396112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637721739640386097" xlink:to="armp_StockIssuedDuringPeriodValueInducementStockAwards_637721739640396112" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_StockIssuedDuringPeriodSharesInducementStockAwards" xlink:label="armp_StockIssuedDuringPeriodSharesInducementStockAwards_637721739640396112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="armp_StockIssuedDuringPeriodValueInducementStockAwards_637721739640396112" xlink:to="armp_StockIssuedDuringPeriodSharesInducementStockAwards_637721739640396112" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637721739640396112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637721739640386097" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637721739640396112" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637721739640406105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637721739640386097" xlink:to="us-gaap_NetIncomeLoss_637721739640406105" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637721739640406105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637721739640386097" xlink:to="us-gaap_StockholdersEquity_637721739640406105" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_637721739640406105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637721739640386097" xlink:to="us-gaap_SharesOutstanding_637721739640406105" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Consolidated Statements of Cash Flows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_372" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_637721739640406105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_372" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_637721739640406105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637721739640406105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_637721739640406105" xlink:to="us-gaap_ProfitLoss_637721739640406105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637721739640406105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_637721739640406105" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637721739640406105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637721739640406105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637721739640406105" xlink:to="us-gaap_Depreciation_637721739640406105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_GainLossOnExtinguishmentOfPaycheckProtectionProgramLoan" xlink:label="armp_GainLossOnExtinguishmentOfPaycheckProtectionProgramLoan_637721739640406105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637721739640406105" xlink:to="armp_GainLossOnExtinguishmentOfPaycheckProtectionProgramLoan_637721739640406105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637721739640416118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637721739640406105" xlink:to="us-gaap_ShareBasedCompensation_637721739640416118" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashExpense" xlink:label="us-gaap_OtherNoncashExpense_637721739640416118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637721739640406105" xlink:to="us-gaap_OtherNoncashExpense_637721739640416118" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_AccruedInterestForDeferredConsiderationOnAssetAcquisition" xlink:label="armp_AccruedInterestForDeferredConsiderationOnAssetAcquisition_637721739640416118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637721739640406105" xlink:to="armp_AccruedInterestForDeferredConsiderationOnAssetAcquisition_637721739640416118" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637721739640416118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637721739640406105" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637721739640416118" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="3" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_IncreaseDecreaseInAwardReceivable" xlink:label="armp_IncreaseDecreaseInAwardReceivable_637721739640416118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637721739640416118" xlink:to="armp_IncreaseDecreaseInAwardReceivable_637721739640416118" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637721739640416118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637721739640416118" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637721739640416118" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCompensation" xlink:label="us-gaap_IncreaseDecreaseInDeferredCompensation_637721739640416118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637721739640416118" xlink:to="us-gaap_IncreaseDecreaseInDeferredCompensation_637721739640416118" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet" xlink:label="armp_IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet_637721739640416118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637721739640416118" xlink:to="armp_IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet_637721739640416118" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637721739640416118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637721739640406105" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637721739640416118" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637721739640416118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637721739640406105" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637721739640416118" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_637721739640416118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_372" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_637721739640416118" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637721739640416118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_637721739640416118" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637721739640416118" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637721739640416118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_637721739640416118" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637721739640416118" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_637721739640416118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_372" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_637721739640416118" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_637721739640426101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_637721739640416118" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_637721739640426101" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ProceedsFromPaycheckProtectionProgram" xlink:label="armp_ProceedsFromPaycheckProtectionProgram_637721739640426101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_637721739640416118" xlink:to="armp_ProceedsFromPaycheckProtectionProgram_637721739640426101" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637721739640426101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_637721739640416118" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637721739640426101" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ProceedsFromExerciseOfWarrantsAndStockOptions" xlink:label="armp_ProceedsFromExerciseOfWarrantsAndStockOptions_637721739640426101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_637721739640416118" xlink:to="armp_ProceedsFromExerciseOfWarrantsAndStockOptions_637721739640426101" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637721739640426101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_637721739640416118" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637721739640426101" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637721739640426101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_372" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637721739640426101" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637721739640426101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_372" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637721739640426101" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6377217396404261011" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_372" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6377217396404261011" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637721739640426101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_372" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637721739640426101" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ForgivenessRelatedToPaycheckProtectionProgram" xlink:label="armp_ForgivenessRelatedToPaycheckProtectionProgram_637721739640426101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637721739640426101" xlink:to="armp_ForgivenessRelatedToPaycheckProtectionProgram_637721739640426101" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_OfferingCostsIncludedInAccountsPayable" xlink:label="armp_OfferingCostsIncludedInAccountsPayable_637721739640426101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637721739640426101" xlink:to="armp_OfferingCostsIncludedInAccountsPayable_637721739640426101" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContributionOfProperty" xlink:label="us-gaap_ContributionOfProperty_637721739640426101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637721739640426101" xlink:to="us-gaap_ContributionOfProperty_637721739640426101" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" xlink:type="extended" xlink:title="00405 - Statement - Consolidated Statements of Cash Flows (Parenthetical)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract_637087921804216533" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_637721739640436099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_637087921804216533" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_637721739640436099" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637721739640436099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_637721739640436099" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637721739640436099" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_637721739640436099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_637721739640436099" xlink:to="us-gaap_RestrictedCashNoncurrent_637721739640436099" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637721739640436099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_637721739640436099" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637721739640436099" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="8" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusiness" xlink:type="extended" xlink:title="10101 - Disclosure - Organization and Description of the Business">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_440" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_637721739640436099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_440" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_637721739640436099" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureLiquidity" xlink:type="extended" xlink:title="10201 - Disclosure - Liquidity">
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_LiquidityAbstract" xlink:label="armp_LiquidityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_637721739640436099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="armp_LiquidityAbstract" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_637721739640436099" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureSignificantAccountingPolicies" xlink:type="extended" xlink:title="10301 - Disclosure - Significant Accounting Policies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_442" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_637721739640436099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_442" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_637721739640436099" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureNetLossPerShare" xlink:type="extended" xlink:title="10401 - Disclosure - Net Loss per Share">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_637026735700018861" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_637721739640436099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_637026735700018861" xlink:to="us-gaap_EarningsPerShareTextBlock_637721739640436099" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureBalanceSheetDetails" xlink:type="extended" xlink:title="10501 - Disclosure - Balance Sheet Details">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_637721739640446111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_637721739640446111" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosurePaycheckProtectionProgramLoan" xlink:type="extended" xlink:title="10601 - Disclosure - Paycheck Protection Program Loan">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock_637721739640446111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtTextBlock_637721739640446111" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureStockholdersEquity" xlink:type="extended" xlink:title="10701 - Disclosure - Stockholders Equity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637721739640446111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637721739640446111" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureEquityIncentivePlans" xlink:type="extended" xlink:title="10801 - Disclosure - Equity Incentive Plans">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_637721739640446111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_637721739640446111" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="10901 - Disclosure - Commitments and Contingencies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_637721739640446111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_637721739640446111" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureGrantsAndAwards" xlink:type="extended" xlink:title="11001 - Disclosure - Grants and Awards">
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_AwardAbstract" xlink:label="armp_AwardAbstract" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_AwardTextBlock" xlink:label="armp_AwardTextBlock_637721739640446111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="armp_AwardAbstract" xlink:to="armp_AwardTextBlock_637721739640446111" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureSyntheticGenomicsAssetAcquisition" xlink:type="extended" xlink:title="11101 - Disclosure - Synthetic Genomics Asset Acquisition">
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_AssetAcquisitionAbstract" xlink:label="armp_AssetAcquisitionAbstract" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_AssetAcquisitionTextBlock" xlink:label="armp_AssetAcquisitionTextBlock_637721739640456111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="armp_AssetAcquisitionAbstract" xlink:to="armp_AssetAcquisitionTextBlock_637721739640456111" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureLiquidityPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - Liquidity (Policies)">
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_LiquidityAbstract" xlink:label="armp_LiquidityAbstract_637026735700038910" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_LiquidityAndGoingConcernPolicyTextBlock" xlink:label="armp_LiquidityAndGoingConcernPolicyTextBlock_637721739640456111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="armp_LiquidityAbstract_637026735700038910" xlink:to="armp_LiquidityAndGoingConcernPolicyTextBlock_637721739640456111" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20302 - Disclosure - Significant Accounting Policies (Policies)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637721739640456111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637721739640456111" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_637721739640456111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_637721739640456111" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_637721739640456111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_637721739640456111" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_637721739640456111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy_637721739640456111" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_637721739640456111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_637721739640456111" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ZeroCouponDebtInstrumentPolicyTextBlock" xlink:label="armp_ZeroCouponDebtInstrumentPolicyTextBlock_637721739640456111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="armp_ZeroCouponDebtInstrumentPolicyTextBlock_637721739640456111" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_637721739640456111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_637721739640456111" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_GrantsAndAwardsPolicyTextBlock" xlink:label="armp_GrantsAndAwardsPolicyTextBlock_637721739640456111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="armp_GrantsAndAwardsPolicyTextBlock_637721739640456111" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_637721739640456111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_637721739640456111" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637721739640456111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637721739640456111" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureNetLossPerShareTables" xlink:type="extended" xlink:title="30403 - Disclosure - Net Loss per Share (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_637026735700094057" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_637721739640466111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_637026735700094057" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_637721739640466111" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsTables" xlink:type="extended" xlink:title="30503 - Disclosure - Balance Sheet Details (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_637721739640466111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_637721739640466111" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureStockholdersEquityTables" xlink:type="extended" xlink:title="30703 - Disclosure - Stockholders Equity (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_637721739640466111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_637721739640466111" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansTables" xlink:type="extended" xlink:title="30803 - Disclosure - Equity Incentive Plans (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_448" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_637721739640466111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_448" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_637721739640466111" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_637721739640466111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_448" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_637721739640466111" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637721739640466111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_448" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637721739640466111" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock" xlink:label="armp_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock_637721739640466111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_448" xlink:to="armp_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock_637721739640466111" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" xlink:label="armp_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_637721739640466111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_448" xlink:to="armp_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_637721739640466111" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureLiquidityNarrativeDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Liquidity (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_LiquidityAbstract" xlink:label="armp_LiquidityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637721739640476111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="armp_LiquidityAbstract" xlink:to="us-gaap_StatementTable_637721739640476111" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637721739640476111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637721739640476111" xlink:to="us-gaap_TypeOfArrangementAxis_637721739640476111" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637721739640476111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637721739640476111" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637721739640476111" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_SecuritiesPurchaseAgreementMember" xlink:label="armp_SecuritiesPurchaseAgreementMember_637721739640476111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637721739640476111" xlink:to="armp_SecuritiesPurchaseAgreementMember_637721739640476111" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_SecuritiesPurchaseAgreementFirstTrancheMember" xlink:label="armp_SecuritiesPurchaseAgreementFirstTrancheMember_637721739640476111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="armp_SecuritiesPurchaseAgreementMember_637721739640476111" xlink:to="armp_SecuritiesPurchaseAgreementFirstTrancheMember_637721739640476111" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_SecuritiesPurchaseAgreementSecondTrancheMember" xlink:label="armp_SecuritiesPurchaseAgreementSecondTrancheMember_637721739640476111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="armp_SecuritiesPurchaseAgreementMember_637721739640476111" xlink:to="armp_SecuritiesPurchaseAgreementSecondTrancheMember_637721739640476111" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis" xlink:label="us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_637721739640476111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637721739640476111" xlink:to="us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_637721739640476111" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain_637721739640476111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_637721739640476111" xlink:to="us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain_637721739640476111" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuritiesSubjectToMandatoryRedemptionMember" xlink:label="us-gaap_SecuritiesSubjectToMandatoryRedemptionMember_637721739640476111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain_637721739640476111" xlink:to="us-gaap_SecuritiesSubjectToMandatoryRedemptionMember_637721739640476111" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSubjectToMandatoryRedemptionMember" xlink:label="us-gaap_CommonStockSubjectToMandatoryRedemptionMember_637721739640476111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SecuritiesSubjectToMandatoryRedemptionMember_637721739640476111" xlink:to="us-gaap_CommonStockSubjectToMandatoryRedemptionMember_637721739640476111" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember" xlink:label="us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember_637721739640476111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain_637721739640476111" xlink:to="us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember_637721739640476111" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637721739640486240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637721739640476111" xlink:to="srt_CounterpartyNameAxis_637721739640486240" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637721739640486240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637721739640486240" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637721739640486240" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_CysticFibrosisFoundationMember" xlink:label="armp_CysticFibrosisFoundationMember_637721739640486240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637721739640486240" xlink:to="armp_CysticFibrosisFoundationMember_637721739640486240" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_InnovivaStrategicOpportunitiesLlcMember" xlink:label="armp_InnovivaStrategicOpportunitiesLlcMember_637721739640486240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637721739640486240" xlink:to="armp_InnovivaStrategicOpportunitiesLlcMember_637721739640486240" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_637721739640486240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637721739640476111" xlink:to="us-gaap_SubsequentEventTypeAxis_637721739640486240" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637721739640486240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_637721739640486240" xlink:to="us-gaap_SubsequentEventTypeDomain_637721739640486240" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_637721739640486240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_637721739640486240" xlink:to="us-gaap_SubsequentEventMember_637721739640486240" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637721739640486240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637721739640476111" xlink:to="srt_RangeAxis_637721739640486240" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637721739640486240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637721739640486240" xlink:to="srt_RangeMember_637721739640486240" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637721739640486240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637721739640486240" xlink:to="srt_MaximumMember_637721739640486240" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637721739640486240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637721739640476111" xlink:to="us-gaap_StatementLineItems_637721739640486240" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637721739640486240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637721739640486240" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637721739640486240" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ProceedsFromEquityOfferingsGross" xlink:label="armp_ProceedsFromEquityOfferingsGross_637721739640486240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637721739640486240" xlink:to="armp_ProceedsFromEquityOfferingsGross_637721739640486240" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernManagementsEvaluation" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernManagementsEvaluation_637721739640496101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637721739640486240" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernManagementsEvaluation_637721739640496101" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_637721739640496101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637721739640486240" xlink:to="us-gaap_SharesIssuedPricePerShare_637721739640496101" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637721739640496101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637721739640486240" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637721739640496101" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637721739640496101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637721739640486240" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637721739640496101" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_637721739640496101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637721739640486240" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_637721739640496101" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637721739640496101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637721739640486240" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637721739640496101" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_NumberOfCommonWarrantsSoldPerShareOfCommonStock" xlink:label="armp_NumberOfCommonWarrantsSoldPerShareOfCommonStock_637721739640496101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637721739640486240" xlink:to="armp_NumberOfCommonWarrantsSoldPerShareOfCommonStock_637721739640496101" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Net Loss Per Share (Antidilutive Shares Excluded from Computation of Diluted Shares Outstanding) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_637026735700379818" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637721739640496101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_637026735700379818" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637721739640496101" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637721739640506111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637721739640496101" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637721739640506111" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_637721739640506111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637721739640506111" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_637721739640506111" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember_637721739640506111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637721739640506111" xlink:to="us-gaap_StockOptionMember_637721739640506111" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_637721739640506111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637721739640506111" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_637721739640506111" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_637721739640506111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637721739640506111" xlink:to="us-gaap_RestrictedStockMember_637721739640506111" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_637721739640506111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637721739640506111" xlink:to="us-gaap_WarrantMember_637721739640506111" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637721739640506111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637721739640496101" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637721739640506111" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637721739640506111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637721739640506111" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637721739640506111" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsNarrativeDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Balance Sheet Details (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637721739640506111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation_637721739640506111" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Balance Sheet Details (Property and Equipment) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637721739640516119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637721739640516119" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637721739640516119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637721739640516119" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637721739640516119" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637721739640516119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637721739640516119" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637721739640516119" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember_637721739640516119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637721739640516119" xlink:to="us-gaap_MachineryAndEquipmentMember_637721739640516119" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TechnologyEquipmentMember" xlink:label="us-gaap_TechnologyEquipmentMember_637721739640516119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MachineryAndEquipmentMember_637721739640516119" xlink:to="us-gaap_TechnologyEquipmentMember_637721739640516119" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember_637721739640516119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MachineryAndEquipmentMember_637721739640516119" xlink:to="us-gaap_OfficeEquipmentMember_637721739640516119" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherTypesMember_637721739640516119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637721739640516119" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherTypesMember_637721739640516119" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_637721739640516119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentOtherTypesMember_637721739640516119" xlink:to="us-gaap_FurnitureAndFixturesMember_637721739640516119" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LandAndBuildingMember" xlink:label="us-gaap_LandAndBuildingMember_637721739640516119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637721739640516119" xlink:to="us-gaap_LandAndBuildingMember_637721739640516119" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_637721739640516119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LandAndBuildingMember_637721739640516119" xlink:to="us-gaap_LeaseholdImprovementsMember_637721739640516119" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_637721739640516119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637721739640516119" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_637721739640516119" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_637721739640516119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637721739640516119" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_637721739640516119" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637721739640516119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637721739640516119" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637721739640516119" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637721739640516119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637721739640516119" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637721739640516119" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosurePaycheckProtectionProgramLoanNarrativeDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Paycheck Protection Program Loan (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637721739640526111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_StatementTable_637721739640526111" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_637721739640526111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637721739640526111" xlink:to="us-gaap_LongtermDebtTypeAxis_637721739640526111" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_637721739640526111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis_637721739640526111" xlink:to="us-gaap_LongtermDebtTypeDomain_637721739640526111" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnsecuredDebtMember" xlink:label="us-gaap_UnsecuredDebtMember_637721739640526111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain_637721739640526111" xlink:to="us-gaap_UnsecuredDebtMember_637721739640526111" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637721739640526111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637721739640526111" xlink:to="us-gaap_DebtInstrumentAxis_637721739640526111" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637721739640526111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637721739640526111" xlink:to="us-gaap_DebtInstrumentNameDomain_637721739640526111" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_PaymentProtectionProgramNoteMember" xlink:label="armp_PaymentProtectionProgramNoteMember_637721739640526111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637721739640526111" xlink:to="armp_PaymentProtectionProgramNoteMember_637721739640526111" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637721739640526111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637721739640526111" xlink:to="us-gaap_StatementLineItems_637721739640526111" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromUnsecuredNotesPayable" xlink:label="us-gaap_ProceedsFromUnsecuredNotesPayable_637721739640526111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637721739640526111" xlink:to="us-gaap_ProceedsFromUnsecuredNotesPayable_637721739640526111" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_637721739640526111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637721739640526111" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_637721739640526111" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_GainLossOnExtinguishmentOfPaycheckProtectionProgramLoan" xlink:label="armp_GainLossOnExtinguishmentOfPaycheckProtectionProgramLoan_637721739640526111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637721739640526111" xlink:to="armp_GainLossOnExtinguishmentOfPaycheckProtectionProgramLoan_637721739640526111" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureStockholdersEquityNarrativeDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Stockholders Equity (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_637026735700615839" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_637721739640526111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_637026735700615839" xlink:to="us-gaap_ScheduleOfStockByClassTable_637721739640526111" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_637721739640526111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637721739640526111" xlink:to="us-gaap_SubsequentEventTypeAxis_637721739640526111" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637721739640526111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_637721739640526111" xlink:to="us-gaap_SubsequentEventTypeDomain_637721739640526111" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_637721739640526111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_637721739640526111" xlink:to="us-gaap_SubsequentEventMember_637721739640526111" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637721739640536109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637721739640526111" xlink:to="srt_CounterpartyNameAxis_637721739640536109" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637721739640536109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637721739640536109" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637721739640536109" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_CysticFibrosisFoundationMember" xlink:label="armp_CysticFibrosisFoundationMember_637721739640536109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637721739640536109" xlink:to="armp_CysticFibrosisFoundationMember_637721739640536109" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_InnovivaStrategicOpportunitiesLlcMember" xlink:label="armp_InnovivaStrategicOpportunitiesLlcMember_637721739640536109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637721739640536109" xlink:to="armp_InnovivaStrategicOpportunitiesLlcMember_637721739640536109" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis" xlink:label="us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_637721739640536109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637721739640526111" xlink:to="us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_637721739640536109" order="3" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain_637721739640536109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_637721739640536109" xlink:to="us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain_637721739640536109" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuritiesSubjectToMandatoryRedemptionMember" xlink:label="us-gaap_SecuritiesSubjectToMandatoryRedemptionMember_637721739640536109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain_637721739640536109" xlink:to="us-gaap_SecuritiesSubjectToMandatoryRedemptionMember_637721739640536109" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSubjectToMandatoryRedemptionMember" xlink:label="us-gaap_CommonStockSubjectToMandatoryRedemptionMember_637721739640536109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SecuritiesSubjectToMandatoryRedemptionMember_637721739640536109" xlink:to="us-gaap_CommonStockSubjectToMandatoryRedemptionMember_637721739640536109" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember" xlink:label="us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember_637721739640536109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain_637721739640536109" xlink:to="us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember_637721739640536109" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637721739640536109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637721739640526111" xlink:to="us-gaap_StatementEquityComponentsAxis_637721739640536109" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637721739640536109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637721739640536109" xlink:to="us-gaap_EquityComponentDomain_637721739640536109" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637721739640536109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637721739640536109" xlink:to="us-gaap_CommonStockMember_637721739640536109" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637721739640536109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637721739640526111" xlink:to="us-gaap_TypeOfArrangementAxis_637721739640536109" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637721739640536109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637721739640536109" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637721739640536109" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_SecuritiesPurchaseAgreementMember" xlink:label="armp_SecuritiesPurchaseAgreementMember_637721739640546103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637721739640536109" xlink:to="armp_SecuritiesPurchaseAgreementMember_637721739640546103" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_SecuritiesPurchaseAgreementFirstTrancheMember" xlink:label="armp_SecuritiesPurchaseAgreementFirstTrancheMember_637721739640546103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="armp_SecuritiesPurchaseAgreementMember_637721739640546103" xlink:to="armp_SecuritiesPurchaseAgreementFirstTrancheMember_637721739640546103" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_SecuritiesPurchaseAgreementSecondTrancheMember" xlink:label="armp_SecuritiesPurchaseAgreementSecondTrancheMember_637721739640546103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="armp_SecuritiesPurchaseAgreementMember_637721739640546103" xlink:to="armp_SecuritiesPurchaseAgreementSecondTrancheMember_637721739640546103" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_637721739640546103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_637721739640526111" xlink:to="us-gaap_ClassOfStockLineItems_637721739640546103" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637721739640546103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637721739640546103" xlink:to="us-gaap_CommonStockSharesAuthorized_637721739640546103" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637721739640546103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637721739640546103" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637721739640546103" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ProceedsFromEquityOfferingsGross" xlink:label="armp_ProceedsFromEquityOfferingsGross_637721739640546103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637721739640546103" xlink:to="armp_ProceedsFromEquityOfferingsGross_637721739640546103" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_637721739640546103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637721739640546103" xlink:to="us-gaap_SharePrice_637721739640546103" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637721739640546103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637721739640546103" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637721739640546103" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637721739640546103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637721739640546103" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637721739640546103" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637721739640546103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637721739640546103" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637721739640546103" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_637721739640546103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637721739640546103" xlink:to="us-gaap_SharesIssuedPricePerShare_637721739640546103" order="8" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_637721739640556101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637721739640546103" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_637721739640556101" order="9" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637721739640556101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637721739640546103" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637721739640556101" order="10" use="optional" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637721739640556101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637721739640546103" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637721739640556101" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637721739640556101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637721739640546103" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637721739640556101" order="12" use="optional" priority="7" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_NumberOfCommonWarrantsSoldPerShareOfCommonStock" xlink:label="armp_NumberOfCommonWarrantsSoldPerShareOfCommonStock_637721739640556101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_637721739640546103" xlink:to="armp_NumberOfCommonWarrantsSoldPerShareOfCommonStock_637721739640556101" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureStockholdersEquitySummaryOfWarrantsOutstandingDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Stockholders Equity (Summary of Warrants Outstanding) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_637026735700796320" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637721739640556101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_637026735700796320" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637721739640556101" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637721739640556101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637721739640556101" xlink:to="us-gaap_TypeOfArrangementAxis_637721739640556101" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637721739640556101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637721739640556101" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637721739640556101" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_SecuritiesPurchaseAgreementMember" xlink:label="armp_SecuritiesPurchaseAgreementMember_637721739640566106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637721739640556101" xlink:to="armp_SecuritiesPurchaseAgreementMember_637721739640566106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis" xlink:label="us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_637721739640566106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637721739640556101" xlink:to="us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_637721739640566106" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain_637721739640566106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_637721739640566106" xlink:to="us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain_637721739640566106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuritiesSubjectToMandatoryRedemptionMember" xlink:label="us-gaap_SecuritiesSubjectToMandatoryRedemptionMember_637721739640566106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain_637721739640566106" xlink:to="us-gaap_SecuritiesSubjectToMandatoryRedemptionMember_637721739640566106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSubjectToMandatoryRedemptionMember" xlink:label="us-gaap_CommonStockSubjectToMandatoryRedemptionMember_637721739640566106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SecuritiesSubjectToMandatoryRedemptionMember_637721739640566106" xlink:to="us-gaap_CommonStockSubjectToMandatoryRedemptionMember_637721739640566106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember" xlink:label="us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember_637721739640566106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SecuritiesSubjectToMandatoryRedemptionMember_637721739640566106" xlink:to="us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember_637721739640566106" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_637721739640566106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637721739640556101" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_637721739640566106" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_637721739640566106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_637721739640566106" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_637721739640566106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ExercisePriceTwoMember" xlink:label="armp_ExercisePriceTwoMember_637721739640566106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637721739640566106" xlink:to="armp_ExercisePriceTwoMember_637721739640566106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ExercisePriceThreeMember" xlink:label="armp_ExercisePriceThreeMember_637721739640566106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637721739640566106" xlink:to="armp_ExercisePriceThreeMember_637721739640566106" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ExercisePriceFourMember" xlink:label="armp_ExercisePriceFourMember_637721739640566106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637721739640566106" xlink:to="armp_ExercisePriceFourMember_637721739640566106" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ExercisePriceFiveMember" xlink:label="armp_ExercisePriceFiveMember_637721739640566106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637721739640566106" xlink:to="armp_ExercisePriceFiveMember_637721739640566106" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ExercisePriceSixMember" xlink:label="armp_ExercisePriceSixMember_637721739640566106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637721739640566106" xlink:to="armp_ExercisePriceSixMember_637721739640566106" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ExercisePriceSevenMember" xlink:label="armp_ExercisePriceSevenMember_637721739640566106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637721739640566106" xlink:to="armp_ExercisePriceSevenMember_637721739640566106" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ExercisePriceEightMember" xlink:label="armp_ExercisePriceEightMember_637721739640566106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637721739640566106" xlink:to="armp_ExercisePriceEightMember_637721739640566106" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637721739640576100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637721739640556101" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637721739640576100" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_637721739640576100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637721739640576100" xlink:to="us-gaap_SharesIssuedPricePerShare_637721739640576100" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637721739640576100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637721739640576100" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637721739640576100" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637721739640576100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637721739640576100" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637721739640576100" order="3" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_637721739640576100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637721739640576100" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_637721739640576100" order="4" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_637721739640576100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637721739640576100" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_637721739640576100" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637721739640576100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637721739640576100" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637721739640576100" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_WarrantExpirationDate" xlink:label="armp_WarrantExpirationDate_637721739640576100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637721739640576100" xlink:to="armp_WarrantExpirationDate_637721739640576100" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_TermOfWarrant" xlink:label="armp_TermOfWarrant_637721739640576100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637721739640576100" xlink:to="armp_TermOfWarrant_637721739640576100" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Equity Incentive Plans (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_260" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637721739640586106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_260" xlink:to="us-gaap_StatementTable_637721739640586106" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_637721739640586106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637721739640586106" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_637721739640586106" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_637721739640586106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_637721739640586106" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_637721739640586106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_EquityIncentivePlan2016Member" xlink:label="armp_EquityIncentivePlan2016Member_637721739640586106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_637721739640586106" xlink:to="armp_EquityIncentivePlan2016Member_637721739640586106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637721739640586106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637721739640586106" xlink:to="us-gaap_AwardTypeAxis_637721739640586106" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637721739640586106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637721739640586106" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637721739640586106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637721739640586106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637721739640586106" xlink:to="us-gaap_EmployeeStockOptionMember_637721739640586106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_637721739640586106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637721739640586106" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_637721739640586106" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_637721739640586106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637721739640586106" xlink:to="us-gaap_RestrictedStockMember_637721739640586106" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_StockOptionsAndRestrictedStockAwardsMember" xlink:label="armp_StockOptionsAndRestrictedStockAwardsMember_637721739640586106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637721739640586106" xlink:to="armp_StockOptionsAndRestrictedStockAwardsMember_637721739640586106" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637721739640586106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637721739640586106" xlink:to="srt_RangeAxis_637721739640586106" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637721739640586106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637721739640586106" xlink:to="srt_RangeMember_637721739640586106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637721739640586106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637721739640586106" xlink:to="srt_MinimumMember_637721739640586106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637721739640586106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637721739640586106" xlink:to="srt_MaximumMember_637721739640586106" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637721739640586106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637721739640586106" xlink:to="us-gaap_PlanNameAxis_637721739640586106" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637721739640586106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637721739640586106" xlink:to="us-gaap_PlanNameDomain_637721739640586106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_Assumed2006And2016PlanMember" xlink:label="armp_Assumed2006And2016PlanMember_637721739640586106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637721739640586106" xlink:to="armp_Assumed2006And2016PlanMember_637721739640586106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_637721739640596101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637721739640586106" xlink:to="srt_TitleOfIndividualAxis_637721739640596101" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_637721739640596101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_637721739640596101" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_637721739640596101" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember_637721739640596101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637721739640596101" xlink:to="srt_ChiefExecutiveOfficerMember_637721739640596101" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637721739640596101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637721739640586106" xlink:to="us-gaap_StatementLineItems_637721739640596101" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637721739640596101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637721739640596101" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637721739640596101" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_637721739640596101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637721739640596101" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_637721739640596101" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637721739640596101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637721739640596101" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637721739640596101" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_637721739640596101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637721739640596101" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_637721739640596101" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_637721739640596101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637721739640596101" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_637721739640596101" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_637721739640596101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637721739640596101" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_637721739640596101" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_637721739640596101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637721739640596101" xlink:to="us-gaap_SharePrice_637721739640596101" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_637721739640596101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637721739640596101" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_637721739640596101" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ShareBasedCompensationArrangementPercentageOfOutstandingAwardsVestedForAdvisoryServicesProvided" xlink:label="armp_ShareBasedCompensationArrangementPercentageOfOutstandingAwardsVestedForAdvisoryServicesProvided_637721739640606102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637721739640596101" xlink:to="armp_ShareBasedCompensationArrangementPercentageOfOutstandingAwardsVestedForAdvisoryServicesProvided_637721739640606102" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_637721739640606102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637721739640596101" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_637721739640606102" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_StockBasedCompensationExpenseRelatedToPreVestingForfeituresReversed" xlink:label="armp_StockBasedCompensationExpenseRelatedToPreVestingForfeituresReversed_637721739640606102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637721739640596101" xlink:to="armp_StockBasedCompensationExpenseRelatedToPreVestingForfeituresReversed_637721739640606102" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637721739640606102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637721739640596101" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637721739640606102" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_637721739640606102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637721739640596101" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_637721739640606102" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_637721739640606102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637721739640596101" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_637721739640606102" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_637721739640606102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637721739640596101" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_637721739640606102" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_637721739640616113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637721739640596101" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_637721739640616113" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Equity Incentive Plans (Assumptions Used in the Black-Scholes Model) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637721739640616113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StatementTable_637721739640616113" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637721739640616113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637721739640616113" xlink:to="srt_RangeAxis_637721739640616113" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637721739640616113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637721739640616113" xlink:to="srt_RangeMember_637721739640616113" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637721739640616113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637721739640616113" xlink:to="srt_MinimumMember_637721739640616113" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637721739640616113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637721739640616113" xlink:to="srt_MaximumMember_637721739640616113" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_637721739640616113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637721739640616113" xlink:to="us-gaap_MeasurementInputTypeAxis_637721739640616113" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_637721739640616113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_637721739640616113" xlink:to="us-gaap_MeasurementInputTypeDomain_637721739640616113" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_637721739640616113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637721739640616113" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_637721739640616113" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_637721739640616113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637721739640616113" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_637721739640616113" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember_637721739640616113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637721739640616113" xlink:to="us-gaap_MeasurementInputExpectedTermMember_637721739640616113" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_637721739640626106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637721739640616113" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_637721739640626106" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637721739640626106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637721739640616113" xlink:to="us-gaap_StatementLineItems_637721739640626106" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_EquitySecuritiesMeasurementInput" xlink:label="armp_EquitySecuritiesMeasurementInput_637721739640626106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637721739640626106" xlink:to="armp_EquitySecuritiesMeasurementInput_637721739640626106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAllocationOfStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="40803 - Disclosure - Equity Incentive Plans (Allocation of Stock-Based Compensation Expense) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_454" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637721739640626106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_454" xlink:to="us-gaap_StatementTable_637721739640626106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_637721739640626106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637721739640626106" xlink:to="us-gaap_IncomeStatementLocationAxis_637721739640626106" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637721739640626106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_637721739640626106" xlink:to="us-gaap_IncomeStatementLocationDomain_637721739640626106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_637721739640626106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637721739640626106" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_637721739640626106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_637721739640626106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637721739640626106" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_637721739640626106" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637721739640626106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637721739640626106" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637721739640626106" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_637721739640626106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637721739640626106" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_637721739640626106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails" xlink:type="extended" xlink:title="40804 - Disclosure - Equity Incentive Plans (Summary of Stock Option Activity) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_220" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637721739640636233" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_220" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637721739640636233" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637721739640636233" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_220" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637721739640636233" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637721739640636233" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_220" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637721739640636233" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_637721739640636233" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_220" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_637721739640636233" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6377217396406362331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_220" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6377217396406362331" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_637721739640636233" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_220" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_637721739640636233" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637721739640636233" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_220" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637721739640636233" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637721739640636233" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_220" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637721739640636233" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637721739640636233" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_220" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637721739640636233" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637721739640636233" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_220" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637721739640636233" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_637721739640636233" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_220" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_637721739640636233" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6377217396406362331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_220" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6377217396406362331" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_637721739640636233" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_220" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_637721739640636233" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637721739640646103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_220" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637721739640646103" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637721739640646103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_220" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637721739640646103" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_637721739640646103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_220" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_637721739640646103" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_637721739640646103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_220" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_637721739640646103" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637721739640646103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_220" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637721739640646103" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_637721739640646103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_220" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_637721739640646103" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6377217396406461031" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_220" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6377217396406461031" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_637721739640646103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_220" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_637721739640646103" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_637721739640646103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_220" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_637721739640646103" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardDetails" xlink:type="extended" xlink:title="40805 - Disclosure - Equity Incentive Plans (Restricted stock award) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637721739640646103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637721739640646103" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637721739640656108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637721739640646103" xlink:to="us-gaap_AwardTypeAxis_637721739640656108" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637721739640656108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637721739640656108" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637721739640656108" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_637721739640656108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637721739640656108" xlink:to="us-gaap_RestrictedStockMember_637721739640656108" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637721739640656108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637721739640646103" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637721739640656108" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637721739640656108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637721739640656108" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637721739640656108" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_637721739640656108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637721739640656108" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_637721739640656108" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_637721739640656108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637721739640656108" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_637721739640656108" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_637721739640656108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637721739640656108" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_637721739640656108" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6377217396406561081" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637721739640656108" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6377217396406561081" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637721739640656108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637721739640656108" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637721739640656108" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_637721739640656108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637721739640656108" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_637721739640656108" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_637721739640656108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637721739640656108" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_637721739640656108" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_637721739640656108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637721739640656108" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_637721739640656108" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6377217396406561081" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637721739640656108" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6377217396406561081" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSharesReservedForFutureIssuanceDetails" xlink:type="extended" xlink:title="40806 - Disclosure - Equity Incentive Plans (Shares Reserved for Future Issuance) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_247" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637721739640666106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_247" xlink:to="us-gaap_StatementTable_637721739640666106" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_637721739640666106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637721739640666106" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_637721739640666106" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_637721739640666106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_637721739640666106" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_637721739640666106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_EquityIncentivePlan2016Member" xlink:label="armp_EquityIncentivePlan2016Member_637721739640666106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_637721739640666106" xlink:to="armp_EquityIncentivePlan2016Member_637721739640666106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637721739640666106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637721739640666106" xlink:to="us-gaap_AwardTypeAxis_637721739640666106" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637721739640666106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637721739640666106" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637721739640666106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_637721739640666106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637721739640666106" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_637721739640666106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637721739640666106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637721739640666106" xlink:to="us-gaap_EmployeeStockOptionMember_637721739640666106" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637721739640666106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637721739640666106" xlink:to="us-gaap_StatementLineItems_637721739640666106" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637721739640666106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637721739640666106" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637721739640666106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_637721739640666106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637721739640666106" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_637721739640666106" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_637721739640666106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637721739640666106" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_637721739640666106" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_637721739640666106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637721739640666106" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_637721739640666106" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_637721739640666106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637721739640666106" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_637721739640666106" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Commitments and Contingencies (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637026735700595403" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_637721739640666106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637026735700595403" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_637721739640666106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_BaseAnnualRentToBePaidYearOne" xlink:label="armp_BaseAnnualRentToBePaidYearOne_637721739640676106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637026735700595403" xlink:to="armp_BaseAnnualRentToBePaidYearOne_637721739640676106" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_MaximumAllowanceForTenantImprovementsReceivable" xlink:label="armp_MaximumAllowanceForTenantImprovementsReceivable_637721739640676106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637026735700595403" xlink:to="armp_MaximumAllowanceForTenantImprovementsReceivable_637721739640676106" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_OperatingLeaseBaseRent" xlink:label="armp_OperatingLeaseBaseRent_637721739640676106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637026735700595403" xlink:to="armp_OperatingLeaseBaseRent_637721739640676106" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_AnnualIncreaseInRentPercentage" xlink:label="armp_AnnualIncreaseInRentPercentage_637721739640676106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637026735700595403" xlink:to="armp_AnnualIncreaseInRentPercentage_637721739640676106" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_OperatingLeaseBaseRentEndOfLeaseTerm" xlink:label="armp_OperatingLeaseBaseRentEndOfLeaseTerm_637721739640676106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637026735700595403" xlink:to="armp_OperatingLeaseBaseRentEndOfLeaseTerm_637721739640676106" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_LeaseAndRentalAbatementCredit" xlink:label="armp_LeaseAndRentalAbatementCredit_637721739640676106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637026735700595403" xlink:to="armp_LeaseAndRentalAbatementCredit_637721739640676106" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_637721739640676106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637026735700595403" xlink:to="us-gaap_OperatingLeaseLiability_637721739640676106" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637721739640676106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637026735700595403" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637721739640676106" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_637721739640676106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637026735700595403" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_637721739640676106" order="10" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureGrantsAndAwardsNarrativeDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Grants and Awards (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_AwardAbstract" xlink:label="armp_AwardAbstract" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_AwardTable" xlink:label="armp_AwardTable_637721739640676106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="armp_AwardAbstract" xlink:to="armp_AwardTable_637721739640676106" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637721739640676106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="armp_AwardTable_637721739640676106" xlink:to="srt_RangeAxis_637721739640676106" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637721739640676106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637721739640676106" xlink:to="srt_RangeMember_637721739640676106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637721739640676106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637721739640676106" xlink:to="srt_MaximumMember_637721739640676106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_637721739640676106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="armp_AwardTable_637721739640676106" xlink:to="dei_LegalEntityAxis_637721739640676106" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_637721739640676106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_637721739640676106" xlink:to="dei_EntityDomain_637721739640676106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_CysticFibrosisFoundationMember" xlink:label="armp_CysticFibrosisFoundationMember_637721739640676106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_637721739640676106" xlink:to="armp_CysticFibrosisFoundationMember_637721739640676106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637721739640686107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="armp_AwardTable_637721739640676106" xlink:to="srt_CounterpartyNameAxis_637721739640686107" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637721739640686107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637721739640686107" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637721739640686107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_MedicalTechnologyEnterpriseConsortiumMember" xlink:label="armp_MedicalTechnologyEnterpriseConsortiumMember_637721739640686107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637721739640686107" xlink:to="armp_MedicalTechnologyEnterpriseConsortiumMember_637721739640686107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_AwardLineItems" xlink:label="armp_AwardLineItems_637721739640686107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="armp_AwardTable_637721739640676106" xlink:to="armp_AwardLineItems_637721739640686107" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_637721739640686107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="armp_AwardLineItems_637721739640686107" xlink:to="us-gaap_RevenueNotFromContractWithCustomer_637721739640686107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ThresholdDevelopmentAward" xlink:label="armp_ThresholdDevelopmentAward_637721739640686107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="armp_AwardLineItems_637721739640686107" xlink:to="armp_ThresholdDevelopmentAward_637721739640686107" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_AwardReceivable" xlink:label="armp_AwardReceivable_637721739640686107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="armp_AwardLineItems_637721739640686107" xlink:to="armp_AwardReceivable_637721739640686107" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_AmountReceivedUponAchievementOfMilestone" xlink:label="armp_AmountReceivedUponAchievementOfMilestone_637721739640686107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="armp_AwardLineItems_637721739640686107" xlink:to="armp_AmountReceivedUponAchievementOfMilestone_637721739640686107" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_AwardAgreementInterruptionPeriod" xlink:label="armp_AwardAgreementInterruptionPeriod_637721739640686107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="armp_AwardLineItems_637721739640686107" xlink:to="armp_AwardAgreementInterruptionPeriod_637721739640686107" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ResearchAndDevelopmentCreditsRecognized" xlink:label="armp_ResearchAndDevelopmentCreditsRecognized_637721739640686107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="armp_AwardLineItems_637721739640686107" xlink:to="armp_ResearchAndDevelopmentCreditsRecognized_637721739640686107" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.armatapharma.com/role/DisclosureSyntheticGenomicsAssetAcquisitionDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Synthetic Genomics Asset Acquisition (Details)">
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_AssetAcquisitionAbstract" xlink:label="armp_AssetAcquisitionAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637721739640686107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="armp_AssetAcquisitionAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637721739640686107" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_AssetAcquisitionAxis" xlink:label="armp_AssetAcquisitionAxis_637721739640696106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637721739640686107" xlink:to="armp_AssetAcquisitionAxis_637721739640696106" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_AssetAcquisitionDomain" xlink:label="armp_AssetAcquisitionDomain_637721739640696106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="armp_AssetAcquisitionAxis_637721739640696106" xlink:to="armp_AssetAcquisitionDomain_637721739640696106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_SyntheticGenomicsIncMember" xlink:label="armp_SyntheticGenomicsIncMember_637721739640696106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="armp_AssetAcquisitionDomain_637721739640696106" xlink:to="armp_SyntheticGenomicsIncMember_637721739640696106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_637721739640696106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637721739640686107" xlink:to="dei_LegalEntityAxis_637721739640696106" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_637721739640696106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_637721739640696106" xlink:to="dei_EntityDomain_637721739640696106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_C3jTherapeuticsIncMember" xlink:label="armp_C3jTherapeuticsIncMember_637721739640696106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_637721739640696106" xlink:to="armp_C3jTherapeuticsIncMember_637721739640696106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_637721739640696106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637721739640686107" xlink:to="srt_StatementScenarioAxis_637721739640696106" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_637721739640696106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_637721739640696106" xlink:to="srt_ScenarioUnspecifiedDomain_637721739640696106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScenarioPlanMember" xlink:label="us-gaap_ScenarioPlanMember_637721739640696106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637721739640696106" xlink:to="us-gaap_ScenarioPlanMember_637721739640696106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ScenarioOriginalExpectedPaymentOneMember" xlink:label="armp_ScenarioOriginalExpectedPaymentOneMember_637721739640696106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioPlanMember_637721739640696106" xlink:to="armp_ScenarioOriginalExpectedPaymentOneMember_637721739640696106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ScenarioOriginalExpectedPaymentTwoMember" xlink:label="armp_ScenarioOriginalExpectedPaymentTwoMember_637721739640696106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioPlanMember_637721739640696106" xlink:to="armp_ScenarioOriginalExpectedPaymentTwoMember_637721739640696106" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ScenarioOriginalExpectedPaymentThreeMember" xlink:label="armp_ScenarioOriginalExpectedPaymentThreeMember_637721739640696106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioPlanMember_637721739640696106" xlink:to="armp_ScenarioOriginalExpectedPaymentThreeMember_637721739640696106" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ScenarioOriginalExpectedPaymentFourMember" xlink:label="armp_ScenarioOriginalExpectedPaymentFourMember_637721739640696106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioPlanMember_637721739640696106" xlink:to="armp_ScenarioOriginalExpectedPaymentFourMember_637721739640696106" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ScenarioAmendedExpectedPaymentOneMember" xlink:label="armp_ScenarioAmendedExpectedPaymentOneMember_637721739640696106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioPlanMember_637721739640696106" xlink:to="armp_ScenarioAmendedExpectedPaymentOneMember_637721739640696106" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ScenarioAmendedExpectedPaymentTwoMember" xlink:label="armp_ScenarioAmendedExpectedPaymentTwoMember_637721739640696106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioPlanMember_637721739640696106" xlink:to="armp_ScenarioAmendedExpectedPaymentTwoMember_637721739640696106" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_ScenarioAmendedExpectedPaymentThreeMember" xlink:label="armp_ScenarioAmendedExpectedPaymentThreeMember_637721739640696106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioPlanMember_637721739640696106" xlink:to="armp_ScenarioAmendedExpectedPaymentThreeMember_637721739640696106" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637721739640706102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637721739640686107" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637721739640706102" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_CashPaidForProductiveAssets" xlink:label="armp_CashPaidForProductiveAssets_637721739640706102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637721739640706102" xlink:to="armp_CashPaidForProductiveAssets_637721739640706102" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_637721739640706102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637721739640706102" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_637721739640706102" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_637721739640706102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637721739640706102" xlink:to="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_637721739640706102" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_PercentageOfFullyDilutedCapitalizationForIssuanceOfCommonStock" xlink:label="armp_PercentageOfFullyDilutedCapitalizationForIssuanceOfCommonStock_637721739640706102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637721739640706102" xlink:to="armp_PercentageOfFullyDilutedCapitalizationForIssuanceOfCommonStock_637721739640706102" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="armp-20210930.xsd#armp_MaximumPotentialMilestonePayments" xlink:label="armp_MaximumPotentialMilestonePayments_637721739640706102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637721739640706102" xlink:to="armp_MaximumPotentialMilestonePayments_637721739640706102" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_637721739640706102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637721739640706102" xlink:to="us-gaap_InterestExpense_637721739640706102" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>armp-20210930x10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:armp="http://www.armatapharma.com/20210930"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="armp-20210930.xsd" xlink:type="simple"/>
    <context id="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MYGe64DLVEKoqqG1PLm-1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DVIyohuaMEqe9vySm_9bHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_28_2021_To_10_28_2021_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_j_mhEXexkkyt_KqjZVElLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:InnovivaStrategicOpportunitiesLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-28</startDate>
            <endDate>2021-10-28</endDate>
        </period>
    </context>
    <context id="Duration_10_28_2021_To_10_28_2021_srt_CounterpartyNameAxis_armp_CysticFibrosisFoundationMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_r2L1o1zLc0ewvdxbb5OLYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:CysticFibrosisFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-28</startDate>
            <endDate>2021-10-28</endDate>
        </period>
    </context>
    <context id="Duration_3_17_2021_To_3_17_2021_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementSecondTrancheMember_7NUySWdWyU2T6PeqoKx_hg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis">us-gaap:CommonStockSubjectToMandatoryRedemptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:SecuritiesPurchaseAgreementSecondTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-17</startDate>
            <endDate>2021-03-17</endDate>
        </period>
    </context>
    <context id="Duration_1_26_2021_To_1_26_2021_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_z5LGiY7OL0Scv3M4U-b1Wg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis">us-gaap:CommonStockSubjectToMandatoryRedemptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-26</startDate>
            <endDate>2021-01-26</endDate>
        </period>
    </context>
    <context id="Duration_1_26_2021_To_1_26_2021_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementFirstTrancheMember_vU5i9LO2uU6jsVJ4911Zlg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis">us-gaap:CommonStockSubjectToMandatoryRedemptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:SecuritiesPurchaseAgreementFirstTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-26</startDate>
            <endDate>2021-01-26</endDate>
        </period>
    </context>
    <context id="Duration_1_27_2020_To_3_27_2020_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_tEurHl-WuEy8GrS4QYXwGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis">us-gaap:CommonStockSubjectToMandatoryRedemptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-27</startDate>
            <endDate>2020-03-27</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BCCyhEU1tEi9VSOL9PeeDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CnAXtkAfOkyr84AqUZmq-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_SPUy-mdqVEWQXJUyR4SwLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rkFIJlcvhkG9sE5lG-I4MQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_5jY2Kblz0kWsExJk25jZVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_KEunbq8Lv0G2CGYZpXLKlA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_nIezyXT0BUyf5xGYCsZfTA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MTZvL_NcmESOrJIA_0-1jw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_NKaGlnEUNkec6voi3tIaYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ZmXsDKp77EKqicmltHHhGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_SxvMMY1Sa0GTX13IRJGJ4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_Lk4NTSOZBE25mumJD7-ddw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_I_LPYFq-_Eu5aKaleEMQgQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KEkptw3IX0mcgqD8P-u1tQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zJn5M0sFjE-rqqEDYPJ3Uw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_W4e7PNLj70SPGz46YLofww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_d2NNZnl0VUWMFpJen2dwnw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_65fdseHmlkygQFXjdAowrA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_aIHcMH7w-kKjUPzazac1VQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SL0WNDAfdkevFGn-ljnxpQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_10_28_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_XMDfJAOuaESQwElJtiy_ew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-28</instant>
        </period>
    </context>
    <context id="As_Of_1_26_2021_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_zFjpWhEkUkiNbRFtUmSseg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis">us-gaap:CommonStockSubjectToMandatoryRedemptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-26</instant>
        </period>
    </context>
    <context id="As_Of_1_26_2021_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_TImvJ_eQD0OgW_ZO7Ry9TQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-26</instant>
        </period>
    </context>
    <context id="As_Of_3_27_2020_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_9mH04W5WikCikSJLnqxw9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis">us-gaap:CommonStockSubjectToMandatoryRedemptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-27</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_PlanNameAxis_armp_Assumed2006And2016PlanMember_jwnQgOCvrEi-zQv25P1M9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">armp:Assumed2006And2016PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_8rl-g37700qfCCqQwUULVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_armp_EquityIncentivePlan2016Member_nK9yLVbEL06fLvTMqAkXxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">armp:EquityIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_armp_EquityIncentivePlan2016Member_owlriQq-j0-oYrcsBY5Gjw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">armp:EquityIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_hi0c_0vE9E-W67zzRNTT2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_UrkFQ9x-qEmjvoP_lxEMWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_TDb9Z5iGoUePxWE6REEZBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_uMrMSnX6sk6VBfvSkKl9Vg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_armp_EquityIncentivePlan2016Member_a2GP2RQyPUaGZD8_SYwXvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">armp:EquityIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_armp_Assumed2006And2016PlanMember_K1n3aKUECkaYA26IMMHaPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">armp:Assumed2006And2016PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_armp_Assumed2006And2016PlanMember_oXCoqIfziE2VJlO7Y9J9yA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">armp:Assumed2006And2016PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_15_2020_To_7_15_2020_srt_CounterpartyNameAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_ITaRqTiHmk-EtdzqEDU-gw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">armp:MedicalTechnologyEnterpriseConsortiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-15</startDate>
            <endDate>2020-07-15</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_TechnologyEquipmentMember_p5J4JOCTc02vC-jcH_EpAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:TechnologyEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_TOBly1V2sk6aoZBdLy5BKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_RNSsP7qTGEmVKWcf_xwJ3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_1p7SIRia1U-1Q9bpInZOaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_TechnologyEquipmentMember_nIlwPHC5LUOeeFklieSIRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:TechnologyEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_v1yZA3mZRkKG-s3xNs7sqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_Va3hG_KZOUiqR-V5nrMt6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_8b0rBWMKHUqzS1cwV6K4xQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_4_20_2020_To_4_20_2020_us-gaap_DebtInstrumentAxis_armp_PaymentProtectionProgramNoteMember_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember_7RzbJhwJ1ESFRjadZeEXiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">armp:PaymentProtectionProgramNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-20</startDate>
            <endDate>2020-04-20</endDate>
        </period>
    </context>
    <context id="Duration_3_17_2021_To_3_17_2021_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementSecondTrancheMember_OI9uPwtYu02QjGR7dFobAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:SecuritiesPurchaseAgreementSecondTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-17</startDate>
            <endDate>2021-03-17</endDate>
        </period>
    </context>
    <context id="Duration_1_26_2021_To_1_26_2021_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementFirstTrancheMember_wOZbvf2jHEW62lNLQlwkHw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:SecuritiesPurchaseAgreementFirstTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-26</startDate>
            <endDate>2021-01-26</endDate>
        </period>
    </context>
    <context id="Duration_2_12_2020_To_2_12_2020_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_kE6uyStxdEyj3mI3KbQoTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-12</startDate>
            <endDate>2020-02-12</endDate>
        </period>
    </context>
    <context id="Duration_1_27_2020_To_3_27_2020_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_9V8h1NEgnkCy2Hyg6zq7fg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-27</startDate>
            <endDate>2020-03-27</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_armp_AssetAcquisitionAxis_armp_SyntheticGenomicsIncMember_dei_LegalEntityAxis_armp_C3jTherapeuticsIncMember_NBfmWnEmKk6A5v2Z9Ffejw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="armp:AssetAcquisitionAxis">armp:SyntheticGenomicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:C3jTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_12_20_2018_To_12_20_2018_armp_AssetAcquisitionAxis_armp_SyntheticGenomicsIncMember_dei_LegalEntityAxis_armp_C3jTherapeuticsIncMember_srt_StatementScenarioAxis_armp_ScenarioAmendedExpectedPaymentTwoMember_rqhFNiTiRE2BmMr7XyphyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">armp:ScenarioAmendedExpectedPaymentTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="armp:AssetAcquisitionAxis">armp:SyntheticGenomicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:C3jTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-20</startDate>
            <endDate>2018-12-20</endDate>
        </period>
    </context>
    <context id="Duration_12_20_2018_To_12_20_2018_armp_AssetAcquisitionAxis_armp_SyntheticGenomicsIncMember_dei_LegalEntityAxis_armp_C3jTherapeuticsIncMember_srt_StatementScenarioAxis_armp_ScenarioAmendedExpectedPaymentThreeMember_R1Aa4SvwlUuog7rLKl3MqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">armp:ScenarioAmendedExpectedPaymentThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="armp:AssetAcquisitionAxis">armp:SyntheticGenomicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:C3jTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-20</startDate>
            <endDate>2018-12-20</endDate>
        </period>
    </context>
    <context id="Duration_12_20_2018_To_12_20_2018_armp_AssetAcquisitionAxis_armp_SyntheticGenomicsIncMember_dei_LegalEntityAxis_armp_C3jTherapeuticsIncMember_srt_StatementScenarioAxis_armp_ScenarioAmendedExpectedPaymentOneMember_zNXu_So6HEuNH4kwwRcmWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">armp:ScenarioAmendedExpectedPaymentOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="armp:AssetAcquisitionAxis">armp:SyntheticGenomicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:C3jTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-20</startDate>
            <endDate>2018-12-20</endDate>
        </period>
    </context>
    <context id="Duration_2_28_2018_To_2_28_2018_armp_AssetAcquisitionAxis_armp_SyntheticGenomicsIncMember_dei_LegalEntityAxis_armp_C3jTherapeuticsIncMember_srt_StatementScenarioAxis_armp_ScenarioOriginalExpectedPaymentTwoMember_gEaPDWofx0qOEWXTSGF3Tw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">armp:ScenarioOriginalExpectedPaymentTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="armp:AssetAcquisitionAxis">armp:SyntheticGenomicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:C3jTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-28</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="Duration_2_28_2018_To_2_28_2018_armp_AssetAcquisitionAxis_armp_SyntheticGenomicsIncMember_dei_LegalEntityAxis_armp_C3jTherapeuticsIncMember_srt_StatementScenarioAxis_armp_ScenarioOriginalExpectedPaymentThreeMember_jidGEQgNYECfuWhjbDYubA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">armp:ScenarioOriginalExpectedPaymentThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="armp:AssetAcquisitionAxis">armp:SyntheticGenomicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:C3jTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-28</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="Duration_2_28_2018_To_2_28_2018_armp_AssetAcquisitionAxis_armp_SyntheticGenomicsIncMember_dei_LegalEntityAxis_armp_C3jTherapeuticsIncMember_srt_StatementScenarioAxis_armp_ScenarioOriginalExpectedPaymentOneMember_clsnrNZH1UazMXYm92c0Pg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">armp:ScenarioOriginalExpectedPaymentOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="armp:AssetAcquisitionAxis">armp:SyntheticGenomicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:C3jTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-28</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="Duration_2_28_2018_To_2_28_2018_armp_AssetAcquisitionAxis_armp_SyntheticGenomicsIncMember_dei_LegalEntityAxis_armp_C3jTherapeuticsIncMember_srt_StatementScenarioAxis_armp_ScenarioOriginalExpectedPaymentFourMember_gxbq2ISe3UijfOm_OFNWLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">armp:ScenarioOriginalExpectedPaymentFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="armp:AssetAcquisitionAxis">armp:SyntheticGenomicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:C3jTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-28</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="Duration_2_28_2018_To_2_28_2018_armp_AssetAcquisitionAxis_armp_SyntheticGenomicsIncMember_dei_LegalEntityAxis_armp_C3jTherapeuticsIncMember_RidG05BOeEyASZ1M8D09rA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="armp:AssetAcquisitionAxis">armp:SyntheticGenomicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:C3jTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-28</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MAx1Qhihl0-QjfrmaUOYJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7TWvDwySBEWUWI9x7ArVBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_bgCDlfNMOkqVq2IlJzSALA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_UxaVXkDGlUCs8nQaDlXZoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_4_30_2020_1iPl4CxS1EenIgtFs0sC1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_joNmkWmSp0eoVV34drwlKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_armp_StockOptionsAndRestrictedStockAwardsMember_pNotzPzMhUuSettHWcT5dw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">armp:StockOptionsAndRestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_4_20_2020_us-gaap_DebtInstrumentAxis_armp_PaymentProtectionProgramNoteMember_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember_etlcSyw6QUy7OhSC2F0meg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">armp:PaymentProtectionProgramNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-20</instant>
        </period>
    </context>
    <context id="As_Of_10_28_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_tDI9aHgnU02SEE2i4-rltw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-28</instant>
        </period>
    </context>
    <context id="As_Of_3_17_2021_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementSecondTrancheMember_8WtQB3s-wk2b0we6rBXeVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis">us-gaap:WarrantsAndRightsSubjectToMandatoryRedemptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:SecuritiesPurchaseAgreementSecondTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-17</instant>
        </period>
    </context>
    <context id="As_Of_1_26_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_z1sUig3BpUiBHLBYltqXRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis">us-gaap:WarrantsAndRightsSubjectToMandatoryRedemptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-26</instant>
        </period>
    </context>
    <context id="As_Of_1_26_2021_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_u_eCCek3qkqRByQzE5fczw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis">us-gaap:WarrantsAndRightsSubjectToMandatoryRedemptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-26</instant>
        </period>
    </context>
    <context id="As_Of_1_26_2021_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementFirstTrancheMember_4VDPa4otSk6JCKDKNZvQ0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis">us-gaap:WarrantsAndRightsSubjectToMandatoryRedemptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:SecuritiesPurchaseAgreementFirstTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-26</instant>
        </period>
    </context>
    <context id="As_Of_3_27_2020_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_VI0dYZLlxkey_j7O6lL4cA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis">us-gaap:WarrantsAndRightsSubjectToMandatoryRedemptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-27</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceTwoMember_NdqVRbX3oU27C0EB3fq9hQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceThreeMember_KFYsa4JmTkqWUhYzwZ9UJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSixMember_WimCD-fx60m_KUK0LywoTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSevenMember_gY_GNEB58Eym-DuN9BtbEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFourMember_JSSFhCnciUaDzuCmVBpOig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFiveMember_CxNNWMACKU-ycnzc8b5FtA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceEightMember_fpCbl3DW_keRXlZj4Fhy1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_9M2XeqAfdE-lB78H_jYHfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_zW8zVq9yIEyTGkUsiRdNWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_DeTK3m4stEG86-3yphL8Ow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_dGzT0B8rlE25dvbTXP9MPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_0tfpWQr4U0atNpxzVyKU4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_C-PpNtLO1EyP8fYs3gQBWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_T0uD7MiwsUiVBvYkYdc0sA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_Lq1HnOsnGU-O85aEcig2uA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_IORuHvJJb02yQ5UUN4uyzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_77ETOpJ7T0afQOPGHLIu-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_1dzTloLluU2mQIMpctnh9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_G0J-iJ-hkEmVgCIOKKuQUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_0sFoug39yEW-7YiIxYw6ZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_iXH_BdY7Yky0pOj-w2anUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_GodB2f3XM0-WcLyJqnzVFg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_v1HeSfyr9Em3B6Qct7RwOA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_we94IQA0Ok-L_lCieSHSdw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9Eff9cku9kikyLYc9MKX0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_0veJ9SwbfEiLVcv9uwtSJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_C3Blutz6cUqC03qQKsaYEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_11_5_2021_r_KKuBvaXUe98RPh8rYZpA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
        </entity>
        <period>
            <instant>2021-11-05</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceTwoMember_JdmRRsSJmk-a_ZNRg_kXxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceThreeMember_EJFiwcEwBEuQa1IR4jmJ5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSevenMember_u78Ah4LoqUKqzJVIAxTUEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFourMember_jfTPvaUXH0maozOHI-CL3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFiveMember_E28RzePRZEuFR_T3YSIfYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceEightMember_xrUR_X3n30aS1ib7pRRXLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">armp:ExercisePriceEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_3_13_2020_dei_LegalEntityAxis_armp_CysticFibrosisFoundationMember_srt_RangeAxis_srt_MaximumMember_QdkZoWNHYkyCGniRryGR1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:CysticFibrosisFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-13</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_armp_StockOptionsAndRestrictedStockAwardsMember_NAa3wvdW6ku9ixKdaxeq_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">armp:StockOptionsAndRestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_8_9_2021_To_8_9_2021_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_armp_StockOptionsAndRestrictedStockAwardsMember_HSuu2yjbeUO8uzqPtQxFDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">armp:StockOptionsAndRestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-09</startDate>
            <endDate>2021-08-09</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VJKQAeK86kCfqs_DrKEH6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VoZ8oQm5tUCLM6PYYrJGCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Rmv1hE9bF0aKaK_8FzTl-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HzaMhmdSwEmOsLQZS5Pg1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_dei_LegalEntityAxis_armp_CysticFibrosisFoundationMember_RpwT93VR-ECLCn7xD0c95g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:CysticFibrosisFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_dei_LegalEntityAxis_armp_CysticFibrosisFoundationMember_oDkg0nbvCUGTMxn-UCPsfA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:CysticFibrosisFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_28_2021_To_10_28_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_46a9XzfZPkSGKc4-ttN9fw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-28</startDate>
            <endDate>2021-10-28</endDate>
        </period>
    </context>
    <context id="Duration_3_27_2020_To_3_27_2020_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_NmhuJtI8WkCb1aWkNG0-5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-27</startDate>
            <endDate>2020-03-27</endDate>
        </period>
    </context>
    <context id="Duration_1_27_2020_To_1_27_2020_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_kxspnM04HEGpag_N6znvkw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">armp:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-27</startDate>
            <endDate>2020-01-27</endDate>
        </period>
    </context>
    <context id="Duration_2_1_2018_To_2_28_2018_armp_AssetAcquisitionAxis_armp_SyntheticGenomicsIncMember_dei_LegalEntityAxis_armp_C3jTherapeuticsIncMember_Z8D7DoUmZ0qMYFL0DwXLPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="armp:AssetAcquisitionAxis">armp:SyntheticGenomicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:C3jTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-01</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_EHL267Iy5kqlAVaXmlK6uQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_M1wYd_bHtkSmPDl5gRx6tg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_Y-YOyctUPkCj1ByCpX0cjA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_ZYsQgyW6mkWdASHXKWLehQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_TcHNTAeDIUqS5KTjdnYf_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_8qAqLG7eF0q7G6Mr5Lp6tg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_i9PzMC1lVUqwLuTxFWfdLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_JmEBEeGO8UeggSG1K-jwFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_si4L1iko2E64STirrO48PA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_c6MOz2oxDUaT_X0fkJA_DA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_vGTpt-wF-kumWbrMGmDgMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_NRyFSCYoD020FMLell9_Bw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_bMElE1RKukaULS3RIlENIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_xmm1FvADiUqkK7ZP4Vv_tA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_2_28_2018_armp_AssetAcquisitionAxis_armp_SyntheticGenomicsIncMember_dei_LegalEntityAxis_armp_C3jTherapeuticsIncMember_mk1RLuCDkk6c_shfOgofxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="armp:AssetAcquisitionAxis">armp:SyntheticGenomicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:C3jTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-02-28</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2021_egZlLrGpKk2-r-0udRYIlQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_13_2020_dei_LegalEntityAxis_armp_CysticFibrosisFoundationMember_Vmk5a-OLzkuheIihAx82BA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:CysticFibrosisFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-13</instant>
        </period>
    </context>
    <context id="Duration_3_13_2020_To_3_13_2020_dei_LegalEntityAxis_armp_CysticFibrosisFoundationMember_bkw-_kZsEUWVZ6CfCvxnag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:CysticFibrosisFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-13</startDate>
            <endDate>2020-03-13</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_4_30_2020_97rB72XwWUSnYAu0RGwgjQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_dei_LegalEntityAxis_armp_CysticFibrosisFoundationMember_tYChB5g8O0GcrXG6pdzhcA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">armp:CysticFibrosisFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_EPrTQjTDQkGfR4N7mgNYUg">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA"
      decimals="INF"
      id="Hidden_Vjudgl28B0mPQxo1Uew1Pg"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">24965086</us-gaap:CommonStockSharesOutstanding>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Hidden_b__5oMo-IECTetnOZMckgw">Armata Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Tc_l1wOJKeGE0ixIvloPIS6Cw_2_1">0000921114</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Tc_qSXV9q-IqkOkkLSJVlBhVw_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Tc_FuoL7QFiTEizq70wqgZUPw_4_1">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Tc_6lt0Owc9XEyaq7iKzYr5HQ_5_1">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Tc_uRfEXY4LI0iriyi8-9HqhQ_6_1">false</dei:AmendmentFlag>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg"
      decimals="INF"
      id="Hidden_vHdyLOLd_0OZchY-bVdk5A"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">18688461</us-gaap:CommonStockSharesIssued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="Duration_1_1_2021_To_9_30_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_armp_Assumed2006And2016PlanMember_K1n3aKUECkaYA26IMMHaPw"
      id="Hidden_FoLyPbG9hUC2OJDlbr-6vQ">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_PlanNameAxis_armp_Assumed2006And2016PlanMember_jwnQgOCvrEi-zQv25P1M9Q"
      decimals="INF"
      id="Hidden_6HHTzro5OEGysvS9SNdMCQ"
      unitRef="Unit_Standard_pure_EPrTQjTDQkGfR4N7mgNYUg">0.0714</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <armp:ShareBasedCompensationArrangementPercentageOfOutstandingAwardsVestedForAdvisoryServicesProvided
      contextRef="Duration_8_9_2021_To_8_9_2021_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_armp_StockOptionsAndRestrictedStockAwardsMember_HSuu2yjbeUO8uzqPtQxFDA"
      decimals="2"
      id="Hidden_9mekj5kubk-rv8woYRxrCg"
      unitRef="Unit_Standard_pure_EPrTQjTDQkGfR4N7mgNYUg">0.50</armp:ShareBasedCompensationArrangementPercentageOfOutstandingAwardsVestedForAdvisoryServicesProvided>
    <dei:DocumentType
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Narr_T7k6-48B2EykGlvJJawkZg">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Tc_frgt2dW24Ueueuq-j8-eHw_1_0">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Narr_TLJpFSXNwkiL812uHlcAag">2021-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Tc_xaeci2mzsECRhK6diGaQRw_1_0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Narr_nb-kP7B8i0iWYpzc8hwx7w">001-37544</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Tc_hCkCIuVPy0ybAiJ5WhmXkQ_1_0">WA</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Tc_pSd92nbU6ESaXltFeP_wnQ_1_1">91-1549568</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Tc_MOVHmt83gECZvg6I_spDwg_5_0">4503 Glencoe Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Narr_W40YDqMtKUq5j_NEMrbBag">Marina del Rey</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Narr_32ECs7bMRkCsWvsi0hiSjw">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Tc_gtU9w88k0EyV-9lQszAXeQ_6_1">90292</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Narr_s-E0czk_r0iXlCnqSahaFw">310</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Narr_1ud0D_6J6kqcDWRUDg3tJA">665-2928</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Narr_ZKHoKuvAQk2MfEHBGk5CVQ">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Tc_29I-m2xMZUKstoRadYkqEw_2_1">ARMP</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Tc_IKds9j-GtEOIYagXF7nmhg_2_2">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Narr_HR4TfOcFAkabl1zPvt8fpw">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Narr_CP0SVGx_w0Cdjz0dWJAFWA">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Narr__3bWzddok06ncOn5TAvB6Q">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Narr_YmHN5EGPc0ScP2D0ScofvQ">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Narr_pg2Fx5k-2Ei1Q4KdYKEyow">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Narr_7F2pHAK2H0GHd092Op8DKw">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_11_5_2021_r_KKuBvaXUe98RPh8rYZpA"
      decimals="INF"
      id="Narr_sWMV5RAYzUy4zeWe2SdSWQ"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">27086299</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA"
      decimals="0"
      id="Tc_MZ9iUOPT1EaH9cD-rP-TaA_5_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">12076000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg"
      decimals="0"
      id="Tc_2Y0GvTrSdU2a2EkwgwHIRg_5_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">9649000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <armp:AwardReceivable
      contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA"
      decimals="0"
      id="Tc_2Ka-XyTnWU2A-N0cfpISpg_6_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">1251000</armp:AwardReceivable>
    <armp:AwardReceivable
      contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg"
      decimals="0"
      id="Tc_DuuZshKZGkimPwPqzrPchA_6_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">561000</armp:AwardReceivable>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA"
      decimals="0"
      id="Tc_ERo4bWSl3UiXObA3FtwaOQ_7_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">851000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg"
      decimals="0"
      id="Tc_JxpMe2Ibz0efUmdwXdqBhA_7_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">636000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA"
      decimals="0"
      id="Tc_LwNdDNTiuEO0JuI62VPwoA_8_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">14178000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg"
      decimals="0"
      id="Tc_37TYBwu8_Ua9VILLcizAfA_8_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">10846000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA"
      decimals="0"
      id="Tc_pGK3OkoFOUuw7afWlZkdhQ_9_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">1200000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg"
      decimals="0"
      id="Tc_k0nVTPkrf0iM972C_25pFg_9_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">1200000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA"
      decimals="0"
      id="Tc_WsGiFR8G8EyM1ofxge4s3w_10_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">2107000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg"
      decimals="0"
      id="Tc_Sg9hhYl5kEiDSSYysmbUXg_10_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">2047000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA"
      decimals="0"
      id="Tc_VfBGphhE50-D25_HQSPfVg_11_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">10531000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg"
      decimals="0"
      id="Tc_nt_JZQoV90-Ve2KPAUQrBw_11_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">10790000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA"
      decimals="0"
      id="Tc__aN9EFpxo0eOC4ganwbJfA_12_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">10256000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg"
      decimals="0"
      id="Tc_JJd6BnZ2KUqMP9Ymve_gqQ_12_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">10256000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA"
      decimals="0"
      id="Tc_9xBN3QGfiUmzNinymEkppw_13_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">3490000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg"
      decimals="0"
      id="Tc_Vs_E2CK1UkatTr-wtOjdBA_13_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">3490000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA"
      decimals="0"
      id="Tc_m4rcI-GOckeAfEmoc3wngw_14_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">909000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg"
      decimals="0"
      id="Tc_DYhft6luW0GJJB05kfNIHg_14_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">887000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA"
      decimals="0"
      id="Tc_n5y2wZZ5rkSGO4MOdtdlYA_15_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">42671000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg"
      decimals="0"
      id="Tc_JVEfv4RDi0iH7bSS4hFCjQ_15_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">39516000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA"
      decimals="0"
      id="Tc_GpggTV24Uker_DHN6ke_xg_19_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">1811000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg"
      decimals="0"
      id="Tc_J9L22cTqVEyXoLE6eL8jqg_19_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">1929000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:DeferredCompensationLiabilityCurrent
      contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA"
      decimals="0"
      id="Tc_BZD-ljl5RUaJMFnAo-AfEw_20_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">1714000</us-gaap:DeferredCompensationLiabilityCurrent>
    <us-gaap:DeferredCompensationLiabilityCurrent
      contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg"
      decimals="0"
      id="Tc_EBHUm3n13UiyoUz4e_9WbQ_20_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">563000</us-gaap:DeferredCompensationLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA"
      decimals="0"
      id="Tc_Uduk8RV1ykev9fmVv8G4eQ_21_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">1729000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg"
      decimals="0"
      id="Tc_JSD9INqH6kmFK5j7yVzeeg_21_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">1551000</us-gaap:OperatingLeaseLiabilityCurrent>
    <armp:PaycheckProtectionProgramLoan
      contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg"
      decimals="0"
      id="Tc_5hvzSW22aka68I17DGYS3g_22_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">722000</armp:PaycheckProtectionProgramLoan>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg"
      decimals="0"
      id="Tc_oPw_c77uLkKvC5nLTmImnA_23_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">1940000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA"
      decimals="0"
      id="Tc_HLInkIm8vUuMApFUD2CGhw_24_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">5254000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg"
      decimals="0"
      id="Tc_4X1B8o7S7Eak5sM_yl-OGg_24_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">6705000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA"
      decimals="0"
      id="Tc_ADkqhs6MAk-FZCFnyVL9QQ_25_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">10585000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg"
      decimals="0"
      id="Tc_zyGWk2cGCUSwePdzl-rV6g_25_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">10877000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA"
      decimals="0"
      id="Tc_KCgf9bj5gkuvxQniokLBQA_26_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">3077000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg"
      decimals="0"
      id="Tc_GPetNfiDzUeri4jzPGg_8A_26_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">3077000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:Liabilities
      contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA"
      decimals="0"
      id="Tc_0V48V47rMk-R7RgalIj0-A_27_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">18916000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg"
      decimals="0"
      id="Tc_pAOOaHfjqEW5Mcz_BCdHZw_27_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">20659000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA"
      decimals="INF"
      id="Narr_gfmfgsijCEiwWh8gOgPBPg"
      unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg"
      decimals="INF"
      id="Narr_oDf9jPBS3U6XZ-j53xOllg"
      unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA"
      decimals="INF"
      id="Narr_Y4e4xlG130CIveNLlHSvvg"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">217000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg"
      decimals="INF"
      id="Narr_yW3WyEpW1UOMFrb1OOjfSw"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">217000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA"
      decimals="INF"
      id="Narr_Qg6efRqDaU6YDFSPm5O6wQ"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">24965086</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg"
      decimals="INF"
      id="Narr_qEQ5ZHMaCkm6l-gNBjGmig"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">18688461</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA"
      decimals="0"
      id="Tc_OubsBbzGk0i7jStfzqnJ7Q_30_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">249000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg"
      decimals="0"
      id="Tc_QNIgXz_jeEeSA8DDDWBdLg_30_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">187000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA"
      decimals="0"
      id="Tc_n1OYREqeOU6CxsoToVDYug_31_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">220316000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg"
      decimals="0"
      id="Tc_gUD8uwaKYUarIkTNXxP53A_31_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">198372000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA"
      decimals="0"
      id="Tc_kEJ6bG0b6Ue8QMkIn7MAxw_32_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">-196810000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg"
      decimals="0"
      id="Tc_kklq83LXsEGyYgehorBhog_32_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">-179702000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA"
      decimals="0"
      id="Tc_QfAAo30UEUyF7v6fvbo8YQ_33_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">23755000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg"
      decimals="0"
      id="Tc_3XAbvrcgV0eUQni9qcxN8Q_33_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">18857000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA"
      decimals="0"
      id="Tc_MScit_fnlkWOsKIZkmZN_w_34_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">42671000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg"
      decimals="0"
      id="Tc_K5BO2fnjlE6icw6aCKgX0Q_34_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">39516000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="Duration_7_1_2021_To_9_30_2021_EHL267Iy5kqlAVaXmlK6uQ"
      decimals="0"
      id="Tc_5FyTwbiTXE-XypM_1l0-QA_5_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">1251000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="Duration_7_1_2020_To_9_30_2020_C3Blutz6cUqC03qQKsaYEg"
      decimals="0"
      id="Tc_2ZVp4zXitEGF_WZVTe2WQQ_5_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">288000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      decimals="0"
      id="Tc_yqiA46pVsUqvfsTBAnDHhA_5_9"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">3485000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw"
      decimals="0"
      id="Tc_djL8fTkkHk27VCj8GBrMQA_5_12"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">319000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_7_1_2021_To_9_30_2021_EHL267Iy5kqlAVaXmlK6uQ"
      decimals="0"
      id="Tc_3GlCR5FA5USHF4QpG88VOg_7_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">5626000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_7_1_2020_To_9_30_2020_C3Blutz6cUqC03qQKsaYEg"
      decimals="0"
      id="Tc_X25tR670lkiZoAi5LTkLxA_7_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">4066000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      decimals="0"
      id="Tc_BtCWGb_2Xkm5BKhT_s0I7g_7_9"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">15201000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw"
      decimals="0"
      id="Tc_WAyXdPiPAkWnrErwxTK6og_7_12"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">9464000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2021_To_9_30_2021_EHL267Iy5kqlAVaXmlK6uQ"
      decimals="0"
      id="Tc_dyXBTULynU6ilw---DhOVw_8_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">1768000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2020_To_9_30_2020_C3Blutz6cUqC03qQKsaYEg"
      decimals="0"
      id="Tc_7_e01iKkmUmyE2XUfG6neA_8_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">1845000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      decimals="0"
      id="Tc__tp4fBp-C0yFsf-eKmxPGw_8_9"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">6058000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw"
      decimals="0"
      id="Tc_4IYCC7G0cEWNmTmkIHkI7w_8_12"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">5989000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_7_1_2021_To_9_30_2021_EHL267Iy5kqlAVaXmlK6uQ"
      decimals="0"
      id="Tc_CvCoL8VxikeercbrQ7vgsA_9_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">7394000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_7_1_2020_To_9_30_2020_C3Blutz6cUqC03qQKsaYEg"
      decimals="0"
      id="Tc_HcTH1m4KBEymgVtoB2PHzw_9_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">5911000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      decimals="0"
      id="Tc_y_XoxQt0v0O9G1xMHSOXuA_9_9"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">21259000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw"
      decimals="0"
      id="Tc_6Wl0XzLtD0STtn8UPD1-yg_9_12"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">15453000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2021_To_9_30_2021_EHL267Iy5kqlAVaXmlK6uQ"
      decimals="0"
      id="Tc_JPGIro_YA02xIJkg_kulKg_10_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">-6143000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2020_To_9_30_2020_C3Blutz6cUqC03qQKsaYEg"
      decimals="0"
      id="Tc_gX-DBaOtS0qphJumAHPE6w_10_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">-5623000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      decimals="0"
      id="Tc_UE4qH_rJSkS2x5HLZH1Cjw_10_9"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">-17774000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw"
      decimals="0"
      id="Tc_ZVC1faV36kKfuTXmnvIxsA_10_12"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">-15134000</us-gaap:OperatingIncomeLoss>
    <armp:GainLossOnExtinguishmentOfPaycheckProtectionProgramSinceInception
      contextRef="Duration_7_1_2021_To_9_30_2021_EHL267Iy5kqlAVaXmlK6uQ"
      decimals="0"
      id="Tc_kGpA4O154USmQCsPW0ighw_12_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">726000</armp:GainLossOnExtinguishmentOfPaycheckProtectionProgramSinceInception>
    <armp:GainLossOnExtinguishmentOfPaycheckProtectionProgramSinceInception
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      decimals="0"
      id="Tc_TdzSA8b5ekW1wlUjj-rS0Q_12_9"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">726000</armp:GainLossOnExtinguishmentOfPaycheckProtectionProgramSinceInception>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_7_1_2020_To_9_30_2020_C3Blutz6cUqC03qQKsaYEg"
      decimals="0"
      id="Tc_dj9Bu4znLkS2kctqmi7EbQ_13_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">4000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      decimals="0"
      id="Tc_VnNnrQ51uEqXHNVMueODLw_13_9"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">4000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw"
      decimals="0"
      id="Tc_3DmP25y57kSIwNK6EZF2MQ_13_12"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">28000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="Duration_7_1_2021_To_9_30_2021_EHL267Iy5kqlAVaXmlK6uQ"
      decimals="0"
      id="Tc_pKnFYrvLREiJIZhUf7u-HA_14_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">2000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_7_1_2020_To_9_30_2020_C3Blutz6cUqC03qQKsaYEg"
      decimals="0"
      id="Tc_X9kfTgo03E-NGx7epS5mcg_14_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">150000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      decimals="0"
      id="Tc_NFkQ0Pw0ykOzp4Qc2btvWg_14_9"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">64000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw"
      decimals="0"
      id="Tc_B7BDqL_qqU654Hh4tO1mfg_14_12"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">451000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_7_1_2021_To_9_30_2021_EHL267Iy5kqlAVaXmlK6uQ"
      decimals="0"
      id="Tc_YClvqI9wwE-GFSgehq94pQ_15_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">724000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_7_1_2020_To_9_30_2020_C3Blutz6cUqC03qQKsaYEg"
      decimals="0"
      id="Tc_jmR-LQPXvUGOu923j6YDPg_15_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">-146000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      decimals="0"
      id="Tc_ha4YRkdMDk6nYf-BaINciQ_15_9"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">666000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw"
      decimals="0"
      id="Tc_YfgVcMTDOEKFco1_qbh-EA_15_12"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">-423000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2021_To_9_30_2021_EHL267Iy5kqlAVaXmlK6uQ"
      decimals="0"
      id="Tc_ZvYt0zw_aU637yuSUUGmSA_16_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">-5419000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2020_To_9_30_2020_C3Blutz6cUqC03qQKsaYEg"
      decimals="0"
      id="Tc_trrJn8Bi2U-uMgc_DPwMmA_16_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">-5769000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      decimals="0"
      id="Tc_d74AcKuKfkytzyWn6uJ9sA_16_9"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">-17108000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw"
      decimals="0"
      id="Tc_ROpiPocBKk2TQR-wfj9E7g_16_12"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">-15557000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_7_1_2021_To_9_30_2021_EHL267Iy5kqlAVaXmlK6uQ"
      decimals="2"
      id="Tc_gYkGpe2CdECqfATWHWQhWw_18_3"
      unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q">-0.22</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_7_1_2020_To_9_30_2020_C3Blutz6cUqC03qQKsaYEg"
      decimals="2"
      id="Tc_9wYVMzp7ykm3DUIw0vt5dw_18_6"
      unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q">-0.31</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      decimals="2"
      id="Tc_INV1cnH3a0e74oF8RjiKuw_18_9"
      unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q">-0.73</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw"
      decimals="2"
      id="Tc_caQwNYC9n0aKGX3cjfcGGg_18_12"
      unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q">-0.99</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_7_1_2021_To_9_30_2021_EHL267Iy5kqlAVaXmlK6uQ"
      decimals="0"
      id="Tc_V3GZVNgWMU-zjkJzsQ5c-A_19_3"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">24820233</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_7_1_2020_To_9_30_2020_C3Blutz6cUqC03qQKsaYEg"
      decimals="0"
      id="Tc_ggMm9I-mSEiyvASIj1n_-w_19_6"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">18394614</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      decimals="0"
      id="Tc_3xwWFtPDsUCSwePZzPg7jQ_19_9"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">23363113</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw"
      decimals="0"
      id="Tc_VNtbNLpgi0aXtd-YqsTgWw_19_12"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">15740858</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_aIHcMH7w-kKjUPzazac1VQ"
      decimals="INF"
      id="Tc_Wua95J5RZkG0bsqGsI4-4A_6_2"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">18641501</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_aIHcMH7w-kKjUPzazac1VQ"
      decimals="0"
      id="Tc_s4JOqc2uLEOUCaM8Cfzokw_6_5"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">186000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_SxvMMY1Sa0GTX13IRJGJ4A"
      decimals="0"
      id="Tc_3xlYJ29N2UuUwDtnNnZnfA_6_8"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">196761000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ZmXsDKp77EKqicmltHHhGA"
      decimals="0"
      id="Tc_k-qxqXN-JUah7bYXcX-SAw_6_11"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">-167309000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2020_Lk4NTSOZBE25mumJD7-ddw"
      decimals="0"
      id="Tc_ZEiFTOvUiUC5hqKEZWgicw_6_14"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">29638000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MYGe64DLVEKoqqG1PLm-1A"
      decimals="INF"
      id="Tc_8LIc-ouy50m1MqCOuTRgHw_7_2"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">27382</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MYGe64DLVEKoqqG1PLm-1A"
      decimals="0"
      id="Tc_VXt6mnCPskKwZagWPkB80g_7_5"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_0veJ9SwbfEiLVcv9uwtSJA"
      decimals="0"
      id="Tc_DguxZdudk0mruqOIHqIqsQ_7_8"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">86000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_7_1_2020_To_9_30_2020_C3Blutz6cUqC03qQKsaYEg"
      decimals="0"
      id="Tc_b_OFFoHDBEKsXuRUXgzf_w_7_14"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">87000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_0veJ9SwbfEiLVcv9uwtSJA"
      decimals="0"
      id="Tc_ylQYsNpbQEuQi35mZICf8A_8_8"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">663000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2020_To_9_30_2020_C3Blutz6cUqC03qQKsaYEg"
      decimals="0"
      id="Tc_-wVB6FXm30aqD4v7VNX6nw_8_14"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">663000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_bgCDlfNMOkqVq2IlJzSALA"
      decimals="0"
      id="Tc_53OuP03NXUeiYSwewmmnmQ_9_11"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">-5769000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2020_To_9_30_2020_C3Blutz6cUqC03qQKsaYEg"
      decimals="0"
      id="Tc_2ViYsztPHUS7lOQThVOSgg_9_14"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">-5769000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_65fdseHmlkygQFXjdAowrA"
      decimals="INF"
      id="Tc_Sbi3IWlWNEuaaEOPJ-yg8A_10_2"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">18668883</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_65fdseHmlkygQFXjdAowrA"
      decimals="0"
      id="Tc__6vgmdZmwkedG_cW2bYpNA_10_5"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">187000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_NKaGlnEUNkec6voi3tIaYQ"
      decimals="0"
      id="Tc_q8mX919bB0isLWF8bTYSHQ_10_8"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">197510000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MTZvL_NcmESOrJIA_0-1jw"
      decimals="0"
      id="Tc_CcT9GIjstkKpltXQU06m_g_10_11"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">-173078000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2020_zW8zVq9yIEyTGkUsiRdNWQ"
      decimals="0"
      id="Tc_Ph83D4IwNUuAWvxshxPJmg_10_14"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">24619000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_W4e7PNLj70SPGz46YLofww"
      decimals="INF"
      id="Tc_UHl3Eyrm1U26c3xQjHRZ1A_12_2"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">24937826</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_W4e7PNLj70SPGz46YLofww"
      decimals="0"
      id="Tc_alDa_vF3R0uciUbRjxs0YQ_12_5"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">249000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rkFIJlcvhkG9sE5lG-I4MQ"
      decimals="0"
      id="Tc_ljzrcHgk-Eav6FzboDgcQA_12_8"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">219761000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_SPUy-mdqVEWQXJUyR4SwLw"
      decimals="0"
      id="Tc_WZPJkOk0OE-7dM03F4AQ8Q_12_11"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">-191391000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_5jY2Kblz0kWsExJk25jZVg"
      decimals="0"
      id="Tc_PGzQZMf2QUSwMfsi99wTLQ_12_14"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">28619000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DVIyohuaMEqe9vySm_9bHg"
      decimals="INF"
      id="Tc_znOXyFyP70OXT9pAy8NSUA_14_2"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">27383</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9Eff9cku9kikyLYc9MKX0Q"
      decimals="0"
      id="Tc_wKykETz0aUyPVuSBsr4FkQ_14_8"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">86000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_7_1_2021_To_9_30_2021_EHL267Iy5kqlAVaXmlK6uQ"
      decimals="0"
      id="Tc_eTX8mr7wT0utD6ZrTuVU-Q_14_14"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">86000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DVIyohuaMEqe9vySm_9bHg"
      decimals="INF"
      id="Tc_xBohw7PlpE6pSOK7fbKdFw_15_2"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">123</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9Eff9cku9kikyLYc9MKX0Q"
      decimals="0"
      id="Tc_yFi0pQ-5h0yjHBMHVRbWBg_16_8"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">469000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2021_To_9_30_2021_EHL267Iy5kqlAVaXmlK6uQ"
      decimals="0"
      id="Tc_HsePT7Fzl0Km1djc9XHhVw_16_14"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">469000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MAx1Qhihl0-QjfrmaUOYJA"
      decimals="0"
      id="Tc_kN4oBrUwmEuSfjG5jxyuyA_17_11"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">-5419000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2021_To_9_30_2021_EHL267Iy5kqlAVaXmlK6uQ"
      decimals="0"
      id="Tc_Jf_QumuD10WjqENgVOqNGw_17_14"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">-5419000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zJn5M0sFjE-rqqEDYPJ3Uw"
      decimals="INF"
      id="Tc_uhMRwiCNFESEJDC9B82f1A_18_2"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">24965086</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zJn5M0sFjE-rqqEDYPJ3Uw"
      decimals="0"
      id="Tc_hCFnQFFm-UaTbJTcgrJDRw_18_5"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">249000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CnAXtkAfOkyr84AqUZmq-Q"
      decimals="0"
      id="Tc_Nfa43BDOVESIN93J1oqMjA_18_8"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">220316000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BCCyhEU1tEi9VSOL9PeeDA"
      decimals="0"
      id="Tc_sJQeahzMWU2HmaDVEWGgUA_18_11"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">-196810000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA"
      decimals="0"
      id="Tc_ZQ9ktrsS30i6JBMyAC4Vog_18_14"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">23755000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SL0WNDAfdkevFGn-ljnxpQ"
      decimals="INF"
      id="Tc_ANwrvgZwg0a7gLBTg-081Q_6_2"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">9922758</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SL0WNDAfdkevFGn-ljnxpQ"
      decimals="0"
      id="Tc_rROVDWyzWEWYJ-BkxmjCGw_6_5"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">99000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KEkptw3IX0mcgqD8P-u1tQ"
      decimals="0"
      id="Tc_Jx5Q_j4we0y5JSbuhgdjDA_6_8"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">172015000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_I_LPYFq-_Eu5aKaleEMQgQ"
      decimals="0"
      id="Tc_ilhzSMOfTUmEMd_Gyi1Sww_6_11"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">-157521000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_9M2XeqAfdE-lB78H_jYHfQ"
      decimals="0"
      id="Tc_ByBs0_1wjk2v3DDsR7HtTw_6_14"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">14593000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HzaMhmdSwEmOsLQZS5Pg1w"
      decimals="INF"
      id="Tc_ueqA1itMB0ajezdEKGKFxg_7_2"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">8710800</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HzaMhmdSwEmOsLQZS5Pg1w"
      decimals="0"
      id="Tc_zohw2wVwWUu0H4Ql6oWD6Q_7_5"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">87000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VoZ8oQm5tUCLM6PYYrJGCA"
      decimals="0"
      id="Tc_0YJ0fYLwA0m8ASMNj__hSQ_7_8"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">22723000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw"
      decimals="0"
      id="Tc_SqIncy23102yKoKZoFGa1Q_7_14"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">22810000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <armp:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HzaMhmdSwEmOsLQZS5Pg1w"
      decimals="INF"
      id="Tc_B06J15zOXkiupc5MVivrIA_8_2"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">14464</armp:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <armp:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VoZ8oQm5tUCLM6PYYrJGCA"
      decimals="0"
      id="Tc_MlLDxwH0uUyAEWZ7gyT5tg_8_8"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">81000</armp:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <armp:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw"
      decimals="0"
      id="Tc_mSgrTtHNMkyhv6k9ttIdrQ_8_14"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">81000</armp:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <armp:RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HzaMhmdSwEmOsLQZS5Pg1w"
      decimals="INF"
      id="Tc_GATy5arK9U20qDergpOp0A_9_2"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">2511</armp:RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings>
    <armp:RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VoZ8oQm5tUCLM6PYYrJGCA"
      decimals="0"
      id="Tc_4lErt86iF0GPhjp7xmIm6Q_9_8"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">8000</armp:RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings>
    <armp:RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings
      contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw"
      decimals="0"
      id="Tc_Kqb1uIMHuUiWW2PRLW2-cA_9_14"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">8000</armp:RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HzaMhmdSwEmOsLQZS5Pg1w"
      decimals="INF"
      id="Tc_KlW3-0QSDUe5XMOoRbU1Rg_10_2"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">4010</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HzaMhmdSwEmOsLQZS5Pg1w"
      decimals="INF"
      id="Tc_xvwBzfxOIE6Wt5TalVM6Rg_11_2"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">27382</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HzaMhmdSwEmOsLQZS5Pg1w"
      decimals="0"
      id="Tc_zi3KC1LIiE63bY2xLnz9pw_11_5"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VoZ8oQm5tUCLM6PYYrJGCA"
      decimals="0"
      id="Tc_M7Zbmk9V3EePezIgB7_XmQ_11_8"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">86000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw"
      decimals="0"
      id="Tc_mbKz5xZ5Sk-oH64wS0kybw_11_14"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">87000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VoZ8oQm5tUCLM6PYYrJGCA"
      decimals="0"
      id="Tc_At0D1D17CUWpEGbayIqIZg_12_8"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">2613000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw"
      decimals="0"
      id="Tc_3S9ftvw7E02g4r_NLnrCjw_12_14"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">2613000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_UxaVXkDGlUCs8nQaDlXZoQ"
      decimals="0"
      id="Tc_55e6e30OWEmfs0xyXb3HxQ_13_11"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">-15557000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw"
      decimals="0"
      id="Tc_gvCOF8lz3E2logY4z9AzwQ_13_14"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">-15557000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_65fdseHmlkygQFXjdAowrA"
      decimals="INF"
      id="Tc_B2tzdLHMGkC0i8A3vjxmbA_14_2"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">18668883</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_65fdseHmlkygQFXjdAowrA"
      decimals="0"
      id="Tc_nG6k6BwvHEyQ5ImX_Pa3-Q_14_5"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">187000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_NKaGlnEUNkec6voi3tIaYQ"
      decimals="0"
      id="Tc_Pr6dJ2ylpk6FRyWzrP1-Kw_14_8"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">197510000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MTZvL_NcmESOrJIA_0-1jw"
      decimals="0"
      id="Tc_k6YyXbp5h0yCSQsT7Go2vA_14_11"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">-173078000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2020_zW8zVq9yIEyTGkUsiRdNWQ"
      decimals="0"
      id="Tc_FFc6wYKUgU-1-mD5oK6Ifw_14_14"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">24619000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_d2NNZnl0VUWMFpJen2dwnw"
      decimals="INF"
      id="Tc_R-EoC0dlCkeazyxwpAbtMA_16_2"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">18688461</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_d2NNZnl0VUWMFpJen2dwnw"
      decimals="0"
      id="Tc_lw5LYPtp5kq8ZomeHlGHRw_16_5"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">187000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_nIezyXT0BUyf5xGYCsZfTA"
      decimals="0"
      id="Tc_Gk9MxZ8lYUuSa8FOwncEFw_16_8"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">198372000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_KEunbq8Lv0G2CGYZpXLKlA"
      decimals="0"
      id="Tc_EVBslbVzZ0KXPjjTvsW7Fw_16_11"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">-179702000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg"
      decimals="0"
      id="Tc_zHEIE6XIT0mcHMmQs031zA_16_14"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">18857000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Rmv1hE9bF0aKaK_8FzTl-Q"
      decimals="INF"
      id="Tc_02WWOs0pAk2vdTEG48EZWA_17_2"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">6153847</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Rmv1hE9bF0aKaK_8FzTl-Q"
      decimals="0"
      id="Tc_n1NT_hiPG0a_WTiEOv8eIg_17_5"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">61000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VJKQAeK86kCfqs_DrKEH6g"
      decimals="0"
      id="Tc__cj5P3iKKEevnwS3DfY3GA_17_8"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">19302000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      decimals="0"
      id="Tc_JZPBQCR8IEG0aMmxJoofmQ_17_14"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">19363000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <armp:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Rmv1hE9bF0aKaK_8FzTl-Q"
      decimals="INF"
      id="Tc_evZ10KAAmEqUhHN5Q8uSGg_18_2"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">52000</armp:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <armp:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Rmv1hE9bF0aKaK_8FzTl-Q"
      decimals="0"
      id="Tc_0O3v-VNjjkyISE5RtMF90Q_18_5"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">1000</armp:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <armp:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VJKQAeK86kCfqs_DrKEH6g"
      decimals="0"
      id="Tc_szaPBAYnCkuIkmELcBDOuA_18_8"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">290000</armp:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <armp:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      decimals="0"
      id="Tc_xJfZu34hGUWUv6rDZ6Eqtg_18_14"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">291000</armp:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <armp:RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Rmv1hE9bF0aKaK_8FzTl-Q"
      decimals="INF"
      id="Tc_G0D4inYtRUOQuKza4qLDdw_19_2"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">25424</armp:RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings>
    <armp:RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VJKQAeK86kCfqs_DrKEH6g"
      decimals="0"
      id="Tc_QqtzvBUf3kieXBPFMv_ewg_19_8"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">106000</armp:RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings>
    <armp:RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      decimals="0"
      id="Tc_OkbUFCEASU2tG6aplDYQrg_19_14"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">106000</armp:RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Rmv1hE9bF0aKaK_8FzTl-Q"
      decimals="INF"
      id="Tc_yqaa1IjnT02JKwIMPZJ5ww_20_2"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">1047</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Rmv1hE9bF0aKaK_8FzTl-Q"
      decimals="INF"
      id="Tc_TLkFf199QEy6g4XeAyXfuQ_21_2"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">73517</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VJKQAeK86kCfqs_DrKEH6g"
      decimals="0"
      id="Tc_QgLyOpBzzkqtB2pbK7rEzw_21_8"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">240000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      decimals="0"
      id="Tc_614K-_JzoEKD-o3KvBUVRA_21_14"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">240000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <armp:StockIssuedDuringPeriodSharesInducementStockAwards
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Rmv1hE9bF0aKaK_8FzTl-Q"
      decimals="INF"
      id="Tc_nmntK40O5UWVwdo47eBKrw_22_2"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">23732</armp:StockIssuedDuringPeriodSharesInducementStockAwards>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VJKQAeK86kCfqs_DrKEH6g"
      decimals="0"
      id="Tc_F6RcVMt5zUSX33qeKVJejQ_23_8"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">2218000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      decimals="0"
      id="Tc_en2TNaE2NUWTkIjZJ8ifmA_23_14"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">2218000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7TWvDwySBEWUWI9x7ArVBg"
      decimals="0"
      id="Tc_ec4LO8pBcEeTjNu0VpCMjA_24_11"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">-17108000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      decimals="0"
      id="Tc_RN59CeLl6ki0qwqkJiPIzw_24_14"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">-17108000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zJn5M0sFjE-rqqEDYPJ3Uw"
      decimals="INF"
      id="Tc_gQHweL8yL0CWyCGBxqrw6w_25_2"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">24965086</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zJn5M0sFjE-rqqEDYPJ3Uw"
      decimals="0"
      id="Tc_4394SgzM_06GmM-bD2CDIg_25_5"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">249000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CnAXtkAfOkyr84AqUZmq-Q"
      decimals="0"
      id="Tc_mOFySPSW1U-S7mW6uFUVvA_25_8"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">220316000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BCCyhEU1tEi9VSOL9PeeDA"
      decimals="0"
      id="Tc_cjSl9qGP9kuJ6pwOhBrvBg_25_11"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">-196810000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA"
      decimals="0"
      id="Tc_wYnpevHwV0Kas_eLM6IuuQ_25_14"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">23755000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      decimals="0"
      id="Tc_cUvHttQn0UCwQUq9NxLw0A_5_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">-17108000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw"
      decimals="0"
      id="Tc_63CLJCaEuEK8sPOURke5LA_5_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">-15557000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      decimals="0"
      id="Tc_9aHrxut2MUCfoUGVAcPTwg_7_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">892000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw"
      decimals="0"
      id="Tc_QAJd8A6_hkKr_28NWcephQ_7_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">840000</us-gaap:Depreciation>
    <armp:GainLossOnExtinguishmentOfPaycheckProtectionProgramLoan
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      decimals="0"
      id="Tc_kgwGiPb-mkmcVg8u9Fl44Q_8_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">722000</armp:GainLossOnExtinguishmentOfPaycheckProtectionProgramLoan>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      decimals="0"
      id="Tc_rwEgsS6uhEu8PlElRpmVNA_9_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">2218000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw"
      decimals="0"
      id="Tc_4EvkYNcvAU2ZdsWRnW-Yrg_9_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">2613000</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherNoncashExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      decimals="0"
      id="Tc_UXL1oEaJv0i7NBU-7evwuw_10_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">60000</us-gaap:OtherNoncashExpense>
    <us-gaap:OtherNoncashExpense
      contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw"
      decimals="0"
      id="Tc_hCx6yuRisU2o_1ryEkMiVg_10_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">457000</us-gaap:OtherNoncashExpense>
    <armp:AccruedInterestForDeferredConsiderationOnAssetAcquisition
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      decimals="0"
      id="Tc_QNZuGRkkQU-MsyLJAMKrAA_11_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">586000</armp:AccruedInterestForDeferredConsiderationOnAssetAcquisition>
    <armp:IncreaseDecreaseInAwardReceivable
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      decimals="0"
      id="Tc_cwMOVjbeF0CEIzcZdCfong_13_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">690000</armp:IncreaseDecreaseInAwardReceivable>
    <armp:IncreaseDecreaseInAwardReceivable
      contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw"
      decimals="0"
      id="Tc_a-KiT0Xp2E-aG4kA7YcBiw_13_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">241000</armp:IncreaseDecreaseInAwardReceivable>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      decimals="0"
      id="Tc_GNze7TFZ0Eyl-UQKFdOefA_14_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">-100000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw"
      decimals="0"
      id="Tc_jA9RV4JZrU-kQqTvHoe5XA_14_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">492000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredCompensation
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      decimals="0"
      id="Tc_L2zMfW_PhkKea_DfLQzL3Q_15_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">1151000</us-gaap:IncreaseDecreaseInDeferredCompensation>
    <us-gaap:IncreaseDecreaseInDeferredCompensation
      contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw"
      decimals="0"
      id="Tc_a9Ry0b0Un0iyI5Gi9IHFEg_15_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">-21000</us-gaap:IncreaseDecreaseInDeferredCompensation>
    <armp:IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      decimals="0"
      id="Tc_7A11xK5z4EWndjlEXqGFew_16_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">145000</armp:IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet>
    <armp:IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet
      contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw"
      decimals="0"
      id="Tc_SyBG0v0AV0uBdY1hfVlJ5Q_16_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">611000</armp:IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      decimals="0"
      id="Tc_A5Piu5kXXEOOWBy5Ro1azg_17_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">237000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw"
      decimals="0"
      id="Tc_wHCN5WbRvEm6L0_-3yoOVw_17_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">1162000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      decimals="0"
      id="Tc_S_pgfwxiukqEtcwOyCAACg_18_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">-14977000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw"
      decimals="0"
      id="Tc_VnDHgC55C0WRRH6pCinl6Q_18_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">-11968000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      decimals="0"
      id="Tc_jlGdhNtoNk6Yvw79hu4UZQ_20_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">1076000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw"
      decimals="0"
      id="Tc_-tsEyVC940mEYWVc4sTUbQ_20_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">458000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      decimals="0"
      id="Tc_kBK2GxMhykSV8IlXN8bf-A_21_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">-1076000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw"
      decimals="0"
      id="Tc_xEOO7S24jkymXGEFK5r6_w_21_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">-458000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      decimals="0"
      id="Tc_E6c2qPyHqkOh9R4x1sLgAQ_23_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">-1414000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw"
      decimals="0"
      id="Tc_xjpGqp_ookmKvsgHUVJ00Q_23_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">-1000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <armp:ProceedsFromPaycheckProtectionProgram
      contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw"
      decimals="0"
      id="Tc_OVC3gVKnZ0-6Bzrega42JQ_24_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">717000</armp:ProceedsFromPaycheckProtectionProgram>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      decimals="0"
      id="Tc_BVCFrAC1Wk-gepnIMWVXEQ_25_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">19363000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw"
      decimals="0"
      id="Tc_7ETSF2GrikOMAqGdH_k-Lw_25_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">22893000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <armp:ProceedsFromExerciseOfWarrantsAndStockOptions
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      decimals="0"
      id="Tc_D_CltQ92J0mckMbwdQKBbA_26_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">531000</armp:ProceedsFromExerciseOfWarrantsAndStockOptions>
    <armp:ProceedsFromExerciseOfWarrantsAndStockOptions
      contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw"
      decimals="0"
      id="Tc_QvyOUohFNE6hmLBmpRvapQ_26_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">168000</armp:ProceedsFromExerciseOfWarrantsAndStockOptions>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      decimals="0"
      id="Tc_V16qHFk89kqS27oERucNiw_27_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">18480000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw"
      decimals="0"
      id="Tc_ZyOExLw3kEq-RaxQRCnlsA_27_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">22778000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      decimals="0"
      id="Tc_Zt6iuoxRs0aX9q2T6aIS4w_28_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">2427000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw"
      decimals="0"
      id="Tc_TU6FtHV_IkWMrXHy6XuQ4g_28_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">10352000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg"
      decimals="0"
      id="Tc_lpjPrUIbrES5C9Ptg3h4kQ_29_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">10849000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2019_9M2XeqAfdE-lB78H_jYHfQ"
      decimals="0"
      id="Tc_hBFWpDn_eUOQmoTA62WjSQ_29_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">6733000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA"
      decimals="0"
      id="Tc_Ex_YwdcDi0ipS6pTfHBekg_30_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">13276000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2020_zW8zVq9yIEyTGkUsiRdNWQ"
      decimals="0"
      id="Tc_wtMi0QB670SD9wPwN-RcvQ_30_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">17085000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <armp:ForgivenessRelatedToPaycheckProtectionProgram
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      decimals="0"
      id="Tc_8XXFBkAR0kyTpCj16D5gig_32_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">722000</armp:ForgivenessRelatedToPaycheckProtectionProgram>
    <armp:OfferingCostsIncludedInAccountsPayable
      contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw"
      decimals="0"
      id="Tc_q09L2sd-ekGfSZBsCOjyng_33_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">65000</armp:OfferingCostsIncludedInAccountsPayable>
    <us-gaap:ContributionOfProperty
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      decimals="0"
      id="Tc_kxuKDFihxku8_Ox9tAxhBw_34_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">124000</us-gaap:ContributionOfProperty>
    <us-gaap:ContributionOfProperty
      contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw"
      decimals="0"
      id="Tc_EBlYHpChCEiDoFVerimOCg_34_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">145000</us-gaap:ContributionOfProperty>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA"
      decimals="0"
      id="Tc_-vtMnKuqF0CZYGWoEV52JQ_3_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">12076000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2020_zW8zVq9yIEyTGkUsiRdNWQ"
      decimals="0"
      id="Tc_SagYOq01GUevs5yMb2FN_Q_3_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">15885000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA"
      decimals="0"
      id="Tc_WKfb3p34PEyfRCcdRLcPBg_4_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">1200000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_9_30_2020_zW8zVq9yIEyTGkUsiRdNWQ"
      decimals="0"
      id="Tc_UP0GLmDl7Ui4RTzy7XCFGw_4_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">1200000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA"
      decimals="0"
      id="Tc_80qu_Wixjk6GRjjZJY1jPA_5_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">13276000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2020_zW8zVq9yIEyTGkUsiRdNWQ"
      decimals="0"
      id="Tc_pQPQ5IliPEmLWyP8en7bSw_5_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">17085000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Tb__6J39S74W0SX-pHMaZeOEg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;1. Organization and Description of the Business&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Armata Pharmaceuticals,&#160;Inc. (&#x201c;Armata&#x201d;, and together with its subsidiaries referred to herein as, the &#x201c;Company&#x201d;) is a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The Company was created as a result of a business combination between C3J Therapeutics, Inc. (&#x201c;C3J&#x201d;), a Washington corporation, and AmpliPhi Biosciences Corporation (&#x201c;AmpliPhi&#x201d;) that closed on May 9, 2019, where Ceres Merger Sub, Inc., a wholly owned subsidiary of AmpliPhi, merged with and into C3J (the&#160;&#x201d;Merger&#x201d;), with C3J surviving the Merger as a wholly owned subsidiary of AmpliPhi. Immediately prior to the closing of the Merger, AmpliPhi changed its name to Armata Pharmaceuticals, Inc. Armata&#x2019;s common stock is traded on the NYSE American exchange under the ticker symbol &#x201c;ARMP&#x201d;.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Tb_nbFZHg30Vkyqku2AcH7bVw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;2. Liquidity&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has prepared its consolidated financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. However, the Company has incurred net losses since its inception and has negative operating cash flows. These circumstances raise substantial doubt about the Company&#x2019;s ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty concerning the Company&#x2019;s ability to continue as a going concern.&lt;/p&gt;&lt;p style="-sec-ix-redline:true;font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman','Times','serif';"&gt;On October 28, 2021, the Company entered into a securities purchase agreement (the &#x201c;October 2021 Securities Purchase Agreement&#x201d;) with the Cystic Fibrosis Foundation, a Delaware corporation (&#x201c;CFF&#x201d;), the Company&#x2019;s partner for its lead Phase 1b/2 clinical development program, and Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc. (Nasdaq: INVA) (collectively, &#x201c;Innoviva&#x201d;) for the private placement of newly issued shares of common stock, par value &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman','Times','serif';"&gt;$0.01&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman','Times','serif';"&gt; per share, of the Company (&#x201c;Common Stock&#x201d;). Pursuant to the October 2021 Securities Purchase Agreement, the Company issued and sold &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman','Times','serif';"&gt;909,091&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman','Times','serif';"&gt; shares to CFF and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman','Times','serif';"&gt;1,212,122&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman','Times','serif';"&gt; shares to Innoviva, each at a per share price of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman','Times','serif';"&gt;$3.30&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman','Times','serif';"&gt; (the &#x201c;October 2021 Private Placements&#x201d;). The Company received aggregate gross proceeds from the October 2021 Private Placements of approximately &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman','Times','serif';"&gt;$7.0&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman','Times','serif';"&gt; million, before deducting transaction expenses&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt; On January&#160;26, 2021, the Company entered into a securities purchase agreement (the &#x201c;January 2021 Securities Purchase Agreement&#x201d;) with &lt;span style="background-color:#ffffff;"&gt;Innoviva, &lt;/span&gt;pursuant to which the Company agreed to issue and sell to Innoviva, in a private placement, up to 6,153,847 newly issued shares of Common Stock, and warrants (the &#x201c;Common Warrants&#x201d;) to purchase up to 6,153,847 shares of Common Stock, with an exercise price per share of $3.25 (the &#x201c;January 2021 Private Placement&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The January 2021 Private Placement closed in two tranches. On January&#160;26, 2021 and concurrently with entering into the January 2021 Securities Purchase Agreement, the Company completed the first tranche (the &#x201c;First Closing&#x201d;) of the January 2021 Private Placement. At the First Closing,&#160;Innoviva purchased 1,867,912 shares of Common Stock and Common Warrants to purchase 1,867,912 shares of common stock, for an aggregate purchase price of approximately $6.1 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;At the closing of the second tranche (the &#x201c;Second Closing&#x201d;), which was approved by the Company&#x2019;s stockholders,&#160;Innoviva purchased 4,285,935 shares of Common Stock and Common Warrants to purchase 4,285,935 shares of Common Stock for an aggregate purchase price of $13.9 million. The Second Closing was completed on March 17, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;On March 27, 2020, the Company completed a private placement transaction and sold to Innoviva Inc. 8,710,800 newly issued shares of Common Stock and warrants to purchase 8,710,800 shares of common stock, with an exercise &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;price per share of $2.87 (the &#x201c;2020 Private Placement&#x201d;). Each share of common stock was sold together with one common warrant granting the warrant holder the right to purchase an additional share of common stock at $2.87 per share. The 2020 Private Placement was closed in two tranches raising total gross proceeds of $25.0 million.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of September 30, 2021, the Company had cash and cash equivalents of $12.1 million. Considering the Company&#x2019;s current cash resources, management believes the Company&#x2019;s existing resources will be sufficient to fund the Company&#x2019;s planned operations into the first quarter of 2022. For the foreseeable future, the Company&#x2019;s ability to continue its operations is dependent upon its ability to obtain additional capital.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Management plans to raise additional capital through equity offerings, debt financings, or other capital sources, including potential collaborations, licenses and other similar arrangements. While management believes this plan to raise additional funds will alleviate the conditions that raise substantial doubt, these plans are not entirely within its control and cannot be assessed as being probable of occurring. The Company&#x2019;s ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic. The Company may not be able to secure additional financing in a timely manner or on favorable terms, if at all. Furthermore, if the Company issues equity securities to raise additional funds, its existing stockholders may experience dilution, and the new equity securities may have rights, preferences and privileges senior to those of the Company&#x2019;s existing stockholders. If the Company raises additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to its potential products on terms that are not favorable to the Company. If the Company is unable to raise capital when needed or on attractive terms, it would be forced to delay, reduce or eliminate its research and development programs or other operations. If any of these events occur, the Company&#x2019;s ability to achieve the development and commercialization goals would be adversely affected.&lt;/p&gt;</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <armp:LiquidityAndGoingConcernPolicyTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Tb_oJNMjFGvD0qXqncsA1rwjg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has prepared its consolidated financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. However, the Company has incurred net losses since its inception and has negative operating cash flows. These circumstances raise substantial doubt about the Company&#x2019;s ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty concerning the Company&#x2019;s ability to continue as a going concern.&lt;/p&gt;&lt;p style="-sec-ix-redline:true;font-family:&amp;quot;'Times New Roman','Times','serif'&amp;quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman','Times','serif';"&gt;On October 28, 2021, the Company entered into a securities purchase agreement (the &#x201c;October 2021 Securities Purchase Agreement&#x201d;) with the Cystic Fibrosis Foundation, a Delaware corporation (&#x201c;CFF&#x201d;), the Company&#x2019;s partner for its lead Phase 1b/2 clinical development program, and Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc. (Nasdaq: INVA) (collectively, &#x201c;Innoviva&#x201d;) for the private placement of newly issued shares of common stock, par value &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman','Times','serif';"&gt;$0.01&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman','Times','serif';"&gt; per share, of the Company (&#x201c;Common Stock&#x201d;). Pursuant to the October 2021 Securities Purchase Agreement, the Company issued and sold &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman','Times','serif';"&gt;909,091&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman','Times','serif';"&gt; shares to CFF and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman','Times','serif';"&gt;1,212,122&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman','Times','serif';"&gt; shares to Innoviva, each at a per share price of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman','Times','serif';"&gt;$3.30&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman','Times','serif';"&gt; (the &#x201c;October 2021 Private Placements&#x201d;). The Company received aggregate gross proceeds from the October 2021 Private Placements of approximately &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman','Times','serif';"&gt;$7.0&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman','Times','serif';"&gt; million, before deducting transaction expenses&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt; On January&#160;26, 2021, the Company entered into a securities purchase agreement (the &#x201c;January 2021 Securities Purchase Agreement&#x201d;) with &lt;span style="background-color:#ffffff;"&gt;Innoviva, &lt;/span&gt;pursuant to which the Company agreed to issue and sell to Innoviva, in a private placement, up to 6,153,847 newly issued shares of Common Stock, and warrants (the &#x201c;Common Warrants&#x201d;) to purchase up to 6,153,847 shares of Common Stock, with an exercise price per share of $3.25 (the &#x201c;January 2021 Private Placement&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The January 2021 Private Placement closed in two tranches. On January&#160;26, 2021 and concurrently with entering into the January 2021 Securities Purchase Agreement, the Company completed the first tranche (the &#x201c;First Closing&#x201d;) of the January 2021 Private Placement. At the First Closing,&#160;Innoviva purchased 1,867,912 shares of Common Stock and Common Warrants to purchase 1,867,912 shares of common stock, for an aggregate purchase price of approximately $6.1 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;At the closing of the second tranche (the &#x201c;Second Closing&#x201d;), which was approved by the Company&#x2019;s stockholders,&#160;Innoviva purchased 4,285,935 shares of Common Stock and Common Warrants to purchase 4,285,935 shares of Common Stock for an aggregate purchase price of $13.9 million. The Second Closing was completed on March 17, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;On March 27, 2020, the Company completed a private placement transaction and sold to Innoviva Inc. 8,710,800 newly issued shares of Common Stock and warrants to purchase 8,710,800 shares of common stock, with an exercise &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;price per share of $2.87 (the &#x201c;2020 Private Placement&#x201d;). Each share of common stock was sold together with one common warrant granting the warrant holder the right to purchase an additional share of common stock at $2.87 per share. The 2020 Private Placement was closed in two tranches raising total gross proceeds of $25.0 million.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of September 30, 2021, the Company had cash and cash equivalents of $12.1 million. Considering the Company&#x2019;s current cash resources, management believes the Company&#x2019;s existing resources will be sufficient to fund the Company&#x2019;s planned operations into the first quarter of 2022. For the foreseeable future, the Company&#x2019;s ability to continue its operations is dependent upon its ability to obtain additional capital.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Management plans to raise additional capital through equity offerings, debt financings, or other capital sources, including potential collaborations, licenses and other similar arrangements. While management believes this plan to raise additional funds will alleviate the conditions that raise substantial doubt, these plans are not entirely within its control and cannot be assessed as being probable of occurring. The Company&#x2019;s ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic. The Company may not be able to secure additional financing in a timely manner or on favorable terms, if at all. Furthermore, if the Company issues equity securities to raise additional funds, its existing stockholders may experience dilution, and the new equity securities may have rights, preferences and privileges senior to those of the Company&#x2019;s existing stockholders. If the Company raises additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to its potential products on terms that are not favorable to the Company. If the Company is unable to raise capital when needed or on attractive terms, it would be forced to delay, reduce or eliminate its research and development programs or other operations. If any of these events occur, the Company&#x2019;s ability to achieve the development and commercialization goals would be adversely affected.&lt;/p&gt;</armp:LiquidityAndGoingConcernPolicyTextBlock>
    <us-gaap:SubstantialDoubtAboutGoingConcernManagementsEvaluation
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Narr_sYlOfWmxGE6p4oL3t_Ra6Q">The Company has prepared its consolidated financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. However, the Company has incurred net losses since its inception and has negative operating cash flows. These circumstances raise substantial doubt about the Company&#x2019;s ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty concerning the Company&#x2019;s ability to continue as a going concern.</us-gaap:SubstantialDoubtAboutGoingConcernManagementsEvaluation>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_10_28_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_tDI9aHgnU02SEE2i4-rltw"
      decimals="2"
      id="Narr_od8vMjiKM02w9px2h5kbYw"
      unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_10_28_2021_To_10_28_2021_srt_CounterpartyNameAxis_armp_CysticFibrosisFoundationMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_r2L1o1zLc0ewvdxbb5OLYQ"
      decimals="0"
      id="Narr_nSo0ER5PyEu89q22RAF6bA"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">909091</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_10_28_2021_To_10_28_2021_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_j_mhEXexkkyt_KqjZVElLw"
      decimals="0"
      id="Narr_3g0S0k5CVkSCnYrLcMgMDQ"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">1212122</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_10_28_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_XMDfJAOuaESQwElJtiy_ew"
      decimals="2"
      id="Narr_O8L2vb50bUujTZT-1W8duQ"
      unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q">3.30</us-gaap:SharesIssuedPricePerShare>
    <armp:ProceedsFromEquityOfferingsGross
      contextRef="Duration_10_28_2021_To_10_28_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_46a9XzfZPkSGKc4-ttN9fw"
      decimals="-5"
      id="Narr_wBgbJVci10uwaCuRlp5aBw"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">7000000.0</armp:ProceedsFromEquityOfferingsGross>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_26_2021_To_1_26_2021_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_z5LGiY7OL0Scv3M4U-b1Wg"
      decimals="INF"
      id="Narr_k7fXWDNhtka4x6j-RBhfxw"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">6153847</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_1_26_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_z1sUig3BpUiBHLBYltqXRg"
      decimals="INF"
      id="Narr_dOOmcPIyvkWs13whT1P1EA"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">6153847</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_1_26_2021_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_zFjpWhEkUkiNbRFtUmSseg"
      decimals="2"
      id="Narr_YwFI9MX1Akii8mXhVICHtw"
      unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q">3.25</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_26_2021_To_1_26_2021_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementFirstTrancheMember_vU5i9LO2uU6jsVJ4911Zlg"
      decimals="INF"
      id="Narr_HLj_2jeSUEWT695u5p_93g"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">1867912</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_1_26_2021_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementFirstTrancheMember_4VDPa4otSk6JCKDKNZvQ0w"
      decimals="INF"
      id="Narr_gf89xAEJJ02pmp8IdkO7_g"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">1867912</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="Duration_1_26_2021_To_1_26_2021_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementFirstTrancheMember_wOZbvf2jHEW62lNLQlwkHw"
      decimals="-5"
      id="Narr_AvhxNk2DfEePRuvEzY2J1A"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">6100000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_3_17_2021_To_3_17_2021_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementSecondTrancheMember_7NUySWdWyU2T6PeqoKx_hg"
      decimals="INF"
      id="Narr_bBTI05xw2kaRC61JofhUqw"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">4285935</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_3_17_2021_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementSecondTrancheMember_8WtQB3s-wk2b0we6rBXeVg"
      decimals="INF"
      id="Narr_l_fTbsTA_k6PdHL-SRJx4w"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">4285935</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="Duration_3_17_2021_To_3_17_2021_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementSecondTrancheMember_OI9uPwtYu02QjGR7dFobAA"
      decimals="-5"
      id="Narr_6xZ0ywZtsk6fnC4i9Y1sug"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">13900000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_27_2020_To_3_27_2020_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_tEurHl-WuEy8GrS4QYXwGQ"
      decimals="INF"
      id="Narr_n6oowjca5EKc4SaG43fDZQ"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">8710800</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_3_27_2020_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_VI0dYZLlxkey_j7O6lL4cA"
      decimals="INF"
      id="Narr_-05Hy1DPtU2XmWENdbX1zQ"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">8710800</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_3_27_2020_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_9mH04W5WikCikSJLnqxw9w"
      decimals="2"
      id="Narr_hiJq-enCtkiTN3e0bE4Vzw"
      unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q">2.87</us-gaap:SharesIssuedPricePerShare>
    <armp:NumberOfCommonWarrantsSoldPerShareOfCommonStock
      contextRef="Duration_3_27_2020_To_3_27_2020_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_NmhuJtI8WkCb1aWkNG0-5Q"
      decimals="INF"
      id="Narr_YrDA87WcXkiyX2ObUBns2g"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">1</armp:NumberOfCommonWarrantsSoldPerShareOfCommonStock>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_3_27_2020_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_9mH04W5WikCikSJLnqxw9w"
      decimals="2"
      id="Narr_nTACFhgpgUW7n_jE3lCS9w"
      unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q">2.87</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="Duration_1_27_2020_To_3_27_2020_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_9V8h1NEgnkCy2Hyg6zq7fg"
      decimals="-5"
      id="Narr_puAQqwJPXEKFZK1kkFGGvg"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">25000000.0</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA"
      decimals="-5"
      id="Narr_1_b2hGKH_Umpi51fluAjIQ"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">12100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Tb_GH-bTE2pIkmQCNEyUwleXQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;3. Significant Accounting Policies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The consolidated financial statements include the accounts of Armata and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated. The accompanying unaudited condensed consolidated financial statements of the Company should be read in conjunction with the audited financial statements and accompanying notes thereto as of and for the year ended December 31, 2020&#160;included in the Company&#x2019;s Form 10-K, filed with the U.S. Securities and Exchange Commission on March 18, 2021. The accompanying unaudited financial statements have been prepared in conformity with accounting principles generally accepted&#160;in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial statements. Any reference in the Notes to applicable guidance is meant to refer to authoritative U.S. GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In the opinion of management, the accompanying consolidated financial statements include all adjustments that are of a normal and recurring nature and that are necessary for the fair presentation of the Company&#x2019;s financial position and the results of its operations and cash flows for the periods presented. Interim results are not necessarily indicative of results for the full year or any future period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in its consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates these estimates and judgments, which are based on historical and anticipated results and trends, and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management&#x2019;s estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Fair Value of Financial Instruments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The carrying amounts of cash equivalents, other current assets, accounts payable, and accrued liabilities approximate fair value because of the short-term nature of these instruments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;In-Process Research and Development (&#x201c;IPR&amp;amp;D&#x201d;) &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:13.2pt;margin:0pt;"&gt;IPR&amp;amp;D assets are intangible assets with indefinite lives and are not subject to amortization. The Company&#x2019;s IPR&amp;amp;D assets represent capitalized incomplete research projects that the Company acquired through the Merger, which is related to the development of AP-SA01, a phage combination for the treatment of &lt;i style="font-style:italic;"&gt;Staphylococcus aureus&lt;/i&gt; infections (&#x201c;&lt;i style="font-style:italic;"&gt;S. aureus&lt;/i&gt;&#x201d;). Such assets are initially measured at their acquisition-date fair values and are subject to impairment testing at least annually until completion or abandonment of research and development efforts associated with the projects. Upon successful completion of each project, the Company makes a determination as to the then remaining useful life of the intangible asset and begins amortization. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Goodwill&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:13.2pt;margin:0pt;"&gt;Goodwill, which has an indefinite useful life, represents the excess of purchase consideration over fair value of net assets acquired. Goodwill is not subject to amortization and is required to be tested for impairment at least on an annual basis. The Company tests goodwill for impairment as of December 31 of each year. The Company determines whether goodwill may be impaired by comparing the carrying value of the single reporting unit, including goodwill, to the fair value of the reporting unit. If the fair value is less than the carrying amount, a more detailed analysis is performed to determine whether goodwill is impaired. The impairment loss, if any, is measured as the excess of the carrying value of the goodwill over the implied fair value of the goodwill and is recorded in the Company&#x2019;s consolidated statements of operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:13.2pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Settlement of Zero-coupon Debt Instrument &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;      &lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;white-space:pre-wrap;"&gt;The Company&#x2019;s deferred purchase consideration arrangement with Synthetic Genomics (Note 11) does not have a stated interest rate.  Upon repayment of deferred purchase consideration, the Company classifies the portion attributable to accreted interest as a cash outflow for operating activities, and the portion relating to principal as a cash outflow for financing activities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Basic and Diluted Net Loss per Share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Net earnings or loss per share (&#x201c;EPS&#x201d;) is calculated in accordance with the applicable accounting guidance provided in ASC 260,&#160;&lt;i style="font-style:italic;"&gt;Earnings per Share.&#160;&lt;/i&gt;The Company uses the two-class method for the computation and presentation of net income (loss) per common share attributable to common stockholders. The two-class method is an earnings allocation formula that calculates basic and diluted net income (loss) per common share for each class of common stock separately based on dividends declared and participation rights in undistributed earnings as if all such earnings had been distributed during the period. Under the two-class method, warrants issued to Innoviva are assumed to participate in undistributed earnings on an as-exercised basis, in accordance with the warrant agreements. Undistributed net losses are allocated entirely to common shareholders since the participating security has no contractual obligation to share in the losses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Accordingly, basic income or loss per share is calculated by dividing net income or loss by the weighted-average number of common shares outstanding, or using the two-class method, whichever is more dilutive.&#160;&#160;Diluted net income or loss per share is computed using the more dilutive of the treasury stock method which reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted to common stock, or the two-class method. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The calculation of diluted loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of liability classified warrants, and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to net loss available to common stockholders used in the calculation is required to remove the change in fair value of the warrants from the numerator for the period. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any, under the treasury stock method. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Grants and Awards&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;        In applying the provisions of ASC Topic 606, &lt;/span&gt;&lt;i style="font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/i&gt; (&#x201c;ASC 606&#x201d;)&lt;i style="font-style:italic;"&gt;, &lt;/i&gt;Armata has determined that grants and awards are out of the scope of ASC 606 because the funding entities do not meet the definition of a &#x201c;customer&#x201d;, as defined by ASC 606, as there is not considered to be a transfer of control of goods or services. With respect to each grant or award, the Company determines if it has a collaboration in accordance with ASC Topic 808, &lt;i style="font-style:italic;"&gt;Collaborative Arrangements&lt;/i&gt; (&#x201c;ASC 808&#x201d;). To the extent the grant or award is within the scope of ASC 808, the Company recognizes amounts received as a contra-expense or grant revenue on the consolidated statement of operations when the related research and development expenses are incurred. For grant and awards outside the scope of ASC 808, the Company applies ASC 606 or International Accounting Standards No. 20, &lt;i style="font-style:italic;"&gt;Accounting for Government Grants and Disclosure of Government Assistance&lt;/i&gt;, by analogy, and revenue is recognized when the Company incurs expenses related to the grants for the amount the Company is entitled to under the provisions of the contract. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:27pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;        Armata also considers the guidance in ASC Topic 730, &lt;/span&gt;&lt;i style="font-style:italic;"&gt;Research and Development &lt;/i&gt;(&#x201c;ASC 730&#x201d;), which requires an assessment, at the inception of the grant or award, of whether the agreement is a liability&lt;i style="font-style:italic;"&gt;. &lt;/i&gt;If Armata is obligated to repay funds received regardless of the outcome of the related research and development activities, then Armata is required to estimate and recognize that liability. Alternatively, if Armata is not required to repay the funds, then payments received are recorded as revenue or contra-expense as the expenses are incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:27pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;       Deferred grant or award liability represents award funds received or receivable for which the allowable expenses have not yet been incurred as of the balance sheet date.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:27pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Research and Development Expenses&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Research and development (&#x201c;R&amp;amp;D&#x201d;) costs consist primarily of direct and allocated salaries, incentive compensation, stock-based compensation and other personnel-related costs, facility costs, and third-party services. Third-party services include studies and clinical trials conducted by clinical research organizations. R&amp;amp;D activities are expensed as incurred. The Company records accruals for estimated ongoing clinical trial expenses. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Judgments and estimates are made in determining the accrued balances at the end of the reporting period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background-color:#ffffff;color:#212529;"&gt;In June 2016, the FASB issued ASU 2016-13,&#160;&lt;/span&gt;&lt;i style="background-color:#ffffff;color:#212529;font-style:italic;"&gt;Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses&lt;/i&gt;&lt;span style="background-color:#ffffff;color:#212529;"&gt;&#160;on Financial Instruments. The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that aren&#x2019;t measured at fair value through net income. For available-for-sale debt securities, entities will be required to recognize an allowance for credit losses rather than a reduction in carrying value of the asset. Entities will no longer be permitted to consider the length of time that fair value has been less than amortized cost when evaluating when credit losses should be recognized.&#160;&lt;/span&gt;This new guidance is effective for calendar-year smaller reporting public entities in the first quarter of 2023. The Company is currently evaluating the impact of this ASU and&#160;&lt;span style="color:#212529;"&gt;does&#160;&lt;/span&gt;not expect that adoption of this standard will have a material impact on its consolidated financial statements or related disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"&gt;In August 2020, the FASB issued &#x200b;ASU No. 2020-06&#x200b;, &#x200b;&lt;i style="font-style:italic;"&gt;Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40)&#x200b; (&#x201c;ASU 2020-06&#x201d;).&lt;/i&gt; &#x200b;ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#x2019;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in ASU &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;2020-06 are effective for the Company as of January 1, 2024. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2020-06 on its financial statements and does not expect the adoption of this ASU to have a material impact on the Company&#x2019;s consolidated financial statements.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Recently Adopted Accounting Standards&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 14pt 0pt;"&gt;In December 2019, the FASB issued ASU 2019-12,&#160;&lt;i style="font-style:italic;"&gt;Income Taxes (&#x201c;ASC 740&#x201d;)&lt;/i&gt;, which simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740 related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill.&#160;The guidance became effective for the Company on January 1, 2021 and the adoption did not have a material impact on its&#160;consolidated financial statements or related disclosures.  &lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Tb_u-hf1hQr2Eq7tCq1RzPYZA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The consolidated financial statements include the accounts of Armata and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated. The accompanying unaudited condensed consolidated financial statements of the Company should be read in conjunction with the audited financial statements and accompanying notes thereto as of and for the year ended December 31, 2020&#160;included in the Company&#x2019;s Form 10-K, filed with the U.S. Securities and Exchange Commission on March 18, 2021. The accompanying unaudited financial statements have been prepared in conformity with accounting principles generally accepted&#160;in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial statements. Any reference in the Notes to applicable guidance is meant to refer to authoritative U.S. GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In the opinion of management, the accompanying consolidated financial statements include all adjustments that are of a normal and recurring nature and that are necessary for the fair presentation of the Company&#x2019;s financial position and the results of its operations and cash flows for the periods presented. Interim results are not necessarily indicative of results for the full year or any future period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Tb_o4Y0UkB6K02uoHHXWOn8NA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in its consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates these estimates and judgments, which are based on historical and anticipated results and trends, and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management&#x2019;s estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Tb_cS_u3kSRC0GSwMyjptUKUw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Fair Value of Financial Instruments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The carrying amounts of cash equivalents, other current assets, accounts payable, and accrued liabilities approximate fair value because of the short-term nature of these instruments.&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:InProcessResearchAndDevelopmentPolicy
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Tb_d_GyFoPEH06op5zfkXc6uw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;In-Process Research and Development (&#x201c;IPR&amp;amp;D&#x201d;) &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:13.2pt;margin:0pt;"&gt;IPR&amp;amp;D assets are intangible assets with indefinite lives and are not subject to amortization. The Company&#x2019;s IPR&amp;amp;D assets represent capitalized incomplete research projects that the Company acquired through the Merger, which is related to the development of AP-SA01, a phage combination for the treatment of &lt;i style="font-style:italic;"&gt;Staphylococcus aureus&lt;/i&gt; infections (&#x201c;&lt;i style="font-style:italic;"&gt;S. aureus&lt;/i&gt;&#x201d;). Such assets are initially measured at their acquisition-date fair values and are subject to impairment testing at least annually until completion or abandonment of research and development efforts associated with the projects. Upon successful completion of each project, the Company makes a determination as to the then remaining useful life of the intangible asset and begins amortization. &lt;/p&gt;</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Tb__lTexhmVdEC3OjDtp3Igpg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Goodwill&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:13.2pt;margin:0pt;"&gt;Goodwill, which has an indefinite useful life, represents the excess of purchase consideration over fair value of net assets acquired. Goodwill is not subject to amortization and is required to be tested for impairment at least on an annual basis. The Company tests goodwill for impairment as of December 31 of each year. The Company determines whether goodwill may be impaired by comparing the carrying value of the single reporting unit, including goodwill, to the fair value of the reporting unit. If the fair value is less than the carrying amount, a more detailed analysis is performed to determine whether goodwill is impaired. The impairment loss, if any, is measured as the excess of the carrying value of the goodwill over the implied fair value of the goodwill and is recorded in the Company&#x2019;s consolidated statements of operations.&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <armp:ZeroCouponDebtInstrumentPolicyTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Tb_X7CYFreUFkuCWS4fKKpvMw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Settlement of Zero-coupon Debt Instrument &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;      &lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;white-space:pre-wrap;"&gt;The Company&#x2019;s deferred purchase consideration arrangement with Synthetic Genomics (Note 11) does not have a stated interest rate.  Upon repayment of deferred purchase consideration, the Company classifies the portion attributable to accreted interest as a cash outflow for operating activities, and the portion relating to principal as a cash outflow for financing activities.&lt;/span&gt;&lt;/p&gt;</armp:ZeroCouponDebtInstrumentPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Tb_In0KbaBOEkmuO0lG1mOLLg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Basic and Diluted Net Loss per Share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Net earnings or loss per share (&#x201c;EPS&#x201d;) is calculated in accordance with the applicable accounting guidance provided in ASC 260,&#160;&lt;i style="font-style:italic;"&gt;Earnings per Share.&#160;&lt;/i&gt;The Company uses the two-class method for the computation and presentation of net income (loss) per common share attributable to common stockholders. The two-class method is an earnings allocation formula that calculates basic and diluted net income (loss) per common share for each class of common stock separately based on dividends declared and participation rights in undistributed earnings as if all such earnings had been distributed during the period. Under the two-class method, warrants issued to Innoviva are assumed to participate in undistributed earnings on an as-exercised basis, in accordance with the warrant agreements. Undistributed net losses are allocated entirely to common shareholders since the participating security has no contractual obligation to share in the losses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Accordingly, basic income or loss per share is calculated by dividing net income or loss by the weighted-average number of common shares outstanding, or using the two-class method, whichever is more dilutive.&#160;&#160;Diluted net income or loss per share is computed using the more dilutive of the treasury stock method which reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted to common stock, or the two-class method. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The calculation of diluted loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of liability classified warrants, and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to net loss available to common stockholders used in the calculation is required to remove the change in fair value of the warrants from the numerator for the period. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any, under the treasury stock method. &lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <armp:GrantsAndAwardsPolicyTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Tb_S7zHWiGlJkyft5FAjiYSNw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Grants and Awards&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;        In applying the provisions of ASC Topic 606, &lt;/span&gt;&lt;i style="font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/i&gt; (&#x201c;ASC 606&#x201d;)&lt;i style="font-style:italic;"&gt;, &lt;/i&gt;Armata has determined that grants and awards are out of the scope of ASC 606 because the funding entities do not meet the definition of a &#x201c;customer&#x201d;, as defined by ASC 606, as there is not considered to be a transfer of control of goods or services. With respect to each grant or award, the Company determines if it has a collaboration in accordance with ASC Topic 808, &lt;i style="font-style:italic;"&gt;Collaborative Arrangements&lt;/i&gt; (&#x201c;ASC 808&#x201d;). To the extent the grant or award is within the scope of ASC 808, the Company recognizes amounts received as a contra-expense or grant revenue on the consolidated statement of operations when the related research and development expenses are incurred. For grant and awards outside the scope of ASC 808, the Company applies ASC 606 or International Accounting Standards No. 20, &lt;i style="font-style:italic;"&gt;Accounting for Government Grants and Disclosure of Government Assistance&lt;/i&gt;, by analogy, and revenue is recognized when the Company incurs expenses related to the grants for the amount the Company is entitled to under the provisions of the contract. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:27pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;        Armata also considers the guidance in ASC Topic 730, &lt;/span&gt;&lt;i style="font-style:italic;"&gt;Research and Development &lt;/i&gt;(&#x201c;ASC 730&#x201d;), which requires an assessment, at the inception of the grant or award, of whether the agreement is a liability&lt;i style="font-style:italic;"&gt;. &lt;/i&gt;If Armata is obligated to repay funds received regardless of the outcome of the related research and development activities, then Armata is required to estimate and recognize that liability. Alternatively, if Armata is not required to repay the funds, then payments received are recorded as revenue or contra-expense as the expenses are incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:27pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;       Deferred grant or award liability represents award funds received or receivable for which the allowable expenses have not yet been incurred as of the balance sheet date.&lt;/span&gt;&lt;/p&gt;</armp:GrantsAndAwardsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Tb_opDtieiPwECk04gDNkud9Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Research and Development Expenses&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Research and development (&#x201c;R&amp;amp;D&#x201d;) costs consist primarily of direct and allocated salaries, incentive compensation, stock-based compensation and other personnel-related costs, facility costs, and third-party services. Third-party services include studies and clinical trials conducted by clinical research organizations. R&amp;amp;D activities are expensed as incurred. The Company records accruals for estimated ongoing clinical trial expenses. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Judgments and estimates are made in determining the accrued balances at the end of the reporting period.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Tb_FhUNzvDkGkSbYh6rxLu8KA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background-color:#ffffff;color:#212529;"&gt;In June 2016, the FASB issued ASU 2016-13,&#160;&lt;/span&gt;&lt;i style="background-color:#ffffff;color:#212529;font-style:italic;"&gt;Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses&lt;/i&gt;&lt;span style="background-color:#ffffff;color:#212529;"&gt;&#160;on Financial Instruments. The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that aren&#x2019;t measured at fair value through net income. For available-for-sale debt securities, entities will be required to recognize an allowance for credit losses rather than a reduction in carrying value of the asset. Entities will no longer be permitted to consider the length of time that fair value has been less than amortized cost when evaluating when credit losses should be recognized.&#160;&lt;/span&gt;This new guidance is effective for calendar-year smaller reporting public entities in the first quarter of 2023. The Company is currently evaluating the impact of this ASU and&#160;&lt;span style="color:#212529;"&gt;does&#160;&lt;/span&gt;not expect that adoption of this standard will have a material impact on its consolidated financial statements or related disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"&gt;In August 2020, the FASB issued &#x200b;ASU No. 2020-06&#x200b;, &#x200b;&lt;i style="font-style:italic;"&gt;Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40)&#x200b; (&#x201c;ASU 2020-06&#x201d;).&lt;/i&gt; &#x200b;ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#x2019;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in ASU &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;2020-06 are effective for the Company as of January 1, 2024. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2020-06 on its financial statements and does not expect the adoption of this ASU to have a material impact on the Company&#x2019;s consolidated financial statements.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Recently Adopted Accounting Standards&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 14pt 0pt;"&gt;In December 2019, the FASB issued ASU 2019-12,&#160;&lt;i style="font-style:italic;"&gt;Income Taxes (&#x201c;ASC 740&#x201d;)&lt;/i&gt;, which simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740 related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill.&#160;The guidance became effective for the Company on January 1, 2021 and the adoption did not have a material impact on its&#160;consolidated financial statements or related disclosures.  &lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Tb_aHrXWp3orkGHBC8tgVyKcg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;4. Net Loss per Share &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The following outstanding securities as of September 30, 2021 and 2020 have been excluded from the computation of diluted weighted average shares outstanding, as they would have been anti-dilutive:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:top;width:69.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,439,651&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,446,614&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested restricted stock units &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 30,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:top;width:69.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted stock awards&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 124,018&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 262,558&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 16,647,219&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 10,547,618&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:top;width:69.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 19,240,888&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 12,256,790&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Tb_Pc71nO4EFUqPUsIEYaTHtA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The following outstanding securities as of September 30, 2021 and 2020 have been excluded from the computation of diluted weighted average shares outstanding, as they would have been anti-dilutive:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:top;width:69.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,439,651&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,446,614&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested restricted stock units &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 30,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:top;width:69.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted stock awards&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 124,018&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 262,558&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 16,647,219&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 10,547,618&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:top;width:69.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 19,240,888&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 12,256,790&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_dGzT0B8rlE25dvbTXP9MPQ"
      decimals="0"
      id="Tc_o4cDakyY40yzgARAIr8evQ_2_2"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">2439651</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_Lq1HnOsnGU-O85aEcig2uA"
      decimals="0"
      id="Tc_sCD7CgoWNUmIE4yLLzxghA_2_4"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">1446614</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_0tfpWQr4U0atNpxzVyKU4w"
      decimals="0"
      id="Tc_rgls6Mc8yUS5eIaBkyMfVg_3_2"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">30000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_C-PpNtLO1EyP8fYs3gQBWw"
      decimals="0"
      id="Tc_YG8QwhaCl0i_bf4Bj-oX1g_4_2"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">124018</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_IORuHvJJb02yQ5UUN4uyzw"
      decimals="0"
      id="Tc_TeuJqcyBk02djwu51hJ4Hw_4_4"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">262558</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_DeTK3m4stEG86-3yphL8Ow"
      decimals="0"
      id="Tc_keYJygxkY0ip-YfgL9ZuLw_5_2"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">16647219</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_T0uD7MiwsUiVBvYkYdc0sA"
      decimals="0"
      id="Tc_JW-a4v3POEOa0SWmbF-Fdw_5_4"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">10547618</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      decimals="0"
      id="Tc_qj__EIqicE6f2uR2XYrdXw_6_2"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">19240888</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw"
      decimals="0"
      id="Tc_XmkjKhNEGEmdNMI91sRsrA_6_4"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">12256790</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Tb_5ar4UJs4GEaumdX3kfCiXA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;5. Balance Sheet Details&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Property and Equipment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Property and equipment as of September 30, 2021 and December 31, 2020 consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:69.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:top;width:69.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 7,362,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 6,547,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 817,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 719,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:top;width:69.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Office and computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 451,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 413,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,423,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,423,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:top;width:69.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 12,053,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 11,102,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9,946,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9,055,000)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:top;width:69.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,107,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,047,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Depreciation expense totaled $0.3 million for each of the three months ended September 30, 2021 and 2020, respectively. Depreciation expense totaled $0.9 million and $0.8 million for the nine months ended September 30, 2021 and 2020, respectively.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Tb_bSyEx-zVQEukH4WfzvNCdg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:69.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:top;width:69.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 7,362,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 6,547,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 817,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 719,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:top;width:69.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Office and computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 451,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 413,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,423,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,423,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:top;width:69.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 12,053,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 11,102,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:69.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9,946,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9,055,000)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:top;width:69.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,107,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,047,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_9_30_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_TechnologyEquipmentMember_p5J4JOCTc02vC-jcH_EpAg"
      decimals="0"
      id="Tc_-bO5esUZn06tov-L5pvY-A_2_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">7362000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_TechnologyEquipmentMember_nIlwPHC5LUOeeFklieSIRw"
      decimals="0"
      id="Tc_VSXhF-VtWE2iDV8OHkA8ZA_2_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">6547000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_9_30_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_1p7SIRia1U-1Q9bpInZOaQ"
      decimals="0"
      id="Tc_xWcB6DuJx0qFvOVYSQId4w_3_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">817000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_8b0rBWMKHUqzS1cwV6K4xQ"
      decimals="0"
      id="Tc_aRstltpo6ECdwGvUZtVy2g_3_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">719000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_9_30_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_TOBly1V2sk6aoZBdLy5BKw"
      decimals="0"
      id="Tc_5Hu4JZXLS0iatGL8L68-jA_4_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">451000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_v1yZA3mZRkKG-s3xNs7sqw"
      decimals="0"
      id="Tc_MX_VPpgJbUmg55Mlg2KWog_4_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">413000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_9_30_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_RNSsP7qTGEmVKWcf_xwJ3Q"
      decimals="0"
      id="Tc_z5_MMBGEw02vrVJKr6XjQA_5_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">3423000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_Va3hG_KZOUiqR-V5nrMt6w"
      decimals="0"
      id="Tc_DNRKgUPH7EqTxeROQxFMuA_5_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">3423000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA"
      decimals="0"
      id="Tc_YYd1AMydpEWL3ehQs07OdA_6_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">12053000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg"
      decimals="0"
      id="Tc_RpaZ-6KZUUeT3hVmbcbk-w_6_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">11102000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA"
      decimals="0"
      id="Tc_Mh-FnbtaD0K7x0FWJtRGkg_7_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">9946000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg"
      decimals="0"
      id="Tc_t5qJaPCWzU2TtTjPUHhdow_7_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">9055000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA"
      decimals="0"
      id="Tc_STBDKHEusEWbZW3obsaHCg_8_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">2107000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg"
      decimals="0"
      id="Tc_S_z6KeeVDEC32tZR1jJMVw_8_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">2047000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="Duration_7_1_2020_To_9_30_2020_C3Blutz6cUqC03qQKsaYEg"
      decimals="-5"
      id="Narr_H1JIXiBZR0CqO32X6BzIyQ"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">300000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_7_1_2021_To_9_30_2021_EHL267Iy5kqlAVaXmlK6uQ"
      decimals="-5"
      id="Narr_GZhlSLwrekOoTR3WNOjfig"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">300000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      decimals="-5"
      id="Narr_kDxVMbC4G0eyD7Gvl7QmuQ"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">900000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw"
      decimals="-5"
      id="Narr_EjWT1Z1oPUe1NTrjmyYVmA"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">800000</us-gaap:Depreciation>
    <us-gaap:LongTermDebtTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Tb_p9hW3U2FfkG8oLaIMioIGw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;6. Paycheck Protection Program Loan &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;"&gt;In April 2020, the Company received loan proceeds of $717,000 (&#x201c;PPP Loan&#x201d;) under the Paycheck Protection Program (&#x201c;PPP&#x201d;).&#160; The PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act, provides for loans to qualifying businesses for amounts up to 2.5 times the average monthly payroll expenses of the qualifying business, calculated as provided under the PPP. The PPP Loan was unsecured, evidenced by a promissory note (the &#x201c;Note&#x201d;) given by the Company as borrower through its bank, serving as the lender.&#160; The interest rate on the Note was 1.0% per annum. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;"&gt;In July 2021, the Company received notification of forgiveness of the full loan amount and associated interest from the Small Business Administration. The Company recorded a gain of $0.7 million from the PPP loan extinguishment in the statement of operations during the three months ended September 30, 2021.  &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:ProceedsFromUnsecuredNotesPayable
      contextRef="Duration_4_20_2020_To_4_20_2020_us-gaap_DebtInstrumentAxis_armp_PaymentProtectionProgramNoteMember_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember_7RzbJhwJ1ESFRjadZeEXiw"
      decimals="0"
      id="Narr_RZPf1skQVky7OQ3KubmnEQ"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">717000</us-gaap:ProceedsFromUnsecuredNotesPayable>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_4_20_2020_us-gaap_DebtInstrumentAxis_armp_PaymentProtectionProgramNoteMember_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember_etlcSyw6QUy7OhSC2F0meg"
      decimals="INF"
      id="Narr_-V9CSU1-HkCzqFS6MHvsbg"
      unitRef="Unit_Standard_pure_EPrTQjTDQkGfR4N7mgNYUg">0.010</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <armp:GainLossOnExtinguishmentOfPaycheckProtectionProgramLoan
      contextRef="Duration_7_1_2021_To_9_30_2021_EHL267Iy5kqlAVaXmlK6uQ"
      decimals="-5"
      id="Narr_tWqzFHA4j0ud4zQwQfLzFQ"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">700000</armp:GainLossOnExtinguishmentOfPaycheckProtectionProgramLoan>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Tb_N1nDQvbwPk-VBtWD8szroA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;7. Stockholders&#x2019; Equity&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Private Investment &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;October 2021 Private Placement&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background-color:#ffffff;color:#222222;"&gt;On October 28, 2021, the Company entered into the October 2021 Securities Purchase Agreement with CFF and Innoviva for the private placement of newly issued shares of the Company&#x2019;s common stock. Pursuant to the October 2021 Securities Purchase Agreement, the Company issued and sold &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#222222;"&gt;909,091&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#222222;"&gt; shares to CFF and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#222222;"&gt;1,212,122&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#222222;"&gt; shares to Innoviva, each at a per share price of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#222222;"&gt;$3.30&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#222222;"&gt;. The Company received aggregate gross proceeds from the October 2021 Private Placements of approximately &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#222222;"&gt;$7.0&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#222222;"&gt; million, before deducting transaction expenses&lt;/span&gt;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;January 2021 Private Placement &lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;On January&#160;26, 2021, the Company entered into the January 2021 Securities Purchase Agreement with Innoviva, pursuant to which the Company agreed to issue and sell to Innoviva, in a private placement, up to 6,153,847 newly issued shares of common stock, and Common Warrants to purchase up to 6,153,847 shares of common stock, with an exercise price per share of $3.25.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The January 2021 Private Placement closed in two tranches. On January&#160;26, 2021 and concurrently with entering into the January 2021 Securities Purchase Agreement, the Company completed the first tranche (the &#x201c;First Closing&#x201d;) of the January 2021 Private Placement. At the First Closing,&#160;Innoviva purchased 1,867,912 shares and Common Warrants to purchase 1,867,912 shares of common stock, for an aggregate purchase price of approximately $6.1 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;At the closing of the second tranche (the &#x201c;Second Closing&#x201d;), which was approved by the Company&#x2019;s stockholders,&#160;Innoviva purchased 4,285,935 shares and Common Warrants to purchase 4,285,935 shares of common stock for an aggregate purchase price of $13.9 million. The Second Closing was completed on March 17, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;On January 27, 2020, the Company entered into a securities purchase agreement with Innoviva, pursuant to which the Company agreed to issue and sell to Innoviva, in the 2020 Private Placement, 8,710,800 newly issued shares of the Company&#x2019;s common stock and warrants to purchase 8,710,800 shares of common stock, with an exercise price per share of $2.87. Each share of common stock was sold together as a unit with one common warrant granting the warrant holder the right to purchase an additional share of common stock at $2.87 per share. The 2020 Private Placement occurred in two tranches. The first closing occurred on February 12, 2020, at which time Innoviva purchased 993,139 units in exchange for an aggregate gross cash payment of approximately $2.8 million. On March 27, 2020, the second closing occurred subsequent to shareholder approval, at which time Innoviva purchased 7,717,661 units in exchange for aggregate gross proceeds of $22.2 million. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The warrants issued to Innoviva during 2021 and 2020 expire five years from the respective issuance date. The Company reviewed the authoritative accounting guidance and determined that the warrants meet the criteria to be accounted for as permanent equity. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Warrants&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;On September 30, 2021, outstanding warrants to purchase shares of common stock are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:36.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares Underlying Outstanding Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:28.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Expiration Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:36.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 597,881&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0.05pt 0pt;"&gt; 21.00&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;May 10, 2022&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,183,491&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0.05pt 0pt;"&gt; 5.60&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;October 16, 2023&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:36.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 993,139&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0.05pt 0pt;"&gt; 2.87&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;February 11, 2025&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 7,717,661&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0.05pt 0pt;"&gt; 2.87&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;March 27, 2025&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:36.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,867,912&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0.05pt 0pt;"&gt; 3.25&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;January 26, 2026&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,285,935&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0.05pt 0pt;"&gt; 3.25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;March 16, 2026&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:36.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,200&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0.05pt 0pt;"&gt; 1,680.00&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;None&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 16,647,219&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_10_28_2021_To_10_28_2021_srt_CounterpartyNameAxis_armp_CysticFibrosisFoundationMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_r2L1o1zLc0ewvdxbb5OLYQ"
      decimals="0"
      id="Narr_yQOenA6TL0-CyhGhsKlH_Q"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">909091</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_10_28_2021_To_10_28_2021_srt_CounterpartyNameAxis_armp_InnovivaStrategicOpportunitiesLlcMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_j_mhEXexkkyt_KqjZVElLw"
      decimals="0"
      id="Narr_VcqL7hQGV0mCIjOhPo0olg"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">1212122</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_10_28_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_XMDfJAOuaESQwElJtiy_ew"
      decimals="2"
      id="Narr_2-eWNj_ULUi7vYLwN6EsBQ"
      unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q">3.30</us-gaap:SharesIssuedPricePerShare>
    <armp:ProceedsFromEquityOfferingsGross
      contextRef="Duration_10_28_2021_To_10_28_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_46a9XzfZPkSGKc4-ttN9fw"
      decimals="-5"
      id="Narr_4TBYYkzECUe_J5E3S2kgCQ"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">7000000.0</armp:ProceedsFromEquityOfferingsGross>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_26_2021_To_1_26_2021_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_z5LGiY7OL0Scv3M4U-b1Wg"
      decimals="INF"
      id="Narr_v4GH1IeGBEq8QOw2KsuJfg"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">6153847</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_1_26_2021_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_u_eCCek3qkqRByQzE5fczw"
      decimals="INF"
      id="Narr_KgTHkDoUSESQLJaQICh3iQ"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">6153847</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_1_26_2021_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_TImvJ_eQD0OgW_ZO7Ry9TQ"
      decimals="2"
      id="Narr_o6SpirV34kGT_kVVet3_6A"
      unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q">3.25</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_26_2021_To_1_26_2021_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementFirstTrancheMember_vU5i9LO2uU6jsVJ4911Zlg"
      decimals="INF"
      id="Narr_bqOUOF_nFUS6PxI_XVFvyA"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">1867912</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_1_26_2021_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementFirstTrancheMember_4VDPa4otSk6JCKDKNZvQ0w"
      decimals="INF"
      id="Narr_mWfEoUGAOkqK30Wugraotw"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">1867912</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="Duration_1_26_2021_To_1_26_2021_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementFirstTrancheMember_wOZbvf2jHEW62lNLQlwkHw"
      decimals="-5"
      id="Narr_LmhXgqCeAUC6NNTGR3wgBA"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">6100000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_3_17_2021_To_3_17_2021_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementSecondTrancheMember_7NUySWdWyU2T6PeqoKx_hg"
      decimals="INF"
      id="Narr_tsiicp9gcEGd1YARbk_iAw"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">4285935</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_3_17_2021_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementSecondTrancheMember_8WtQB3s-wk2b0we6rBXeVg"
      decimals="INF"
      id="Narr_GZ194enIXESuIwODnnQCzA"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">4285935</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="Duration_3_17_2021_To_3_17_2021_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementSecondTrancheMember_OI9uPwtYu02QjGR7dFobAA"
      decimals="-5"
      id="Narr_2qV1xtuoV0CG8eeJvMrVKg"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">13900000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_27_2020_To_3_27_2020_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_tEurHl-WuEy8GrS4QYXwGQ"
      decimals="INF"
      id="Narr_qHL6J1lJOEybZvlDHsGHQw"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">8710800</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_3_27_2020_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_VI0dYZLlxkey_j7O6lL4cA"
      decimals="INF"
      id="Narr_XJeQSrlJBkmtL8-aAVdM7g"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">8710800</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_3_27_2020_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_9mH04W5WikCikSJLnqxw9w"
      decimals="2"
      id="Narr_OA6Oj4kGi0SxPbRYIGWjnA"
      unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q">2.87</us-gaap:SharesIssuedPricePerShare>
    <armp:NumberOfCommonWarrantsSoldPerShareOfCommonStock
      contextRef="Duration_1_27_2020_To_1_27_2020_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_kxspnM04HEGpag_N6znvkw"
      decimals="INF"
      id="Narr_CX0W9NZPq0yIyaFL6tfKPg"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">1</armp:NumberOfCommonWarrantsSoldPerShareOfCommonStock>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_3_27_2020_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_us-gaap_CommonStockSubjectToMandatoryRedemptionMember_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_9mH04W5WikCikSJLnqxw9w"
      decimals="2"
      id="Narr_9mOtoDkBK0-gNmUaKNbwtQ"
      unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q">2.87</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_2_12_2020_To_2_12_2020_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_kE6uyStxdEyj3mI3KbQoTg"
      decimals="INF"
      id="Narr_wU_GDJkh2EeiRMqnqQLPAA"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">993139</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="Duration_2_12_2020_To_2_12_2020_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_kE6uyStxdEyj3mI3KbQoTg"
      decimals="-5"
      id="Narr_Fc183NoAYkWMzigAHIe2Pw"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">2800000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_3_27_2020_To_3_27_2020_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_NmhuJtI8WkCb1aWkNG0-5Q"
      decimals="INF"
      id="Narr_HYMVfVyVcU2frBcOsj9mrg"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">7717661</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="Duration_3_27_2020_To_3_27_2020_us-gaap_TypeOfArrangementAxis_armp_SecuritiesPurchaseAgreementMember_NmhuJtI8WkCb1aWkNG0-5Q"
      decimals="-5"
      id="Narr_XS6Gu6Mz40G2dgapDGr0bA"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">22200000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <armp:TermOfWarrant
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Narr_FWFEWEcEr0mixU26_M4TyA">P5Y</armp:TermOfWarrant>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Tb_OUW2t0ayd0WDjtSZ1urd6A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;On September 30, 2021, outstanding warrants to purchase shares of common stock are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:36.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares Underlying Outstanding Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:28.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Expiration Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:36.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 597,881&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0.05pt 0pt;"&gt; 21.00&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;May 10, 2022&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,183,491&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0.05pt 0pt;"&gt; 5.60&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;October 16, 2023&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:36.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 993,139&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0.05pt 0pt;"&gt; 2.87&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;February 11, 2025&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 7,717,661&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0.05pt 0pt;"&gt; 2.87&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;March 27, 2025&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:36.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,867,912&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0.05pt 0pt;"&gt; 3.25&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;January 26, 2026&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,285,935&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0.05pt 0pt;"&gt; 3.25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;March 16, 2026&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:36.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,200&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0.05pt 0pt;"&gt; 1,680.00&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;None&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 16,647,219&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceTwoMember_NdqVRbX3oU27C0EB3fq9hQ"
      decimals="INF"
      id="Tc_4hxvAQMroEa-lOibOzqnLw_2_0"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">597881</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceTwoMember_NdqVRbX3oU27C0EB3fq9hQ"
      decimals="2"
      id="Tc_2UAOfFsLfUWmVhv4RJzKiw_2_3"
      unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q">21.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <armp:WarrantExpirationDate
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceTwoMember_JdmRRsSJmk-a_ZNRg_kXxQ"
      id="Tc_nuvhmyDyo0yzMGi8YtuQlw_2_5">2022-05-10</armp:WarrantExpirationDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceThreeMember_KFYsa4JmTkqWUhYzwZ9UJQ"
      decimals="INF"
      id="Tc_XwK97JmS30qPd3Otpz-pDw_3_0"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">1183491</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceThreeMember_KFYsa4JmTkqWUhYzwZ9UJQ"
      decimals="2"
      id="Tc_DXXa5qD4IEi06mxTz2TgqQ_3_3"
      unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q">5.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <armp:WarrantExpirationDate
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceThreeMember_EJFiwcEwBEuQa1IR4jmJ5g"
      id="Tc_kWxjaRN280eGa1jimCw1_g_3_5">2023-10-16</armp:WarrantExpirationDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFourMember_JSSFhCnciUaDzuCmVBpOig"
      decimals="INF"
      id="Tc_KuyMEvSnE0Clyp5L0c7P5A_4_0"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">993139</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFourMember_JSSFhCnciUaDzuCmVBpOig"
      decimals="2"
      id="Tc_ECwIhdZCsE-TTOD0yRzsMg_4_3"
      unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q">2.87</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <armp:WarrantExpirationDate
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFourMember_jfTPvaUXH0maozOHI-CL3g"
      id="Tc_ljOOlqBdWEuOIrZj-XCCtg_4_5">2025-02-11</armp:WarrantExpirationDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFiveMember_CxNNWMACKU-ycnzc8b5FtA"
      decimals="INF"
      id="Tc_w6qLtxSvF0izFdkKIsLshA_5_0"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">7717661</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFiveMember_CxNNWMACKU-ycnzc8b5FtA"
      decimals="2"
      id="Tc_UM3ED7uwqUySYptj7QXo-A_5_3"
      unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q">2.87</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <armp:WarrantExpirationDate
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceFiveMember_E28RzePRZEuFR_T3YSIfYw"
      id="Tc_Pz0mV53XZkSuVpKr2Tw_wA_5_5">2025-03-27</armp:WarrantExpirationDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSevenMember_gY_GNEB58Eym-DuN9BtbEw"
      decimals="INF"
      id="Tc_IWdGEbImgkmO9FnVEUonZw_6_0"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">1867912</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSevenMember_gY_GNEB58Eym-DuN9BtbEw"
      decimals="2"
      id="Tc_5Mawu2Jq-kKjxIJe9hckMg_6_3"
      unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q">3.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <armp:WarrantExpirationDate
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSevenMember_u78Ah4LoqUKqzJVIAxTUEA"
      id="Tc_PxSgtEjejUmOJqzvCEqDGQ_6_5">2026-01-26</armp:WarrantExpirationDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceEightMember_fpCbl3DW_keRXlZj4Fhy1A"
      decimals="INF"
      id="Tc_w6M4-u7aHkmEkRXSPjROMw_7_0"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">4285935</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceEightMember_fpCbl3DW_keRXlZj4Fhy1A"
      decimals="2"
      id="Tc_T-Dx-n8q006qNpk7S4_zkQ_7_3"
      unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q">3.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <armp:WarrantExpirationDate
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceEightMember_xrUR_X3n30aS1ib7pRRXLA"
      id="Tc_43pvc1GqIE6pI4ZlCc1fTA_7_5">2026-03-16</armp:WarrantExpirationDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSixMember_WimCD-fx60m_KUK0LywoTg"
      decimals="INF"
      id="Tc_FvOxF1BkL06DNk2rwbAqBQ_8_0"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">1200</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_armp_ExercisePriceSixMember_WimCD-fx60m_KUK0LywoTg"
      decimals="2"
      id="Tc_QHrPSDGDaEu8t80TdjpagA_8_3"
      unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q">1680.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA"
      decimals="INF"
      id="Tc_7MERSqkpGkudjgBi5oe7BQ_9_0"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">16647219</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Tb_mIG1lkVL-0atlGMJAE4_KQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;8. Equity Incentive Plans&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Stock Award Plans&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company maintains a 2016 Equity Incentive Plan (the &#x201c;2016 Plan&#x201d;), which provides for the issuance of incentive share awards in the form of non-qualified and incentive stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards and performance-based stock awards. The awards may be granted by the Company&#x2019;s Board of Directors to its employees, directors and officers and to consultants, agents, advisors and independent contractors who provide services to the Company or to a subsidiary of the Company. The exercise price for stock options must not be less than the fair market value of the underlying shares on the date of grant. Stock options expire no later than ten years from the date of grant and generally vest and typically become exercisable over a four-year period following the date of grant. Under the 2016 Plan, the number of shares authorized for issuance automatically increases annually beginning January 1, 2017 and through January 1, 2026. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In connection with the Merger, the Company assumed the C3J Jian, Inc. Amended 2006 Stock Option Plan (the &#x201c;Assumed 2006 Plan&#x201d;) and the C3J Therapeutics, Inc. 2016 Stock Plan (the &#x201c;Assumed 2016 Plan&#x201d;). These plans provided for stock option and restricted stock awards (&#x201c;RSAs&#x201d;) to C3J employees in years prior to the merger with AmpliPhi. The number of shares subject to each outstanding stock option and RSA under those assumed plans, along with the exercise price of stock options, were equitably adjusted pursuant to the terms of the plans to reflect the impact of the Merger and the one-for-&lt;span style="-sec-ix-hidden:Hidden_6HHTzro5OEGysvS9SNdMCQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;fourteen&lt;/span&gt;&lt;/span&gt; reverse stock split, in each case in a manner intended to preserve the then-current intrinsic value of the awards. No additional awards will be made under either plan. The assumed C3J stock options were substantially vested and expensed as of the merger date. Vesting of the assumed C3J RSAs is based on the occurrence of a public liquidity event, or a change in control. In the event of a public liquidity event, service or milestone based vesting schedules begins. Service periods are generally &lt;span style="-sec-ix-hidden:Hidden_FoLyPbG9hUC2OJDlbr-6vQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;two&lt;/span&gt;&lt;/span&gt; to four years. In the event of a change in control, 100% vesting occurs upon the closing of such an event. The merger with AmpliPhi constituted a public liquidity event and triggered the start of vesting of RSAs. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock-based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company estimates the fair value of stock options with performance and service conditions using the Black-Scholes valuation model. Compensation expense related to stock options granted is measured at the grant date based on the estimated fair value of the award and is recognized on the accelerated attribution method over the requisite service period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The assumptions used in the Black-Scholes model are presented below:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;width:31.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine months ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:top;width:68.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;0.73% -- 1.29%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;0.25% -- 1.51%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;84.04% -- 93.37%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;90.43%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:top;width:68.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;5.50 - 7.00&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;5.50 - 7.00&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. Expected volatility is based on the historical volatility of Armata and peer companies&#x2019; common stock. The expected term represents the period that the Company expects its stock options to be outstanding. The expected term assumption is estimated using the simplified method set forth in the SEC Staff Accounting Bulletin 110, which is the mid-point between the option vesting date and the expiration date. For stock options granted to parties other than employees or directors, the Company elects, on a grant by grant basis, to use the expected term or the contractual term of the option award. The Company has never declared or paid dividends on its common stock and has no plans to do so in the foreseeable future. Forfeitures are recognized as a reduction of stock-based compensation expense as they occur.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="color:#231f20;"&gt;On August 1, 2021, Todd R. Patrick, who has served as the Company&#x2019;s Chief Executive Officer (&#x201c;CEO&#x201d;) since May 2019, retired from day-to-day active management of the Company and resigned as CEO. On August 9, 2021, the Company and Mr. Patrick entered into a letter agreement, which among other things, provides that if&lt;/span&gt; Mr. Patrick provides advisory services through the end of December 31, 2022 (the &#x201c;Transition Period&#x201d;), &lt;span style="-sec-ix-hidden:Hidden_9mekj5kubk-rv8woYRxrCg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;one half&lt;/span&gt;&lt;/span&gt; of the outstanding and unvested Company stock options and restricted share units held by Mr. Patrick as of the last day of the Transition Period will become fully vested, and all vested stock options held by Mr. Patrick as of that date will remain exercisable for the remainder of the 10-year term from the original grant date. The Company measured the stock-based compensation expense related to the modification and pre-vesting forfeitures of Mr. Patrick&#x2019;s stock options and restricted share units to be a net credit of approximately $0.3 million, which will be amortized as a credit to stock-based compensation over the remaining substantive requisite service period through December 31, 2021. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="color:#231f20;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The tables below summarize the total stock-based compensation expense included in the Company&#x2019;s consolidated statements of operations for the periods presented:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 369,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 205,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,121,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 841,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 100,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 458,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,097,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,772,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 469,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 663,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,218,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,613,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="background-color:#ffff00;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Stock option transactions during the nine months ended September 30, 2021 are presented below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:40.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&#160;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:top;width:58.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,668,926&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 6.30&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 8.32&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:58.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 856,150&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4.77&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:top;width:58.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercised &lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (73,517)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3.27&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 98,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:58.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited/Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (11,908)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 48.67&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:top;width:58.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at September&#160;30,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,439,651&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5.65&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 8.19&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 609,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:58.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vested and expected to vest at September&#160;30,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,439,651&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5.65&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 8.19&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 609,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:top;width:58.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercisable at September&#160;30,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 733,721&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 9.48&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 6.55&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 252,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Restricted stock awards and restricted stock units during the nine months ended September 30, 2021 are presented below: &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted Avg&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December 31, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 322,756&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 19.55&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited/Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,047)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 6.89&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested and Issued as Common Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (167,691)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 12.33&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at September&#160;30,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 154,018&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 27.49&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     &lt;/span&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;      The aggregate intrinsic value of options at September 30, 2021 is based on the Company&#x2019;s closing stock price on that date of $3.62 per share. As of September 30, 2021, there was $3.9&lt;/span&gt; million of total unrecognized compensation expense related to unvested stock options and RSAs, which the Company expects to recognize over the weighted average remaining period of approximately 1.8 years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Shares Reserved for Future Issuance&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;As of September 30, 2021, the Company had reserved shares of its common stock for future issuance as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&#160;Reserved&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:top;width:84.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock options outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,439,651&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:84.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unvested restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 30,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:top;width:84.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Employee stock purchase plan&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 9,748&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:84.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Available for future grants under the 2016 Plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 227,856&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:top;width:84.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrants outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 16,647,219&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:84.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total shares reserved&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 19,354,474&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2021_To_9_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_armp_EquityIncentivePlan2016Member_owlriQq-j0-oYrcsBY5Gjw"
      id="Narr_VpQCGr030EKsK8iqt9-psA">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_armp_EquityIncentivePlan2016Member_a2GP2RQyPUaGZD8_SYwXvg"
      id="Narr_3OjoO_imCESTvj2hkdZUKw">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_PlanNameAxis_armp_Assumed2006And2016PlanMember_jwnQgOCvrEi-zQv25P1M9Q"
      decimals="0"
      id="Narr_J66k4trYLkmedeHcnqow2Q"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="Duration_1_1_2021_To_9_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_armp_Assumed2006And2016PlanMember_oXCoqIfziE2VJlO7Y9J9yA"
      id="Narr_xkwVoL5yDkWw8743uTGsWw">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      decimals="2"
      id="Narr_C2GaHAyHpE6EcXNP5iHB6w"
      unitRef="Unit_Standard_pure_EPrTQjTDQkGfR4N7mgNYUg">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Tb_AupTqBP7MEWlwFe049z-Vw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The assumptions used in the Black-Scholes model are presented below:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;width:31.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine months ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:top;width:68.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;0.73% -- 1.29%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;0.25% -- 1.51%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;84.04% -- 93.37%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;90.43%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:top;width:68.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;5.50 - 7.00&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;5.50 - 7.00&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:68.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <armp:EquitySecuritiesMeasurementInput
      contextRef="As_Of_9_30_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_M1wYd_bHtkSmPDl5gRx6tg"
      decimals="2"
      id="Narr_mZebpA0e2U2V1voGwvnL6Q"
      unitRef="Unit_Standard_pure_EPrTQjTDQkGfR4N7mgNYUg">0.73</armp:EquitySecuritiesMeasurementInput>
    <armp:EquitySecuritiesMeasurementInput
      contextRef="As_Of_9_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_TcHNTAeDIUqS5KTjdnYf_A"
      decimals="2"
      id="Narr_PaOtGrsaRE6URshfiwrjYQ"
      unitRef="Unit_Standard_pure_EPrTQjTDQkGfR4N7mgNYUg">1.29</armp:EquitySecuritiesMeasurementInput>
    <armp:EquitySecuritiesMeasurementInput
      contextRef="As_Of_9_30_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_si4L1iko2E64STirrO48PA"
      decimals="2"
      id="Narr_eIGnbYkwvEiARNniqZUMVQ"
      unitRef="Unit_Standard_pure_EPrTQjTDQkGfR4N7mgNYUg">0.25</armp:EquitySecuritiesMeasurementInput>
    <armp:EquitySecuritiesMeasurementInput
      contextRef="As_Of_9_30_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_vGTpt-wF-kumWbrMGmDgMA"
      decimals="2"
      id="Narr_vqSlAKUUZkqKrMbNPu4sPw"
      unitRef="Unit_Standard_pure_EPrTQjTDQkGfR4N7mgNYUg">1.51</armp:EquitySecuritiesMeasurementInput>
    <armp:EquitySecuritiesMeasurementInput
      contextRef="As_Of_9_30_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_Y-YOyctUPkCj1ByCpX0cjA"
      decimals="2"
      id="Narr_qklNxGLWAEypGHpBvwgAgQ"
      unitRef="Unit_Standard_pure_EPrTQjTDQkGfR4N7mgNYUg">84.04</armp:EquitySecuritiesMeasurementInput>
    <armp:EquitySecuritiesMeasurementInput
      contextRef="As_Of_9_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_8qAqLG7eF0q7G6Mr5Lp6tg"
      decimals="2"
      id="Narr__9CHtHYp3EmDy7edvmD1UQ"
      unitRef="Unit_Standard_pure_EPrTQjTDQkGfR4N7mgNYUg">93.37</armp:EquitySecuritiesMeasurementInput>
    <armp:EquitySecuritiesMeasurementInput
      contextRef="As_Of_9_30_2020_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_bMElE1RKukaULS3RIlENIw"
      decimals="2"
      id="Tc_pOmYlvyftkm7vPCiFBIM3w_4_3"
      unitRef="Unit_Standard_pure_EPrTQjTDQkGfR4N7mgNYUg">90.43</armp:EquitySecuritiesMeasurementInput>
    <armp:EquitySecuritiesMeasurementInput
      contextRef="As_Of_9_30_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_ZYsQgyW6mkWdASHXKWLehQ"
      decimals="2"
      id="Narr_rtk9eoSNLEW0Qls9-11sng"
      unitRef="Unit_Standard_pure_EPrTQjTDQkGfR4N7mgNYUg">5.50</armp:EquitySecuritiesMeasurementInput>
    <armp:EquitySecuritiesMeasurementInput
      contextRef="As_Of_9_30_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_i9PzMC1lVUqwLuTxFWfdLA"
      decimals="2"
      id="Narr_Hgyp5lJJsk6JLeOwrKMZww"
      unitRef="Unit_Standard_pure_EPrTQjTDQkGfR4N7mgNYUg">7.00</armp:EquitySecuritiesMeasurementInput>
    <armp:EquitySecuritiesMeasurementInput
      contextRef="As_Of_9_30_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_c6MOz2oxDUaT_X0fkJA_DA"
      decimals="2"
      id="Narr_KhzOHvR6oEqUaDte-T3NLg"
      unitRef="Unit_Standard_pure_EPrTQjTDQkGfR4N7mgNYUg">5.50</armp:EquitySecuritiesMeasurementInput>
    <armp:EquitySecuritiesMeasurementInput
      contextRef="As_Of_9_30_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_NRyFSCYoD020FMLell9_Bw"
      decimals="2"
      id="Narr_cym8a42UEkGrRvG2h2bbmA"
      unitRef="Unit_Standard_pure_EPrTQjTDQkGfR4N7mgNYUg">7.00</armp:EquitySecuritiesMeasurementInput>
    <armp:EquitySecuritiesMeasurementInput
      contextRef="As_Of_9_30_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_JmEBEeGO8UeggSG1K-jwFw"
      decimals="0"
      id="Tc_4s9wGSZn80mIZxeCfU17Vw_6_1"
      unitRef="Unit_Standard_pure_EPrTQjTDQkGfR4N7mgNYUg">0</armp:EquitySecuritiesMeasurementInput>
    <armp:EquitySecuritiesMeasurementInput
      contextRef="As_Of_9_30_2020_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedDividendRateMember_xmm1FvADiUqkK7ZP4Vv_tA"
      decimals="0"
      id="Tc_Tj4JXXzZAka_4OVNzhEEFQ_6_3"
      unitRef="Unit_Standard_pure_EPrTQjTDQkGfR4N7mgNYUg">0</armp:EquitySecuritiesMeasurementInput>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_8_9_2021_To_8_9_2021_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_armp_StockOptionsAndRestrictedStockAwardsMember_HSuu2yjbeUO8uzqPtQxFDA"
      id="Narr_4g5c-Hjq1UyPI6ln_pM_ow">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <armp:StockBasedCompensationExpenseRelatedToPreVestingForfeituresReversed
      contextRef="Duration_1_1_2021_To_9_30_2021_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_AwardTypeAxis_armp_StockOptionsAndRestrictedStockAwardsMember_NAa3wvdW6ku9ixKdaxeq_Q"
      decimals="-5"
      id="Narr_xoG7HNqJpkKHPQyV2x9Baw"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">300000</armp:StockBasedCompensationExpenseRelatedToPreVestingForfeituresReversed>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Tb_gAWVsV3hrUqHsHllEjO7Rg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The tables below summarize the total stock-based compensation expense included in the Company&#x2019;s consolidated statements of operations for the periods presented:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 369,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 205,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,121,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 841,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 100,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 458,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,097,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,772,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 469,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 663,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,218,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,613,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_77ETOpJ7T0afQOPGHLIu-g"
      decimals="0"
      id="Tc_Ab6mexXUTk-1ZlokGAJo4A_4_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">369000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_iXH_BdY7Yky0pOj-w2anUw"
      decimals="0"
      id="Tc_OOrV9FHKakmkmJX-O0pEeA_4_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">205000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_G0J-iJ-hkEmVgCIOKKuQUA"
      decimals="0"
      id="Tc_bCZArh26gEyD0w6XY6knYQ_4_9"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">1121000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_v1HeSfyr9Em3B6Qct7RwOA"
      decimals="0"
      id="Tc_EYHIoOtaJE-Ukdp1NFR_lA_4_12"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">841000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_1dzTloLluU2mQIMpctnh9g"
      decimals="0"
      id="Tc_AvzHaewS2Ei5VEgG_bHZ8g_5_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_GodB2f3XM0-WcLyJqnzVFg"
      decimals="0"
      id="Tc_QEg4C0gKKUabrb-mMx4pXw_5_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">458000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_0sFoug39yEW-7YiIxYw6ZA"
      decimals="0"
      id="Tc_pmVpBKM6c0GUUKGLcl1RDw_5_9"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">1097000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_we94IQA0Ok-L_lCieSHSdw"
      decimals="0"
      id="Tc_-JSG3b22Hkq5Dc1tjNMCIw_5_12"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">1772000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2021_To_9_30_2021_EHL267Iy5kqlAVaXmlK6uQ"
      decimals="0"
      id="Tc_XtmdsEp5mkiiI26QyTQf2w_6_3"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">469000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2020_To_9_30_2020_C3Blutz6cUqC03qQKsaYEg"
      decimals="0"
      id="Tc_DtSvMhIfHk61fgEwGxtHxw_6_6"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">663000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      decimals="0"
      id="Tc_2DwAXzjBKUiuwv7S-5EHSw_6_9"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">2218000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw"
      decimals="0"
      id="Tc_q4zFh0m5eEWWcNE5CGGkoA_6_12"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">2613000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Tb_8CdI1D5X20SRfD1ucyxKdQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Stock option transactions during the nine months ended September 30, 2021 are presented below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:40.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&#160;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:top;width:58.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,668,926&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 6.30&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 8.32&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:58.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 856,150&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4.77&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:top;width:58.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercised &lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (73,517)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3.27&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 98,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:58.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited/Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (11,908)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 48.67&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:top;width:58.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at September&#160;30,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,439,651&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5.65&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 8.19&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 609,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:58.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vested and expected to vest at September&#160;30,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,439,651&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5.65&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 8.19&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 609,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:top;width:58.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercisable at September&#160;30,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 733,721&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 9.48&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 6.55&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 252,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg"
      decimals="INF"
      id="Tc_p06NfnjXykOW1VGJD_YdZA_8_2"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">1668926</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg"
      decimals="2"
      id="Tc_ubJMFjGnUUaM8BpdWi1a6g_8_5"
      unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q">6.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2020_To_12_31_2020_8rl-g37700qfCCqQwUULVg"
      id="Tc_Ul3YgzbZ0UOsPCJaysN0ZQ_8_7">P8Y3M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      decimals="INF"
      id="Tc_8HygOds5xE6QKjtvEa03Wg_9_2"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">856150</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      decimals="2"
      id="Tc_rrAGQvk570mYbqVErDBW5w_9_5"
      unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q">4.77</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      decimals="INF"
      id="Tc_IG4Rr5oiaUeZGAdGIISfZA_10_2"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">73517</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      decimals="2"
      id="Tc_7M7BdoKM-EOZuGUW6H5qsA_10_5"
      unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q">3.27</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      decimals="-3"
      id="Tc_7QLiW2SinEagarbHlyXq1g_10_10"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">98000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      decimals="INF"
      id="Tc_JnonAZg8tEKsU7FS_xv3nw_11_2"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">11908</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      decimals="2"
      id="Tc_ttEidR7r906ymderfHZ7ag_11_5"
      unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q">48.67</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA"
      decimals="INF"
      id="Tc_9-9JcLnQEke3ssPsgm_bJw_12_2"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">2439651</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA"
      decimals="2"
      id="Tc_TnzBp82gSEas9-wvlNIrXg_12_5"
      unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q">5.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Tc_-NDD9k0xckCdFXW8RVgPtQ_12_7">P8Y2M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA"
      decimals="0"
      id="Tc_88Eigdu5TkWbDy9WWilSkg_12_10"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">609000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA"
      decimals="INF"
      id="Tc_ls0v5vEaZE2XraKOLhPhuQ_13_2"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">2439651</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA"
      decimals="2"
      id="Tc_Kz6kPzo0fEuJKJB1n1x8ww_13_5"
      unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q">5.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Tc_zN4hUJcg30ukW0XOohxrLA_13_7">P8Y2M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA"
      decimals="0"
      id="Tc_4YrMwclAmkev3WSOW4RfBA_13_10"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">609000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA"
      decimals="INF"
      id="Tc_b7bGCQzTU06PoEnhdP5t4g_14_2"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">733721</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA"
      decimals="2"
      id="Tc_nA0sMj9peke-YboNvllHTw_14_5"
      unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q">9.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Tc_c3n5a02F2UWaWhejjayezw_14_7">P6Y6M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA"
      decimals="0"
      id="Tc_JKwYX2Upb0ulIF683zMMrQ_14_10"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">252000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <armp:ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Tb_SOYehXkkdEm18jByP9QMZg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;Restricted stock awards and restricted stock units during the nine months ended September 30, 2021 are presented below: &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted Avg&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December 31, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 322,756&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 19.55&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited/Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,047)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 6.89&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested and Issued as Common Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (167,691)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 12.33&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at September&#160;30,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 154,018&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 27.49&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;     &lt;/span&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</armp:ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_TDb9Z5iGoUePxWE6REEZBg"
      decimals="INF"
      id="Tc_AiCEJ6oSQEmzdPzSjivTiw_4_2"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">322756</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_TDb9Z5iGoUePxWE6REEZBg"
      decimals="2"
      id="Tc_bSwhliAVEES44eTF2pXEqQ_4_5"
      unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q">19.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_uMrMSnX6sk6VBfvSkKl9Vg"
      decimals="INF"
      id="Tc_0l4SBd3hbECisgfSd97ycw_6_2"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">1047</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_uMrMSnX6sk6VBfvSkKl9Vg"
      decimals="2"
      id="Tc_GH67I8p-YEqT3jUfV4qx6g_6_5"
      unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q">6.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_uMrMSnX6sk6VBfvSkKl9Vg"
      decimals="INF"
      id="Tc_ntG8Hn0VUU2p2IgK5ypgnw_7_2"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">167691</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_uMrMSnX6sk6VBfvSkKl9Vg"
      decimals="2"
      id="Tc_2IUMg_lupkWCawbqeoljhw_7_5"
      unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q">12.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_UrkFQ9x-qEmjvoP_lxEMWQ"
      decimals="INF"
      id="Tc_iPT2uSbTtU-AfDw7i-lqsQ_8_2"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">154018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_UrkFQ9x-qEmjvoP_lxEMWQ"
      decimals="2"
      id="Tc_knJyw7xpykC5MzIYNnUVUA_8_5"
      unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q">27.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharePrice
      contextRef="As_Of_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_joNmkWmSp0eoVV34drwlKA"
      decimals="2"
      id="Narr_zMj_xreAbU-oFmAMbW410w"
      unitRef="Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q">3.62</us-gaap:SharePrice>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_joNmkWmSp0eoVV34drwlKA"
      decimals="-5"
      id="Narr_bXOX3UdRikSziF6X--Fr2A"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">3900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_armp_StockOptionsAndRestrictedStockAwardsMember_pNotzPzMhUuSettHWcT5dw"
      id="Narr_ZkSdQsPah0-A5zvpfxrMtg">P1Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <armp:ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Tb_7RIzWjyxL0iMZyUtb48o2A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;As of September 30, 2021, the Company had reserved shares of its common stock for future issuance as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&#160;Reserved&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:top;width:84.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock options outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,439,651&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:84.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unvested restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 30,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:top;width:84.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Employee stock purchase plan&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 9,748&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:84.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Available for future grants under the 2016 Plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 227,856&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:top;width:84.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrants outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 16,647,219&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:84.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total shares reserved&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 19,354,474&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</armp:ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA"
      decimals="INF"
      id="Tc_HKQIeuwM4Ei-Kss2c3BNRg_2_2"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">2439651</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_hi0c_0vE9E-W67zzRNTT2g"
      decimals="INF"
      id="Tc_x67k3SMdNkCNExDjRcPbGA_3_2"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">30000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_joNmkWmSp0eoVV34drwlKA"
      decimals="INF"
      id="Tc_uIBRjoBgc0muX7tWNlx7Zg_4_2"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">9748</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_9_30_2021_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_armp_EquityIncentivePlan2016Member_nK9yLVbEL06fLvTMqAkXxg"
      decimals="INF"
      id="Tc_im9GablRjkeZZjuIuXi20w_5_2"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">227856</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA"
      decimals="INF"
      id="Tc_Qawt27rV906ktG1cA9YYyw_6_2"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">16647219</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA"
      decimals="INF"
      id="Tc_Xxj7S6sYl0CsSij_m2QllA_7_2"
      unitRef="Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg">19354474</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Tb_goDr4Ik9fUGt2bT1Lwseig">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;9. Commitments and Contingencies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company leases office and research and development space under a non-cancelable operating lease in Marina del Rey, CA. The lease commenced January&#160;1, 2012 and in April 2020, the Company amended the lease (&#x201c;Lease Amendment&#x201d;) which, among other things, extended the lease term through December 31, 2031. Base annual rent for calendar year 2022, the first year under the Lease Amendment extended term, will be approximately $1.9 million, and base rent increases by 3% annually and will be $2.5&lt;span style="white-space:pre-wrap;"&gt; million by the end of the amended term.  In addition, the Company received a six-month rent abatement in 2020. The Company is entitled to use an allowance for tenant improvements of &lt;/span&gt;$0.8 million during 2021, with any unused tenant improvement amount as of December 31, 2021 to offset future payments. In accordance with authoritative guidance, the Company re-measured the lea&lt;span style="background-color:#ffffff;color:#222222;"&gt;se liability in April 2020 to be &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#222222;"&gt;$11.7&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#222222;"&gt; million and related&#160;right of use asset of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#222222;"&gt;$11.0&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#222222;"&gt; million as of the Lease Amendment date with an incremental borrowing rate of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#222222;"&gt;12.89%&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#222222;"&gt;. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background-color:#ffffff;color:#222222;"&gt;On October 28, 2021, the Company entered into a lease for office and research and development space under a non-cancellable lease in Los Angeles, CA (the &#x201c;2021 Lease&#x201d;). The 2021 Lease payment start date is May 1, 2022 and the total lease term is for &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#222222;"&gt;16 years&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#222222;"&gt; and runs through 2038. Monthly rent for 2022 and 2023 will be fully or partially abated while the lessor and the Company complete planned tenant improvements to the facility. Base monthly rent will be approximately &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#222222;"&gt;$0.25&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#222222;"&gt; million in 2024. The Company is entitled to receive an allowance for tenant improvements of up to &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#222222;"&gt;$6.5&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#222222;white-space:pre-wrap;"&gt; million.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;From time to time, the Company may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of business. Any of these claims could subject the Company to costly legal expenses and, while management generally believes that there is adequate insurance to cover many different types of liabilities, the Company&#x2019;s insurance carriers may deny coverage or policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on the consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage the Company&#x2019;s reputation and business. The Company is currently not a party to any legal proceedings, &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;the adverse outcome of which, in management&#x2019;s opinion, individually or in the aggregate, would have a material adverse effect on our consolidated results of operations or financial position.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <armp:OperatingLeaseBaseRent
      contextRef="Duration_4_1_2020_To_4_30_2020_97rB72XwWUSnYAu0RGwgjQ"
      decimals="-5"
      id="Narr_SdEVG1sj7UO58d6EhJYSiQ"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">1900000</armp:OperatingLeaseBaseRent>
    <armp:AnnualIncreaseInRentPercentage
      contextRef="Duration_4_1_2020_To_4_30_2020_97rB72XwWUSnYAu0RGwgjQ"
      decimals="2"
      id="Narr_-g-SEEGIV0mlwX0i5V0pVg"
      unitRef="Unit_Standard_pure_EPrTQjTDQkGfR4N7mgNYUg">0.03</armp:AnnualIncreaseInRentPercentage>
    <armp:OperatingLeaseBaseRentEndOfLeaseTerm
      contextRef="Duration_4_1_2020_To_4_30_2020_97rB72XwWUSnYAu0RGwgjQ"
      decimals="-5"
      id="Narr_Sn-fqXh6B0Ox5VMJzJN-3A"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">2500000</armp:OperatingLeaseBaseRentEndOfLeaseTerm>
    <armp:LeaseAndRentalAbatementCredit
      contextRef="Duration_4_1_2020_To_4_30_2020_97rB72XwWUSnYAu0RGwgjQ"
      decimals="-5"
      id="Narr_pN-P5jzCn0uc_8j2evihqQ"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">800000</armp:LeaseAndRentalAbatementCredit>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_4_30_2020_1iPl4CxS1EenIgtFs0sC1g"
      decimals="-5"
      id="Narr_C0uec1SFo06bsyYQQFeA1g"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">11700000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_4_30_2020_1iPl4CxS1EenIgtFs0sC1g"
      decimals="-5"
      id="Narr_5A63Ey2QnEaC_ETzms82AA"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">11000000.0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="As_Of_4_30_2020_1iPl4CxS1EenIgtFs0sC1g"
      decimals="4"
      id="Narr_qHtYj7jSJUyVkCDR19tnUA"
      unitRef="Unit_Standard_pure_EPrTQjTDQkGfR4N7mgNYUg">0.1289</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1
      contextRef="As_Of_10_31_2021_egZlLrGpKk2-r-0udRYIlQ"
      id="Narr_P9zda716GU-9NzjCDjFb0g">P16Y</us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1>
    <armp:BaseAnnualRentToBePaidYearOne
      contextRef="As_Of_10_31_2021_egZlLrGpKk2-r-0udRYIlQ"
      decimals="-4"
      id="Narr_Qs_y_0LSkkCVGT50EyhmRg"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">250000</armp:BaseAnnualRentToBePaidYearOne>
    <armp:MaximumAllowanceForTenantImprovementsReceivable
      contextRef="As_Of_10_31_2021_egZlLrGpKk2-r-0udRYIlQ"
      decimals="-5"
      id="Narr_0OPjtn7XXkCjgdPPYkDX4Q"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">6500000</armp:MaximumAllowanceForTenantImprovementsReceivable>
    <armp:AwardTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Tb_T6XRdTFWGkq0Xyb2v6mydQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;10. Grants and Awards&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;MTEC Grant &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On June 15, 2020, the Company entered into a Research Project Award agreement (the &#x201c;MTEC Agreement&#x201d;) with the Medical Technology Enterprise Consortium (&#x201c;MTEC&#x201d;), pursuant to which the Company expects to receive a $15.0 million&#160;grant and entered into a three-year program administered by the U.S. Department of Defense through MTEC with funding from the Defense Health Agency and Joint Warfighter Medical Research Program. The MTEC funds are to partially fund a Phase&#160;1b/2, randomized, double-blind, placebo-controlled, dose escalation clinical study of Armata's therapeutic phage-based candidate, AP-SA02, for the treatment of complicated&#160;&lt;i style="font-style:italic;"&gt;Staphylococcus aureus&lt;/i&gt;&#160;bacteremia infections. The MTEC Agreement specifies that the grant will be paid to the Company through a cost reimbursable model, based on agreed upon cost share percentages, and the grant money received is not refundable to MTEC. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;width:36pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; &#160; &#160; &#160; &#160;&lt;/span&gt;&lt;/span&gt;Upon license or commercialization of intellectual property developed with the funding from the MTEC Agreement, additional fees will be due to MTEC. &#160;The Company will elect whether to (a) pay a fixed royalty amount, which is subject to a cap based upon total funding received, or (b) pay an additional assessment fee, which would also be subject to a cap based upon a percentage of total funding received. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The MTEC Agreement will be effective through January 25, 2024. &#160;The MTEC Agreement may be terminated in whole or in part, 30 calendar days following the written notice from the Company to MTEC. In addition, MTEC has the right to terminate the MTEC Agreement upon material breach by the Company. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company determined that the MTEC Agreement is not in the scope of ASC 808 or ASC 606. Applying ASC 606 by analogy the Company recognizes proceeds received under the MTEC Agreement as grant revenue on the statement of operations when related costs are incurred. The Company recognized $1.3 million and $3.5 million in grant revenue from the MTEC Agreement during the three and nine months ended September 30, 2021, respectively. The Company recognized $0.3 million in grant revenue from the MTEC Agreement during each of the three and nine months ended September 30, 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;CFF Therapeutics Development Award &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;On March 13, 2020, the Company entered into an award agreement (the &#x201c;Agreement&#x201d;) with CFF, pursuant to which the Company received a Therapeutics Development Award of up to $5.0 million (the &#x201c;Award&#x201d;). The Award will be used to fund a portion of the Company&#x2019;s Phase 1b/2 clinical trial of the&#160;&lt;i style="font-style:italic;"&gt;Pseudomonas aeruginosa&lt;/i&gt;&#160;(&#x201c;&lt;i style="font-style:italic;"&gt;P. aeruginosa&lt;/i&gt;&#x201d;) phage candidate, AP-PA02, as a treatment for&#160;&lt;i style="font-style:italic;"&gt;Pseudomonas&lt;/i&gt;&#160;airway infections in people with cystic fibrosis (&#x201c;CF&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The first payment under the Agreement, in the amount of $1.0 million, became due upon signing the Agreement and was received in April 2020. During the quarter ended September 30, 2021, an additional $0.8&lt;span style="white-space:pre-wrap;"&gt; million was received upon achievement of a milestone.  The remainder of the Award will be paid to the Company incrementally in installments upon the achievement of certain milestones related to the development program and progress of the Phase 1b/2 clinical trial of AP-PA02, as set forth in the Agreement. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;If the Company ceases to use commercially reasonable efforts directed to the development of AP-PA02, or any other Product (as defined in the Agreement), for a period of 360 days (an &#x201c;Interruption&#x201d;) and fails to resume the development of the Product after receiving from CFF notice of an Interruption, then the Company must either repay the amount of the Award actually received by the Company, plus interest, or grant to CFF (1) an exclusive (even as to the Company), worldwide, perpetual, sublicensable license under technology developed under the Agreement that covers the Product for use in treating infections in CF patients (the &#x201c;CF Field&#x201d;), and (2) a non-exclusive, worldwide, perpetual, sublicensable license under certain background intellectual property covering the Product, to the extent necessary to commercialize the Product in the CF Field.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Upon commercialization by the Company of any Product, the Company will owe a fixed royalty amount to CFF, which is to be paid in installments determined, in part, based on commercial sales volumes of the Product. The Company will be obligated to make an additional fixed royalty payment upon achieving specified sales milestones. The Company may also be obligated to make a payment to CFF if the Company transfers, sells or licenses the Product in the CF Field, or if the Company enters into a change of control transaction.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;&#160;&lt;/span&gt;&lt;/span&gt;The term of the Agreement commenced on March 10, 2020 and expires on the earlier of the date on which the Company has paid CFF all of the fixed royalty payments set forth therein, the effective date of any license granted to CFF following an Interruption, or upon earlier termination of the Agreement. Either CFF or the Company may terminate the agreement for cause, which includes the Company&#x2019;s material failure to achieve certain development milestones. The Company&#x2019;s payment obligations survive the termination of the Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company concluded that the CFF award is in the scope of ASC 808. Accordingly, as discussed in Note 3, award amounts received from CFF upon achievement of certain milestones are recognized as credits to research and development expenses in the period the expenses are incurred. During the three months ended September 30, 2021 and 2020, the Company did not recognize any credits to research and development expenses related to the CFF award. During the nine months ended September 30, 2021 and 2020, the Company recognized $0.8 million and $1.0&lt;span style="white-space:pre-wrap;"&gt; million in credits to research and development expenses related to the CFF award, respectively. In addition, the Company concluded under the guidance in ASC 730 that it does not have an obligation to repay funds received once related research and development expenses are incurred.  &lt;/span&gt;&lt;/p&gt;</armp:AwardTextBlock>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="Duration_7_15_2020_To_7_15_2020_srt_CounterpartyNameAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_ITaRqTiHmk-EtdzqEDU-gw"
      decimals="-5"
      id="Narr_XJTKfs1BgU6aKmB9oA0JIQ"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">15000000.0</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="Duration_7_1_2021_To_9_30_2021_EHL267Iy5kqlAVaXmlK6uQ"
      decimals="-5"
      id="Narr_8IfgGJqHjUuc9MdCF_xeEg"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">1300000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      decimals="-5"
      id="Narr__wz_Ubkz9kiqMQn19eZlbQ"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">3500000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw"
      decimals="-5"
      id="Narr__NnXVV8gI0aDX6BEYieDeQ"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">300000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="Duration_7_1_2020_To_9_30_2020_C3Blutz6cUqC03qQKsaYEg"
      decimals="-5"
      id="Narr_gCtQYfAjjU6QBzL_6G8sSA"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">300000</us-gaap:RevenueNotFromContractWithCustomer>
    <armp:ThresholdDevelopmentAward
      contextRef="As_Of_3_13_2020_dei_LegalEntityAxis_armp_CysticFibrosisFoundationMember_srt_RangeAxis_srt_MaximumMember_QdkZoWNHYkyCGniRryGR1w"
      decimals="-5"
      id="Narr_vzkAwgdWI0GBjvg_8vAGyA"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">5000000.0</armp:ThresholdDevelopmentAward>
    <armp:AwardReceivable
      contextRef="As_Of_3_13_2020_dei_LegalEntityAxis_armp_CysticFibrosisFoundationMember_Vmk5a-OLzkuheIihAx82BA"
      decimals="-5"
      id="Narr_Gr3H9cU3L0WmGGPi3YHbrw"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">1000000.0</armp:AwardReceivable>
    <armp:AmountReceivedUponAchievementOfMilestone
      contextRef="Duration_7_1_2021_To_9_30_2021_dei_LegalEntityAxis_armp_CysticFibrosisFoundationMember_tYChB5g8O0GcrXG6pdzhcA"
      decimals="-5"
      id="Narr_lL_Q4Ab-jUKIZxnba79k5Q"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">800000</armp:AmountReceivedUponAchievementOfMilestone>
    <armp:AwardAgreementInterruptionPeriod
      contextRef="Duration_3_13_2020_To_3_13_2020_dei_LegalEntityAxis_armp_CysticFibrosisFoundationMember_bkw-_kZsEUWVZ6CfCvxnag"
      id="Narr_Rl9vaqdtIES5htHknBnlCA">P360D</armp:AwardAgreementInterruptionPeriod>
    <armp:ResearchAndDevelopmentCreditsRecognized
      contextRef="Duration_1_1_2021_To_9_30_2021_dei_LegalEntityAxis_armp_CysticFibrosisFoundationMember_RpwT93VR-ECLCn7xD0c95g"
      decimals="-5"
      id="Narr_A6Y80DgIx0KN1-ijysfYbA"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">800000</armp:ResearchAndDevelopmentCreditsRecognized>
    <armp:ResearchAndDevelopmentCreditsRecognized
      contextRef="Duration_1_1_2020_To_9_30_2020_dei_LegalEntityAxis_armp_CysticFibrosisFoundationMember_oDkg0nbvCUGTMxn-UCPsfA"
      decimals="-5"
      id="Narr_OaASiwxC0Eq5FZJwGv5Dmg"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">1000000.0</armp:ResearchAndDevelopmentCreditsRecognized>
    <armp:AssetAcquisitionTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      id="Tb_FAjFAcysCk-hpcvErqiDWw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;11. Synthetic Genomics Asset Acquisition &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On February&#160;28, 2018, C3J completed an acquisition of certain synthetic phage assets (the &#x201c;synthetic phage assets&#x201d;) from Synthetic Genomics, Inc. (&#x201c;SGI&#x201d;) for consideration consisting of $8.0 million in cash and $27.0 million in equity. The cash payments consisted of: $1.0 million paid at closing on February 28, 2018, $1.0 million at one year from closing, $1.0 million at two years from closing, and $5.0 million at three years from closing (the payments due on the one, two, three year anniversary are collectively the &#x201c;time-based payment obligation&#x201d;). The equity payment (the &#x201c;equity payment&#x201d; and, together with the time-based payment obligation, the &#x201c;deferred purchase price arrangement&#x201d;) was due upon the earlier of the initial public offering of shares of C3J&#x2019;s common stock pursuant to an effective registration statement under the Securities Act of 1933, as amended, the sale of all or substantially all of C3J&#x2019;s assets to a third party, or a consolidation or merger into a third party. On December&#160;20, 2018, in contemplation of the Merger (see Note&#160;1), the deferred purchase price arrangement was amended. Under the amended agreement, the purchase consideration consisted of (i)&#160;closing consideration of $1.0 million paid on February&#160;28, 2018, (ii)&#160;cash payments of $1.0 million on January&#160;31, 2019, $1.0 million on January&#160;31, 2020, and $2.0 million on January&#160;31, 2021, (iii)&#160;an issuance of that number of shares of C3J&#x2019;s common stock equal to ten&#160;percent of C3J&#x2019;s fully-diluted capitalization, excluding options and restricted stock awards, immediately prior to the closing of the Merger, and (iv)&#160;potential milestone payments of up to $39.5 million related to the development and relevant regulatory approval of products utilizing bacteriophage from the synthetic phage assets acquired from SGI (the &#x201c;milestone payment obligation&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The equity payment was settled on May 9, 2019, the date of the Merger (Note 1). &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The present value of the time-based payment obligations was included in the Company&#x2019;s balance sheet, with interest accreted to the maturity date. The Company paid the last installment of the time-based payment obligation in the amount of $2.0 million during the three months ended March 31, 2021. For the nine months ended September 30, 2021 and 2020, the Company recognized $0.1 million and $0.5 million of interest expense related to the time-based payment obligations, respectively.&lt;/p&gt;</armp:AssetAcquisitionTextBlock>
    <armp:CashPaidForProductiveAssets
      contextRef="As_Of_2_28_2018_armp_AssetAcquisitionAxis_armp_SyntheticGenomicsIncMember_dei_LegalEntityAxis_armp_C3jTherapeuticsIncMember_mk1RLuCDkk6c_shfOgofxw"
      decimals="-5"
      id="Narr_21YBChtJs0SnLso8ISd_LA"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">8000000.0</armp:CashPaidForProductiveAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="Duration_2_28_2018_To_2_28_2018_armp_AssetAcquisitionAxis_armp_SyntheticGenomicsIncMember_dei_LegalEntityAxis_armp_C3jTherapeuticsIncMember_RidG05BOeEyASZ1M8D09rA"
      decimals="-5"
      id="Narr_lbNnDYDfvkCunF3nqqgquA"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">27000000.0</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="Duration_2_28_2018_To_2_28_2018_armp_AssetAcquisitionAxis_armp_SyntheticGenomicsIncMember_dei_LegalEntityAxis_armp_C3jTherapeuticsIncMember_srt_StatementScenarioAxis_armp_ScenarioOriginalExpectedPaymentOneMember_clsnrNZH1UazMXYm92c0Pg"
      decimals="-5"
      id="Narr_58cAe3JpakabZ7EeRXvqGA"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">1000000.0</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="Duration_2_28_2018_To_2_28_2018_armp_AssetAcquisitionAxis_armp_SyntheticGenomicsIncMember_dei_LegalEntityAxis_armp_C3jTherapeuticsIncMember_srt_StatementScenarioAxis_armp_ScenarioOriginalExpectedPaymentTwoMember_gEaPDWofx0qOEWXTSGF3Tw"
      decimals="-5"
      id="Narr_euZqF872M0KAAdepcL_y0A"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">1000000.0</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="Duration_2_28_2018_To_2_28_2018_armp_AssetAcquisitionAxis_armp_SyntheticGenomicsIncMember_dei_LegalEntityAxis_armp_C3jTherapeuticsIncMember_srt_StatementScenarioAxis_armp_ScenarioOriginalExpectedPaymentThreeMember_jidGEQgNYECfuWhjbDYubA"
      decimals="-5"
      id="Narr_noevNoeUiUq3YWUVx8Td2w"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">1000000.0</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="Duration_2_28_2018_To_2_28_2018_armp_AssetAcquisitionAxis_armp_SyntheticGenomicsIncMember_dei_LegalEntityAxis_armp_C3jTherapeuticsIncMember_srt_StatementScenarioAxis_armp_ScenarioOriginalExpectedPaymentFourMember_gxbq2ISe3UijfOm_OFNWLw"
      decimals="-5"
      id="Narr_AI-j1D9540CvPPT4YeRGCg"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">5000000.0</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="Duration_2_28_2018_To_2_28_2018_armp_AssetAcquisitionAxis_armp_SyntheticGenomicsIncMember_dei_LegalEntityAxis_armp_C3jTherapeuticsIncMember_RidG05BOeEyASZ1M8D09rA"
      decimals="-5"
      id="Narr_ClnA7Gh2ZUKe4gRN55_XEg"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">1000000.0</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="Duration_12_20_2018_To_12_20_2018_armp_AssetAcquisitionAxis_armp_SyntheticGenomicsIncMember_dei_LegalEntityAxis_armp_C3jTherapeuticsIncMember_srt_StatementScenarioAxis_armp_ScenarioAmendedExpectedPaymentOneMember_zNXu_So6HEuNH4kwwRcmWw"
      decimals="-5"
      id="Narr_wgr4-YBNn0SDlniTKP0k2g"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">1000000.0</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="Duration_12_20_2018_To_12_20_2018_armp_AssetAcquisitionAxis_armp_SyntheticGenomicsIncMember_dei_LegalEntityAxis_armp_C3jTherapeuticsIncMember_srt_StatementScenarioAxis_armp_ScenarioAmendedExpectedPaymentTwoMember_rqhFNiTiRE2BmMr7XyphyQ"
      decimals="-5"
      id="Narr_sSsCYeKa0k-Rg-1wceAZ7A"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">1000000.0</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="Duration_12_20_2018_To_12_20_2018_armp_AssetAcquisitionAxis_armp_SyntheticGenomicsIncMember_dei_LegalEntityAxis_armp_C3jTherapeuticsIncMember_srt_StatementScenarioAxis_armp_ScenarioAmendedExpectedPaymentThreeMember_R1Aa4SvwlUuog7rLKl3MqA"
      decimals="-5"
      id="Narr_Mv2fGIL5Y0eI1jcKSuxdTA"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">2000000.0</us-gaap:PaymentsToAcquireProductiveAssets>
    <armp:PercentageOfFullyDilutedCapitalizationForIssuanceOfCommonStock
      contextRef="Duration_2_1_2018_To_2_28_2018_armp_AssetAcquisitionAxis_armp_SyntheticGenomicsIncMember_dei_LegalEntityAxis_armp_C3jTherapeuticsIncMember_Z8D7DoUmZ0qMYFL0DwXLPw"
      decimals="INF"
      id="Narr_2EF_DCyfb0S_eETDfoNGgQ"
      unitRef="Unit_Standard_pure_EPrTQjTDQkGfR4N7mgNYUg">0.10</armp:PercentageOfFullyDilutedCapitalizationForIssuanceOfCommonStock>
    <armp:MaximumPotentialMilestonePayments
      contextRef="Duration_2_1_2018_To_2_28_2018_armp_AssetAcquisitionAxis_armp_SyntheticGenomicsIncMember_dei_LegalEntityAxis_armp_C3jTherapeuticsIncMember_Z8D7DoUmZ0qMYFL0DwXLPw"
      decimals="-5"
      id="Narr_SEfw6pdqykGnCQyuoEP6JQ"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">39500000</armp:MaximumPotentialMilestonePayments>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="Duration_1_1_2021_To_3_31_2021_armp_AssetAcquisitionAxis_armp_SyntheticGenomicsIncMember_dei_LegalEntityAxis_armp_C3jTherapeuticsIncMember_NBfmWnEmKk6A5v2Z9Ffejw"
      decimals="-5"
      id="Narr_gTPLyV9pzkmTlW5wt51kGw"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">2000000.0</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA"
      decimals="-5"
      id="Narr__O_0QSzHPEO2arABuaglPQ"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">100000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2020_To_9_30_2020_9a2Odvt8K0Szx4rFw8gOmw"
      decimals="-5"
      id="Narr_QxTgJ0E1T0KyDduYvntqQw"
      unitRef="Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g">500000</us-gaap:InterestExpense>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140428514820840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Nov. 05, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Armata Pharmaceuticals, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">WA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">91-1549568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4503 Glencoe Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Marina del Rey<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">90292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">665-2928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ARMP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,086,299<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000921114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140428590932024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 12,076,000<span></span>
</td>
<td class="nump">$ 9,649,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_AwardReceivable', window );">Awards receivable</a></td>
<td class="nump">1,251,000<span></span>
</td>
<td class="nump">561,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">851,000<span></span>
</td>
<td class="nump">636,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">14,178,000<span></span>
</td>
<td class="nump">10,846,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,107,000<span></span>
</td>
<td class="nump">2,047,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">10,531,000<span></span>
</td>
<td class="nump">10,790,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">In-process research and development</a></td>
<td class="nump">10,256,000<span></span>
</td>
<td class="nump">10,256,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">3,490,000<span></span>
</td>
<td class="nump">3,490,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">909,000<span></span>
</td>
<td class="nump">887,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">42,671,000<span></span>
</td>
<td class="nump">39,516,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">1,811,000<span></span>
</td>
<td class="nump">1,929,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityCurrent', window );">Accrued compensation</a></td>
<td class="nump">1,714,000<span></span>
</td>
<td class="nump">563,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">1,729,000<span></span>
</td>
<td class="nump">1,551,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_PaycheckProtectionProgramLoan', window );">PPP Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">722,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Deferred asset acquisition consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,940,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">5,254,000<span></span>
</td>
<td class="nump">6,705,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">10,585,000<span></span>
</td>
<td class="nump">10,877,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">3,077,000<span></span>
</td>
<td class="nump">3,077,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">18,916,000<span></span>
</td>
<td class="nump">20,659,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value; 217,000,000 shares authorized; 24,965,086 and 18,688,461 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">249,000<span></span>
</td>
<td class="nump">187,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">220,316,000<span></span>
</td>
<td class="nump">198,372,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(196,810,000)<span></span>
</td>
<td class="num">(179,702,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">23,755,000<span></span>
</td>
<td class="nump">18,857,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 42,671,000<span></span>
</td>
<td class="nump">$ 39,516,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_AwardReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount as of the balance sheet date of award receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_AwardReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_PaycheckProtectionProgramLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Paycheck protection program loan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_PaycheckProtectionProgramLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable within one year (or the operating cycle, if longer). Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=6409733&amp;loc=d3e19512-108361<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 30<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6409875&amp;loc=d3e20028-108363<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140428510058232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">217,000,000<span></span>
</td>
<td class="nump">217,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">24,965,086<span></span>
</td>
<td class="nump">18,688,461<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">24,965,086<span></span>
</td>
<td class="nump">18,688,461<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140428590838120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Consolidated Statements of Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Grant revenue</a></td>
<td class="nump">$ 1,251,000<span></span>
</td>
<td class="nump">$ 288,000<span></span>
</td>
<td class="nump">$ 3,485,000<span></span>
</td>
<td class="nump">$ 319,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">5,626,000<span></span>
</td>
<td class="nump">4,066,000<span></span>
</td>
<td class="nump">15,201,000<span></span>
</td>
<td class="nump">9,464,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">1,768,000<span></span>
</td>
<td class="nump">1,845,000<span></span>
</td>
<td class="nump">6,058,000<span></span>
</td>
<td class="nump">5,989,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">7,394,000<span></span>
</td>
<td class="nump">5,911,000<span></span>
</td>
<td class="nump">21,259,000<span></span>
</td>
<td class="nump">15,453,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(6,143,000)<span></span>
</td>
<td class="num">(5,623,000)<span></span>
</td>
<td class="num">(17,774,000)<span></span>
</td>
<td class="num">(15,134,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpensesAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_GainLossOnExtinguishmentOfPaycheckProtectionProgramSinceInception', window );">Gain upon extinguishment of Paycheck Protection Program loan</a></td>
<td class="nump">726,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">726,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(2,000)<span></span>
</td>
<td class="num">(150,000)<span></span>
</td>
<td class="num">(64,000)<span></span>
</td>
<td class="num">(451,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">724,000<span></span>
</td>
<td class="num">(146,000)<span></span>
</td>
<td class="nump">666,000<span></span>
</td>
<td class="num">(423,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (5,419,000)<span></span>
</td>
<td class="num">$ (5,769,000)<span></span>
</td>
<td class="num">$ (17,108,000)<span></span>
</td>
<td class="num">$ (15,557,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Per share information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="num">$ (0.31)<span></span>
</td>
<td class="num">$ (0.73)<span></span>
</td>
<td class="num">$ (0.99)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average shares outstanding, basic and diluted</a></td>
<td class="nump">24,820,233<span></span>
</td>
<td class="nump">18,394,614<span></span>
</td>
<td class="nump">23,363,113<span></span>
</td>
<td class="nump">15,740,858<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_GainLossOnExtinguishmentOfPaycheckProtectionProgramSinceInception">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on extinguishment of paycheck protection program since inception.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_GainLossOnExtinguishmentOfPaycheckProtectionProgramSinceInception</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueNotFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue that is not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueNotFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140428591048808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2019</a></td>
<td class="nump">$ 99,000<span></span>
</td>
<td class="nump">$ 172,015,000<span></span>
</td>
<td class="num">$ (157,521,000)<span></span>
</td>
<td class="nump">$ 14,593,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in shares) at Dec. 31, 2019</a></td>
<td class="nump">9,922,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Forfeiture of restricted stock awards (in shares)</a></td>
<td class="num">(4,010)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock, net of issuance costs</a></td>
<td class="nump">$ 87,000<span></span>
</td>
<td class="nump">22,723,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,810,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock, net of issuance costs (in shares)</a></td>
<td class="nump">8,710,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_StockIssuedDuringPeriodValueExerciseOfWarrants', window );">Exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Exercise of warrants (in shares)</a></td>
<td class="nump">14,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings', window );">Return of restricted stock awards for tax withholdings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings', window );">Return of restricted stock awards for tax withholdings, shares</a></td>
<td class="num">(2,511)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise stock options</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">86,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">27,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,613,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,613,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,557,000)<span></span>
</td>
<td class="num">(15,557,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Sep. 30, 2020</a></td>
<td class="nump">$ 187,000<span></span>
</td>
<td class="nump">197,510,000<span></span>
</td>
<td class="num">(173,078,000)<span></span>
</td>
<td class="nump">24,619,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in shares) at Sep. 30, 2020</a></td>
<td class="nump">18,668,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Jun. 30, 2020</a></td>
<td class="nump">$ 186,000<span></span>
</td>
<td class="nump">196,761,000<span></span>
</td>
<td class="num">(167,309,000)<span></span>
</td>
<td class="nump">29,638,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in shares) at Jun. 30, 2020</a></td>
<td class="nump">18,641,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise stock options</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">86,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">27,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">663,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">663,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,769,000)<span></span>
</td>
<td class="num">(5,769,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Sep. 30, 2020</a></td>
<td class="nump">$ 187,000<span></span>
</td>
<td class="nump">197,510,000<span></span>
</td>
<td class="num">(173,078,000)<span></span>
</td>
<td class="nump">24,619,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in shares) at Sep. 30, 2020</a></td>
<td class="nump">18,668,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2020</a></td>
<td class="nump">$ 187,000<span></span>
</td>
<td class="nump">198,372,000<span></span>
</td>
<td class="num">(179,702,000)<span></span>
</td>
<td class="nump">18,857,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in shares) at Dec. 31, 2020</a></td>
<td class="nump">18,688,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Forfeiture of restricted stock awards (in shares)</a></td>
<td class="num">(1,047)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock, net of issuance costs</a></td>
<td class="nump">$ 61,000<span></span>
</td>
<td class="nump">19,302,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,363,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock, net of issuance costs (in shares)</a></td>
<td class="nump">6,153,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_StockIssuedDuringPeriodValueExerciseOfWarrants', window );">Exercise of warrants</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">290,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">291,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Exercise of warrants (in shares)</a></td>
<td class="nump">52,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings', window );">Return of restricted stock awards for tax withholdings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(106,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(106,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings', window );">Return of restricted stock awards for tax withholdings, shares</a></td>
<td class="num">(25,424)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 240,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">73,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_StockIssuedDuringPeriodSharesInducementStockAwards', window );">Issuance of inducement stock awards (in shares)</a></td>
<td class="nump">23,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,218,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,218,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,108,000)<span></span>
</td>
<td class="num">(17,108,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Sep. 30, 2021</a></td>
<td class="nump">$ 249,000<span></span>
</td>
<td class="nump">220,316,000<span></span>
</td>
<td class="num">(196,810,000)<span></span>
</td>
<td class="nump">23,755,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in shares) at Sep. 30, 2021</a></td>
<td class="nump">24,965,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Jun. 30, 2021</a></td>
<td class="nump">$ 249,000<span></span>
</td>
<td class="nump">219,761,000<span></span>
</td>
<td class="num">(191,391,000)<span></span>
</td>
<td class="nump">28,619,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in shares) at Jun. 30, 2021</a></td>
<td class="nump">24,937,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Forfeiture of restricted stock awards (in shares)</a></td>
<td class="num">(123)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">27,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">469,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">469,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,419,000)<span></span>
</td>
<td class="num">(5,419,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Sep. 30, 2021</a></td>
<td class="nump">$ 249,000<span></span>
</td>
<td class="nump">$ 220,316,000<span></span>
</td>
<td class="num">$ (196,810,000)<span></span>
</td>
<td class="nump">$ 23,755,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in shares) at Sep. 30, 2021</a></td>
<td class="nump">24,965,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted stock returned shares issued net of tax withholdings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted stock returned value shares issued net of tax withholdings .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_StockIssuedDuringPeriodSharesExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued on exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_StockIssuedDuringPeriodSharesExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_StockIssuedDuringPeriodSharesInducementStockAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of inducement stock awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_StockIssuedDuringPeriodSharesInducementStockAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_StockIssuedDuringPeriodValueExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of shares issued on exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_StockIssuedDuringPeriodValueExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares related to Restricted Stock Award forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140428514779896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (17,108,000)<span></span>
</td>
<td class="num">$ (15,557,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">892,000<span></span>
</td>
<td class="nump">840,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_GainLossOnExtinguishmentOfPaycheckProtectionProgramLoan', window );">Gain upon extinguishment of Paycheck Protection Program loan</a></td>
<td class="nump">722,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">2,218,000<span></span>
</td>
<td class="nump">2,613,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashExpense', window );">Non-cash interest expense</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="nump">457,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_AccruedInterestForDeferredConsiderationOnAssetAcquisition', window );">Payment of accreted interest for deferred consideration for asset acquisition</a></td>
<td class="num">(586,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_IncreaseDecreaseInAwardReceivable', window );">Award receivable</a></td>
<td class="num">(690,000)<span></span>
</td>
<td class="num">(241,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="num">(100,000)<span></span>
</td>
<td class="nump">492,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredCompensation', window );">Accrued compensation</a></td>
<td class="nump">1,151,000<span></span>
</td>
<td class="num">(21,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet', window );">Operating lease right-of-use asset and liability, net</a></td>
<td class="nump">145,000<span></span>
</td>
<td class="nump">611,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(237,000)<span></span>
</td>
<td class="num">(1,162,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(14,977,000)<span></span>
</td>
<td class="num">(11,968,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(1,076,000)<span></span>
</td>
<td class="num">(458,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(1,076,000)<span></span>
</td>
<td class="num">(458,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Principal payment of deferred consideration for asset acquisition</a></td>
<td class="num">(1,414,000)<span></span>
</td>
<td class="num">(1,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_ProceedsFromPaycheckProtectionProgram', window );">Proceeds from Paycheck Protection Program Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">717,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock, net of offering costs</a></td>
<td class="nump">19,363,000<span></span>
</td>
<td class="nump">22,893,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_ProceedsFromExerciseOfWarrantsAndStockOptions', window );">Proceeds from exercise of warrants and stock options</a></td>
<td class="nump">531,000<span></span>
</td>
<td class="nump">168,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">18,480,000<span></span>
</td>
<td class="nump">22,778,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents and restricted cash</a></td>
<td class="nump">2,427,000<span></span>
</td>
<td class="nump">10,352,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">10,849,000<span></span>
</td>
<td class="nump">6,733,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">13,276,000<span></span>
</td>
<td class="nump">17,085,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_ForgivenessRelatedToPaycheckProtectionProgram', window );">Paycheck Protection Program loan forgiveness</a></td>
<td class="nump">722,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_OfferingCostsIncludedInAccountsPayable', window );">Unpaid offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContributionOfProperty', window );">Property and equipment included in accounts payable</a></td>
<td class="nump">$ 124,000<span></span>
</td>
<td class="nump">$ 145,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_AccruedInterestForDeferredConsiderationOnAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued interest for deferred consideration on asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_AccruedInterestForDeferredConsiderationOnAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_ForgivenessRelatedToPaycheckProtectionProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Forgiveness related to paycheck protection program.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_ForgivenessRelatedToPaycheckProtectionProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_GainLossOnExtinguishmentOfPaycheckProtectionProgramLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on extinguishment of paycheck protection program loan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_GainLossOnExtinguishmentOfPaycheckProtectionProgramLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_IncreaseDecreaseInAwardReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of award receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_IncreaseDecreaseInAwardReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net increase (decrease) in operating lease right of use asset and liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_OfferingCostsIncludedInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of offering costs included in accounts payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_OfferingCostsIncludedInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_ProceedsFromExerciseOfWarrantsAndStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from exercise of warrants and stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_ProceedsFromExerciseOfWarrantsAndStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_ProceedsFromPaycheckProtectionProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from paycheck protection program.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_ProceedsFromPaycheckProtectionProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContributionOfProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of property contributed in noncash investing and financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContributionOfProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense or loss included in net income that result in no cash flow, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140428508641960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash, cash equivalents, and restricted cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 12,076,000<span></span>
</td>
<td class="nump">$ 9,649,000<span></span>
</td>
<td class="nump">$ 15,885,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 13,276,000<span></span>
</td>
<td class="nump">$ 10,849,000<span></span>
</td>
<td class="nump">$ 17,085,000<span></span>
</td>
<td class="nump">$ 6,733,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140428508735016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of the Business<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Description of the Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Description of the Business</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1. Organization and Description of the Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Armata Pharmaceuticals,&#160;Inc. (&#8220;Armata&#8221;, and together with its subsidiaries referred to herein as, the &#8220;Company&#8221;) is a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The Company was created as a result of a business combination between C3J Therapeutics, Inc. (&#8220;C3J&#8221;), a Washington corporation, and AmpliPhi Biosciences Corporation (&#8220;AmpliPhi&#8221;) that closed on May 9, 2019, where Ceres Merger Sub, Inc., a wholly owned subsidiary of AmpliPhi, merged with and into C3J (the&#160;&#8221;Merger&#8221;), with C3J surviving the Merger as a wholly owned subsidiary of AmpliPhi. Immediately prior to the closing of the Merger, AmpliPhi changed its name to Armata Pharmaceuticals, Inc. Armata&#8217;s common stock is traded on the NYSE American exchange under the ticker symbol &#8220;ARMP&#8221;.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140428514757672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_LiquidityAbstract', window );"><strong>Liquidity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">Liquidity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2. Liquidity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has prepared its consolidated financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. However, the Company has incurred net losses since its inception and has negative operating cash flows. These circumstances raise substantial doubt about the Company&#8217;s ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty concerning the Company&#8217;s ability to continue as a going concern.</p><p style="-sec-ix-redline:true;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';"> </span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman','Times','serif';">On October 28, 2021, the Company entered into a securities purchase agreement (the &#8220;October 2021 Securities Purchase Agreement&#8221;) with the Cystic Fibrosis Foundation, a Delaware corporation (&#8220;CFF&#8221;), the Company&#8217;s partner for its lead Phase 1b/2 clinical development program, and Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc. (Nasdaq: INVA) (collectively, &#8220;Innoviva&#8221;) for the private placement of newly issued shares of common stock, par value </span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman','Times','serif';">$0.01</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman','Times','serif';"> per share, of the Company (&#8220;Common Stock&#8221;). Pursuant to the October 2021 Securities Purchase Agreement, the Company issued and sold </span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman','Times','serif';">909,091</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman','Times','serif';"> shares to CFF and </span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman','Times','serif';">1,212,122</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman','Times','serif';"> shares to Innoviva, each at a per share price of </span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman','Times','serif';">$3.30</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman','Times','serif';"> (the &#8220;October 2021 Private Placements&#8221;). The Company received aggregate gross proceeds from the October 2021 Private Placements of approximately </span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman','Times','serif';">$7.0</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman','Times','serif';"> million, before deducting transaction expenses</span><span style="font-family:'Times New Roman','Times','serif';">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"> On January&#160;26, 2021, the Company entered into a securities purchase agreement (the &#8220;January 2021 Securities Purchase Agreement&#8221;) with <span style="background-color:#ffffff;">Innoviva, </span>pursuant to which the Company agreed to issue and sell to Innoviva, in a private placement, up to 6,153,847 newly issued shares of Common Stock, and warrants (the &#8220;Common Warrants&#8221;) to purchase up to 6,153,847 shares of Common Stock, with an exercise price per share of $3.25 (the &#8220;January 2021 Private Placement&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The January 2021 Private Placement closed in two tranches. On January&#160;26, 2021 and concurrently with entering into the January 2021 Securities Purchase Agreement, the Company completed the first tranche (the &#8220;First Closing&#8221;) of the January 2021 Private Placement. At the First Closing,&#160;Innoviva purchased 1,867,912 shares of Common Stock and Common Warrants to purchase 1,867,912 shares of common stock, for an aggregate purchase price of approximately $6.1 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">At the closing of the second tranche (the &#8220;Second Closing&#8221;), which was approved by the Company&#8217;s stockholders,&#160;Innoviva purchased 4,285,935 shares of Common Stock and Common Warrants to purchase 4,285,935 shares of Common Stock for an aggregate purchase price of $13.9 million. The Second Closing was completed on March 17, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On March 27, 2020, the Company completed a private placement transaction and sold to Innoviva Inc. 8,710,800 newly issued shares of Common Stock and warrants to purchase 8,710,800 shares of common stock, with an exercise </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">price per share of $2.87 (the &#8220;2020 Private Placement&#8221;). Each share of common stock was sold together with one common warrant granting the warrant holder the right to purchase an additional share of common stock at $2.87 per share. The 2020 Private Placement was closed in two tranches raising total gross proceeds of $25.0 million.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of September 30, 2021, the Company had cash and cash equivalents of $12.1 million. Considering the Company&#8217;s current cash resources, management believes the Company&#8217;s existing resources will be sufficient to fund the Company&#8217;s planned operations into the first quarter of 2022. For the foreseeable future, the Company&#8217;s ability to continue its operations is dependent upon its ability to obtain additional capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Management plans to raise additional capital through equity offerings, debt financings, or other capital sources, including potential collaborations, licenses and other similar arrangements. While management believes this plan to raise additional funds will alleviate the conditions that raise substantial doubt, these plans are not entirely within its control and cannot be assessed as being probable of occurring. The Company&#8217;s ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic. The Company may not be able to secure additional financing in a timely manner or on favorable terms, if at all. Furthermore, if the Company issues equity securities to raise additional funds, its existing stockholders may experience dilution, and the new equity securities may have rights, preferences and privileges senior to those of the Company&#8217;s existing stockholders. If the Company raises additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to its potential products on terms that are not favorable to the Company. If the Company is unable to raise capital when needed or on attractive terms, it would be forced to delay, reduce or eliminate its research and development programs or other operations. If any of these events occur, the Company&#8217;s ability to achieve the development and commercialization goals would be adversely affected.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_LiquidityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liquidity [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_LiquidityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 40<br> -URI http://asc.fasb.org/subtopic&amp;trid=51888271<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140428514211464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3. Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The consolidated financial statements include the accounts of Armata and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated. The accompanying unaudited condensed consolidated financial statements of the Company should be read in conjunction with the audited financial statements and accompanying notes thereto as of and for the year ended December 31, 2020&#160;included in the Company&#8217;s Form 10-K, filed with the U.S. Securities and Exchange Commission on March 18, 2021. The accompanying unaudited financial statements have been prepared in conformity with accounting principles generally accepted&#160;in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial statements. Any reference in the Notes to applicable guidance is meant to refer to authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In the opinion of management, the accompanying consolidated financial statements include all adjustments that are of a normal and recurring nature and that are necessary for the fair presentation of the Company&#8217;s financial position and the results of its operations and cash flows for the periods presented. Interim results are not necessarily indicative of results for the full year or any future period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in its consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates these estimates and judgments, which are based on historical and anticipated results and trends, and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management&#8217;s estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair Value of Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The carrying amounts of cash equivalents, other current assets, accounts payable, and accrued liabilities approximate fair value because of the short-term nature of these instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">In-Process Research and Development (&#8220;IPR&amp;D&#8221;) </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:13.2pt;margin:0pt;">IPR&amp;D assets are intangible assets with indefinite lives and are not subject to amortization. The Company&#8217;s IPR&amp;D assets represent capitalized incomplete research projects that the Company acquired through the Merger, which is related to the development of AP-SA01, a phage combination for the treatment of <i style="font-style:italic;">Staphylococcus aureus</i> infections (&#8220;<i style="font-style:italic;">S. aureus</i>&#8221;). Such assets are initially measured at their acquisition-date fair values and are subject to impairment testing at least annually until completion or abandonment of research and development efforts associated with the projects. Upon successful completion of each project, the Company makes a determination as to the then remaining useful life of the intangible asset and begins amortization. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Goodwill</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:13.2pt;margin:0pt;">Goodwill, which has an indefinite useful life, represents the excess of purchase consideration over fair value of net assets acquired. Goodwill is not subject to amortization and is required to be tested for impairment at least on an annual basis. The Company tests goodwill for impairment as of December 31 of each year. The Company determines whether goodwill may be impaired by comparing the carrying value of the single reporting unit, including goodwill, to the fair value of the reporting unit. If the fair value is less than the carrying amount, a more detailed analysis is performed to determine whether goodwill is impaired. The impairment loss, if any, is measured as the excess of the carrying value of the goodwill over the implied fair value of the goodwill and is recorded in the Company&#8217;s consolidated statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:13.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Settlement of Zero-coupon Debt Instrument </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">      </span><span style="font-style:normal;font-weight:normal;white-space:pre-wrap;">The Company&#8217;s deferred purchase consideration arrangement with Synthetic Genomics (Note 11) does not have a stated interest rate.  Upon repayment of deferred purchase consideration, the Company classifies the portion attributable to accreted interest as a cash outflow for operating activities, and the portion relating to principal as a cash outflow for financing activities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basic and Diluted Net Loss per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net earnings or loss per share (&#8220;EPS&#8221;) is calculated in accordance with the applicable accounting guidance provided in ASC 260,&#160;<i style="font-style:italic;">Earnings per Share.&#160;</i>The Company uses the two-class method for the computation and presentation of net income (loss) per common share attributable to common stockholders. The two-class method is an earnings allocation formula that calculates basic and diluted net income (loss) per common share for each class of common stock separately based on dividends declared and participation rights in undistributed earnings as if all such earnings had been distributed during the period. Under the two-class method, warrants issued to Innoviva are assumed to participate in undistributed earnings on an as-exercised basis, in accordance with the warrant agreements. Undistributed net losses are allocated entirely to common shareholders since the participating security has no contractual obligation to share in the losses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Accordingly, basic income or loss per share is calculated by dividing net income or loss by the weighted-average number of common shares outstanding, or using the two-class method, whichever is more dilutive.&#160;&#160;Diluted net income or loss per share is computed using the more dilutive of the treasury stock method which reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted to common stock, or the two-class method. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The calculation of diluted loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of liability classified warrants, and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to net loss available to common stockholders used in the calculation is required to remove the change in fair value of the warrants from the numerator for the period. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any, under the treasury stock method. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Grants and Awards</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="white-space:pre-wrap;">        In applying the provisions of ASC Topic 606, </span><i style="font-style:italic;">Revenue from Contracts with Customers</i> (&#8220;ASC 606&#8221;)<i style="font-style:italic;">, </i>Armata has determined that grants and awards are out of the scope of ASC 606 because the funding entities do not meet the definition of a &#8220;customer&#8221;, as defined by ASC 606, as there is not considered to be a transfer of control of goods or services. With respect to each grant or award, the Company determines if it has a collaboration in accordance with ASC Topic 808, <i style="font-style:italic;">Collaborative Arrangements</i> (&#8220;ASC 808&#8221;). To the extent the grant or award is within the scope of ASC 808, the Company recognizes amounts received as a contra-expense or grant revenue on the consolidated statement of operations when the related research and development expenses are incurred. For grant and awards outside the scope of ASC 808, the Company applies ASC 606 or International Accounting Standards No. 20, <i style="font-style:italic;">Accounting for Government Grants and Disclosure of Government Assistance</i>, by analogy, and revenue is recognized when the Company incurs expenses related to the grants for the amount the Company is entitled to under the provisions of the contract. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="white-space:pre-wrap;">        Armata also considers the guidance in ASC Topic 730, </span><i style="font-style:italic;">Research and Development </i>(&#8220;ASC 730&#8221;), which requires an assessment, at the inception of the grant or award, of whether the agreement is a liability<i style="font-style:italic;">. </i>If Armata is obligated to repay funds received regardless of the outcome of the related research and development activities, then Armata is required to estimate and recognize that liability. Alternatively, if Armata is not required to repay the funds, then payments received are recorded as revenue or contra-expense as the expenses are incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="white-space:pre-wrap;">       Deferred grant or award liability represents award funds received or receivable for which the allowable expenses have not yet been incurred as of the balance sheet date.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development (&#8220;R&amp;D&#8221;) costs consist primarily of direct and allocated salaries, incentive compensation, stock-based compensation and other personnel-related costs, facility costs, and third-party services. Third-party services include studies and clinical trials conducted by clinical research organizations. R&amp;D activities are expensed as incurred. The Company records accruals for estimated ongoing clinical trial expenses. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Judgments and estimates are made in determining the accrued balances at the end of the reporting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Accounting Pronouncements Not Yet Adopted</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="background-color:#ffffff;color:#212529;">In June 2016, the FASB issued ASU 2016-13,&#160;</span><i style="background-color:#ffffff;color:#212529;font-style:italic;">Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses</i><span style="background-color:#ffffff;color:#212529;">&#160;on Financial Instruments. The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that aren&#8217;t measured at fair value through net income. For available-for-sale debt securities, entities will be required to recognize an allowance for credit losses rather than a reduction in carrying value of the asset. Entities will no longer be permitted to consider the length of time that fair value has been less than amortized cost when evaluating when credit losses should be recognized.&#160;</span>This new guidance is effective for calendar-year smaller reporting public entities in the first quarter of 2023. The Company is currently evaluating the impact of this ASU and&#160;<span style="color:#212529;">does&#160;</span>not expect that adoption of this standard will have a material impact on its consolidated financial statements or related disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:18pt;margin:6pt 0pt 0pt 0pt;">In August 2020, the FASB issued &#8203;ASU No. 2020-06&#8203;, &#8203;<i style="font-style:italic;">Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)&#8203; (&#8220;ASU 2020-06&#8221;).</i> &#8203;ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#8217;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in ASU </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="white-space:pre-wrap;">2020-06 are effective for the Company as of January 1, 2024. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2020-06 on its financial statements and does not expect the adoption of this ASU to have a material impact on the Company&#8217;s consolidated financial statements.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recently Adopted Accounting Standards</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 14pt 0pt;">In December 2019, the FASB issued ASU 2019-12,&#160;<i style="font-style:italic;">Income Taxes (&#8220;ASC 740&#8221;)</i>, which simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740 related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill.&#160;The guidance became effective for the Company on January 1, 2021 and the adoption did not have a material impact on its&#160;consolidated financial statements or related disclosures.  </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140428509998456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">4. Net Loss per Share </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following outstanding securities as of September 30, 2021 and 2020 have been excluded from the computation of diluted weighted average shares outstanding, as they would have been anti-dilutive:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,439,651</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,446,614</p></td></tr><tr><td style="vertical-align:top;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 30,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock awards</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 124,018</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 262,558</p></td></tr><tr><td style="vertical-align:top;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 16,647,219</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 10,547,618</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 19,240,888</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 12,256,790</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140428514754840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Balance Sheet Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Balance Sheet Details</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">5. Balance Sheet Details</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Property and equipment as of September 30, 2021 and December 31, 2020 consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:69.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:69.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,362,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6,547,000</p></td></tr><tr><td style="vertical-align:top;width:69.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 817,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 719,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:69.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Office and computer equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 451,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 413,000</p></td></tr><tr><td style="vertical-align:top;width:69.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,423,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,423,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:69.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 12,053,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 11,102,000</p></td></tr><tr><td style="vertical-align:top;width:69.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,946,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,055,000)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:69.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,107,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,047,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Depreciation expense totaled $0.3 million for each of the three months ended September 30, 2021 and 2020, respectively. Depreciation expense totaled $0.9 million and $0.8 million for the nine months ended September 30, 2021 and 2020, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140428514211464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Paycheck Protection Program Loan<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Paycheck Protection Program Loan.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Paycheck Protection Program Loan</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">6. Paycheck Protection Program Loan </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;">In April 2020, the Company received loan proceeds of $717,000 (&#8220;PPP Loan&#8221;) under the Paycheck Protection Program (&#8220;PPP&#8221;).&#160; The PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act, provides for loans to qualifying businesses for amounts up to 2.5 times the average monthly payroll expenses of the qualifying business, calculated as provided under the PPP. The PPP Loan was unsecured, evidenced by a promissory note (the &#8220;Note&#8221;) given by the Company as borrower through its bank, serving as the lender.&#160; The interest rate on the Note was 1.0% per annum. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.5pt;margin:0pt;">In July 2021, the Company received notification of forgiveness of the full loan amount and associated interest from the Small Business Administration. The Company recorded a gain of $0.7 million from the PPP loan extinguishment in the statement of operations during the three months ended September 30, 2021.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140428514218760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Stockholders Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders Equity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">7. Stockholders&#8217; Equity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Private Investment </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">October 2021 Private Placement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background-color:#ffffff;color:#222222;">On October 28, 2021, the Company entered into the October 2021 Securities Purchase Agreement with CFF and Innoviva for the private placement of newly issued shares of the Company&#8217;s common stock. Pursuant to the October 2021 Securities Purchase Agreement, the Company issued and sold </span><span style="background-color:#ffffff;color:#222222;">909,091</span><span style="background-color:#ffffff;color:#222222;"> shares to CFF and </span><span style="background-color:#ffffff;color:#222222;">1,212,122</span><span style="background-color:#ffffff;color:#222222;"> shares to Innoviva, each at a per share price of </span><span style="background-color:#ffffff;color:#222222;">$3.30</span><span style="background-color:#ffffff;color:#222222;">. The Company received aggregate gross proceeds from the October 2021 Private Placements of approximately </span><span style="background-color:#ffffff;color:#222222;">$7.0</span><span style="background-color:#ffffff;color:#222222;"> million, before deducting transaction expenses</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">January 2021 Private Placement </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On January&#160;26, 2021, the Company entered into the January 2021 Securities Purchase Agreement with Innoviva, pursuant to which the Company agreed to issue and sell to Innoviva, in a private placement, up to 6,153,847 newly issued shares of common stock, and Common Warrants to purchase up to 6,153,847 shares of common stock, with an exercise price per share of $3.25.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The January 2021 Private Placement closed in two tranches. On January&#160;26, 2021 and concurrently with entering into the January 2021 Securities Purchase Agreement, the Company completed the first tranche (the &#8220;First Closing&#8221;) of the January 2021 Private Placement. At the First Closing,&#160;Innoviva purchased 1,867,912 shares and Common Warrants to purchase 1,867,912 shares of common stock, for an aggregate purchase price of approximately $6.1 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">At the closing of the second tranche (the &#8220;Second Closing&#8221;), which was approved by the Company&#8217;s stockholders,&#160;Innoviva purchased 4,285,935 shares and Common Warrants to purchase 4,285,935 shares of common stock for an aggregate purchase price of $13.9 million. The Second Closing was completed on March 17, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On January 27, 2020, the Company entered into a securities purchase agreement with Innoviva, pursuant to which the Company agreed to issue and sell to Innoviva, in the 2020 Private Placement, 8,710,800 newly issued shares of the Company&#8217;s common stock and warrants to purchase 8,710,800 shares of common stock, with an exercise price per share of $2.87. Each share of common stock was sold together as a unit with one common warrant granting the warrant holder the right to purchase an additional share of common stock at $2.87 per share. The 2020 Private Placement occurred in two tranches. The first closing occurred on February 12, 2020, at which time Innoviva purchased 993,139 units in exchange for an aggregate gross cash payment of approximately $2.8 million. On March 27, 2020, the second closing occurred subsequent to shareholder approval, at which time Innoviva purchased 7,717,661 units in exchange for aggregate gross proceeds of $22.2 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The warrants issued to Innoviva during 2021 and 2020 expire five years from the respective issuance date. The Company reviewed the authoritative accounting guidance and determined that the warrants meet the criteria to be accounted for as permanent equity. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Warrants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On September 30, 2021, outstanding warrants to purchase shares of common stock are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares Underlying Outstanding Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:28.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Expiration Date</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 597,881</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0.05pt 0pt;"> 21.00</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">May 10, 2022</p></td></tr><tr><td style="vertical-align:bottom;width:36.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,183,491</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0.05pt 0pt;"> 5.60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">October 16, 2023</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 993,139</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0.05pt 0pt;"> 2.87</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">February 11, 2025</p></td></tr><tr><td style="vertical-align:bottom;width:36.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,717,661</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0.05pt 0pt;"> 2.87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">March 27, 2025</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,867,912</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0.05pt 0pt;"> 3.25</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">January 26, 2026</p></td></tr><tr><td style="vertical-align:bottom;width:36.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,285,935</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0.05pt 0pt;"> 3.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">March 16, 2026</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,200</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0.05pt 0pt;"> 1,680.00</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">None</p></td></tr><tr><td style="vertical-align:bottom;width:36.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 16,647,219</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140428509933976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity Incentive Plans</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">8. Equity Incentive Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Stock Award Plans</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company maintains a 2016 Equity Incentive Plan (the &#8220;2016 Plan&#8221;), which provides for the issuance of incentive share awards in the form of non-qualified and incentive stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards and performance-based stock awards. The awards may be granted by the Company&#8217;s Board of Directors to its employees, directors and officers and to consultants, agents, advisors and independent contractors who provide services to the Company or to a subsidiary of the Company. The exercise price for stock options must not be less than the fair market value of the underlying shares on the date of grant. Stock options expire no later than ten years from the date of grant and generally vest and typically become exercisable over a four-year period following the date of grant. Under the 2016 Plan, the number of shares authorized for issuance automatically increases annually beginning January 1, 2017 and through January 1, 2026. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the Merger, the Company assumed the C3J Jian, Inc. Amended 2006 Stock Option Plan (the &#8220;Assumed 2006 Plan&#8221;) and the C3J Therapeutics, Inc. 2016 Stock Plan (the &#8220;Assumed 2016 Plan&#8221;). These plans provided for stock option and restricted stock awards (&#8220;RSAs&#8221;) to C3J employees in years prior to the merger with AmpliPhi. The number of shares subject to each outstanding stock option and RSA under those assumed plans, along with the exercise price of stock options, were equitably adjusted pursuant to the terms of the plans to reflect the impact of the Merger and the one-for-<span style="-sec-ix-hidden:Hidden_6HHTzro5OEGysvS9SNdMCQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">fourteen</span></span> reverse stock split, in each case in a manner intended to preserve the then-current intrinsic value of the awards. No additional awards will be made under either plan. The assumed C3J stock options were substantially vested and expensed as of the merger date. Vesting of the assumed C3J RSAs is based on the occurrence of a public liquidity event, or a change in control. In the event of a public liquidity event, service or milestone based vesting schedules begins. Service periods are generally <span style="-sec-ix-hidden:Hidden_FoLyPbG9hUC2OJDlbr-6vQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">two</span></span> to four years. In the event of a change in control, 100% vesting occurs upon the closing of such an event. The merger with AmpliPhi constituted a public liquidity event and triggered the start of vesting of RSAs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company estimates the fair value of stock options with performance and service conditions using the Black-Scholes valuation model. Compensation expense related to stock options granted is measured at the grant date based on the estimated fair value of the award and is recognized on the accelerated attribution method over the requisite service period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The assumptions used in the Black-Scholes model are presented below:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:31.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine months ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:68.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:68.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">0.73% -- 1.29%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">0.25% -- 1.51%</p></td></tr><tr><td style="vertical-align:top;width:68.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">84.04% -- 93.37%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">90.43%</p></td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="background-color:#cceeff;vertical-align:top;width:68.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (in years)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">5.50 - 7.00</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">5.50 - 7.00</p></td></tr><tr><td style="vertical-align:top;width:68.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">0%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">0%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. Expected volatility is based on the historical volatility of Armata and peer companies&#8217; common stock. The expected term represents the period that the Company expects its stock options to be outstanding. The expected term assumption is estimated using the simplified method set forth in the SEC Staff Accounting Bulletin 110, which is the mid-point between the option vesting date and the expiration date. For stock options granted to parties other than employees or directors, the Company elects, on a grant by grant basis, to use the expected term or the contractual term of the option award. The Company has never declared or paid dividends on its common stock and has no plans to do so in the foreseeable future. Forfeitures are recognized as a reduction of stock-based compensation expense as they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="color:#231f20;">On August 1, 2021, Todd R. Patrick, who has served as the Company&#8217;s Chief Executive Officer (&#8220;CEO&#8221;) since May 2019, retired from day-to-day active management of the Company and resigned as CEO. On August 9, 2021, the Company and Mr. Patrick entered into a letter agreement, which among other things, provides that if</span> Mr. Patrick provides advisory services through the end of December 31, 2022 (the &#8220;Transition Period&#8221;), <span style="-sec-ix-hidden:Hidden_9mekj5kubk-rv8woYRxrCg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">one half</span></span> of the outstanding and unvested Company stock options and restricted share units held by Mr. Patrick as of the last day of the Transition Period will become fully vested, and all vested stock options held by Mr. Patrick as of that date will remain exercisable for the remainder of the 10-year term from the original grant date. The Company measured the stock-based compensation expense related to the modification and pre-vesting forfeitures of Mr. Patrick&#8217;s stock options and restricted share units to be a net credit of approximately $0.3 million, which will be amortized as a credit to stock-based compensation over the remaining substantive requisite service period through December 31, 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="color:#231f20;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The tables below summarize the total stock-based compensation expense included in the Company&#8217;s consolidated statements of operations for the periods presented:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 369,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 205,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,121,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 841,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 100,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 458,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,097,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,772,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total stock-based compensation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 469,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 663,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,218,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,613,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="background-color:#ffff00;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Stock option transactions during the nine months ended September 30, 2021 are presented below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:40.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options&#160;Outstanding</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:58.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,668,926</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6.30</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 8.32</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:58.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 856,150</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4.77</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:58.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (73,517)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3.27</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 98,000</p></td></tr><tr><td style="vertical-align:top;width:58.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited/Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11,908)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 48.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:58.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at September&#160;30,&#160;2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,439,651</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5.65</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 8.19</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 609,000</p></td></tr><tr><td style="vertical-align:top;width:58.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested and expected to vest at September&#160;30,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,439,651</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5.65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 8.19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 609,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:58.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable at September&#160;30,&#160;2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 733,721</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9.48</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6.55</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 252,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Restricted stock awards and restricted stock units during the nine months ended September 30, 2021 are presented below: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted Avg</b></p></td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December 31, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 322,756</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 19.55</p></td></tr><tr><td style="vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited/Cancelled</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,047)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6.89</p></td></tr><tr><td style="vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested and Issued as Common Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (167,691)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 12.33</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at September&#160;30,&#160;2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 154,018</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 27.49</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">     </span><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">      The aggregate intrinsic value of options at September 30, 2021 is based on the Company&#8217;s closing stock price on that date of $3.62 per share. As of September 30, 2021, there was $3.9</span> million of total unrecognized compensation expense related to unvested stock options and RSAs, which the Company expects to recognize over the weighted average remaining period of approximately 1.8 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Shares Reserved for Future Issuance</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of September 30, 2021, the Company had reserved shares of its common stock for future issuance as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares&#160;Reserved</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options outstanding</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,439,651</p></td></tr><tr><td style="vertical-align:top;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 30,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Employee stock purchase plan</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9,748</p></td></tr><tr><td style="vertical-align:top;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Available for future grants under the 2016 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 227,856</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants outstanding</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 16,647,219</p></td></tr><tr><td style="vertical-align:top;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total shares reserved</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 19,354,474</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140428509832424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">9. Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company leases office and research and development space under a non-cancelable operating lease in Marina del Rey, CA. The lease commenced January&#160;1, 2012 and in April 2020, the Company amended the lease (&#8220;Lease Amendment&#8221;) which, among other things, extended the lease term through December 31, 2031. Base annual rent for calendar year 2022, the first year under the Lease Amendment extended term, will be approximately $1.9 million, and base rent increases by 3% annually and will be $2.5<span style="white-space:pre-wrap;"> million by the end of the amended term.  In addition, the Company received a six-month rent abatement in 2020. The Company is entitled to use an allowance for tenant improvements of </span>$0.8 million during 2021, with any unused tenant improvement amount as of December 31, 2021 to offset future payments. In accordance with authoritative guidance, the Company re-measured the lea<span style="background-color:#ffffff;color:#222222;">se liability in April 2020 to be </span><span style="background-color:#ffffff;color:#222222;">$11.7</span><span style="background-color:#ffffff;color:#222222;"> million and related&#160;right of use asset of </span><span style="background-color:#ffffff;color:#222222;">$11.0</span><span style="background-color:#ffffff;color:#222222;"> million as of the Lease Amendment date with an incremental borrowing rate of </span><span style="background-color:#ffffff;color:#222222;">12.89%</span><span style="background-color:#ffffff;color:#222222;">. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="background-color:#ffffff;color:#222222;">On October 28, 2021, the Company entered into a lease for office and research and development space under a non-cancellable lease in Los Angeles, CA (the &#8220;2021 Lease&#8221;). The 2021 Lease payment start date is May 1, 2022 and the total lease term is for </span><span style="background-color:#ffffff;color:#222222;">16 years</span><span style="background-color:#ffffff;color:#222222;"> and runs through 2038. Monthly rent for 2022 and 2023 will be fully or partially abated while the lessor and the Company complete planned tenant improvements to the facility. Base monthly rent will be approximately </span><span style="background-color:#ffffff;color:#222222;">$0.25</span><span style="background-color:#ffffff;color:#222222;"> million in 2024. The Company is entitled to receive an allowance for tenant improvements of up to </span><span style="background-color:#ffffff;color:#222222;">$6.5</span><span style="background-color:#ffffff;color:#222222;white-space:pre-wrap;"> million.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">From time to time, the Company may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of business. Any of these claims could subject the Company to costly legal expenses and, while management generally believes that there is adequate insurance to cover many different types of liabilities, the Company&#8217;s insurance carriers may deny coverage or policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on the consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage the Company&#8217;s reputation and business. The Company is currently not a party to any legal proceedings, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">the adverse outcome of which, in management&#8217;s opinion, individually or in the aggregate, would have a material adverse effect on our consolidated results of operations or financial position.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140428515056168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Grants and Awards<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_AwardAbstract', window );"><strong>Grants and Awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_AwardTextBlock', window );">Grants and Awards</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">10. Grants and Awards</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">MTEC Grant </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On June 15, 2020, the Company entered into a Research Project Award agreement (the &#8220;MTEC Agreement&#8221;) with the Medical Technology Enterprise Consortium (&#8220;MTEC&#8221;), pursuant to which the Company expects to receive a $15.0 million&#160;grant and entered into a three-year program administered by the U.S. Department of Defense through MTEC with funding from the Defense Health Agency and Joint Warfighter Medical Research Program. The MTEC funds are to partially fund a Phase&#160;1b/2, randomized, double-blind, placebo-controlled, dose escalation clinical study of Armata's therapeutic phage-based candidate, AP-SA02, for the treatment of complicated&#160;<i style="font-style:italic;">Staphylococcus aureus</i>&#160;bacteremia infections. The MTEC Agreement specifies that the grant will be paid to the Company through a cost reimbursable model, based on agreed upon cost share percentages, and the grant money received is not refundable to MTEC. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> &#160; &#160; &#160; &#160;</span></span>Upon license or commercialization of intellectual property developed with the funding from the MTEC Agreement, additional fees will be due to MTEC. &#160;The Company will elect whether to (a) pay a fixed royalty amount, which is subject to a cap based upon total funding received, or (b) pay an additional assessment fee, which would also be subject to a cap based upon a percentage of total funding received. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The MTEC Agreement will be effective through January 25, 2024. &#160;The MTEC Agreement may be terminated in whole or in part, 30 calendar days following the written notice from the Company to MTEC. In addition, MTEC has the right to terminate the MTEC Agreement upon material breach by the Company. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company determined that the MTEC Agreement is not in the scope of ASC 808 or ASC 606. Applying ASC 606 by analogy the Company recognizes proceeds received under the MTEC Agreement as grant revenue on the statement of operations when related costs are incurred. The Company recognized $1.3 million and $3.5 million in grant revenue from the MTEC Agreement during the three and nine months ended September 30, 2021, respectively. The Company recognized $0.3 million in grant revenue from the MTEC Agreement during each of the three and nine months ended September 30, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CFF Therapeutics Development Award </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On March 13, 2020, the Company entered into an award agreement (the &#8220;Agreement&#8221;) with CFF, pursuant to which the Company received a Therapeutics Development Award of up to $5.0 million (the &#8220;Award&#8221;). The Award will be used to fund a portion of the Company&#8217;s Phase 1b/2 clinical trial of the&#160;<i style="font-style:italic;">Pseudomonas aeruginosa</i>&#160;(&#8220;<i style="font-style:italic;">P. aeruginosa</i>&#8221;) phage candidate, AP-PA02, as a treatment for&#160;<i style="font-style:italic;">Pseudomonas</i>&#160;airway infections in people with cystic fibrosis (&#8220;CF&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The first payment under the Agreement, in the amount of $1.0 million, became due upon signing the Agreement and was received in April 2020. During the quarter ended September 30, 2021, an additional $0.8<span style="white-space:pre-wrap;"> million was received upon achievement of a milestone.  The remainder of the Award will be paid to the Company incrementally in installments upon the achievement of certain milestones related to the development program and progress of the Phase 1b/2 clinical trial of AP-PA02, as set forth in the Agreement. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">If the Company ceases to use commercially reasonable efforts directed to the development of AP-PA02, or any other Product (as defined in the Agreement), for a period of 360 days (an &#8220;Interruption&#8221;) and fails to resume the development of the Product after receiving from CFF notice of an Interruption, then the Company must either repay the amount of the Award actually received by the Company, plus interest, or grant to CFF (1) an exclusive (even as to the Company), worldwide, perpetual, sublicensable license under technology developed under the Agreement that covers the Product for use in treating infections in CF patients (the &#8220;CF Field&#8221;), and (2) a non-exclusive, worldwide, perpetual, sublicensable license under certain background intellectual property covering the Product, to the extent necessary to commercialize the Product in the CF Field.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Upon commercialization by the Company of any Product, the Company will owe a fixed royalty amount to CFF, which is to be paid in installments determined, in part, based on commercial sales volumes of the Product. The Company will be obligated to make an additional fixed royalty payment upon achieving specified sales milestones. The Company may also be obligated to make a payment to CFF if the Company transfers, sells or licenses the Product in the CF Field, or if the Company enters into a change of control transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#160;</span></span>The term of the Agreement commenced on March 10, 2020 and expires on the earlier of the date on which the Company has paid CFF all of the fixed royalty payments set forth therein, the effective date of any license granted to CFF following an Interruption, or upon earlier termination of the Agreement. Either CFF or the Company may terminate the agreement for cause, which includes the Company&#8217;s material failure to achieve certain development milestones. The Company&#8217;s payment obligations survive the termination of the Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the CFF award is in the scope of ASC 808. Accordingly, as discussed in Note 3, award amounts received from CFF upon achievement of certain milestones are recognized as credits to research and development expenses in the period the expenses are incurred. During the three months ended September 30, 2021 and 2020, the Company did not recognize any credits to research and development expenses related to the CFF award. During the nine months ended September 30, 2021 and 2020, the Company recognized $0.8 million and $1.0<span style="white-space:pre-wrap;"> million in credits to research and development expenses related to the CFF award, respectively. In addition, the Company concluded under the guidance in ASC 730 that it does not have an obligation to repay funds received once related research and development expenses are incurred.  </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_AwardAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents about award abstract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_AwardAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_AwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>represents about award text block.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_AwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140428514196264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Synthetic Genomics Asset Acquisition<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_AssetAcquisitionAbstract', window );"><strong>Synthetic Genomics Asset Acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_AssetAcquisitionTextBlock', window );">Synthetic Genomics Asset Acquisition</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">11. Synthetic Genomics Asset Acquisition </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February&#160;28, 2018, C3J completed an acquisition of certain synthetic phage assets (the &#8220;synthetic phage assets&#8221;) from Synthetic Genomics, Inc. (&#8220;SGI&#8221;) for consideration consisting of $8.0 million in cash and $27.0 million in equity. The cash payments consisted of: $1.0 million paid at closing on February 28, 2018, $1.0 million at one year from closing, $1.0 million at two years from closing, and $5.0 million at three years from closing (the payments due on the one, two, three year anniversary are collectively the &#8220;time-based payment obligation&#8221;). The equity payment (the &#8220;equity payment&#8221; and, together with the time-based payment obligation, the &#8220;deferred purchase price arrangement&#8221;) was due upon the earlier of the initial public offering of shares of C3J&#8217;s common stock pursuant to an effective registration statement under the Securities Act of 1933, as amended, the sale of all or substantially all of C3J&#8217;s assets to a third party, or a consolidation or merger into a third party. On December&#160;20, 2018, in contemplation of the Merger (see Note&#160;1), the deferred purchase price arrangement was amended. Under the amended agreement, the purchase consideration consisted of (i)&#160;closing consideration of $1.0 million paid on February&#160;28, 2018, (ii)&#160;cash payments of $1.0 million on January&#160;31, 2019, $1.0 million on January&#160;31, 2020, and $2.0 million on January&#160;31, 2021, (iii)&#160;an issuance of that number of shares of C3J&#8217;s common stock equal to ten&#160;percent of C3J&#8217;s fully-diluted capitalization, excluding options and restricted stock awards, immediately prior to the closing of the Merger, and (iv)&#160;potential milestone payments of up to $39.5 million related to the development and relevant regulatory approval of products utilizing bacteriophage from the synthetic phage assets acquired from SGI (the &#8220;milestone payment obligation&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The equity payment was settled on May 9, 2019, the date of the Merger (Note 1). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The present value of the time-based payment obligations was included in the Company&#8217;s balance sheet, with interest accreted to the maturity date. The Company paid the last installment of the time-based payment obligation in the amount of $2.0 million during the three months ended March 31, 2021. For the nine months ended September 30, 2021 and 2020, the Company recognized $0.1 million and $0.5 million of interest expense related to the time-based payment obligations, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_AssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition [Abstract].</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_AssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_AssetAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_AssetAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140428509829080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_LiquidityAbstract', window );"><strong>Liquidity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_LiquidityAndGoingConcernPolicyTextBlock', window );">Liquidity Policy</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has prepared its consolidated financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. However, the Company has incurred net losses since its inception and has negative operating cash flows. These circumstances raise substantial doubt about the Company&#8217;s ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty concerning the Company&#8217;s ability to continue as a going concern.</p><p style="-sec-ix-redline:true;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';"> </span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman','Times','serif';">On October 28, 2021, the Company entered into a securities purchase agreement (the &#8220;October 2021 Securities Purchase Agreement&#8221;) with the Cystic Fibrosis Foundation, a Delaware corporation (&#8220;CFF&#8221;), the Company&#8217;s partner for its lead Phase 1b/2 clinical development program, and Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc. (Nasdaq: INVA) (collectively, &#8220;Innoviva&#8221;) for the private placement of newly issued shares of common stock, par value </span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman','Times','serif';">$0.01</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman','Times','serif';"> per share, of the Company (&#8220;Common Stock&#8221;). Pursuant to the October 2021 Securities Purchase Agreement, the Company issued and sold </span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman','Times','serif';">909,091</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman','Times','serif';"> shares to CFF and </span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman','Times','serif';">1,212,122</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman','Times','serif';"> shares to Innoviva, each at a per share price of </span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman','Times','serif';">$3.30</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman','Times','serif';"> (the &#8220;October 2021 Private Placements&#8221;). The Company received aggregate gross proceeds from the October 2021 Private Placements of approximately </span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman','Times','serif';">$7.0</span><span style="background-color:#ffffff;color:#222222;font-family:'Times New Roman','Times','serif';"> million, before deducting transaction expenses</span><span style="font-family:'Times New Roman','Times','serif';">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"> On January&#160;26, 2021, the Company entered into a securities purchase agreement (the &#8220;January 2021 Securities Purchase Agreement&#8221;) with <span style="background-color:#ffffff;">Innoviva, </span>pursuant to which the Company agreed to issue and sell to Innoviva, in a private placement, up to 6,153,847 newly issued shares of Common Stock, and warrants (the &#8220;Common Warrants&#8221;) to purchase up to 6,153,847 shares of Common Stock, with an exercise price per share of $3.25 (the &#8220;January 2021 Private Placement&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The January 2021 Private Placement closed in two tranches. On January&#160;26, 2021 and concurrently with entering into the January 2021 Securities Purchase Agreement, the Company completed the first tranche (the &#8220;First Closing&#8221;) of the January 2021 Private Placement. At the First Closing,&#160;Innoviva purchased 1,867,912 shares of Common Stock and Common Warrants to purchase 1,867,912 shares of common stock, for an aggregate purchase price of approximately $6.1 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">At the closing of the second tranche (the &#8220;Second Closing&#8221;), which was approved by the Company&#8217;s stockholders,&#160;Innoviva purchased 4,285,935 shares of Common Stock and Common Warrants to purchase 4,285,935 shares of Common Stock for an aggregate purchase price of $13.9 million. The Second Closing was completed on March 17, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On March 27, 2020, the Company completed a private placement transaction and sold to Innoviva Inc. 8,710,800 newly issued shares of Common Stock and warrants to purchase 8,710,800 shares of common stock, with an exercise </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">price per share of $2.87 (the &#8220;2020 Private Placement&#8221;). Each share of common stock was sold together with one common warrant granting the warrant holder the right to purchase an additional share of common stock at $2.87 per share. The 2020 Private Placement was closed in two tranches raising total gross proceeds of $25.0 million.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of September 30, 2021, the Company had cash and cash equivalents of $12.1 million. Considering the Company&#8217;s current cash resources, management believes the Company&#8217;s existing resources will be sufficient to fund the Company&#8217;s planned operations into the first quarter of 2022. For the foreseeable future, the Company&#8217;s ability to continue its operations is dependent upon its ability to obtain additional capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Management plans to raise additional capital through equity offerings, debt financings, or other capital sources, including potential collaborations, licenses and other similar arrangements. While management believes this plan to raise additional funds will alleviate the conditions that raise substantial doubt, these plans are not entirely within its control and cannot be assessed as being probable of occurring. The Company&#8217;s ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic. The Company may not be able to secure additional financing in a timely manner or on favorable terms, if at all. Furthermore, if the Company issues equity securities to raise additional funds, its existing stockholders may experience dilution, and the new equity securities may have rights, preferences and privileges senior to those of the Company&#8217;s existing stockholders. If the Company raises additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to its potential products on terms that are not favorable to the Company. If the Company is unable to raise capital when needed or on attractive terms, it would be forced to delay, reduce or eliminate its research and development programs or other operations. If any of these events occur, the Company&#8217;s ability to achieve the development and commercialization goals would be adversely affected.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_LiquidityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liquidity [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_LiquidityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_LiquidityAndGoingConcernPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reporting when there is a substantial doubt about an entity's ability to continue as a going concern for a reasonable period of time (generally a year from the balance sheet date). Disclose: (a) pertinent conditions and events giving rise to the assessment of substantial doubt about the entity's ability to continue as a going concern for a reasonable period of time, (b) the possible effects of such conditions and events, (c) management's evaluation of the significance of those conditions and events and any mitigating factors, (d) possible discontinuance of operations, (e) management's plans (including relevant prospective financial information), and (f) information about the recoverability or classification of recorded asset amounts or the amounts or classification of liabilities. If management's plans alleviate the substantial doubt about the entity's ability to continue as a going concern, disclosure of the principal conditions and events that initially raised the substantial doubt about the entity's ability to continue as a going concern would be expected to be considered. Disclose whether operations for the current or prior years generated sufficient cash to cover current obligations, whether waivers were obtained from creditors relating to the company's default under the provisions of debt agreements and possible effects of such conditions and events, such as: whether there is a possible need to obtain additional financing (debt or equity) or to liquidate certain holdings to offset future cash flow deficiencies. Disclose appropriate parent company information when parent is dependent upon remittances from subsidiaries to satisfy its obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_LiquidityAndGoingConcernPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140428514829592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The consolidated financial statements include the accounts of Armata and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated. The accompanying unaudited condensed consolidated financial statements of the Company should be read in conjunction with the audited financial statements and accompanying notes thereto as of and for the year ended December 31, 2020&#160;included in the Company&#8217;s Form 10-K, filed with the U.S. Securities and Exchange Commission on March 18, 2021. The accompanying unaudited financial statements have been prepared in conformity with accounting principles generally accepted&#160;in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial statements. Any reference in the Notes to applicable guidance is meant to refer to authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In the opinion of management, the accompanying consolidated financial statements include all adjustments that are of a normal and recurring nature and that are necessary for the fair presentation of the Company&#8217;s financial position and the results of its operations and cash flows for the periods presented. Interim results are not necessarily indicative of results for the full year or any future period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in its consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates these estimates and judgments, which are based on historical and anticipated results and trends, and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management&#8217;s estimates.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair Value of Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The carrying amounts of cash equivalents, other current assets, accounts payable, and accrued liabilities approximate fair value because of the short-term nature of these instruments.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">In-Process Research and Development ("IPR&amp;D")</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">In-Process Research and Development (&#8220;IPR&amp;D&#8221;) </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:13.2pt;margin:0pt;">IPR&amp;D assets are intangible assets with indefinite lives and are not subject to amortization. The Company&#8217;s IPR&amp;D assets represent capitalized incomplete research projects that the Company acquired through the Merger, which is related to the development of AP-SA01, a phage combination for the treatment of <i style="font-style:italic;">Staphylococcus aureus</i> infections (&#8220;<i style="font-style:italic;">S. aureus</i>&#8221;). Such assets are initially measured at their acquisition-date fair values and are subject to impairment testing at least annually until completion or abandonment of research and development efforts associated with the projects. Upon successful completion of each project, the Company makes a determination as to the then remaining useful life of the intangible asset and begins amortization. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Goodwill</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:13.2pt;margin:0pt;">Goodwill, which has an indefinite useful life, represents the excess of purchase consideration over fair value of net assets acquired. Goodwill is not subject to amortization and is required to be tested for impairment at least on an annual basis. The Company tests goodwill for impairment as of December 31 of each year. The Company determines whether goodwill may be impaired by comparing the carrying value of the single reporting unit, including goodwill, to the fair value of the reporting unit. If the fair value is less than the carrying amount, a more detailed analysis is performed to determine whether goodwill is impaired. The impairment loss, if any, is measured as the excess of the carrying value of the goodwill over the implied fair value of the goodwill and is recorded in the Company&#8217;s consolidated statements of operations.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_ZeroCouponDebtInstrumentPolicyTextBlock', window );">Settlement of Zero-coupon Debt Instrument</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Settlement of Zero-coupon Debt Instrument </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">      </span><span style="font-style:normal;font-weight:normal;white-space:pre-wrap;">The Company&#8217;s deferred purchase consideration arrangement with Synthetic Genomics (Note 11) does not have a stated interest rate.  Upon repayment of deferred purchase consideration, the Company classifies the portion attributable to accreted interest as a cash outflow for operating activities, and the portion relating to principal as a cash outflow for financing activities.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Net Loss per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basic and Diluted Net Loss per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net earnings or loss per share (&#8220;EPS&#8221;) is calculated in accordance with the applicable accounting guidance provided in ASC 260,&#160;<i style="font-style:italic;">Earnings per Share.&#160;</i>The Company uses the two-class method for the computation and presentation of net income (loss) per common share attributable to common stockholders. The two-class method is an earnings allocation formula that calculates basic and diluted net income (loss) per common share for each class of common stock separately based on dividends declared and participation rights in undistributed earnings as if all such earnings had been distributed during the period. Under the two-class method, warrants issued to Innoviva are assumed to participate in undistributed earnings on an as-exercised basis, in accordance with the warrant agreements. Undistributed net losses are allocated entirely to common shareholders since the participating security has no contractual obligation to share in the losses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Accordingly, basic income or loss per share is calculated by dividing net income or loss by the weighted-average number of common shares outstanding, or using the two-class method, whichever is more dilutive.&#160;&#160;Diluted net income or loss per share is computed using the more dilutive of the treasury stock method which reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted to common stock, or the two-class method. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The calculation of diluted loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of liability classified warrants, and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to net loss available to common stockholders used in the calculation is required to remove the change in fair value of the warrants from the numerator for the period. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any, under the treasury stock method. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_GrantsAndAwardsPolicyTextBlock', window );">Grants and Awards</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Grants and Awards</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="white-space:pre-wrap;">        In applying the provisions of ASC Topic 606, </span><i style="font-style:italic;">Revenue from Contracts with Customers</i> (&#8220;ASC 606&#8221;)<i style="font-style:italic;">, </i>Armata has determined that grants and awards are out of the scope of ASC 606 because the funding entities do not meet the definition of a &#8220;customer&#8221;, as defined by ASC 606, as there is not considered to be a transfer of control of goods or services. With respect to each grant or award, the Company determines if it has a collaboration in accordance with ASC Topic 808, <i style="font-style:italic;">Collaborative Arrangements</i> (&#8220;ASC 808&#8221;). To the extent the grant or award is within the scope of ASC 808, the Company recognizes amounts received as a contra-expense or grant revenue on the consolidated statement of operations when the related research and development expenses are incurred. For grant and awards outside the scope of ASC 808, the Company applies ASC 606 or International Accounting Standards No. 20, <i style="font-style:italic;">Accounting for Government Grants and Disclosure of Government Assistance</i>, by analogy, and revenue is recognized when the Company incurs expenses related to the grants for the amount the Company is entitled to under the provisions of the contract. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="white-space:pre-wrap;">        Armata also considers the guidance in ASC Topic 730, </span><i style="font-style:italic;">Research and Development </i>(&#8220;ASC 730&#8221;), which requires an assessment, at the inception of the grant or award, of whether the agreement is a liability<i style="font-style:italic;">. </i>If Armata is obligated to repay funds received regardless of the outcome of the related research and development activities, then Armata is required to estimate and recognize that liability. Alternatively, if Armata is not required to repay the funds, then payments received are recorded as revenue or contra-expense as the expenses are incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:27pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="white-space:pre-wrap;">       Deferred grant or award liability represents award funds received or receivable for which the allowable expenses have not yet been incurred as of the balance sheet date.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development (&#8220;R&amp;D&#8221;) costs consist primarily of direct and allocated salaries, incentive compensation, stock-based compensation and other personnel-related costs, facility costs, and third-party services. Third-party services include studies and clinical trials conducted by clinical research organizations. R&amp;D activities are expensed as incurred. The Company records accruals for estimated ongoing clinical trial expenses. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Judgments and estimates are made in determining the accrued balances at the end of the reporting period.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements Not Yet Adopted and Recently Adopted Accounting Standards</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Accounting Pronouncements Not Yet Adopted</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="background-color:#ffffff;color:#212529;">In June 2016, the FASB issued ASU 2016-13,&#160;</span><i style="background-color:#ffffff;color:#212529;font-style:italic;">Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses</i><span style="background-color:#ffffff;color:#212529;">&#160;on Financial Instruments. The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that aren&#8217;t measured at fair value through net income. For available-for-sale debt securities, entities will be required to recognize an allowance for credit losses rather than a reduction in carrying value of the asset. Entities will no longer be permitted to consider the length of time that fair value has been less than amortized cost when evaluating when credit losses should be recognized.&#160;</span>This new guidance is effective for calendar-year smaller reporting public entities in the first quarter of 2023. The Company is currently evaluating the impact of this ASU and&#160;<span style="color:#212529;">does&#160;</span>not expect that adoption of this standard will have a material impact on its consolidated financial statements or related disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:18pt;margin:6pt 0pt 0pt 0pt;">In August 2020, the FASB issued &#8203;ASU No. 2020-06&#8203;, &#8203;<i style="font-style:italic;">Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)&#8203; (&#8220;ASU 2020-06&#8221;).</i> &#8203;ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#8217;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in ASU </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="white-space:pre-wrap;">2020-06 are effective for the Company as of January 1, 2024. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2020-06 on its financial statements and does not expect the adoption of this ASU to have a material impact on the Company&#8217;s consolidated financial statements.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recently Adopted Accounting Standards</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 14pt 0pt;">In December 2019, the FASB issued ASU 2019-12,&#160;<i style="font-style:italic;">Income Taxes (&#8220;ASC 740&#8221;)</i>, which simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740 related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill.&#160;The guidance became effective for the Company on January 1, 2021 and the adoption did not have a material impact on its&#160;consolidated financial statements or related disclosures.  </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_GrantsAndAwardsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents about the grants and awards policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_GrantsAndAwardsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_ZeroCouponDebtInstrumentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The policy related to the zero coupon debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_ZeroCouponDebtInstrumentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140428510100168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Antidilutive Securities Excluded from Computation of Diluted Weighted Shares Outstanding</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following outstanding securities as of September 30, 2021 and 2020 have been excluded from the computation of diluted weighted average shares outstanding, as they would have been anti-dilutive:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,439,651</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,446,614</p></td></tr><tr><td style="vertical-align:top;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 30,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock awards</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 124,018</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 262,558</p></td></tr><tr><td style="vertical-align:top;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 16,647,219</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 10,547,618</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 19,240,888</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 12,256,790</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140428514779544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Balance Sheet Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:69.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:69.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,362,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6,547,000</p></td></tr><tr><td style="vertical-align:top;width:69.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 817,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 719,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:69.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Office and computer equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 451,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 413,000</p></td></tr><tr><td style="vertical-align:top;width:69.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,423,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,423,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:69.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 12,053,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 11,102,000</p></td></tr><tr><td style="vertical-align:top;width:69.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,946,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,055,000)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:69.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,107,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,047,000</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140428514782936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Stockholders Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary of Warrant Information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On September 30, 2021, outstanding warrants to purchase shares of common stock are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares Underlying Outstanding Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:28.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Expiration Date</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 597,881</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0.05pt 0pt;"> 21.00</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">May 10, 2022</p></td></tr><tr><td style="vertical-align:bottom;width:36.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,183,491</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0.05pt 0pt;"> 5.60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">October 16, 2023</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 993,139</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0.05pt 0pt;"> 2.87</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">February 11, 2025</p></td></tr><tr><td style="vertical-align:bottom;width:36.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,717,661</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0.05pt 0pt;"> 2.87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">March 27, 2025</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,867,912</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0.05pt 0pt;"> 3.25</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">January 26, 2026</p></td></tr><tr><td style="vertical-align:bottom;width:36.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,285,935</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0.05pt 0pt;"> 3.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">March 16, 2026</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,200</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 9.6pt 0.05pt 0pt;"> 1,680.00</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">None</p></td></tr><tr><td style="vertical-align:bottom;width:36.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 16,647,219</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140428515198552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Assumptions used in the black-Scholes model</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The assumptions used in the Black-Scholes model are presented below:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:31.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine months ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:68.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:68.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">0.73% -- 1.29%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">0.25% -- 1.51%</p></td></tr><tr><td style="vertical-align:top;width:68.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">84.04% -- 93.37%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">90.43%</p></td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="background-color:#cceeff;vertical-align:top;width:68.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (in years)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">5.50 - 7.00</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">5.50 - 7.00</p></td></tr><tr><td style="vertical-align:top;width:68.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">0%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">0%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Allocation of Stock-Based Compensation Expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The tables below summarize the total stock-based compensation expense included in the Company&#8217;s consolidated statements of operations for the periods presented:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 369,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 205,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,121,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 841,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 100,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 458,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,097,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,772,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total stock-based compensation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 469,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 663,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,218,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,613,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Stock option transactions during the nine months ended September 30, 2021 are presented below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:40.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options&#160;Outstanding</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:58.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December&#160;31,&#160;2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,668,926</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6.30</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 8.32</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:58.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 856,150</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4.77</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:58.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (73,517)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3.27</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 98,000</p></td></tr><tr><td style="vertical-align:top;width:58.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited/Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11,908)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 48.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:58.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at September&#160;30,&#160;2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,439,651</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5.65</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 8.19</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 609,000</p></td></tr><tr><td style="vertical-align:top;width:58.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested and expected to vest at September&#160;30,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,439,651</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5.65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 8.19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 609,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:58.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable at September&#160;30,&#160;2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 733,721</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9.48</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6.55</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 252,000</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock', window );">Schedule of restricted stock awards</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Restricted stock awards and restricted stock units during the nine months ended September 30, 2021 are presented below: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted Avg</b></p></td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December 31, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 322,756</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 19.55</p></td></tr><tr><td style="vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited/Cancelled</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,047)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6.89</p></td></tr><tr><td style="vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested and Issued as Common Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (167,691)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 12.33</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:72.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at September&#160;30,&#160;2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 154,018</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 27.49</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">     </span><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock', window );">Shares Reserved for Future Issuance</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of September 30, 2021, the Company had reserved shares of its common stock for future issuance as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares&#160;Reserved</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options outstanding</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,439,651</p></td></tr><tr><td style="vertical-align:top;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 30,000</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Employee stock purchase plan</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9,748</p></td></tr><tr><td style="vertical-align:top;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Available for future grants under the 2016 Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 227,856</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants outstanding</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 16,647,219</p></td></tr><tr><td style="vertical-align:top;width:84.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total shares reserved</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 19,354,474</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of components of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were assumed in merger during the reporting period pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140428510939464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 28, 2021</div></th>
<th class="th"><div>Mar. 17, 2021</div></th>
<th class="th"><div>Jan. 26, 2021</div></th>
<th class="th"><div>Mar. 27, 2020</div></th>
<th class="th"><div>Feb. 12, 2020</div></th>
<th class="th"><div>Jan. 27, 2020</div></th>
<th class="th"><div>Mar. 27, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,076,000<span></span>
</td>
<td class="nump">$ 9,649,000<span></span>
</td>
<td class="nump">$ 15,885,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernManagementsEvaluation', window );">Liquidity, management evaluation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company has prepared its consolidated financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. However, the Company has incurred net losses since its inception and has negative operating cash flows. These circumstances raise substantial doubt about the Company&#8217;s ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty concerning the Company&#8217;s ability to continue as a going concern.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=armp_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,717,661<span></span>
</td>
<td class="nump">993,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,200,000<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_NumberOfCommonWarrantsSoldPerShareOfCommonStock', window );">Number of common warrants sold per share of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=armp_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_ProceedsFromEquityOfferingsGross', window );">Proceeds from equity offerings, gross</a></td>
<td class="nump">$ 7,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="nump">$ 3.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=armp_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Cystic Fibrosis Foundation [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="nump">909,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=armp_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Innoviva Strategic Opportunities LLC [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="nump">1,212,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=armp_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Common Stock Subject to Mandatory Redemption [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.25<span></span>
</td>
<td class="nump">$ 2.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,153,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,710,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=armp_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Warrants and Rights Subject to Mandatory Redemption [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,153,847<span></span>
</td>
<td class="nump">8,710,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,710,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=armp_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Warrants and Rights Subject to Mandatory Redemption [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,153,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=armp_SecuritiesPurchaseAgreementFirstTrancheMember', window );">Securities Purchase Agreement First Tranche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=armp_SecuritiesPurchaseAgreementFirstTrancheMember', window );">Securities Purchase Agreement First Tranche [Member] | Common Stock Subject to Mandatory Redemption [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,867,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=armp_SecuritiesPurchaseAgreementFirstTrancheMember', window );">Securities Purchase Agreement First Tranche [Member] | Warrants and Rights Subject to Mandatory Redemption [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,867,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=armp_SecuritiesPurchaseAgreementSecondTrancheMember', window );">Securities Purchase Agreement Second Tranche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=armp_SecuritiesPurchaseAgreementSecondTrancheMember', window );">Securities Purchase Agreement Second Tranche [Member] | Common Stock Subject to Mandatory Redemption [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,285,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=armp_SecuritiesPurchaseAgreementSecondTrancheMember', window );">Securities Purchase Agreement Second Tranche [Member] | Warrants and Rights Subject to Mandatory Redemption [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,285,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_NumberOfCommonWarrantsSoldPerShareOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common warrants sold per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_NumberOfCommonWarrantsSoldPerShareOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_ProceedsFromEquityOfferingsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross cash inflow, before deducting the underwriting discount and commissions and other offering expenses payable from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_ProceedsFromEquityOfferingsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernManagementsEvaluation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of management's evaluation of the significance of conditions or events in relation to the ability to meet its obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 40<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846462&amp;loc=SL51888443-203568<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 40<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846462&amp;loc=SL51888449-203568<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernManagementsEvaluation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=armp_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=armp_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=armp_CysticFibrosisFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=armp_CysticFibrosisFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=armp_InnovivaStrategicOpportunitiesLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=armp_InnovivaStrategicOpportunitiesLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis=us-gaap_CommonStockSubjectToMandatoryRedemptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis=us-gaap_CommonStockSubjectToMandatoryRedemptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis=us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis=us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=armp_SecuritiesPurchaseAgreementFirstTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=armp_SecuritiesPurchaseAgreementFirstTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=armp_SecuritiesPurchaseAgreementSecondTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=armp_SecuritiesPurchaseAgreementSecondTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140428590976408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Antidilutive Shares Excluded from Computation of Diluted Shares Outstanding) (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted weighted shares outstanding</a></td>
<td class="nump">19,240,888<span></span>
</td>
<td class="nump">12,256,790<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted weighted shares outstanding</a></td>
<td class="nump">2,439,651<span></span>
</td>
<td class="nump">1,446,614<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted weighted shares outstanding</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted weighted shares outstanding</a></td>
<td class="nump">124,018<span></span>
</td>
<td class="nump">262,558<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted weighted shares outstanding</a></td>
<td class="nump">16,647,219<span></span>
</td>
<td class="nump">10,547,618<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140428514283480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Balance Sheet Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 892,000<span></span>
</td>
<td class="nump">$ 840,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140428594139368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details (Property and Equipment) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 12,053,000<span></span>
</td>
<td class="nump">$ 11,102,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(9,946,000)<span></span>
</td>
<td class="num">(9,055,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,107,000<span></span>
</td>
<td class="nump">2,047,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_TechnologyEquipmentMember', window );">Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">7,362,000<span></span>
</td>
<td class="nump">6,547,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office and Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">451,000<span></span>
</td>
<td class="nump">413,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">817,000<span></span>
</td>
<td class="nump">719,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 3,423,000<span></span>
</td>
<td class="nump">$ 3,423,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_TechnologyEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_TechnologyEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140428511023976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Paycheck Protection Program Loan (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 20, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_GainLossOnExtinguishmentOfPaycheckProtectionProgramLoan', window );">Gain upon extinguishment of Paycheck Protection Program loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">$ 722,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt [Member] | Payment Protection Program Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromUnsecuredNotesPayable', window );">Proceeds from unsecured notes payable</a></td>
<td class="nump">$ 717,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_GainLossOnExtinguishmentOfPaycheckProtectionProgramLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on extinguishment of paycheck protection program loan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_GainLossOnExtinguishmentOfPaycheckProtectionProgramLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromUnsecuredNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from borrowings supported by a written promise to pay an obligation that is uncollateralized (where debt is not backed by the pledge of collateral).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromUnsecuredNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=armp_PaymentProtectionProgramNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=armp_PaymentProtectionProgramNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140428505983976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders Equity (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 28, 2021</div></th>
<th class="th"><div>Mar. 17, 2021</div></th>
<th class="th"><div>Jan. 26, 2021</div></th>
<th class="th"><div>Mar. 27, 2020</div></th>
<th class="th"><div>Feb. 12, 2020</div></th>
<th class="th"><div>Jan. 27, 2020</div></th>
<th class="th"><div>Mar. 27, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,363,000<span></span>
</td>
<td class="nump">$ 22,893,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=armp_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued in registered public financings (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,717,661<span></span>
</td>
<td class="nump">993,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,200,000<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,717,661<span></span>
</td>
<td class="nump">993,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_NumberOfCommonWarrantsSoldPerShareOfCommonStock', window );">Number of common warrants sold per share of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=armp_SecuritiesPurchaseAgreementFirstTrancheMember', window );">Securities Purchase Agreement First Tranche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=armp_SecuritiesPurchaseAgreementSecondTrancheMember', window );">Securities Purchase Agreement Second Tranche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued in registered public financings (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,153,847<span></span>
</td>
<td class="nump">8,710,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,153,847<span></span>
</td>
<td class="nump">8,710,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis=us-gaap_CommonStockSubjectToMandatoryRedemptionMember', window );">Common Stock Subject to Mandatory Redemption [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued in registered public financings (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,153,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,710,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.25<span></span>
</td>
<td class="nump">$ 2.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,153,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,710,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis=us-gaap_CommonStockSubjectToMandatoryRedemptionMember', window );">Common Stock Subject to Mandatory Redemption [Member] | Securities Purchase Agreement First Tranche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued in registered public financings (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,867,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,867,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis=us-gaap_CommonStockSubjectToMandatoryRedemptionMember', window );">Common Stock Subject to Mandatory Redemption [Member] | Securities Purchase Agreement Second Tranche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued in registered public financings (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,285,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,285,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis=us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember', window );">Warrants and Rights Subject to Mandatory Redemption [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,153,847<span></span>
</td>
<td class="nump">8,710,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,710,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,153,847<span></span>
</td>
<td class="nump">8,710,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,710,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis=us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember', window );">Warrants and Rights Subject to Mandatory Redemption [Member] | Securities Purchase Agreement First Tranche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,867,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,867,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis=us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember', window );">Warrants and Rights Subject to Mandatory Redemption [Member] | Securities Purchase Agreement Second Tranche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,285,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,285,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_ProceedsFromEquityOfferingsGross', window );">Proceeds from equity offerings, gross</a></td>
<td class="nump">$ 7,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="nump">$ 3.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Cystic Fibrosis Foundation [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued in registered public financings (in shares)</a></td>
<td class="nump">909,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="nump">909,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Innoviva Strategic Opportunities LLC [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued in registered public financings (in shares)</a></td>
<td class="nump">1,212,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="nump">1,212,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_NumberOfCommonWarrantsSoldPerShareOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common warrants sold per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_NumberOfCommonWarrantsSoldPerShareOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_ProceedsFromEquityOfferingsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross cash inflow, before deducting the underwriting discount and commissions and other offering expenses payable from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_ProceedsFromEquityOfferingsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=armp_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=armp_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=armp_SecuritiesPurchaseAgreementFirstTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=armp_SecuritiesPurchaseAgreementFirstTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=armp_SecuritiesPurchaseAgreementSecondTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=armp_SecuritiesPurchaseAgreementSecondTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis=us-gaap_CommonStockSubjectToMandatoryRedemptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis=us-gaap_CommonStockSubjectToMandatoryRedemptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis=us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis=us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=armp_CysticFibrosisFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=armp_CysticFibrosisFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=armp_InnovivaStrategicOpportunitiesLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=armp_InnovivaStrategicOpportunitiesLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140428505928568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders Equity (Summary of Warrants Outstanding) (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 26, 2021</div></th>
<th class="th"><div>Mar. 27, 2020</div></th>
<th class="th"><div>Feb. 12, 2020</div></th>
<th class="th"><div>Mar. 27, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,647,219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_TermOfWarrant', window );">Term of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceTwoMember', window );">Exercise Price $21.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">597,881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_WarrantExpirationDate', window );">Warrant Expiration Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 10,  2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceThreeMember', window );">Exercise Price $5.60 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,183,491<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_WarrantExpirationDate', window );">Warrant Expiration Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 16,  2023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceFourMember', window );">Exercise Price $2.87 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">993,139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_WarrantExpirationDate', window );">Warrant Expiration Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 11,  2025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceFiveMember', window );">Exercise Price $2.87 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,717,661<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_WarrantExpirationDate', window );">Warrant Expiration Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 27,  2025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceSixMember', window );">Exercise Price $1,680.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,680.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceSevenMember', window );">Exercise Price $3.25 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,867,912<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_WarrantExpirationDate', window );">Warrant Expiration Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 26,  2026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceEightMember', window );">Exercise Price $3.25 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,285,935<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_WarrantExpirationDate', window );">Warrant Expiration Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 16,  2026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=armp_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="nump">$ 3.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,717,661<span></span>
</td>
<td class="nump">993,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.2<span></span>
</td>
<td class="nump">$ 2.8<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=armp_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Common Stock Subject to Mandatory Redemption [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="nump">$ 3.25<span></span>
</td>
<td class="nump">$ 2.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="nump">6,153,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,710,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=armp_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Warrants and Rights Subject to Mandatory Redemption [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="nump">6,153,847<span></span>
</td>
<td class="nump">8,710,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,710,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_TermOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_TermOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_WarrantExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the terms related with expiration of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_WarrantExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=armp_ExercisePriceEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=armp_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=armp_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis=us-gaap_CommonStockSubjectToMandatoryRedemptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis=us-gaap_CommonStockSubjectToMandatoryRedemptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis=us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis=us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140428594068920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 09, 2021</div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 469,000<span></span>
</td>
<td class="nump">$ 663,000<span></span>
</td>
<td class="nump">$ 2,218,000<span></span>
</td>
<td class="nump">$ 2,613,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,439,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,439,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=armp_Assumed2006And2016PlanMember', window );">Assumed 2006 and 2016 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Additional awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Assumed 2006 and 2016 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Employee service period for share-based award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Assumed 2006 and 2016 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Employee service period for share-based award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common stock closing price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost related to unvested options | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">322,756<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested, RS units, grant date fair value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.55<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=armp_StockOptionsAndRestrictedStockAwardsMember', window );">Stock Options And Restricted Stock Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average remaining period for recognition of compensation costs related to unvested options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=armp_StockOptionsAndRestrictedStockAwardsMember', window );">Stock Options And Restricted Stock Awards [Member] | Mr.Patrick</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period of share-based payment award</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_ShareBasedCompensationArrangementPercentageOfOutstandingAwardsVestedForAdvisoryServicesProvided', window );">Percentage of outstanding awards vested for advisory services provided</a></td>
<td class="nump">0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_StockBasedCompensationExpenseRelatedToPreVestingForfeituresReversed', window );">Stock based compensation reversed amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=armp_EquityIncentivePlan2016Member', window );">Equity Incentive Plan 2016 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of share-based compensation award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=armp_EquityIncentivePlan2016Member', window );">Equity Incentive Plan 2016 [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period of share-based payment award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_ShareBasedCompensationArrangementPercentageOfOutstandingAwardsVestedForAdvisoryServicesProvided">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of outstanding awards that are vested in exchange for advisory services provided under share based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_ShareBasedCompensationArrangementPercentageOfOutstandingAwardsVestedForAdvisoryServicesProvided</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_StockBasedCompensationExpenseRelatedToPreVestingForfeituresReversed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock based compensation expense related to pre-vesting forfeitures reversed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_StockBasedCompensationExpenseRelatedToPreVestingForfeituresReversed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=armp_Assumed2006And2016PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=armp_Assumed2006And2016PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=armp_StockOptionsAndRestrictedStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=armp_StockOptionsAndRestrictedStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=armp_EquityIncentivePlan2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=armp_EquityIncentivePlan2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140428590783544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity Incentive Plans (Assumptions Used in the Black-Scholes Model) (Details)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_EquitySecuritiesMeasurementInput', window );">Fair value input, equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.43<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_EquitySecuritiesMeasurementInput', window );">Fair value input, equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_EquitySecuritiesMeasurementInput', window );">Fair value input, equity securities</a></td>
<td class="nump">0.73<span></span>
</td>
<td class="nump">0.25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_EquitySecuritiesMeasurementInput', window );">Fair value input, equity securities</a></td>
<td class="nump">84.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_EquitySecuritiesMeasurementInput', window );">Fair value input, equity securities</a></td>
<td class="nump">5.50<span></span>
</td>
<td class="nump">5.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_EquitySecuritiesMeasurementInput', window );">Fair value input, equity securities</a></td>
<td class="nump">1.29<span></span>
</td>
<td class="nump">1.51<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_EquitySecuritiesMeasurementInput', window );">Fair value input, equity securities</a></td>
<td class="nump">93.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_EquitySecuritiesMeasurementInput', window );">Fair value input, equity securities</a></td>
<td class="nump">7.00<span></span>
</td>
<td class="nump">7.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_EquitySecuritiesMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure investment in equity security measured at fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_EquitySecuritiesMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140428591614136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans (Allocation of Stock-Based Compensation Expense) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 469,000<span></span>
</td>
<td class="nump">$ 663,000<span></span>
</td>
<td class="nump">$ 2,218,000<span></span>
</td>
<td class="nump">$ 2,613,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">369,000<span></span>
</td>
<td class="nump">205,000<span></span>
</td>
<td class="nump">1,121,000<span></span>
</td>
<td class="nump">841,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 458,000<span></span>
</td>
<td class="nump">$ 1,097,000<span></span>
</td>
<td class="nump">$ 1,772,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140428515542504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans (Summary of Stock Option Activity) (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Balance Beginning | shares</a></td>
<td class="nump">1,668,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares, Granted | shares</a></td>
<td class="nump">856,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares, Exercised | shares</a></td>
<td class="num">(73,517)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Shares, Forfeited/Cancelled | shares</a></td>
<td class="num">(11,908)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Balance Ending | shares</a></td>
<td class="nump">2,439,651<span></span>
</td>
<td class="nump">1,668,926<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest at December 31, 2020 | shares</a></td>
<td class="nump">2,439,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at September 30, 2020 | shares</a></td>
<td class="nump">733,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding Beginning | $ / shares</a></td>
<td class="nump">$ 6.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted | $ / shares</a></td>
<td class="nump">4.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised | $ / shares</a></td>
<td class="nump">3.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited/Cancelled | $ / shares</a></td>
<td class="nump">48.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding Ending | $ / shares</a></td>
<td class="nump">5.65<span></span>
</td>
<td class="nump">$ 6.30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Vested or expected to vest at September 30, 2020 | $ / shares</a></td>
<td class="nump">5.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable at September 30, 2020 | $ / shares</a></td>
<td class="nump">$ 9.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (Years), Outstanding</a></td>
<td class="text">8 years 2 months 8 days<span></span>
</td>
<td class="text">8 years 3 months 25 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (Years), Vested or expected to vest at September 30, 2020</a></td>
<td class="text">8 years 2 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (Years), Exercisable at September 30, 2020</a></td>
<td class="text">6 years 6 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate Intrinsic Value, Exercised | $</a></td>
<td class="nump">$ 98,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding Ending | $</a></td>
<td class="nump">609,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested or expected to vest at September 30, 2020 | $</a></td>
<td class="nump">609,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable at September 30, 2020 | $</a></td>
<td class="nump">$ 252,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140428590896472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans (Restricted stock award) (Details) - Restricted Stock Awards [Member]<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at beginning of period (in shares) | shares</a></td>
<td class="nump">322,756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited/Cancelled (in shares) | shares</a></td>
<td class="num">(1,047)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested and Issued as Common Stock (in shares) | shares</a></td>
<td class="num">(167,691)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at end of period (in shares) | shares</a></td>
<td class="nump">154,018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Avg Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at beginning of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 19.55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited/Cancelled (in dollars per share) | $ / shares</a></td>
<td class="nump">6.89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested and Issued as Common Stock (in dollars per shares) | $ / shares</a></td>
<td class="nump">12.33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 27.49<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140428515536696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity Incentive Plans (Shares Reserved for Future Issuance) (Details) - shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding</a></td>
<td class="nump">2,439,651<span></span>
</td>
<td class="nump">1,668,926<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">16,647,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares reserved</a></td>
<td class="nump">19,354,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Stock outstanding</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Stock outstanding</a></td>
<td class="nump">9,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=armp_EquityIncentivePlan2016Member', window );">Equity Incentive Plan 2016 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Available for future grants under the 2016 Plan</a></td>
<td class="nump">227,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=armp_EquityIncentivePlan2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=armp_EquityIncentivePlan2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140428590976568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">16 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_BaseAnnualRentToBePaidYearOne', window );">Base annual rent for 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_MaximumAllowanceForTenantImprovementsReceivable', window );">Maximum allowance for tenant improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_OperatingLeaseBaseRent', window );">Operating lease base rent</a></td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_AnnualIncreaseInRentPercentage', window );">Annual increase in rent percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_OperatingLeaseBaseRentEndOfLeaseTerm', window );">Base rent at the end of lease term</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_LeaseAndRentalAbatementCredit', window );">Lease and rental abatement credit</a></td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease, Liability</a></td>
<td class="nump">11,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="nump">$ 11,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,531,000<span></span>
</td>
<td class="nump">$ 10,790,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Lessee, Operating Lease, Discount Rate</a></td>
<td class="nump">12.89%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_AnnualIncreaseInRentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual increase in rent percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_AnnualIncreaseInRentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_BaseAnnualRentToBePaidYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount for base rent to be paid in year one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_BaseAnnualRentToBePaidYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_LeaseAndRentalAbatementCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease and rental abatement credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_LeaseAndRentalAbatementCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_MaximumAllowanceForTenantImprovementsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of maximum allowance for tenant improvements receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_MaximumAllowanceForTenantImprovementsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_OperatingLeaseBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease base rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_OperatingLeaseBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_OperatingLeaseBaseRentEndOfLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of base rent for operating lease at the end of lease term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_OperatingLeaseBaseRentEndOfLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140428515585960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Grants and Awards (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 15, 2020</div></th>
<th class="th"><div>Mar. 13, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_AwardLineItems', window );"><strong>Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Revenue from grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,251,000<span></span>
</td>
<td class="nump">$ 288,000<span></span>
</td>
<td class="nump">$ 3,485,000<span></span>
</td>
<td class="nump">$ 319,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_AwardReceivable', window );">Award receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,251,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,251,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 561,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=armp_MedicalTechnologyEnterpriseConsortiumMember', window );">Medical Technology Enterprise Consortium [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_AwardLineItems', window );"><strong>Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Revenue from grants</a></td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=armp_CysticFibrosisFoundationMember', window );">Cystic Fibrosis Foundation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_AwardLineItems', window );"><strong>Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_AwardReceivable', window );">Award receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_AmountReceivedUponAchievementOfMilestone', window );">Additional amount received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_AwardAgreementInterruptionPeriod', window );">Award agreement interruption period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">360 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_ResearchAndDevelopmentCreditsRecognized', window );">Research and development credits recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Cystic Fibrosis Foundation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_AwardLineItems', window );"><strong>Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_ThresholdDevelopmentAward', window );">Amount of threshold development award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_AmountReceivedUponAchievementOfMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount received during the period for the achievement of milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_AmountReceivedUponAchievementOfMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_AwardAgreementInterruptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the period for which the company ceases to use commercially reasonable efforts directed to the development of the product.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_AwardAgreementInterruptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_AwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents about award line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_AwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_AwardReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount as of the balance sheet date of award receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_AwardReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_ResearchAndDevelopmentCreditsRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development credits recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_ResearchAndDevelopmentCreditsRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_ThresholdDevelopmentAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The threshold amount of development award under the award agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_ThresholdDevelopmentAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueNotFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue that is not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueNotFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=armp_MedicalTechnologyEnterpriseConsortiumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=armp_MedicalTechnologyEnterpriseConsortiumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=armp_CysticFibrosisFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=armp_CysticFibrosisFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140428516387016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Synthetic Genomics Asset Acquisition (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 20, 2018</div></th>
<th class="th"><div>Feb. 28, 2018</div></th>
<th class="th"><div>Feb. 28, 2018</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="nump">$ 64,000<span></span>
</td>
<td class="nump">$ 451,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_AssetAcquisitionAxis=armp_SyntheticGenomicsIncMember', window );">Synthetic Genomics Inc [Member] | C3J [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_CashPaidForProductiveAssets', window );">Cash paid for productive assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000.0<span></span>
</td>
<td class="nump">$ 8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Cash paid acquisition of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets', window );">Issuance of common stock and conversion of deferred consideration for asset acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_PercentageOfFullyDilutedCapitalizationForIssuanceOfCommonStock', window );">Percentage of fully diluted capitalized for issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_MaximumPotentialMilestonePayments', window );">Maximum potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_AssetAcquisitionAxis=armp_SyntheticGenomicsIncMember', window );">Synthetic Genomics Inc [Member] | C3J [Member] | Scenario Original Expected Payment One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Cash paid acquisition of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_AssetAcquisitionAxis=armp_SyntheticGenomicsIncMember', window );">Synthetic Genomics Inc [Member] | C3J [Member] | Scenario Original Expected Payment Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Cash paid acquisition of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_AssetAcquisitionAxis=armp_SyntheticGenomicsIncMember', window );">Synthetic Genomics Inc [Member] | C3J [Member] | Scenario Original Expected Payment Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Cash paid acquisition of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_AssetAcquisitionAxis=armp_SyntheticGenomicsIncMember', window );">Synthetic Genomics Inc [Member] | C3J [Member] | Scenario Original Expected Payment Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Cash paid acquisition of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_AssetAcquisitionAxis=armp_SyntheticGenomicsIncMember', window );">Synthetic Genomics Inc [Member] | C3J [Member] | Scenario Amended Expected Payment One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Cash paid acquisition of assets</a></td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_AssetAcquisitionAxis=armp_SyntheticGenomicsIncMember', window );">Synthetic Genomics Inc [Member] | C3J [Member] | Scenario Amended Expected Payment Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Cash paid acquisition of assets</a></td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_armp_AssetAcquisitionAxis=armp_SyntheticGenomicsIncMember', window );">Synthetic Genomics Inc [Member] | C3J [Member] | Scenario Amended Expected Payment Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Cash paid acquisition of assets</a></td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_CashPaidForProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash paid for productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_CashPaidForProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_MaximumPotentialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of maximum potential milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_MaximumPotentialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_PercentageOfFullyDilutedCapitalizationForIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of fully diluted capitalized for issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_PercentageOfFullyDilutedCapitalizationForIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>armp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_armp_AssetAcquisitionAxis=armp_SyntheticGenomicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">armp_AssetAcquisitionAxis=armp_SyntheticGenomicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=armp_C3jTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=armp_C3jTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=armp_ScenarioOriginalExpectedPaymentOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=armp_ScenarioOriginalExpectedPaymentOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=armp_ScenarioOriginalExpectedPaymentTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=armp_ScenarioOriginalExpectedPaymentTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=armp_ScenarioOriginalExpectedPaymentThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=armp_ScenarioOriginalExpectedPaymentThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=armp_ScenarioOriginalExpectedPaymentFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=armp_ScenarioOriginalExpectedPaymentFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=armp_ScenarioAmendedExpectedPaymentOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=armp_ScenarioAmendedExpectedPaymentOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=armp_ScenarioAmendedExpectedPaymentTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=armp_ScenarioAmendedExpectedPaymentTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=armp_ScenarioAmendedExpectedPaymentThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=armp_ScenarioAmendedExpectedPaymentThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>53
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( -R :E,'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " #<@&I3CRDFSNX    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9)-
M:L,P$$:O4K2W1W)"%L+Q)J6K%@H-M'0GI$DB:OT@3;%S^\INXE#: Q2TT<RG
M-V] K8Y2AX3/*41,9#'?C:[W6>JX92>B* &R/J%3N2X)7YJ'D)RB<DU'B$I_
MJ"-"P_D&')(RBA1,P"HN1-:U1DN=4%%(%[S1"SY^IGZ&&0W8HT-/&40M@'73
MQ'@>^Q9N@ E&F%S^+J!9B'/U3^S< 79)CMDNJ6$8ZF$UY\H. MZ>'E_F=2OK
M,RFOL;S*5M(YXI9=)[^N=O?[!]8UO!&5*(?O&R'Y1J[7[Y/K#[^;L O&'NP_
M-KX*=BW\^A?=%U!+ P04    " #<@&I3F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M -R :E/R\ "N- 4  (05   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MI5C?<^(V$'Z^_A4:GMJ9([9D(.&&,$.XY"[32XY VINTTP=A"_#$EJ@L0_CO
MN[+!)HQ9N^T+^-=^^K1:?;NKP5;IUV0EA"%O<223Z];*F/4GQTG\E8AY<J'6
M0L*;A=(Q-W"KETZRUH('F5$<.<QU>T[,0]D:#K)G$ST<J-1$H10339(TCKG>
MW8A(;:];M'5X, V7*V,?.,/!FB_%3)C?UA,-=TZ!$H2QD$FH)-%B<=T:T4]C
MCUF#[(O?0[%-CJZ)G<I<J5=[<Q]<MUS+2$3"-Q:"P]]&C$44623@\?<>M%6,
M:0V/KP_H=]GD83)SGHBQBGZ$@5E=MZY:)! +GD9FJK9?Q7Y"78OGJRC)?LDV
M_[;3:1$_38R*]\; ( YE_L_?]HXX,F#],P9L;\!.#.BY$;R]@9=--&>63>LS
M-WPXT&I+M/T:T.Q%YIO,&F832KN,,Z/A;0AV9OA9^2FLBB$C&9!;:4*S(_<R
M#P_KYC9)5ER+9. 8&,W:./X>^29'9F>0^^1!2;-* #40P7M[!U@65-F!Z@U#
M 6=B?4$\]R-A+J,5?,:X^:/:7!"W6V7^CHY7>,[+\+S_Z+D_1_/$: C3OY#!
M.L5@G6RP3MU@S[NUJ%H+W)RZ[2>$1;=@T6W&XBGEV@@=[<A4K)4V58QP**-3
M@3#J%8QZ#?VB.4A+YOCSE'"L!8\2C--EP>FR&:>)T*&RL1$0V)N5RX8C'2+^
MIP\?:H+VJN!VA2+NX_0NC 1Y3..YT%6L< S7I6WOLMOI('SZ!9]^$SY3L0SM
M9@&G/?*XTE,XSLCN.DXFH%4Q]T5J0A]6\R-L2/\"H4G=4B;=)D0!3VD(KVR+
M?R0S ^M*E"9CE4JC=_ ?5+*O0?\QPD@>:3EM0O*9OY'[ "(P7( ;LCUQ?JUK
M(/NT3;N=?K=WA3%D)4/6A.$H"""GP/KL+\@W^(Y\E]6^PR$[7=<C7R(!*R/(
M:",D*BRTE'?J_2NJ8WL'2_VLMK*2)@[WP'4H.508$43[#F-8Y@2*J_HIPR(:
M)UIM0NE7>Q/''*.16"8*BLO[*;6)2@R/R!_A^OP6P1'[+NLSC%N9,BBN\]E"
MCJ#F/4\%!_"HBQ$I\P3%Y?V; I$"S5(2$^,:D%ZOVP;/H-NSS X4E_;GT$!B
M4 M"V<_S7\A,^*D&;U72PI'&*HY!=V9&^:\8M3)14%SA(<$'H5R2V2Z>JZB2
M44V*F#Y,L"JT3 4,%^N#5\CMF[_B<BG.YJP:H,>7V>WHX7:*L2JUGS72_G&J
MM:T]\B(H<QBH0EI9O]<@OIQ6_>^9E9K/&FF^K3D@48)$+96N#*D:G$<EV]SW
MH0.$]"N"'!!C6$H]:R3U]Q)JVKROM 4;/SBSDBN.6..[4N)9(XF?Q3R*R$V:
MP.ND>BUQG)IRFY7"SAH)^VTL]-)&UQ= ,"M0TGC-9?6JXH!U53<K=9WALGSP
MU4J KS!"_Z\-8*6^,UR:#UOR2 HA26?M-/F>&LB(TDI:92N;(W<S9'L4LQFR
M2_>JQ_K]@;.I8E5J/&O4 HPAL#6DGWOHSM_(KZ<ER=Y5=9V Z_89I11K!5@I
M\0Q7Z(-VW86)38PO@FNT>:J!:[<I:WMHJU]JOH=+=='3'7.[@X>5F[$&K.X
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M>+Z9DI$QQ,^81RV*KSM1P812/]K%YO>#>AIXA SQ0V8CZAIFJS+QE^B'X#K
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M=&, OV^%T.\WYGQO.,]=_P]02P,$%     @ W(!J4\BP>XU] @  J 8  !@
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M[8OMQ*K:MY:ULM2H_+"D3PEJ%T#[&Z7LX\1UJ_[CE/T#4$L#!!0    ( -R
M:E,8N=_7RP0  &42   8    >&PO=V]R:W-H965T<R]S:&5E=#0N>&ULI5C;
M;N,V$/T5PNA#%D@B47<%CH'$=ML%NJV1[.6AZ -CT;80271)VL[^?8>2+%\X
MU@;=%^OB,S,\AZ/AD,.=D*]JQ;DF;V51J?O!2NOUG>.H^8J73-V*-:_@GX60
M)=/P*)>.6DO.LMJH+!S/=2.G9'DU& WK=S,Y&HJ-+O**SR11F[)D\OLC+\3N
M?D '^Q=/^7*ES0MG-%RS)7_F^LMZ)N')Z;QD><DKE8N*2+ZX'SS0NRE-C$&-
M^)KSG3JZ)X;*BQ"OYN%C=C]PS8AXP>?:N&!PV?(Q+PKC"<;Q;^MTT,4TAL?W
M>^^_UN2!S M3?"R*;WFF5_>#9$ ROF";0C^)W>^\)10:?W-1J/J7[!IL!!'G
M&Z5%V1K#<YE7S96]M4(<&8 ?W,!K#;QS@^""@=\:^.^-$+0&P7LCA*U!3=UI
MN-?"39AFHZ$4.R(-&KR9FUK]VAKTRBN3*,]:PK\YV.G16%1*%'G&-,_(LX8+
M9(%61"S(7VLNF9E-16[(E^<)N?KEP]#1$-28.O,VP&,3P+L0P">?1*57BDRK
MC&>(_:3?/NVQ=X!LQ]C;,W[T>AT^\_4M\=UKXKD>1<8S?K^YB]'YN>C3_QW]
M1 R_FWZ_]N?_U/3__?"BM(1O^I^>D$$7,JA#!A="_B99I:'&;'FUX5@^->91
M;6[JW'9$O9"Z+O#='L^3C?.2Q()-;)@?)*&%FR(XFA[#3MB&'=NP5^!6Q6I)
M^!L4=\55CX11YS3JE?")*\[D?$58E4%5W$*Y7YMYP]1L/(5'M,+(BVPU;5S@
M1C9N8N-HZ+GV]$QM8!I$P45!XXY[W)\^O )%BYHZRZ BYB8US6J#L8_MT<:1
MG21C!)<$=I),;%SDAK:_J8T+T^1R-B4=^:27_&>A@;KX04XUU!-K"+&?!C9U
M&Q>FU)[/B8WSX+M,;>XVD(9!Z%\DGW;DTU[R?PBER$**<B\ E":,>&K%OXEH
MX-O,$2!\&S9P@@!I',>VF%,,&5+_<MI3][!0N_V51*^X)'DU%R4G5^W,?^BI
M)O2H!Z#]WQ0TE&2SAKZ-OYF\VN1J9>J)609F[#LTI_-7,I-"M]T=W"XE*TDA
M6(5V!-3./:3F3'Z,.R7D'0AYO80^5II+KG0K%[;*MQY."YX]PO>@I@C*2R[3
M."S.U'\?C7:V4:U].^4\.]<Q&#4%SF*, ".,,X(+3I?I4]:'_H#V-PAMD4/3
M_9I4'%WF6I^GJ814.P1W0P,L-VU@A*R'4\QAX%VN=O30.="P5X<_89M80,U#
MZ896MW(3!M2NQF,4&4<V<H(A:4Q=9'E#H6$8QI=I'WH;&O76N1E,NUHQR6'R
MFXTPE)R[OCIW:!UH?^^P5Y2L]S&NS2XSGS>-5%YL3!M\!<4P$T7!Y!$0W_DT
MX>)C&=Q;SSN? A3FTW/]45CLGVN/PM+T@NZ'UH+V]Q;?ZCTU\&=;6%V7O.$-
M6X&-5AKT@74!40N5!6D5@@1V++Y_K@S2*R30I<!Z?2X.XM/W(Y]22Q^L_X"U
M.@F3,XF<HVUSR>6R/J]09"XVE6ZV4-W;[DSDH3X).'O_2._&%'D_,6<H]3;]
MX+XY@/G$Y#*'G57!%Q *9AF&*YLSC>9!BW6]:7\16HNROEUQEG%I /#_0L!J
MW#Z8 -W)TN@_4$L#!!0    ( -R :E/J*69,^@8  ,HF   8    >&PO=V]R
M:W-H965T<R]S:&5E=#4N>&ULM9I;;]LV%,>_BF ,6 O4M7C1K4@"-+:'M4"'
MH%FWAV$/BD3'0G5Q);I.O_U(63&E\)"2L_3%MN3#HS\/J?,[I'1QJ.JOS98Q
M[CP4>=E<SK:<[]XM%DVR947<O*UVK!3_;*JZB+DXK.\7S:YF<=HV*O(%=EU_
M4<19.;NZ:,_=U%<7U9[G6<EN:J?9%T5<_[AF>76XG*'9XXG/V?V6RQ.+JXM=
M?,]N&?^RNZG%T>+D)<T*5C9953HUVUS.WJ-W:QK)!JW%7QD[-+W?CNS*755]
ME0<?TLN9*Q6QG"5<NHC%UW>V9'DN/0D=WSJGL],U9</^[T?OO[6=%YVYBQNV
MK/*_LY1O+V?AS$G9)M[G_'-U^)UU'?*DOZ3*F_;3.1QM?3)SDGW#JZ)K+!04
M67G\CA^Z0/0:8&QH@+L&^$D#XAL:D*X!>7J%R-" =@WHDP;(U >O:]!V?7'L
M>QNX5<SCJXNZ.CBUM!;>Y(\V^FUK$:^LE!/EEM?BWTRTXU?+JFRJ/$MCSE+G
MEHLO,0MXXU0;<50E7[=5GK*Z^=59?]MG_(<S=[[<KIQ7O[R^6'!Q>>EDD727
MNCY>"ALO511B:K1NG7\^L>*.U?\";I9V-^_3-)-S+,Z=FSA+YUGI+.-=QL6Q
MQ>EJQ&F2[(M]WD9AQ399DG&;M[7=VY^54#-LMA#C<AH<?!H<W/JA!C_7<1Z7
M"6N<F M5R5N'H#<.=E$$!?_HRF]=R?3P_2J*7->]6'SOQU:W0H'PZ&F6*]UR
MCKS PT@S70-.J1>1ON&@_^34?S*M_Z_$(#?;N&;-ZTFQ.+KU!K' ./!"6 \]
MZ:%6/2(U;5C&]S63]X=0P^LLD5.F:>=T?(CK=" 6TD8U;7/J(D.DO),RSZKL
M-LY;3<GQ'FOUO'%* 1IQ,FN:O8RC^+?A#:3)TP8P#/2YXVG*14PQT><#9!C*
M>6/HI7_JI?]2O1P;!5^3& ;(#4T*@Y/"P*IP_<#J)&M:E6(VU'$)!GP9Z)<'
M[JLQJX'$\"0Q/%OB6+1"30BBU*>PD.@D)+(*^<S$G53:[B11!SD\?A!(Y%L)
MHJR\!Z,9Z;=4J$=SS&K0">0J@+H_H1MONG"#&'5UI=A#R*"TAWHT;>2/ZJJ=
MQ"BL .D97<\'G=5@?OIZW"&SP!QX!4=DIV-_(@]Z-#:;.[^#_!20$!L$*5HA
M.Z[:RF8NR]94IBA1RS>Q% 36.#JBL(^ 7#K!<"A7P0S9:?:'R)MYU4 38(4
M2B'/\W0JK">9#B4JJB$[UOH%T"W;">B[$OK8!8=5IQB",(9T/*$H\(9\ZL*@
MF\Y10-P 2"^ +:8^BLQA4-A#=NZ9ZJ#QD.B80Z'OAV%(#)H4Z)"==/VA^;@O
M1W0$P-#HJ6*)=.*AR ]\/?FL -,Y\L78Z$7O&K#%D4\LV5_!%-EI:AJ:\9
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M(,2FH5' I'9@OLP#06@!B@V+-]I[5OE2A*0Z(:']G5&SH5#%1_J3^$B!'=>
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M@F':I!04D_60YVI6ST5(N]=R&+;G0_,8HN>27V*%PWQ,O:C;X^[O!D4:[+G
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MO_B_3/?=P_'T7P-,K!MMZ9:E!.ER?O+\*(5"]R.ZFF^_URY&5_'7K9*(8CJ
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M^F!^/W,W>MLTEB"^-$H+$;UY;D^9*U=Q!3 9(7^1IJ?7-_'=YH,9]6_T2H%
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ME,9BT.Q#K,42I E-._^0\QCL=-FMF-L >DRGP&Y%4?%RRW 12$A85FIA)G8
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MV-&@J>MY/"K1>L3>'O5?#1A![0W75E(W!=+0'^V+%PC;=K-?]-W4BS6J.P'
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MH^GXS+]2:WY8M7%OA>^5M:IT7]>"0V_:@.=+I6SS@PYH_YO ZW\#4$L#!!0
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MMF2R)J+Y9(%#_"K=AC, N=Y00^LSJIGXRF;D,U@\/.R(%69$2FK=Q,=0Z*9
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M/:0<66!VTB<!#K@7)[.7_0-E#E#TWCR F]>N\W],&%&4@:E%F<H7<?D2*#Y
MOX;*705"#)*O$EMU\SC,Q0#FCZ**Q("Y?A@=RL7UAP^,J0MFCU0%H+:*\E/"
M1]'X'#/1\N3YJ@$C/U$E'BD0 /%<BN\9)9^#"T/4%0MY,<S_(Q2\KD.07)*V
M=OFEYE0&"6U&K;@T049KXA82"UB^?NL'"7>?,4.,V7;#C:<::=@:D%Z2J[?*
M6(]$/1O=#18QHHUR/B C-2D7]''4FW#:1;$L;9WB!63O-9Y"D4R6!))02B5>
M@6PMB0>!"!5W<A"RD'J%JJQ;@KS?,_\WI%@N48]S7>Y3'M0'J<]Z!XS.B'C
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M#%@KWE)&Q0S/)Z,-U8T,(,JIK-[H ^.\38'V YCVIXNDQ@>I@!=LEFQ24_5
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MK=^)^K'A$V=T3G"U6EFXCKA'TD_'3UG"UQ<7U_Q]\O0^JY3=2M<'.843PLH
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M6W0U% '\A+B76WJ*4 U1/>C+ ]91)7QB71O2BFXH4>*@4BVM8D]#_E76HS6
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M$1$Y? \8K&TY1$N'QU09:9X:?CCP-%\I.(\N+@Y,"BB1YYTH3N'2?/_7%;'
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M@PJ1__B??U!\;GZS'7.E>&(N9Y1$5&@!>#[A7#U^T#\#K_X%X^(_4$L#!!0
M   ( -R :E-";9;T1 ,  #0-   9    >&PO=V]R:W-H965T<R]S:&5E=#(V
M+GAM;,U774_;,!3]*U:>0-I(['RTG=I*4)B&-#9$Q7A >S#);6N1V)GM4/;O
M9SLA:4OH^E@>B#_NO3[G'M>^'J^%?%8K (U>BYRKB;?2NOSB^RI=04'5F2B!
MFYF%D 75IBN7OBHET,PY%;E/@B#Q"\JX-QV[L5LY'8M*YXS#K42J*@HJ_UY
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M@N%P./9?-I7I,20D3@:CH#7<(ANW9..]9.=:I,_H9VEY*/1X \43R'U93-K
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ME#_Z;*Z\; ROF6A1N1N]%MKX@QL6YAL!TB:8]8T0^C"Q MU7)WD!4$L#!!0
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M+!I'I( M.Y3V01U_AR:@@?/+56G\?W*LQP[3B.0'8Y5HQ$@@N*RO[*5)Q(D
M?;H%:2-(_RWH7Q!DC2#[J*#?"/H?%0P:@0\]KF/WB5LSR^93K8Y$N]'HYFY\
M]KT:\\6E*Y1'J_$K1YV=KY00W.+*6T.8+,A*2<OE#F3.P9"K/YC6S"WE-;E:
M@V6\--?DACP]KLG5+]?3V"*",XKS9KIE/5UZ83I*[G""O2&WLH#B1WV,Z"U_
M^L:_3(.&BTKW2)9\(FF2)AT\J[#\6VY13KV<=LC78?DC5.WL7?+;L'P->3M[
M$DA&UBYFYOVR_[.8 ?]^Z]_W_OT+_E\!MR2QH$57IL-:.B2OP'0(8]!B#()6
M2T?!I#RP$L\J:0F>ERZ%61=5;37T5N[4?)ZG@P3_IO%S!\*P11@&$>[8"Q<'
M05B))RV3.7@&"Y(A#A>55L_@UZ$+:7B&-/1(%YA&+=,HR/2M K=7Y8Z4?IW<
M^>GST[5-1V<,=!)@&+<,XR##HEX5+G/M&;BL5PC1<KSB3T\73-@SZR7)KX&R
MF;1LDY^7C:=AEM@]$, MHK9-MBY4]7)RH7XN)(HF[P=O\H'-Y+:I8\*DL0VS
MOF@()J_@G<O6> Y.<,8AFI.? ?K!XO%<G\A7SC:\Y/:U$X.>85 Z"H&D[R#I
M?P/QO<N-VMX\8;H6QD!W8M+S@J;)CT3UB=XU,AED]&SD;>?(T200Y?M!3;.?
M+#X&@L&=1;OF)E<'K($'+(;.0,/&-.V-)YV[)3YI$@3HG>_.#/&SU?U"^[;M
M !>^[XG?A]?MXQW3.RX-[IPM2I/>" M!UQU9_6!5Y5N.C;+8P/C;/7:QH-T
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MJ7N^OX$ZH,#PQ9Q)^XOVE6T0."@NI>)9#=8KR&A>_9/'.A%' 'P*X-< _V?
M^ 1@5 -&0P'C&C >"@AJ0# 4$-: <"A@4@,F0P%1#8AL=:MRV%HNB2+SJ>![
M)(RU9C,/5A 6K4M(<Z/=!R7T6ZIQ:GXM2*XD(GF"/NZ)2"0Z^T*$($91Y^AL
M"8I0)L_1;^CKPQ*=_7(^=95V:\!N7+NXJESX)US\7K(+A(-?D>_Y7@=\T0^_
M)4+#1R?ARW[X Q07:.19..Z ?QH.[_*^>IOWZ[=YO^F'+R'6<-P%=[5.&K'X
MC5A\RS<ZP6<5@K[]H:?19P69_*>'=-20CBSI^ 3I/>P@+P%M!,_0ULJQJ\H5
M26A)3$/>S;$?8,_3<>V.R]FV\Z.H9;9JFXW&4="RN^ZPPY?'9B]B'C<QCWMC
MKA(I( :Z(VL&70%7#,%K :\&VMV,6Y$$(3X92=!$$O1&<@L)C0E#?T*<YISQ
M[1/ZE"L0A: 2T(+GD@M%RPQ]NX5L#:)/,6'C,WP_&4X:TLD[R/!JTI:A4<W)
M/$:-^ZC7_>))*AJC%5T++JE$*U[F";''^X#,739>+M\O<]@[G"'>6^6\J"E>
M9*XO<?CH!,/]WI.$FD1I%9),ITW5*X&D\[3 K75$?<LX]$;L#T@"V0H ?;=3
MB)IM(,K"UK  07G7>A:OL(Y"#R7D2?;5Z=!I\6NM5@(1<6J/^T0+GO'"KC46
M>AOK:X!.'-_F]+_.U*UPNQG^E+KZ3.OHU;VE/K1-W-\W;\DCS8Z:"?H?O6WC
MX$.?P\$[;IU#*\-AOVHJQ?(-4JD F7+VLC+$N.W43=CNYYU)=H\NA^9S1-^G
MMC27B,%&([V+B8Y;5#?\:J!X8>^+:Z[T[=,^IOJK"(0QT.\WG*OG@;F"-M]9
M\Q]02P,$%     @ W(!J4^WW.A2A!   X1@  !D   !X;"]W;W)K<VAE971S
M+W-H965T-# N>&ULS5EM;]LV$/XKA+$!+=#%(N77PC&0Q$WCH5Z#>.T^%/U
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M[(Q/H*@9WZTKJW"NZ;K;ZY.M@[O9(%.E<Z;;,%VR,8V'@A4@1_/Y NY&53&
MQJC2#G).YTI2IV'CT0PL[8P)<0O/Q(]BCWM5[%2N W63[= *:H:>QD^ ?Y?-
M<^_2OHXWJOB#,I^7=CO2S:'5V(UF!5^Y^:IH!6#L79R=5I58?Q)\+DOF-__B
M@.,AW?A%"Z7YHXT&K3*S!J9)],"TX;-=RR]-JSNV,IMV6A6XYMX1:OZ[>9XS
MR305NZ)M[[_E++]:<7+YKR2[_RJ'@H,:FX/NK8OL'X/(]!A$'D%/)MF;U!@W
M1^/.^;MW^K;6"-YR1N0[O#6);=!HNN3"<-G,%CS/F7QR"%MZ0Z?V=7>/WZ[/
M64&7PMRUX(ALQ]]8SI=EUJZZ@40TJ[;CK["];MJ^8ME87.9LQ?)),]7SJ1M&
M=F"C-A<X'"+7[@HCF(_'P@A@6!Q, >;CO; X_]-^!NA^/(9I&P21 >HS0'V\
M5PB9N \6)^R3V2N\TRQ+DC3%,CJ9!!5,L+RE*7S#;)@V\,#B0*0_RS5>;;Q#
MGN\#K*;/=0BV4[P3L9WBN08DG#?PR+)PM;$XX(%5 >L=B!^. ST5]DD2J"JF
M#7N"<23+, 1Z,=RC:8ID)X5/N#[84Y(D619&  LK2!(,@:<11S %H %#DL2=
M@P?G4;PYI^+M;T#CWU!+ P04    " #<@&I3EXJ[',     3 @  "P   %]R
M96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:
MI7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$
MVV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_
M,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH
M^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( -R :E.WSZNWO@,  #0;
M   /    >&PO=V]R:V)O;VLN>&ULQ9E!;]HP%(#_BI43O0R24+I6I1)KNZY2
MU:(R]3H9QX"%8S/;*6M__9Z34IP5GG9Q.8$=XWQYP>][3L[7VBRG6B_)GU(J
M.TP6SJW.NEW+%KRD]HM><05'9MJ4U$'3S+MV93@M[()S5\INUNL-NB45*KDX
MW\PU-MVPH1UG3F@%G;[C2?"UW1[W3?(LK)@**=S+,*F_2YZ04BA1BE=>#)->
M0NQ"KW]H(UZU<E1.F-%2#I.T.?#$C1/L0_?$0_ZD4UOW.#I]I  R3 8]F' F
MC'7UB'I^"HS/' 8WK<KI[T(Z;JZHXS=&5RNAYGX:N(IN<!EU'#:?31#/S/^$
M4<]F@O$KS:J2*]?$T7#I 95=B)5-B*(E'R:;(62D"G*M' 2)W*IF*ACKKQ1.
M?5LT5^T -XBA.1-PP-P6-7@\R$MH:RD*.'M!OE%)%>.D#JX- #,$,#L8(.F,
M:0"9(Y#Y)T)./(3_@25Z1AY6W 20?02R?S#(B=,L@#Q&((\/!GE)[2* '""0
M@P-"_LH"R!,$\B0NY(.94R5>ZP.$0@JZXI89L:K;>A9 ?D4@O\:%O!._*U%
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MJ'?Q3KU#O-0^/'KN:[S_.ZF.UVO]X_:WY7T3GQ?%#6<'_P^6OU!+ P04
M" #<@&I3F,0A):(!  "F&   $P   %M#;VYT96YT7U1Y<&5S72YX;6S-F<UN
M@S 0A%\%<8V"8SM-?Y3DTO;:YM 7<&$)*( MVTF3MZ\A/U*K%#5*I<X%"[P[
M,WBE[P#3MYTA%VWKJG&SN/#>/##FTH)JY1)MJ D[N;:U\N'6+IE1Z4HMB8G1
M:,)2W7AJ_-"W&O%\^D2Y6E<^>MZ&QZ[4S2RV5+DX>MP7MEZS6!E3E:GR89]M
MFNR;R_#@D(3.KL85I7&#4!"SLP[MSL\&A[[7#5E;9A0ME/4OJ@Y5;%LQYW<5
MN:1?XDQ&G>=E2IE.UW5H29RQI#)7$/FZ2O:B@WYG'TZ8]E=^M7\GTV<8*A=6
M&Q<F9NERN^-(VNZA"4)D?=G_BB?'('WU^U$[[8RR7WJ'X_W0=M7-P[%NN?Z,
MO\[XI']A#@&20X+D&(/DN '),0')<0N2XPXDQSU(#CY""8)"5(Z"5(["5(X"
M58Y"58Z"58["58X"5HY"5H%"5H%"5H%"5H%"5H%"5H%"5H%"5H%"5H%"5H%"
M5HE"5HE"5HE"5HE"5HE"5HE"5HE"5HE"5HE"5HE"UO%_DO5=Z]5??SEOUZ16
M97/T9]WOB?DG4$L! A0#%     @ W(!J4P=!36*!    L0   !
M     ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #<@&I3CRDF
MSNX    K @  $0              @ &O    9&]C4')O<',O8V]R92YX;6Q0
M2P$"% ,4    " #<@&I3F5R<(Q &  "<)P  $P              @ ', 0
M>&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( -R :E/R\ "N- 4  (05
M   8              " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q0
M2P$"% ,4    " #<@&I33 7148T%  #;%0  &               @(%W#0
M>&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ W(!J4\BP>XU]
M @  J 8  !@              ("!.A,  'AL+W=O<FMS:&5E=',O<VAE970S
M+GAM;%!+ 0(4 Q0    ( -R :E,8N=_7RP0  &42   8              "
M@>T5  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " #<@&I3
MZBEF3/H&  #*)@  &               @('N&@  >&PO=V]R:W-H965T<R]S
M:&5E=#4N>&UL4$L! A0#%     @ W(!J4X61-0 X!@  ?1@  !@
M     ("!'B(  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    (
M -R :E-DZ4>$A (  'P'   8              " @8PH  !X;"]W;W)K<VAE
M971S+W-H965T-RYX;6Q02P$"% ,4    " #<@&I3"F?2X-(#  #!"   &
M            @(%&*P  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#
M%     @ W(!J4YM!D$!^"0  &AD  !@              ("!3B\  'AL+W=O
M<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( -R :E.Y^6"U @X  (HD
M   9              " @0(Y  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL
M4$L! A0#%     @ W(!J4V\D#";% @  1@8  !D              ("!.T<
M 'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " #<@&I3L(Y]
MUQ<#   *"   &0              @($W2@  >&PO=V]R:W-H965T<R]S:&5E
M=#$R+GAM;%!+ 0(4 Q0    ( -R :E-;6^)3KP,  #((   9
M  " @85-  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @
MW(!J4\V:2*U&!@  <Q(  !D              ("!:U$  'AL+W=O<FMS:&5E
M=',O<VAE970Q-"YX;6Q02P$"% ,4    " #<@&I3?_:=PO\*   R(   &0
M            @('H5P  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4
M Q0    ( -R :E-]VO?/_@4  #8.   9              " @1YC  !X;"]W
M;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ W(!J4ZS[G .="
MV18  !D              ("!4VD  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX
M;6Q02P$"% ,4    " #<@&I3(GQ4"Z0%  !H#@  &0              @($G
M<@  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( -R :E,V
MK[Z?A0D  !\9   9              " @0)X  !X;"]W;W)K<VAE971S+W-H
M965T,3DN>&UL4$L! A0#%     @ W(!J4\\!J2"U#@  Q"D  !D
M     ("!OH$  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4
M" #<@&I3=1H =>$"  !W!@  &0              @(&JD   >&PO=V]R:W-H
M965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( -R :E-C_IODLP(  'H&   9
M              " @<*3  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L!
M A0#%     @ W(!J4]XT9UOR @  HP8  !D              ("!K)8  'AL
M+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " #<@&I3\=.2IC,&
M  !/%   &0              @('5F0  >&PO=V]R:W-H965T<R]S:&5E=#(T
M+GAM;%!+ 0(4 Q0    ( -R :E.[W"UB8P<  (XA   9              "
M@3^@  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ W(!J
M4T)MEO1$ P  - T  !D              ("!V:<  'AL+W=O<FMS:&5E=',O
M<VAE970R-BYX;6Q02P$"% ,4    " #<@&I3PR(#54@"  "!!@  &0
M        @(%4JP  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0
M   ( -R :E-)9ARV- ,  /X+   9              " @=.M  !X;"]W;W)K
M<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ W(!J4P"<R$MW @  5 8
M !D              ("!/K$  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q0
M2P$"% ,4    " #<@&I3;O0]3#\'   ]*P  &0              @('LLP
M>&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( -R :E.\MQYY
MX 4  )P?   9              " @6*[  !X;"]W;W)K<VAE971S+W-H965T
M,S$N>&UL4$L! A0#%     @ W(!J4V_5-<N9!0  MA<  !D
M ("!><$  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " #<
M@&I3MX3ZR"H#  "R#   &0              @(%)QP  >&PO=V]R:W-H965T
M<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( -R :E/H>,2@. ,  $4+   9
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M970S."YX;6Q02P$"% ,4    " #<@&I31K<8ZYP#  !S#0  &0
M    @('5W   >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    (
M -R :E/M]SH4H00  .$8   9              " @:C@  !X;"]W;W)K<VAE
M971S+W-H965T-# N>&UL4$L! A0#%     @ W(!J4_[3;$(> P  $!(   T
M             ( !@.4  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #<@&I3
MEXJ[',     3 @  "P              @ ')Z   7W)E;',O+G)E;'-02P$"
M% ,4    " #<@&I3M\^KM[X#   T&P  #P              @ &RZ0  >&PO
M=V]R:V)O;VLN>&UL4$L! A0#%     @ W(!J4SQA]1J- 0  3Q@  !H
M         ( !G>T  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#
M%     @ W(!J4YC$(26B 0  IA@  !,              ( !8N\  %M#;VYT
D96YT7U1Y<&5S72YX;6Q02P4&     #  ,  '#0  -?$

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>151</ContextCount>
  <ElementCount>275</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>54</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="armp-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="armp-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="armp-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="armp-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="armp-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="armp-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00400 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="armp-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00405 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical</Role>
      <ShortName>Consolidated Statements of Cash Flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="armp-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Organization and Description of the Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusiness</Role>
      <ShortName>Organization and Description of the Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="armp-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureLiquidity</Role>
      <ShortName>Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="armp-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureSignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="armp-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="armp-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Balance Sheet Details</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureBalanceSheetDetails</Role>
      <ShortName>Balance Sheet Details</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="armp-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Paycheck Protection Program Loan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosurePaycheckProtectionProgramLoan</Role>
      <ShortName>Paycheck Protection Program Loan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="armp-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Stockholders Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="armp-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Equity Incentive Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureEquityIncentivePlans</Role>
      <ShortName>Equity Incentive Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="armp-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="armp-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Grants and Awards</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureGrantsAndAwards</Role>
      <ShortName>Grants and Awards</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="armp-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Synthetic Genomics Asset Acquisition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureSyntheticGenomicsAssetAcquisition</Role>
      <ShortName>Synthetic Genomics Asset Acquisition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="armp-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>20202 - Disclosure - Liquidity (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureLiquidityPolicies</Role>
      <ShortName>Liquidity (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="armp-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>20302 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="armp-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureNetLossPerShare</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="armp-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Balance Sheet Details (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsTables</Role>
      <ShortName>Balance Sheet Details (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureBalanceSheetDetails</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="armp-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>30703 - Disclosure - Stockholders Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureStockholdersEquity</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="armp-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>30803 - Disclosure - Equity Incentive Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureEquityIncentivePlansTables</Role>
      <ShortName>Equity Incentive Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureEquityIncentivePlans</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="armp-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Liquidity (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureLiquidityNarrativeDetails</Role>
      <ShortName>Liquidity (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureLiquidityPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="armp-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Net Loss Per Share (Antidilutive Shares Excluded from Computation of Diluted Shares Outstanding) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails</Role>
      <ShortName>Net Loss Per Share (Antidilutive Shares Excluded from Computation of Diluted Shares Outstanding) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="armp-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Balance Sheet Details (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsNarrativeDetails</Role>
      <ShortName>Balance Sheet Details (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="armp-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>40502 - Disclosure - Balance Sheet Details (Property and Equipment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails</Role>
      <ShortName>Balance Sheet Details (Property and Equipment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="armp-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Paycheck Protection Program Loan (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosurePaycheckProtectionProgramLoanNarrativeDetails</Role>
      <ShortName>Paycheck Protection Program Loan (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosurePaycheckProtectionProgramLoan</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="armp-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Stockholders Equity (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureStockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders Equity (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureStockholdersEquityTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="armp-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40702 - Disclosure - Stockholders Equity (Summary of Warrants Outstanding) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureStockholdersEquitySummaryOfWarrantsOutstandingDetails</Role>
      <ShortName>Stockholders Equity (Summary of Warrants Outstanding) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureStockholdersEquityTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="armp-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Equity Incentive Plans (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails</Role>
      <ShortName>Equity Incentive Plans (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureEquityIncentivePlansTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="armp-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40802 - Disclosure - Equity Incentive Plans (Assumptions Used in the Black-Scholes Model) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails</Role>
      <ShortName>Equity Incentive Plans (Assumptions Used in the Black-Scholes Model) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureEquityIncentivePlansTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="armp-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40803 - Disclosure - Equity Incentive Plans (Allocation of Stock-Based Compensation Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAllocationOfStockBasedCompensationExpenseDetails</Role>
      <ShortName>Equity Incentive Plans (Allocation of Stock-Based Compensation Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureEquityIncentivePlansTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="armp-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40804 - Disclosure - Equity Incentive Plans (Summary of Stock Option Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails</Role>
      <ShortName>Equity Incentive Plans (Summary of Stock Option Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureEquityIncentivePlansTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="armp-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40805 - Disclosure - Equity Incentive Plans (Restricted stock award) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardDetails</Role>
      <ShortName>Equity Incentive Plans (Restricted stock award) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureEquityIncentivePlansTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="armp-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40806 - Disclosure - Equity Incentive Plans (Shares Reserved for Future Issuance) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSharesReservedForFutureIssuanceDetails</Role>
      <ShortName>Equity Incentive Plans (Shares Reserved for Future Issuance) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureEquityIncentivePlansTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="armp-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Commitments and Contingencies (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="armp-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Grants and Awards (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureGrantsAndAwardsNarrativeDetails</Role>
      <ShortName>Grants and Awards (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureGrantsAndAwards</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="armp-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>41101 - Disclosure - Synthetic Genomics Asset Acquisition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.armatapharma.com/role/DisclosureSyntheticGenomicsAssetAcquisitionDetails</Role>
      <ShortName>Synthetic Genomics Asset Acquisition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.armatapharma.com/role/DisclosureSyntheticGenomicsAssetAcquisition</ParentRole>
      <Position>40</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="armp-20210930x10q.htm">armp-20210930x10q.htm</File>
    <File>armp-20210930.xsd</File>
    <File>armp-20210930_cal.xml</File>
    <File>armp-20210930_def.xml</File>
    <File>armp-20210930_lab.xml</File>
    <File>armp-20210930_pre.xml</File>
    <File>armp-20210930xex31d1.htm</File>
    <File>armp-20210930xex31d2.htm</File>
    <File>armp-20210930xex32d1.htm</File>
    <File>armp-20210930xex32d2.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>armp-20210930x10q001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>59
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "armp-20210930x10q.htm": {
   "axisCustom": 1,
   "axisStandard": 19,
   "contextCount": 151,
   "dts": {
    "calculationLink": {
     "local": [
      "armp-20210930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "armp-20210930_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "armp-20210930x10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "armp-20210930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "armp-20210930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "armp-20210930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 354,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 4,
    "http://www.armatapharma.com/20210930": 1,
    "http://xbrl.sec.gov/dei/2020-01-31": 6,
    "total": 11
   },
   "keyCustom": 43,
   "keyStandard": 232,
   "memberCustom": 26,
   "memberStandard": 25,
   "nsprefix": "armp",
   "nsuri": "http://www.armatapharma.com/20210930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document And Entity Information",
     "role": "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - Significant Accounting Policies",
     "role": "http://www.armatapharma.com/role/DisclosureSignificantAccountingPolicies",
     "shortName": "Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - Net Loss per Share",
     "role": "http://www.armatapharma.com/role/DisclosureNetLossPerShare",
     "shortName": "Net Loss per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - Balance Sheet Details",
     "role": "http://www.armatapharma.com/role/DisclosureBalanceSheetDetails",
     "shortName": "Balance Sheet Details",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - Paycheck Protection Program Loan",
     "role": "http://www.armatapharma.com/role/DisclosurePaycheckProtectionProgramLoan",
     "shortName": "Paycheck Protection Program Loan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - Stockholders Equity",
     "role": "http://www.armatapharma.com/role/DisclosureStockholdersEquity",
     "shortName": "Stockholders Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - Equity Incentive Plans",
     "role": "http://www.armatapharma.com/role/DisclosureEquityIncentivePlans",
     "shortName": "Equity Incentive Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10901 - Disclosure - Commitments and Contingencies",
     "role": "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "armp:AwardTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11001 - Disclosure - Grants and Awards",
     "role": "http://www.armatapharma.com/role/DisclosureGrantsAndAwards",
     "shortName": "Grants and Awards",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "armp:AwardTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "armp:AssetAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11101 - Disclosure - Synthetic Genomics Asset Acquisition",
     "role": "http://www.armatapharma.com/role/DisclosureSyntheticGenomicsAssetAcquisition",
     "shortName": "Synthetic Genomics Asset Acquisition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "armp:AssetAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "armp:LiquidityAndGoingConcernPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20202 - Disclosure - Liquidity (Policies)",
     "role": "http://www.armatapharma.com/role/DisclosureLiquidityPolicies",
     "shortName": "Liquidity (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "armp:LiquidityAndGoingConcernPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - Consolidated Balance Sheets",
     "role": "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20302 - Disclosure - Significant Accounting Policies (Policies)",
     "role": "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies",
     "shortName": "Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30403 - Disclosure - Net Loss per Share (Tables)",
     "role": "http://www.armatapharma.com/role/DisclosureNetLossPerShareTables",
     "shortName": "Net Loss per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30503 - Disclosure - Balance Sheet Details (Tables)",
     "role": "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsTables",
     "shortName": "Balance Sheet Details (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30703 - Disclosure - Stockholders Equity (Tables)",
     "role": "http://www.armatapharma.com/role/DisclosureStockholdersEquityTables",
     "shortName": "Stockholders Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30803 - Disclosure - Equity Incentive Plans (Tables)",
     "role": "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansTables",
     "shortName": "Equity Incentive Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - Liquidity (Narrative) (Details)",
     "role": "http://www.armatapharma.com/role/DisclosureLiquidityNarrativeDetails",
     "shortName": "Liquidity (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "armp:LiquidityAndGoingConcernPolicyTextBlock",
       "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernManagementsEvaluation",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - Net Loss Per Share (Antidilutive Shares Excluded from Computation of Diluted Shares Outstanding) (Details)",
     "role": "http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails",
     "shortName": "Net Loss Per Share (Antidilutive Shares Excluded from Computation of Diluted Shares Outstanding) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:Depreciation",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_7_1_2021_To_9_30_2021_EHL267Iy5kqlAVaXmlK6uQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - Balance Sheet Details (Narrative) (Details)",
     "role": "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsNarrativeDetails",
     "shortName": "Balance Sheet Details (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:Depreciation",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_7_1_2021_To_9_30_2021_EHL267Iy5kqlAVaXmlK6uQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40502 - Disclosure - Balance Sheet Details (Property and Equipment) (Details)",
     "role": "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails",
     "shortName": "Balance Sheet Details (Property and Equipment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_7_1_2021_To_9_30_2021_EHL267Iy5kqlAVaXmlK6uQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "armp:GainLossOnExtinguishmentOfPaycheckProtectionProgramLoan",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - Paycheck Protection Program Loan (Narrative) (Details)",
     "role": "http://www.armatapharma.com/role/DisclosurePaycheckProtectionProgramLoanNarrativeDetails",
     "shortName": "Paycheck Protection Program Loan (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_7_1_2021_To_9_30_2021_EHL267Iy5kqlAVaXmlK6uQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "armp:GainLossOnExtinguishmentOfPaycheckProtectionProgramLoan",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_NRjonq23P0KKsokMR6lA3Q",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00105 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - Stockholders Equity (Narrative) (Details)",
     "role": "http://www.armatapharma.com/role/DisclosureStockholdersEquityNarrativeDetails",
     "shortName": "Stockholders Equity (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40702 - Disclosure - Stockholders Equity (Summary of Warrants Outstanding) (Details)",
     "role": "http://www.armatapharma.com/role/DisclosureStockholdersEquitySummaryOfWarrantsOutstandingDetails",
     "shortName": "Stockholders Equity (Summary of Warrants Outstanding) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA",
      "decimals": null,
      "lang": "en-US",
      "name": "armp:TermOfWarrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_EPrTQjTDQkGfR4N7mgNYUg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - Equity Incentive Plans (Narrative) (Details)",
     "role": "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails",
     "shortName": "Equity Incentive Plans (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_EPrTQjTDQkGfR4N7mgNYUg",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2020_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_bMElE1RKukaULS3RIlENIw",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "armp:EquitySecuritiesMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_EPrTQjTDQkGfR4N7mgNYUg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40802 - Disclosure - Equity Incentive Plans (Assumptions Used in the Black-Scholes Model) (Details)",
     "role": "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails",
     "shortName": "Equity Incentive Plans (Assumptions Used in the Black-Scholes Model) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2020_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_bMElE1RKukaULS3RIlENIw",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "armp:EquitySecuritiesMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_EPrTQjTDQkGfR4N7mgNYUg",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_7_1_2021_To_9_30_2021_EHL267Iy5kqlAVaXmlK6uQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40803 - Disclosure - Equity Incentive Plans (Allocation of Stock-Based Compensation Expense) (Details)",
     "role": "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAllocationOfStockBasedCompensationExpenseDetails",
     "shortName": "Equity Incentive Plans (Allocation of Stock-Based Compensation Expense) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_77ETOpJ7T0afQOPGHLIu-g",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "As_Of_12_31_2020_3XkWxHnS1E-fu4Gi2yzQGg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40804 - Disclosure - Equity Incentive Plans (Summary of Stock Option Activity) (Details)",
     "role": "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails",
     "shortName": "Equity Incentive Plans (Summary of Stock Option Activity) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_TDb9Z5iGoUePxWE6REEZBg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40805 - Disclosure - Equity Incentive Plans (Restricted stock award) (Details)",
     "role": "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardDetails",
     "shortName": "Equity Incentive Plans (Restricted stock award) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_uMrMSnX6sk6VBfvSkKl9Vg",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40806 - Disclosure - Equity Incentive Plans (Shares Reserved for Future Issuance) (Details)",
     "role": "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSharesReservedForFutureIssuanceDetails",
     "shortName": "Equity Incentive Plans (Shares Reserved for Future Issuance) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "armp:ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_f2W27J9F2U-_Iz7Q0pzFzg",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "As_Of_10_31_2021_egZlLrGpKk2-r-0udRYIlQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - Commitments and Contingencies (Narrative) (Details)",
     "role": "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
     "shortName": "Commitments and Contingencies (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "As_Of_10_31_2021_egZlLrGpKk2-r-0udRYIlQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_7_1_2021_To_9_30_2021_EHL267Iy5kqlAVaXmlK6uQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueNotFromContractWithCustomer",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41001 - Disclosure - Grants and Awards (Narrative) (Details)",
     "role": "http://www.armatapharma.com/role/DisclosureGrantsAndAwardsNarrativeDetails",
     "shortName": "Grants and Awards (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "armp:AwardTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_7_15_2020_To_7_15_2020_srt_CounterpartyNameAxis_armp_MedicalTechnologyEnterpriseConsortiumMember_ITaRqTiHmk-EtdzqEDU-gw",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:RevenueNotFromContractWithCustomer",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_7_1_2021_To_9_30_2021_EHL267Iy5kqlAVaXmlK6uQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueNotFromContractWithCustomer",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - Consolidated Statements of Operations",
     "role": "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_7_1_2021_To_9_30_2021_EHL267Iy5kqlAVaXmlK6uQ",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_7_1_2021_To_9_30_2021_EHL267Iy5kqlAVaXmlK6uQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestExpense",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41101 - Disclosure - Synthetic Genomics Asset Acquisition (Details)",
     "role": "http://www.armatapharma.com/role/DisclosureSyntheticGenomicsAssetAcquisitionDetails",
     "shortName": "Synthetic Genomics Asset Acquisition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "armp:AssetAcquisitionTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_2_28_2018_To_2_28_2018_armp_AssetAcquisitionAxis_armp_SyntheticGenomicsIncMember_dei_LegalEntityAxis_armp_C3jTherapeuticsIncMember_RidG05BOeEyASZ1M8D09rA",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:PaymentsToAcquireProductiveAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SL0WNDAfdkevFGn-ljnxpQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - Consolidated Statements of Stockholders' Equity",
     "role": "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SL0WNDAfdkevFGn-ljnxpQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_QRnvYDAKy0-Q3RlEgqVvyA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00405 - Statement - Consolidated Statements of Cash Flows (Parenthetical)",
     "role": "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical",
     "shortName": "Consolidated Statements of Cash Flows (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2020_zW8zVq9yIEyTGkUsiRdNWQ",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:RestrictedCashNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_1Vqig3cVxEi5ElKn_dnD0g",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - Organization and Description of the Business",
     "role": "http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusiness",
     "shortName": "Organization and Description of the Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - Liquidity",
     "role": "http://www.armatapharma.com/role/DisclosureLiquidity",
     "shortName": "Liquidity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "armp-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_I9v0hl2tfU-03sBuFYULmA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 54,
   "tag": {
    "armp_AccruedInterestForDeferredConsiderationOnAssetAcquisition": {
     "auth_ref": [],
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued interest for deferred consideration on asset acquisition.",
        "label": "Accrued Interest For Deferred Consideration On Asset Acquisition",
        "negatedLabel": "Payment of accreted interest for deferred consideration for asset acquisition"
       }
      }
     },
     "localname": "AccruedInterestForDeferredConsiderationOnAssetAcquisition",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "armp_AmountReceivedUponAchievementOfMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount received during the period for the achievement of milestone.",
        "label": "Amount Received Upon Achievement of Milestone",
        "terseLabel": "Additional amount received"
       }
      }
     },
     "localname": "AmountReceivedUponAchievementOfMilestone",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureGrantsAndAwardsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "armp_AnnualIncreaseInRentPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual increase in rent percentage.",
        "label": "Annual Increase in Rent Percentage",
        "terseLabel": "Annual increase in rent percentage"
       }
      }
     },
     "localname": "AnnualIncreaseInRentPercentage",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "armp_AssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition [Abstract].",
        "label": "Synthetic Genomics Asset Acquisition"
       }
      }
     },
     "localname": "AssetAcquisitionAbstract",
     "nsuri": "http://www.armatapharma.com/20210930",
     "xbrltype": "stringItemType"
    },
    "armp_AssetAcquisitionAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSyntheticGenomicsAssetAcquisitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "armp_AssetAcquisitionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSyntheticGenomicsAssetAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "armp_AssetAcquisitionTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for asset acquisition.",
        "label": "Asset Acquisition [Text Block]",
        "terseLabel": "Synthetic Genomics Asset Acquisition"
       }
      }
     },
     "localname": "AssetAcquisitionTextBlock",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSyntheticGenomicsAssetAcquisition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "armp_Assumed2006And2016PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to assumed 2006 and 2016 plan.",
        "label": "Assumed2006 And2016 Plan [Member]",
        "terseLabel": "Assumed 2006 and 2016 Plan [Member]"
       }
      }
     },
     "localname": "Assumed2006And2016PlanMember",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "armp_AwardAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents about award abstract.",
        "label": "Grants and Awards"
       }
      }
     },
     "localname": "AwardAbstract",
     "nsuri": "http://www.armatapharma.com/20210930",
     "xbrltype": "stringItemType"
    },
    "armp_AwardAgreementInterruptionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the period for which the company ceases to use commercially reasonable efforts directed to the development of the product.",
        "label": "Award Agreement, Interruption Period",
        "terseLabel": "Award agreement interruption period"
       }
      }
     },
     "localname": "AwardAgreementInterruptionPeriod",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureGrantsAndAwardsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "armp_AwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents about award line items.",
        "label": "Award [Line Items]"
       }
      }
     },
     "localname": "AwardLineItems",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureGrantsAndAwardsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "armp_AwardReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount as of the balance sheet date of award receivable.",
        "label": "Award Receivable",
        "terseLabel": "Award receivable",
        "verboseLabel": "Awards receivable"
       }
      }
     },
     "localname": "AwardReceivable",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureGrantsAndAwardsNarrativeDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "armp_AwardTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents about award table.",
        "label": "Award [Table]"
       }
      }
     },
     "localname": "AwardTable",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureGrantsAndAwardsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "armp_AwardTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "represents about award text block.",
        "label": "Award Text Block",
        "terseLabel": "Grants and Awards"
       }
      }
     },
     "localname": "AwardTextBlock",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureGrantsAndAwards"
     ],
     "xbrltype": "textBlockItemType"
    },
    "armp_BaseAnnualRentToBePaidYearOne": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount for base rent to be paid in year one.",
        "label": "Base Annual Rent To Be Paid, Year One",
        "terseLabel": "Base annual rent for 2023"
       }
      }
     },
     "localname": "BaseAnnualRentToBePaidYearOne",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "armp_C3jTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "C3j Therapeutics Inc [Member]",
        "label": "C3j Therapeutics Inc [Member]",
        "terseLabel": "C3J [Member]"
       }
      }
     },
     "localname": "C3jTherapeuticsIncMember",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSyntheticGenomicsAssetAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "armp_CashPaidForProductiveAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash paid for productive assets.",
        "label": "Cash Paid for Productive Assets",
        "terseLabel": "Cash paid for productive assets"
       }
      }
     },
     "localname": "CashPaidForProductiveAssets",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSyntheticGenomicsAssetAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "armp_CysticFibrosisFoundationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Cystic Fibrosis Foundation.",
        "label": "Cystic Fibrosis Foundation [Member]",
        "terseLabel": "Cystic Fibrosis Foundation [Member]"
       }
      }
     },
     "localname": "CysticFibrosisFoundationMember",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureGrantsAndAwardsNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureLiquidityNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "armp_EquityIncentivePlan2016Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Incentive Plan 2016 [Member]",
        "label": "Equity Incentive Plan2016 [Member]",
        "terseLabel": "Equity Incentive Plan 2016 [Member]"
       }
      }
     },
     "localname": "EquityIncentivePlan2016Member",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSharesReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "armp_EquitySecuritiesMeasurementInput": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure investment in equity security measured at fair value.",
        "label": "Equity Securities Measurement Input",
        "terseLabel": "Fair value input, equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesMeasurementInput",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "armp_ExercisePriceEightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Eight [Member].",
        "label": "Exercise Price Eight [Member]",
        "terseLabel": "Exercise Price $3.25 [Member]"
       }
      }
     },
     "localname": "ExercisePriceEightMember",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersEquitySummaryOfWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "armp_ExercisePriceFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Five [Member].",
        "label": "Exercise Price Five [Member]",
        "terseLabel": "Exercise Price $2.87 [Member]"
       }
      }
     },
     "localname": "ExercisePriceFiveMember",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersEquitySummaryOfWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "armp_ExercisePriceFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Four [Member].",
        "label": "Exercise Price Four [Member]",
        "terseLabel": "Exercise Price $2.87 [Member]"
       }
      }
     },
     "localname": "ExercisePriceFourMember",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersEquitySummaryOfWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "armp_ExercisePriceSevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Seven [Member].",
        "label": "Exercise Price Seven [Member]",
        "terseLabel": "Exercise Price $3.25 [Member]"
       }
      }
     },
     "localname": "ExercisePriceSevenMember",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersEquitySummaryOfWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "armp_ExercisePriceSixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Exercise Price Five Member.",
        "label": "Exercise Price Six [Member]",
        "terseLabel": "Exercise Price $1,680.00 [Member]"
       }
      }
     },
     "localname": "ExercisePriceSixMember",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersEquitySummaryOfWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "armp_ExercisePriceThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Three [Member].",
        "label": "Exercise Price Three [Member]",
        "terseLabel": "Exercise Price $5.60 [Member]"
       }
      }
     },
     "localname": "ExercisePriceThreeMember",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersEquitySummaryOfWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "armp_ExercisePriceTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Two [Member].",
        "label": "Exercise Price Two [Member]",
        "terseLabel": "Exercise Price $21.00 [Member]"
       }
      }
     },
     "localname": "ExercisePriceTwoMember",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersEquitySummaryOfWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "armp_ForgivenessRelatedToPaycheckProtectionProgram": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forgiveness related to paycheck protection program.",
        "label": "Forgiveness Related To Paycheck Protection Program",
        "terseLabel": "Paycheck Protection Program loan forgiveness"
       }
      }
     },
     "localname": "ForgivenessRelatedToPaycheckProtectionProgram",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "armp_GainLossOnExtinguishmentOfPaycheckProtectionProgramLoan": {
     "auth_ref": [],
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (loss) on extinguishment of paycheck protection program loan.",
        "label": "Gain Loss On Extinguishment of Paycheck Protection Program Loan",
        "terseLabel": "Gain upon extinguishment of Paycheck Protection Program loan"
       }
      }
     },
     "localname": "GainLossOnExtinguishmentOfPaycheckProtectionProgramLoan",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosurePaycheckProtectionProgramLoanNarrativeDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "armp_GainLossOnExtinguishmentOfPaycheckProtectionProgramSinceInception": {
     "auth_ref": [],
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (loss) on extinguishment of paycheck protection program since inception.",
        "label": "Gain Loss On Extinguishment Of Paycheck Protection Program Since Inception",
        "terseLabel": "Gain upon extinguishment of Paycheck Protection Program loan"
       }
      }
     },
     "localname": "GainLossOnExtinguishmentOfPaycheckProtectionProgramSinceInception",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "armp_GrantsAndAwardsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents about the grants and awards policy.",
        "label": "Grants And Awards Policy Text Block",
        "terseLabel": "Grants and Awards"
       }
      }
     },
     "localname": "GrantsAndAwardsPolicyTextBlock",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "armp_IncreaseDecreaseInAwardReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the carrying value of award receivable.",
        "label": "Increase (Decrease) In Award Receivable",
        "negatedLabel": "Award receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAwardReceivable",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "armp_IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net increase (decrease) in operating lease right of use asset and liability.",
        "label": "Increase Decrease In Operating Lease Right of Use Asset And Liability, Net",
        "terseLabel": "Operating lease right-of-use asset and liability, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "armp_InnovivaStrategicOpportunitiesLlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Innoviva Strategic Opportunities LLC [Member].",
        "label": "Innoviva Strategic Opportunities Llc [Member]",
        "terseLabel": "Innoviva Strategic Opportunities LLC [Member]"
       }
      }
     },
     "localname": "InnovivaStrategicOpportunitiesLlcMember",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureLiquidityNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "armp_LeaseAndRentalAbatementCredit": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease and rental abatement credit.",
        "label": "Lease And Rental Abatement Credit",
        "terseLabel": "Lease and rental abatement credit"
       }
      }
     },
     "localname": "LeaseAndRentalAbatementCredit",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "armp_LiquidityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity [Abstract]",
        "label": "Liquidity"
       }
      }
     },
     "localname": "LiquidityAbstract",
     "nsuri": "http://www.armatapharma.com/20210930",
     "xbrltype": "stringItemType"
    },
    "armp_LiquidityAndGoingConcernPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reporting when there is a substantial doubt about an entity's ability to continue as a going concern for a reasonable period of time (generally a year from the balance sheet date). Disclose: (a) pertinent conditions and events giving rise to the assessment of substantial doubt about the entity's ability to continue as a going concern for a reasonable period of time, (b) the possible effects of such conditions and events, (c) management's evaluation of the significance of those conditions and events and any mitigating factors, (d) possible discontinuance of operations, (e) management's plans (including relevant prospective financial information), and (f) information about the recoverability or classification of recorded asset amounts or the amounts or classification of liabilities. If management's plans alleviate the substantial doubt about the entity's ability to continue as a going concern, disclosure of the principal conditions and events that initially raised the substantial doubt about the entity's ability to continue as a going concern would be expected to be considered. Disclose whether operations for the current or prior years generated sufficient cash to cover current obligations, whether waivers were obtained from creditors relating to the company's default under the provisions of debt agreements and possible effects of such conditions and events, such as: whether there is a possible need to obtain additional financing (debt or equity) or to liquidate certain holdings to offset future cash flow deficiencies. Disclose appropriate parent company information when parent is dependent upon remittances from subsidiaries to satisfy its obligations.",
        "label": "Liquidity and Going Concern Policy Text Block",
        "verboseLabel": "Liquidity Policy"
       }
      }
     },
     "localname": "LiquidityAndGoingConcernPolicyTextBlock",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureLiquidityPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "armp_MaximumAllowanceForTenantImprovementsReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of maximum allowance for tenant improvements receivable.",
        "label": "Maximum Allowance For Tenant Improvements Receivable",
        "terseLabel": "Maximum allowance for tenant improvements"
       }
      }
     },
     "localname": "MaximumAllowanceForTenantImprovementsReceivable",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "armp_MaximumPotentialMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of maximum potential milestone payments.",
        "label": "Maximum Potential Milestone Payments",
        "terseLabel": "Maximum potential milestone payments"
       }
      }
     },
     "localname": "MaximumPotentialMilestonePayments",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSyntheticGenomicsAssetAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "armp_MedicalTechnologyEnterpriseConsortiumMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Technology Enterprise Consortium [Member].",
        "label": "Medical Technology Enterprise Consortium [Member]",
        "terseLabel": "Medical Technology Enterprise Consortium [Member]"
       }
      }
     },
     "localname": "MedicalTechnologyEnterpriseConsortiumMember",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureGrantsAndAwardsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "armp_NumberOfCommonWarrantsSoldPerShareOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common warrants sold per share of common stock.",
        "label": "Number Of Common Warrants Sold Per Share Of Common Stock",
        "terseLabel": "Number of common warrants sold per share of common stock"
       }
      }
     },
     "localname": "NumberOfCommonWarrantsSoldPerShareOfCommonStock",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureLiquidityNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "armp_OfferingCostsIncludedInAccountsPayable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the portion of offering costs included in accounts payable.",
        "label": "Unpaid offering costs"
       }
      }
     },
     "localname": "OfferingCostsIncludedInAccountsPayable",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "armp_OperatingLeaseBaseRent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease base rent.",
        "label": "Operating Lease Base Rent",
        "terseLabel": "Operating lease base rent"
       }
      }
     },
     "localname": "OperatingLeaseBaseRent",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "armp_OperatingLeaseBaseRentEndOfLeaseTerm": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of base rent for operating lease at the end of lease term.",
        "label": "Operating Lease Base Rent, End OF Lease Term",
        "terseLabel": "Base rent at the end of lease term"
       }
      }
     },
     "localname": "OperatingLeaseBaseRentEndOfLeaseTerm",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "armp_PaycheckProtectionProgramLoan": {
     "auth_ref": [],
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Paycheck protection program loan.",
        "label": "Paycheck Protection Program Loan",
        "terseLabel": "PPP Loan"
       }
      }
     },
     "localname": "PaycheckProtectionProgramLoan",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "armp_PaymentProtectionProgramNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment Protection Program Note [Member].",
        "label": "Payment Protection Program Note [Member]",
        "terseLabel": "Payment Protection Program Note [Member]"
       }
      }
     },
     "localname": "PaymentProtectionProgramNoteMember",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosurePaycheckProtectionProgramLoanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "armp_PercentageOfFullyDilutedCapitalizationForIssuanceOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of fully diluted capitalized for issuance of common stock.",
        "label": "Percentage of Fully Diluted Capitalization for Issuance of Common Stock",
        "terseLabel": "Percentage of fully diluted capitalized for issuance of common stock"
       }
      }
     },
     "localname": "PercentageOfFullyDilutedCapitalizationForIssuanceOfCommonStock",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSyntheticGenomicsAssetAcquisitionDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "armp_ProceedsFromEquityOfferingsGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross cash inflow, before deducting the underwriting discount and commissions and other offering expenses payable from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from equity offerings, gross"
       }
      }
     },
     "localname": "ProceedsFromEquityOfferingsGross",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureLiquidityNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "armp_ProceedsFromExerciseOfWarrantsAndStockOptions": {
     "auth_ref": [],
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from exercise of warrants and stock options.",
        "label": "Proceeds From Exercise Of Warrants And Stock Options",
        "terseLabel": "Proceeds from exercise of warrants and stock options"
       }
      }
     },
     "localname": "ProceedsFromExerciseOfWarrantsAndStockOptions",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "armp_ProceedsFromPaycheckProtectionProgram": {
     "auth_ref": [],
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from paycheck protection program.",
        "label": "Proceeds From Paycheck Protection Program",
        "terseLabel": "Proceeds from Paycheck Protection Program Loan"
       }
      }
     },
     "localname": "ProceedsFromPaycheckProtectionProgram",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "armp_ResearchAndDevelopmentCreditsRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development credits recognized.",
        "label": "Research And Development Credits Recognized",
        "terseLabel": "Research and development credits recognized"
       }
      }
     },
     "localname": "ResearchAndDevelopmentCreditsRecognized",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureGrantsAndAwardsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "armp_RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted stock returned shares issued net of tax withholdings.",
        "label": "Restricted Stock Returned Shares Issued Net Of Tax Withholdings",
        "negatedLabel": "Return of restricted stock awards for tax withholdings, shares"
       }
      }
     },
     "localname": "RestrictedStockReturnedSharesIssuedNetOfTaxWithholdings",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "armp_RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted stock returned value shares issued net of tax withholdings .",
        "label": "Restricted Stock Returned Value Shares Issued Net Of Tax Withholdings",
        "negatedLabel": "Return of restricted stock awards for tax withholdings"
       }
      }
     },
     "localname": "RestrictedStockReturnedValueSharesIssuedNetOfTaxWithholdings",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "armp_ScenarioAmendedExpectedPaymentOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario Amended Expected Payment One [Member].",
        "label": "Scenario Amended Expected Payment One [Member]",
        "terseLabel": "Scenario Amended Expected Payment One [Member]"
       }
      }
     },
     "localname": "ScenarioAmendedExpectedPaymentOneMember",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSyntheticGenomicsAssetAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "armp_ScenarioAmendedExpectedPaymentThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario Amended Expected Payment Three [Member].",
        "label": "Scenario Amended Expected Payment Three [Member]",
        "terseLabel": "Scenario Amended Expected Payment Three [Member]"
       }
      }
     },
     "localname": "ScenarioAmendedExpectedPaymentThreeMember",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSyntheticGenomicsAssetAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "armp_ScenarioAmendedExpectedPaymentTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario Amended Expected Payment Two [Member].",
        "label": "Scenario Amended Expected Payment Two [Member]",
        "terseLabel": "Scenario Amended Expected Payment Two [Member]"
       }
      }
     },
     "localname": "ScenarioAmendedExpectedPaymentTwoMember",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSyntheticGenomicsAssetAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "armp_ScenarioOriginalExpectedPaymentFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario Original Expected Payment Four [Member].",
        "label": "Scenario Original Expected Payment Four [Member]",
        "terseLabel": "Scenario Original Expected Payment Four [Member]"
       }
      }
     },
     "localname": "ScenarioOriginalExpectedPaymentFourMember",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSyntheticGenomicsAssetAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "armp_ScenarioOriginalExpectedPaymentOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario Original Expected Payment One [Member].",
        "label": "Scenario Original Expected Payment One [Member]",
        "terseLabel": "Scenario Original Expected Payment One [Member]"
       }
      }
     },
     "localname": "ScenarioOriginalExpectedPaymentOneMember",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSyntheticGenomicsAssetAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "armp_ScenarioOriginalExpectedPaymentThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario Original Expected Payment Three [Member]",
        "label": "Scenario Original Expected Payment Three [Member]",
        "terseLabel": "Scenario Original Expected Payment Three [Member]"
       }
      }
     },
     "localname": "ScenarioOriginalExpectedPaymentThreeMember",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSyntheticGenomicsAssetAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "armp_ScenarioOriginalExpectedPaymentTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario Original Expected Payment Two [Member].",
        "label": "Scenario Original Expected Payment Two [Member]",
        "terseLabel": "Scenario Original Expected Payment Two [Member]"
       }
      }
     },
     "localname": "ScenarioOriginalExpectedPaymentTwoMember",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSyntheticGenomicsAssetAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "armp_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of components of common shares reserved for future issuance.",
        "label": "Schedule of Common Stock, Capital Shares Reserved for Future Issuance [Table Text Block]",
        "verboseLabel": "Shares Reserved for Future Issuance"
       }
      }
     },
     "localname": "ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "armp_ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were assumed in merger during the reporting period pertaining to the stock option plan.",
        "label": "Schedule of Share Based Compensation Restricted Stock Award Activity [Table Text Block]",
        "terseLabel": "Schedule of restricted stock awards"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockAwardActivityTableTextBlock",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "armp_SecuritiesPurchaseAgreementFirstTrancheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities Purchase Agreement First Tranche [Member].",
        "label": "Securities Purchase Agreement First Tranche [Member]",
        "terseLabel": "Securities Purchase Agreement First Tranche [Member]"
       }
      }
     },
     "localname": "SecuritiesPurchaseAgreementFirstTrancheMember",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureLiquidityNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "armp_SecuritiesPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities Purchase Agreement [Member].",
        "label": "Securities Purchase Agreement [Member]",
        "terseLabel": "Securities Purchase Agreement [Member]"
       }
      }
     },
     "localname": "SecuritiesPurchaseAgreementMember",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureLiquidityNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersEquitySummaryOfWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "armp_SecuritiesPurchaseAgreementSecondTrancheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities Purchase Agreement Second Tranche [Member]",
        "label": "Securities Purchase Agreement Second Tranche [Member]",
        "terseLabel": "Securities Purchase Agreement Second Tranche [Member]"
       }
      }
     },
     "localname": "SecuritiesPurchaseAgreementSecondTrancheMember",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureLiquidityNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "armp_ShareBasedCompensationArrangementPercentageOfOutstandingAwardsVestedForAdvisoryServicesProvided": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of outstanding awards that are vested in exchange for advisory services provided under share based payment arrangement.",
        "label": "Share Based Compensation Arrangement, Percentage Of Outstanding Awards Vested For Advisory Services Provided",
        "terseLabel": "Percentage of outstanding awards vested for advisory services provided"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementPercentageOfOutstandingAwardsVestedForAdvisoryServicesProvided",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "armp_StockBasedCompensationExpenseRelatedToPreVestingForfeituresReversed": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock based compensation expense related to pre-vesting forfeitures reversed.",
        "label": "Stock Based Compensation Expense Related To Pre-vesting Forfeitures Reversed",
        "terseLabel": "Stock based compensation reversed amount"
       }
      }
     },
     "localname": "StockBasedCompensationExpenseRelatedToPreVestingForfeituresReversed",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "armp_StockIssuedDuringPeriodSharesExerciseOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued on exercise of warrants.",
        "label": "Stock Issued During Period, Shares, Exercise Of Warrants",
        "terseLabel": "Exercise of warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesExerciseOfWarrants",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "armp_StockIssuedDuringPeriodSharesInducementStockAwards": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of inducement stock awards issued during the period.",
        "label": "Stock Issued During Period, Shares, Inducement Stock Awards",
        "terseLabel": "Issuance of inducement stock awards (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesInducementStockAwards",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "armp_StockIssuedDuringPeriodValueExerciseOfWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of shares issued on exercise of warrants.",
        "label": "Stock Issued During Period, Value, Exercise Of Warrants",
        "terseLabel": "Exercise of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueExerciseOfWarrants",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "armp_StockIssuedDuringPeriodValueInducementStockAwards": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of inducement stock awards issued during the period.",
        "label": "Stock Issued During Period, Value, Inducement Stock Awards",
        "terseLabel": "Issuance of inducement stock awards"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueInducementStockAwards",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "armp_StockOptionsAndRestrictedStockAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Options And Restricted Stock Awards [Member].",
        "label": "Stock Options And Restricted Stock Awards [Member]",
        "terseLabel": "Stock Options And Restricted Stock Awards [Member]"
       }
      }
     },
     "localname": "StockOptionsAndRestrictedStockAwardsMember",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "armp_SyntheticGenomicsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Synthetic Genomics Inc.",
        "label": "Synthetic Genomics Inc [Member]",
        "terseLabel": "Synthetic Genomics Inc [Member]"
       }
      }
     },
     "localname": "SyntheticGenomicsIncMember",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSyntheticGenomicsAssetAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "armp_TermOfWarrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of warrant.",
        "label": "Term Of Warrant",
        "terseLabel": "Term of warrant"
       }
      }
     },
     "localname": "TermOfWarrant",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersEquitySummaryOfWarrantsOutstandingDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "armp_ThresholdDevelopmentAward": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The threshold amount of development award under the award agreement.",
        "label": "Threshold Development Award",
        "terseLabel": "Amount of threshold development award"
       }
      }
     },
     "localname": "ThresholdDevelopmentAward",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureGrantsAndAwardsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "armp_WarrantExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the terms related with expiration of warrants.",
        "label": "Warrant Expiration Date"
       }
      }
     },
     "localname": "WarrantExpirationDate",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersEquitySummaryOfWarrantsOutstandingDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "armp_ZeroCouponDebtInstrumentPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The policy related to the zero coupon debt instrument.",
        "label": "Zero Coupon Debt Instrument [Policy Text Block]",
        "terseLabel": "Settlement of Zero-coupon Debt Instrument"
       }
      }
     },
     "localname": "ZeroCouponDebtInstrumentPolicyTextBlock",
     "nsuri": "http://www.armatapharma.com/20210930",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document And Entity Information [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureGrantsAndAwardsNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureSyntheticGenomicsAssetAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureGrantsAndAwardsNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureSyntheticGenomicsAssetAcquisitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]",
        "terseLabel": "Mr.Patrick"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r38",
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureGrantsAndAwardsNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureLiquidityNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r151",
      "r153",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r256",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureGrantsAndAwardsNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureLiquidityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r151",
      "r153",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r256",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r150",
      "r151",
      "r153",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r256",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureGrantsAndAwardsNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureLiquidityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r150",
      "r151",
      "r153",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r256",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureGrantsAndAwardsNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureLiquidityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repurchase Agreement Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureGrantsAndAwardsNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureLiquidityNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario Unspecified [Domain]",
        "terseLabel": "Scenario, Unspecified [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSyntheticGenomicsAssetAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r127",
      "r152",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSyntheticGenomicsAssetAcquisitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r109",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title Of Individual With Relationship To Entity [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r26",
      "r120"
     ],
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r17",
      "r183"
     ],
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital, Total",
        "verboseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r71",
      "r72",
      "r73",
      "r180",
      "r181",
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments required to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r154",
      "r156",
      "r185",
      "r186"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r156",
      "r177",
      "r184"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share-based Compensation Expense",
        "terseLabel": "Stock based compensation expense",
        "verboseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAllocationOfStockBasedCompensationExpenseDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Antidilutive securities excluded from computation of diluted weighted shares outstanding"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureLiquidityNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersEquitySummaryOfWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r67",
      "r101",
      "r103",
      "r107",
      "r111",
      "r200",
      "r204",
      "r216",
      "r243",
      "r251"
     ],
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Total",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r37",
      "r67",
      "r111",
      "r200",
      "r204",
      "r216"
     ],
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current, Total",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r157",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSharesReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "verboseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r196",
      "r197"
     ],
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Deferred asset acquisition consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r5",
      "r24",
      "r59"
     ],
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value, Total",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureLiquidityNarrativeDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r54",
      "r59",
      "r63"
     ],
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period",
        "totalLabel": "Cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]",
        "verboseLabel": "Reconciliation of cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r54",
      "r217"
     ],
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redeemable Convertible Preferred Stock",
        "verboseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r146",
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersEquitySummaryOfWarrantsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class Of Warrant Or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersEquitySummaryOfWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise Price",
        "verboseLabel": "Exercise price of warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersEquitySummaryOfWarrantsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "verboseLabel": "Number of securities called by warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureLiquidityNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersEquitySummaryOfWarrantsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSharesReservedForFutureIssuanceDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants outstanding",
        "verboseLabel": "Warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSharesReservedForFutureIssuanceDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersEquitySummaryOfWarrantsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r124",
      "r125",
      "r126",
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "verboseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSharesReservedForFutureIssuanceDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "totalLabel": "Total shares reserved"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSharesReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r71",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureLiquidityNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r16",
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "verboseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSubjectToMandatoryRedemptionMember": {
     "auth_ref": [
      "r132",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares that embody an unconditional obligation requiring the issuer to redeem the securities by transferring the assets at a specified or determinable date (or dates) or upon an event that is certain to occur, that represent equity ownership in a corporation, provide voting rights, entitle the holder to a share of the company's success through dividends and/or capital appreciation and, in the event of liquidation, provide rights to a company's assets only after bondholders, other debt holders, and preferred stockholders have been satisfied.",
        "label": "Common Stock Subject To Mandatory Redemption [Member]",
        "terseLabel": "Common Stock Subject to Mandatory Redemption [Member]"
       }
      }
     },
     "localname": "CommonStockSubjectToMandatoryRedemptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureLiquidityNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersEquitySummaryOfWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.01 par value; 217,000,000 shares authorized; 24,965,086 and 18,688,461 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContributionOfProperty": {
     "auth_ref": [
      "r60",
      "r61",
      "r62"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of property contributed in noncash investing and financing activities.",
        "label": "Contribution of Property",
        "terseLabel": "Property and equipment included in accounts payable"
       }
      }
     },
     "localname": "ContributionOfProperty",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Paycheck Protection Program Loan."
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r244",
      "r245",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosurePaycheckProtectionProgramLoanNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt instrument, interest rate, stated percentage",
        "terseLabel": "Interest rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosurePaycheckProtectionProgramLoanNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosurePaycheckProtectionProgramLoanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredCompensationLiabilityCurrent": {
     "auth_ref": [
      "r148",
      "r149"
     ],
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable within one year (or the operating cycle, if longer). Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.",
        "label": "Deferred Compensation Liability, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "DeferredCompensationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r192",
      "r193"
     ],
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net, Noncurrent",
        "verboseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r57",
      "r118"
     ],
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation, Total",
        "verboseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsNarrativeDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]",
        "verboseLabel": "Equity Incentive Plans"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "verboseLabel": "Net loss per share, basic and diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "verboseLabel": "Per share information:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r64",
      "r85",
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "verboseLabel": "Basic and Diluted Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r85",
      "r86",
      "r87",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureNetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAllocationOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition",
        "verboseLabel": "Weighted-average remaining period for recognition of compensation costs related to unvested options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r178"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options",
        "verboseLabel": "Unrecognized compensation cost related to unvested options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Stock Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSharesReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of employee stock ownership plan.",
        "label": "Employee Stock Ownership Plan (ESOP) Name [Axis]"
       }
      }
     },
     "localname": "EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSharesReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entities identify multiple employee stock ownership plans by unique name.",
        "label": "Employee Stock Ownership Plan E S O P Plan [Domain]",
        "terseLabel": "Employee Stock Ownership Plan (ESOP), Plan [Domain]"
       }
      }
     },
     "localname": "EmployeeStockOwnershipPlanESOPPlanDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSharesReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r71",
      "r72",
      "r73",
      "r75",
      "r80",
      "r82",
      "r89",
      "r112",
      "r137",
      "r144",
      "r180",
      "r181",
      "r182",
      "r194",
      "r195",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r258",
      "r259",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSyntheticGenomicsAssetAcquisitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSyntheticGenomicsAssetAcquisitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r64",
      "r214",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture And Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense, Total",
        "verboseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General And Administrative Expense [Member]",
        "terseLabel": "General and administrative expense [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAllocationOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r113",
      "r114",
      "r242"
     ],
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r64",
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentPolicy": {
     "auth_ref": [
      "r27",
      "r64",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.",
        "label": "In Process Research and Development, Policy [Policy Text Block]",
        "verboseLabel": "In-Process Research and Development (\"IPR&amp;D\")"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Operations [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAllocationOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAllocationOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredCompensation": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future.",
        "label": "Increase (Decrease) in Deferred Compensation",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets, Total",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r116",
      "r117"
     ],
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "verboseLabel": "In-process research and development"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r41",
      "r100",
      "r225",
      "r226",
      "r248"
     ],
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSyntheticGenomicsAssetAcquisitionDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r46",
      "r99"
     ],
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LandAndBuildingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Real estate held for productive use and structures used in the conduct of business, including but not limited to, office, production, storage and distribution facilities.",
        "label": "Land And Building [Member]",
        "terseLabel": "Land and Building [Member]"
       }
      }
     },
     "localname": "LandAndBuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments.",
        "label": "Lessee, Operating Lease, Discount Rate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r30",
      "r67",
      "r104",
      "r111",
      "r201",
      "r204",
      "r205",
      "r216"
     ],
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities, Total",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r21",
      "r67",
      "r111",
      "r216",
      "r246",
      "r253"
     ],
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity, Total",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "Liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r31",
      "r67",
      "r111",
      "r201",
      "r204",
      "r205",
      "r216"
     ],
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current, Total",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "Long-term Debt [Text Block]",
        "terseLabel": "Paycheck Protection Program Loan"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosurePaycheckProtectionProgramLoan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosurePaycheckProtectionProgramLoanNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r33",
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Longterm Debt Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosurePaycheckProtectionProgramLoanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery And Equipment [Member]",
        "terseLabel": "Machinery and Equipment [Member]"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.",
        "label": "Measurement Input Expected Dividend Rate [Member]",
        "terseLabel": "Measurement Input, Expected Dividend Rate [Member]"
       }
      }
     },
     "localname": "MeasurementInputExpectedDividendRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input Expected Term [Member]",
        "terseLabel": "Measurement Input, Expected Term [Member]"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input Price Volatility [Member]",
        "terseLabel": "Measurement Input, Price Volatility [Member]"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input Risk Free Interest Rate [Member]",
        "terseLabel": "Measurement Input, Risk Free Interest Rate [Member]"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "verboseLabel": "Financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "verboseLabel": "Investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r54",
      "r55",
      "r58"
     ],
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "verboseLabel": "Operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r39",
      "r40",
      "r43",
      "r58",
      "r67",
      "r74",
      "r76",
      "r77",
      "r78",
      "r79",
      "r81",
      "r82",
      "r83",
      "r101",
      "r102",
      "r105",
      "r106",
      "r108",
      "r111",
      "r216",
      "r247",
      "r255"
     ],
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent, Total",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "verboseLabel": "Recent Accounting Pronouncements Not Yet Adopted and Recently Adopted Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Office and Computer Equipment [Member]"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses, Total",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "verboseLabel": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r101",
      "r102",
      "r105",
      "r106",
      "r108"
     ],
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss), Total",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r228"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r228"
     ],
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r228"
     ],
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r227"
     ],
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Description of the Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r4",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "verboseLabel": "Organization and Description of the Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureOrganizationAndDescriptionOfBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Expenses [Abstract]",
        "verboseLabel": "Other income (expense)"
       }
      }
     },
     "localname": "OtherExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherNoncashExpense": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other.",
        "label": "Other Noncash Expense",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "OtherNoncashExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r48"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "terseLabel": "Cash paid acquisition of assets"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSyntheticGenomicsAssetAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment, Total",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r157",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r6",
      "r22",
      "r23"
     ],
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "verboseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from issuance of common stock",
        "terseLabel": "Proceeds from sale of common stock, net of offering costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r49"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Proceeds from issuance of private placement"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureLiquidityNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersEquitySummaryOfWarrantsOutstandingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r51",
      "r52",
      "r69"
     ],
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Principal payment of deferred consideration for asset acquisition"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromUnsecuredNotesPayable": {
     "auth_ref": [
      "r50"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from borrowings supported by a written promise to pay an obligation that is uncollateralized (where debt is not backed by the pledge of collateral).",
        "label": "Proceeds from unsecured notes payable"
       }
      }
     },
     "localname": "ProceedsFromUnsecuredNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosurePaycheckProtectionProgramLoanNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r0",
      "r39",
      "r40",
      "r53",
      "r67",
      "r74",
      "r81",
      "r82",
      "r101",
      "r102",
      "r105",
      "r106",
      "r108",
      "r111",
      "r199",
      "r202",
      "r203",
      "r206",
      "r207",
      "r216",
      "r249"
     ],
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Details"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r26",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r123",
      "r264",
      "r265",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Balance Sheet Details"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetails"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r25",
      "r119"
     ],
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r9",
      "r10",
      "r121",
      "r254"
     ],
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net, Total",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentOtherTypesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.",
        "label": "Property Plant And Equipment Other Types [Member]",
        "terseLabel": "Property, Plant and Equipment, Other Types [Member]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentOtherTypesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r9",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r9",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property Plant And Equipment Type [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r190"
     ],
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and development expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAllocationOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r64",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "verboseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r8",
      "r11",
      "r63",
      "r263"
     ],
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash",
        "verboseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock Awards [Member]"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardDetails",
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units R S U [Member]",
        "terseLabel": "Unvested Restricted Stock Units [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSharesReservedForFutureIssuanceDetails",
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r18",
      "r144",
      "r183",
      "r252",
      "r261",
      "r262"
     ],
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit), Total",
        "verboseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r71",
      "r72",
      "r73",
      "r75",
      "r80",
      "r82",
      "r112",
      "r180",
      "r181",
      "r182",
      "r194",
      "r195",
      "r258",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueNotFromContractWithCustomer": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue that is not accounted for under Topic 606.",
        "label": "Revenue From Grants Non Gaap",
        "terseLabel": "Revenue from grants",
        "verboseLabel": "Grant revenue"
       }
      }
     },
     "localname": "RevenueNotFromContractWithCustomer",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureGrantsAndAwardsNarrativeDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScenarioPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The scenario under which facts represent plans as distinct from actual.",
        "label": "Scenario Plan [Member]",
        "terseLabel": "Scenario, Plan [Member]"
       }
      }
     },
     "localname": "ScenarioPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSyntheticGenomicsAssetAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "verboseLabel": "Antidilutive Securities Excluded from Computation of Diluted Weighted Shares Outstanding"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r156",
      "r176",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]",
        "verboseLabel": "Allocation of Stock-Based Compensation Expenses"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r26",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r157",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersEquitySummaryOfWarrantsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r161",
      "r170",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]",
        "verboseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Assumptions used in the black-Scholes model"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis": {
     "auth_ref": [
      "r131",
      "r132",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents settlement terms for the group of mandatorily redeemable securities, including the description and the details of all terms for each outstanding financial instrument and each settlement option.",
        "label": "Schedule of Financial Instruments Subject to Mandatory Redemption by Settlement Terms [Axis]"
       }
      }
     },
     "localname": "ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureLiquidityNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersEquitySummaryOfWarrantsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r34",
      "r65",
      "r90",
      "r91",
      "r134",
      "r135",
      "r136",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r146",
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "verboseLabel": "Summary of Warrant Information"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuritiesSubjectToMandatoryRedemptionMember": {
     "auth_ref": [
      "r132",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities issued in the form of shares that embody an unconditional obligation requiring the issuer to redeem the securities by transferring the assets at a specified or determinable date (or dates) or upon an event that is certain to occur.",
        "label": "Securities Subject To Mandatory Redemption [Member]",
        "terseLabel": "Securities Subject to Mandatory Redemption [Member]"
       }
      }
     },
     "localname": "SecuritiesSubjectToMandatoryRedemptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureLiquidityNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersEquitySummaryOfWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Compensation, Total",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period",
        "terseLabel": "Employee service period for share-based award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "verboseLabel": "Vesting period of share-based compensation award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited/Cancelled (in shares)",
        "terseLabel": "Cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited/Cancelled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r167"
     ],
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSharesReservedForFutureIssuanceDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding at end of period (in shares)",
        "periodStartLabel": "Outstanding at beginning of period (in shares)",
        "verboseLabel": "Stock outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSharesReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding at end of period (in dollars per share)",
        "periodStartLabel": "Outstanding at beginning of period (in dollars per share)",
        "verboseLabel": "Nonvested, RS units, grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Avg Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested and Issued as Common Stock (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested and Issued as Common Stock (in dollars per shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersEquitySummaryOfWarrantsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r179"
     ],
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSharesReservedForFutureIssuanceDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Available for future grants under the 2016 Plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSharesReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "verboseLabel": "Exercisable at September 30, 2020"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "verboseLabel": "Weighted Average Exercise Price, Exercisable at September 30, 2020"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r171"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "verboseLabel": "Aggregate Intrinsic Value, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Shares, Forfeited/Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Shares, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r179"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate Intrinsic Value, Outstanding Ending",
        "periodStartLabel": "Aggregate Intrinsic Value, Outstanding Beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r163",
      "r179"
     ],
     "calculation": {
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSharesReservedForFutureIssuanceDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance",
        "periodEndLabel": "Shares, Balance Ending",
        "periodStartLabel": "Shares, Balance Beginning",
        "verboseLabel": "Stock options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSharesReservedForFutureIssuanceDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance",
        "periodEndLabel": "Weighted Average Exercise Price, Outstanding Ending",
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding Beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r172"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "verboseLabel": "Aggregate Intrinsic Value, Vested or expected to vest at September 30, 2020"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested (in shares)",
        "verboseLabel": "Vested and expected to vest at December 31, 2020"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "verboseLabel": "Weighted Average Exercise Price, Vested or expected to vest at September 30, 2020"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "verboseLabel": "Additional awards"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r155",
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansRestrictedStockAwardDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSharesReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Forfeited/Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "verboseLabel": "Common stock closing price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "verboseLabel": "Expiration period of share-based payment award"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r179"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "verboseLabel": "Aggregate Intrinsic Value, Exercisable at September 30, 2020"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term (Years), Exercisable at September 30, 2020"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Weighted Average Remaining Contractual Term (Years), Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Weighted Average Remaining Contractual Term (Years), Vested or expected to vest at September 30, 2020"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureLiquidityNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersEquitySummaryOfWarrantsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balances (in shares)",
        "periodStartLabel": "Balances (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain": {
     "auth_ref": [
      "r132",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifying description of each financial instrument that embodies an unconditional obligation requiring the issuer to redeem the securities by transferring the assets at a specified or determinable date (or dates) or upon an event that is certain to occur. Examples are preferred stock or trust preferred securities, each of which has redemption rights beyond the control of the issuer on a specified date or upon an event that is certain to occur.",
        "label": "Shares Subject To Mandatory Redemption Financial Instrument [Domain]",
        "terseLabel": "Financial Instruments Subject to Mandatory Redemption, Financial Instrument [Domain]"
       }
      }
     },
     "localname": "SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureLiquidityNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersEquitySummaryOfWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "verboseLabel": "Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r36",
      "r71",
      "r72",
      "r73",
      "r75",
      "r80",
      "r82",
      "r89",
      "r112",
      "r137",
      "r144",
      "r180",
      "r181",
      "r182",
      "r194",
      "r195",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r258",
      "r259",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSharesReservedForFutureIssuanceDetails",
      "http://www.armatapharma.com/role/DisclosureLiquidityNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosurePaycheckProtectionProgramLoanNarrativeDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r71",
      "r72",
      "r73",
      "r89",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAllocationOfStockBasedCompensationExpenseDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansAssumptionsUsedInBlackScholesModelDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSharesReservedForFutureIssuanceDetails",
      "http://www.armatapharma.com/role/DisclosureLiquidityNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosurePaycheckProtectionProgramLoanNarrativeDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r15",
      "r16",
      "r137",
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Sale of common stock, net of issuance costs (in shares)",
        "verboseLabel": "Common stock issued in registered public financings (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureLiquidityNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersEquitySummaryOfWarrantsOutstandingDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": {
     "auth_ref": [
      "r15",
      "r16",
      "r137",
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited",
        "negatedLabel": "Forfeiture of restricted stock awards (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r15",
      "r16",
      "r137",
      "r144",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Shares, Exercised",
        "verboseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetails",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r15",
      "r16",
      "r137",
      "r144"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Sale of common stock, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.",
        "label": "Stock Issued During Period, Value, Purchase of Assets",
        "terseLabel": "Issuance of common stock and conversion of deferred consideration for asset acquisition"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValuePurchaseOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSyntheticGenomicsAssetAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures": {
     "auth_ref": [
      "r15",
      "r16",
      "r137",
      "r144"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards forfeited during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Forfeitures",
        "negatedLabel": "Forfeiture of restricted stock awards"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r36",
      "r137",
      "r144"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "verboseLabel": "Exercise stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Stock Option [Member]",
        "terseLabel": "Stock Options [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r16",
      "r19",
      "r20",
      "r67",
      "r110",
      "r111",
      "r216"
     ],
     "calculation": {
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders Equity Attributable to Parent, Total",
        "periodEndLabel": "Balances",
        "periodStartLabel": "Balances",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets",
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r66",
      "r144",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "Stockholders Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureEquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r224",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureLiquidityNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r224",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureLiquidityNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r224",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureLiquidityNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernManagementsEvaluation": {
     "auth_ref": [
      "r1",
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of management's evaluation of the significance of conditions or events in relation to the ability to meet its obligations.",
        "label": "Substantial Doubt about Going Concern, Management's Evaluation",
        "verboseLabel": "Liquidity, management evaluation"
       }
      }
     },
     "localname": "SubstantialDoubtAboutGoingConcernManagementsEvaluation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureLiquidityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.",
        "label": "Substantial Doubt about Going Concern [Text Block]",
        "verboseLabel": "Liquidity"
       }
      }
     },
     "localname": "SubstantialDoubtAboutGoingConcernTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureLiquidity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TechnologyEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment used in the creation, maintenance and utilization of information systems which include computers and peripherals.",
        "label": "Technology Equipment [Member]",
        "terseLabel": "Laboratory Equipment [Member]"
       }
      }
     },
     "localname": "TechnologyEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureBalanceSheetDetailsPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type of Arrangement and Non-arrangement Transactions [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureLiquidityNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersEquitySummaryOfWarrantsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnsecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets.",
        "label": "Unsecured Debt [Member]",
        "terseLabel": "Unsecured Debt [Member]"
       }
      }
     },
     "localname": "UnsecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosurePaycheckProtectionProgramLoanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r92",
      "r93",
      "r94",
      "r95",
      "r96",
      "r97",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureNetLossPerShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity"
       }
      }
     },
     "localname": "WarrantsAndRightsNoteDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_WarrantsAndRightsSubjectToMandatoryRedemptionMember": {
     "auth_ref": [
      "r132",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants and rights that embody an unconditional obligation requiring the issuer to redeem the instrument by transferring its assets at a specified or determinable date (or dates) or upon an event certain to occur.",
        "label": "Warrants And Rights Subject To Mandatory Redemption [Member]",
        "terseLabel": "Warrants and Rights Subject to Mandatory Redemption [Member]"
       }
      }
     },
     "localname": "WarrantsAndRightsSubjectToMandatoryRedemptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/DisclosureLiquidityNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.armatapharma.com/role/DisclosureStockholdersEquitySummaryOfWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "verboseLabel": "Weighted average shares outstanding, basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.armatapharma.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=116846462&loc=SL51888443-203568"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=118255708&loc=SL5909891-110878"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262807&loc=d3e22026-110879"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262807&loc=d3e22047-110879"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19512-108361"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409875&loc=d3e20028-108363"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=116846462&loc=SL51888449-203568"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r267": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r268": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r269": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.15)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r271": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r272": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "40",
   "Topic": "205",
   "URI": "http://asc.fasb.org/subtopic&trid=51888271"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>60
<FILENAME>0001558370-21-015483-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-21-015483-xbrl.zip
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M-M#>T^A*O=<';WP5(^Z='%#@CK!B<+V?,9;=[<(;9H7IV^E]WEL8:841@^=
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MEDY2S[QY'1<3%(F2N,,B:TF6;,U??TB 'V 1 ,$O),K[P^ZX59F)3# SD4@
MF?_V/[_N$O)$\R+.TC]]]_;UF^\(3<,LBM.'/WUW*%X%11C'W_W/?_\__X]_
M^[]>O?I?[VXN292%AQU-2Q+F-"AI1+[$Y2.YR_;[("6?:)['24+>Y7'T0 GY
M^?5/K__UYS=_?/W#CV]__IF\>E51>A<4##-+"2?YP^NWS2_O*ZI9^@MY^_;[
MMV^^_^'-#V_)'W_YYY]^>?,OY/I3 _F)L;F-AT&3./W[/1N/,%G3XD_?/9;E
M_I?OO__RY<OKK_=Y\CK+'QCBFQ^_KP&_$Y"_?"WB#O27'VO8M]__KT^7M^$C
MW06OXK0H@S1LL8","H]-P,_?\U\9:!'_4G#\RRP,2C[[@WP1+03\UZL:[!7\
MZ=7;'U[]^/;UUR+ZCLT!(?^69PF]H5O"&?BE?-[3/WU7Q+M] HSSOSWF=*OF
M(LGS[P'_^Y0^P,>!$7Z&$=[^!"/\M^K/E\$]3;XC /G;S856H)\[M"JD[P67
M"?S7)>.FPR?]6M(THE'-*> ;YHN3Y_/,B0+9+.P03&#2L[PO><$(<F(%#5\_
M9$_?1S0&K7H#_W@%_WCUYFTUL?^-_>EO[S-F/6?W19D'85G3XU+\Z3O%[]\W
M' '(6=YE*\C#F@3[YX"4%<3W8<:4;U^^2L1$"O1MGNV4#%3#98H?_Y;<)\<<
M=MC+:9$=\I".^@PR5[IY$2,S\V$0X'AH^NJWV^_^_4/M:<[2B)RG95P^DXMT
MF^4[;C'D]QK___LW,<[ZG[MFZ8[154C5_=G]QU:Q5W]K^3>GG[H_L/Y+ XSS
MC_G_'H*\I'GR?$/W6:ZR8BTDWB?6,'W\M8_ 4#Z\D@>]#C3@1,"[-^X\2(L8
M7,R@0O1!$8U>PW;/ 1S!X3@#)1,&Q]# 8VG%-<WC+#I/HP\L;#%(=@2'IP]*
MAH^5H0.$H@D*#O1J((!9,! 1 '>F!"+Z^!@G]/-A=T]SA3Q]$/>?7L=F_=6/
M?W?ZP=6#][YU%>@!'!& CK_R#7V((:Y,R\_!3F7I:C"LKZUFM_O%NS (7UW%
M@.[+M[ $@!U__8LTS'*VP/ MQFW)G,S[[)"6^?/[+-(KPP 6EFY8"=-5%2,*
M@N98\*-3I [JAG!DDN6D(D" @F/MN@N^7D1L(8NWL4C[#"PG6G@LC1H0H*M+
M&F $+3)RHM,?AD2Z6#@+TED4L1DIJO^YC%/Z5BNH$A9+60R,=Q5% 8B@)%HN
M= I206[J?Q# (5>I:Z]2#?^>_?,JO\N^I$,BRI#(RM%G6JD:+1B>8ASS,*@6
M@  +#J#@J 1?\Z[RZSQ[BM-0'[_HP)&50\.^4D..8/'41,G(H*XTT4F-AZ,P
MUUE1!LG_CO?&<%<-C*PL2M:5JM*!Q%,4!1N#:B)P"$-R&[Z"*SO+::!1B^[/
M"*=<"O::0R[I-[=G7+V!>Y^7KQ  X_9KPJ%S<OV8I?IT5A_$_5?5L5E_V>/?
MG7Y=]>"]+\S!"(=SO7NXI>$A9PKV]H?[N[A,5';;!W'_E75LUE_Y^'>G7UD]
M>.\K\]](MB5O?WAQ_Y+46,X^]5T>P)V=V^?=?:82X^AW]Q]9R6#]A3L_.OV\
MBI'[WU; $ 'DW'K/OX:/C!VJ24:KP?"L6,7NL27+,"C6W&>@]]5K4%+#8B2C
MWQ_RG*:E./$$/66;A$.AC2MUX%B!N9G];FBNAD4(SDV,Z,+S"H<T2$1@(9Q/
MYN_9/O(ARY^-)W 2%.8I98_9_D%E X)T5GDTONFX,B<UK/,SJY+"/;CXB7X(
MRJ#21L.1BAH<[Y3*Q/[Q\90*%N5<2L^(_D"JP8'K"T'M-QRKR^TN2))WAR).
M::%?3(Z@L)1#R6Q7)SH@"*J@&%^G 1R4U+".O_OYCN8/;''Z-<^^E(_OL]T^
M2/7+A 8:2P^,S'?U00F*H!<&/G3Z4:,0@4,J)-<.XI$FR9!^=('0W(."U2/O
M($%@.(?>\%K? )!(7YR-NH/K%5GX]]O'@,W"U:&$9RVP\=5'RD8DM$V'A2A'
M6P\#!L8&9) =[3:$8Q*.NB$"F4C8KI6*A39YD%RD$?WZ_U"])^G!H:F.FN$C
M;>D"82B(B@.M3@A@PJ$) W=W9"2"VX]Q$0;)7VF0Z^].ZT$1CI(&V&Z.E31P
M;H^8C$STCYNJ/(6 )X#@_BYU?9F[9?HC^XMJ(Z*%Q+M4KV'Z^%K]$1C*Q7HE
M#_JK];).< 0DA1!7_.U4H@.+K10*QM5J(0$B*D:/BT'5J!Y?N%6.,\9!Q+E.
M E4H>O2[>R50,EA_^,Z/3C^V8N3>!VY@" !-_:3U%]T&Q3UG[E"\>@B"O?BL
M-"F+^B_'W[?Z\]_XW2?@XVK[,4Z#-(R9>F;BN9?F;?4X5+=:,44L4)@Q>,YT
M:3Q3_:.T&A4.R!MD4F,O\(Y[O@J>%04MBP%E.P;"42LUJ[("=2&<JXIJ^+[O
MX4"&;[\(FT\TO\\*>KD,M]CJ687O5EK:@\545@WC?9T] D127247&IW8-(>_
MOJBR'?<UUP&R9K\/BL>S-(+_.?_/0_P4)(RKXJQ\'^3Y<YP^_#E(#L<I@Y&X
M.)H_2C#9$JP0G5O&"*[ZNL:02)!&A/]#0M^0H"0U!<));,A=5@:]:U:+R%?2
MW&Q BP@9PC]HBX[E#9P(8^,H@GS'S?_MFY]_?,.-'_[RM[,O01[=T) RVO>]
MVZEJ$+>F;&(3+%;U^RJ&6==<XX\0+29*=Y/QD;(/6EE;L(-GL,S_0U1>LE_N
M@P3JF)'BD=*21/PYRI8$0)GD#>G7JZBSRO.,$(Q#D1;,K?<8S6B^+J,&WS"6
MU<+ J[L8X3JG^R".SK_N:5I0YM.NF+[FG6A'XP.M,''B@Q%"R=&!!9KSV,":
MIYZ259BD0N5+#D<F1]$UUB(Z7S0J4 LN6\9E"SV)O6TLR M;&;0*7/VW48<C
M?5XUS 7*UOM$7:P 1+S1U!O*-K-Q6%(>SGYF&F-46CTXCOX.L2^KL@[6N5:;
M&>DI3 O.MWD;TF+@;.:F\P^;'JP%9UFN7<9HV9[FY?,U8Z]DZR1L.?>P9_E,
M]<&9"04K*AL6HQN.Z>$1XK A9A11BD#9$([$@Y0&C=DP77>E&K+A&1)Q46@K
M2DI7\D-#J^VZ,KBS\"O&4@"/FRYI4-";^.&QO-K^QH)BB TTL@_@X-BXE2"R
MD1L1G%NY!3<]A6IP"$?:$([V*MN^8HABKX5CX/.$20")Y+4L!]A!JF1Q9R07
M:<E8C>\3(4'!;/S\:Y@<X/KMKUD6?8D3W538H>*8S!BQ9,NQP7-N0/9,]52O
M16T2% R;O&CP24W@)58 .4NZ5_L\"Z&2&6..,OT0AP 1?:))QM<@/,L:L!YL
M"S%9 9JF#WSO^F<<US^1.8<!3YOJ&\PX:&"1 AP3XYW 1@7H/J#1<]%?^SO)
M8>P4PWC.L1-I@EEC7A WR:O/[B*E=0?RN>AI7&/^%EO=+N/@/D[B,J8%V_GR
MAVF/61(QNX)=</D\<)7-'AU'9<>*)RNU+:YSM1_'6+_@68O>9)/*9P]NQRTL
M5R$1^">>I)E>[VM10[.[)6I"0#<FB_NB>FA,@[&[>RDA^'1]=+0<->M)BX@8
MV80A7&@JKH-GN*W"3)S])3_0J"^6;CT=0P$I1AHO9">0LD=W'VV-Y:T?DE44
M2$6"N^F*"%'9',ZF84%!]Y*@026H%\;X@6XIDR"":A8T+?B]Q5J\9[,5VJ'B
MF-\8L62[L\%S;G#V3/5?AE:H1,9M3.P9V<!F"%9[BU!"]>7$S=)^AI!\.'.S
ML1DS!O*IFZ4Z]8[=?#&12=+4X1ZO<<GL/=N2[.@H;N;BHWDIP%;*\)&&?[_.
MLY*&,#;[UT,>["ZS0'D=?@ !X16!E0C-FP(C-,X+ PN6^M<8*ARR;Y#@GX!%
M$H;F^"W!+!%:)%)A$4!#>&DP28SK:R6[[M:RNN8A6Y3OXY2KV?LL!=?!M([]
MJX@CFH^)$^<0Q%D#YT^!O#Y.I^9\[9S+:D^=:X)$HLA6U(8FZ1#U9]E=?"*:
M0)PG^MD>\#\/<555(93)^928M,X^^9.(M$M >I!X')%P1#VZLN:\^PS!B]R&
M)G8>OB(PC.?5WFS@ZL 0DB\[M.&#><,F#?V"P6R9>OLR?HL8]FYA=SN'GRR$
M?KT[>A=\E;R#_O7 (!9NBG! &%5V4(."EA@T\J,/1:!M;F?!X8\(5K8DB^.M
MF6*53*S:C/PXZ!U>6SV(H 9")\R8R298\B-&,@9'7@1%HZ_V^'>99]SU'8\N
M[(R^RB(CU/=SSLHRC^\/)3]/+#-R'7AR*V&6=/@7<Z1J[L925CTPI*I5&G8[
M!:J.8-S7HE(RT#^OZ)3#KZI+713%@49(Y:5&\5T(OO_PYO6;MV0?Y.0)</X'
M^>'MOV[>O'D#_T<*4>,_.)2/61[_@T;LYW_>_/S3OVS>_/$G?BW@[1\W/_WQ
MCYM__NEM#1SS&1#E*-K> %")ZY8I!X46I>3'-QL"YS <Z@,-J[^^Y7]EOS$Z
M>\H;&26(MG4613S7%2370<SBNO?!/F8KHN[>A0X:Z2J/F?G.M1TUJ/LK.B8^
M^F?I#30!<!*GI$)8,ZRR*9,X50RHY_**B1$*!,QR&&40IS0Z#_*4V6YQ%H:'
MW2$)2AJQ_4H<QOK"&,.(6"4R;$7J%LL8PD(HFV''DJ*4@T D-29Y(>&2"ODE
MLO%,%D^6)1*0/FU7K*-/?[8G=ML2#[8CL[<A:^K\GG<U.$^C<9L0W<FD***X
M3M%/P>IM&>2E_\P.YC>LV11I#F_?6R@?DPSG=#1HZ D[HSAC'C!Y]W!IU(,E
M7U)_8R3IY0,]?*@D[8&9;[_*>7.(B&^'KVG.>]8-[Y[UF.A9DR&A-(D4'1IF
M;L7,TT"ZA2&3+"<"721?H(&0Z$J(5A)[KG!53J;)QI 7;#L894D2L!"&+<\B
MQ]*K_8%B7J+_XUF3&AJ>DSX&NCGIA-"8T3$XIOFH>1DPFZII9XOE@:F,$Z0R
MD5YFTB.;$#E@6\%K:$]LH<N\T0X$*+X-R'Q8Z?^J:?HIRF\C05?Q8Z4 B$JO
M[^ALA^*)^FNZ.=O XQO"<"=GM348>CBCF82U+%V[R.:WHUZB2A]< 6KZT@U<
M5=!"8]7B,S+?+;^G!$6HN&?@0Z$W:9$E<<1W#@T2[U-2W6MD %YT#6R8NU-T
ML-$!(3>CO#ON8J.&P&LP>6=H2M*VDOR=@_GP[2_CE%ZP?^KNXZD D76@Q[)2
M#QHH/%TX8L&D#P!*."RB4MS0)YH>Z.>L_,AF'M[V@(?Z2UP^OC^P=7!'<XW$
M-HA8![.V(G4/9H>P$ YF[5A2',QR1 )HY-<\@+7H,PML?F54L5H;S!0%/C%Y
MX*+@'21/E(%_ 9(+= ^> 56]@8::!QO@D9_]Z 10/O<Y!L9[YJ/FQ/ 4ID;P
MX%+K="'J=E*HO7AX:>BS-/K0%H:N!&E*39_!4U3^VN):E)1^GQ6&=CW3*:)U
M])D["4=-?Z:2P^@+-(]751.;MMBX1+-I"R?55Z_IPG7"BC(!TNO46[=I,K3F
M9/A1>9VFS/LD4*@LVL5I#)X*KOY64FIF9A +J4Z[G3"=\NUF%/=5W6WXZ8=-
M DL4Q>O@U6:&?+-POEA!!\^CT- V"O F%+0* ?%#/^N0#_4VCRW;XOI.YE&H
MUW N$KB763&HRC(DLC+WF5:J<PN&I]#'/!A46H"2%P"\ZF5P>[T>Y!Y^$CF'
MK$G@(_?UL-VUJV$1^WI8[=95@#A]/6PWN+P[AD\[]-',QY5A5FY[TB4P30'$
M7X,X!1NZ2L^_@L$=XN(1]@176VTQN%O&#KW@*J6IZ+< 481"BHM-15-L<39%
MG(*,"['=#Z@97?(B@=6%9"D+0F3B< :[-U1U+& $L 0QA.,"CZM."5_#KE+2
M)4VNML14(Y+3)\T ".4B5YV4PUZI(J8925#+4%ZD3[0H@4\1M%RD;/:H-C.I
M!\>Z^V%FOWOY0PV+</O#Q(BB"V$-7L6Z&U)CX.3X1O,O?JX" M1>I)P1<YZN
M!X76853%[%$S41D$HV]H?WS]YZ_ EM79GP6;*7V VU%FK1W%+5V#6WL+6X)7
MQSO(SUF:=7? 9D,;0D+<4PZ*TMM<:C%P=ID#[&AV;#)6DU<YUVS?'.54IDA3
M)0Z5NU#DIO&?:3F8.SR"P;$#):.RVG< G&NY8O2>&D GZDYV$.$U_:""VPH"
M&U"LW,\<'MV95EV!HWZY^"XHXA#.H>/DP&*#@<2F-3:..8X43C942U3G)CR*
MKYZ^-45AFD>T&\(IB$L3@H8'>=-Y4E[73VC9.K;-\AW/?OWBK8U-FP-/;6J"
M+?EF0W-LQU.#&5A^VD?G&W+?B!15[L"WU^E_H?'#(W@!-B_! _U\@+*"5ULN
MM_2>S,[*IA+#,;YYHLLV.8V2<U.=PV9/W6MBI*)&!#G(-5<OYB62'AGW.I,0
M5)/0?U*I< (>O)!B H\O#VV%B_R.RD8PY=,J$R+>:ZMAK@P/L, 4.Y6&!AN_
M.]1$RQ?PWCQ[MWKKCO_ W?8EN*MW[':U_"R9KJOC\2A*N-IUDH*V9?T6Y-MQ
MI4U1/N/#(6=<7W-I><VE&\H\0QRR18I#G7T)\NACEF]I7!YR[:W96101:W?.
MFX1>D<]IY'"J@<[A55TVM"H00P1-(H@V1=Y;PF)-(ISTADC$L8[EEI^/%@+6
MX+P5G1?>( %0P>X,TA=8>#.#Q-I]WQR"7IG_B"FPL'X+:KX8OS6KHVR_#C(&
MC'_IS>!LTY\^&U:6[W\8\)E^X;],6? E7*]L6RV8[2+>(/IBL2JNIBS,C(0
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M9\4>+@$]T;I)#)MOJ>+L2U&AY\7VI?Q7Z5OD-,R>V-C5EV S'2;L2W*1ZWD
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MV7\<]NS7G#*W4H*_J-M!,H5DZUB00_J6,07G;,66D839:S^KXTASWNK:5JN
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M6QC@I'_)MX'WQ@S&BL!H93GHL8T([BS@"OI+4SOMU\#B:+Z1<5GKE8#.-=[
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MJ<VUVDF,'OY;\ZGJZ77C3;MC?T-^5"48H@>M3@=.MW?%,A,N'45=%,4!_EG
MS._8G(MP]06;HH)[TI??HBMMUI.C2[F\IN8']O4^!G'.TZE>Q++CN/S6'/.L
MC^4X&A[#XC?DYF?([T<\W;M=SSDGP#H!WL79"OG][+[@5^V_W0A[@2\H3>:#
M>B*_Q35%*H0W.(?./^\XYKZU%63*IW&S<(SA[!M:+\:+C;A,2,S:+A3?VNJP
MP/=2%/#DNXR(+2=!7I ]FW>^X_@F-QS=;9E_Z\-H_KZU)6+B!\)(#_U76B@F
M2>Y1@NF_ZH*QS'>SRU/U5A#,G-7Y;I]DSY1R]JZ^I.P3/,9[N!%Q?GMU_2$N
MPB0K8!U]]PQ_--R#FT0)QRW/$%IVH!/(.'=UDWGL7X"I*%6:W- 2EX%> +F7
MU9T@Y.M[9IGA?XU7\NS1?=3>OGCV*MOB>J:GQXR-5,YS<DNNR+7X#]P;:ZO*
M*8QP8Y;3Q@Z#?,>MZ^V;GW]\PVT+_O*W>AD-V1(:/U$8YH<W;W]27CZS07!K
M/_8B@,4,0Z]B(U$6\@B%1S:CI]1\=[%!$@H":.M>45,9_+)"K"^#UJ)=?HT3
M2"F(&SY76W&?Y>PIB!-XT?$QRWGXO'1$/SC<B6WX+:=OD?W[P%BGLQVW$F2-
MW77O.ELS-MEFN=@RG]@6>=I<=N7>'B#E2AYRWC/UD$8\WT"%;P,OA^?7Q"Z<
M1TWO@WU<!HD0](86-'^B$9/S(^<>-NZ0\-7,[P0Z.)YHLL"RBQE-Q+GOF,AA
M3Y'E+,V&5*1JZZZ)<247Y$A-;QTSA[H@)C-?2FQ>@*3*0I&\0L:STDM:%)1>
M[6G.W%;Z<$F9E^+_[W-6_I66(#5EPD10-?!J6]<1U#T@GTP-QV)G"B_;[412
MSJUW%I\]91;4X.5U18]P6AOQ/X31),^T) W5C:@^R5;QFC+.FKWT+("PI:($
MZ8R=/X0+9VEZ")(;%C#<9>_H=1!'4+;S*CU>*FT0$';^5B(T.W\C-,[.WX*E
M?GRVRPXL;(5U"P)9YN+9?Y49N:=DSY#AX.>9$2!92E^[30%,D09PB$ B@$7N
M,O*.[9\9XH8 *F&X"%F R;($0A;^5> ;,</[<4&K_11\C7>'W5F29%\@"&!1
MP1U-67!^L=OGV9-X(7M#0QH_00RO$FTT"03+GBAF8^LC\7&L?Q*3.G_ EKR=
MH$>"FB!7P)*3)+%$DVEG3=2QBUA&Y(H*:<C !2DB"!&9$FE)(?B0984=_*H+
M>IENX )^#;R@2D8=)(+/,#/=N 8U&(X',/%B,/2LB883'ADV<8!C:Q[%_E$(
MSVM2\"4?P3(G,GXTVPL:G @U+M(PAR$N4F#GFN9PG! \*%?Q(0P$ [03HC%$
M,SB.0=KPU#=,$?+%%19$X#S\VS>(CNURCA07DA0\(&\1$0QUI>^Q^E)YGD97
M6_X7V.';NZ!C/&^64;5  XMJ%\FG)5;%F6'!;3?:$'L=+[]!R8]$:!H!;-(D
M:[Q8C:TDU:[-&^AA0*X^5G]WWP5GKF3OFB^G^TH+^@+.S%D: 7=!<G8?E#PR
M?Y_3*%9&SP,("-9O)4)C]D9H''NW8$F37X4[OCG'(D&-1D*.Y]B2I\L E=P$
M%FG0B,!#L-M5O@7>4=91.C\.[N,D+I\U1P!::)RCJ 'FY:,F#:CSHR0C'T-K
MV(8T"'X=?L(%;8@K;IA:CS@]ZJ+Y<YRI$F?HW%+&\>* LL^0_4EDC4L ><F4
M "]GJ4OBR[]B;/5[S+7;^N8GI"W\T?B*PHA[N!8!Z>'@/CNPR) 7 "T1TN&#
MO%:U23G(DM>^.=W+.*47;&T]?OZCA,!2LAZ3745K?D94MB,>;!6.$:,D!CP,
MK1MBNM(\ ",<;DGUNV._%H]9$GV@3S3)]LV5116[!F $I1QDO=%/+22.J@ZP
MT[]'QC;+98U#@B87$K7HE2*WMT+%?P</.>41NV.]'B]A+9V$(.X#(VR6QG+?
M9J?:K]3[-DLN&7P\<5Q)H]_V67H6/L94'#Y>;3_%"2W*3'UUR!X78YD9*5B[
M %DB(BU-H[A3FG]E]'E%@T2'' )?L'31?U0<10-D2YK?1*B)NU[9YLE<F52-
M3X  .>N*UM# . V9*5X4Q: MD%3I?MFE(\NS>@6X2)E$^8&_R%<6C;7$P8H^
M+03IQJ,&!,0(=9 K4\QZ9.Y?'N/PD?\QS';[('TF(6R$"[B#>"CX7W?0_2=(
MDF<"!W!,X> U"=TR;$8NBO.F*1I0D=<LOIBQT?(L.H2NPX>),U5UTZCQ>#^H
M!G.5(J]VOF*.-$T$1V)9F+U2F!G. MXV,'M\/$OEJ$?DA^%F5/:0QO^@2I]A
MC8K@.D:*U7@02SP<1S**.54W"H[-,_NRR8ND/K^26%%P;/8+R04G+_(VHB)
M6@H(3L#9-\-+L3<%?,Z*@I8%D[3.^\>T^,26GP-C]BIEPAYRB%X9P.<LS>O_
M?!<4<:'*LJY 'R=IO_@$R=G]Q8@[/P98F/-^L<&V9&]%C5_2W9"&(C<KF>8:
M>5X0[BS\ST-<\-!?4>S) (<1=1L8;B-M!1!2=*WEI*<0%RF+?W?B6?K],PD
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MX^EX"4("=GL@:,WJ%^(Y#MP_YX$W07/HS;\2Q&*EPM0UKU^H*R>:WWK!3[7
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M<V:BE^K#[CG#5:">H6"L^FZ)'XAEFB@S_.AD9,I[41K.K5"K=A)KO8@XW-4
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MA5C4NNUN_=4://@:KD&#(8-Q:W]S\#(3)A6^TM_M Y#1KS*$?#FL #'*48R
M^^LL>/LR 3 %$?VPC1_Z%=IXS!SO!FUAXE7-=%A3PAH,Y29%44ET17U) Y/V
MLS8X:_O/UD BJN0R+%Q1C(\LRB[N:A7%T+V%KV$0P>@6[=4G#C4$1:"&53AR
M4=G:_C40S3BNS9>]*WPP R%28;S" 3:4K61=L;(JSI J3KLP@4J)L[,H$;$-
M)E@FH3O'YM99"%(KZY8DM?.L5%UK8)4":FN?VDI8X\.9YKD )M!UO!?@SOW
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MP';E<6U&B=L@"1LS8E-Y/PC!D;<3[@SK??*"W$8VV3MPJO:,"TVD[82K UM
MH8T#I^I>,$%HVZ#9XT$O$\1V#=S*^\$&L3V#RNQ&QG._J["\W7,>)%+ZC1(R
MIT.$S,%^V"YWITT=,1:T^PHGFN-\L[=!^!@&D\3%"512P6JO+.C%>\D+-D[;
M5Q^2RM%J(C$4A),_P/X2D.OZ$'!8)5QOK^G53DM:K2^F'@'"[S?@%QK Y#K!
M^DQ]IPD@CUE0XWC*I)Q,$Q_L4Z&P3@2N;%+MCJ>WB>>MKJ&7H#UJ]E@(_(O
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M-TH);=@VQ6%^P,:9"?DHI#48O@SS]0;Z'D36Y/,B2/[<H$:PO-N!Y?K2S1>
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M2LMEF%'5H*N1F1LV<RDR<R,S]YN8N0T;F$MH[]BY,P 5G1PN'#%9Z^595<^
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MQLX_@,)CI'1])?O^8>;L)W-E+X3 Q9>,R#"1]WJ2F6".R>44-\A\U"73,V:
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MECF[?WDF\%3=A>K'CN!'TB6$&(ZDRQ'*\42$>(3U/$54DI89&&Q^]D0"&$@
MP7H/0M>12(87\!!$6] ,$8S]K:_-N<96DXTM9[L7@;D@KJ$NAP]V;PP(*WE'
M<O8+Y&RH*>"@@'NVJRRM/(++/4U'H@F&.'AX,QR2;L,:M+38\[PO6>;1;WD6
M_"W#A-JUB$1AY&.$$N%O2KY@([QG&2JT'7'LZ9<B^3;GO<ITB/GS=^>7+ F9
MR['^KHY5(C,Q,A/?$)9)X/32AC5%5B*-TQ1]*<+2GW<LF/@E"T?N<H1C9 ^>
MP1X,-:0W9<N284N6"QW7VF3;IZ _8M\0R)9@ADM2=JW8"Y+FT$;%)4L9_G*D
M3&2"719IA<,$.ZET\_=8R6*\%,^(13_G+Y6K)YOU>JY<BI=2Z'&A4\_5)8X+
M@71[W@XF;_]48)U7E5P0L(O !-U .3P=2TCICN(M[Y/UJS_$36#,'3VP5Y]U
MBJ]TEN>B_#8UZ'C&-44^">&"F#S2-A=%6]]$VU!5_\KW7"/>R+5$)/?0U\+J
MFT20#$T=K/%X-EU#7;"NN0A05_USKKH;9$('2@,],-;??9UC6([G'YB+RY;G
MQHK 'D W5M.=P24K$I*](/Z-%,E%T=8W422T?TZI5B[4D62KU,I),=6LB76)
MIGF:#$/JT[,.H2]8AX0=ROXI/MLRG$!U5&Q+@:JO+2+=</FR--(-(=4-83_K
M\RS!_%,_N5RYD15K&R=]) %G6#X,QN_&J:3<;2R8Y_:1I N68M'V7PBF>1U9
M7EL6"5& 76 $JCZHF^U(#(]S1!B,D>T32Y=J\H48P,',8AM3BR1D:$5/)"'/
MQL!Q/SR6!HIKV8Y$(VN'#L.>TH9TC%^R> PG=/U)Q5:SBJ1B:,5-)!7/MO/>
M-)_O0JP# SJ6MLQ ?[XL*@1\?"5I#I<![,U9QH)I^KD*RXENWB'F!Q>;3E V
M;&5\7K2,9<A(QIY_FE<H8ZD4U("?\N.-++,.3=VRG[E(8CD<.9(A8/LKV=Z_
M#&"O9QGSIQE;SG-#MD9R-+0"*I*C9]MU+>HFK ,-NO.-%!B)$"A<",,IIBO9
MVPXYE/WIQ9;SV\R$BB1F:$51)#'/Q<M,V;\%(F<NR]0'MQT0),N$@8V?A25S
MP<(RQ  .9A;;F%HD(4,K>B()>2X&9L593Y=U%QDX',-0? @8]UDRLA<L&4,(
MV/6,+EH01J7U0C#-#PO"RTD.K.<RI7@C2&?F6 H/0S[@\Y0NFG-WRR)]_36%
M_HT,7WI-X:>S;+_BHN#-:2U_B:Z!^L0U4)QP^](M4,O[FF(;GP-A&=T#]>WN
M@0**(#,*SDF*IN(2K<B4Q&N0DF0%X"0N YSEU)O?9[SW*>X[S2!6Z0'T08%>
MH%><'\B?5I9E]Y<+>;O6]/F6\,XJT^$1]FO:X&6*D3E&XCF>EFA&%229(QE)
MXQE&4TD%IU1Z!=CUK6*<S) RQ4JXC&L2#0@H\;@&)55C.0[UQ9 "N_V&IJ@X
MY"A58@22\]_')4#@L@19C<4A3Q,"S6R_(? 4HPB"(E$*X<\*34B@9$;B.)GG
M:9;B-8;:?D.6>8U6&4(B(6 0C1.,!$@:2A0!:0$P !=88N<- J=H- &)EE46
MO0$X2< Y7I)Y#C"X A1* ]MOX(2BRCR:ADRC[FD9L9"@*I1$X3+-:0S)$PJW
M_0;#D1HEL)RDTKR*WA TQ'0JE%C(*I3"$3QDX/8;!$O0"J,"26-E!"M!8]&$
M<%KB&4+6")H%)-AY@\<9GE1959(I3I!H5E,DF0$($*I R*JF*@*^O8Z&(JEM
M\CXG5%0:9XUF:3'J4#JYF/IWL^ZV+/4[@^8T-W'P=K]>JM->-M<IQ%'+'8Q!
M50$,JR(<4SR0: U1E, 0"*X:*R@JA:B/97;[GA2GT]%L/-1P=M!]Q+(+8TS1
M<8G<F86D$"HKXSR+\*/($@U5A"2!)26!I'F*%"B.PK7=OJ?VM-*?3\H9G,6D
MR=!E&E;:GDJ4M'WCG<0J/$6Q+.J1]:E9Y=&\99*0("0!(1.$)FO\;M\NH,R>
MYR6*>&;,=*@^0S=UOBK1NWVKA*K(!,4A(E04U#>B9YZ1@83ZY0F"DP%#T[M]
M&^24%BAGNAB0Z2*K\I2<';I=B=GI&[5LMKE$LYD93L7D@ZJU>L,,%7>G_E6G
MNRTQ.Y>A,/F>:&8PNV0\U&3"5OP^=W!(JB0O,$J 0Q[Q*6)6 7"41- <(?,T
M(Z _NWT7'GD]0^K-(8ZEJQ;#],J<:,<E=A<6 !",!@A20DR'8,$A"N=5#DH<
M12*Q@=,$I(@].$\3\[12Y)N#<GRFEF?Y>S=_'Y>XW;Z10*)Y!B<1,@'IXY"6
M! W0DLIR *<UE<-WN,R'2848*=I# \?KIIAIP&(RD6&Z$K_;-R- )%EX$@%!
M0S!A$??S/ XEOW8!J_$\"Y0]S&1AFYG-C 8<9+@&HYF8F .MJB3L]DTANF!D
M!4>25$!T+2,1 :!"('F"/@L*TMKD'L\D4KWB9#@H&R*H)V79U*UA>M25"'P/
M*"Q+H#Y(B4-=232./B%D"D@8<Z0, &+]?8"GZ4)/[D_I.*[/ZZR:ZL^\]*SK
M7Z"[TSEB:H+5-$0I&D22D&(!DL](=N) (%6D'1"RJ=W.Q7Y#+!&R/L2!A!6P
MCJ."4@W)''*W<P(2')+6FL13FB_\%5;B:4V3 ,,!A:0T@I+WR% NND*5D=JS
M)N S,)WOF%,QA\34'K^3 BEPM, AY8,C?))(;@)"0/_(! 1(8B$%H^YV'K<R
M0,?D1!4'&):EAIR<MW)51!&[G<L"Q0A(+R %X<,<R7=)4%A!(@F ^)[F2986
M=CLONG5Q)A(@B;.E3G*!(TDHU%#G!SB^;P_U_$+G"@/X0*?J]X]Y,(==O^D>
MRQ?%5K56G26TP;#6[(M"Q<J-ZT&O.SR/V /AD((2P2F\K\UII$H9I-,TG$.:
MDX*"MJ/3$#.I.+(9)450$.[1ZSYA(8;'<8@0AM2-H.Q.ATV1KII5D^( )(O6
MXZ3BD5,5H6>/E5D :1G1OT21".TT#BC_I"0N\21'DX+*LPJW1U@Z*':2#2F3
M;R:Q7MVVN"G58%#G>[R,:RH+:):62 H@'45I,D*4BN0$AQ:IT@)DP!Z_M?""
MHE?:(P^'\7:+RG:!X680U>XRL\^:F6)5$8>>("9SFJ6:8@I;S(.F>^A1:F0W
MFVC>3\4,PY8@Z9085XO[37?0H])0%I U))'(3)*0I41*O*SA$DM#9*5!7E&5
MO<X]"GL4$AU2Q+'*@[C@,9MPQU6)W!,1J&,<DA0?0%>B:<0& B>S:%!!@ #9
M?BJUIU>9^?V"Z(OQQH"=BKV$*Q1E(CY%%+ZG_$C$:C3%2"QB6P1L 9F)-$(G
M1)):H16-4LD]Y?=8KSI$^\&%^+CF/.3B[L!JC;L2N2LB4-,<SK5&M3IRBSTN
MV8.IL9=OM:9^TQW#D&09*% \1'2K(@5/(+("+(4HBJ 97-!X5E#W(-CI5!2O
M5Y7B [9OJ7VJVYZ2]V@>N]($-4W*<:W615TVDU9R+@^RHT?](>XWW9D'JPH"
M*^ J&ICA?)&)9 .'/@$DSCBHD8I"[2FIA3:/=Y1.=XK#RD-ZZ+;+*:0*)7)/
M\$ -%Q!M(WKF2:1)--]J9&6D230>F<(RQ,G]S@=XI9+I-BU>3&;:D_ZB-(4R
MAQ:Y*WB0/40@0"D:ZHWSU2N2FX**U"OJ&-!(#2)#80^"_7;;KN<51QQD3 KP
MHX2>LQU$@WMV :7(I*PB,E%8I&8052.;@T-D@I07&I325%5A=SN?S4LEKJ(^
MWN.^RYOKT%0;I!%8]J2)"E2<9GT-(Q,(+(QOE'*(F02:1NH/L!R4MX4]TNV\
MIB"+'=DK/M5"Y*4(0.5\JP61,Z=0*MC3/=@LP8K5QXDWJ&LDT%W0T&II!,@]
M?8]X514H39 4@*Q7&ND'Y&LA+#&:0J)!D!'$[ZF'<J&I+;R%O&B6L;Q3*>;%
M(>=6D8FP!TB>XFD:>3(0TLBG4574.26C81B&AKQ \QJY+[%:6'/\\ B;S?;]
M WV//?:M--(]U!XS,S@/<4I&D*-8I-A(#=$M1'2 %(>J(F:&.+&G-?FN,,@L
M4C2!SW.U)I<RDWJNCBSP/7U/D@0'659&./<YPY=Q@J^<H<8 "D*!4[2]F=L=
M6+6\H>H.V Q)3DB]!PRD4*@]?8_DF$"R))08DD;:RB<M0>%P1"P<ZI<D%%[;
M,X,T:J'B;04X3=A=8*/NC!P L2M1NVR'F@ZSN-T22)(3,Z XLZ2>9]'DU&^Z
MQQ*\9=7*.1?4\;:<DFR-*F23\:K?="WSCW7#]"KT%H3P@.=:ZP?+^%WPY"LO
MH6:Y6^H+-@2.')-_?;=C&;/^->WI+L302XH?^?.O65Z#[98]:]V0\RR9_VY+
M)F\)X;NM^5M2-OG=EAQ1]@4M^>W<E/7:PZ:0^:M!+K^W8GFKR\V]I'4:S/Z_
M?_^4MU?[=B[+FRNG;GE^O4?\M-D^FL6"7:K8>O?YQ*!Y8_OL56#5X<B%0QG:
MJP-S^(_5Z62<)/8 %I''Q\F#O&CR2$%EDSJ(9^K OS-U1$KA_'C]T)+W,/U!
M&!Q-5828U__R3."I:/KJ?V*7PMQ?2@1A]G#>0GSHH/(U3M#%@>5Z&.: CMQ/
MSU04"#7M5[CBFZ\)R;CC!,EFA\7C>Q<8=C+X,UH_XNK/&NT\\^J_7#(>LY!T
MQ M'7_U9XZ,1+X0*'A?$"Q\YU!<Z-9_T;!O9BS'PJKJ_8NQ=[%;EE7HOIY%+
M$0%?B\:-"/C:"/@R_>?8^O]LT'\2.+V@O*KB?X!C3Y\ 8WD<+[*2KL9[_N_K
M]@%BE'_&=DW9:,C8W_K,/Q:=MH$2W(;LF;I;\T^_-M$'J>XBB@>V*C7K*8EH
MC?4NI;1FHLZ(1MZ45#.%=V]B04+A;/E6W)'*FB3XF:?^OJM4K9F33BJ>G^-8
ME:H98G?<FLSC-S$5*OH0&,X_-_A-;%D.Z9\;?>;>F=Y0M=S5SS<Q$PP1.#P'
MZP(PNO-Y,&ZJ_A_QF0'C;A+8]AS!L04,#][$'(02&/2\/N?P*.C-<J5!B" K
M*"G,KF -$)<8/_N:('_@'/L#Q_&_?V[#(O)_KBD6$''V,3B;(/V\;W_37*(>
M!NU9UJP3(J9Y=$8GYXMJIOO5K$UV\,RD8=?5)@E(<3#M3K.YFG]JD;WY+?Q@
M:2'B[$N-;.P88/$I(E<G9D,%(O+P<^"_F1D=!3(B$7P"XPK8P]%=P%RU)]8Z
M)&CS 'N8-\QVDXQC)5S11KGZJ"NQ@0WU@V2(=PO:B$5#81!%+'HY5M([>33E
M>8].+_^8&>C#RK0R7M@5I>>764#&$,-&''HML:B*#4= 5V-P-O*K"2VO_;&"
MXL+*SG9/9.>>,C9UQGSHCQ3-/+*;>^Y5GU_ GRK M6)L<<G7R!\.*H8O,[56
M&[D'Q+Y8LVBY73>HIOY0EN-4VIV"<E7B?-.,_X!A%DF&X\6VSLTCD62X$M/O
M<Z+A?C8J0C(G+W"H-8?J]$$=)WI^<2QD$;)4%/:^V.#86VD_#<L%QIXU&"7_
MA#AF]NZBYY&??6(S["VI6IB6U%2IH7MB&;_W<BS9JDRMN,0'L3#Z!\'QD:M]
M6<&PB/="8^B\Q7P4U^@DIAXO-8'0RA4*BKZ(:S[S(9.&P'_P]/NMFBMFOLN,
M<Z$^:]!Q;5WQRV+[F5:1,7I%V55A6OUWD=.GLI&>^=3/V2A9IO*BQ!YE\E1Y
M8*7+36_* :UM/ [4GE_I>+EUB..1&WKMV5=A6OUWX?R366@?8/T!;K8:E8&M
MX7I1X,BD1#*C=!>Q/ANQ_N5'H"JV-4+SF0?[CWY*_&B(R.!'S(3N-S.WHSC3
M-4O2TVWW+?FG8@#3C9NJN&:A$CPD3-M.1D_7^ POSHN$I<VZD':HJ7^K S*D
MR!\$SD6>;Q1VNFY6/.'^VH=XL=X5>KV.P0Q$/56O=^;.4&X^!#>LL#XOXG3$
MBY^+0KT%AG/8.V5$(<!%8\0,"!P8"W@ LS3,0U^"/;;(<KVB<-67I4U<O]@^
ME07UQ)$%GR%K_N+*6M.!P2;" ;'=TA*94:\G,CB6(ADI6ZU7M%9P=Q45[!XP
M5)0N=?7!J(BOPV^.?92Q35>Z?ZQ:+0''6I#,5^+-JIV8^HR]W!;DA"C4=,FA
MIIR)C6Q+@8Y_ M"!P%:6U1A4.(&&%1CJW\RVOJ204W36Z.(LJYR)YM/596,I
M<AWD!HLSQ?!\&&8L2YWJAG% #DN@)(CIT<S"83E)=X$YE>_].PO)E8%%,E%Z
MQH4%J2+FO3SSZ0^Y]_Y>91/F(YEOCHL5H3.<0*D[KOK39"/NO8+DJC7J(ZOW
MBL)485K]=Q'<I[*Z7I'-PBQ1HJH936\.%R7=G _%P6@T]2\O1Y85]8..'-SK
MCUR%:?7?A=5/9J.]PNLM1Q+)9)YH#H#;L+&I6^ZKB;C/ZVS$ZY<?S J.;KY2
MHN&*4?/)J-6Y#QB?-'OCW(L[OZP]V3;A\UGI5]-5A[2MY+!,61G N"8.+86:
MFEUD8]&^C27@[R\F&''PA1=&B#@X9-;2>UDXU>EI+FMX;3QS?Y_ F8%6RF6[
M/@LCTXGGH[2L2XY?O:/DP>NE#KZC-?PUQ:\H).Q4R_/KLIY%E']%?>>SK_C\
M\OVT)1<.)78P<W+Z^,C8@WJF3!?+JJL:'>0*!\7;:?('RT496^<O<!5Q_[?@
M_A,7?3BT(]D2M0E=2^FXGN7D>IWNI9/]JL_^?B1,^,$041&K2PZ%13<G13E>
MEYLF$A%PE.<4$? U$_!UADH*.@@ H*]JASNNI0QZZ#=H.SXD".Y7<)[?G4>!
ME"O+%OH.AU^>EOD%B_WN]!L=WHKH-_)EWU:YZWO8C6?5&]5COE!->8T")2*Z
MD*NWB.@NBN@NTW'<O7-34=!T72<V O/@RDW?602*8GM0W=9DD85R-1YB=%-R
MJ#?*5RQ967)DW%3C2W[<B.F\7#P],^IV&RV2;@Z@+:6R)78 I5E7(E:U>'DB
MVDR_>@\ZXN]P;X5_BL'OA0))*HUQ2YP_6 61A06^/PX8/*BX*Y#1A>@7&V+8
M-\X".TRQAOZ=8,!'Y#<SLB\IG/ =MQ<OW-9*00TB0:LF-SAL+87G+\O@Q&,*
M,_H&4VN"^V+:C%M87!.G$HDOC2R.H*,D],N*RD2\>WEVU!\RKYC(-H>425!-
M?6XU%S24A+9<]9DWN$2=BECW2F);ZPV9D64'U&QI,6NGOF\4X;K."%>85O]=
MY/S75 !^AX!OJMZ K[6(^0!.!&W8FO 9&B(!3ZRLL\A#OOX06)A6_UT$P!>5
M"GZ'!+BOIX1<:9QE!\-TGNES\]8"PJXO 8(8&<-$0?!KB9%5P%SI0640J]B6
M"Y?4C#YV;3",%2RT_F]FN4<!LTN3Q4$Z-OG=LB>BX-"ET>EEV S 'H[NUDKA
M62>L5(*O$0[8"TQOLJBW21(, ,OG""Z5Z=0I9"\$57$YDHQ"0E<2$EJ'#)=%
M1&) &7L(! $Y(]IT=#4P- _OLGU'2_!K*HN<N494F*!S@56F7K%?(I8Y53F.
MB&4NF64NPY1:AU\2GJ.;T'&2UE#6S4 _)M'H"(30=).;:O,=H1FK,I44CO,*
M@_PDR9B%QC W-.,22:W2E^BH\.W%AF;>.B&UK-^F1.>D+BQ.<T5'5BY\+^Q=
M&:+90LX<Y(;\I.D5XZ-T,T4F,[VI1 8U;ID?)!-E)UU8 "IBP- 80^_B0/J!
M2/ 65^=$,&"<HC0WL'*FZW,@,G+8'QS.1!SX9,NL7^TM;06"OF66_5Y4H.G7
M_N7A&P;.CY@)73\!2=G.28K,VBCI*,HY"*&A]4+*P:N%R>.IP;CGL,7X $L_
M)M/FO%40JE6)9-97C_/O%_N1$(@2CR(A<&YC[T^DP&*>:0]()9-LUJ>PHBX,
MS&ZQ75\*+&_8Y+GWWU#P':5 V"-<3UN(+I@]F7CS;V:Z7],E3V?+[C@W%,XO
MN$]]K"]G*M80-L!LPVLOP4-2.Y_L:H+<9[H#;S*KFKHU*"2J<8EDEW=OXA\0
MVA';?Y<MS(CM0V:O?9SO,Q7HEC0]M6@B6-']1273E?B []F([R\\]^M]VY'O
MV(;\CF;X543DOD,IV0LWU38D] 'QC+=HOD5S=G& U;A:%QBY/HXA\<P%(37^
MAQ!=#G/](;6(B\-O>;W.QJ-XN0RR6G\LMIFBLI 2237[./79&%E9)/Z#9:(C
MN9<<$]M:V)ZE%5TY<L&Y7]_Q[-.Y</LM"/@"-^0B KXV K[.@$8]NN0IBFQ<
MCT_TM,SHDIS(IX_H]UKH-]3.[&X)06LXM/Q5(L7Z(_;?K\=D4OI$5V$0D7%Z
MP(:.5*KU+7-,4A4\GW>L0;'&&G&J^MGP:JZ4_D!D9KF$P#2H +MLUUW@0K4%
M# ]6H%WW)[H;L2D!VY:ZVE#K.GH_*>K3=H_OEKN51*6+0'XR&'PH./4U0+!2
MFM"O).I4DWUXQ/H,-2L;!@("?HL3!Z)5.P]B(V#')OX@O]X;SEL!32/;)'<O
MI,DF)N467!4?+=*+3\?E_QAF 8"<N.?V+!LQC7H05AT:TC,C0U!X,C>!I8*1
MK4\F;Q+,GZ_\:\CE74N?MZGV7!RUB6:YF+9EHESN:_7IS6]D@?MQS1=BF[O4
MLH1 ##R-=154DW,<[P6P5;LLU&KC%&BRG52Z7ADR979:16"C?P@L\P/GV7T@
M^?<370-%E3W7\2>*=-E!V(S%*O.8+8+D8,@:6+>4Z&>&>C?8]&)Y_@?-[LN?
M-0%M:6;,@0JFS["E6K[+!G^D25:=%\H%5<++CTJO@\DM=<#$#T9R_U2G+K_Z
M':%)(B@9OS8]UM6C#>O)@)JO<?6 7)Z,AN#/$NEOKZK5]]2N0?()?%BISBRB
M":=$I1N&55G/V-Y=FANKPY$+AS*T8Q3^(^9S9;#@%%163XG@*?H-87?DUS.:
M0"/*.+U$Y_SB?)@+SR[8$+N!L7=@;[+LR4Y"7F0&N,[UZZZV&)OW7-6?#^5K
MHO=O3$;,%_+(0L1\7YP4\ [NJY9RW8>%U(<BK,?Y5"K53JB%KL]]_FD9/LJ^
M?/F<-'E+7NA!Z3@:P$<D,)"'K*N8;L84,-)=8$0QLFB/(A+17WC7Z!,G5A C
MYLSDD@T/"&J3*'=JXAB6FVQRYE@-JY7J>%U?<?AF$G).J"@5,]JVB5CZ_%;7
M^WFZVTSQWA3D.TU@YP:-TL.LPE!Q?UJ^\27P/RCN_:6/OR-/'[;,A%MBURX+
ME_FE*-[0,_P=$$1BFJ[H[C>SJ*_I^/*Q_=US+^[U#?787Q=E7]6@"W03JB*P
M300I9X/U4DO.0V(9+?6?&^R ?!Z(]ZR<P66V"?EJ<9 SN6)\-I4H,CC](K _
M>.+PWM)_(GZ^V'/)$3^'V;CZ)$,/C#%/%1X<,3/O=&'/LA,]J^LSM&]P<<(/
M#C]L<'TWAK[._-SE@6,GRM*-;I[X8G?ZW*L^O[M]*@MO,^=>#+CXT"Z'%H];
M%-X4F_,T-V&UB6SQG:I$44'PC/K!,5%EP&]_IT8D#"X_]O8N:4 ]Q.6)K71;
M.&Q635T8*[,2'TB#8,_S!\]$%0(O-H'\?3;@1M&9(-?KXS;A%>/WJ-$Y"HDW
MU?)D YY'JO_WJ3SY,RSL_(+["ZK0Q$WU75*\6$?.OJ29QJ!==O*YQ\'PL21-
M)2JX98,F?[#<^R^9CICY?19:Q,S7Q,Q?48SFO=R<9Q)E4C/[ALCJRI0%R7SW
M :_ZW.S7 11^,!_(;KAB;@Y,KY\N0(0:FHF! (<2I#6&Q7%! IK 2S1#0HDG
M*5Y2> 7(. 5EB,MH@)_@! RD0$3;]O*);J*9NG<$O[NV.H0QH"C6$,U\[M\2
M8EHN&M"U?-9 [SA0#2ZA]7VQ8&]6TTU@*GH0,D0/AJA;YS98<D@@_U/5)[__
M1O^LWU,,"&R?X'NKSI_DFS_(BMQQ_'].(L562%BMBJ0W#G,NETAM3#KX]__\
MU^;D]UVIE23>6-5JAY\,N+0+,=F&8( !#0U\!XPIF#NK57+"+;46\G=/PMP'
M0XS ;RGF?V(;GWUP[,%R"&;8!L160@'S#Y3<K5Y;/[.7":&KA];R0N,[&QK
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MUU$US\LZGK^OK&O!S+:I/$])8C%/MA8%ENTVIM% B!^_J32-?[R &(2 *X6
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M.]%T/W#C^ E7\WQ75WUM_,"G*6$TUS!FXGH)X804/APJ>:?<6/O)!.)F/#"
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MR\8F;IH8V,+1O$R7+BX,B^UA<C$_&''%%FB:&%B)R,NBJ>9921=EG[:RA>8
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M7-N.A4JADE]/90;PDVR:P= T^T$O EK/%2SMIQ_S75"09T>+3V\>DEC15<Q
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MBH$HD^C%OQ0S5#;>(WG#_7Q:*GX]0241JQ#ZDZ#^F7KV&8@C(4M+62//)/:
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M\<1KG/XK?2'*2C$EU<((9RF:IJC3)L(8YS#&#!;!NGM$[F'XM[A8MQ]O]EM
MUH'U*%#!41UTJ=A(ZC(6OE4B,X[(X$POK=GU!%]DI]+DL;^4ZZ54/]GC<37;
M2.CM70'NHN<N>NZBY_9$S_<XKCXB>NJ+=;5MC+(5(3J:EE/366,ASNH@>N H
M[$2!D)_JP'I;!M",!@TS_34S.!+=>L\"NL?\WP7A#6&P5X+^CP<''!1+XJ+S
M?'823TSF33YF" U'JJC(#L85<;EX(!P_'A1PEP1W27"7!#<"B;Y$$KRLJ\*J
MO Q-A'FP(:[JC;2N64F0!,0C%HM] !7]1(\8("*5EA>&E&A 1P&"D: (S@*M
MF^L5,Q7+-E7)ACAJ]/O=-OW'!$7\(](A?AM2 N$(_Q>V;-SP.!A^0(;C[A>^
M*VMH^0SYL.ZXI#FP*\)*&HGZ4&F(MB(,!HITK/+$BQU5'6/5L%CQ*3'G6U&Q
MT PCM(4+W_*!,/]:Y,1=KMSEREVNW!KNNKI<:;6C63O?Z14FW4?S*;^./CGU
M\!#D"KBSV$ H\ENZ@Y-7I-\,R0),7T&/T<&7!24-\6+?C=>[\7HW7E\7HDFK
M5QWT.+X7HC(T]#3IKO)ZDQ." R><4_GUIIX;7D5L'I&"VFQ<,]N%OBDT(^E$
MS1Z&1N%)O<<GL"^+#<3#B;LOZRX.[N+@2\0!E^@E'ODG99X<R$)02\7B^=[X
M.3^HWXHX&*6RW5E&[RGM:GUJM))1OCMN8G$ #2X#L= _),+K/6!)@:Z8YV#2
MW>S\IE"+$)(NLN'T->4F1.E_?7OTQ!46X";DZ];Y56_HB^=,LK1F@_500Q.&
M\\YB?1WGU[%J JO>\U*6,BJKSIK166N03RF3(0P>T%8HP)\H''B7*G>I<I<J
MUY(J;&_3C6\Z\\2Z(*Q;N4G;4AMRI7LSH&UI/ZIL/16-L<U,8EE;5H(-:5&'
MP8,G*Q9@XY%?Y<DZ&YO5=&8S38&2#Z+&R*HE:8;EF"3]$.#<0#.6C*J3S4*K
M\"=S#]+ZP<E(_\"V.7<*O5/H;5/H+W$"G"MRHT&1&Z1$ANI"T17KGM[U#SIO
M_@X$_LL!]O<E7&6W/-I0-!$!ZI;QGK(=\:>G;&J2;+"3=6N6'G/13&2H(I.=
M!Y,]QK]V1GP7!G=A\.N$P4$]JY]E/[;UF:C*]\(SOP-?'V7 7\IG=]*\D^9M
MD.9/##W$>+!*I7X:A#Z)&(1\CZ0D(75M6P@:BGU-.0($YVRBS%MR4)GD!LV7
ME)6NCM<Z H*X$FST Q[6'VD2'VUO#*D?>!TA]4.D*PF5\V$I[Y;Q'0S_9C#\
M$RUC[R0*O=A4^PZ\L#IPF?M8P[N54\IDU=%JXL1[U57"3JY&J64O%,8'U_SQ
M(OAWQO_G,/YEI?P_DO,OFW[Q5LX74MIS?I8>I04U8V0[:.&FU?00.!\.E\-O
MPCW_L0$(7&";) 0^%)-\H^J([>P_=REUGT_)+UXT*H^N>"/K?N'83XVT-5+0
M!FJ:L02O!%XSM\*(Q8B,J2!JD=!(2=LA>J!]&*48.!:FB#[/#!,^+55[A&":
MC5X&?8P@&!>\HDQ?U* ((&.-% 6A-WLDVHSE3!G;P-?:!ARHHY?"!PO1$B-.
M"<ZS1L82FB ?/M*RT7_<[DG>Z3OT_/N>!?VBK1<Q+_2X0:(OQZ50+Q118KUP
M*";U1%GA>A(?B88&;)B/15GTSO^([AV(>VKYN9.HE>P^.Q]+'2N^5#-/FSKP
M]_Z5[8+19U.]X+BM-C*Q9<9DIZJ<[/&'5Y8W+=WLE9,<6Q(:C72D9VZFST-T
M963_2CF_+)IRIR<(W:R9+,H1*UMG$>_V#L:Y< K/X1AZL.!TH_%"DEW,N!>X
M\N#M?-Z43(.+5]K-X2!1BB3X?+%71U<>O-WNMNKCB9S<M$NEP6"9KH=24/ Z
M?/CVYVYA/*P(F:S0+4B9%MN/MPNQ82]R>"4BGUAH8PHC@1_Q=M^.5&.#>A)=
M>3#._N*Q$TFVV\5)T^9KU6Q&%2O).KK2'2?A+U=3D8 GI*4T<68I?[I_^,D-
M*8"_1B369"JN@EATZR[%!35E8/\I.K;A?H%5"/F&:BMRC4]]T6O@&ZKH6/:_
M@6YMTQT8?2%'Z/EM[E7^K*Z4U<61AQOH@<"<+B.XGX.@AO_LFXHX"2[1(OTU
M,TB#LS]-.$U1%\K>,[W?Q3X2!(ZM_(7&=F2*WPS0?/>]G?'_@^;E_?LI+P[[
MD(A?<5.HT,,O/MB??_*^< ^1^[[<XKZP#Y'(?6-N;V/XAW#BOB^WMR](D,7N
M^W*#^X($V5G?S'UC/K4QKT<>O+9#KP+F;UX7ZBD;#'"BQ?8I\7>LTD6QZL]=
M#_0H^/+__1'YXZ/J+_H0"U\UJ3E^U /VX72)BJHKS"/Z?F0Q@@Y'>$UE9BO3
MOF*2J-X0&W##>_UI$G>^N_/=^_F._RC?<?P#=]W""5_,=W"8]T6)1Z]!\B^9
M^EN3 $ZFK'P-#7"_C ;85Z7JAZ)$KBU8(6<1GT+LGTU<\I3PQN3GM8^$SSNV
M?GHLR&O^H5]Q(GSYX@9)?3^_.&FG1=-<HZ7LB)IS+! NN+ ?]9(SS[+IE^=<
MUQ Z$3C7"9%0D ![A1H&%U>!/XSUS[J"?@'K?T.TRTVQ_B4J$'R$]9OB\+DZ
M9[E<6UE8D?5CG\]6\.$OQ()$ O&O+C1P;1S3>+U6^3\1I'P(BUR[$-R-K0D!
M,-=>E)N2<E\-<'9KJ%0,77),$PFZ(X*M6QKT0[-0N":L!XVT)#?*4BTU[)'P
MU@#/7JRARZ] +C\.H%R'WV^@\N=-\?M7HYIW\'N[QN;*TXP6:ZOA1FNSCCVE
ML[EECP2UOH'??Y.CYOI]6GX%*/I:S\W5*[!=V[5S]06X*5%YZX4MX^S<Z775
MU7@2S37&XY?B,S>N05SN]>I:_@ID];4^H:OSU+6=1E=?@)L2*K=>UW)6K]4C
M!4VM"=-R=UV+*WJLWUPBH?*NLI872#[Z.:E&)].DN/C^X)N*@G.WIV@<X -D
M=,-&+[0-H"!TCP5 T)_=0QL>B]HVS\=Z^,()G%[:=P6+^8+A)$T139 5H[]V
M=R<$+[E$--S)TV(^[,I C]EC^Q%N__M_[43R'8A"*K-\LZ(1A#P67T,E2 (%
MQ0%Z\9^BMA37EFMZ)!X\<?BG)_9@&1@D*D.1_V9\?\-R'*PEI,#X5FPGQ87>
MMIOEXG[Y2L BW1A(&N$YD(A_3=%'.K$P]Q"+7&BK]G13:+LQ_R,R(Q/$Y_]I
M5=/'HA@_^DKR$1Z$!!@2LMI?_B@!^I6/A&!Q(4\09RX9 R9-4I LC^C%MQ#^
M[KX=VPZ:\*;PH0379Y6>.(CW>V'$:+W$(!KK\2(G*B%6C$AACB93?<T6',1(
MG NV0 --@F(2F=I(1'](BH,1@15@"KKTX,O<2[ORJP(2S3;2/BF6=848TJ57
MG0L>&XF;02+7&S+C'RSCC99I>B+W"R7NN\:,N034&N62?[5UT9$1_I+_C8=$
MM'+%F:)725]1XF 7;%3-H:BK&_R@[1JA#PADU$S%@@+0)+G9O\5TS3)>7>@6
M&E1*,Z0)11W]7B]:#"6:L7"7;3X%9_E'\46I"@A'*0B?S-  ;--1ODSH'*SX
MZ?7E'AC_G+&/)H,&9:HS-Q\8$G!3CJ5"L<,+Y=@>XH833$A(&3B1^1?H9I[]
MBUR)/W!_D2QEVQ@J:-0FSDIF5,@F=OJ6*JNBJ:(Q(JFKF*8"US'H*@7*RR#^
MAGG29Z8)7J$/_3>C0J:TI*DZ-@X0,!DJ3%^%,H\C'6G-X9JA" ?!6LD!!C-(
MXK*L+!3-F+G9RC,385Q+T=:,C2:KD 1I!%M-U9B-X*$P:D0/,%T+(#))DD;Z
MUG8?(>JV"J]6I2"B1Q6-!7T/DY;5P4"5',U&6BZ(;W&?C1A;U0>D)*7%P$X.
M\:+,3&.&%@0-9;T[C&!?A#ELI_? 0!8Y715F*5H,]$:$X8LDA]Q"[\6C8_J4
M4F!%^HA',!7U%7NI*#J3#A7A2=X4B5#UMA+]["XYVDBFB[ \&JN-'B 9YLP@
M_$VV.#F=(0@_4IF4:EB2JN@2VMCT]JHM>= +O;W$*>C IV27'L4UDP@PT$4I
MP"R!')@T^L=B'A6T0R;3=/IDE#"BY<C0T.892QWRT%V:6L/,W?<$F"G<2#+B
M\5!5'40OFOF_T&:ZD8QX,.05VRGC6^!*)$,6Z@+GZZ-UIR/!2_V&$3PPA>E4
M05_;0&AHAX&,2+H]3)OV7]P^.+!=3-+@4L;4 8(1[CNG#IDM\W&QO_">3PU
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M^I#.[U?-DCA3D9C])H?M/O]LRV;@%21E$G AA\,AHD5!IOF0,(\-R=DT8#^
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MPY8=>E$?/<W0W34Z>4RG#-":DKX>AJ3B??$\O.Y&/S!MB!%!F![8:>#LOFM
M:K[2BW<CFL"4@^X.L@*RS]U%T7+WWH9C25.9(N,!NX$M!9ZNJ0-/<NXS IY
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MT#NNL1 7F"HMEP6@9D$.#M&<:5P -N:#Y/C,_XNO9!;"KI:AZXH6='4&'D:
M&8@2=0B3S\0%K)IR$ Y_UC[CHW7D6R^#VK(=V:U/(&G(8(+<.]M4H2H,U'-P
MW'I3WH^>SC+,H:C3,#OT&B]BVE-=6-)3R8'%PQ9'M_8L &S]00(!O!>?/%+-
M)GN9AKNC\R02U ^#$A4DZ]"UCD49J311<FOH'$M.V$/F$)P&1@BNS./3W'2!
M_/%S&([B. ^L[':"?1>T[I&^,/ Z;_4EZ32)$:N[BP],T4V'Q+_OIA9.T20
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M]<4\[/!5"RIG0HU!?PT=!9<% !B"UPB2_! E!G%Q$&L*-31-O^9PD)TK;;>
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M2V+Y13HXEO(]898<?O38^.28<J9A64?.@X/]:D2QVB\Z&[6-1; <F2V>@Y!
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M/<T=J6RWUR_';08S%57=1O^'EIH\RT6/;S'S+^CO F/GV;_P9? M_LS]]>\
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MV+^P>"AFR^?.K3B][BS2Y8OV,GT)#)C9O'*D66>M9'E\63K/BY?-5;=P7=,
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ME^(O/W-7CB?H/9&)O9L6-_@;4;[*Y)\OR05'.?H>U_A+[\K1&#\067'89^#
MC?$?R ??2"$<U"L?NM5\9/4?:@'GZ0O)(_*E#."#HO /%&:';KH>+=5O++:/
MENK!;,KW8HS?'XJ=B>4^%R7E1X:[#DH6'KP]UR136=6WLJ-'&A\MNJ-%=[3H
M#O%0'RVZ@]F4[\48/\"B^\[AFV/..I3D!?H1=/,[LO8MR;[S0YZ+B9\[1^JW
M#_EH9)*1;)-CQ>.7YNRCH7,PF_*]&.,'&#JE!V(.5.MHZ?P@2Z=-S.FWI/?1
MQ-DD=97:M*INJ8.CB7-HG+V-)_0<(5F7SO9_/^@<HS'SA7N9$![+^BI"[9-(
M_U'FRA?F@X:I#KZ,+7-0$H!9+5^8]']TB6Q:?_YPXG^43?.%&>%:UIR70SJO
M!>>TC=D>K:! 6ZX@VT*1#! !D1$_(478#X"?^IT 2#V&_UQ0WMW&;YZ"W'TS
MWJZ%MDYO&+^)9\YRY7@GVJL^9J[$V6/Y<0-R-V_UZL.>%.\E..)NXG9R\W"J
MMZ12=.@D*VI\]7A56</]KUZ6WP"S&PY+FC=-61_AA*R3E7])0U[!1_DE?0O>
M?![@[TL'.#ML[)V8OASJ][>K2?U&NJZ<%7M=Y2[?R_9P0E4ZG8WDXNEO#<B[
MZ0[M&\U[YW4<GXK.O?,>@M^5!$5UH2H$<;>Y++ALWAOZ/)YHB.?GEC&I-=-:
M/G'UV[(@OA])X);3\22L&Z)$VSY$/CC]LUKYOJ)W.G(M>S)3;E1)3H^H?$C]
M^B<=2WQOK.Z=J,I/CVB^^82\ 7@;8>8#;)\UM>@HD<F(XGQ8*,ROEIW.Q?5H
MC=.C%AG\I3CFBGH4H7S>?YG/^V_F<Z_$,)")AE!MW./TCI;HCA[[=V*G;C4*
M9_+*NA3OKBBG9ZC,H-9I? MB_7MQ^L]6@@?T]CNO:WQ99<++2_&_WQ+CWJ]K
M5Z$2 VO&#S]6\1:=<_3"MKRPWQZAM%N?#!G3JNH-NI>&4C$-RPJQNK*GJU%=
ML5(/I?35^;V]*,EBXF9$7XMZ9=E4.B*EOL74X(^1NX>O7#[L0/\0;^JWS_2'
M^E;6FX[T&_TKT\Q7KA:35$:<=OOSZY)9/+E)+>G+4O\J&<MDOLDQ_[ 3L'=O
M:4\RZ^M2[&L:\S_#9O\:>1I7ABK"T>7^K@D;X-@_OKYW ,/7JI;E$*6(T]:8
M3< *:(+SY#R6#C$)JI5DTTP9JMPA=Y6\4JE66\.[?$\2P?K/)"(I:=LJ^/-X
M,H[!J&/^YH=X'*[T>*_3D:EE3A3CO!8MU>^<2N<F?9J:6RAAJ->1B,5?YW4<
MQ<NW2/\<UG;\;&;X;MG_ W2+/GGN]IL51S2QP^CSEN)H&[:L>7T,6-P7IB^N
M+M2;>$O52_)(-ONGVNIV+HU 7TCBKW]RV1>&=A]ZLJALF$-".5CY3T'6!T33
MCHFC/7<L_!!O\3=/,^=;Q_3/<\CA/:-[E+\;9>W2N=7)E%N]AT5"7_8D"4O\
MI$A.S+[.G3Q\_M]7,FG?)^4SDTW[?K>C:_@FUS!$)KS1.;3MDJHT,V9.3*^F
ME/3#T[N,/ )Y 2FI;"Q]S$D=6G?/,6?U*3FK?5/T('):^]Z$'YKSVNA-:I&9
M'6Q.$OWF).F;A6-VU)RTSM<)RM>*X?0U<IB,_5G=2[X=<]74%]UB_GPE1J\2
M3:TTFE\O5GMT;E[3O)2+YLX&%_I5:4(2EM6P1M->_VP)]>C4M8E'DHE<))V2
MCL'L'<<O]WZT=MW>M/<7WKN3]'9I\C7:G]KZX\DL&Q^U2K*5BRX7VF75O!V!
MA*'.4"J63GUWX;*K_J<O=83>T"#URFC!%^B/BEX6B[F)^#"8%)3R[4VV>3UJ
MV%=P%%B#E)0[-D@=]>RG)A+W_L+[S#2^7<6*^U&Q+Z83L]F2.E*<5'MRTR^N
M<C<WJM::H%*%=&):S'WQ?.(UL:A@%>AN".1A1@;PBVT("_KQ>WSYPY>,GYEW
M_":G_!MYYHR]\[I2XLS=-N"CUSCLFB4N4HN2?%>*WYKR>?UBW!@[U(9(O-UA
M/_Q3<1C9R(,T"XY>]C?TLE^6"V]TOL\?TY/&HR$.2\[9^=F)I$L/V>42I,5;
MG._#%Q2?FH@\\'/R95WI-W/[4QZVY/'[XV5RW#D;C!*B,[D1;^O&^,&\R ._
MO\7#/GQ^/RK&CU*,1[?XP-WBEZ6$-R?E1;<YV35KRX&6GT[((G'3JM\DF\,3
M% _O=IN_1BZ<VPDRL/0Q%W[,A?\XCSMP )YTK?N9?J5P]=CNB.F&4=+'2B-E
M)T<]*<FZ1A.13/R8"3]&Z(^9\!_MHP<DR1N=<3TO6K7[W(Q,2+3;-RX7FG;:
M7H)\H<YX+I;<;B+X9L+EF G_3N[[TP?A93]]D-!3LABG)L6-?#,F]_?RBCSB
M40 _/1U+I8Z9\*.>/6;"O[#+_S&29=VEE\*:\\Z7W=MX9]87':U:3F<3C[6:
M>06B!'SZ>"K^&I_^/S8\[)\MH7,@)__#502CEVQ.*;$&8Z(X&JD/PRVC)K$H
M"2#P@N@[2*<\W<0%770;=JU-UW*BT3]QDO1[K7J7C&\G$Z4TE;+W)ZM&[JIV
MQSE0U1VJ)^QGKNO!9932A))Z1E=IFP[YV$.GZG2G[;^DK1DW_KO2A]$W$F1X
M6POK$,S-O\$1M 0%08H$>TP$JO&(,*7/&UL"H8]0_#B+D! C E!$H%LLS.B]
M8&J,(O2)9BS_8J!<!\)K>!(\D<N$)!6WFCRSR%_N#\&G4DGU]YA-N)G*#U'D
M3MV3F5&-#.V@$(VBL,-/N/X1Q7_#6FW3?2J_F\3>X14E*IEX[%G0!T5=A-S;
MH/<;PO[S[7!_CX*N^*MO$GD27=(-^'MF6"H<A;],HM$SL2 ;]_3^+O<M0W-L
M\C==6L@;?C2%F8*(B2G?F R?2@AO^UHC@[Z7]]_?BJQ3FNR3*%RQXX.WZ/.3
MZ2*)L<RS@%1'PAP/S)$N00?I>%P.D2Q'.?:IA'GC$.:7;+"][<'.1C*_)+_W
MN@/XV\YGS;]X1H]<\:6YXO?'N4KQ6#R]UQGU(1OVW/A6-]8MY!>CD"FN3T62
MX'<>_Y!Y! I%;4"A##0BF[!A8[XZ+SCY6:[DD]L23_KA1[XI4FI33?SO_ZRI
MPZWH+(^C!EZ+J^$X4GE$HDS;RD/ZY+]D;2FO+%>9Y&)>3/HO+Q0+^R!0D9)(
M_5L(_ S[L;69$(H(;-E:-()_;3T@X7[X@M;GE $'/RY!E/;O*?V5OUA2HN)N
M-VY_(I!!DH6Q"<' _VO7"V''_;V/9+_"C2@KFU-96Y,7_*, #\'FTO5@5% P
MAD*!A8(L3W+(05/C*<Y?IUL8.62O#2KYL&@4AOGAA$R'HWBA<)9I7"Y[\5[R
M%WN:=^6M?79^<U(6NZ55M'T?K]N.EDV,>M@UL7YE83#(IL32PV4I*DWS=_'$
M0R%ZLJ17;MVS?5]8FLO98M11-26U:E\/'Z2+92_9$S>OG/9F\>Y55%YU2.4Q
M<3_+I;*+NQ&]<NN>2FN9;2;59D),KVYO[W.UX:Q[M^REMN]I#N\FJ4RB61=)
M:=D9=*2^K)Q=T2NWWJC2KR0?H^<ZZ:B=9+%9ZDWCI_=P96KSRE-)'MY&[U*-
M4N5QHM0RR734DJ]ZZ9"GY_JEU#1Z.^K,L]%HHF?>]\?UJUYF^TKY-EJ]=[3\
M9<>1-:U8:"2,$WO9RVY?>7=>ZF5;\N*VH^9GBI-.="SG# ;IKN]23U$&2;&?
M3/1RJ;[<2\;[Z5XV(TJ]1&:8CB?CZ4&:##;O?5.?-7N=:?:B,ZTJ"67<ZY[E
M)U<]:7NW&M-AW>S6JM+$Z683O6O#ELXFP%-;ZR6S6FT\'%27$V=\GK]8S._,
M\A7PU-:5I7:SFSH;Y<XZJT?%*LVKS7%B%,HIY_WIHG,9)4YG-;T95.(%JYZA
M>Q!&_US&NNRKO?FD/B?9OMJ<K>:S?!BM4N?U5J;>[%7$FV:\,"E*M[:CYP.T
MVE!-;AA_6JU(VN3Z(BK*ME:IG>5+R=[Y%8;GX[^>_-:S0?V]AI>/GLS19CUT
M3^:-ANJA[=*W9IP?Z.S@8#:A*-LDQ-4Y2M0#.AC9ES;@.3*SPKSM_ZX3_7=E
MYQYQ$#_X6+!I1!^T.]^$-3Y,.GX?-BG+JBE@X=*+TO/M;43[EZD; )M%,N"U
M+A+6NHB?6<-WB(;&[UM;'U;2N7-C]:D*QN".?5K;D13O);#Z3>SQ$L0>EJFU
M5S.2?U M[].-6K8:\FNO7>SG[E)JQ>B0QL--*=TLE>Y.1GOH52K-'<HP59TN
MTD&D\KH])F9[+.N\,/+2T!?8#OED#U->+93.TD;KJC1]5!J/K7MUT58ATD ]
M]D0\'LFDTCOM,CBP<[KO2NN#\R _M=#Z2XJAW^E9^G1!M)-&I]>+H8V^#_06
MP5D$P^>I'NQ^:SG6U/QUJ=1*)DF[')_=EN97/6R"DG*!SH_?A"W;OWV$V_$A
M@Y"^A13]'L)C"Q__NQ!U3V'57:C$(V._A[&_B9?ZRM%T1X/W>QJ 6]NSAZEW
M[[$%G9I9:^FW:6N2OCX9+EJ3<RUW?9!.J7? GIF@)VK)UHF2&/=+!=4:#5M*
M+K,:+'MI'* 7$9,['L=^/*2'I((_'Q;@ .30KAS1O8BBPW!+ X/[WN.85D[3
MF6IV%NV6YNW$?6=XG9P_I$=41E''-!W+YKZ-7QH UZY:E@,_6@(EQI2R(-+]
M^SDWNS3L#WG<V]$:^FPAQ [7,Z:0;E>RI[IXW>G$9_'JZ#RUFHWT92^#IE Z
M$TGGMD'&/F*8\(\\D8<PA/O MN3PA=315-JQE'J/M12O=FJCGN;,)C<%>=F?
M$T.['X,8@S ^R)K/AE'=OQUU( -&OX5@_V!/[RN .^VD-.+WQ%G'G)2O<@_1
M>6EZOS :/>VA5+NY.D2SZ^7*"+71CCNM?MON1//#XC*C1K6Y==7+HMV52D9$
M:;?XB\=C^[RAME<(NOT42NQ] P[!*MN-W#H,,^RW"BDF^MEJF7F8K2:%5.VQ
MVKW4.]<=:)>C%E@\$TN^&+!R6Y4_'EDMY#!)\7"Y$SP3,Y,@"@>P%OSC"I[W
MR*FM=NN#?4NA/2:"[,XP$%07\5!8 .&AC]9@W+)F9/J(<JHE()"B0 \@P- !
MD\KZ"O.YF;\M8: 9%IBH#+5N!N#$[%)Z.P6>2)_PK_V?Y-)TIADK0O <L_/!
M3_.]<3F=W$Q;,Y$8U]>)I&(NM?/?PW\.A6B^E$VS]UB[[SV8)-_O1(WR-%_K
MWR0E<?GK'RK^XEL'2IA10N".Q(2\!1NY39\($,4DPE*V7MKFWX;Q_+P=CJ;>
ML,7>@XBYH/L<+C\]V8>+M=J&+6O!OQ<,R[XT["ZAKSHP1CH]@DI@Y99'O72
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MM?7",PW+UB!:/*)WY-WH&,^.<-E+-TUFA1G"B.AT*2"=^T13J0%@,<P'!D=
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MF.>&4J;@6-2V"70V!#VMV[/V^="23D:=M'P^/<D9>?&L"AGS5$C(VG6,6(8
MNP3PM&VPE$V5)(EBU0(USNAE4RH]J?)6+7893VQV8JV84"2PC:ZA6R1#1*MR
M@SS(;\A=0X>A%@_10:+?=B\]);)&_YZ'NAB6C#XSZ#J$&]D<(BR5Z7%ED-5A
M5<S:Q&? [<$Q0BO<#Q+!Q_2%&F.,&V*52?\_<>I4T><84P!LBO :P6A?4\&G
MF6G4F>P;"!AC&C"Z"ZX O0&;S[3H@%Z*"[)L1T%W*@]$EO_?_R5R?UOH[5!9
MZMA4 \S&:+TA6-X :E855%'Y1K25%^E",.X $4EJWWF[B"$K^@ OE_-?=;T
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M! IQ9ODD@]3<N F/WT#ZAEKG-@NF+<>&1KA7 %H@0KT_OSA/H6XS1T##@!I
M'YJJ33TOD"J0Q?(X+Q  8URU5JN#2Z$Z!2]EB7:0BNY20GB7$<]S1L"=IV3G
MBI0_[,"(YFZ!0MB+834)5PL;+\?%,G?%K $]UJ@56P4A*V:!'O!C6DS'A/QL
MIJU@]_DGL ?4VT-3<Z,$BD$J6FZ R/+5@%]+N;$02A*F-TQF3;E!-,MVRZ;6
M?3LJ#G0/6A,T$K,A5!WC5LIZ."L T?F95FN(<U@ZO8BG,]55:C+7\M?R[50[
M3SMO#^__IJF9K0Y'E;/YZ7W'&>1J2J'<>R EQ*[<KB]<JTOYM-UZFRN]V]WJ
M+1][G?[D,3=1Y[4K7<J1.ZU_!;BPVRF08/YJG7^?4(5N$1J:CF"MXS[K])"R
MI"5DO*#0, Q-TB1@YX'8U5:[9W I4 :8\\L Y7A=6=C9<['U^) TR\OLJ#[=
MN2_5N]1OKZ^SHZHH%V_3)Z6N2HKDZM45,N\][!M[44B<:([]F!YTY@4Q,;\Z
MM^1NZ?U54._<BU'!ONH.\_?WG?35R>-%+UW)6JT\)&_#QNQ\%#^C5N3U4&_B
M:_$C<7+?8.P_!U)6*)?A>+F^H$5=7K\DAD5I/,RR3X\QL;!2#=UG*?%R7$EG
MN:HGXDA/A)#H&[\4! J4-K^P-U[J_7.RYXF>E& '3B%J[P)2426H$ECYT:#"
MBAI.@[+:-PU+M<J0L9$#$!D02FI"4SI^ W[CJ7/^]RME<F?<7)YV)ZM"15>;
MYJK2E-XNU##VVZ:'P:+&K1+8)]RFT,.[>)SDER/EIBI63NX7HUYVD:^LZ.%]
M+B:T3E^X]7JA%2.*:[JS8F?##;#,(#+& <U#LH48?Q$@].+'3FPTA-D77A/E
M:%C$40PJ!:B-)Q/3H7QM6+(?YG CDB_<);;U9<[ &*G9B-$T,$8##PP$:"C!
MWKA>?Y&R:B[E52 .@XX*,68:+_4<(,M1CY3QG!=G+90]:GR@O'BJ&7<7TJCM
MM4>YB7+?J@^X_&YZAQ71OSPW8F_2X'HZ2<G1^L7CQ!F3JCK./V3C)V^W.OU,
MSPLE-A4S<9H;=!(7XLVT4FFHB>YIWUR"-?[T&8_0HSN@C\& "7JD%G4074,R
MX$9!2Y <<+C6BO]C0M&W/N?47X<8[=/VYGK\8\>>TWNI:7<+XY/4*%L7*P/S
MMI*>*8_CP7NIB;S;Y'L)(;/\8 S5,;#7]6%-U0@UQ)XHHM,N>E?)?#]ZWSFO
MWCWH?3F3FZ2>:%%Y4W?2&GU9:,E?%1:MP*5L93$V,8:-A8!#RN7\NDX(BPX'
MZM8U["%1=0M^9M5U+(0&QWO]T0-BVC+D@=T%6,'Y%_"%8'6QEZ.@7(L_$\LK
MJG]6\P0E/#;@4"TV=B6.=QH^HYY[GX*WNJ:CZ5YCKR3O%O,#N%CW*EOTT$*8
MG0QA<RQ!42G//$&'X(YB(>Z*=]LV3$-Q!M2"I/NLD"&&DC9W^4^6"Y$#$T=>
MDTSWY38]]K\OQ/N39;0WN;-*G9OKNW1A6%@\Z/+H-=7<OMSV7JD*!K7I($J9
M.YO9.]=-+;>0YXI=+;528_MTHI_H6@'&QJ1%C%-N30/Y@QYM;@P$;^S9+U@$
M)JL:SZ]:SI2$40@/!:<'EA-Q(>#%W<%KX=%0K%P3@D]#CV%MYI,PI5ZD0%0D
MM$D@X+VNKWTY(6,&0 OX .OQ3TB^.1:F"P H%9F(>8_TC6!9?TCPF@)Y&-#K
M(&S\!WB5<'K7I<Z?4 -B:LI25:@=1QEJ1N#)$0BLLV0%ZSO@>0MN=_@I;S\U
M$6*2L" HUA5::[L)[.NP1@8T%F%'UPV]0IG*2%M%T1>TMNGG995HBI](!V+^
M$?^3-TMX+_R>]W)EJ5]U]D1"!E_)5>O\I2+NSF*/NBWH!$H$(4*/99M^LH>L
M;04_W.Y[Q;Y%55_F6-5WK.H[Y*J^9PN\OH/ETF%U YLIYG4MXM9;^Q)L,Q-L
M+,D325^N: *Y7];GC);MIO'JY\4B?KK1*W7PERE8U*BWA(6A.5-B;>C@]0"\
M:TD;5)R/7'-W*D_(AA.UOG;/?_:->!R^R*LY%+X WYA>?R@D4MW,<\B#O=MS
M):RNFX\V5=#6D.I"JH6H4L%R2:Z K.=T FKWC7NA"+;<*J3!&&)KK!X&:W'8
MLYBO\UGAWFVF>P^PTF?C.SU=5A*(6A](60D7BF'5(\"%V'[IFHF>C>5#!!E>
MT)H'^EG!VL-,Q<EGC*FH]-14WRUE(T;UD.@SY.SQ, ,GRYH;?PP_4$&G$#M8
M5-[9X=<MN,-,L9N!FUUHLK(3!$_QZPVV;&DP&.',NLMW"P@"D=2 %UIB-C;<
MDQ>-!4_P>O&!'[5GZ$34+O6$&G89\<.Y&:CU"A3 DW!8-1WWS3U#,NA0/"%3
MO/MY/3!,KJ A;#GF@M5\D.??>"='::<G^IT5&%3^(<T"!1C(O^A5J=93=1<Q
M(8_H(93WL/\'O'=KX%@6<[\O#<HLB8B;YT$%& @)><Y@6&PH)$ #=1.!!#)]
MV@"!5UQ_-+PSW&LHX^_ O7_F<KB]9FL5&<7-S/<+"6^WF7@CVZ50(<!*"=UQ
MJ+C3;UGR1DC*(\G:&E^3DW]BB3M,QW]0U+0Y6[9SB>MFM%2X*.B9AZ(XR*7>
MGKK&6(I;[)O7@SDO!N9C^0-70X.F^70W*Q9'U0?Q_%**JO<K:]CMYU_ ]=E%
MI<I&JO^]^VP4)R-1[R\*G4J[]J!'.X6&-7QG=/IW]KDNYUOJ\J$@EN:I\MW9
MLK)(%:>C\!S$FX+35!I\R%'<K'9Y$G'+%[%^R,=%5\+L!Q6IF83(!+!J"XI!
M6,T;:S/2 QJ.K1@"8:PHW9.H!MS+7>G+[[0N]H3G$44_M>\(\'+R@[FC,E]T
MNP6IG+\OYP<KJS")CF>#1<F<J\6;Y0$T%4DQH;6BLI= 4K5"=&,*M0;X0D+@
MC3ZKS^<%J):Z+I1)W_0A,!GTBD3_6TB<><@5"GI_@=4&%+#EO1W+7R/0TWIT
M,?P2+VZ,>GY[DR+TK QB7OZY5:GZWS!8WYRJ\#I*]IN%$<]/R]#&>_%L#S:'
M2<A-I@Q,$7??Q7T5^B)<;CXM;Q/WP6H4_QO3B=2\< K%R20]Z%GC87UD#!_>
M6<-1D*TQ8&:4#9,[Q50LX'N$3Y:/2]V3PM@^L\26?F$9V6I+Z5U0+99]KHH#
M)"=]SN=J,Y\65);LAS!-5:F(J9,Z*:WRK3NIEBV*.?/]19X(:@VPU41AQAM+
MV%S+FD,:?.I2??@,L;3^I5[L%H>+2<'1RPE]/A_-'4"1S+Q +8+#-9C[A)3S
MO$]^JD!S#/_ZUL2$VJF66Z+=HFZT3#<_\"S^2=U4J22E]\5&0F_X1UTG_#X#
MS=+-R[M3J2,_UFZ[TUQ\(#;>7SK)[V^U#=P"D[SJV*:R@SQ)G,WDB=R_RY1(
M\W8QK^2?+\Q@00G(*VD&@_;P58/@:X4C#SS% ^VEP>\S*LF-X@V5TN*\7KJY
M;;<JY43[_:7$[^,!XMS-R]E,O":>Y_,*F0TN>BOQ)1Z0H2N=,+1HU,J<&8YT
M?X;N$ )P1Y91E5"Z&EUV2X6A<S.^[Q>[3O_]*N%]E-<-LK@T2$?MS!/=F\[U
M0[:MQ%\HRP+*VTN#P:YMD/Z[Z_'?(S_UC$WWW#_TY_%JBR0ZZOVP/NW5RY<W
M%[L^]_EJ]%XJYE))L;!H--K)+FE6"J,7"F\QI >1K&WZ,T/>LP@4OZ.)2HH(
M,$TD\%W ]%:A+@&T!KB/ P/3_.C\"@&7 ("I>%/R=H1VO>R7F2?>94''8OU/
M_&L,&<HV1JS/TNOM?/:1D>#B%#(DX/,&IEV:B##I3P#SJ\YERZ]E#,D$J/1\
M(&P'%D@ 5B4K<:!_Y@-T($V;./,"U@,<<>*/V_0JV:'NQ O[FV1$#3/N_/B]
M97[HH$6HWXZ05=3-Q(BIE$LD6"DQPP!GKPR9.<P?0"K"A#H.F&SD(ARR_$1P
M>=R]XUWZJJDP0"56;Q4 ,T$OT12FQ!P1TV_K][X0$ZCOZ6)1<]]3=*T,56?2
M@GJ?:Y'Y&KO;'Q9E-P@>\X;Z/R.\SNA%LB&Y^/O'A(ZW6RXLNNR7_2+;NS<*
M=3;1+!;^4/]DRW /S/JUG^"-'I+P_& GZ'TRKZ#I^4QE'+_KG)/DJ'F92O5N
M2T\$ =?M7>/I^,<?JD?8-9_H,PDJ42**'D4#OQV@/LRS(_.D)_1X>>OT6D;Z
MM.1<GB8GRV5S,+W9M39<CLQDM'MRJ8NMHJ:K[?.&.(F_Q!GTW[6Q, PH7\I]
MHA7\]0GONS_F?%R^5-MJLQ0_F=;,S.UJ-EZ]OU7X?82W6E:A2\YE<1)MCJ+2
M<D#R=YF7W)]PPH-:^MS,S-<G?L ':DIY.=E:++6.8XPRYL6YEJC-=ZT1:HOX
ML%*]2'5%4I7N!^<MYT%IXT25MY-?0EW@*@- PN>SY9A50FUG'<>^OM*D ZA/
M#?%\/VLP4!S3+/NT"NZRQ4S1Z$SOQ'FM6[X0B\O;B\;RN;%_6--.]S&LIMV?
M.50?E@$>M:AJ#F4^/@&0%^&5#=,=^@<8Y=Z<P' X_GBIW"L65L.^V.J14KLX
M-"XKHZM?_]A$WV(01G@.>K))6\1KC2IL10"5$EA2A!6*(RZ*P4:%NRCU-K5,
MX0N,)Q@H*[5[IU.BJ S7F]JNANFF$[V@7- .YD7:ZH*SYLR 6D]P-KRBB#6S
MY7-Z6;\4V[T9@[KA[JG7(^4*I/!)3J7A,CU3YJM)12]<K1RCU$B? >1"[CG,
MA6<ZB_A0%;)@+>PCAUYI@&\-&/ +UD0T8Q+1$NAV4-8#/F&(6ZK!\FU>R_L3
MN3J9259><=.J5-><["UF"O/4]S=,<",\L&2=5 BUCI5[*R'GFF]^9=ZZ.XEU
M2-*?'X]^\_JWF$$VGBY_ >D>#W_@N8B%A:^JND4#ZEI/C">>^K*&JLH:$V+S
M85%N>PN,=C))@/'HL8"8P0HW:;U$EW76T0\TV;*#5<BO6NOG]]"&UA@D/'3Z
M74JARY/A]$8O3<\GZ7QJ$;_+E8?D?M>.SZC=N%A=YV:/DVE;NTDM[90TJ2Q?
M,("V(%W6JL98$:QK%,6$,J\!_9+U91^,T%/E1ZK$2F?"L5WJ/?&J]7C:*-7C
MLID_<>21UL ^6NF@2L(^& GG-5MS]= >G8DEJ2V>KXJ*TUWH]OQJ"5OSC-;D
MN'XHR7C)TJ8F?5Z ;I1FA;:([7=XTMY*@P]VD;]=1OW5>OZRQYZ_8\_?0?3\
MR2BO>W(_+B>3R71/S$BDEU32U,=+ID@O+F=3V;28RF33\5_LJ>P;56H+Q&OY
MRWRE5"M=MEO%:JO0:;6J]<O\99%^?-%M55N]3(9_:><EFK ^'OR/"?XZN0G=
M$OSU"G3!@KMBH5X6RE7Z#H5J_D(HU"^+U;9[3;/4ZERT\9)ZH]3,PQ]:^W,N
M_ 8@WG[A6A8 >[D"D!_ I'2"4P:HO<"*E-V 1<A8 FN,F+%]4+NRPI-V]X[.
MC!1T->"FCBX[]%X(;QD8=> _RTM?NM$1IL-UZI5M.CATJ5<,[D5;"4T"H$^8
MPZ&'@HJEZ!4+B<!3W6<^^1AV>^RJ@MRDQ9JH% \/&]/9S)[=')DKKJT*GN8N
MX)P^S_,\L6>,CS+TT]"(61[(SL(S2P^\U1#B5BJC3] %;_D0]_MR4NL.0+$3
M!=OO#1/J@X4S5=99E6[$=48-D]($R>>GHC5YZ36=8H@9I1057G2K=56&S;J$
MJ5Y>(C@)>R:F,$6\D9Y+HR^?QCPVY)$93(Q)#',DZVX[;J!+<V.=+!_- 9]E
M!.N%&1Y+P .!U+>JJ%"YP&)\:_!P&]7(/ 3H8R4$UH-LBI"QEK7Y?-@F>@P6
MQ.1FJLRF0=%?_$'' [>/F+W4FS83C&_%?^C%10&W<2T.LE':C="(,)B$)^MQ
M<_(  -\8J\*):E@#%5HA+<J>C+RXL?)&E&EMW":"0[OOX6Z:>T]_YY8XEJL
M1KP;C6DY?9>G7 )%PPCDWBRR3E.=PP?".\(18GSCSHK 1_A'J;R&Q,RW9*O>
M@!-8^!<U5D3/_8!^#39:"D*U"YG-=QSPGD<F=:!\"IL[J7B QDFZ)LP0 (P>
M]!FS]UJ?YYA)_]L5QVMY Q>5GM_+H\^+-XPG0V^X+T'RFBZ<ZE-Q<)<@WML'
MV5B*TKV)2DF/G]G&6?12%DAE0I8R"%4!<$[@KFQN J TT1\&>-:IC\M/:WV3
M"-"/;\H*D_"PH,MNJP03DZFSR'!AF!SWSZNUFE+[PT,U;-8:,;=.2;@A6",U
MIMJ3@Y@QC4)5!^4?>J!@X,0*!M%B28PL)%(1:ML+%EQ-Z-MB]^ 373SN)%&A
M[Z@:Z\+E@>*URQCFGSSS)MS!J%Q=]\!X^O3DC]GD/P"O6FM@PA9]=6 :?15A
M:R*! +/W$?"KHW&9,1B3*=0MK7SS S><BK4^"!;#]&;L>>N'X9ES1YWY0/U+
MPVUU5H1*K2$HIC."B4W.$ !^,(9E.2JH=P+84>[YYJ_/JKT(:Q9QX^LRFU+H
M(72Y;<BQ78]O;/E6"L1L9!^JZB7;A^4B@:%PEIY_'_I>],NPMP/LJQZPJRAA
M(.T4U0QC@EOF?P.VF8=LIT36 YDGM%X:7-X%K)@+;UXD71J0W*\ZRU%%WH*I
M?\\\D-M3+$ -0R51*7*FL=:V9$!,7% 8,\. 72L2/@/"<+P#P#F,\"0V);8Y
M@>'T,]A3"*ZMV%SIK6\X?)9E4.\Q"VXCLX(%<A/$TF#70@6@3%]M1&"!8WG!
M9B58]!F@6"T'9EBK'.0"(4WAZ6MS-=T)P8A8Z8(>TM7 O&)ZS!P;NN7=,0S\
MQA%W("8[;WR$CHD^G=?G%]D$ID,;VF9P6B_T"$8X9CU=Q]H!=#\/S@Z%-PH%
M?HJX>5-V6RI<Z*ML$HD*(C)4;<]7L>FI0<'/K \;;3647_!^!$0/'GH_*<JH
M'$)9^<'K]40U(9OF*LJYE<^#\>>A1EW_A(H(  N)"3>0L^;3-2U7TO/QHQ%7
MV/./H;1RH,X WG7C+\"[FY^QE]_\%/905S8_!>26S<]&AKSUF;<A@7)9P:+'
M30-_YP$241;+5&/WI\U<($H^%226.EP]<XYARW&*!H[:I-S_S)%W@;RH#'4E
M'1 ,X,OX@^ +6 ^ J2B+K'EPYMJ0$E.U)HQXCLX;$T$L,0W.4-\\)Y9/%L4Q
MKYZ<ATE-+$L*DY9\*KF)->M9>8GXO.S^P)X+J)1Q+!2UAKDV5Y?=WT?U8(8"
MA" $B6IY3J,F?1VAS+[MDFG;TWR%HQIYV1^EOF6$[]QKEX+X)YI%F/7^*N7D
MDO"93;1F1)[0+T'=L>?B; &IK-BDVZD,V@)18KFU90-6D&YLM$$[,[P#>"%/
M/WI'V>N]!L[?$!"K4^MYH=([[\=!X%:Q[&FE*/,FJ4490$AT?<NA,7 LWQ[?
MP)IT=6Z40U$--GQ6.P@ 'SH)#40!/%D=4,$/5=_NQ#H0(.J GOBH;43Q*P%=
M'T!==/B@;-0XU)DA-CBP:\O@*2K_[6+"R;J)05?FBF_\P#V)?,3HS*"'8N@P
MS3VF--8"<ZQ5IJT(N":JA5!'/(^(!B.:R/01?959#MAIH*#Q$L#P\C9.]JKS
M3:@$ *.$.D0N+%C?-&0%-]LVG6E@\T!-$G<F-WLP?S63N+4/,NS0E T6![.3
M@6H^N;,1 ;-W3'@SN8KWQ3WQ 31=JO%!W]QEMWC2%(U^'-KGV@_KTIK*:B-*
M>1"$*'5C;!5\C0 G^(2Q'&K+])V12QHP0U3="MB+<DSP>)MZ'/@$=YUHR87P
M))-[\!UJE\X==(AY<)['CQ0%T881+L)DP0P/HA/3^/+3?!RVK;$OF2;+'=-D
MQS390:3)]J4OJ4*D(CQ,UV X4.9.'+@4IJTRE." I0VQ&=ED\N#1C8QPZ805
MA?3]!1T*Q&2,R Y DKK7$9VNC6#XZ@_/$_YSTT_V,D+!Q3$%Z&D95SZ/#$/9
M".G,L ($ 6Q&/*#D198'E5K#:\E;_]I:; L%Y@*5@<R4E3!39P0P#%F89#2.
M0GTVQLW6+ 4WW."-YPC1:!M!@$AP7Y@9P!^.8&,6H?(<@\0;$00>.F/V  A]
MK%1Y5DNZ+Q74(*N@)@O:&8HJCW3#0OV"\?(IU)+"53X:/L]$T#WA-'=O_6D:
MV5=03^OBMVG@D-#+[BQ]?BH#)XA%8!8L+X#G (P /_:R,?[E'5->-@;+8.*G
M3CTW\ BEI.L1\HBW!PJ%]';+B6%V,1MVZ%<-8\RO# <27J$(P=9\()(4.(;E
M8GX-HP<B*E5] ;%6YI+1)\ &XSWH,W'$,-P +N;(_7BL(!C" +[9!/D@CP?S
MHC?Y9BWZTKP=.188L\,G)F-V'US9P'P&:MHB@S%K8W,L<W!@<]B(9CB0&I14
M#P@SI'%F\Q^M?)$AX^.M9R%7U."*C0@<?5T"I< NFJ8E#XG-@N:VH='3X9]/
M51_+8)WR[4/)P@(CECL2BR<_3$,'T>1HP"QN1O4-PXI< %7U'^_(1P04'6O
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M0^"<+]&.<C$HW H=YA:L?4F,9;PO!2YSK]DL#0O6R&) 'C[T!G1!-1>T^H(
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M U'<G7-%-C'&>T5$,QGC%VZ,J5C0%4)!V*JI@NA2.2-+&4_72I#I<M'5'ED
M+2K*+NWCZY5?!+*)^X,B)+XFXY^,_Y:-OT*:=7;J*L:14$ZI =K>VS/ADA7Q
M#\AW&_P&_MH\&FOILLDX)^.\'>/\ 4E^_X]ZJL6:D$V23$WBMHC/X<J%4>)
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MF%Q44.#J#XO@JS\5@O,*&WPW;BS7&Q*-1*-XEU'[2;<%JK(O@PA0R-K*AV9
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MKV-S+OX\V]%I3>M+^\?[HZ5MY-A]9$V)N 3&]MHVZ/]X],VS)Y:^)],FR_!
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M$2C]_=&(JC*>F?Q)%AL0F$);?!!Y$V]%9T$RVF[\E&[1\5'+RY#(,RDKS%N
M39(EBEUQ4F:X "0;Q=,=$%U,(QG&7X>:7"<6]E&WD361>%3#V43)&2S/I:!"
MK<?XI17&'DZ%L:DP]ALJC-V,M[9W9,=C/8M;2\]UMQP- C:"T)7C<)<58&0K
M#_M9(U ?W>()'=+S.;H*,B'<O"H\Y#Z@:#:&5SM3C]=LE,6>ER#_A[6T.5%
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M-&JOT_CMB\0:/9JP1A/6Z#>$-=I]JAFBT51QWC!A"JDAG1M=17R6'+IPVS*
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MY!D(JU@0VHFEWX'DS@ZA)J-K!%C)0F=297^XCD7UH7$%(,Z0A<H^TK>X)*\
M.[9^[A-WDPV%M#U" =KN32.F[4V78O HQQ;MG)AW[.R&Q^T]"'@Q7(R$N)Z>
M63+/09C$VY>$XOW"6#L0WT)6I#7[**>;=!GZ=0WQ%]XV_1.66[]SPQ"_R"K7
MXZG*-56Y?A=5KA3[$#ABG?"^)70_EB.6HLV%WS4:=,Z?-50Z-]J&2.@W32XA
MO\KK4<Z(]C3+QK5+;>Q.Z1636A-Q+/)Q8 _P*QU)VNU7K+V&XAC_B7=1RDY?
MY6B.AB,2EXK^!/4/[PBC*&RQ<'+V+LQO E.3]9]A!<GASVVO_H!INB(1>HNB
M?Z9<*OZ&Z#E&O:TL3GOO-/*CH]4''RP63+IT6E 0JUW 0QKPA& R7U @F$*7
MZ5".[JO$::VPZN'I<G:#9/S(*:14L\*QZBYP)(?ZDRE,VF$+5A"$\52XHP^F
MT[-W]."-68!JD= 7\P$<6)>#]:7!1C\_%!OH\Q*T:\@D5=[RZHR]21\A$WQM
M9*&GW<QWE[[^&W,N8\F=P*7W(0FH$EY6.,C]0_I;UY=,6281R%)1HMS<4\1/
M*A]LSX>KP#04C5F*4IA\[_J11)H.MRX8<TVN26D!A9;R8AA)2?1)#KZ[Y."$
MWR3Z]E(62C=$_'$7=R2MSAVQ$4TZR+*A@*.10H RL5#(R%"DNUI(M%BC"$+$
M7XZZXKLH%M5V<W!94$"AHG?Z(C$'+^G%HE=[EM*BI,%D&1OJA7B! EGKG E%
M=EU_(")DGTT_6]RUNL K,P"2G&WE2+#;Q@"A:]Z6M:S##EE49\SQIO&5#62&
MD,.$O/FL6^?5S,;'<6F^H9IB*6SR8/\C4A!*:R,M*\B$;/=\)VMY(FWXG3:P
ML!Q(G0B,L,^PZ=44V1F96NXFZS'M3_YX7#;Y95XR,U/BZ7+@5)SG4Z?F9#:]
M38=3Y,CKK06(M:OC<C*<R7""X135+UT,8QMWWC%=^&0EDY5$*S$8"A+1F:QC
MLHYH'3;P7-<5@X-R$80-2*VITW\RF]1G*8#4%\RAR?D&5%I,2U&]]KW;]KL2
M$S7@+ZI]GE-!IC80\Q1176IGIF&@'UV1X%\"9E1$*NH$K'OED&G*%_WF9ND_
MW(7R$MT8R2;-Q*],'I=2WU 8''D* [(.21YP:KJ<TJS@N5U8S1#+LX3<)$8:
MN52K(9,KJP.!O1.];$;3+2-X/8+Q" HID!EP =#7VZX]Y[YH;KJRT9>FU>\.
MU$AIV*$5A/2@YEDOB&)Z1 "Q.^=!_N/1@\,'*N'LI[0BH"$0)HRG14T).!BH
M8?"0DM9+!"^Z#^>J:!CO3C=&H9Y!.B33P2;'A<U4/Y'GM5B-@9Z*-L+C=H<N
M5%T!-B* 8Q@0*%#5=91A-5*C(X\[:&,;UT,/_!TCEZ"^.M/G"[>('H\P>;$1
M;FRPY'$#!"S>6.6" L31P%=XY</BZ\BY^Z6!(YY,X(@)'/&[ $?<O,ST';B_
MN4/,GXD.>],8ZP!M3%0.W%7C-Q5#L[G@FN>L [BK^2UP+14)Z+0 +1)!P5!^
MM@@"H_HJ<DP]/'DH8S?UJE ]GKNO2.V Q1-[483E*NJ:)!#6-<$NMVWAQZ0B
M% N!#?Q_G;F\W)PM4)PZ][%#8_M'EHI+60.TNV7%K$A:/KP1]3;J=%MT9T\_
MT@IKK90>(B!2I^K3[S2HHAXT!1%54LR4SE[8T?]K[TJ;VT:2[%]!.&8B[ B*
M)GB)[)[I"%FVI[5C=VLL]^Q^4X $**)- @P<DCB_?BN/JLH"#TDV)9$:[(?9
MMD@"=61E9N7Q7AVYJ:7%E19 " /0@W'$3>- &::9X)9.[5DM/+7P6.&Q=Q,7
MZ#B,<_D'N,9(&/D"2M;G-=AL+4ZN.&GG'+F1HB0V&@E+Z$ ;A4A6RW6=M?#4
MPN,:,B49!H]2A)B0%Q2ZS$8E\]-C#UTM/[7\5!VAV#*Z&:!0""A@B'V4I[.R
MX/Y;KF-GC047W?46KLYYU7+FIDI-M:_L<C>Q8<2)C>>C,LL)SN3PTEH;0DO;
M0EI*,^NJ:!TP OID'0V?04R?.F5-F 18)T4P9GT(QH9H1("?H*0*FU=!A&1H
M-9:;0RS(T!);B5P]0H7Z]Q:E6PJ[ F$[4K48A28WK#0".%)EM5<4,G\A]W 1
M>)H;SGM$[+3-:P!4[[3F/TWC4(D>'O%!N]7Y^:E1<S^O!@/AGJP[:C AE40F
M8;D9_Z(2P7.W9)'.8M-KK+&$<1,(08C13(2@(R#%'/@* >(F]]8!"!&V8V)P
MV1Q4_*;W#]'K7!;3-*,<+X4O)0C'DKA&F;E>MT+38"C'%?&9X[]A[BQ***29
M704)0_VHIX31&&(*%$>F!FA,S>+R4-K+:?.#UQ/($>B!'!.3ZX!N@J*RI!J!
MT 6YWHKN#5B^T-ZT 4MGY15FU_!=Q$B%/"S4F:!+,0T^#/D8BR#6?Q8I;^P/
M<1_/=.1V @!OE\M_)X@F0OR4R&#4V)#,Q%*#/"=(41>Z!#GO-W"WW9@&B\?*
M@J,M/PA%<+86H0O^]!GC_.I,GJN#.,YBHB-^KV2[X9W-,9)/_2D@#Y]3Y5+I
M\X"M9TH<VZU6QWL-SX+)M5L_?_Y\@O_E__RF@3S, "D G]^HO37OX]0_&;LE
MM:A5-+_3? 8<IW%._-5.(ZV= = XO[? 8Y#VEY\;5X72](7NN5S(F1,26)FI
M<4,)B4:!FZF)*^D#<V_ T;3>(<9F%&4-1FD3'%I+!!)65(U#X^8MG9Z>\2S(
M>;IJ%:GV1.>P$'X'>NC<@T8H3]0A9]'F>*:DZO'HZA5FS^-(QR1P*#C*^IA\
M76N$,*X,")[K+!$A!ZK_4")!B!%JE9W&4V5*QLAX(?->1IBYC$/XE@"BE>90
M @.U%'A\/&+C-O8S7ZI]FX, 0=& ;%EDYR>&;FN;RT0X5?B;2<EIWW"V5':#
M$H1@#Z#*Z)LXEO"?&XVSLF@1(M4+QFS9&2?YIPE!# $Y<$;XV)49<6<GA430
MQ;M*82&P("?1N!WB9UC2V_!B5%3P&3:S%@A8\A9IB!=,WQV@#8'%L#]'X)H-
M>G$#-K_:VISXN ,!!J!$8USJ?%5NH?,)U8=_X,*?2 =I'OP)"D2(1 PP2?B?
M2AO<(#8<P]\@+$K,()M$Z +ZR_A18^@Y)^X2NY9<U"2LY8J-],(RTI")$(T*
M->0AE3>&8MD:7!Z$?1N$SCR9E1HC\VXO"DNV+!F7G+>1_5H7*='\C) W[9;?
MHB4_9X-U[K)YGU@ A5,X%"<0_%%2%\RI)9QMV*^T,?@5^-D')0=LR/D!I"^^
M1$J&H&C26OG7$-'1-" T%K;U)Z?"U@/ [QP@K6[6*@UMF471M3H(!UD,=EP7
M@]7%8"^R& S <2HNN["W0#.+>%VD5C#";%''&+5!W['UY5K V_+-E&D5E#Y0
M-D@9[X#@[B=1B([6AHNJNM?GSBT '6KTM8"ICG'6D9O*B?YX2+P#EG>FM9=2
M6PSAOR0U.6?8;^6P8)6:A+8(TYL$3:$VM/"";4$JE]QLM=)L7>F4K;NEBS9?
MA0&3FFXL[HU;W^@W1B8QUD"0-NZ:H^WF)9^8A4"'T2Z$FJ#R9X(<X=AU8D%]
M5]J5AD8AS77:85[.; %_"% YL\BXMN@LQQJ QK"W*<M0:K<7K*^ V,>=A:$O
MHX)<* H!F(<@<.1^1#6?U''8)=;I:3I7[K^RT.GXVX[Q3H4V_%,YS_%D^:.1
MXS,ER==*N3 _'8 ]N\ FPA--=*\%BRE(7 ZSG*9PF?>N$<1:-G; ?1P$7ND1
M.E[+M-3!?4Z]/E;]YY95(HCU)Y'S,,X7LV#Y4YS,E.(\0E)*QTNUOA?ZJWM@
M7VEU-OVOV2W\?_2WCX:D$/3/_P1)"3U_[5;;5WXU&:[S63"VV8;?QT4*M_;U
M7VEX1BA!L')2P+<QL+HHF>H-F_V_FIZOL@!)Q?MHKA0[WZ/];F/0[S;ZW6-E
M;@$]CDG7. BEOVIA->' HBACW-6\'X&F\8H( 5*"2;5/G +]"%T%Y@T.6Q,-
M30IQ V?4Q]WFL1DU4V-0#\W*!+A7QHQ(+K\>&8/!YXR$!VP763Z-09R)\@,@
M^-2F /<.C_^!!SOX\:,M07&E2T 5YWC5Y[2)^EZ:+=*,"0"",%UHHV<R&B(D
M8U!5-*%IH*,Z=%U'XEZ(CL\7RO^!<48 "=Q /A0F@M)]A<:E46L^BA.FMD(B
M#AAWJ6_7.CVI =@YQ*#'#5?\(,D#G4QQ\'M7=@V75NP:-BL!-&Q)_42BU8?A
MZ#)-U/J--J=@N+X)X_Y98AOF.]#D6-179!9E(EA;X$999KHKCW,5L#4T/"Z!
ML*ML/B*AX$Y,=<EBKEQ IXKF<3GW#"*[>%)3W7O5:H$T@,^X\C!:5<0<<XS2
M2,*L6Z$5/:*$;<LGU,Q4#\$B;KV\7.6.@<ULU4M5+8H@G4:82PF4F_$]U7E1
M1V<6/3F-J3-162.B9/$(JT1>_7*"2N9"70TBC!9W6@VT/0U"MW.U,$][K=V
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M93FGHMVHZAU"<*39*!35U; $"B,U4T9J5C%$R&ZEKV<N ==S!>D<>R^*).#
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M#ILEOL-5TZA A!)0TG!E192NTN>)M1*&0JU,69E;TWA$G:^FM$!:5:VPT,3
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M4M48NA[7.-_&$!B01;21>4[DA^.ITO91PF!6516OU#KU[TTPI8 F;$5QR_I
M#OIK/XJL!\48@A#XZ-:_AF 5LPB3#X[SQ4X7WGQQ$#RM++I&3H_*HS9"G.H<
MA^.$P6/+:DZ!"4*T1<2[ CV4:Y9A/,1),M.F-TPC6JG@"D!$#%.V^0YE%X'>
MU.X'C1$&9,PH/;TA[@3(%UJR:2#,;6_-KNN]-6MGU\V9NG16;'FXN]"5]V'
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MIN%(,S>.!>:0R,W^(K_YA;YII%!OM35;6E(AWUZ5[JV/HF0=F/D)W+TJ0\1
M'QW(!+!VY][%D0_FA?^[XXSY8AK-)N[K+O0#S) QW*73!TQZQ04VLJ6W<L06
MWWUB[1K]T;QH5I7L!^[:1Q9D]5+, (@IV3^;"2".*E\C(:(P"O+8C2( (1>I
M_*[?8]0(S8T=A38+0!]5N+J@PVW8Z4B>;7>1G:^+KEK,3"(7F'HKN#OHW3C]
M4EC"P3B#VO@0LH!H.!\Q_C#3AD8!!1U"V-1X9  Q*K^C>((41&["8O#I)7.P
M+ZDW'02N9 R/=4C5&N(<;NQ8WP7/WB9?S.MHZ)E,\GC[<M/? M2+\P4$L^"_
MTYQ*.6SV?$)X*^CR I*I6@?MMU,\^77\!E#A((#")4GT,_4$]?'4>^WWBND;
M+\1"*,D_S$_F([!UBG$E@*W>QT(!OG5THYL1..]E9;>AAK=V?'E\JU8"AM=O
M[7QX/#:=3K]SC$I U3#5.*L/"NX]3<S?))$W59N>L?XH;B#]@)/TVS\\2Z=#
M4]?=0UQ_L?.$SW.'@E?M5^*=L$:"A?T2H7D(O7]3,6)%Y1HO3[I\0"X\;CH*
MK?IKJ]*D3J7KQ[9GHAT-4>NI[P,#-";#L3<6LI.F^>9&'?\B0I+AW(QVE?UP
M79&B9D24KW8&P1DBZ+9 / <1A*89&#"8AL$_UQY:0Z!8=(?-WCWZG-T*RO4T
MW=3>;SI^D0TB T#L@HP"EY*^)H7.;<AB?Y2)A)NDZT-;#D:J/]:A8S;/II1Y
MI559??B.*NFX9(\2=O9+QB^EKVD7GO[UF5YG1L%K";.F;#/7-*\%9'K-FQ.$
M?ZK/$E/0E.;%0BF-.2/T@()_HRNMU;_C;+/LX"9RYSHD)LMDIE'&:, &V2*W
MLJNE$Q?<6=T5471F_73)Y._QJOG^/FQU_-:D/;GT!V'WLCMN32X''7]\.5 7
M^" 8C5K'W=7[>^=]- D@3@ H]1=1$J>9-=.7_>/6H'7\_/?W3M/3XR0X?1JI
M<"F?)O9?'>%OJ>Y0YSTX;G>BT7 ROFP-1FH/1G[O<C08=2[]X^/CT7'8[XZ#
M[LH>=#_'2435,>\-"TM^J7S1UK#[_(O?;7HP0%V_(X;X7(M>B"R0L_R#0=3K
M^7[_4OW/\++;'AZK4S$)+@?CX[ [41(TZ(4KR]_['53/F<5TO_3]=K^W!RO?
M:WHX-D\,[KD%_= 27NTZX54GO/8BX<4ZJML+QT'8'5SVPW"L_A5$E\-)JWTY
M"=NM;F>@+$5OU4SW/]Q.E2M0**MPW.MU!D^EFQQUU&]Z>AB/%1+?'F5<TS%_
M3Q?I ?V@-# X(GP\8&_')!-:P^%Y!- F_0<ZC/@7Y\RV;#<E?V=5*7+OIQH%
MC/?OK]JOC/^W"G.D?]KT>UK3F/58W'J80_*T#A,K6>G6?(1K\F]X2:*3PIVB
M#YE2N]D:_/5I1TQ2O?J_WSV'P7'SN+]GV_+>=LG8>6&GJ=MSO'%2P^;Q\(DW
MIM/TOWL/_.;PJ8?[/7>V[Q*O;K/??NJY!?J91WDT/E*J&CAA?XK(#OS\BFWX
MM"@6^4]OW][<W#35]YI7Z?7;DVP\5:8O?QN%5T'V%@B4W@[;ON]WWZI3X/NM
M;K\W;+=:W5;O>/"VF+=;?M<_'H;^973;.?*;TV*^!V[!B8#Q.-$@'Q @D!^<
M.?@>'#LZ9>2NUS8@_AF+_=M]3.VVWGBOG:9I+.C DD2"0&-CZZGCH ,X_$Q3
M5<+ <=Z7B+C>.%4T./IG [-*H<W!7'PXA<]I")T6#T$X.<V#T0^.4*QZ\!/U
M?TK-/N))K)7,?LQMS^6TTVS7(K8G(O9H=JS7&W2.6_ZPU1KX_<';()LOCMKP
M[WZGI0Q9SV]WQUTUY3TQ9^NR2.\(*+%JM^YIG'J;C-._RB K(FCAKI@GOW7T
MKTWVZ:2\@@RUWP4#Y0]?@(&J[=#!*(D7:X<ZM8CMB8@]\GU*V9UC?]#KJON4
M/VQWAUV?[U/M?3) Y@ZU>VO4WMU524.5>[Y?&Z-:4QS*W/9<'#O-;BUB>R)B
MCQ_<:_<ZQST*[K6&_<&^!?<>V1CM,&[W,1IEP 1BHX?2&'D'<_QK:W28JN*%
M6J-NG6K:%Q'[8G0H0A>$4I?FI$P994*Y$-Q"0HH6BF .U!^OLQ<'+[<O535"
MD8E7"]F>"-EN776H0UEUUWV_XP];Z*ZK_^IV6NBN^ZV]\=?O:!"F[OG5#NH1
MH0X2&)5PQV4/"7P!>H?OY]KCV=B9;V]&/*01UW&F6K/L_]SV7!S5$:VS[_LB
M8\]JO?8E]7$'&L"36J\=IDEJZU5KEMIZ[=YZU3G[?9&Q9[5>G3VQ7O?"'_AQ
M*U:%*[BO0>O4!JTV:"]!V;Q<@U;G_?=%QI[(H"F+I@W:<:>W;\'$3]'#PH<:
MK5L6 L#?>ZU6S_L\/DV3))K-O)/K*"FCAO?IT^FS!!-_2Z^I:JU-X[_;>'U'
MY^F+/(K/T(+Z9%J&.E,/8VZ'))L=_P<*"&J!>PZSQATZ;;\U[+1NH]N.'^Z+
M23J%Y03.&MU'>IXI"Q(O@'7J-AJ7V$3Z.U!H1IDE^%-VQ>)>^IW@R.^^#M[0
M/]-,?M8+Z;/:)M1'M+8)CV@3OC_S]&PX&(<E1]^MZO<E&;1%U7\T</X[4/5-
MH>L/\SC5JKY6]?LJFYWV8;G__T6JOGV87OV7;:I^M$75Z\^0_&* D/NG3<_O
M]%JU"=CC$UF;@,,W ;6WOZ\FX""]_=H$U":@-@$'))M^RV^>_79Q2#)W@%;@
M+)D!#/W_O?ORR3M+@&1C''GOF?,8*3-\_V?FG>1/-2.RX)Q<+*(@TP0@9X >
M'A VX_N@")0RG@$%,A$?0=LAOJT(KHB+&!*K8<A)5_,,.RS]ODW]V/LNR+62
MK97LOLHF*-F+TU\/2>8.7,E^#6[3))TOO0^W190@0=_%>!K- Z-UZ^3AOHE<
MK>9>@)H[/?ET2#+W\M3<:3 ;ES.ZK'^*DV\CJ!2LE=Z^"F"M]%Z TGO_X>,A
MR=S+4WKOHTF<Q+7..PSYJW7>"]!YYU\^')+,O3R==TXLMO?T]-XBC=@O!\>!
MV*DY$*.: _$>:<I'YT!\F3Q\AV$<]]^^U#[-"_!I/IV\.R29>WD^S:=@%,WJ
M*]S^BUZM[@Y>W7T_I$$M;SN=VVFJAN.=JZO)AJ*.UQ-P>@OHPP]RIV@#JN7
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M2P<(29M3'VH! @"K 1, 4$L#!!0   @( -R :E-#98CO?GX  ,.8   8
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M88EU/U8AE#P9.PHVB<94TTB.%N554_9C'$FO\S)J'?H1]0D=^E50_!8"I%5
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MI<(8Z_S;A3@21LB2IVGLY# C!V*-F =X4+?X]A8I0PI9EBOK(@9XTWD<GU*
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M!Z^0;2 WY/'.Y4_^T@<2P;>7VH S\C?.L.J7/1D#U.^CE0.Q3YR_W ?(PUL
M+&( RYL,Q@B!$^[8P)/!-][FS>^G;.D?;P&7(H',2>[DDJJ*LOXR G*)HH$
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M]5#S@G'.%?(\' &*W ?J=RG($/,O9EA'!U+T5W+Q!M 5H(:*6J?<+R.$^]H
M17W0^<W1CSP4M?H&7P?U^B1)L)G-R[D9TK6' "T8B0,E637@4MOUGF_8"?0Z
M;WJ,OCE8$)6,F2.\XLF]"_(]&!-06Z^3_F+&"F.2^*MG>WU*] NU^L@;8Q>
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M=1%U??YVC(( %=A\S@R]4KIBR!NW_:Y*EY^80IY_+M)^/VOS1S+J$B..G=%
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M.SO]&YX#2[\;O+<(.5#9.Q<Y08"@:-T(D-?U,;->*Q^6EE"]4)?^U#$@W+R
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MB7OK299Y[.":AGH^3Q,A_V1N\#W#0*8_."(F<(77UNUT$$__^$2YT4^A)D7
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ME$(X*K"8%%$,:Y2C,I^K#*:!(;,RCD[QKX(YYXAL9C9ET-D5'4<B*^028Z*
MD+,$ YKT$%AXRN-$;;(ZA*"14/G3EO,> .ZT7IW/FZ&<JT$A7/WNIX=G$DKB
METTN"$K;N!2^!Q"<+8-SX=':4@A^'3%'^.ZRU^(81PL?DV\+%7PE:C- )]A"
MZC[P7-E \U[BP8SK%!(I<D\OQ'KNJM'9-F'$6#3<3<[V+M5-\8QLW#Y6JK0[
M,&VA25'&A7?A4O>U$[3C>_BUK4A+=NEA=&RH[6A;E35S/0\"S[08LC-OMYWX
M+GT,.0KS<AV61U[%(:-Y;QBS_]>:[LXE_4@$;!U()P(J#MT80RX)@"&+KN3+
M1KHD6/$B667:\AHS@&!O2?J]A/3PF_S<WP#G8NZ=WU&ZGK*51W;GOOGB!(KE
M;KI)].0>PM!HB,J$5$YI?^?B#2P,=EB?O' AJK6)+&U)KEZYFL2^!Z!:V5V*
M!_C?523Z+\P('I2GOC,F+ '^]!8\>7LH%<RYLQEZ$<K"^B&&)V2F@E<#$37L
M+@CYL$ ?[=*#/( 30U&ZH5;^#=H6&B^;#;&L/Q6A</3LL"B9==8M?3#D[1@G
MJ;@R3ZW:,:%-1&>EG/FN>OG69)@U.VL &0=8?72OWHG=DO&W?"$):X[!CGZ=
M!,#>7=-G=530T7&9>PRA@*NV>37N4!) .)=J50P%1(TN XXD0W.9XWX8[8_V
MT)@-SJ^2<31?G^BM_;_]@^\_&AQ)U(\/QIR#%>3[X0-1H$;AZ-"B[7++H ^5
ME=V.CHZO@WGG%9D_9RX^;,^>N1&#;MYN/K[NX SL -V.<BTK-286<4:DW$VH
M#J=$DG7*QSGO1+N82HJ*WX$\)>ALFG25D,)GL"ZD-J0>7[4CK*Z=1M_%3$Z,
MU@/B<>C%<>''4(M^[IPG-%0@#U2%[6O=CEJ5(SFIN%([;?E=#B%M_)4X+W]K
M1#^1NJG2NG0"CB&6_*N.Z4!Y#N0J<'+"UPDC<-ZPWB<**Z<!8'4'\P*?/G_R
M>KPX1<VT1U<XKRC5EX-3G!"-.4+81.9H"<G.$ <#F9G.8DMK8]!<5>9,+==^
MT,WVO<D=S$480CKX:[\C\_YUX #N*M,X?)KL5AOX_!#/L9C:XF0OCE9+D(U@
MZ=UIL%+[YS0EI-B_4*GMES 7&G+,S4H@B!?T+*E]?I7!G^Q=>F/?4/4BV?,>
MP/GA]EH)Z>M?*+1B9_; C5]9\LR.]"6KGZYUH=;A  @)]ZWFBB"ZNK.=@=QO
MU!VB]FW:3 ((KF#3T7\@_GO)DG^J_;<J)?]:!+>-FXR3AZ(H&2=_*[52*\(O
M_/CZM\(L__NW*W,<_+;IQZ;N >,E(\G_QV7N_A4-;^-F94M7)'B_4#&P N+U
M!FI-1QFZ?O+>67+6E8 !4V#27F2!7-8G2[KR(%+5OF7_@\DUECM@E:IF6"$R
MEZLX)W\[X@=V'_H@HV3.I;>AB&QGJ']'8AYS5-9B5:7T"'0&*:A/(N"RYY0)
MGY:R@7"?4@:/.AX/$JWQ\>DUJH-T6=JGC]ON[)5BMQ;P7QL:ALU&6-:'"W4;
MBN)]B3,#._)-* 1+ATI7GS=W%LDY9C''9.1,6<9TDU1JX/1&*\<X/ E)V> K
M[L]2-]&,%.=K\9UBLD_"TJ>W@.\_9100B.?<I!IS(LSR^3(J<<X;(;KRO:$G
M8&=?IJ#)3.IPKG_R1_:.>L-T?4D?;N-K(21$%W;9R%QVZ=R:WRR_T:&<VX"E
MC$2YJH;QPC,!0MN2??-CE85NIA'QWZ)%0RQ\M%2X<G8?*J&TXSKCNFW"[38-
M+C9JHM6$]P"+L^+QXO=Z/:,===(:2**O%47=MJUD 8LE+ZPI'$K;UT-%W@5/
M!:"+LGQV]%]=Q!Q;P C<%U2U7M7K=$0$%]A$,;*6YP@:NMAUU-T.1[E_%R5I
M;+*WM%P60 O5(O\EA18WU:&',+T/$%S),M?ECK7QREK0LSR>WL)Q&]V-H50W
MI[8Q5TZNT8T\F*E+BAP:CN)_+DJ"H'Q7O*<OH%E5-@96BZ'KP9TCD8GQ:JAZ
MAK6D1^[O\UT^Y<AGSL6):?;:'/X4K^;O==;D<21-+%K3(T5IX-%]MB4 _/\+
M^0B:_3V@P""+/Y'\&GRM^E__!?#_@^U)_3W TXLQ_,AF;"O?8DA'AVN\,V&4
M6G2%1HI0*$!19Y<6]B1H%V5WS/1824JQ4[_">X>1]CS*RU&4!)PAV4@T!N[]
MRF%5'(Y;]'+]U=9:[B[?K1767JC"M&1\EH1#Q%1':?S+T="N*/F:ETG>&6?%
M83NMSA<<L]4U"73[>M0QU/#6[$D;J?JGO27H4O8N]DPZH7N%/-3$WUP)WW39
MAU7WK#K!LK.\5+6)LV0\([5?];[]^V8G/^=6RR/\4#P.W<\YRZRO\P[WBB96
M@QI'#O7TI6Q-M5JB>+Z<\I++CM8<]O1^OHB92=[[$8XJ^I;X(Y7RA1OR3LK/
M9-H (^D]I%0OEQQPA1F-A;1-CYN WY.G@WP[HH3?K?'?="K>F%3R6%/W4R10
MHY>]]1/X]7D'Q%#R?IG\F=[\3-^'_?[Z8\ 0R*SL)P64E4<0JE549X>F#72C
MZDMX&T9/Q7!YU7NW#HO:9.58,9@S2SFV72;9?J-4!6L0&^VE &:E&BW@X;3M
M6"DBNYZZ%=3O*MZ>^+B*Q.'^<BU12E2K,*D+T"IF:1,Q"^NO1*#-C5NQ[Q1B
M QZZZH_@54DF6!H'S,MY%?E42W\VXSU0FKE4[:HM3;#1N=[ZH,M5K[([E8%@
M#'!LWID,!M0M,^XDB\B8ETV?UU!+I\^S\[!URG;63'!Y45I?LMHR[^O9"%[J
M\#I_^+!B2<A'6(3US+**J*@C\4.* ["P0]LLT%O5X@JD([9DH?\T9OEZ>WW9
M13)F6:\NCKY+%\Y;^ =<4FU'>=:<Z RXOWZXV^P"1QR7&!THVD$LN'JDM)5P
M$<CB1$R;,+)7M$^-QB0E;S&"*])&,\B[DKM>*Q#Z8F;_'!@T/2OWP2;$G #5
M?:71JC%U:<G4$7W42K/*=TX6TBD *,5,QL7H)#%9]Z;CKG.?QZ\94Y'N&YFK
MX/YJ^-N P^AHH29_)J"D^"F7QS=@HD71!U)E\=^DF9[HQ1[H*6#WA>8A\7-.
M+]ES:P^^+Y6'?'I!O@J\)&?;;@6A2U-$+1[B]BS3^Y]'J0Q-DC;L1D.4D#3/
MYXNR]?J<Z&TV%$OO<KH#F%. YG NYK3"V5G!-[JEC:,&*K45,6@;=$/4 NBT
MMDL!@_UA5T5RR:@S^\OGVG.S>F\H3!81E;<NQZ4%68)H$QWSYN=E(RI><ZZ!
M' @,HP$ !8$$0%?5A.>;<PVBS%CN1HGQ[5:\W*JKS- X;SES/Y\I+RM@OS/0
MDDL@,+,B0++^183TH:U7;H9]2^B &"U\6M'X4-$$\RL*ZD3."2RBQ<^'_@P\
MG]U6&M3LT"0I_+K&;/?VWR=HQZR_KNN.6/-!,"9?$B7XY5JE%-9R2C(_2]V-
M4?=-,BCI5W>?E^N=M6+K3$JI(XBYX99'$3FVQCSA-^1]><\*-5&T((UMI6.+
M70F9MCG^D[4XM[R7I&*=7.G9EE2*EJ91^^O'Z[IV"4L!'_D!2 !R,5$BSO^B
M*.5_;L#P.YV[?R]GCUTO-N 8;#?=>1'ZL$IR;G^W(O7_;8 R-!\YB_G?8$D(
MUI#OI_\'4$L#!!0   @( -R :E-R0?E>6 D  - [   8    87)M<"TR,#(Q
M,#DS,'AE>#,Q9#$N:'1M[5MM<]LV$OXK.'7N8L^(HNB7UD<YGG$49:J9Q'8=
MI==^!$E0Q!DD6 "4K/OUMPN0,B7;B7*)$K6GS,0V\;)8+/ \NPL2YW_SO%&1
MT2)F"?EY\NXM261<Y:PP)%:,&BB=<Y.1B2Q+6I!W3"DN!'FE>#)EA/RS%P2]
M?N_LU/,NSD'4L.XCBY $@1_T_:/^44#Z9^')C^%QG]R\(P<?)L-#V_SU]7#R
M^\W(#7OSX=7;\9!T/-__U_'0]U]/7KN*DUX_(!-%"\T-EP45OC^ZZI!.9DP9
M^OY\/N_-CWM23?W)K9^97)SX0DK->HE).A?G6 (_&4TNSG-F*(DSJC0S+SL?
M)F^\,VAAN!'LXMQO?KNVD4P6%^<)GQ%M%H*][.1437GA&5G"1$HS@)X^5*^U
MN??F/#%9&/3[?Q^4-$EX,?4$2TUXVCL[>RA2?)HMRZ2;6JB8H(;/&,IN28T%
MHRJ,I,D&ZP,\U;-L^J6R,%Y*<RX6X8L)SYDF5VQ.;F5.BQ==5P*_-5,\?3&P
MK37_#P/1,#W#[HU'!9^"<-1UX.8?UE./5@:9,SN=2(H$*D?W&8^X(<=!+SCW
M([!3N06M8MBC3*VIA<V;@69<@QJ"FT68\21A!33XQP]G1_WCP;F/#;^E8L_;
MR_9,6"P5M4M9%0E3@A=LO<:+I9 J_*%O_X'0X>AV,GXS'EY.QM=7Y/H-N;D=
M7PW'-Y=OR>BWT?##9/SK"(JAQ>@6\'7[_L/EU81,KNV:;$.A\TA=;$WX^]'0
MSO.X?X1SG?P\(N\O;U]=7HW>>]>_O1W]3BZ'$ZPYZO>/MK'M.*A:F/#XQW(=
M#-]WUSVKU[B+/ VL_2M5195W2<R4X>F"F(R:\"NJL<)S5H^V8M[7L9BAD6 D
MD@HVS,M.OP.S$:(>>?FL2QHWS[5XUP.WDZ"E9F'SQ^"+IEQ[ R!E(_.P58+^
MP2X-JNL)NI"5"5-^SY)!B[B=4HTU#,#&)!LMQ;H>,US2F(J:>ZS=087!/..&
M>6@.%A9RKFA9#V\7HS9;/7[0 ^>7M%58K5]9K2^RFGM$0:"4RJD8M FB+FI1
M*6XHW,@DHS-&%)MQ-H?HPF1<DS\JJH!GQ0+*2ZD,Q!SD#4@@0=_[A<B47((T
M\/<WX.]S,$-E[:2[9%S$O8>=A1/W<0%\NV)[2.PA >,?[3HD7E%MPVR2+\@=
MS$8PB,>[#ADU'A()BA02 GD02'E!:+$@56%4Q4!S"--ME ] H02  LI105(:
M0Y$B,H?XS4C7[E&#@L5,:ZH6V"2G=PS&;<G44): ,C"DP%G@&-@@Y@I2"V@&
MR88FUO,36)0X([K"'P_]YTRQ6@A.(.<:0F TOTM&%-,EBZV"*+<$U60"TX25
M!Z-$B[89]DC?(_UC2#_^TR*=D907@"6$Y0-VN@!S: [5JE7/BQ3E8V -?\>B
M2D FX+,%E"Y@FZ,[+0%>R S(&)#J+Z%?HTZO#0WLDM@DM(LM*@$- .\20&F'
MTU:?F.J,I$+.=4,&BDVY-I#6&T*QT.D-6G9;F-:-,H^TW<-Z#^N/P?IDUV$]
M6<$ [HW@IX&N@5LG:NCP9)IR>+3H&!.JF,4AX(KCU@&\$*9Q7;C.L#DVR\'9
MH\/'YX3K6$A=03\, Y04#I"EDC%+H%B3 \!?P@#0#F2C^SBCQ9212_"PMY6
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MHJ7FALN2BC"<7'9()S>FBL)PL5CT%L.>5+-P>A/FIA"'H9!2LUYJTL[I":;
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MM3M8[V#],5@?;CNLIVL8P+4Q^'6D/7#]1@T#GLPR#I<6'1>$*F9Q"+CBN'0
M+X1IG!>N<RR.Q0H(]ACP\3KE.A%2UU /98"2P@&R4C)A*21KL@?X2QD VH%L
M<I?DM)PQ<@81]J864&(PI,'@:(_MVZJ#H]1=N4N.1P"E(P)LGV 8;O&#PRO:
M\NR.LK6.X J'N4D:4 !W!=&."'XD(F@!MG.Z"=%OSA)T?\M9(F4:K@ O5B%_
M&LQ=%.\)K?7SJZ"*CAE9]>1TN:P5- !1&!<PQG8HQ4K;#IX>W:N"MK)PI]*
M="_,[^':]:H#,SDH!+!%2\%3>_- U['F*:>*XP"XVSY8K5-B2[5&26^)45O]
M;Y6 U P,,J \L%*%)UQ)+2@*&!B6->)^:P UW$:CO3^"7S'#@J QH#ZLX>VB
M$M+\-VAI+T8/2-N21<..9[:89^(?BV>>'=(?T,WSQ<"S60>8:LY3)!.J96G7
M+]5 1'B*@ Q#5=J@'?B'4X<"W&8\UBURGR4&BWE'6VM%6Z<05ES=^0%5M:J
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M_<-M(:K&/)NPU7M3^R+V]$]02P,$%   " @ W(!J4W"SC%3_!@  &A\  !@
M  !A<FUP+3(P,C$P.3,P>&5X,S)D,BYH=&WM66MOVS84_2MW+K:F@/6RD\*5
MTP"NXZ &TL2S%6S]2(N4Q4TF58J*X_WZ75*2(WOKUG5-FQ8-X-CB\]SW(77Z
M@^-,1$I$S"B\CMY< I5QN69"0ZP8T=BZX3J%2.8Y$?"&*<6S#%XI3E<,X(4;
M!*[O#DX<Y^P4EQK7<Z0((0B\P/=Z?B\ ?Q >/P_[ YB]@:.;:/S,#C^_'D=O
M9Y-JV]G-J\OI&#J.Y_W2'WO>>71>=1R[?@"1(J+@FDM!,L^;7'6@DVJ=AYZW
MV6S<3=^5:N5%<R_5Z^S8RZ0LF$LU[9R=FA;\SP@].UTS32!.B2J8?MFYB2Z<
M 8[07&?L[-1KOJNQ2TFW9Z>4WT*AMQE[V5D3M>+"T3(/^WZNASC3P^Z#,7?.
MAE.=AH'O_SC,":5<K)R,)3H\<0>#^R;%5^FN35:BA8IE1/-;9M9NK1IGC*AP
M*74Z/-S@[V;FS;Q$"NTD9,VS;?@TXFM6P!7;P%RNB7C:K5KPNV"*)T^'=G3!
M_V"X-(JGV9UV2,97N+C!.JSD#VO1EWN;;)@59RDSBIV3NY0ON89^S^V=>DO4
M4_X J&+T4:8.8)GAS4:WO$ 8&=?;,.64,H$#?GHRZ/G]X:EG!GY.8._7EYU)
M62P5L:8L!64JXX(=]CBQS*0*G_CV#Q<=3^;1]&(Z'D73ZRNXOH#9?'HUGLY&
MEW QO1KA3_QU?8$C)O//;(>'$'=V,U_<C*XBB*XA&,"-NW#'+BPF8RM^T#_Q
MN]^ E*,%C,ZO9]'D'%H"?P."-89ZX3\WOAJ]GL!B-'\UNIHLG.M?+R=O832.
M3$_/]Q\P;?Q6%IHGVZJ)(WJAP_[S_#"_/89$TD#=0S85$$LA6&R47-5FG3)X
M5Q*%=LRVH%@NE0:9P$BM"1:\&1:\-8E9J7E,LJ(+4Q&[<&1F&2EZ_G LUUC<
MM_8I&#[#Z@T74JTA\)V?(9'*[I C7$F!H<HH+%BNV7K)%/3]+M@:3PI(>-;P
M!3-CP>)287U"^8F@,+G#TBN0->!V:UX4!G\;Q=P";T @S"XL-+ME,'?A#4K'
M11?&*6<)7'"!A(63#*Z3A,>( J4U*]6"="%EBBVW@%U&@P9;/8(B/;&],NE"
M(3.&&C,2YJ7"8LKLN,@0 4PQ9CN"<BIXWN\:::S*3:)I5KL1W+"=A<95"]R=
MLBZV$PU:VOXE*ZPEUEOX7<@-:F?%PD_H+'L$(Q@T[E.[M6-;[KT'FL_)\5^=
MO*8W=B6S] <ZO29+U-52*DP#+SM^!U6>936LW7.1D[AYKK>K9I@DD9&\8&'S
M8_B_]%$+@51)RW78:C&LS4:7@>MD9"M+'2;\CM%ABTY5H)H4H!5^: .X&F8S
MA6%^FK8[_Q'T(<A;XY08B7646XLAON$F16=RC*Y8B,ZB2-Y@&]R;N@9W%#P[
MQ+ _8,^V_TNGU:-9"%%A(LF&[:)0-[6REO$@!&#<OXIH2,H,HRS&V,Q,+MCE
M!\7>E5PQ<]BP<7<?84<$DY""X.2(8B+ Z"4YSHV-\;I-[+6RRRZSC&(;;L&+
M_G'7Y)R=IQI5><:@GO6 +QQ_C1=]C[^O-OYZ7T/\<9&8;AM42!HT09Y&L17:
MP4FX80VY8H6)PZ[I)GC"QVD(!TLL=N08F$77SDIVI1<7I/;P:8L[CBJS*HPE
M,@6[9W%0EL$4QKH&5Y1@GUL4N#=%RV!)=1\Z<K\A1CB" OO,I0L>U-$\6:5V
MCID6\Z-F E&@3NV=3IUR*2 Y:M(M$O*NR;82+:'NKW](B<_"1 HRKQ6FT[BA
M,/:QF;#A!0-"96Y&66,:-$27BE54"%,W(ZJP;K?-F37ZVA:!VA%9AD"4%#P&
M#$U+"S]"@!2KQ)+AV%S)6VXX:LW!=LXG##5%SUZ:RE/' JYR."8IE>!%>K_
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M=[S+156;;P.V>NEKWR*?_0E02P$"%  4   (" #<@&I3.5'EED</  "^F@
M$0                      87)M<"TR,#(Q,#DS,"YX<V102P$"%  4   (
M" #<@&I3/K-FGLL*  !_BP  %0                !V#P  87)M<"TR,#(Q
M,#DS,%]C86PN>&UL4$L! A0 %   " @ W(!J4\\W(P\3(   C2(" !4
M            =!H  &%R;7 M,C R,3 Y,S!?9&5F+GAM;%!+ 0(4 !0   @(
M -R :E-P/"#2%%8  /[D!  5                 +HZ  !A<FUP+3(P,C$P
M.3,P7VQA8BYX;6Q02P$"%  4   (" #<@&I3GPF^S $]  "T500 %0
M           !D0  87)M<"TR,#(Q,#DS,%]P<F4N>&UL4$L! A0 %  (" @
MZ(!J4TF;4Q]J 0( JP$3 !4                 -<X  &%R;7 M,C R,3 Y
M,S!X,3!Q+FAT;5!+ 0(4 !0   @( -R :E-#98CO?GX  ,.8   8
M         .+/ @!A<FUP+3(P,C$P.3,P>#$P<3 P,2YJ<&=02P$"%  4   (
M" #<@&I3<D'Y7E@)  #0.P  &                 "63@, 87)M<"TR,#(Q
M,#DS,'AE>#,Q9#$N:'1M4$L! A0 %   " @ W(!J4Z*_E<:#"0  #SL  !@
M                )%@# &%R;7 M,C R,3 Y,S!X97@S,60R+FAT;5!+ 0(4
M !0   @( -R :E, L=22[ 8  %T>   8                 -UA P!A<FUP
M+3(P,C$P.3,P>&5X,S)D,2YH=&U02P$"%  4   (" #<@&I3<+.,5/\&   :
M'P  &                 #_: , 87)M<"TR,#(Q,#DS,'AE>#,R9#(N:'1M
64$L%!@     +  L [ (  #1P P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
